0000926326-24-000008.txt : 20240228 0000926326-24-000008.hdr.sgml : 20240228 20240228171813 ACCESSION NUMBER: 0000926326-24-000008 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 126 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OMNICELL, INC. CENTRAL INDEX KEY: 0000926326 STANDARD INDUSTRIAL CLASSIFICATION: ELECTRONIC COMPUTERS [3571] ORGANIZATION NAME: 06 Technology IRS NUMBER: 943166458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33043 FILM NUMBER: 24696981 BUSINESS ADDRESS: STREET 1: 4220 NORTH FREEWAY CITY: FORT WORTH STATE: TX ZIP: 76137 BUSINESS PHONE: 8774159990 MAIL ADDRESS: STREET 1: 4220 NORTH FREEWAY CITY: FORT WORTH STATE: TX ZIP: 76137 FORMER COMPANY: FORMER CONFORMED NAME: OMNICELL, Inc DATE OF NAME CHANGE: 20070412 FORMER COMPANY: FORMER CONFORMED NAME: OMNICELL INC /CA/ DATE OF NAME CHANGE: 20010625 FORMER COMPANY: FORMER CONFORMED NAME: OMNICELL COM /CA/ DATE OF NAME CHANGE: 20000419 10-K 1 omcl-20231231.htm 10-K omcl-20231231
FYFALSE20230000926326http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006MemberP1YP1Yhttp://fasb.org/us-gaap/2023#OtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent0.0102751http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTaxP1Y325252500009263262023-01-012023-12-3100009263262023-06-30iso4217:USD00009263262024-02-21xbrli:shares00009263262023-10-012023-12-3100009263262023-12-3100009263262022-12-31iso4217:USDxbrli:shares0000926326us-gaap:ProductMember2023-01-012023-12-310000926326us-gaap:ProductMember2022-01-012022-12-310000926326us-gaap:ProductMember2021-01-012021-12-310000926326us-gaap:ServiceMember2023-01-012023-12-310000926326us-gaap:ServiceMember2022-01-012022-12-310000926326us-gaap:ServiceMember2021-01-012021-12-3100009263262022-01-012022-12-3100009263262021-01-012021-12-310000926326us-gaap:CommonStockMember2020-12-310000926326us-gaap:TreasuryStockCommonMember2020-12-310000926326us-gaap:AdditionalPaidInCapitalMember2020-12-310000926326us-gaap:RetainedEarningsMember2020-12-310000926326us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100009263262020-12-310000926326us-gaap:RetainedEarningsMember2021-01-012021-12-310000926326us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000926326us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000926326us-gaap:CommonStockMember2021-01-012021-12-310000926326us-gaap:CommonStockMember2021-12-310000926326us-gaap:TreasuryStockCommonMember2021-12-310000926326us-gaap:AdditionalPaidInCapitalMember2021-12-310000926326us-gaap:RetainedEarningsMember2021-12-310000926326us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100009263262021-12-310000926326us-gaap:RetainedEarningsMember2022-01-012022-12-310000926326us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000926326us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000926326us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000926326us-gaap:CommonStockMember2022-01-012022-12-310000926326us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310000926326us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310000926326srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310000926326us-gaap:CommonStockMember2022-12-310000926326us-gaap:TreasuryStockCommonMember2022-12-310000926326us-gaap:AdditionalPaidInCapitalMember2022-12-310000926326us-gaap:RetainedEarningsMember2022-12-310000926326us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000926326us-gaap:RetainedEarningsMember2023-01-012023-12-310000926326us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000926326us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000926326us-gaap:CommonStockMember2023-01-012023-12-310000926326us-gaap:CommonStockMember2023-12-310000926326us-gaap:TreasuryStockCommonMember2023-12-310000926326us-gaap:AdditionalPaidInCapitalMember2023-12-310000926326us-gaap:RetainedEarningsMember2023-12-310000926326us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31omcl:segment00009263262024-01-012023-12-310000926326omcl:TenLargestGroupPurchasingOrganizationsGPOsMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-31xbrli:pure0000926326srt:MinimumMember2023-01-012023-12-310000926326srt:MaximumMember2023-01-012023-12-310000926326srt:MinimumMember2023-12-310000926326srt:MaximumMember2023-12-310000926326omcl:PrimarySupplierMember2023-12-310000926326omcl:PrimarySupplierMember2023-01-012023-12-310000926326omcl:PrimarySupplierMember2022-01-012022-12-310000926326omcl:PrimarySupplierMember2021-01-012021-12-310000926326us-gaap:ShippingAndHandlingMember2023-01-012023-12-310000926326us-gaap:ShippingAndHandlingMember2022-01-012022-12-310000926326us-gaap:ShippingAndHandlingMember2021-01-012021-12-310000926326omcl:InternalUseSoftwareandSoftwareDevelopmentCostsMemberus-gaap:PropertyPlantAndEquipmentMember2023-01-012023-12-310000926326omcl:InternalUseSoftwareandSoftwareDevelopmentCostsMemberus-gaap:PropertyPlantAndEquipmentMember2022-01-012022-12-310000926326srt:MinimumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310000926326srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310000926326srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2023-12-310000926326srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2023-12-310000926326srt:MinimumMemberus-gaap:EquipmentMember2023-12-310000926326srt:MaximumMemberus-gaap:EquipmentMember2023-12-310000926326us-gaap:OtherAssetsMember2023-01-012023-12-310000926326us-gaap:OtherAssetsMember2022-01-012022-12-31omcl:reporting_unit0000926326omcl:HubAndSpokeInnovationsLimitedMember2022-01-102022-01-10iso4217:GBP0000926326omcl:HubAndSpokeInnovationsLimitedMember2022-01-100000926326omcl:MarkeTouchMediaLLCMember2021-12-312021-12-310000926326omcl:ReCeptHoldingsIncMember2021-12-292021-12-290000926326omcl:FDSAmplicareMember2021-09-092021-09-090000926326omcl:FDSAmplicareMember2021-01-012021-12-310000926326omcl:FDSAmplicareMember2021-09-090000926326omcl:ReCeptHoldingsIncMember2021-12-290000926326omcl:MarkeTouchMediaLLCMember2021-12-310000926326omcl:FDSAmplicareMemberus-gaap:CustomerRelationshipsMember2021-01-012021-12-310000926326omcl:FDSAmplicareMember2022-01-012022-12-310000926326omcl:ReCeptHoldingsIncMember2022-01-012022-12-310000926326omcl:MarkeTouchMediaLLCMember2022-01-012022-12-310000926326omcl:FDSAmplicareMemberus-gaap:CustomerRelationshipsMember2021-09-092021-09-090000926326omcl:ReCeptHoldingsIncMemberus-gaap:CustomerRelationshipsMember2021-12-292021-12-290000926326omcl:MarkeTouchMediaLLCMemberus-gaap:CustomerRelationshipsMember2021-12-312021-12-310000926326omcl:FDSAmplicareMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-09-092021-09-090000926326srt:MinimumMemberomcl:FDSAmplicareMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-09-092021-09-090000926326srt:MaximumMemberomcl:FDSAmplicareMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-09-092021-09-090000926326omcl:ReCeptHoldingsIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-12-292021-12-290000926326omcl:MarkeTouchMediaLLCMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-12-312021-12-310000926326us-gaap:OrderOrProductionBacklogMemberomcl:FDSAmplicareMember2021-09-092021-09-090000926326omcl:ReCeptHoldingsIncMemberus-gaap:OrderOrProductionBacklogMember2021-12-292021-12-290000926326omcl:MarkeTouchMediaLLCMemberus-gaap:OrderOrProductionBacklogMember2021-12-312021-12-310000926326us-gaap:TradeNamesMemberomcl:FDSAmplicareMember2021-09-092021-09-090000926326omcl:ReCeptHoldingsIncMemberus-gaap:TradeNamesMember2021-12-292021-12-290000926326omcl:MarkeTouchMediaLLCMemberus-gaap:TradeNamesMember2021-12-312021-12-310000926326omcl:MeasurementInputRoyaltyRateMemberomcl:FDSAmplicareMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-09-090000926326omcl:MarkeTouchMediaLLCMemberomcl:MeasurementInputRoyaltyRateMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310000926326omcl:MeasurementInputRoyaltyRateMemberus-gaap:TradeNamesMemberomcl:FDSAmplicareMember2021-09-090000926326us-gaap:MeasurementInputDiscountRateMemberomcl:FDSAmplicareMember2021-09-090000926326omcl:ReCeptHoldingsIncMemberus-gaap:MeasurementInputDiscountRateMember2021-12-290000926326omcl:MarkeTouchMediaLLCMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310000926326omcl:ConnectedDevicesSoftwareLicensesAndOtherMember2023-01-012023-12-310000926326omcl:ConnectedDevicesSoftwareLicensesAndOtherMember2022-01-012022-12-310000926326omcl:ConnectedDevicesSoftwareLicensesAndOtherMember2021-01-012021-12-310000926326omcl:ConsumablesMember2023-01-012023-12-310000926326omcl:ConsumablesMember2022-01-012022-12-310000926326omcl:ConsumablesMember2021-01-012021-12-310000926326omcl:TechnicalServicesMember2023-01-012023-12-310000926326omcl:TechnicalServicesMember2022-01-012022-12-310000926326omcl:TechnicalServicesMember2021-01-012021-12-310000926326omcl:AdvancedServicesMember2023-01-012023-12-310000926326omcl:AdvancedServicesMember2022-01-012022-12-310000926326omcl:AdvancedServicesMember2021-01-012021-12-310000926326country:US2023-01-012023-12-310000926326country:US2022-01-012022-12-310000926326country:US2021-01-012021-12-310000926326us-gaap:NonUsMember2023-01-012023-12-310000926326us-gaap:NonUsMember2022-01-012022-12-310000926326us-gaap:NonUsMember2021-01-012021-12-310000926326us-gaap:StockCompensationPlanMember2023-01-012023-12-310000926326us-gaap:StockCompensationPlanMember2022-01-012022-12-310000926326us-gaap:StockCompensationPlanMember2021-01-012021-12-310000926326us-gaap:ConvertibleDebtSecuritiesMember2023-01-012023-12-310000926326us-gaap:ConvertibleDebtSecuritiesMember2022-01-012022-12-310000926326us-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-12-310000926326us-gaap:WarrantMember2023-01-012023-12-310000926326us-gaap:WarrantMember2022-01-012022-12-310000926326us-gaap:WarrantMember2021-01-012021-12-310000926326omcl:ConvertibleDebtSecuritiesAndWarrantsMember2023-01-012023-12-310000926326omcl:ConvertibleDebtSecuritiesAndWarrantsMember2022-01-012022-12-310000926326omcl:ConvertibleDebtSecuritiesAndWarrantsMember2021-01-012021-12-310000926326us-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2023-12-310000926326us-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2022-12-310000926326us-gaap:EquipmentMember2023-12-310000926326us-gaap:EquipmentMember2022-12-310000926326us-gaap:FurnitureAndFixturesMember2023-12-310000926326us-gaap:FurnitureAndFixturesMember2022-12-310000926326us-gaap:LeaseholdImprovementsMember2023-12-310000926326us-gaap:LeaseholdImprovementsMember2022-12-310000926326us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310000926326us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-12-310000926326us-gaap:ConstructionInProgressMember2023-12-310000926326us-gaap:ConstructionInProgressMember2022-12-310000926326country:US2023-12-310000926326country:US2022-12-310000926326us-gaap:NonUsMember2023-12-310000926326us-gaap:NonUsMember2022-12-310000926326us-gaap:CustomerRelationshipsMember2023-12-310000926326us-gaap:CustomerRelationshipsMember2023-01-012023-12-310000926326srt:MinimumMemberus-gaap:CustomerRelationshipsMember2023-12-310000926326srt:MaximumMemberus-gaap:CustomerRelationshipsMember2023-12-310000926326us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000926326us-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310000926326srt:MinimumMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000926326srt:MaximumMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000926326us-gaap:OrderOrProductionBacklogMember2023-12-310000926326us-gaap:OrderOrProductionBacklogMember2023-01-012023-12-310000926326us-gaap:TradeNamesMember2023-12-310000926326us-gaap:TradeNamesMember2023-01-012023-12-310000926326srt:MinimumMemberus-gaap:TradeNamesMember2023-12-310000926326srt:MaximumMemberus-gaap:TradeNamesMember2023-12-310000926326us-gaap:PatentsMember2023-12-310000926326us-gaap:PatentsMember2023-01-012023-12-310000926326srt:MinimumMemberus-gaap:PatentsMember2023-12-310000926326srt:MaximumMemberus-gaap:PatentsMember2023-12-310000926326us-gaap:CustomerRelationshipsMember2022-12-310000926326us-gaap:CustomerRelationshipsMember2022-01-012022-12-310000926326srt:MinimumMemberus-gaap:CustomerRelationshipsMember2022-12-310000926326srt:MaximumMemberus-gaap:CustomerRelationshipsMember2022-12-310000926326us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000926326us-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-12-310000926326srt:MinimumMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000926326srt:MaximumMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000926326us-gaap:OrderOrProductionBacklogMember2022-12-310000926326us-gaap:OrderOrProductionBacklogMember2022-01-012022-12-310000926326us-gaap:TradeNamesMember2022-12-310000926326us-gaap:TradeNamesMember2022-01-012022-12-310000926326srt:MinimumMemberus-gaap:TradeNamesMember2022-12-310000926326srt:MaximumMemberus-gaap:TradeNamesMember2022-12-310000926326us-gaap:PatentsMember2022-12-310000926326us-gaap:PatentsMember2022-01-012022-12-310000926326srt:MinimumMemberus-gaap:PatentsMember2022-12-310000926326srt:MaximumMemberus-gaap:PatentsMember2022-12-310000926326us-gaap:NoncompeteAgreementsMember2022-12-310000926326us-gaap:NoncompeteAgreementsMember2022-01-012022-12-310000926326omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-11-152019-11-150000926326omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-11-150000926326omcl:IncrementalLoanFacilityMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:LineOfCreditMember2019-11-150000926326omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2019-11-150000926326us-gaap:BridgeLoanMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:LineOfCreditMember2019-11-150000926326omcl:DebtInstrumentCovenantPeriod1Memberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-09-220000926326omcl:DebtInstrumentCovenantPeriod2Memberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-09-220000926326srt:MinimumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberomcl:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-03-292023-03-290000926326srt:MaximumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberomcl:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-03-292023-03-290000926326omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:FederalFundsEffectiveSwapRateMemberus-gaap:LineOfCreditMember2023-03-292023-03-290000926326omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberomcl:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-03-292023-03-290000926326srt:MinimumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberomcl:SecuredOvernightFinancingRateSOFRPlus100Memberus-gaap:LineOfCreditMember2023-03-292023-03-290000926326srt:MaximumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberomcl:SecuredOvernightFinancingRateSOFRPlus100Memberus-gaap:LineOfCreditMember2023-03-292023-03-290000926326srt:MinimumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:LineOfCreditMember2023-03-292023-03-290000926326srt:MaximumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:LineOfCreditMember2023-03-292023-03-290000926326omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-10-102023-10-100000926326omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-10-100000926326omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2023-10-100000926326omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMemberus-gaap:BridgeLoanMemberus-gaap:LineOfCreditMember2023-10-100000926326srt:MinimumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberomcl:SecuredOvernightFinancingRateSOFRApplicableMarginMemberus-gaap:LineOfCreditMember2023-10-102023-10-100000926326srt:MaximumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberomcl:SecuredOvernightFinancingRateSOFRApplicableMarginMemberus-gaap:LineOfCreditMember2023-10-102023-10-100000926326omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:FederalFundsEffectiveSwapRateMemberus-gaap:LineOfCreditMember2023-10-102023-10-100000926326omcl:OneMonthSecuredOvernightFinancingRateSOFRMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:LineOfCreditMember2023-10-102023-10-100000926326srt:MinimumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberomcl:OneMonthSecuredOvernightFinancingRateSOFRApplicableMarginMemberus-gaap:LineOfCreditMember2023-10-102023-10-100000926326srt:MaximumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberomcl:OneMonthSecuredOvernightFinancingRateSOFRApplicableMarginMemberus-gaap:LineOfCreditMember2023-10-102023-10-100000926326srt:MinimumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:LineOfCreditMember2023-10-102023-10-100000926326srt:MaximumMemberomcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:LineOfCreditMember2023-10-102023-10-100000926326omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMemberus-gaap:LineOfCreditMember2023-10-100000926326us-gaap:LineOfCreditMember2023-10-100000926326omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310000926326omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310000926326us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310000926326us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310000926326us-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2020-09-2500009263262020-09-252020-09-250000926326us-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2020-09-252020-09-250000926326us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2020-09-252020-09-25omcl:day0000926326us-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2020-09-252020-09-250000926326omcl:ConvertibleSeniorNotesMember2021-12-132021-12-130000926326us-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2021-12-130000926326us-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2023-01-012023-12-310000926326us-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2022-01-012022-12-310000926326us-gaap:ConvertibleDebtMemberomcl:ConvertibleSeniorNotesMember2021-01-012021-12-310000926326omcl:ConvertibleNoteHedgeRightsMember2020-09-250000926326us-gaap:StockOptionMember2020-09-250000926326us-gaap:WarrantMember2020-09-250000926326us-gaap:CostOfSalesMember2022-01-012022-12-310000926326us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000926326us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000926326us-gaap:EmployeeStockMember2023-12-310000926326us-gaap:EmployeeStockMember2023-01-012023-12-310000926326omcl:A2009PlanMember2023-12-310000926326us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000926326us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:EmployeeStockOptionMember2023-01-012023-12-310000926326us-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:EmployeeStockOptionMember2023-01-012023-12-310000926326us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310000926326us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-01-012023-12-310000926326us-gaap:CostOfSalesMember2023-01-012023-12-310000926326us-gaap:CostOfSalesMember2021-01-012021-12-310000926326us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310000926326us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310000926326us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310000926326us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310000926326srt:MinimumMemberus-gaap:EmployeeStockMember2023-01-012023-12-310000926326srt:MaximumMemberus-gaap:EmployeeStockMember2023-01-012023-12-310000926326srt:MinimumMemberus-gaap:EmployeeStockMember2022-01-012022-12-310000926326srt:MaximumMemberus-gaap:EmployeeStockMember2022-01-012022-12-310000926326srt:MinimumMemberus-gaap:EmployeeStockMember2021-01-012021-12-310000926326srt:MaximumMemberus-gaap:EmployeeStockMember2021-01-012021-12-310000926326us-gaap:EmployeeStockMember2022-01-012022-12-310000926326us-gaap:EmployeeStockMember2021-01-012021-12-310000926326us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000926326us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000926326us-gaap:EmployeeStockOptionMember2023-12-310000926326us-gaap:RestrictedStockUnitsRSUMember2022-12-310000926326us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000926326us-gaap:RestrictedStockUnitsRSUMember2023-12-310000926326us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310000926326us-gaap:RestrictedStockMember2022-12-310000926326us-gaap:RestrictedStockMember2023-01-012023-12-310000926326us-gaap:RestrictedStockMember2023-12-310000926326us-gaap:RestrictedStockMember2022-01-012022-12-310000926326us-gaap:RestrictedStockMember2021-01-012021-12-310000926326srt:OfficerMemberus-gaap:PerformanceSharesMember2022-01-012022-12-310000926326srt:OfficerMemberus-gaap:PerformanceSharesMember2023-01-012023-12-310000926326srt:MinimumMemberus-gaap:PerformanceSharesMember2023-01-012023-12-310000926326srt:MaximumMemberus-gaap:PerformanceSharesMember2023-01-012023-12-310000926326us-gaap:PerformanceSharesMember2023-01-012023-12-310000926326us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:PerformanceSharesMember2023-01-012023-12-310000926326us-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:PerformanceSharesMember2023-01-012023-12-310000926326us-gaap:PerformanceSharesMember2022-12-310000926326us-gaap:PerformanceSharesMember2023-12-310000926326us-gaap:PerformanceSharesMember2022-01-012022-12-310000926326us-gaap:PerformanceSharesMember2021-01-012021-12-310000926326omcl:RestrictedStockRSAsRestrictedStockUnitsRSUsAndPreformanceSharesPSUsMember2023-12-310000926326omcl:FutureGrantsAndAwardsMember2023-12-310000926326us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberomcl:OmnicellPlanMember2023-01-012023-12-310000926326us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberomcl:OmnicellPlanMember2022-01-012022-12-310000926326us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberomcl:OmnicellPlanMember2021-01-012021-12-310000926326us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-01-012023-12-310000926326omcl:A2016RepurchaseProgramMember2016-08-020000926326omcl:A2014ShareRepurchaseProgramMember2014-11-040000926326omcl:A2016and2014ShareRepurchaseProgramsMember2023-12-310000926326omcl:A2016and2014ShareRepurchaseProgramsMember2022-01-012022-12-310000926326us-gaap:DomesticCountryMember2023-12-310000926326us-gaap:StateAndLocalJurisdictionMember2023-12-310000926326us-gaap:ForeignCountryMember2023-12-310000926326us-gaap:DomesticCountryMemberus-gaap:ResearchMember2023-12-310000926326us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2023-12-3100009263262021-01-012021-03-310000926326omcl:AccountsReceivableAndUnbilledReceivablesMember2020-12-310000926326omcl:AccountsReceivableAndUnbilledReceivablesMember2021-01-012021-12-310000926326omcl:AccountsReceivableAndUnbilledReceivablesMember2021-12-310000926326omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember2020-12-310000926326omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember2021-01-012021-12-310000926326omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember2021-12-310000926326omcl:NetInvestmentInSalesTypeLeasesMember2020-12-310000926326omcl:NetInvestmentInSalesTypeLeasesMember2021-01-012021-12-310000926326omcl:NetInvestmentInSalesTypeLeasesMember2021-12-310000926326omcl:AccountsReceivableAndUnbilledReceivablesMember2022-01-012022-12-310000926326omcl:AccountsReceivableAndUnbilledReceivablesMember2022-12-310000926326omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember2022-01-012022-12-310000926326omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember2022-12-310000926326omcl:NetInvestmentInSalesTypeLeasesMember2022-01-012022-12-310000926326omcl:NetInvestmentInSalesTypeLeasesMember2022-12-310000926326omcl:AccountsReceivableAndUnbilledReceivablesMember2023-01-012023-12-310000926326omcl:AccountsReceivableAndUnbilledReceivablesMember2023-12-310000926326omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember2023-01-012023-12-310000926326omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember2023-12-310000926326omcl:NetInvestmentInSalesTypeLeasesMember2023-01-012023-12-310000926326omcl:NetInvestmentInSalesTypeLeasesMember2023-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________
FORM 10-K
(Mark One)
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to
Commission File No. 000-33043
OMNICELL, INC.
(Exact name of registrant as specified in its charter)
Delaware94-3166458
(State or other jurisdiction of
incorporation or organization)		(IRS Employer
Identification No.)
4220 North Freeway
Fort Worth, TX 76137
(Address of registrant’s principal executive offices, including zip code)

(877) 415-9990
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.001 par valueOMCLNASDAQ Global Select Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ý    No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o    No ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý    No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
ý
Accelerated filer
¨
Non-accelerated filer
¨
Smaller reporting company
¨
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ý

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. o
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o    No ý
The aggregate market value of the registrant’s common stock, $0.001 par value, held by non-affiliates of the registrant as of June 30, 2023 was $3.3 billion (based upon the closing sales price of such stock as reported on the NASDAQ Global Select Market on such date) which excludes an aggregate of 639,650 shares of the registrant’s common stock held by officers, directors and affiliated stockholders. For purposes of determining whether a stockholder was an affiliate of the registrant at June 30, 2023, the registrant has assumed that a stockholder was an affiliate of the registrant at June 30, 2023 if such stockholder (i) beneficially owned 10% or more of the registrant’s common stock and/or (ii) was affiliated with an executive officer or director of the registrant at June 30, 2023. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.
As of February 21, 2024, there were 45,915,296 shares of the registrant’s common stock, $0.001 par value, outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the United States Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference in Part III, Items 10-14 of this Form 10-K.


OMNICELL, INC.
TABLE OF CONTENTS
Page
OTHER

3
FORWARD-LOOKING STATEMENTS AND FACTORS THAT MAY AFFECT FUTURE RESULTS
This Annual Report on Form 10-K (or “Annual Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements are contained throughout this Annual Report including in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include, but are not limited to, statements about:
•our expectations regarding our future sales pipeline and bookings;
•the extent and timing of future revenues, including the amounts of our current backlog;
•the size or growth of our market or market share;
•our beliefs about drivers of demand for our products, services, and solutions, opportunities in certain market categories, and continued expansion in these market categories, as well as our belief that our technology, services, and solutions within these market categories position us well to address the needs of retail, acute, post-acute, and specialty pharmacy providers;
•continued investment in the industry vision of the Autonomous Pharmacy, our beliefs about the anticipated benefits of such investments, and our expectations regarding continued growth in current and future subscription and cloud-based offerings as we execute on this vision;
•our goal of advancing our platform with the development of new products, services, or solutions or the enhancement of existing products, services, or solutions;
•growth opportunities presented by new products, services, solutions, and markets;
•our projected target revenues, operating costs, and cash flows;
•our ability to align our medication management infrastructure development and global workforce headcount with our current business expectations;
•our goal to deliver on the industry vision of the Autonomous Pharmacy, as well as our plan to migrate our customers from an on-premise infrastructure to our cloud-based platform;
•our belief that our solutions that support the industry vision of the Autonomous Pharmacy, are strongly aligned with trends in the healthcare market, and are well-positioned to address the evolving needs of healthcare institutions;
•our expectation to continue to acquire companies, businesses, products, services, or technologies and to effectively integrate or manage these acquired companies, businesses, products, services, or technologies;
•our ability to secure adequate supplies of raw materials and components utilized in the manufacture of our products of a quality that we require, on a timely basis, and at acceptable prices;
•our containment of the impacts of the ransomware incident we experienced in May 2022, and any further impacts on the Company, including its business, operating results, cash flow, or financial condition;
•our expected future uses of cash and the sufficiency of our sources of funding; and
•our ability to generate cash from operations and our estimates regarding the sufficiency of our cash resources.
In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goals,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “target,” “will,” “would,” and variations of these terms and similar expressions.
Forward-looking statements are based on our current expectations and assumptions, and are subject to known and unknown risks and uncertainties, many of which are beyond our control, which may cause our actual results, performance, or achievements to be materially different from those expressed or implied in the forward-looking statements. Such risks and uncertainties include those described throughout this Annual Report, including in Part I - Item 1A. “Risk Factors” and Part II - Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements should be considered in light of these risks and uncertainties. You should carefully read this Annual Report and the documents
4
that we reference in this Annual Report and have filed as exhibits, as well as other documents we file with, or furnish to, the U.S. Securities and Exchange Commission (“SEC”) from time to time, with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this Annual Report represent our current estimates and assumptions and speak only as of the date of this Annual Report. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, future events, even if new information becomes available in the future, or otherwise.
Other Information
All references in this Annual Report to “Omnicell,” “our,” “us,” “we,” or “the Company” collectively refer to Omnicell, Inc., a Delaware corporation, and its subsidiaries. The term “Omnicell, Inc.” refers only to Omnicell, Inc., excluding its subsidiaries.
We own various registered and unregistered trademarks and service marks used in our business, some of which appear in this Annual Report, including Omnicell®. This Annual Report may also include the trademarks and service marks of other companies. Such trademarks and service marks are the marks of their respective owners.
Information posted on or accessible through websites referenced in this Annual Report is not incorporated by reference or otherwise included in this Annual Report, and any references to these websites are intended to be inactive textual references only.
5
PART I
ITEM 1.    BUSINESS
Overview
Omnicell, a leader in transforming the pharmacy care delivery model, is committed to solving the critical challenges inherent in medication management and elevating the role of clinicians within healthcare as an essential component of care delivery. Omnicell is focused on helping its customers to define and deliver a cost effective medication management strategy that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. We are doing this with an industry-leading medication management infrastructure which includes robotics, smart devices, intelligent software, and expert services. This comprehensive set of solutions provides the critical foundation for customers to realize the industry vision of the Autonomous Pharmacy, a vision defined by pharmacy leaders for improving operational efficiencies and ultimately targeting zero-error medication management.
Business Strategy
The U.S. spent a total of $634 billion on prescription drugs in 2022, an increase of 9% compared to 2021, and prescription drugs impact the vast majority of patients in virtually all settings of care. We believe there are significant challenges facing the practice of pharmacy today including, but not limited to, budget constraints, increased healthcare worker turnover rates, labor shortages, drug shortages, drug diversion, manual and error-prone processes, complex compliance requirements, and limited inventory visibility. Each of these challenges may lead to poor medication management outcomes including, but not limited to, medication errors, adverse drug events, lack of patient adherence, and medication waste. We also recognize that these challenges may impact the timing of contracting for, or implementing, our products, solutions, or services. However, we believe that over time these significant challenges to the practice of pharmacy will drive demand for increased automation, visibility, insights, and improved medication management outcomes that our solutions are designed to enable. Because of this, we believe that our solutions are well-positioned to address the evolving needs of healthcare institutions and therefore present opportunities for long-term growth.
In an effort to address these challenges and deliver solutions to help drive positive medication management outcomes, we continue to make significant investments in our research and development efforts to further advance the industry vision of the Autonomous Pharmacy. Furthermore, we believe a combination of robotics, smart devices, intelligent software, and expert services is needed in every care setting where medications are managed. We are focused on delivering solutions to help our customers realize the industry vision of the Autonomous Pharmacy and drive positive medication management outcomes with outstanding customer experience through a mature channel in four market categories:
•Point of Care. As a market leader, we expect to continue expansion into this product market as customers increase the use of our dispensing systems in more areas within their hospitals and increasingly in ambulatory care settings. However, we recognize that the current macroeconomic environment, with significant labor constraints, may impact our customers’ considerations in the near term when they are determining whether to implement new workflows that may affect those same stressed labor pools. As we are largely through the replacement cycle of our previous generation of automated dispensing systems, we are seeing demand moderate. We continue to invest in next-generation point of care enhancements and solutions and believe that customers will upgrade their current installed base over time as we deliver these new solutions to market. We also believe there is an opportunity for us to expand this offering and define a new standard for dispensing systems in ambulatory settings. We believe our current solutions within the Point of Care market and new innovation and services will continue to help customers drive improved clinical and financial outcomes.
•Central Pharmacy and IV Compounding. This market represents the beginning of the medication management process in acute care settings, and we believe it is a significant automation opportunity for high volumes of manual, repetitive, and error-prone processes that are often common in pharmacies today. Manual medication dispensing processes are usually labor intensive, error-prone, and may lead to excess medication waste and expirations for our healthcare partners. Automating the central pharmacy dispensing process should enable customers to reallocate pharmacy labor, enhance dispensing accuracy and patient safety, and reduce medication waste and expirations. Likewise, the manual compounding of sterile IV preparations can be error-prone and create significant patient safety risks, and outsourcing sterile IV compounding could lead to increased medication costs and lack of access to needed medications as a result of being unable to source medications when they are required. As a result, we believe IV automation provides a significant opportunity to enhance patient safety and reduce costs. We anticipate that these technology-enabled services will become more critical as health systems continue to face labor shortages, increased financial pressure, and supply chain disruptions.
6
•Specialty Pharmacy and 340B Program. We believe that health systems will continue to invest in programs that are intended to improve patient outcomes and drive cost savings by utilizing specialty pharmacies and the federal 340B Drug Pricing Program (the “340B Program”). The 340B Program allows qualifying hospitals and health systems to stretch federal resources and expand patient access to healthcare by requiring manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to eligible healthcare organizations and covered entities. Specialty drugs are used for treatment of complex conditions and often require intensive patient management and specialized workflows for dispensing and care coordination. Specialty medications are projected to account for nearly 60% of U.S. total spending on medications, with total spending projected to be approximately $420 billion in 2025. Specialty pharmacies serve as the connection between patients, prescribing physicians, and payers and work to streamline access and adherence to these specialty drugs. We believe a solution that is designed to help health systems start or optimize their specialty pharmacy programs and the related pharmaceutical aspects of patient care will help ensure continuity of care and should contribute to the revenue and profitability of those organizations. We believe that a fully optimized specialty pharmacy operation represents one of the largest economic opportunities for hospitals and health systems.
•Retail, Institutional, and Payer. We believe the Retail, Institutional, and Payer market represents a significant opportunity as healthcare evolves. Retail drug prescriptions represent 85% of all prescription drugs dispensed in the U.S., growing at a rate of 1.7% annually through 2022. Additionally, the COVID-19 pandemic accelerated the shift of outpatient care from hospitals and physician offices to other, more convenient settings, such as retail pharmacies and the home (including through telehealth technologies). New technologies and increased scope of practice for pharmacists appear to be spurring innovation and expansion of the provision of clinical services by retail pharmacies, which, combined with the move to value-based care, we believe will drive the adoption of our patient engagement solutions, that are intended to help providers (including pharmacists) and payers engage patients in new ways that are expected to improve outcomes, reduce the total cost of care, and lead to more profitable operations. Because of the complexity of relationships between payers and providers, as well as the large number of retail pharmacies, including a significant number of independent pharmacies, we believe a network of established relationships between payers, providers and pharmacies will continue to be important.
Products and Services
Our products and services span the evolving continuum of care, including inpatient, outpatient, and retail settings. We provide a range of point of care medication and supply dispensing systems, including automated systems. We also offer advanced automation solutions including robotics designed to automate work, streamline workflows, and reduce human error. Across these settings, we provide central pharmacy automation solutions for both medication dispensing and IV compounding. We also provide patient engagement solutions to help improve adherence to prescriptions. With certain automation and technology-enabled service offerings, we provide expert services designed to help optimize utilization through subscription agreements, inclusive of expert personnel to operate the equipment. Our offerings include:
Point of Care
Our point of care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. Automated dispensing systems are an essential part of medication management because they are designed to safeguard medications, including controlled substances, and provide automation to track inventory. We strive to continually innovate our automated dispensing systems by designing features that are intended to help our customers close gaps in safety and enable clinicians to spend less time managing medications and more time caring for patients.
Our XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. Our Point of Care Service combines market-leading automation with expert services in an effort to improve solution adoption and optimization, enhance data-driven performance, and drive nursing and pharmacy efficiency. For the operating room, we also offer specialized automated dispensing systems. Our interoperability solutions enable integration of our automated dispensing systems with key electronic health record systems to streamline workflow and increase accuracy.
Central Pharmacy and IV Compounding
Our Central Pharmacy Dispensing Service offers a comprehensive service that is meant to help optimize medication dispensing, which combines advanced central pharmacy robotics, dispensing optimization tools, and remote and onsite experts to operate our equipment. Our Central Pharmacy Dispensing Service is designed to assist the customer in their goals of enhanced patient safety and dispensing accuracy, reduced medication waste and expirations, and optimized pharmacy labor and workflows.
7
Our IV Compounding Service offers a comprehensive service that is intended to help optimize IV robotic compounding operations, which combines advanced IV robotics, clinical data that may be used to support extended expiration dates and reduce medication waste, and remote and onsite experts to operate the IV robotic equipment. Our IV Compounding Service is designed to assist customers in their goals of enhanced patient safety, reduced medication expense from outsourcing facilities and operating room medication waste, and improved supply chain control.
Specialty Pharmacy and 340B
Our Specialty Pharmacy Services offering includes a comprehensive set of technology, services, and expertise to provide a fully managed in-house specialty pharmacy delivered through a value-based commercial model. This solution is intended for health systems, federally qualified health centers, and provider groups to support on-site management of specialty pharmacy services, including payer contracting, staffing, assistance with licensing, 340B Program administration, and to assist with obtaining access to specialty medication and limited distribution drugs. This offering is designed to increase specialty growth and improve cost savings, improve access to limited distribution drugs, and increase physician utilization for targeted disease states.
Inventory Optimization
Our Inventory Optimization Service (formerly known as Omnicell OneTM), offers a comprehensive service that includes advanced software, robust benchmarking, predictive and prescriptive analytics, and clinical experts meant to help identify and execute on inventory optimization opportunities. Our Inventory Optimization Service is designed to provide greater medication inventory visibility as well as reduce medication waste and expirations, stockouts and shortages.
Patient Engagement, Clinical and Financial Solutions
Our EnlivenHealth brand offers a portfolio of products that are designed to digitally enable pharmacies with connected patient engagement, clinical, and financial workflows that are intended to result in an elevated patient-pharmacy experience, exceptional patient care, and enhanced financial performance.
Our patient engagement solutions are designed to better educate, inform, and enrich patients’ lives with our personalized interactive voice response, outbound communications, and mobile app offerings. We also enable digital delivery of medication information (medication guides, vaccine information sheets, and drug monographs) in an effort to unlock patient preferences, staff efficiency, and environmental value. Additionally, our clinical workflows help to enable pharmacies to accelerate health and wellness in their community through our targeted patient interventions, appointment scheduling, immunization, medication therapy management, medication synchronization, and Medicare plan comparison capabilities. Furthermore, our financial workflows are designed to streamline payments, cashflow and claims for durable medical equipment, vaccination, clinical care, and specialty drugs through our medical billing and reconciliation solutions. By leveraging these digitally enabled services, we strive to provide data-driven intelligence to optimize pharmacy operations continuously, driving operational and execution excellence, as well as patient adherence and outcomes.
We advocate for a world where pharmacy teams stand at the forefront of healthcare, seeking to empower them to practice at the top of their license, and aiding them with their commitment to patient care, collaboration, and continuous learning.
Medication Adherence
Our medication adherence solutions, which include our consumables and medication packaging systems, are used by institutional pharmacies serving long-term care and other sites outside the acute care hospital, as well as retail, community, and outpatient pharmacies, and are designed to improve pharmacy operations and patient adherence to prescriptions.
Our single-dose automation solutions allow customers to fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions. Our fully automated and semi-automated filling equipment is designed specifically for institutional pharmacies with enough order volume to warrant automated packaging of medications. Our automated solutions interface with pharmacy information systems to obtain prescription information.
For multi-medication prescriptions, we offer software that guides users through the manual filling process to help streamline workflow with a goal of increased packaging accuracy. In addition, we also offer a wide range of medication blister card packaging and packaging supplies designed to enhance medication adherence in a variety of non-acute care settings.
Professional, Technical, and Customer Success Services
As the complexity of the introduction and implementation of new innovations increases for our health system customers, we also offer Professional Services, such as technology installation, program management, customer education and
8
training, and change management services. We view our customers as partners in the pursuit of better health outcomes for patients and improved satisfaction for the clinicians who serve them. We find that every engagement is an opportunity for us to help our customers reach their clinical and business objectives while we work with our customers to accelerate the recognition of value for their initiatives.
After Omnicell solutions are implemented, our Customer Success team provides support through remote and onsite experts who help customers fully adopt and optimize utilization of our solutions.
Our technical services include post-installation technical support with phone and web-based support through our U.S.-based technical support centers, on-site service, parts, and access to software upgrades. Product support is available through fixed-period service contracts and on a time-and-materials basis. On-site service is provided by our field service team.
Retail Pharmacy and Hospital Automation Outside the United States
Additional products sold outside the United States include robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. For management of medical supplies, a specialized cabinet that uses radio frequency identification is also available, which is designed to improve the accuracy of inventory management.
Advancing Our Solutions
With more than 30 years of experience delivering medication management solutions, Omnicell believes a combination of robotics, smart devices, intelligent software, and expert services, which we refer to as Advanced Services, will help deliver improved medication management outcomes. Advanced Services include services such as Central Pharmacy Dispensing Service, IV Compounding Service, Point of Care Service, EnlivenHealth solutions, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions and licensing support. Because thousands of facilities utilize our solutions, we believe we can provide actionable insights to help customers better understand their medication usage and improve pharmacy supply chain management. We offer specialized services and analytics software designed to help healthcare facilities improve their bottom line and patient care by harnessing data from automation and other systems.
Operating Segments
We manage our operations as a single segment for the purposes of assessing performance and making operating decisions. Our Chief Operating Decision Maker (“CODM”) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Omnicell at the consolidated level using information about our revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of Omnicell as one operating segment, which is the same as our reporting segment.
Industry Background and Market
We believe our solutions support the industry vision of the Autonomous Pharmacy, are strongly aligned with trends in the healthcare market, and are well-positioned to address the evolving needs of healthcare institutions.
The healthcare industry continues to experience a significant degree of consolidation, with healthcare providers combining to create larger healthcare delivery organizations. We believe this trend has increased the market’s need for integrated medication management solutions on a single platform to help improve clinical and financial outcomes for both inpatient and outpatient settings. Our portfolio of hardware, which we may refer to as connected devices; digital workflows; analytics; and experts, combined with innovation, is designed with this objective in mind.
In addition, healthcare providers and facilities continue to be affected by significant economic and other pressures. Annual prescription drug expenditures in the United States were approximately $634 billion in 2022, according to the IQVIA National Sales Perspective database. Based on a 2020 report by the Health Care Cost Institute, the rise in prescription drug spending accounted for 49% of the total increase in annual spending per person from 2016 to 2020. In addition, the largest growth in spending for professional services—defined as payments to physicians and other clinical care team members for services provided in physician offices and hospitals—occurred among administered drugs, which accounted for the biggest share, at 76% of the total net cumulative increase in professional services spending from 2016 to 2020. Rising costs of labor, prescription drugs, and new medical technology all contribute to increased spending. Governmental pressures surrounding healthcare reform and compliance have led to increased scrutiny of the cost and efficiency with which healthcare providers deliver their services. These factors, combined with continuing consolidation in the healthcare industry, have increased the need for the efficient delivery of healthcare in order to control costs and elevated the strategic importance of medication management and pharmacy automation across the continuum of care.
9
Furthermore, while complexities in medication management have increased over time along with the volume of patients and medications, many manual processes are still used, resulting in inefficient tracking and delivery of medications and supplies and increased administrative burden on many clinical staff. According to a survey conducted by the American Society of Health-System Pharmacists in 2019, approximately 75% of pharmacist activities are non-clinical in nature. In addition, many existing healthcare information systems are unable to support the modernization of healthcare delivery processes or address mandated patient safety initiatives. These factors contribute to medical errors and unnecessary process costs across the healthcare sector including in medication management.
Regulation and industry guidelines, such as those issued by the U.S. Food and Drug Administration (“FDA”), the U.S. Drug Enforcement Administration (“DEA”), The Joint Commission (an organization that accredits U.S. health care organizations and programs), the U.S. Pharmacopeial Convention, the Institute for Safe Medication Practices, and state boards of pharmacy in the areas of medication management—including storage, security, and labeling—have created an environment of increased patient safety, awareness, and regulatory control. Against this backdrop, healthcare organizations, desiring to improve quality and avoid liability, are driven to prioritize investments in capital equipment, including pharmacy automation, which is a standard of care, to improve patient safety. While the overall storage and security of medications in hospitals have improved, there has been an increased focus on controlled substance management in recent years, particularly in light of the opioid crisis in the United States. According to a research report published by the Butler Center for Research in 2015, studies in the United States have shown that 10% to 15% of healthcare professionals misuse substances during their lifetime, with significantly higher levels of opioid abuse in particular. Joint Commission surveyors are seeking more documentation from hospitals demonstrating that their medication policies and procedures are adequate to prevent illicit use of controlled substances.
Medication non-adherence is widely recognized as a common and costly problem. Poor adherence results in increased hospital readmissions, deteriorated treatment outcomes, and avoidable healthcare costs. The estimated annual cost of prescription-drug related morbidity and mortality resulting from non-optimized medication therapy, including medication non-adherence, was $528 billion in 2016, according to a study published in the Annals of Pharmacotherapy in 2018. In addition, a 2017 study published in the Journal of the American Pharmacists Association found that medication issues are responsible for 26% of hospital readmissions. With approximately 74 million Americans taking five or more medications routinely (based on statistics published by the Center for Health Care Strategies and the U.S. Census Bureau in 2019), we believe pharmacists need ways to support the arduous task of maintaining patient compliance. Medication adherence can be improved through attitudinal and behavioral changes, which pharmacists can encourage and help facilitate by providing interventional support, including adherence tools such as blister cards, reminders, prescription synchronization, and patient engagement tools. We believe our EnlivenHealth portfolio has the potential to reduce admissions and emergency department visits and improve patient health by increasing medication adherence.
The 2022 American College of Healthcare Executives survey of hospital CEOs found that workforce challenges were their top concern, with 90% of survey respondents mentioning shortages of nurses and 83% citing shortages of technicians. As of the summer of 2022 there were more than 203,000 open registered nurse positions nationwide, more than twice the number just before the COVID-19 pandemic in January 2020, according to staffing firm Aya Healthcare. In addition, the shortage of pharmacy technicians, who are critical to clinical care in inpatient, outpatient and retail settings, is also acute. A nationwide survey conducted in May 2021 by the National Community Pharmacists Association found that nearly 90% of the survey’s 278 independent pharmacy owner/manager respondents said they couldn’t find pharmacy technicians to staff their pharmacies at an ideal capacity. In addition, a survey conducted by the American Society of Health-System Pharmacists found that vacancy rates for pharmacy technician positions averaged from 20% to 30%, and one in ten health systems surveyed reported pharmacy technician shortages of 41% or more in 2021.
Healthcare workforce labor constraints have come at a time when admissions continue to fluctuate dramatically. In addition, even apart from the impact of the COVID-19 pandemic, patient volume is projected to rebound and exceed pre-pandemic levels. A 2021 McKinsey & Co. survey of the leaders of 100 large private-sector hospitals in the United States—which was conducted several months prior to the emergence of the COVID-19 Omicron variant—concluded that on average hospitals’ inpatient admissions have returned to 2019 levels. Furthermore, according to McKinsey, in 2024 health systems are expected to look to technology to gain end-to-end process improvement to drive value for patients and for their business, selectively employing technologies to promote efficiency and patient experience.
Omnicell’s medication management infrastructure—incorporating technologies such as robotics, smart devices, intelligent software, and expert services—is designed to automate many labor-intensive medication management tasks. We believe this will help healthcare providers optimize the use of existing pharmacy staff, which is expected to free up clinicians’ time for higher-value, patient-engaging activities, such as medication therapy management, immunizations, point-of-care testing, and disease state management.
10
Government Regulation
Our global operations may be affected by complex state, federal, and international laws and regulations. These laws and regulations relate to healthcare (including medical devices and pharmaceuticals), privacy, data protection and information security, compliance, import and export, trade, healthcare fraud, waste and abuse (including anti-kickback and false claims laws), environmental standards, anti-corruption, anti-bribery, labor and employment, as well as other areas of focus.
We receive, store, and process personal information and other data from our customers, employees, and service providers. Our customers also use our products or services to obtain and store personal information, including personal health information, from their patients and customers. As a result, we or our customers are subject to various laws and regulations related to privacy, data protection, and information security. In the United States, these include federal health information privacy and security laws (such as the Health Information Portability and Accountability Act of 1996), various state and federal security breach notification laws, consumer protection laws, and state laws addressing privacy and security. Internationally, various foreign jurisdictions in which we operate, including the European Union (the “EU”), have established, or are developing, their own data privacy and security legal frameworks with which we or our customers are subject to including, for example, the UK and the EU’s General Data Protection Regulation (together, the “GDPR”). The GDPR imposes accountability and transparency requirements, data protection requirements, reporting obligations, and transfer restrictions.
Additionally, data and digital services regulation continues to expand, particularly with respect to the artificial intelligence (“AI”) and automated decision making, which may further impact our or our customer’s business and regulatory compliance strategies. For example, AI regulation or regulatory guidance continues to emerge in response to President Biden’s Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence issued on October 30, 2023. In the EU, a number of new laws related to digital data and AI have recently entered into force or have been proposed. For example, on December 8, 2023, EU legislators reached agreement on the AI Act, which imposes regulatory requirements onto AI system providers, importers, distributors, and users of AI systems, in accordance with the level of risk involved with the AI system. The UK has not adopted formal legislation to regulate AI but has adopted guidelines in the form of a White Paper.
The manufacture and sale of most of our current medication management solutions are not directly regulated by the FDA or the DEA. However, the pharmacy, dispensing, and compounding activities of other persons (our customers) that use our current medication management solutions may be subject to regulation by those agencies and by state boards of pharmacy. With respect to our products and solutions, we manufacture and develop specifications for products classified as Class I and Class II medical devices, which are subject to FDA regulation and require compliance with the FDA Quality System Regulation as well as medical device reporting. We also offer a sterile disposable product that required FDA 510(k) review and clearance prior to marketing and distribution. Products designated as medical devices are also subject to various other regulatory requirements, including as applicable, premarket clearance or approval, establishment registration and device listing, complaint handling, notification and repair, replace, refund, mandatory recalls, unique device identifier requirements, reports of removals and corrections, cybersecurity requirements, and post-marketing surveillance.
We also provide services and solutions to independent and health system specialty pharmacies that may require us to observe U.S. Department of Health and Human Services regulations for credentialing of providers (pharmacists). These services and solutions may also be subject to DEA regulations concerning the management, storing, dispensing, and disposal of, and accounting for, controlled substances.
Similarly, certain provisions of the Federal Food, Drug, and Cosmetic Act (“FDCA”) govern the approval, manufacture, handling, distribution, and tracking and tracing of pharmaceuticals. The FDCA also regulates which medications may be compounded, and how certain compounded medications may be manufactured, distributed, and dispensed. Companies engaged in distributing or dispensing compounded pharmaceuticals may be subject to a number of requirements enforced by the FDA or other regulators. These requirements may include compliance with United States Pharmacopoeia (“USP”) or National Formulary standards, certificates of analysis, facility registration, and compliance with current good manufacturing practice (“cGMP”). Furthermore, our customers may also be subject to other laws, rules, or regulations that apply to dispensers and licensing and other requirements under laws governing, and regulations promulgated by, state boards of pharmacy, including those, as applicable, that apply to compounding facilities.
In the United States, even though we do not bill Medicare, Medicaid, or other government or commercial third-party payers, our relationships with pharmacies, healthcare providers, physicians, pharmaceutical manufacturers, and third-party payers can subject us or our customers to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business. The healthcare fraud and abuse laws and regulations that may impact our or our customers’ operations include but are not limited to:
•The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback or bribe), directly or indirectly, overtly or covertly, in
11
cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, arranging for, or recommending the purchase, lease, or order of any item or service for which payment may be made, in whole or in part, under federal healthcare programs like Medicare or Medicaid. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. A conviction for violation of the federal Anti-Kickback Statute can result in criminal fines and/or imprisonment and requires mandatory exclusion from participation in federal healthcare programs. Exclusion from the federal healthcare programs may also be imposed if the government determines that an entity has committed acts that are prohibited by the federal Anti-Kickback Statute. Although there are a number of statutory exceptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological products, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor. Our or our customers’ practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability.
•The federal civil and criminal false claims laws, including the civil False Claims Act (“FCA”), which prohibits, among other things: (i) knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent; (ii) knowingly making, or using or causing to be made or used, a false record or statement material to a false or fraudulent claim; (iii) knowingly making, using or causing to made or used a false record or statement material to an obligation to pay money to the government; or (iv) knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Private individuals, commonly known as “whistleblowers,” can bring FCA qui tam actions, on behalf of the government and may share in amounts paid by the entity to the government in recovery or settlement. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Moreover, entities can be held liable under the FCA even when they do not submit claims directly to government payers if they are deemed to “cause” the submission of false or fraudulent claims. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false or fraudulent claim or statement for violations. Such per-claim penalties are currently set at $13,508 to $27,018 per false claim or statement for penalties assessed after January 30, 2023, with respect to violations occurring after November 2, 2015. Criminal penalties, including imprisonment and criminal fines, are also possible for making or presenting a false, fictitious or fraudulent claim to the federal government.
•The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which, among other things, prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, and prohibits (i) knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement or representation and (ii) making or using any false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating the HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it.
•The Federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity that engages in activities including, among others (i) knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (ii) arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; (iii) violations of the federal Anti-Kickback Statute; or (iv) failing to report and return a known overpayment.
•Analogous U.S. state and local laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers.
•Federal laws, regulations, and guidance that govern communications and marketing to Medicare enrollees and establish limits on compensation paid for lead generation activities, including the Centers for Medicare and Medicaid Services (“CMS”) Medicare Communications and Marketing Guidelines (“MCMG”).
•The 340B Program, which requires pharmaceutical manufacturers participating in Medicaid to sell covered outpatient drugs at discounted prices to specified health care organizations (called 340B covered entities), including, but not limited to: sole community hospitals, critical access hospitals, rural referral centers, and certain disproportionate share hospitals serving low-income and indigent patients. These 340B covered entities are responsible for certain statutory obligations, such as a prohibition on duplicate discounts and on diversion, and are required to have certain policies and
12
records regarding their compliance with the 340B Program. 340B covered entities may be audited with respect to their 340B Program compliance.
•The federal Stark Law (“Stark Law”), also known as the physician self-referral law, which prohibits a physician from referring Medicare patients to an entity (including pharmacies) for the furnishing of “designated health services,” if the physician or a member of the physician’s immediate family has a direct or indirect “financial relationship” with the entity, unless a specific exception applies. The law further prohibits the entity from billing for any services that arise out of such prohibited referrals. Certain of these provisions are applicable to the referral of Medicaid patients as well. Designated health services include outpatient prescription drug services. The prohibition applies regardless of the rationale for the financial relationship and the reason for ordering the service. Therefore, intent to commit an illegal act is not required in order for the government to prove that a physician has violated the Stark Law. Additionally, some states have enacted statutes and regulations similar to the Stark Law, but which may be applicable to the referral of patients regardless of their payer source and which may apply to different types of services. These state laws may contain statutory and regulatory exceptions that are different from those of the federal law and that may vary from state to state.
•The federal payment transparency tracking and reporting requirements known as the Physician Payments Sunshine Act, implemented as the Open Payments Program, which requires certain manufacturers of drugs, devices, biologics and medical supplies, among others, to report annually to CMS information related to payments and other transfers of value made by that entity to U.S.-licensed physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, certified nurse midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.
Furthermore, our operations are impacted by trade regulations in many countries that govern the import of raw materials and finished products, and we are also subject to laws and regulations that seek to prevent corruption and bribery in the marketplace (including the U.S. Foreign Corrupt Practices Act and the United Kingdom Bribery Act) as well as laws and regulations pertaining to healthcare fraud, waste, and abuse, including, as applicable, state and federal anti-kickback and false claims laws in the United States.
Since we manufacture and sell our products outside of the United States, certain products of a local nature and variations of product lines must also meet other state and local regulatory requirements. Additional risks are inherent to conducting business outside the United States, including more robust information governance and environmental regulations in the European Union, expropriation, nationalization, and other governmental actions. Demand for many of our existing and new products is, and will continue to be, affected by the extent to which local regulatory requirements increase our risk and/or expense to do business in those countries.
Compliance with the laws and regulations applicable to our global operations is costly and requires sufficient resources to actively maintain various governance, risk, and compliance systems in several areas to enable us to keep abreast of the constantly evolving legal and regulatory landscape both in the United States and abroad. These areas include, without limitation, FDCA and FDA, Controlled Substances Act and DEA regulations, state board of pharmacy regulations, and laws and regulations regarding quality, privacy, information governance and security, and environmental, health and safety. We expect that there will continue to be U.S. federal and state laws and regulations and international laws and regulations that are adopted that could impact our operations and business. Any failure to comply with these laws and regulations could result in a range of fines, penalties, damages, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and/or other sanctions.
Recent Acquisitions
In addition to our own organic development, we have, from time to time, acquired businesses and technologies that expand our product lines and are strategic fits for our business, and we expect to continue to seek to acquire businesses, technologies, or products in the future. For more information, refer to Item 7, Management’s Discussion of Analysis and Financial Condition and Results of Operations, under the heading “Acquisitions.”
Sales and Distribution
We sell our products and services primarily in the United States. Approximately 88% of our revenue was generated in this market for the year ended December 31, 2023. Our sales force is organized by geographic region in the United States and Canada, with account management executives dedicated to our customers in the top 300 U.S. health systems and health system executives focused on generating new business. Our sales in the United States and Canada are primarily made direct to end-user customers with the exception of some distribution of medication adherence consumables in parts of Canada. Outside of the
13
United States and Canada, we have direct sales employees in the United Kingdom, France, Germany, the United Arab Emirates, Belgium, and Australia. For other geographies, we generally sell through distributors and resellers. Our foreign operations are discussed in Note 3, Revenues, and Note 7, Property and Equipment, of the Notes to Consolidated Financial Statements and Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of this Annual Report on Form 10-K. Our combined direct, corporate sales support, and international distribution sales teams consisted of approximately 450 staff members as of December 31, 2023. Nearly all of our direct sales team members have hospital capital equipment, services, or clinical systems experience.
The sales cycle for our automation systems, from the initial sales meeting to completion of installation, can take in excess of 12 to 24 months. This is due in part to the cost of our systems and the number of people within each healthcare facility involved in the purchasing decision and installation process. To initiate the selling process, the sales representative generally contacts the chief financial officer, chief pharmacy officer, chief information officer, chief nursing officer, director of pharmacy, director of nursing, director of information technology, director of materials management, or other decision makers, and actively engages with each group within the healthcare facility about the economic, safety, efficiency, and compliance benefits of our solutions relative to competing methods of managing medications or medical and surgical supplies.
We contract with Group Purchasing Organizations (“GPOs”), each of which functions as a purchasing agent on behalf of member hospitals and other healthcare providers. Pursuant to the terms of GPO agreements, each member contracts directly with us and can purchase our product at pre-negotiated contract terms and pricing. These GPO contracts are typically for multiple years with options to renew or extend for up to two years and some of which can be terminated by either party at any time. Our current most significant GPO contracts include Vizient, Inc., Premier Inc., and HealthTrust Purchasing Group. We also have a Federal Supply Schedule contract with the Department of Veterans Affairs (the “GSA Contract”), allowing the Department of Veterans Affairs, the Department of Defense, and other federal government customers to purchase our products. Some of our contracts with these organizations are terminable at the convenience of either party. The accounts receivable balances are with individual members of the GPOs and federal agencies that purchase under the GSA Contract, and therefore no significant concentration of credit risk exists. During our fiscal year ended December 31, 2023, sales to members of the ten largest GPOs and federal agencies that purchase under the GSA Contract accounted for approximately 64% of our total consolidated revenues.
We offer multi-year, non-cancelable lease payment terms to assist healthcare organizations in purchasing our systems by reducing their cash flow requirements in a lease structure. We sell a portion of our multi-year lease receivables to third-party leasing finance companies.
Our clinical and technical consulting team supports our sales force by working with our customers to identify potential solutions intended to help them achieve their desired outcomes. Our Professional Services team assists customers with the technology installations of our solutions, including configuring our systems to address the specific needs of each individual customer. After the solutions are implemented, our Customer Success team provides remote and onsite experts who help our customers fully adopt and optimize utilization of our solutions in an effort to achieve their desired clinical and business outcomes.
We offer telephone and web-based technical support through our U.S.-based technical support centers. Our support centers are staffed 24 hours a day, 365 days a year. We have found that a majority of our customers’ service issues can be addressed by our support engineers either by phone or with remote diagnostic tools. In addition, our customers can enable access to allow us to remotely monitor system performance of certain products. Where applicable, this suite of support tools is designed to proactively monitor certain system status and can alert service personnel to potential problems to preempt system failure.
In addition, our international team handles direct sales, installation, and service for healthcare facilities in the United Kingdom, France, and Germany, and for non-acute customers in Australia. Sales, installation, and service to healthcare facilities is handled through distribution partners in other parts of Europe, Asia, Australia, the Middle East, South Africa, and South America. Our products are available in a variety of languages including Traditional Chinese, Simplified Chinese, Japanese, Korean, French, Swedish, Dutch, Spanish, and German.
Manufacturing and Inventory
The manufacturing process for our automation products allows us to uniquely configure hardware and software to meet a wide variety of individual customer needs. The automation product manufacturing process consists primarily of the final assembly of components and testing of the completed product. Many of the sub-assemblies and components we use are provided by third-party contract manufacturers or other suppliers. A portion of these contract manufacturers and other suppliers are based in Asia. We and our partners test these sub-assemblies and perform inspections to assure the quality and reliability of our products. While many components of our systems are standardized and available through multiple sources, certain
14
components or subsystems are fabricated by a sole supplier according to our specifications, schedules, and customer requirements, or are only available from limited sources. Our medication adherence product manufacturing process consists of fabrication and assembly of equipment and mechanized process manufacturing of consumables. We rely on a limited number of suppliers for the raw materials that are necessary in the production of our consumable medication packages.
Our arrangements with contract manufacturers generally set forth quality, cost, and delivery requirements, as well as manufacturing process terms, such as continuity of supply, inventory management, capacity flexibility, quality and cost management, oversight of manufacturing, and conditions for the use of our intellectual property.
Our manufacturing organization procures components and schedules production based on the backlog of customer orders. Installation of equipment and software typically occurs anywhere between three weeks to 12 months after the initial order is received. Larger or more complex implementations such as software-enabled connected devices for Central Pharmacy, including, but not limited to, our Central Pharmacy Dispensing Service and IV Compounding Service, are often installed between 12 and 24 months after the initial order is received. We utilize our backlog to manage our installation, procurement, and production activities to help improve inventory turns, reduce inventory scrap, and manage shipping costs. Shipment of consumables typically occurs between one and four weeks after an order is received.
Competition
The markets in which we operate are intensely competitive. We compete directly with a number of companies in the medication management automation solutions market, as well as the medication adherence solutions market, on the basis of many factors, including price, quality, customer outcome, return on investment, cost of operation, innovation, product features and capabilities, installation and service, reputation and brand recognition, size of installed base, range of services and solutions, distribution, and promotion. We expect continued and increased competition from current and future competitors in the markets in which we operate, and are affected by evolving and new technologies, changes in industry standards (including standards of care), and dynamic customer requirements.
Furthermore, the healthcare industry has experienced a significant degree of consolidation. This consolidation may require us to adapt how we market, sell, or distribute our products. Similarly, healthcare providers have consolidated to create larger healthcare delivery organizations. As market demands, government regulations, and societal pressures continue to cause the healthcare industry to evolve, it could result in further business consolidations and alliances among the industry participants with whom we engage and compete.
We believe our industry-leading medication management infrastructure products and services compare favorably with the offerings of our competitors, particularly with respect to the medication management outcomes that we have helped enable our customers to achieve across the continuum of care, from inpatient to outpatient, in each setting of care where medications are managed. We believe we have a strongly differentiated outcome-centric approach to medication management that combines robotics, smart devices, software, and expert services.
Intellectual Property and Proprietary Technology
We rely on a combination of patents, trademarks, copyright and trade secret laws, confidentiality procedures, contractual restrictions, and licensing arrangements to protect our intellectual property rights.
We pursue patent protection in the United States and foreign jurisdictions for technology that we believe to be proprietary and that may offer a potential competitive advantage for our products. Our issued patents expire on various dates between 2024 and 2041. We intend to seek and obtain additional United States and foreign patents on our technology.
Our product software is generally subject to copyright protection under applicable United States and foreign copyright laws. We have also obtained United States and certain foreign registrations of various trademarks, and we intend to seek and obtain additional registrations of our trademarks in the United States and foreign jurisdictions.
Trade secrets and other confidential information are also important to our business. We protect our trade secrets through a combination of contractual restrictions and confidentiality and licensing agreements.
Research and Development
Our research and development efforts generally begin with customer collaboration. The insight that we gain through this collaboration helps us to develop solutions to address the unmet needs and challenges faced by our customers. We continue to make significant investments in enhancing the value of our XT Series automated dispensing systems through both hardware and software upgrades. We are also making significant investments in helping our customers in the realization of the industry vision of the Autonomous Pharmacy, in particular, on our cloud-based platform and in the migration of our customers from an on-premise infrastructure to our cloud-based platform. We are also investing in the further development of technology-enabled
15
software and services including further enhancements to our Advanced Services offerings, as well as continuing to build software that is designed to enable scaling of our current service offerings. In addition, our robotic automation capabilities continue to evolve, while we work to further enhance new-to-market solutions, as well as new solutions currently in development. We have also begun work on longer-term solutions that we believe will benefit our cloud platform offerings. The results of our research and development efforts will further drive the advancement of our cloud-based offerings and accelerate the realization of the industry vision of the Autonomous Pharmacy.
Business under Government Contracts
A number of our U.S. government-owned or government-run hospital customers have signed five-year leases, with payment terms that are subject to one-year government budget funding cycles. Failure of any of our U.S. government customers to receive their annual funding could impair our ability to sell to these customers, or to collect payments on our existing unsold leases. Effective September 2021, the U.S. government mandated changes in its Federal Supply Schedule contract that resulted in our determination not to enter into future leases with U.S. government customers. Our existing leases with U.S. government customers are unaffected by this change. As such, our volume of U.S. government customer leases has declined over time and will likely cease in the future. In addition, under the terms of the Federal Supply Schedule contract, certain of our U.S. government customer contracts are terminable at the convenience of the applicable U.S. government customer. If any of our government-owned or government-run hospital customers decide to terminate their agreements early for any reason, we would not derive the expected financial benefits from any such customer. For additional information regarding these leases, see the risk factor captioned “Our U.S. government lease agreements are subject to annual budget funding cycles and mandated changes, which may affect our ability to recognize revenues and sell receivables based on such leases,” under Item 1A “Risk Factors”.
Financing Practices Relating to Working Capital
We assist healthcare facilities in financing their purchases of our systems by offering multi-year, non-cancelable lease payment terms. We typically sell the majority of the multi-year lease receivables (other than those associated with our Advanced Services, as described further below) to third-party leasing finance companies, although our ability to sell these receivables may be influenced by the perception of our customers’ ability to pay, or other restrictions, which may be influenced by factors outside of our control.
As part of our Advanced Services offering, we provide equipment and software at the inception of the contract period, which is accounted for as a multi-year sales-type lease. These agreements are generally multi-year and non-cancellable. We typically retain these lease receivables for such Advanced Services in-house and service them for the duration of the associated service term.
For additional information regarding these financing activities, refer to Note 1, Organization and Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K.
Backlog
Backlog is the dollar amount of bookings that have not yet been recognized as revenue. Bookings for those Advanced Services contracts without a minimum commitment are not included in backlog. In addition, dependent upon counterparty or credit risk, which is evaluated at the time of contract signing, for a given multi-year subscription contract we may reduce the portion of the contractual commitment booked at a given time, and these excluded amounts are not included in backlog. A majority of our connected devices and software license products are installable and recognized as revenues within twelve months of booking. Larger or more complex implementations such as software-enabled connected devices for Central Pharmacy, including, but not limited to, our Central Pharmacy Dispensing Service and IV Compounding Service, are often installed and recognized as revenue between 12 and 24 months after booking. Service revenues from Advanced Services are recorded over the contractual term. Due to industry practice that allows customers to change order configurations with limited advance notice prior to shipment and as customer installation schedules may change, backlog as of any particular date may not necessarily indicate the timing of future revenue. However, we do believe that backlog is an indication of a customer’s willingness to install our solutions and revenue we expect to generate over time. We consider backlog that is expected to be converted to revenues in more than twelve months to be long-term backlog. We believe a majority of long-term product backlog will be convertible into revenues in 12-24 months. Long-term Advanced Services backlog typically represents multi-year subscription agreements (usually with contractual terms of 2-7 years, some of which have not yet been implemented) that will be converted to revenue over the contractual term.
16
The chart below further summarizes our backlog:
December 31,
20232022
(In thousands)
Total backlog$1,142,686 $1,215,462 
By type:
Product backlog$610,832 $796,967 
Advanced Services backlog (1)
531,854 418,495 
By duration and type:
Short-term product backlog$377,936 $503,303 
Long-term product backlog232,896 293,664 
Short-term Advanced Services backlog (1)
$72,455 $49,567 
Long-term Advanced Services backlog (1)
459,399 368,928 
_________________________________________________
(1)     Includes only the value of Advanced Services non-cancelable contracts with minimum commitments.
Environmental, Social, and Governance (“ESG”) Initiatives
We view Omnicell as a purpose-driven company with a social mission: Our goal of fundamentally transforming the pharmacy care delivery model is designed to dramatically improve health outcomes and lower healthcare costs for everyone. Our teams are motivated by knowing that our work to improve medication management across the continuum of care has a tangible, real-world impact on healthcare workers, patients, and communities.
We recognize that we are accountable not only to our customers and stockholders, but also to the global community. In April 2023, we published our 2022 ESG Report, which highlights our approach to being responsible corporate citizens and describes and updates our contributions and work towards achieving a more sustainable future. We define corporate responsibility through four strategic pillars – Environmental, Social, Governance, and Innovation. We adhere to internationally-recognized Organisation for Economic Co-operation and Development guidance for the responsible sourcing of raw materials and continually work to enhance the sustainability attributes of our products and improve the sustainability of our designs. In addition, we seek to ensure access to high-quality, equitable, and integrated care for all patients worldwide. Furthermore, we are focused on elevating our diversity, equity, inclusion, and belonging initiatives at the Company, and creating a culture of inclusivity, engagement, and well-being for our employees.
There continues to be evolving and increasing expectations from regulators, customers, investors, and employees with respect to reducing and limiting greenhouse gas emissions, without a consistent framework in which to operate globally. The enhanced stakeholder focus on matters relating to ESG activities requires deliberate, conscientious efforts to effect change while the reporting frameworks are still being finalized, both in the United States and abroad. We are carefully studying ways we can contribute to realize a 1.5° Celsius future by 2030, reduce waste in our product design and manufacturing processes and develop product end-of-life solutions, as well as enhance our social and governance initiatives, taking cues from our internal and external stakeholders, internal assessments, and direction from the Corporate Governance Committee of Omnicell’s Board of Directors. As an organization, we have adopted a risk-management approach using the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) framework to assess and reduce the impact of climate change on our business strategy and operations. We continually seek to innovate and improve our business practices as we strive to build “A Better Way.”
More information on our ESG initiatives and a copy of our 2022 ESG Report are available on our corporate website, www.omnicell.com, under the “About Us―Corporate Responsibility” tab. We are not including the information contained on, or that can be accessed through, this website as part of, or incorporating it by reference into, this Annual Report on Form 10-K.
Human Capital Management
As of December 31, 2023, we had approximately 3,650 employees worldwide (with approximately 3,040 located in either the United States or Canada), excluding individuals who are classified as temporary or contractors, which is a decrease of approximately 580 employees since December 31, 2022. The decrease in employee headcount reflects the impact of restructuring initiatives the Company announced in November 2022 and November 2023.
17
We currently conduct our employee engagement survey (the “Employee Engagement Survey”) twice annually, and starting in 2024, we will move to conducting the Employee Engagement Survey once annually. We most recently completed the Employee Engagement Survey via the Glint platform in September 2023 and achieved an overall employee satisfaction score of 68, which is below the benchmark average score of similarly-sized global companies identified by Glint that use the Glint platform. While our score is below the benchmark, we believe that through our continued investment in talent, processes and acting on employee feedback we were able to increase our employee satisfaction score by three points from the score we achieved at the beginning of 2023. We believe this intra-year increase reflects improved employee relations and that Omnicell is generally viewed by our employees as a good place to work.
Compensation and Benefits
•We embrace a strong pay-for-performance total rewards philosophy that we believe is competitive, performance-based, and cost-effective. We offer market-competitive pay and a comprehensive benefits package.
•Our quarterly bonus program is designed to incentivize our employees to focus on work that will further our strategic priorities.
•We offer reward and recognition programs that embed our guiding principles into our culture and everything we do, allowing for peer-to-peer recognition and motivating our employees to continually work to advance our promise, our purpose, and our guiding principles.
•Our quarterly performance review process is designed to enable our talent to reach their optimum levels of contribution to Omnicell’s business strategies, facilitates regular employee feedback, and supports our pay-for-performance philosophy.
Health and Wellness
•We offer a comprehensive wellness program designed to promote a healthy lifestyle, including on-site gym facilities, on-site bio-metric screening, and health coaching. In addition to making physical health a priority, we offer mental health counseling and resources, financial coaching, and Teladoc Health services (i.e., telephone health services).
Employee Development
•Our Organizational Development function plays a strategic role in helping us develop and retain talent through an array of developmental experiences for employees to enable them to reach their highest level of performance and potential at Omnicell. We strive to develop career growth opportunities while delivering consistent learning and development experiences across all roles, functions, and locations. Our engagement survey scores in employee growth opportunities and career path, both landing above industry benchmarks, as measured by the Employee Engagement Survey platform, reflect our commitment to employee development.
•We invest in our employees’ learning through robust training programs via Omnicell University and leadership development curriculums, including our Guiding Principles in Action training series, Change Leadership Enablement series, New Manager Lead Program, and coaching engagements. All employees also have access to LinkedIn Learning for their “on-demand” learning needs. In 2023 we created self-paced learning journeys with an emphasis on key capabilities needed for Omnicell’s future success.
•Our approach to talent development is designed to enable our organizational transformation by aligning how we lead across all levels. Most recently, we launched The Lead Program, prioritizing early managers and new managers in our revenue-generating organizations with the intention to scale across multiple leader levels in 2024.
•We have also launched a Change Leadership Enablement curriculum to better equip our leaders as they navigate high levels of organizational change. This includes live instructor-led workshops by level, toolkits, and self-guided resources to help leaders engage their employees and teams, practice resilience, and lead our organizations into the future.
•We also launched our THRIVE Senior Leadership Talent Review and Succession Process, which facilitates dialogue to identify top and high potential talent, align aspirations, bolster our leadership pipeline through succession planning, and support readiness via individual development plans.
•In order to further develop our leaders, we launched a consistent 360 feedback methodology for all people leaders in the organization and complemented it with development planning cohorts who complete individual development planning activities with peer coaching support.
18
•In 2023, we automated Talent Management activities by implementing Oracle, a cloud-based human resources management software program, which includes Talent Profiles to capture employees’ internal mobility interests and facilitates internal job searches.
Recruiting and Retention
•We are expanding the role of our talent acquisition team into the role of talent advisor. This transformation goes beyond traditional recruitment, as we integrate ourselves deeply within the business framework. By partnering closely with different departments, we gain an in-depth understanding of their unique challenges and goals. This collaboration enhances our ability to not only align our talent acquisition strategies with Omnicell’s overarching business objectives, but also to proactively address future talent needs. Leveraging digital recruiting platforms, social media engagement, and university partnerships, we’re not just expanding our employer brand but also ensuring a talent pipeline that is both diverse and attuned to the evolving dynamics of our industry. Our commitment is to deliver strategic counsel and insights that support business leaders in making informed decisions about workforce planning and development, ultimately driving organizational growth and innovation through the power of talent.
•We implemented a new applicant tracking module to enhance recruiting efforts and better leverage the existing capital system investment. This enhancement is intended to enable faster and better decisions, save time for value-added work, improve ease of job posting, and more efficiently manage the talent acquisition experience.
Diversity, Equity, Inclusion, and Belonging (“DEIB”)
•At Omnicell, our ongoing commitment is to foster a positive, supportive, inclusive, and diverse work environment. This involves valuing each individual for their differences and recognizing the entirety of the person beyond just their work identity.
•In 2022, we developed a long-term DEIB data strategy as an integral component of our three-year plan. In 2023, we took a significant step forward by launching an internal self-identification campaign, with broadened gender options to elevate inclusivity within our organization. By anchoring our DEIB strategy in data, we anticipate gaining insights into areas for enhancement and achieving a more precise measurement of the effectiveness of our human resources processes and diversity programs.
•Our external-facing aspirational long-term DEIB strategy includes supporting vendor/supplier diversity as well as strategies aimed at ensuring our products and services are inclusive and accessible. We also believe we have a role in advocating for health equity and fair and equal access to medication and medication management support.
•In 2023, we introduced four Employee Impact Groups (“EIGs”)—based on diverse employee characteristics—Black Inclusion B.R.A.I.N., The Proud Collective (LGBTQ+), BREATHE (Mental Health & Disability Inclusion), and Women in Technology (WIT). These groups empower our employees to advocate for marginalized communities and serve as thought leaders, contributing valuable insights to shape our DEIB vision and strategy. We believe that the EIG model generates sustained momentum and, coupled with our comprehensive DEIB strategy, reflects our unwavering commitment to employee diversity, equity, and inclusion. Our EIG Advisory Council comprises Executive Sponsors for each EIG, with program support from our people organization.
Available Information
We file reports and other information with, and furnish reports and other information to, the United States Securities and Exchange Commission (“SEC”) including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and Proxy or Information Statements. Those reports and statements as well as all amendments to those documents filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available: (1) at the SEC’s Internet site (www.sec.gov) and (2) free of charge through our investor relations website, under the heading “Financials,” as soon as reasonably practicable after electronic filing with, or furnishing to, the SEC. Our website address is www.omnicell.com and our investor relations website is located at ir.omnicell.com.
19
Information About Our Executive Officers
The following table sets forth certain information about our executive officers as of the date of this Annual Report on Form 10-K:
NameAgePosition
Randall A. Lipps66President, Chief Executive Officer, and Chairman of the Board of Directors
Nchacha E. Etta53Executive Vice President and Chief Financial Officer
Corey J. Manley46Executive Vice President and Chief Legal and Administrative Officer
Randall A. Lipps was named Chief Executive Officer and President of Omnicell in October 2002. Mr. Lipps has served as Chairman of the Board and a Director of Omnicell since founding Omnicell in September 1992. Mr. Lipps received both a B.S. in economics and a B.B.A. from Southern Methodist University.
Nchacha E. Etta joined Omnicell in June 2023 as Executive Vice President and Chief Financial Officer. Prior to joining Omnicell, Mr. Etta served as Senior Vice President and Chief Financial Officer of Essilor of America, Inc., a subsidiary of EssilorLuxottica SA, a global leader in ophthalmic medical devices and products, from May 2019 to March 2022. From June 2015 to May 2019, Mr. Etta served as Worldwide Vice President and Chief Financial Officer of Johnson & Johnson Vision, an operating company of Johnson & Johnson, a global healthcare company. From February 2006 to June 2015, Mr. Etta held senior finance roles at The Coca-Cola Company, a total beverage company. Prior to The Coca-Cola Company, Mr. Etta served in financial roles of increasing responsibility at Microsoft Corporation, Eli Lilly & Company, and the Carlyle Group. He started his career with Orano Cycle (previously Cogema) in Bethesda, MD. Mr. Etta received a B.S. in accounting from George Mason University and an MBA in finance from Howard University.
Corey J. Manley joined Omnicell in April 2021 as Vice President and General Counsel. In May 2022, Mr. Manley was named Senior Vice President and Chief Legal Officer. Subsequently, in June 2023, Mr. Manley was named Executive Vice President and Chief Legal and Administrative Officer. Prior to joining Omnicell, he was Chief Legal Officer, Corporate Secretary, and Chief Compliance Officer with BFS Capital, Inc., a global fintech company, from April 2018 to April 2021. From August 2014 until April 2018, Mr. Manley was a partner in the law firm of Duane Morris LLP and prior to that he was a partner in the law firm of Kirkland & Ellis LLP from November 2009 until August 2014. Mr. Manley holds a J.D. from the University of Notre Dame Law School and a B.S. in mechanical engineering from Purdue University.
ITEM 1A.    RISK FACTORS
Summary of Risk Factors
An investment in our company involves various risks. The following is a summary of these risks, but does not address all of the risks that we face. Additional discussion of the risks that we face can be found following this summary and should be carefully considered together with all of the other information appearing in this Annual Report on Form 10-K.
Risk Factors Related to our Business and Industry
•Economic Conditions and Demand Risks. Weak or uncertain economic conditions may adversely impact our business, as well as any reduction in demand for or adoption or installation of Omnicell’s medication management solutions, medication packaging systems, or related services.
•Strategic Risks. Our investments in new business strategies or initiatives, including our transition to selling more products and services on a subscription basis, are inherently risky and may not be successful or we may be unable to maintain our Advanced Services customers. In addition, we may be unable to realize the potential benefits of our expense containment measures or our acquired businesses, including RxInnovation Inc., operating as FDS Amplicare® (“FDS Amplicare”), ReCept Holdings, Inc., (“ReCept”), which was subsequently renamed Omnicell Specialty Pharmacy Services, Inc. (“Omnicell Specialty Pharmacy Services”), MarkeTouch Media, LLC (“MarkeTouch Media”), and Hub and Spoke Innovations, and risks related to investments in new business strategies and initiatives could disrupt ongoing business and present risks not originally contemplated.
•Market Risks. We are subject to continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, including price competition, industry and competitor consolidation, competitor brand recognition, and in relationships with our suppliers and current and potential customers.
20
•Technology Risks. We may be unable to develop new solutions or enhance existing solutions to react to changes in technology and customer requirements in a timely and cost-effective manner or we may experience errors in the provision of our Advanced Services that could expose us to liability.
•Institutional, Retail, and Specialty Pharmacy Risks. We may fail to meet the demands of, or maintain relationships with, our institutional and retail pharmacy customers and we may be unable to secure or maintain access to existing and future specialty drugs.
•Debt Risks. We have substantial debt, which could impair our financial flexibility and access to capital, and are subject to covenants in our Second A&R Credit Agreement (as defined below) that restrict our business and operations.
•Legal, Regulatory, and Healthcare Industry Risks. Government regulations, legislative changes, fraud and anti-kickback statutes, product liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could adversely impact our business and operating results.
•Data Security Risks. A significant disruption in our information technology systems, breaches of data security, or cyber-attacks on our systems or solutions could adversely impact our business and operating results.
•International Operations Risks. Our operations in foreign countries expose us to additional risks, including distribution, management, and systems integration issues, reduced intellectual property protections, adverse changes in international laws, fluctuations in currency exchange rates, political unrest, foreign conflicts, and pandemics or other major public health crises.
•Workforce Risks. We may be unable to recruit and retain skilled and motivated personnel.
•Intellectual Property Risks. Any failure to protect our intellectual property rights could negatively affect our ability to compete.
•Materials Risks. We use raw materials and components that may be subject to price fluctuations, shortages, or interruptions of supply.
•Suppliers/Third-Party Vendors Risks. We may be unable to obtain an adequate supply of components, equipment, and raw materials on a timely basis. We depend on technologies provided by third-party vendors.
Risks Related to Ownership of Our Common Stock
•The market price of our common stock may be volatile and the anti-takeover provisions of Delaware law and in our governing documents may make a change in control of our Company more difficult, even if a change in control would be beneficial to our stockholders.
Risks Related to Our Notes
•Any conversion of our Notes (as defined below) may dilute the ownership interest of our stockholders, depress the price of our common stock or, if the conditional conversion feature of the Notes is triggered, adversely affect our business, operating results, cash flow, or financial condition. Also, our convertible note hedge transactions may decrease the value of our common stock.
General Risks
•We may be subject to adverse consequences related to tax rates and changes in tax legislation, and any failure to maintain effective internal control over financial reporting.
Risk Factors
We have identified the following risks and uncertainties that may have a material adverse effect on our business, operating results, cash flow, or financial condition. Our business faces significant risks and the risks described below may not be the only risks we face. Additional risks not presently known to us or that we currently believe are not material may also significantly impair our business operations. If any of these risks occur, our business, operating results, cash flow, or financial condition could suffer and the market price of our common stock could decline.
In assessing these risks, you should also refer to other information contained in this Annual Report on Form 10-K, including the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our Consolidated Financial Statements and related Notes to Consolidated Financial Statements.
21
Risk Factors Related to our Business and Industry
Unfavorable economic and market conditions and a decreased demand in the capital equipment market could adversely affect our business, operating results, cash flow, or financial condition.
Customer demand for our products is significantly linked to the strength of the economy. From time to time, the U.S. and global economy has experienced cyclical downturns impacting economic activity, the results of which include decreased demand for goods and services, reduced government spending, rising inflation, increasing interest rates, liquidity or credit constraints, declines in corporate profitability, credit, equity, or foreign exchange market volatility, increased bankruptcies, and general economic uncertainty. If decreases in demand for capital equipment caused by weak or uncertain economic conditions and decreased corporate and government spending, any effects of fiscal budget balancing at the federal level or proposed legislative changes, or generally reduced expenditures for capital solutions occur, we will experience decreased revenues and lower revenue growth rates, and our business, operating results, cash flow, or financial condition could be materially and adversely affected. In addition, within the current macroeconomic environment, we have seen some customers defer or delay implementation of capital equipment projects, including due to customer labor shortages and increased healthcare worker turnover, along with longer timeframes both for capital equipment purchasing decisions and for entering into agreements for our products or solutions due to customer capital budget constraints or customers seeking to stagger or elongate the timeframes between the adoption of new or updated technologies, which has resulted in moderated demand, and may lead to decreased revenues and could result in our business, operating results, cash flow, or financial condition being materially and adversely affected. Furthermore, the foregoing factors may also impact the willingness or ability of our customers to pay their existing obligations or honor their contractual commitments, which could result in decreased revenue and negatively impact our business, operating results, cash flow, or financial condition.
The broader U.S. and global economy has experienced elevated inflationary pressures as well as continued supply chain disruptions, labor shortages and geopolitical instability. We are unable to predict future changes in the state of the U.S. or global economy or whether inflationary pressures will continue to intensify or subside. If the current inflationary trends continue, or fail to improve, it could adversely affect our profits, margins or operating results as a result of increasing costs.
We may not realize the benefits of our expense containment efforts.
In November 2022 and November 2023, we announced restructuring initiatives through which we expect to achieve certain efficiencies. As part of these initiatives, the Company has reduced its workforce across many of its functions and is in the process of reducing its real estate footprint. The estimates of the charges and costs that the Company expects to incur and the potential benefits that the Company expects to achieve in connection with the foregoing, and the timing thereof, are subject to a number of assumptions and actual results may differ materially. In addition, the Company may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur as a result of or in connection with the implementation of these initiatives. There can be no assurance that these initiatives will achieve the expected benefits to our business as intended. The execution and implementation of these initiatives involve risk, including that significant amounts of management’s time and resources could be diverted from our core operations in order to complete such initiatives. In addition, these initiatives could fail to realize expected benefits or present unforeseen obstacles, lead to operating inefficiencies and negatively disrupt our corporate culture, which could lead to further employee attrition, any of which would have a material adverse effect on our business, operating results, cash flows and financial condition.
We may fail to develop new solutions or enhance existing solutions to react to changes in technology and customer requirements in a timely and cost-effective manner, or our new or enhanced solutions may not achieve market acceptance.
We must develop new products and services or enhance existing products to react to evolving technologies and industry standards and regulatory requirements, and meet changing demands of our customers. This process can be time-consuming, costly, and complex, and usually requires us to accurately anticipate technological innovations and market trends. Our ability to fund product development and enhancements partially depends on our ability to generate revenues from our existing products. If we inaccurately anticipate technological innovations or market trends or fail to generate sufficient revenue to develop new products, enhance existing products to meet customer needs or technological or regulatory change, or are unable to fund investment in, or achieve expected return on investment from, future product development, our ability to generate future revenues or revenue growth may be negatively impacted, which could have a material adverse effect on our business, operating results, cash flow, or financial condition.
New product and service developments or enhancements may be delayed, have technical problems (including software defects or errors), fail to meet customer or market specifications, regulatory requirements, or industry standards, which could result in increased or unexpected expenses related to further developments or modifications. In addition, they also may not be competitive with other products using new or alternative technologies that offer comparable performance and functionality, may not be accepted in new or existing markets, or may not achieve expected return on investment. Any of the foregoing could
22
make our existing and future solutions obsolete and unmarketable, or result in loss of market share or a determination to exit a particular business or product line, damage our reputation or otherwise harm our business, operating results, cash flow, or financial condition.
Our ability to execute successfully on the industry vision of the Autonomous Pharmacy depends on our ability to continue to develop and introduce new products and services or product and service enhancements, and integrate new products and services with existing offerings, in furtherance of this vision in a timely manner and on a cost-effective basis. If we fail to do so, we may be unable to achieve the industry vision of the Autonomous Pharmacy or we may not realize the anticipated benefits of our investments in support of this vision, either of which could have a material adverse effect on our business, operating results, cash flow, or financial condition.
Any reduction in the demand for or adoption of our medication management solutions, medication packaging systems, or related services would reduce our revenues.
A significant portion of domestic and international healthcare facilities still use traditional approaches to medication and/or supply management in some form that do not include fully automated methods of medication management. As a result, we must continuously educate existing and prospective customers about the potential advantages of our medication management solutions and medication packaging systems, which requires significant sales efforts and can cause longer sales cycles. Despite our significant efforts and extensive time commitments targeting sales to healthcare facilities, we cannot be assured that our efforts will result in sales to these customers.
In addition, our medication management solutions and our more complex automated packaging systems typically represent a sizable initial capital expenditure and potential time and labor commitment to implement for healthcare organizations. Changes in the budgets of these organizations and the timing of spending under these budgets, as well as customer labor shortages, can have a significant effect on the demand for our medication management solutions, medication packaging systems, and related services. Customer budgets are often supported by cash flows that can be negatively affected by declining investment income and influenced by limited resources, increased operational and financing costs, macroeconomic conditions, and conflicting spending priorities among different departments. Any decrease in expenditures or change in spending priorities by healthcare facilities or increased financing costs, including as a result of the impacts of public health crises such as the COVID-19 pandemic, could decrease demand for our medication management solutions, medication packaging systems, and related services, and reduce our revenues.
Also, the continuing gradual transition to a value-based care healthcare delivery model could shift more of the burden of financial risk onto healthcare provider organizations and could decrease utilization of healthcare per patient. Value-based care could also cause a shift in sites of care from traditional venues, such as hospitals and clinics, to the home, and could impact our revenues.
Delays in installations of our medication management solutions, including our central pharmacy automation solutions, could harm our competitive position, operating results, and financial condition.
The purchase of our medication management solutions, including our central pharmacy automation solutions, is often part of a customer’s larger initiative to re-engineer its pharmacy and distribution and materials management systems. The purchase of our systems often entails larger strategic purchases by customers that generally require more complex and stringent contractual requirements, involve a significant commitment of management attention and resources by prospective customers, and require the input and approval of many decision-makers. In addition, new product announcements can cause a delay in our customers’ decisions to purchase our products or convert pending orders for our older products to those of our newer products. For these and other reasons, the sales cycle associated with sales of our systems is often lengthy and subject to a number of delays over which we have little or no control. A delay in, or loss of, sales of these systems (including as a result of the impacts of public health crises such as the COVID-19 pandemic or due to customer labor shortages, increased healthcare worker turnover, or customer budgetary constraints) could have an adverse effect upon our business, operating results and could harm our business, cash flow, or financial condition.
In addition, and in part as a result of the complexities inherent in larger transactions, the time between the purchase and installation of our systems can generally range up to 24 months. Delays in installation can occur for reasons that are often outside of our control, such as customer labor shortages or increased healthcare worker turnover, as well as customers seeking to stagger or elongate the timeframes between the adoption of new or updated technologies. We have also experienced fluctuations in our customer and transaction size mix, which makes our ability to forecast our bookings more difficult. Because we recognize revenues for our medication management solutions and our more complex medication packaging systems only upon installation at a customer’s site, any delay in installation (including as a result of the impacts of public health crises such as the COVID-19 pandemic or due to customer labor shortages or healthcare worker turnover) will also cause a delay in the recognition of the revenues for those systems.
23
The transition to selling more Advanced Services, which include a software as a service or solution as a service subscription, presents a number of risks.
We currently offer Advanced Services, which often contain a combination of robotics, smart devices, intelligent software, and expert services. These offerings include, but are not limited to, Central Pharmacy Dispensing Service, IV Compounding Service, and Point of Care Service. We also offer our Inventory Optimization Service, certain patient engagement, clinical and financial products and services under EnlivenHealth, Specialty Pharmacy Services, and 340B solutions, as a subscription. As we continue to execute on the industry vision of the Autonomous Pharmacy and grow subscription and cloud-based offerings, we may offer additional products and services on a subscription basis. The transition to selling more products and services on a subscription basis presents a number of risks. The shift requires an investment of technical, financial, compliance, and sales resources, and we cannot guarantee that we will recoup the costs of such investments, or that these investments will improve our long-term growth and operating results. Although we work to anticipate the rate of transition, if adoption of subscription solutions takes place faster than anticipated, the shift to subscription revenues will change the timing of revenue recognition and we may experience a temporary reduction of revenues and revenue growth rate. In addition, our cash flows may be impacted by the timing of invoicing of our subscription solutions. If any of our subscription solutions do not substantially meet customer requirements, contracts may be modified, causing a decline in revenue. Customers may elect not to renew their subscriptions upon expiration, or they may attempt to renegotiate pricing or other contractual terms at or prior to renewal to terms that are less favorable to us. In addition, since revenues are generally recognized over the term of the subscription, any decrease in customer purchases of our subscription-based products and services will not be fully reflected in our operating results until future periods, which may result in inflated revenue growth rates that do not reflect such decreases initially. Similarly, any additional subscription sales would not be fully reflected in our operating results until future periods.
If errors occur during the provision of certain of our Advanced Services, or if we fail to maintain expected service levels, we may be liable to our customers or third parties which may result in a decline in our Advanced Services offerings revenue.
Certain of our Advanced Services offerings are highly complex and may be susceptible to errors, including human or technological error. We may be required to bear the cost of correcting any errors and the cost of such corrections may be significant, which could adversely affect our business, operating results, cash flow, or financial condition. In addition, our customers, or third parties such as our customers’ patients, may assert claims that they suffered damages due to our errors. These claims could result in litigation and substantial costs, including legal defense costs. Although we believe our aggregate insurance policy limits are sufficient to cover reasonably expected claims, there can be no assurance that any liability insurance we purchase will be adequate to cover claims asserted against us. We could also be subject to adverse publicity as a result of such claims, regardless of the merits or eventual outcome, which may negatively impact our ability to attract and retain customers. Furthermore, if we cannot maintain the expected level of service or if our customers fail to achieve agreed upon milestone improvements in financial or operating metrics, payments to us from such customers may be lower than anticipated.
We may not be able to retain our Advanced Services customers.
An increasing percentage of our revenue is derived from our subscription-based Advanced Services offerings. In connection with those offerings, our customers, generally, have no obligation to renew their subscriptions. If our Advanced Services customers decline to renew their subscriptions or decide to terminate their agreements early, we would not derive the expected financial benefits from that customer, which could have a material adverse effect on our business, operating results, cash flow, or financial condition.
In addition, some of our Advanced Services agreements require us to adhere to additional data, security, network access, and other institutional procedures and requirements of our customers, and in certain cases may obligate us to agreed upon services levels. If we do not meet our obligations under any such Advanced Services agreement, we could be liable for damages. In addition, should a customer undergo a change in control or ownership, it may cause us or the customer to seek to modify or terminate an Advanced Services agreement.
If we are unable to maintain our relationships with group purchasing organizations (“GPOs”) or other similar organizations, we may have difficulty selling our products and services to customers represented by these organizations.
A number of GPOs have negotiated standard contracts for our products on behalf of their member healthcare organizations. Members of these GPOs may purchase under the terms of these contracts, which obligate us to pay the GPO a fee. We also have a Federal Supply Schedule contract with the Department of Veterans Affairs, allowing the Department of Veterans Affairs, the Department of Defense, and other federal government customers to purchase our products. These contracts enable us to sell our products and services more readily to customers represented by these organizations. Some of our contracts with these organizations are terminable at the convenience of the applicable customer. The loss of any of these relationships could impact the breadth of our customer base and could impair our ability to meet our revenue or revenue growth
24
rate targets or our ability to increase our revenues. The GPOs may increase the fees we pay or these organizations may not renew our contracts on similar terms, if at all, and they may choose to terminate our contracts before they expire, any of which could cause our revenues to decline.
If we are unable to meet the demands of, or maintain our relationships with, our institutional and retail pharmacy customers, our revenue from sales of medication packages, other consumables, or our Advanced Services may decline.
Approximately 7% of our revenues during the year ended December 31, 2023 were generated from the sale of consumable medication packages, most of which are produced in our St. Petersburg, Florida facility on a continuous basis and are shipped out to fulfill the demands of our institutional and retail pharmacy customers domestically and abroad. The demands placed on institutional and retail pharmacies by their customers represent real time requirements of those customers. Our customer agreements for the sale of consumable medication packages are typically short-term in nature and typically do not impose volume commitments on the customer. If we are unable to supply quality packaging to our customers in a timely manner, they may use alternative methods of distributing medications to their customers, including consumable medication packaging sold by our competitors, and our revenues will decline. Any disruption in the production capabilities of our St. Petersburg facilities, including as a result of extreme weather conditions or natural disasters, which may become more frequent as a result of climate change, will adversely affect our ability to ship our consumable medication packages globally and would reduce our revenues.
In addition, the institutional pharmacy market consists of significant national suppliers of medications to non-acute care facilities, smaller regional suppliers, and very small local suppliers. If we are unable to maintain our relationships with the major institutional pharmacies we do business with, they may purchase consumable blister card components from alternative sources, or choose to use alternatives to blister cards for medication control, and our revenues would decline.
Similarly, our EnlivenHealth brand offers a portfolio of web-based, mobile, and telephonic patient engagement, medication management, financial management, clinical, analytics, and population health solutions to pharmacies, which is designed to support improvement in health outcomes related to medication use. The success of these offerings depends on the trust our customers place in us and our reputation and ability to provide high-quality service. If we are unable to maintain the satisfaction or meet the expectations of our customers, our reputation with current and potential customers could be harmed, which could have a material adverse effect on our business, operating results, cash flow, or financial condition. In addition, if we fail to maintain our relationships with existing customers or are unable to create new relationships with other pharmacies, this could have an adverse effect on our business, operating results, cash flow, or financial condition.
Our inability to secure or maintain access to existing and future specialty drugs or pharmacy provider networks for our specialty pharmacy customers could have a material adverse effect on our business.
We provide Specialty Pharmacy Services to provider groups, federally qualified health centers, and health systems, including payer contracting and providing access to limited distribution drugs (“LDDs”). We have historically been able to obtain most of the payer and LDD products through our current network. However, if we are unable to obtain access to new LDDs or maintain access to current LDDs for our customers, it could have a material adverse effect on our business, profitability, and operating results. In addition, if we are not able to secure participation in the networks of pharmacy providers for our customers at acceptable reimbursement rates or if we lose access to current pharmacy networks, this could result in loss of customers, which could adversely affect our business, operating results, cash flow, or financial condition. We endeavor to demonstrate continued value and growth for each of our customers during the term of their respective contracts with us. However, if any of our customers elect to manage their own specialty pharmacy business, such customers could reduce or cease doing business with us upon the expiration of such customer’s contract term, which could have a material adverse effect on our business, operating results, cash flow, or financial condition.
We operate in highly competitive markets, and we may be unable to compete successfully.
The markets in which we operate are intensely competitive. We expect continued and increased competition from current and future competitors, in the medication management automation solutions market and the medication adherence solutions market, many of which have significantly greater financial, technical, marketing, and other resources than we do.
The competitive challenges we face in the markets in which we operate include, but are not limited to, the following:
•current or future competitors may offer or have the ability to offer a broader range of solutions than us, develop alternative solutions that provide a better customer outcome or lower cost of operation, develop new features or capabilities for their products, including artificial intelligence (“AI”), machine learning, and generative AI capabilities, which are part of an intensely competitive and rapidly evolving market, that could compete with our solutions, respond more quickly and efficiently to new or changing technologies, standards, or regulations, or devote greater resources to the development, promotion, and sale of their products than we do;
25
•competitive pressures could result in increased price competition for our products and services, fewer customer orders, and reduced gross margins;
•current and potential competitors may make strategic acquisitions or establish cooperative relationships among themselves or with third parties, including larger, more established healthcare supply companies, thereby increasing their ability to develop and offer a broader suite of products and services;
•our industry has recently experienced a significant degree of consolidation which could lead to competitors developing new business models that require us to adapt how we market, sell, or distribute our products or could also lead to competitors with greater economies of scale that have lower cost of operations allowing them to sell their products and services at a lower cost;
•certain competitors have greater brand name recognition and a more extensive installed base than we do, and such advantages could be used to increase their market share;
•certain competitors may have existing business relationships with our current and potential customers, which may cause these customers to purchase competing products and services from these competitors; and
•our competitors may secure products and services from suppliers on more favorable terms or secure exclusive arrangements with suppliers or buyers that may impede the sales of our products and services.
If we fail to compete successfully against current or future competitors, it could materially adversely affect our business, operating results, cash flow, or financial condition.
We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position.
Our debt may limit our ability to borrow additional funds or use our existing cash flow for working capital, capital expenditures, acquisitions, or other general business purposes or may require us to use a substantial portion of our cash flow for debt service payments; limit our flexibility to plan for, or react to, changes in our business and industry; place us at a competitive disadvantage compared to our less leveraged competitors; and increase our vulnerability to the impact of adverse economic and industry conditions.
Our ability to make payments of the principal, to pay interest, or to refinance our indebtedness, including the Notes, depends on our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. Our business may not continue to, and we cannot provide assurance that our business will, generate cash flow from operations in the future sufficient to fund our cash requirements, service our debt or make necessary capital expenditures. Our failure to generate sufficient cash flow to pay our debts could have a material adverse effect on our business. In addition, if we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as borrowing more money, selling assets, restructuring debt, or obtaining additional equity capital on terms that may be onerous or highly dilutive. Any of these actions still may not be sufficient to allow us to service our debt obligations, could increase the risks related to our business or our ability to service or repay our indebtedness or may otherwise have an adverse effect on our business.
Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at the time of any such refinancing. We may not be able to engage in any of these activities or to do so on desirable terms, which could result in a default on our debt obligations. In addition, as more fully described below in the risk factor captioned “Covenants in our Second A&R Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our business, operating results, cash flow, or financial condition could be adversely affected,” our second amended and restated agreement with certain lenders, and Wells Fargo Bank, National Association, as administrative agent (the “Second A&R Credit Agreement”) includes customary restrictive covenants that impose operating and financial restrictions on us.
We are subject to laws, regulations, and other legal obligations related to privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could harm our business.
We receive, store, and process personal information and other data from and about customers, in addition to our employees and services providers. In addition, our customers use our solutions to obtain and store personal information, including health information. For example, our customers use our EnlivenHealth platform to guide and track patient notes, interventions, and appointments, which involves the collection of personal health information of patients. Our handling of data is subject to a variety of laws and regulations by federal, state, local, and foreign agencies, as well as contractual obligations and industry standards. Regulatory focus on data privacy and security concerns continues to increase globally, and laws and regulations concerning the collection, use, and disclosure of personal information are expanding and becoming more complex.
26
In the United States, these include federal health information privacy laws (such as the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), discussed below), security breach notification laws, and consumer protection laws, as well as state laws addressing privacy and data security (such as the California Consumer Privacy Act of 2018 (“CCPA”), as amended by the California Privacy Rights Act of 2020 (“CPRA”)).
While HIPAA does not create a private right of action, its standards have been used as the basis for civil suits and HIPAA is enforced by the U.S. Department of Health and Human Services (“HHS”) Office for Civil Rights (“OCR”), which can bring actions against entities for noncompliance, including for failures to implement security measures sufficient to reduce risks to electronic protected health information or to conduct an accurate and thorough risk analysis, among other violations. HIPAA enforcement actions may lead to monetary penalties and costly and burdensome corrective action plans. We are also required to report known breaches of protected health information consistent with applicable breach reporting requirements set forth in applicable laws and regulations. Additionally, on December 10, 2020, OCR issued proposed revisions to the Privacy Rule aimed at reducing regulatory burdens that may exist in discouraging coordination of care and patient access to their health information, among other changes. While a final rule has not yet been issued, if adopted, these proposed changes may require us to update our HIPAA policies and procedures to comply with the new requirements. Additionally, pursuant to legislation passed in 2021, OCR recently issued guidance on recognized security practices for covered entities and business associates. OCR indicated that recognized security practices will not be an aggravating factor in OCR investigations, but that implementation of recognized security practices strengthen an organization’s cybersecurity and regulatory posture, as well as possibly lessening enforcement penalties in a potential regulatory enforcement action. Moreover, compliance with state laws related to health privacy may result in additional compliance costs.
We may encounter vendors that engage in information blocking practices that may inhibit our ability to access the relevant data on behalf of patients or impose new or additional costs. Specifically, the information blocking rules were implemented as part of the 21st Century Cures Act, and are primarily designed to facilitate technology interoperability and enable the free flow of healthcare information for healthcare treatment, payment or operation purposes. HHS-OIG may impose penalties for information blocking that has occurred after September 1, 2023, and ONC and HHS proposed a rule on November 1, 2023 listing certain disincentives for actors that conduct information blocking. The impact on the information blocking rules to our business is currently unclear.
The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches which is expected to increase data breach litigation. Additionally, the CPRA, came into effect in January 2023, and imposes additional data protection obligations on companies doing business in California, created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Laws similar to those in California have passed in states such as Virginia and Colorado, and have been proposed in other states and at the federal level that may ultimately have conflicting requirements that would further complicate compliance. Furthermore, new health information standards, whether implemented pursuant to HIPAA, Health Information Technology for Economic and Clinical Health (“HITECH”) Act, congressional action or otherwise could have a significant effect on the manner in which we handle health-related information, and the cost of complying with these standards could be significant. If we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions.
Additionally, the Federal Trade Commission (“FTC”) and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the collection, use, dissemination and security of health-related and other personal information. Courts may also adopt the standards for fair information practices promulgated by the FTC, which concern consumer notice, choice, security and access. Consumer protection laws require us to publish statements that describe how we handle personal information and the choices individuals may have about the way we handle their personal information. If such information that we publish is considered untrue, we may be subject to government claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences. Furthermore, according to the FTC, violating consumers’ privacy rights or failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair acts or practices in, or affecting, commerce in violation of Section 5 of the FTC Act. Additionally, the FTC recently published an advance notice of proposed rulemaking on commercial surveillance and data security, and is seeking comment on whether it should implement new trade regulation rules or other regulatory alternatives concerning the ways in which companies (1) collect, aggregate, protect, use, analyze, and retain consumer data, as well as (2) transfer, share, sell, or otherwise monetize that data in ways that are unfair or deceptive.
Additionally, data and digital services regulation continues to expand, particularly with respect to the artificial intelligence (“AI”) and automated decision making, which may further impact our business and regulatory compliance strategies. For example, AI regulation or regulatory guidance continues to emerge in response to President Biden’s Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence issued on October 30, 2023.
27
Internationally, various jurisdictions outside of the United States in which we operate have established, or are currently developing, their own data privacy and security legal frameworks with which we or our customers must comply. In certain cases, these international laws and regulations are more restrictive than many regulations in the United States. For example, within the European Union (“EU”), the General Data Protection Regulation 2016/679 (“EU GDPR”) went into effect on May 25, 2018, and introduced strict requirements for the processing of personal information of individuals. The EU GDPR governs the collection, use, disclosure, transfer, and other processing of personal information (i.e., data which identifies an individual or from which an individual is identifiable). The UK has implemented the EU GDPR as the UK GDPR which sits alongside the UK Data Protection Act 2018 (the UK GDPR, together with the EU GDPR, the “GDPR”). The GDPR has direct effect where an entity is established in the European Economic Area (“EEA”) or the UK (as applicable) and has extraterritorial effect, including where an organization outside of the EEA or the UK processes personal information in relation to the offering of goods or services to those individuals or the monitoring of their behavior.
The GDPR imposes stringent obligations on companies that fall within its scope, including inter alia: (i) accountability and transparency requirements, requiring controllers to demonstrate and record compliance with the GDPR and to provide more detailed information to data subjects regarding processing of their personal information; (ii) obligations to comply with data protection rights of data subjects including a right: (x) of access to, erasure of, or rectification of personal data; (y) to restriction of processing or to withdraw consent to processing; and (z) to object to processing or to ask for a copy of personal data to be provided to a third party; (iii) obligations to consider data protection as any new products or services are developed and designed (including e.g., to limit the amount of personal information processed); (iv) requirements to process personal information lawfully including specific requirements for obtaining valid consent where consent is the lawful basis for processing; (v) an obligation to report personal data breaches to: (x) the data supervisory authority without undue delay (and no later than 72 hours after discovering the personal data breach, where feasible), unless the personal data breach is unlikely to result in a risk to the data subjects’ rights and freedoms; and (y) affected data subjects, where the personal data breach is likely to result in a high risk to their rights and freedoms. The EU GDPR also provides that EU Member States may introduce further laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use, and share EU personal information, cause our compliance costs to increase, require us to change our practices, adversely impact our business, and harm our financial condition.
In addition, the EU GDPR prohibits the international transfer of personal information from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having “adequate” data protection laws unless a data transfer mechanism has been put in place or a derogation under the EU GDPR can be relied upon. In July 2020, the Court of Justice of the EU (“CJEU”) in its Schrems II judgement limited how organizations could lawfully transfer personal data from the EEA to the US by invalidating the EU-US Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses (“EU SCCs”), including a requirement for companies to carry out a transfer privacy impact assessment (“TIAs”). A TIA, among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under EU SCCs will need to be implemented to ensure an “essentially equivalent” level of data protection to that afforded in the EEA.
On October 7, 2022, US President Biden introduced an Executive Order to facilitate a new Trans-Atlantic Data Privacy Framework (“DPF”) and on 10 July 2023, the European Commission adopted its Final Implementing Decision granting the U.S. adequacy (“Adequacy Decision”) for EU-US transfers of personal data for entities self-certified to the DPF. Entities relying on EU SCCs for transfers to the U.S. are also able to rely on the analysis in the Adequacy Decision as support for their TIA regarding the equivalence of U.S. national security safeguards and redress. This may have implications for our cross-border data flows and has and may in the future result in increased compliance costs.
The UK GDPR also imposes similar restrictions on transfers of personal data from the UK to jurisdictions that the UK Government does not consider adequate, including the United States. The UK Government has published its own form of the EU SCCs, known as the International Data Transfer Agreement and an International Data Transfer Addendum to the new EU SCCs. The UK Information Commissioner’s Office has also published its version of the TIA and guidance on international transfers, although entities may choose to adopt either the EU or UK style TIA. Further, on September 21, 2023, the UK Secretary of State for Science, Innovation and Technology established a UK-U.S. data bridge (i.e., a UK adequacy decision) and adopted UK regulations to implement the UK-U.S. data bridge (“UK Adequacy Regulations”). The UK Adequacy Regulations have now been passed in the UK Parliament, and personal data may be transferred from the UK under the UK-U.S. data bridge through the UK extension to the DPF, from October 12, 2023, to organizations self-certified under the DPF.
The GDPR imposes fines for serious breaches of up to the higher of 4% of the organization’s annual worldwide turnover or €20m (under the EU GDPR) or £17.5m (under the UK GDPR). The GDPR identifies a list of points to consider when determining the level of fines for data supervisory authorities to impose (including the nature, gravity and duration of the
28
infringement). Data subjects also have a right to compensation, as a result of an organization’s breach of the GDPR which has affected them, for financial or non-financial losses (e.g., distress).
In the EU a number of new laws related to digital data and AI have recently entered into force, or are expected to enter into force in the foreseeable future. We are still assessing the scope of application, impact, and risk of these recent EU laws on our business, and will continue to assess this moving forward, including for example: (i) the EU’s Data Act, which was adopted on November 27, 2023 and seeks to, among other things regulate the use of, and access to, data generated through connected (or Internet-of-Things) devices and introduces a new means for public sector bodies to access, use and re-use private sector data; and (ii) the proposed European Health Data Space Regulation which is expected to be agreed in Q3 2024 and seeks to, among other things, provide individuals with more control over their electronic health data (“EHD”), enable cross-border sharing of EHD between national EU healthcare systems and facilitate the sharing of EHD for secondary research purposes. In addition to government regulation, privacy advocates and industry groups may propose new and different self-regulatory standards that may legally or contractually apply to us, and other regulatory protections may lose their applicability to our business as regulations and legal proceedings continue to evolve globally. We also expect that there will continue to be new proposed laws, regulations, and industry standards relating to privacy, data protection, and information security, including in the UK (see above), where we have business operations. We cannot predict the scope of any such future laws, regulations, and standards that may be applicable to us, or how courts, agencies, or data protection authorities might interpret current ones. It is possible that these laws and other obligations may be interpreted and applied in a manner that is inconsistent with our existing data management practices or the functionality of our solutions.
Compliance with privacy, data protection, and information security laws, regulations, and other obligations is costly, and we may encounter difficulties, delays, or significant expenses in connection with our compliance, or because of our customers’ need to comply or our customers’ interpretation of their own legal requirements. For example, as previously disclosed in connection with the cybersecurity event we experienced on May 4, 2022, we provided breach notification to fewer than 350 individuals as required by applicable law. Additionally, we have in the past been subject to certain class action lawsuits asserting, among other allegations, claims of violation of the Illinois Biometric Information Privacy Act.
In addition, any future event that results in the failure or perceived failure by us to comply with laws, regulations, policies, legal or contractual obligations, industry standards, or regulatory guidance relating to privacy or data security could result in governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity, all of which could have an adverse effect on our reputation, as well as our business, financial condition, and operating results.
Significant disruptions in our information technology systems, breaches of data security, or cyber-attacks on our systems or solutions, could adversely impact our business.
We rely on information technology (“IT”) systems to keep financial records and corporate records, communicate with staff and external parties, and operate other critical functions, including sales and manufacturing processes. As our business needs change, we may need to expand or update our IT systems. We also utilize third-party cloud services in connection with our operations, which also may need to be expanded or updated as our business needs change. Our IT systems and third-party cloud services are potentially vulnerable to disruption due to breakdown, malicious intrusion and computer viruses, public health crises such as the COVID-19 pandemic, other catastrophic events or environmental impact, as well as due to system upgrades and/or new system implementations. Our systems may also experience vulnerabilities from third-party or open source software code that may be incorporated into our own or our vendors’ systems. Any prolonged system disruption in our IT systems or third-party services could negatively impact the coordination of our sales, planning, and manufacturing activities, which could harm our business. In addition, in order to maximize our information technology efficiency, we have physically consolidated our primary corporate data and computer operations. This concentration, however, exposes us to a greater risk of disruption to our internal IT systems. Although we maintain offsite back-ups of our data, a disruption of operations at our facilities could materially disrupt our business if we are not capable of restoring function within an acceptable time frame.
Our IT systems and third-party cloud services are potentially vulnerable to cyber-attacks, including ransomware, or other data security incidents, by employees or others, which may expose sensitive data to unauthorized persons. In addition, we have a large number of employees working remotely, which number may continue to grow, and such arrangements may involve increased use of office equipment off premises, which may make our systems more susceptible to security breaches or breach attempts. As previously disclosed, on May 4, 2022, we determined that certain of our information technology systems were affected by ransomware impacting certain internal systems. Upon detecting the security event, we took immediate steps designed to contain the incident and implement its business continuity plans to restore and support continued operations. We contained the incident and restored substantially all of its critical information technology systems. We do not believe the security event will have a material adverse effect on its business, operating results, cash flow or financial condition.
29
We may also be subject to various cybersecurity laws in the EU and the UK, including the UK Network and Information Systems Regulation 2018 (“NIS Regulations”), and the EU Network and Information Systems Security 1 Directive (“NISD1”) as implemented into EU Member State law (and as updated by the EU Network and Information Systems Security 2 Directive (“NISD2”)) which apply to certain operators of “essential services” and digital service providers, such as cloud providers, and medical device manufacturers. In addition, the EU Critical Entities Resilience Directive entered into force on January 17, 2023 which applies to, among other things, “essential services” including manufacturers of medical devices, imposes stringent cybersecurity and resilience requirements in particular in relation to incidents significantly impacting the continuation of the critical infrastructure service offering in the EU.
Future data security incidents could lead to the loss of trade secrets or other intellectual property, or to the public exposure of sensitive and confidential information of our employees, customers, suppliers, and others, any of which could have a material adverse effect on our business, operating results, cash flow, or financial condition. Moreover, the current and/or a future security breach or privacy violation that leads to disclosure or modification of, or prevents access to, patient information, including personally identifiable information or protected health information, could harm our reputation, result in litigation, compel us to comply with federal and/or state breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of database contents, and otherwise subject us to liability under laws and regulations that protect personal information, resulting in increased costs or loss of revenues. For additional information, see the risk factor captioned “We are subject to laws, regulations, and other legal obligations related to privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could harm our business” above for additional information.
We sell certain solutions that receive, store, and process our customers’ data. For example, our Inventory Optimization Service solution combines a cloud-based predictive intelligence platform with expert services designed to monitor pharmacy operations and recommend opportunities to help improve efficiency, regulatory compliance, and patient outcomes. As another example, our EnlivenHealth patient engagement platform is a private cloud-based solution that supports improving patient adherence goals through a single web-based platform that hosts functionality to guide and track patient notes, interventions, and appointments. These solutions require that we maintain an information technology infrastructure that is robust and reliable within competitive and regulatory constraints that continue to evolve. Operational malfunctions, including loss of customer data or power or telecommunications infrastructure outages, or an effective attack on our solutions could disrupt the proper functioning of our solutions, allow unauthorized access to sensitive and confidential information of our customers (including protected health information), and disrupt our customers’ operations, which could result in reduced quality of services and contract liability or claims by customers and other third parties. In addition to the risks and impacts noted above, any of these events could damage our reputation or cause our solutions to be perceived as having security vulnerabilities and reduce demand, which could have a material adverse effect on our business, operating results, cash flow, or financial condition. These risks are likely to increase as we continue to grow our cloud-based offerings, including in support of the industry vision of the Autonomous Pharmacy, and as we receive, store, and process more of our customers’ data.
While we have implemented a number of security measures designed to protect our systems and data, including firewalls, antivirus and malware detection tools, patches, log monitors, routine back-ups, system audits, routine password modifications, and disaster recovery procedures, and have designed certain security features into our solutions, we and our third party service providers regularly defend against and respond to data security incidents and such measures may not be adequate or implemented properly to prevent or fully address the adverse effect of such events. In some cases, we may be unaware of an incident or its magnitude and effects as breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm. In addition, while we possess insurance that currently includes coverage for cyber-attacks, we have seen a trend where the amount of coverage being offered by insurance providers for such cyber-attacks is decreasing while the cost of obtaining such coverage is increasing. If this trend continues, the insurance coverage we possess may not be adequate or the cost to obtain such coverage may become prohibitive.
We use third-party cloud providers in connection with certain of our cloud-based offerings or third-party providers to host our own data, in which case we rely on the processes, controls, and security such third parties have in place to protect the infrastructure. We also may acquire companies, products, services, and technologies and inherit such risks when we integrate these acquisitions within Omnicell.
Any failure to prevent such security breaches or privacy violations, or implement satisfactory remedial measures, could require us to expend significant resources to investigate security breaches and notify affected individuals, remediate any damage, disrupt our operations or the operations of our customers, damage our reputation or cause us incur costs to manage public relations issues, damage our relationships with our customers, or expose us to a risk of financial loss, litigation, regulatory penalties, contractual indemnification obligations, or other liability.
30
We may fail to realize the potential benefits of acquired businesses, which could negatively affect our business, operating results, cash flow, or financial condition.
We have in the past acquired businesses, and expect to continue to seek to acquire businesses, technologies, or products in the future. For example, we acquired FDS Amplicare in September 2021, Omnicell Specialty Pharmacy Services (formerly, ReCept) and MarkeTouch Media, each in December 2021, respectively, and Hub and Spoke Innovations in January 2022. We cannot provide assurance that any acquisition or future transaction we complete will result in long-term benefits to us or our stockholders, or that we will be able to effectively integrate or manage the acquired businesses, including FDS Amplicare, Omnicell Specialty Pharmacy Services, MarkeTouch Media, or Hub and Spoke Innovations.
These transactions may involve significant challenges, uncertainties, and risks, including:
•difficulties in combining previously separate businesses into a single unit and the complexity of managing a more dispersed organization as sites are acquired;
•difficulties in right-sizing organizations and gaining synergies across acquired operations;
•complying with regulatory requirements, such as those of the U.S. Food and Drug Administration (“FDA”), the U.S. Drug Enforcement Administration (“DEA”), or state boards of pharmacy, that we were not previously subject to;
•failure to understand and compete effectively in markets in which we have limited previous experience;
•substantial costs and diversion of management’s attention when evaluating and negotiating such transactions and then integrating an acquired business, including any unforeseen delays and expenditures that may result;
•incurring additional debt in connection with the financing of an acquisition;
•discovery, after completion of the acquisition, of liabilities assumed or internal control, regulatory or compliance issues in acquisitions that are broader in scope and magnitude or are more difficult to manage than originally assumed or identified;
•difficulties assimilating and retaining key personnel of an acquired business;
•failure to achieve anticipated benefits such as revenue enhancements and operational and cost efficiencies;
•difficulties in integrating newly acquired products and solutions in our offerings, or inability or failure to provide high quality service, expand bookings and sales, or effectively coordinate sales and marketing efforts after the acquisition;
•inability to maintain business relationships with customers and suppliers of newly acquired companies due to post-acquisition disruption;
•inability or failure to successfully integrate financial reporting and information technology systems; and
•other additional risks relating to legal, regulatory or tax matters.
If we are not able to successfully integrate or manage the acquired businesses and their operations, or if there are delays in combining the businesses, the anticipated benefits of the acquisition may not be realized fully or at all or may take longer to realize than expected and our business, operating results, cash flow, or financial condition may be negatively impacted.
If goodwill or other intangible assets that we recorded in connection with our prior acquisitions become impaired, we could be required to take significant charges against earnings.
In connection with the accounting for prior acquisitions, we recorded a significant amount of goodwill and other intangible assets. Under GAAP, we must assess, at least annually and potentially more frequently, whether the value of goodwill and other indefinite-lived intangible assets has been impaired. Intangible assets subject to amortization will be assessed for impairment in the event of an impairment indicator. As of December 31, 2023, we had recorded approximately $946.0 million net of accumulated amortization, in goodwill and intangible assets, in connection with past acquisitions. Any future reduction or impairment of the value of goodwill or other intangible assets will result in a charge against earnings, which could materially adversely affect our operating results and shareholders’ equity in future periods.
31
The healthcare industry is subject to legislative and regulatory changes, as well as financial constraints and consolidation, which could adversely affect the demand for our products and services.
The healthcare industry has faced, and will likely continue to face, significant financial constraints. U.S. government legislation and program rulemaking may cause customers to postpone purchases of our products due to reductions in federal healthcare program reimbursement rates and/or needed changes to their operations in order to meet the requirements of legislation or in anticipation of future rulemaking. For example, the Budget Control Act of 2011, among other things, resulted in reductions in payments to Medicare providers of 2% per fiscal year, which went into effect on April 1, 2013 and, following a temporary suspension during the COVID-19 pandemic that expired on July 1, 2022, will remain in effect through the first six months of the fiscal year 2023 sequestration order unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced Centers for Medicare & Medicaid Services (“CMS”) payments to several types of providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years. Our automation solutions often involve a significant financial commitment from our customers and, as a result, our ability to grow our business is largely dependent on our customers’ capital and operating budgets. To the extent current or proposed legislation and program rules promote spending on other initiatives or healthcare providers’ spending declines or increases more slowly than we anticipate, demand for our products and services could decline.
In addition, certain healthcare legislation and regulations may be challenged from time to time, in an effort to modify or repeal that legislation or those regulations. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”), which was passed in March 2010 and substantially changed the way healthcare is financed by both governmental and private insurers, has been subject to numerous judicial, legislative, and regulatory efforts to replace it or to alter its interpretation or implementation. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the law. It is unclear how this decision, and other efforts to challenge, repeal, replace, or otherwise modify, or alter the implementation or interpretation of the ACA will affect our business, operating results, cash flow, or financial condition.
We cannot predict the success of our business with respect to any such challenges or the effect that subsequent changes or new resulting legislation or regulations would have on our business or the healthcare industry in general. Furthermore, many existing healthcare laws and regulations, when enacted, did not anticipate the services we may provide. Any future actions or developments could adversely impact the healthcare industry, including with respect to the cost of prescription drugs, regulation of pharmacy services, the administration of the federal 340B Program, changes to pharmacy reimbursement rates, or could challenge or change the way we do business, which could have an adverse impact on our business.
Healthcare providers have consolidated to create larger healthcare delivery organizations in order to achieve economies of scale and/or greater market power. If this consolidation continues, it would increase the size of certain target customers, which could increase the cost, effort, and difficulty in selling our products to such customers, or could cause our existing or potential customers to begin utilizing our competitors’ products if such customers are acquired by healthcare providers that prefer our competitors’ products to ours. In addition, the resulting organizations could have greater bargaining power, which may lead to price erosion. This consolidation could also result in new entrants in the markets in which we operate, which presents additional risk and could result in adverse impacts on our business, see “We operate in highly competitive markets, and we may be unable to compete successfully” above for additional information.
Government regulation of the healthcare industry could reduce demand for our products or services, or substantially increase the cost to produce our products or deliver our services.
The manufacture and sale of most of our current medication management solutions are not directly regulated by the FDA or the DEA, although such products and services are used by other persons (our customers) whose pharmacy, dispensing, and compounding activities may be subject to regulation by those agencies and by state boards of pharmacy. However, we manufacture and develop specifications for products classified as Class I and Class II medical devices, which are subject to FDA regulation and require compliance with the FDA Quality System Regulation as well as medical device reporting, including a sterile disposable product that required FDA 510(k) review and clearance prior to marketing and distribution. Medical devices are also subject to various other regulatory requirements, including as applicable, premarket clearance or approval, establishment registration and device listing, complaint handling, notification and repair, replace, refund, mandatory recalls, unique device identifier (“UDI”) requirements, reports of removals and corrections, cybersecurity requirements and post-marketing surveillance. Additional products and services may require us to observe HHS regulations for credentialing of providers (pharmacists) or be subject to DEA regulations concerning the management, storing, dispensing, and disposal of, and accounting for, controlled substances, and may be regulated in the future by the FDA, DEA, or other federal agencies due to future legislative and regulatory initiatives or reforms. In addition, certain provisions of the Federal Food, Drug and Cosmetic Act (“FDCA”) related to the handling, distribution and compounding of pharmaceuticals, govern all parts of the drug
32
distribution chain, which our customers may be required to comply with and which may influence customer demand for our products. Direct regulation of our business and products by the FDA, DEA, CMS, or other federal agencies could substantially increase the cost to produce our products or deliver our services and increase the time required to bring those products and services to market, reduce the demand for our products and services, and reduce our revenues. In addition, our customers include healthcare providers and facilities subject to regulation by the DEA, pharmacies subject to regulation by the FDA and individual state boards of pharmacy and hospitals subject to accreditation by accrediting organizations approved by the CMS, such as the Joint Commission, and the rules, regulations, and standards of such regulators and accrediting organizations. Any failure of our customers to comply with the applicable rules, regulations, and standards could reduce demand for our products or services and harm our business, competitive position, operating results, cash flow, or financial condition. Given our customers, products, services, and industry relationships, we may also be subject to rules, regulations, standards, and civil or criminal enforcement imposed by HHS, the U.S. Department of Justice, the HHS Office of Inspector General, CMS, the Health Resources and Services Administration, and state attorneys general, including with respect to state and federal False Claims Act statutes, federal Anti-Kickback Statute, and federal Physician Payments Sunshine Act, among others. As such, from time to time, we may be subject to various state or federal governmental inspections, reviews, audits and investigations to verify our compliance with governmental rules and regulations to the extent governing our products and services. The costs to respond to or defend any such reviews, audits and investigations can be significant and are likely to increase in the current enforcement environment. These audits and investigations may result in other adverse consequences, particularly if the underlying conduct is found to be pervasive or systemic. These consequences may include, but are not limited to: (1) refunding or retroactively adjusting amounts that have been paid under the relevant government program or from other payers; (2) state or federal agencies imposing significant fines, penalties and other sanctions on us; (3) losing our right to participate in certain governmental programs; and (4) damaging our reputation in various markets, which could adversely affect our ability to attract customers and employees. If these were to occur, the consequences could have a material adverse effect on our business, operating results, cash flow, or financial condition.
While we have implemented a Privacy and Use of Information Policy and adhere to established privacy principles, use of customer information guidelines, and related federal and state statutes, we cannot assure you that we will be in compliance with all international, federal and state healthcare information privacy and security laws that we are directly or indirectly subject to, including, without limitation, HIPAA. Under HIPAA, we are considered a “business associate” in relation to many of our customers that are covered entities, and, as such, most of these customers have required that we enter into written agreements governing the way we handle and safeguard certain patient health information we may encounter in providing our products and services, and may impose liability on us for failure to meet our contractual obligations. Furthermore, pursuant to changes in HIPAA under the American Recovery and Reinvestment Act of 2009, we are covered under HIPAA similar to other covered entities and, in some cases, subject to the same civil and criminal penalties as a covered entity. A number of states and countries have also enacted privacy and security statutes and regulations that, in some cases, are more stringent than HIPAA and may also apply directly to us. If our past or present operations are found to violate any of these laws, we may be subject to fines, penalties, and other sanctions.
In addition, we cannot predict the potential impact of future privacy standards and other federal, state, and international privacy and security laws that may be enacted at any time on our customers or on Omnicell. These laws could restrict the ability of Omnicell and/or our customers to obtain, use, or disseminate patient information, which could reduce the demand for our products or services or force us to redesign our products or services in order to meet regulatory requirements. For more information, you should also refer to the risk factor above captioned “We are subject to laws, regulations, and other legal obligations related to privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could harm our business”.
Changes to the 340B Program could negatively impact our 340B Program-related services.
Any changes to the 340B Drug Pricing Program, such as changes to the scope of, or requirements for participation in, the 340B Program, could negatively impact our 340B Program-related services. Current litigation brought by multiple manufacturers is challenging the Health Resources and Services Administration’s requirement to offer the 340B ceiling price on drugs dispensed at contract pharmacies. The decisions that have been issued to date have been narrowly tailored and appeals have been filed in some of the cases. While the litigation is ongoing, a number of manufacturers have restricted access to the 340B ceiling price for drugs dispensed at contract pharmacies. It is not yet clear how the litigation will resolve. If 340B ceiling prices are not required to be offered for drugs dispensed at contract pharmacies or the requirements for participation by 340B covered entities make participation in the program less beneficial, our 340B Program-related offerings may become less useful to 340B covered entities, and our 340B Program-related businesses could decline, which could materially adversely affect our business, operating results, cash flow, or financial condition. Furthermore, uncertainty around the 340B Program could lead to lower levels of participation by 340B covered entities, which could reduce demand for our 340B Program-related businesses and could adversely affect our business. In addition, Congress has considered legislative changes to the 340B Program. Any legislative changes to the 340B Program could also affect our 340B Program-related services.
33
We must comply with anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations.
Our current and future operations are subject to various federal and state healthcare laws and regulations that affect our sales, marketing, and other promotional activities by limiting the kinds of financial arrangements we can enter into with respect to our products and services and/or requiring disclosure of certain of our financial arrangements to government agencies. They also impose additional administrative and compliance burdens on us. These laws include, but are not limited to, the healthcare fraud and abuse laws described in the section titled “Business - Government Regulation” above.
The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, and it is possible that some of our business activities could be subject to challenge under one or more of such laws or that such laws could be applied to our business in ways we did not anticipate. Ensuring that our business arrangements with third parties comply with applicable healthcare laws, as well as responding to investigations by government authorities (which have increased in recent years as the healthcare industry has come under greater scrutiny) can be time and resource consuming and can divert management’s attention from the business.
If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to significant financial penalties and possible exclusion from participation in federal and state funded healthcare programs, and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. This could harm our ability to operate our business and our financial results.
Our international operations may subject us to additional risks that can adversely affect our business, operating results, cash flow, or financial condition.
We currently have operations outside of the United States, including sales efforts centered in Canada, Europe, the Middle East, and the Asia-Pacific regions, and supply chain efforts in Asia. We intend to continue to expand our international operations, particularly in certain markets that we view as strategic, including the Middle East. Our international operations subject us to a variety of risks, including:
•our reliance on distributors for the sale of our medication management solutions outside the United States, Canada, the UK, France, and Germany;
•the difficulty of managing an organization operating in various countries;
•reduced protection for intellectual property rights in certain jurisdictions;
•the imposition of, or adverse changes in, international laws and regulations, including privacy and security, labor, import, export, trade, environmental standards, product compliance, tax, anti-bribery, and employment laws;
•fluctuations in currency exchange rates and difficulties in repatriating funds from certain countries;
•additional investment, coordination, and lead-time necessary to successfully interface our automation solutions with the existing information systems of our customers or potential customers outside of the United States;
•political unrest, terrorism, and other potential hostilities (such as the ongoing conflicts between Russia and Ukraine or Israel and Hamas), including in areas in which we have facilities or operations; and
•epidemics, pandemics, or other major public health crises, such as the COVID-19 pandemic.
If we are unable to anticipate and address these risks properly our business, operating results, cash flow, or financial condition could be harmed.
Furthermore, changes in export or import regulation and other trade barriers and uncertainties may have an adverse effect on our business. For example, in recent years, the U.S. government advocated greater restrictions on trade generally and tariff increases on certain goods imported into the United States, particularly from China. We cannot predict what actions may ultimately be taken with respect to tariffs or trade relations between the United States and other countries (including China), what products may be subject to such actions, or what actions may be taken by the other countries in retaliation. The adoption and expansion of trade restrictions, the occurrence of a trade war, other governmental action related to tariffs or trade agreements or policies, or the related uncertainties, has the potential to adversely impact our ability to do business outside of the United States as well as our supply chain and costs, which could, in turn, adversely affect our business, operating results, cash flow, or financial condition.
34
Covenants in our Second A&R Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our financial conditions and operating results could be adversely affected.
The Second A&R Credit Agreement contains various customary covenants that require us to provide financial and other information reporting as well as notice upon certain events and limit or restrict our ability and/or our subsidiaries’ ability to, among other things, incur or assume liens or additional debt or provide guarantees in respect of obligations of other persons; issue redeemable preferred stock; pay dividends or distributions or redeem or repurchase capital stock; prepay, redeem, or repurchase certain debt; make loans, investments, acquisitions, and capital expenditures; enter into agreements that restrict distributions from our subsidiaries; sell assets and capital stock of our subsidiaries; enter into certain transactions with affiliates; and consolidate or merge with or into, or sell substantially all of our assets to, another person.
The Second A&R Credit Agreement also includes financial covenants requiring us (i) not to exceed a maximum consolidated secured net leverage ratio of 3.00:1 and (ii) to maintain a minimum consolidated interest coverage ratio of 3.00:1. Our ability to comply with these financial covenants may be affected by events beyond our control. Our failure to comply with any of the covenants under the Second A&R Credit Agreement could result in a default under the terms of the Second A&R Credit Agreement, which could permit the administrative agent or the lenders to declare all or part of any outstanding borrowings to be immediately due and payable or foreclose on our assets, or to refuse to permit additional borrowings under the revolving credit facility, which could restrict our operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us. In addition, if we are unable to repay those amounts, the administrative agent and the lenders under the Second A&R Credit Agreement could proceed against the collateral granted to them to secure that debt and foreclose on our assets, which would seriously harm our business.
Climate change, legal, regulatory or market measures to address climate change and related emphasis on environmental, social and corporate governance (“ESG”) matters by various stakeholders may negatively affect our business and operating results.
Climate changes, such as extreme weather conditions and natural disasters or the occurrence of extreme weather conditions and natural disasters with increased frequency and severity, resulting from increased concentrations of greenhouse gases in the atmosphere, could present risks to our operations by decreasing the availability or increasing cost of materials needed for manufacturing, or increasing insurance and other operating costs. Natural disasters and extreme weather conditions, such as hurricanes, tornadoes, earthquakes, wildfires, or flooding, may also pose physical risks to our facilities and disrupt the operation of our supply chain.
In addition, increased awareness and concern over climate change may result in new or additional regional and/or federal legal or regulatory requirements designed to reduce greenhouse gas emissions and/or mitigate the effects of climate change on the environment. Currently, there continues to be a lack of consistent climate legislation, which creates economic and regulatory uncertainty. If such laws or regulations are more stringent than current legal or regulatory obligations, we may experience disruption in, or an increase in the costs associated with sourcing, manufacturing and distribution of our products, which may adversely affect our business, operating results, cash flow or financial condition.
Furthermore, regulators’, customers’, investors’, and employees’ expectations for ESG matters have been rapidly evolving and increasing. The enhanced stakeholder focus on these issues requires continuous monitoring of various and evolving standards and the associated reporting requirements. A failure to adequately meet stakeholder expectations, combined with inconsistent standards by which to measure ESG performance, may result in the loss of business, diluted market valuation, an inability to attract customers or an inability to attract and retain top talent.
Catastrophic events may disrupt our business and harm our operating results.
We rely on our network infrastructure, data centers, enterprise applications, and technology systems for the development, marketing, support, and sales of our products, and for the internal operation of our business. These systems are susceptible to disruption or failure in the event of an extreme weather condition, including earthquake, fire, flood, ice and snowstorms or other natural disasters, as well as cyber-attack, terrorist attack, telecommunications failure, health emergencies, including epidemics or pandemics (such as the COVID-19 pandemic), or other catastrophic event. Many of these systems are housed or supported in or around our corporate facility located in Northern California, near major earthquake faults and which may be vulnerable to climate change effects, and where a significant portion of our research and development activities and other critical business operations take place. Other critical systems are housed in communities that have been subject to significant tropical storms such St. Petersburg, Florida, which is the location of our manufacturing facilities for our consumable medication packages. In the future, tropical storms may be intensified or occur with increasing frequency as a result of climate change. Disruptions to, or the failure of any of these systems, and the resulting loss of critical data, which is not quickly
35
recoverable by the effective execution of disaster recovery plans designed to reduce such disruption, could cause delays in our product development, prevent us from fulfilling our customers’ orders, and could severely affect our ability to conduct normal business operations, the result of which would adversely affect our operating results.
Our success is dependent on our ability to recruit and retain skilled and motivated personnel.
Our success is highly dependent upon the continuing contributions of our key management, sales, technical, and engineering staff, and on our ability to attract, train, and retain highly skilled and motivated personnel. As more of our products are installed in increasingly complex environments, greater technical expertise will be required. As our installed base of customers increases, we will require additional resources to meet increased demands on our customer service and support personnel. Furthermore, as we execute on the industry vision of the Autonomous Pharmacy and grow and develop our cloud-based software as a service and solution as a service offerings, more specialized expertise will be required. This growth and shift in products and offerings could lead to increased labor costs, and thereby increased costs of our products and offerings, which could result reduced customer demand and our business, operating results, cash flow, or financial condition could be materially and adversely affected. Additionally, competition for specialized and technical personnel can be intense, and the pool of suitable candidates may be limited. We may not be successful in attracting and retaining qualified personnel. If we lose the services of one or more of our key personnel, we may not be able to find a suitable replacement and our business could be materially adversely affected. Furthermore, external (such as the COVID-19 pandemic) and internal (such as our continued growth or internal restructuring initiatives) factors may result in greater workloads for our employees compared to those at companies with which we compete for personnel, which may lead to higher levels of employee burnout and turnover.
Competitors have in the past attempted, and may in the future attempt, to recruit our employees. In addition, since equity compensation is a key component of our employee compensation program, any further decrease in our stock price or failure to receive stockholder approval for future proposed increases to the number of shares reserved for issuance under our equity incentive plans could prevent us from granting equity compensation at competitive levels and make it more difficult to attract, retain, and motivate employees, including key employees of acquired businesses. Failure to attract and retain key personnel could harm our competitive position, operating results, and financial condition.
Our failure to protect our intellectual property rights could negatively affect our ability to compete.
Our success depends in part on our ability to obtain patent protection for technology and processes, and our ability to preserve our trademarks, copyrights, and trade secrets. We have pursued patent protection in the United States and foreign jurisdictions for technology that we believe to be proprietary and for technology that we find offers us a potential competitive advantage for our products. We intend to continue to pursue such protection in the future. Our issued patents relate to various features of our medication management solutions and medication packaging systems. We cannot assure you that we will file any patent applications in the future and that any of our patent applications will result in issued patents, or that, if issued, such patents will provide significant protection for our technology and processes or a competitive advantage. Furthermore, we cannot assure you that such patents will not be challenged or invalidated or that others will not design around the patents we own. All of our system software is copyrighted and subject to the protection of applicable copyright laws; however, the laws of certain foreign countries do not protect our proprietary rights as effectively as they do in the U.S. Despite our efforts to protect our proprietary rights, there can be no assurance that our efforts to protect our proprietary rights are or will be adequate. that competitors will not independently develop similar technology, and that unauthorized parties will not attempt to copy aspects of our products or obtain and use information that we regard as proprietary, which could harm our competitive position.
Our products use raw materials and components that may be subject to price fluctuations, shortages, or interruptions of supply, and if we are unable to maintain supply sources for such raw materials and components, or if such sources fail to satisfy our supply requirements, in particular with regard to semiconductor chips, we may experience a loss of sales, increased component costs, and reduced profitability.
Factors that are largely beyond our control, such as the cost, quality, and availability of the raw materials and components utilized in the manufacture of our products, may affect the cost of such products, and we may not be able to pass those costs on to our customers. Our products use raw materials and components that may be subject to price fluctuations, shortages, or other disruptions of supply for many reasons outside of our control. In addition, we may be dependent upon a limited number of suppliers for certain components which may be unduly affected by supply chain disruptions. The cost, quality, and availability of these raw materials and components are essential to the successful manufacture and sale of our products. If we are unable to maintain supply sources of these raw materials and components, or if such sources fail to satisfy our supply requirements, we may lose sales and experience increased component costs.
We have developed and implemented strategies in an effort to mitigate the impact of price fluctuations, shortages, or other disruptions of supply, but these strategies, particularly in a prolonged inflationary environment, may only offset a portion of the adverse impact. We carry some inventory of critical components and are otherwise working to secure supplies necessary
36
to ensure fulfillment of customer demand, but global shortages could result in our need to secure supplies at higher costs as well as manufacturing delays. Supply interruptions may result in increased component delivery lead times and increased costs to obtain components and as a result the production of our products may be impacted. If we or our suppliers are unable to obtain components from third parties in the quantities and of the quality that we require, on a timely basis and at acceptable prices, we may not be able to deliver our products on a timely or cost-effective basis to our customers, or it may lead to us delivering products that are of a lower quality that may result in increased repair and replacement costs, which could harm our business and reputation, operating results, cash flow, and financial condition. We have also seen a period of sustained price increases for commodities used in the manufacture of our products that may continue as demand increases and supply remains constrained, which has resulted in, and may continue to result in, increased costs for Omnicell and thereby potentially lower profit margins. If the costs of these commodities increase or remain elevated, it could adversely affect our business, operating results, cash flow, or financial condition.
We depend on a limited number of suppliers for our products, and our business may suffer if we were required to change suppliers to obtain an adequate supply of components, equipment, and raw materials on a timely basis.
Although we generally use parts and components for our products with a high degree of modularity, certain components are presently available only from a single source or limited sources. We rely on a limited number of suppliers for the raw materials necessary to produce our consumable medication packages. While we have generally been able to obtain adequate supplies of all components and raw materials in a timely manner from existing sources, or where necessary, from alternative sources, we entered into relationships with new suppliers in connection with the launch of our XT Series products. We engage multiple single source third-party manufacturers to build several of our sub-assemblies. The risks associated with changing to alternative vendors, if necessary, for any of the numerous components used to manufacture our products could limit our ability to manufacture our products or result in the use of substitute components in our products that could lead to additional complexity or cost in maintaining our products and thereby harm our business. Due to our reliance on a few single source partners to build our hardware sub-assemblies and on a limited number of suppliers for the raw materials that are necessary in the production of our consumable medication packages, a reduction or interruption in supply from our partners or suppliers, or a significant increase in the price of one or more components could have an adverse impact on our business, operating results, cash flow, or financial condition. In certain circumstances, the failure of any of our suppliers or us to perform adequately could result in quality control issues affecting end users’ acceptance of our products, which could damage customer relationships and harm our business.
Our U.S. government lease agreements are subject to annual budget funding cycles and mandated changes, which may affect our ability to recognize revenues and sell receivables based on such leases.
Prior to September 2021, U.S. government customers that leased our equipment typically signed contracts with five-year payment terms that are subject to one-year government budget funding cycles. Effective September 2021, the government has mandated changes in its Federal Supply Services contract that has resulted in our determination not to enter into future leases with U.S. government customers. Our existing leases with U.S. government customers are unaffected by this change. As a result, our volume of U.S. government customer leases will decline over time and cease in the future. In addition, under the terms of the Federal Supply Schedule contract, certain of our U.S. government customer contracts are terminable at the convenience of the applicable U.S. government customer. If any of our government-owned or government-run hospital customers decide to terminate their agreements early for any reason, we would not derive the expected financial benefits from any such customer which could result in lower than expected revenue and adversely affect our business, operating results, cash flow, or financial condition. In addition, the failure of any of our U.S. government customers to receive their annual funding, or the government mandating changes to the Federal Supply Services contract, could impair our ability to sell equipment to these customers or to sell our U.S. government receivables to third-party leasing companies. In addition, the ability to collect payments on unsold receivables could be impaired and may result in a write-down of our unsold receivables from U.S. government customers. The balance of our unsold leases to U.S. government customers was $10.6 million as of December 31, 2023.
If we fail to manage our inventory properly, our revenue, gross margin, and profitability could suffer.
Managing our inventory of components and finished products is a complex task. A number of factors, including, but not limited to, the need to maintain a significant inventory of certain components that are in short supply or that must be purchased in bulk to obtain favorable pricing, the general unpredictability of demand for specific products and customer requests for quick delivery schedules, may result in us maintaining large amounts of inventory. Other factors, including changes in market demand, customer requirements, and technology, may cause our inventory to become obsolete. Any excess or obsolete inventory could result in inventory write-downs, which in turn could harm our business, operating results, cash flow, or financial condition.
37
Intellectual property claims against us could harm our competitive position, operating results, and financial condition.
We expect that developers of medication management solutions and medication packaging systems will be increasingly subject to infringement claims as the number of products and competitors in our industry grows and the functionality of products in different industry segments overlaps. In the future, third parties may claim that we have infringed upon, misappropriated, or otherwise violated their intellectual property rights with respect to current or future products. We do not carry special insurance that covers intellectual property infringement claims, however, such claims may be covered under our traditional insurance policies. These policies contain terms, conditions, and exclusions that make recovery for intellectual property infringement claims difficult to guarantee. Any infringement claims, with or without merit, could be time-consuming to defend, result in costly litigation, divert management’s attention and resources, cause product shipment delays, or require us to enter into royalty or licensing agreements. These royalty or licensing agreements, if required, may not be available on terms acceptable to us, or at all, which could harm our competitive position, operating results, and financial condition.
Product liability claims against us could harm our competitive position, operating results, and financial condition.
Our products include medication management solutions and medication adherence products and services for healthcare systems and pharmacies. Despite the presence of healthcare and pharmacy professionals as intermediaries between our products and patients, if our products fail to provide accurate and timely information or operate as designed, customers, patients, or their family members could assert claims against us for product liability. Moreover, failure of health care facility and pharmacy employees to use our products properly or for their intended purposes could result in product liability claims against us. Litigation with respect to product liability claims, regardless of any outcome, could result in substantial cost to us, divert management’s attention from operations, and decrease market acceptance of our products. We possess a variety of insurance policies that include coverage for general commercial liability and technology errors and omissions liability. We attempt to mitigate these risks through contractual terms negotiated with our customers. However, these policies and protective contractual terms may not be adequate against product liability claims and in the past we have been subject to certain lawsuits asserting, among other allegations, claims of product liability. A successful claim brought against us, or any claim or product recall that results in negative publicity about us, could harm our competitive position, operating results, and financial condition. Also, in the event that any of our products is defective, we may be required to recall or redesign those products, which could result in increased costs and have an adverse impact on our results of operation.
We are dependent on technologies provided by third-party vendors, the loss of which could negatively and materially affect our ability to market, sell, or distribute our products.
Some of our products incorporate technologies owned by third parties that are licensed to us for use, modification, and distribution. If we lose access to third-party technologies or we lose the ongoing rights to modify and distribute these technologies with our products, we will have to devote resources to independently develop, maintain, and support the technologies ourselves, pay increased license costs, or transition to another vendor. Any independent development, maintenance, or support of these technologies by us or the transition to alternative technologies could be costly, time consuming, and could delay our product releases and upgrade schedules. These factors could negatively and materially affect our ability to market, sell, or distribute our products.
Investment in new business strategies, initiatives, products or solutions could disrupt ongoing business and present risks not originally contemplated.
We have invested, and in the future may invest, in new business strategies, initiatives, products or solutions, including with respect to our software as a service or solution as a service subscription products and services or other subscription and cloud-based offerings. Such endeavors may involve significant risks and uncertainties, including distraction of management from current operations, lack of expertise to effectively execute such strategies or initiatives or to develop such products or solutions, delays, technical problems (including software defects or errors) or unexpected expenses related to the entry into new business strategies or initiatives or development of new products or solutions, insufficient revenue to offset liabilities assumed and expenses associated with a strategy, initiative, product or solution, inadequate return of capital or return on investment, and unidentified issues not discovered in our due diligence. These new ventures may be inherently risky and may not be successful. Even if successful, they may not have the projected or actual impact that we initially expected or that recoups our initial
38
investment and we may make a determination to exit a particular business strategy, initiative, product line or solution. As a result, such initiatives may materially adversely affect our business, operating results, cash flow, or financial condition.
Risks Related to Ownership of Our Common Stock
The market price of our common stock may continue to be highly volatile.
Our common stock traded between $77.14 and $28.72 per share during the year ended December 31, 2023. The market price of our common stock has been and may continue to be highly volatile in response to various factors discussed in this “Risk Factors” section, many of which are beyond our control, including:
•actual or anticipated changes in our operating results or forecasts, and whether our operating results meet our publicly announced guidance or expectations of securities analysts or investors;
•changes in the ratings of our common stock by securities analysts or changes in their earnings estimates;
•changes in our business model and initiatives, such as our ongoing transition to focus on a subscription-based business model or a decision to exit a particular business or product line, and our ongoing restructuring initiatives to contain costs;
•developments in our customer relationships;
•changes in our Board of Directors, senior management, or key personnel;
•announcements by us or our competitors of technological innovations or new products;
•mergers, acquisitions, combinations, and other significant transactions involving us or our competitors;
•our sale of our common stock or other securities;
•level of demand for our common stock, and actions by stockholders or short sellers of our common stock;
•changes in laws or regulations applicable to our products or services;
•our involvement in any litigation or investigations by government authorities, including litigation judgments, settlements, or other litigation-related costs;
•cyber events, such as the ransomware incident we experienced in May 2022;
•epidemics, pandemics, or other major public health crises, such as the COVID-19 pandemic; or
•general economic, regulatory, political and market conditions.
Furthermore, the stock market in general, and the market for technology companies in particular, have experienced extreme price and volume fluctuations. These broad market fluctuations may cause the market price of our common stock to decline irrespective of our performance. In addition, sales of substantial amounts of our common stock in the public market, or the perception that such sales could occur, could lower the market price of our common stock.
In addition, stockholders have initiated class action lawsuits against companies following periods of volatility in the market prices of these companies’ stock. For example, in July 2019, a putative class action lawsuit was filed against Omnicell and certain of our officers alleging that the defendants violated federal securities laws by making certain materially false and misleading statements. While this action was concluded in December 2019 following the lead plaintiff’s voluntary dismissal as to all defendants, we may in the future be subject to other class action lawsuits, especially following periods of volatility in our stock price.
Our quarterly and annual operating results may fluctuate, which makes our future operating results difficult to predict, and may cause our stock price to decline.
Our quarterly and annual operating results have varied and may vary in the future. In addition to other factors discussed in this “Risk Factors” section, factors, many of which are outside of our control and are difficult to predict, that may cause our quarterly or annual operating results to fluctuate include, but are not limited to, the following:
•the size, product mix, and timing of orders for our products, and their installation and integration and whether our estimates for the same were proper;
39
•our ability to successfully install our products on a timely basis and meet other contractual obligations necessary to recognize revenue;
•fluctuations in customer demand for our products, including due to changes in our customers’ budgets, healthcare worker turnover rates and labor shortages and whether customer demand was properly estimated;
•our ability to control costs, including operating expenses, and continue cost reduction efforts, such as our restructuring initiative;
•changes in pricing policies by us or our competitors;
•the number, timing, and significance of product enhancements and new product announcements by us or our competitors;
•the timing and significance of any acquisition or business development transactions that we may consider or negotiate and the revenues, costs, and earnings that may be associated with these transactions;
•the relative proportions of revenues we derive from products and services;
•our ability to generate cash from our accounts receivable on a timely basis;
•changes in, and our ability to successfully execute on, our business strategy; and
•macroeconomic and political conditions, including fluctuations in interest rates, tax increases, availability of credit markets, and trade and tariff actions.
Due to all of these factors, our quarterly or annual revenues and operating results are difficult to predict and may fluctuate, which in turn may cause the market price of our stock to decline.
If financial or industry analysts have difficulty understanding the changes to our business model, or we fail to meet (or significantly exceed) our publicly announced financial guidance, our stock price and trading volume could decline.
We are transitioning to focus on a subscription-based business model, which industry or financial analysts that publish reports about our business, may not have historically reflected, or may not accurately reflect in the future. As a result, analysts’ ability to accurately forecast our results may be negatively impacted and it may be more likely that we fail to meet their estimates. As a result, if our financial results fail to meet (or significantly exceed) our publicly announced financial guidance or the expectations of analysts or investors, analysts could downgrade our common stock or publish unfavorable research that could cause our stock price or trading volume to decline, potentially significantly.
Raising additional capital may cause dilution to our existing stockholders, restrict our operations or harm our business, operating results, cash flow, or financial condition.
We may seek additional capital through a variety of means, including through private and public equity offerings and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, or the refinancing of our existing convertible notes, the ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures, entering into licensing arrangements, or declaring dividends. If we raise additional funds from third parties, we may have to relinquish valuable rights to our technologies, or grant licenses on terms that are not favorable to us.
If we are unable to raise additional funds through equity or debt financing when needed, our ability to market, sell, or distribute our products and/or fund our operations may be negatively impacted and could harm our business, operating results, cash flow, or financial condition.
Certain provisions in our charter documents and under Delaware law may discourage, delay, or prevent an acquisition of us and limit our stockholders’ ability to obtain a favorable judicial forum for certain disputes.
Certain anti-takeover provisions of Delaware law and our charter documents may make a change in control of our Company more difficult, even if a change in control would be beneficial to the stockholders. Our certificate of incorporation provides that stockholders’ meetings may only be called by our Board of Directors. Our bylaws provide that stockholders may not take action by written consent, and require that stockholders comply with advance notice procedures to nominate director candidates for election or to propose matters to be acted upon at a meeting of our stockholders. Delaware law also prohibits corporations from engaging in a business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities, our Board of Directors approves the transaction. Our Board
40
of Directors may use these provisions to prevent changes in the management and control of our Company. Also, under applicable Delaware law, our Board of Directors may adopt additional anti-takeover measures in the future including, without limitation, a stockholder rights plan.
In addition, our bylaws also establish the Delaware Court of Chancery as the exclusive forum for certain legal actions, including certain stockholder disputes, and establish the federal district courts of the United States of America as the exclusive forum for any action asserting a cause of action arising under the Securities Act of 1933, as amended, which exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers, or other employees.
Risk Factors Related to Our Notes
Conversion of the Notes may dilute the ownership interest of our stockholders, depress the price of our common stock or, if the conditional conversion feature of the Notes is triggered, adversely affect our business, operating results, cash flow, or financial condition.
The Notes are convertible at the option of the holders on or after May 15, 2025 and, in certain circumstances, prior to May 15, 2025. The initial conversion rate for the Notes is 10.2751 shares of our common stock per $1,000 principal amount of Notes, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. On December 13, 2021, we made an irrevocable election under the Indenture to require the principal portion of our Notes to be settled in cash (up to $1,000 in cash per $1,000 principal amount of Notes) and any conversion consideration in excess of $1,000, in cash and/or shares of our common stock, at our option, upon conversion. The conversion of some or all of the Notes may dilute the ownership interests of our stockholders. As we have the option to settle the excess of the principal amount in shares of our common stock, any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling of our common stock by market participants because the conversion of the Notes could be used to satisfy short positions, or the anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.
Following our irrevocable election, only the shares of common stock expected to be settled in excess of the principal amount are considered dilutive for calculating earnings per share under the if-converted method. Accordingly, as the price of our common stock increases, our diluted earnings per share could be adversely affected.
Prior to May 15, 2025, if a circumstance that permits early conversion occurs, holders of the Notes will be entitled to convert their Notes at any time during specified periods at their option.
If one or more holders elect to convert their Notes, we will be required to settle at least the principal amount of our conversion obligation through the payment of cash (up to $1,000 in cash per $1,000 principal amount of Notes), which could adversely affect our liquidity. In addition, as a result of the irrevocable election, in periods when the conditional conversion feature of the Notes is triggered, we must reclassify all of the outstanding principal of the Notes as a current rather than long-term liability, which could result in a material reduction of our net working capital during those periods.
The convertible note hedge and warrant transactions may affect the value of our common stock.
In connection with the offering of the Notes, we entered into convertible note hedge transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”). We also entered into warrant transactions with the option counterparties. The convertible note hedge transactions are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be. However, the warrant transactions separately have, and could continue to have a dilutive effect on our common stock to the extent that the market price per share of our common stock exceeds the strike price of the warrants. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the maturity of the Notes (and are likely to do so in connection with any conversion of the Notes or redemption or repurchase of the Notes), which could cause or avoid an increase or a decrease in the market price of our common stock.
Changes in the credit quality of the option counterparties may affect the efficacy of our hedge and warrant transactions. By entering into the hedge and warrant transactions, we are subject to the risk that the option counterparties may incur significant financial hardships, potentially resulting in their default under the convertible note hedge transactions. Our exposure to the credit risk of the option counterparties will not be secured by any collateral. If an option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the convertible note hedge transactions with such option counterparty. Our exposure will depend on many factors but, generally, an increase in our exposure will be correlated to an increase in the market price and in the volatility
41
of our common stock. In addition, upon a default by an option counterparty, we may suffer adverse tax consequences and more dilution than we currently anticipate with respect to our common stock. We can provide no assurances that the hedge or warrant transactions will have the intended effects or as to the financial stability or viability of the option counterparties.
General Risk Factors
Changes in our tax rates, exposure to additional tax liabilities, or the adoption of new tax legislation could adversely affect our business, operating results, cash flow, or financial condition.
We are subject to taxes in the United States and foreign jurisdictions in which we operate. Our future effective tax rates could be affected by several factors, many of which are outside of our control, including: changes in the mix of earnings with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in federal, state, and international tax laws or their interpretation, adjustments to income tax expense upon the finalization of tax returns, changes in tax attributes, or changes in accounting principles. We regularly assess the likelihood of adverse outcomes to determine the adequacy of our provision for taxes. We are also subject to examination of our income tax returns by the Internal Revenue Service and other tax authorities. There can be no assurance that the outcomes from these examinations will not materially adversely affect our business, operating results, cash flow, or financial condition. Forecasting our estimated annual effective tax rate is complex and subject to uncertainty, and there may be a material difference between the forecasted and the accrued effective tax rates. Any increase in our effective tax rate would reduce our profitability.
Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could cause our stock price to decline.
Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the United States Securities and Exchange Commission (“SEC”) require annual management assessments of the effectiveness of our internal control over financial reporting, and a report by our independent registered public accounting firm attesting to the effectiveness of internal control. If we fail to maintain effective internal control over financial reporting, as such standards are modified, supplemented, or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting. Should that occur, we may not be able to accurately report our financial results, prevent fraud, or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price. In addition, our failure to timely file our periodic reports could eventually result in the delisting of our common stock, regulatory sanctions from the SEC, and/or the breach of the terms contained in our credit facility, or any preferred equity or debt securities we may issue in the future, any of which could have a material adverse impact on our operations and your investment in our common stock.
ITEM 1B.    UNRESOLVED STAFF COMMENTS
There are currently no unresolved issues with respect to any SEC staff’s written comments.
42
ITEM 1C. CYBERSECURITY
In general, the Company addresses cybersecurity risks through a comprehensive approach that is focused on preserving the security of its information and by identifying, preventing and mitigating cybersecurity threats, as well as effectively responding to cybersecurity incidents when they occur. The Company believes that this comprehensive approach helps to ensure that the highest levels of oversight is provided to its cybersecurity risk management activities and fosters collaborative consultation between management and the Board.
Board Oversight
As part of its risk oversight function, the Audit Committee of the Company’s Board of Directors is primarily responsible for overseeing and reviewing the Company’s information security and technology risks, including cybersecurity. In this role, the Audit Committee monitors the prevention, detection, mitigation and remediation of cybersecurity incidents through the regular receipt of reports from management on the effectiveness of its cybersecurity programs. These reports include semi-annual cybersecurity updates from the Company’s Chief Information Officer and quarterly reports from the Company’s risk management personnel on the progress of the Company’s broader Enterprise Risk Management (“ERM”) risk mitigation activities. As part of the ERM process, the Audit Committee provides input on key risks for the Company to consider. In addition, the Board also provides quarterly input on its views regarding potential emerging risk areas for the Company. The Audit Committee then reports to the full Board on a quarterly basis regarding its oversight activities and the risk management activities of the Company. In addition, the full Board receives periodic presentations from management on emerging information security and cybersecurity risks, as well as incident reports as significant matters may arise.
Enterprise Risk Management
Omnicell utilizes a structured, biannual ERM process to identify, assess, and address material risks facing the Company, including cybersecurity risks, during which business leaders across the Company are surveyed about current and emerging risk areas. After the ERM survey is completed and risk areas are identified, the results are discussed with the relevant management personnel across the organization in the key risk areas, root causes are analyzed and risk mitigation plans are developed. The Chief Information Officer works closely with Omnicell’s management team in all facets of its ERM risk mitigation activities related to cybersecurity and information security risks.
Ongoing Mitigation Efforts
The Company has implemented a number of security measures designed to protect its systems and data, including firewalls, antivirus and malware detection tools, patches, log monitors, routine back-ups, system audits, system hardening, penetration testing and privileged access session management. In addition, the Company has continued its efforts to migrate its platforms to cloud-based computing, which is designed to further strengthen its security posture. The Company has focused on its incident response procedures and retained a leading incident response provider. The Company has also recently strengthened its disaster recovery procedures. The Company’s solutions incorporate cybersecurity features that are routinely analyzed. In addition, the Company maintains insurance that includes coverage for cyber-attacks, which coverage is discussed and reviewed with the Audit Committee annually.
The Company has what it believes are appropriate physical, technical, and administrative controls in place that are designed to protect customers’ data. However, as previously disclosed, on May 4, 2022, the Company determined that certain of its information technology systems were affected by ransomware impacting certain internal systems. Upon detecting the security event, the Company took immediate steps designed to contain the incident and implement its business continuity plans to restore and support continued operations. Subsequently, the Company contained the incident and restored substantially all of its critical information technology systems.
Following this cybersecurity event, the Company immediately implemented several key learnings from the incident, including using a three-pronged approach focused on further reducing exposure, raising greater security awareness, and further strengthening the Company’s cybersecurity defenses. This approach resulted in the Company further hardening its identity computing environments as part of its progress to a zero trust environment, heightened cybersecurity awareness efforts through increased comprehensive information security awareness training for employees on a quarterly basis, and the strengthening of the Company’s cybersecurity defenses through implementation of multifactor authentication for Privileged Access Management and Endpoint Detection and Response solutions across the Company’s computing environment.
Incident Response
In the event of a cybersecurity incident, dependent upon the nature of the incident, the Company has a Security Incident Response Team (“SIRT”) that is comprised of employees who have responsibility and authority to act during a cyber incident without delay, including, dependent upon the nature of the incident, the Company’s Chief Legal Officer, Chief
43
Information Security Officer and Chief Information Officer. The SIRT includes individuals responsible for assessing, containing, and responding to incidents, as well as those responsible for assessing the business and legal impacts, reporting incidents as appropriate, communicating to internal and external stakeholders, and engaging with industry and government response partners to coordinate information and resource sharing when needed. During a cybersecurity incident, as warranted, the SIRT keeps the Company’s senior leadership and Board apprised of the response to the incident, any operational or business impacts, and any internal or external communications regarding the incident. The SIRT will also seek the input of the Company’s senior leadership and Board, as needed, when addressing a cybersecurity incident. Upon resolution of a cybersecurity incident, generally, the Audit Committee will review the incident, the impact and the mitigation efforts and remediation actions the Company will implement. The Audit Committee then monitors the completion of the remediation actions and mitigation efforts.
Cybersecurity Leaders in Management
The Company’s IT strategy and implementation is overseen by a dedicated Chief Information Officer with over 20 years of experience in the field, including previously serving a 17-year tenure, most recently as Vice President of Global IT, with a global technology leader of fiber optic subsystems and components. He holds a Bachelor of Science in Computer Science and Engineering from Andhra University in India and an MBA from the Indian School of Business. In addition, the Company has recently engaged a Chief Information Security Officer (“CISO”). The Company’s CISO has built and managed world-class information security programs and technology teams for industry leading global companies. She has deep experience securing healthcare-focused companies in both the provider and supplier space. She holds a Bachelor of Science from the University of Redlands and an MBA from Notre Dame De Namur University along with holding certified information systems security professional (“CISSP”) and certified information security manager (“CISM”) certifications.
Third Parties
The Company utilizes third-party service providers, such as cloud services, in connection with its operations, and its information security department implements a third-party risk assessment and review process in connection with those services to evaluate security posture and risk. The Company also engages third parties to assist in its cybersecurity management efforts, such as the leading incident response provider mentioned above and another provider to perform continuous monitoring and regular penetration testing of its information security systems and environment. The Company and its personnel also actively engage with a number of other key vendors, industry participants and intelligence and law enforcement communities as part of its information security and cybersecurity efforts.
Impact of Recent Cyber Incident
While the previously disclosed ransomware incident led to (i) temporarily delayed invoicing that impacted the timing of cash collections and free cash flow in 2022 and (ii) customer implementation delays in 2022, as the Company recovered from the impacts of the ransomware incident, substantially all delayed implementations due to the ransomware incident were completed as of the end 2022. Furthermore, any delayed or impacted processes have returned to normal operations. To date, the Company does not believe the ransomware incident, or other identified cyber risks, have had, or will have, a material adverse effect on its business, operating results, cash flow, or financial condition.
44
ITEM 2.    PROPERTIES
Our headquarters are located in a leased facility in Fort Worth, Texas. The following is a list of our material leased facilities and their primary functions:
SiteMajor ActivityApproximate Square Footage
St. Petersburg, FloridaAdministration, marketing, research and development, sales, and manufacturing167,700
Warrendale, Pennsylvania Manufacturing and research and development107,400
Cranberry Township, PennsylvaniaAdministration, marketing, research and development, sales, technical support, and training58,400
Irlam, United KingdomAdministration, sales, marketing, and distribution center61,000
Milpitas, CaliforniaAdministration, manufacturing, and research and development46,300
Waukegan, IllinoisTechnical services, support, training, and repair center38,500
Fort Worth, TexasAdministration, sales, marketing, and research and development34,400
Bochum, GermanyAdministration, sales, marketing, distribution, and manufacturing center19,000
We also have smaller rented facilities in Strongsville, Ohio; Grapevine, Texas; New York, New York; Germany; France; India; Italy; the People’s Republic of China; the United Arab Emirates; Australia; and the United Kingdom.
We believe that these facilities are sufficient for our current operational needs and that suitable additional space will be available on commercially reasonable terms to accommodate expansion of our operations, if necessary.
For additional information regarding our obligations pursuant to operating leases, refer to Note 13, Lessee Leases, of the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K.
ITEM 3.    LEGAL PROCEEDINGS
Refer to the information set forth under “Legal Proceedings” in Note 14, Commitments and Contingencies, of the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K.
ITEM 4.    MINE SAFETY DISCLOSURES
Not applicable.
45
PART II
ITEM 5.    MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES
Market for Our Common Stock
Our common stock is traded on the NASDAQ Global Select Market under the symbol “OMCL.”
Stockholders
There were 76 registered stockholders of record as of February 21, 2024. A substantially greater number of stockholders are beneficial holders, whose shares of record are held by banks, brokers, and other financial institutions.
Dividend Policy
We have never declared or paid any cash dividends on our common stock. We currently expect to retain any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future.
Performance Graph
The following graph compares total stockholder returns for Omnicell’s common stock for the past five years to two indexes: the NASDAQ Composite Index and the NASDAQ Health Care Index. The graph assumes $100 was invested in each of Omnicell’s common stock, the NASDAQ Composite Index, and the NASDAQ Health Care Index as of the market close on December 31, 2018. The total return for Omnicell’s common stock and for each index assumes the reinvestment of all dividends, although cash dividends have never been declared on Omnicell’s common stock, and is based on the returns of the component companies weighted according to their capitalization as of the end of each annual period.
The NASDAQ Composite Index tracks the aggregate price performance of equity securities traded on the NASDAQ Stock Market. The NASDAQ Health Care Index tracks the aggregate price performance of healthcare and health services equity securities. Omnicell’s common stock is traded on the NASDAQ Global Select Market and is a component of both indexes. The stock price performance shown on the graph is based on historical results and should not be relied upon as an indication of future price performance.
46
COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN (1) (2)
Among Omnicell, Inc., the NASDAQ Composite Index, and the NASDAQ Health Care Index
2225
_________________________________________________
(1)$100 invested on December 31, 2018 in stock or index, including reinvestment of dividends.
(2)This section is not deemed “soliciting material” or to be “filed” with the SEC and is not to be incorporated by reference into any filing of Omnicell, Inc. under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
Year Ended December 31,
201820192020202120222023
Omnicell, Inc. $100.00 $133.44 $195.98 $294.64 $82.33 $61.45 
NASDAQ Composite100.00 136.69 198.10 242.03 163.28 236.17 
NASDAQ Health Care100.00 110.75 140.85 126.71 95.29 96.06 
Stock Repurchase Program
We did not repurchase any shares of our common stock during the year ended December 31, 2023. Refer to Note 16, Stock Repurchase Programs, of the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K for additional information.
ITEM 6.    [Reserved]
ITEM 7.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with our Consolidated Financial Statements and related Notes to Consolidated Financial Statements in this Annual Report on Form 10-K. This discussion and analysis may contain forward-looking statements based upon our current expectations and assumptions that involve risks and uncertainties.
47
Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Item 1A, “Risk Factors,” and elsewhere in this Annual Report on Form 10-K. Unless otherwise stated, references in this Annual Report to particular years or quarters refer to our fiscal year and the associated quarters of those fiscal years.
We have elected to omit discussion of the earliest of the three years covered by the Consolidated Financial Statements presented. Such omitted discussion can be found under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” located in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 1, 2023, for reference to discussion of the fiscal year ended December 31, 2021, the earliest of the three fiscal years presented.
OVERVIEW
Our Business
Omnicell, a leader in transforming the pharmacy care delivery model, is committed to solving the critical challenges inherent in medication management and elevating the role of clinicians within healthcare as an essential component of care delivery. Omnicell is focused on helping its customers to define and deliver a cost effective medication management strategy that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. We are doing this with an industry-leading medication management infrastructure which includes robotics, smart devices, intelligent software, and expert services. This comprehensive set of solutions provides the critical foundation for customers to realize the industry vision of the Autonomous Pharmacy, a vision defined by pharmacy leaders for improving operational efficiencies and ultimately targeting zero-error medication management.
Omnicell solutions are helping healthcare facilities worldwide to reduce costs, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry vision of the Autonomous Pharmacy. We sell our product and consumable solutions together with related service offerings. Revenues generated in the United States represented 88% of our total revenues for the year ended December 31, 2023.
Over the past several years, our business has expanded from a single-point solution to a platform of products and services that will help to further advance the industry vision of the Autonomous Pharmacy. This expansion has resulted in larger deal sizes across multiple products, services, and implementations for customers and, we believe, more comprehensive, valuable, and enduring relationships. As our business evolves, we continue to evaluate the metrics and methods we use to measure the success of our business.
We utilize bookings as an indicator of the success of our business. We define bookings generally as: (i) the value of non-cancelable contracts for our connected devices, software products, and Advanced Services (although, for those Advanced Services contracts without a minimum commitment, bookings only include the amount of revenue that has been recognized once the services have been provided); and (ii) for our consumables, the value of orders placed through our Omnicell Storefront online platform or through written or telephonic orders. We typically exclude technical services and other less significant items ancillary to our products and services, such as freight revenue from bookings. In addition, dependent upon counterparty or credit risk, which is evaluated at the time of contract signing, for a given multi-year subscription contract we may reduce the portion of the contractual commitment booked at a given time. As noted, the portfolio of products, solutions and services we offer has evolved. As a result, the ordering process for certain of our solutions has also evolved. For example, orders for certain solutions may not include a purchase order. Connected devices and software license bookings are recorded as revenue upon customer acceptance of the installation or receipt of goods. Revenues from Advanced Services bookings are recorded over the contractual term. Bookings decreased by 19%, from $1.054 billion in 2022 to $854 million in 2023, primarily driven by lower-than-expected orders for our Advanced Services, particularly our technology-enabled services, which include Central Pharmacy Dispensing Service and IV Compounding Service.
We generally provide installation planning and consulting as part of most connected device product sales, which is typically included in the initial price of the solution. To help ensure the maximum availability of our systems, our customers typically purchase technical services contracts (maintenance and support) in increments of one to five years. In addition to connected device product sales, we provide a range of services to our customers. We also provide Advanced Services such as Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions, which typically are provided over 2-7 years.
48
The following table summarizes each revenue category:
Revenue Category
Revenue Type
Income Statement Classification
Included in Bookings
Connected devices, software licenses, and other
Nonrecurring
Product
Yes (1)
Consumables
Recurring
Product
Yes
Technical services
Recurring
Service
No
Advanced Services (2) (3)
Recurring
Service
Yes
_________________________________________________
(1)    Certain other insignificant revenue streams ancillary to our products and services, such as freight revenue, are not included in bookings.
(2)    Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions.
(3)    For those Advanced Services contracts without a minimum commitment, bookings only include the amount of revenue that has been recognized once the services have been provided.
Our full-time employee headcount was approximately 3,650 on December 31, 2023, a decrease of approximately 580 employees since December 31, 2022. The decrease in employee headcount reflects the impact of restructuring initiatives announced in November 2022 and November 2023.
Operating Segments
We manage our operations as a single segment for the purposes of assessing performance and making operating decisions. Our Chief Operating Decision Maker (“CODM”) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Omnicell at the consolidated level using information about our revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of Omnicell as one operating segment, which is the same as our reporting segment.
Business Strategy
The U.S. spent a total of $634 billion on prescription drugs in 2022, an increase of 9% compared to 2021, and prescription drugs impact the vast majority of patients in virtually all settings of care. We believe there are significant challenges facing the practice of pharmacy today including, but not limited to, budget constraints, increased healthcare worker turnover rates, labor shortages, drug shortages, drug diversion, manual and error-prone processes, complex compliance requirements, and limited inventory visibility. Each of these challenges may lead to poor medication management outcomes including, but not limited to, medication errors, adverse drug events, lack of patient adherence, and medication waste. We also recognize that these challenges may impact the timing of contracting for, or implementing, our products, solutions, or services. However, we believe that over time these significant challenges to the practice of pharmacy will drive demand for increased automation, visibility, insights, and improved medication management outcomes that our solutions are designed to enable. Because of this, we believe that our solutions are well-positioned to address the evolving needs of healthcare institutions and therefore present opportunities for long-term growth.
49
In an effort to address these challenges and deliver solutions to help drive positive medication management outcomes, we continue to make significant investments in our research and development efforts to further advance the industry vision of the Autonomous Pharmacy. Furthermore, we believe a combination of robotics, smart devices, intelligent software, and expert services is needed in every care setting where medications are managed. We are focused on delivering solutions to help our customers realize the industry vision of the Autonomous Pharmacy and drive positive medication management outcomes with outstanding customer experience through a mature channel in four market categories:
•Point of Care. As a market leader, we expect to continue expansion into this product market as customers increase the use of our dispensing systems in more areas within their hospitals and increasingly in ambulatory care settings. However, we recognize that the current macroeconomic environment, with significant labor constraints, may impact our customers’ considerations in the near term when they are determining whether to implement new workflows that may affect those same stressed labor pools. As we are largely through the replacement cycle of our previous generation of automated dispensing systems, we are seeing demand moderate. We continue to invest in next-generation point of care enhancements and solutions and believe that customers will upgrade their current installed base over time as we deliver these new solutions to market. We also believe there is an opportunity for us to expand this offering and define a new standard for dispensing systems in ambulatory settings. We believe our current solutions within the Point of Care market and new innovation and services will continue to help customers drive improved clinical and financial outcomes.
•Central Pharmacy and IV Compounding. This market represents the beginning of the medication management process in acute care settings, and we believe it is a significant automation opportunity for high volumes of manual, repetitive, and error-prone processes that are often common in pharmacies today. Manual medication dispensing processes are usually labor intensive, error-prone, and may lead to excess medication waste and expirations for our healthcare partners. Automating the central pharmacy dispensing process should enable customers to reallocate pharmacy labor, enhance dispensing accuracy and patient safety, and reduce medication waste and expirations. Likewise, the manual compounding of sterile IV preparations can be error-prone and create significant patient safety risks, and outsourcing sterile IV compounding could lead to increased medication costs and lack of access to needed medications as a result of being unable to source medications when they are required. As a result, we believe IV automation provides a significant opportunity to enhance patient safety and reduce costs. We anticipate that these technology-enabled services will become more critical as health systems continue to face labor shortages, increased financial pressure, and supply chain disruptions.
•Specialty Pharmacy and 340B Program. We believe that health systems will continue to invest in programs that are intended to improve patient outcomes and drive cost savings by utilizing specialty pharmacies and the federal 340B Drug Pricing Program (the “340B Program”). The 340B Program allows qualifying hospitals and health systems to stretch federal resources and expand patient access to healthcare by requiring manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to eligible healthcare organizations and covered entities. Specialty drugs are used for treatment of complex conditions and often require intensive patient management and specialized workflows for dispensing and care coordination. Specialty medications are projected to account for nearly 60% of U.S. total spending on medications, with total spending projected to be approximately $420 billion in 2025. Specialty pharmacies serve as the connection between patients, prescribing physicians, and payers and work to streamline access and adherence to these specialty drugs. We believe a solution that is designed to help health systems start or optimize their specialty pharmacy programs and the related pharmaceutical aspects of patient care will help ensure continuity of care and should contribute to the revenue and profitability of those organizations. We believe that a fully optimized specialty pharmacy operation represents one of the largest economic opportunities for hospitals and health systems.
50
•Retail, Institutional, and Payer. We believe the Retail, Institutional, and Payer market represents a significant opportunity as healthcare evolves. Retail drug prescriptions represent 85% of all prescription drugs dispensed in the U.S., growing at a rate of 1.7% annually through 2022. Additionally, the COVID-19 pandemic accelerated the shift of outpatient care from hospitals and physician offices to other, more convenient settings, such as retail pharmacies and the home (including through telehealth technologies). New technologies and increased scope of practice for pharmacists appear to be spurring innovation and expansion of the provision of clinical services by retail pharmacies, which, combined with the move to value-based care, we believe will drive the adoption of our patient engagement solutions, that are intended to help providers (including pharmacists) and payers engage patients in new ways that are expected to improve outcomes, reduce the total cost of care, and lead to more profitable operations. Because of the complexity of relationships between payers and providers, as well as the large number of retail pharmacies, including a significant number of independent pharmacies, we believe a network of established relationships between payers, providers and pharmacies will continue to be important.
Ransomware Incident
Further information with respect to the ransomware incident we experienced in May 2022 may be found under the headings “Ongoing Mitigation Efforts” and “Impact of Recent Cyber Incident” in Part I, Item 1C of this Annual Report on Form 10-K. Such information is incorporated herein by reference.
Acquisitions
On January 10, 2022, we completed the acquisition of Hub and Spoke Innovations Limited (“Hub and Spoke Innovations”), pursuant to the terms and conditions of the Share Purchase Agreement, dated January 10, 2022, by and among Omnicell Limited (a wholly-owned subsidiary of the Company), Hub and Spoke Innovations Limited, and certain beneficial stockholders specified therein for a base purchase price of £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date), prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The Hub and Spoke Innovations acquisition is expected to complement Omnicell’s total solution technology portfolio for retail pharmacy in the United Kingdom to help pharmacies improve workflows, offer patients 24/7 access to their medications and provide enhanced patient care. The results of the operations of Hub and Spoke Innovations have been included in our consolidated results of operations beginning January 10, 2022.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based on our Consolidated Financial Statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. We regularly review our estimates and assumptions, which are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of certain assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates and assumptions. We believe the following critical accounting policies are affected by significant judgments and estimates used in the preparation of our Consolidated Financial Statements:
Revenue Recognition
We earn revenues from sales of our products and related services, which are sold in the healthcare industry, our principal market.
Prior to recognizing revenue, we identify the contract, performance obligations, and transaction price, and allocate the transaction price to the performance obligations. All identified contracts meet the following required criteria:
Parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations. A majority of our contracts are evidenced by a non-cancelable written agreement. Contracts for consumable products are generally evidenced by an order placed via our online portal, phone, or a purchase order.
Entity can identify each party’s rights regarding the goods or services to be transferred. Contract terms are documented within the written agreements. Where a written contract does not exist, such as for consumable products, the rights of each party are understood as following our standard business process and terms.
The entity can identify the payment terms for the goods or services to be transferred. Payment terms are documented within the agreement and are generally net 30 to 60 days from shipment of tangible product or services performed for
51
customers in the United States. Where a written contract does not exist, our standard payment terms are net 30 day terms.
The contract has commercial substance (that is the risk, timing, or amount of the entity’s future cash flows is expected to change as a result of the contract). Our agreements are an exchange of cash for a combination of products and services which result in changes in the amount of our future cash flows.
It is probable the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. We perform a credit check for all significant customers or transactions and where collectability is not probable, payment in full or a substantial down payment prior to shipment is typically required to help ensure the full agreed upon contract price will be collected.
Distinct goods or services are identified as performance obligations. A series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer are considered a single performance obligation. Where a good or service is determined not to be distinct, we combine the good or service with other promised goods or services until a bundle of goods or services that is distinct is identified. To identify our performance obligations, we consider all products or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. When performance obligations are included in separate contracts, we consider an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Most of our sales, other than renewals of support and maintenance, contain multiple performance obligations, with a combination of hardware systems, software products, support and maintenance, and professional services.
The transaction price of a contract is determined based on the fixed consideration, net of an estimate for variable consideration such as various discounts or rebates provided to customers. As a result of our commercial selling practices, contract prices are generally fixed with minimal, if any, variable consideration.
The transaction price is allocated to separate performance obligations proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price we charge for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, our products and services are not generally sold separately. We use an amount discounted from the list price as a best estimated selling price.
We recognize revenue when the performance obligation has been satisfied by transferring a promised good or service to a customer. The good or service is transferred when or as the customer obtains control of the good or service. Determining when control transfers requires management to make judgments that affect the timing of revenues recognized. Generally, for products requiring a complex implementation, control passes when the product is installed and ready for use. For all other products, control generally passes when product has been shipped and title has passed. For maintenance contracts and certain other services, including Advanced Services provided on a subscription basis, control passes to the customer over time, generally ratably over the service term as we provide a stand-ready service for the customer’s equipment. Time and material services transfer control to the customer at the time the services are provided. The portion of the transaction price allocated to our unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues, net of deferred cost of goods sold.
Revenues, contract assets, and contract liabilities are recorded net of associated taxes.
From time to time, we enter into change orders which modify the product to be received by the customer pursuant to certain contracts. Changes to any contract are accounted for as a modification of the existing contract to the extent the goods and services to be delivered as part of the contract are generally consistent with the nature and type of those to be provided under the terms of the original contract. Examples of such change orders include the addition or removal of units of equipment or changes to the configuration of the equipment where the overall nature of the contract remains intact. Our change orders generally result in the change being accounted for as modifications of existing contracts given the nature of the impacted orders.
In the normal course of business, we typically do not accept product returns unless the item is defective as manufactured or the configuration of the product is incorrect. We establish provisions for estimated returns based on historical product returns. The allowance for sales returns is not material to our Consolidated Financial Statements for any periods presented.
Lessor Leases
We determine if an arrangement is or contains a lease at inception. The transaction price is allocated to separate performance obligations, generally consisting of a combination of hardware systems, software products, support and maintenance, and professional services, proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price we charge for the good or service when selling it separately in similar
52
circumstances to similar customers. Other than for the renewal of annual technical services contracts, our products and services are not generally sold separately. We use an amount discounted from the list price as a best estimated selling price.
Sales-Type Leases
We enter into non-cancelable sales-type lease arrangements, most of which do not have an option to extend the lease term. At the end of the lease term, the customer must either return the equipment or negotiate a new agreement, resulting in a new purchase or lease transaction. Failure of the customer to either return the equipment or negotiate a new agreement results in the contract becoming a month-to-month rental. Certain sales-type leases automatically renew for successive one-year periods at the end of each lease term without written notice from the customer. Our sales-type lease agreements do not contain any material residual value guarantees.
For sales-type leases, we recognize revenues for our hardware and software products, net of lease execution costs, post-installation product maintenance, professional services associated with Advanced Services offerings, and technical support, at the net present value of the lease payment stream upon customer acceptance. We recognize service revenues associated with sales-type leases ratably over the term of the agreement in service revenues in the Consolidated Statements of Operations. We recognize interest income from sales-type leases using the effective interest method. Both hardware and software revenues, and interest income from sales-types leases are recorded in product revenues in the Consolidated Statements of Operations.
We optimize cash flows by selling a majority of our sales-type leases, other than those relating to U.S. government hospitals and Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. We have no obligation to the leasing company once the lease has been sold.
Allowance for Credit Losses
We are exposed to credit losses primarily through sales of our products and services, as well as our sales-type leasing arrangements. We perform credit evaluations of our customers’ financial condition in order to assess each customer’s ability to pay. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history, and a financial review of the customer. We continue to monitor customers’ creditworthiness on an ongoing basis.
We maintain an allowance for credit losses for accounts receivable, unbilled receivables, and net investment in sales-type leases based on expected credit losses resulting from the inability of our customers to make required payments. The allowance for credit losses is measured using a loss rate method, considering factors such as customers’ credit risk, historical loss experience, current conditions, and forecasts. The allowance for credit losses is measured on a collective (pool) basis by aggregating customer balances with similar risk characteristics. We also record a specific allowance based on an analysis of individual past due balances or customer-specific information, such as a decline in creditworthiness or bankruptcy. Actual collection losses may differ from management’s estimates, and such differences could be material to our financial position and results of operations.
Inventory
Inventories are stated at the lower of cost, computed using the first-in, first-out method, and net realizable value. Inbound shipping costs are included in cost of inventory. We regularly monitor inventory quantities on hand and record write-downs for excess and obsolete inventories based on our estimate of demand for our products, potential obsolescence of technology, product life cycles, and whether pricing trends or forecasts indicate that the carrying value of inventory exceeds its estimated selling price. These factors are impacted by market and economic conditions, technology changes, and new product introductions and require estimates that may include elements that are uncertain. Actual demand may differ from forecasted demand and may have a material effect on gross margins. If inventory is written down, a new cost basis is established that cannot be increased in future periods. Shipments from suppliers or contract manufacturers before we receive them are recorded as in-transit inventory when title and the significant risks and rewards of ownership have passed to us.
Internal-Use Software Development Costs
We capitalize costs related to computer software developed or obtained for internal-use in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software. Software developed or obtained for internal-use includes certain costs for the development of our subscription and cloud-based offerings sold to our customers, as well as enterprise-level business and finance software that we customize to meet our specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred.
53
External-Use Software Development Costs
We capitalize certain software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed, under which those costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. We establish technological feasibility when we complete a detail program design or a working model. We amortize development costs over the estimated lives of the related products, which is generally five years. All development costs prior to the completion of a detail program design or a working model are recognized as research and development expense.
Lessee Leases
We determine if an arrangement is or contains a lease at inception. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of our lease contracts do not provide an implicit rate, we use our incremental borrowing rate based on information available at the commencement date in determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term. We do not recognize a right-of-use asset and a lease liability for leases with an initial term of twelve months or less. We elected the practical expedient to not separate lease components from nonlease components and applied that practical expedient to all material classes of leased assets.
Many of our operating leases include an option to extend the lease. The specific terms and conditions of the extension options vary from lease to lease, but are consistent with standard industry practices in each area that we operate. We review each of our lease options at a time required by the terms of the lease contract, and notify the lessor if we choose to exercise the lease renewal option. Until we are reasonably certain that we will extend the lease contract, the renewal option periods will not be recognized as right-of-use assets or lease liabilities.
Certain leases include provisions for early termination, which allow the contract parties to terminate their obligations under the lease contract. The terms and conditions of the termination options vary by contract. When we have made a decision to exercise an early termination option, the right-of-use assets and associated lease liabilities are remeasured in accordance with the present value of the remaining cash flows under the lease contract.
Certain building lease agreements include rental payments subject to change annually based on fluctuations in various indexes (i.e., Consumer Price Index (“CPI”), Retail Price Index, and other international indexes). Certain data center lease agreements include rental payments subject to change based on usage and CPI fluctuations. The changes based on usage and indexes are treated as variable lease costs and recognized in the period in which the obligation for those payments was incurred. 
Business Combinations
We use the acquisition method of accounting under ASC 805, Business Combinations. Each acquired company’s operating results are included in our Consolidated Financial Statements starting on the acquisition date. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the acquisition date are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed.
Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on available historical information as well as future expectations, and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, acquired technology, backlog, trade names, and non-compete agreements.
Goodwill and Acquired Intangible Assets
Goodwill
We assess goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. This assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. We have one reporting unit, which is the same as our operating segment. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. A qualitative assessment includes, among others, consideration of: (i) past, current, and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this qualitative assessment indicates that it is more likely than not that impairment exists, or if we decide to bypass this option, we proceed to the quantitative assessment. The quantitative assessment involves a comparison
54
between the estimated fair value of our reporting unit with its carrying amount including goodwill. If the carrying value exceeds estimated fair value, we will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill.
To determine the reporting unit’s fair value under the quantitative approach, we use a combination of income and market approaches, such as estimated discounted future cash flows of the reporting unit, multiples of earnings or revenues, and analysis of recent sales or offerings of comparable entities. We also consider our market capitalization on the date of the analysis to ensure the reasonableness of our reporting unit’s fair value.
Intangible Assets
In connection with our acquisitions, we generally recognize assets for customer relationships, acquired technology, backlog, trade names, and non-compete agreements. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets. Amortization for acquired technology and backlog is recognized in cost of revenues, and amortization for customer relationships, trade names, non-compete agreements, and patents is recognized in selling, general, and administrative expenses.
We assess the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. Our cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of our intangible assets are subjective and are affected by changes to our business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of our assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on our operating results and financial condition.
Valuation of Share-Based Compensation
We account for share-based compensation in accordance with ASC 718, Stock Compensation. We recognize compensation expense related to share-based compensation based on the grant date estimated fair value.
The fair value of stock options (“options”) on the grant date is estimated using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of our common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on our historical experience of employee stock option exercises, including forfeitures. Expense is recognized on a straight-line basis over the requisite service period.
The fair value of restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) is based on the stock price on the grant date. The RSUs and RSAs are subject to a service vesting condition and are recognized on a straight-line basis over the requisite service period.
The fair value of performance-based stock unit awards (“PSUs”) with service and market conditions is estimated using a Monte Carlo simulation model applying a multiple awards approach. Expense is recognized when it is probable that the performance condition will be met using the accelerated attribution method over the requisite service period.
Forfeiture rates are estimated based on our historical experience with equity awards that were granted and forfeited prior to vesting. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods.
Accounting for Income Taxes
We record an income tax provision for (benefit from) the anticipated tax consequences of the reported results of operations. In accordance with ASC 740, Income Taxes, the provision for (benefit from) income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, we will incur a benefit or detriment on our income tax expense in the period of enactment. If we were to
55
determine that all or part of the net deferred tax assets are not realizable in the future, we will record a valuation allowance that would be charged to earnings in the period such determination is made.
In accordance with ASC 740, we recognize the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of ASC 740 and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on our financial condition and operating results.
Recently Issued Authoritative Guidance
Refer to “Recently Issued Authoritative Guidance” in Note 1, Organization and Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial position, and cash flows.
RESULTS OF OPERATIONS
Total Revenues
Year Ended December 31, Change in
20232022$%
(Dollars in thousands)
Product revenues$708,561 $903,222 $(194,661)(22)%
Percentage of total revenues62%70%
Services and other revenues438,551 392,725 45,826 12%
Percentage of total revenues38%30%
Total revenues$1,147,112 $1,295,947 $(148,835)(11)%
Product revenues represented 62% and 70% of total revenues for the years ended December 31, 2023 and 2022, respectively. Product revenues decreased by $194.7 million, primarily due to lower volumes from our automated dispensing systems business primarily as a result of ongoing health systems’ capital budget and labor constraints, partially offset by an increase of $9.7 million in revenues from consumables.
Services and other revenues represented 38% and 30% of total revenues for the years ended December 31, 2023 and 2022, respectively. Services and other revenues include revenues from technical services and Advanced Services offerings. Services and other revenues increased by $45.8 million, primarily due to an increase of $26.7 million in Advanced Services revenues due to continued customer demand and an increase of $19.1 million in technical services revenues as a result of growth in our installed customer base as well as the impact of pricing actions.
Our international sales represented 12% and 10% of total revenues for both of the years ended December 31, 2023 and 2022, respectively, and are expected to be affected by foreign currency exchange rate fluctuations. We are unable to predict the extent to which revenues in future periods will be impacted by changes in foreign currency exchange rates.
Our ability to grow revenues is dependent on our ability to continue to obtain orders from customers, which may be dependent upon customers’ capital equipment budgets and/or capital equipment approval cycles, our ability to produce quality products and consumables to fulfill customer demand, the volume of installations we are able to complete, our ability to meet customer needs by providing a quality installation experience, our ability to develop new or enhance existing solutions, and our flexibility in workforce allocations among customers to complete installations on a timely basis. The timing of our product revenues for equipment is primarily dependent on when our customers’ schedules and/or staffing levels allow for installations.
Cost of Revenues and Gross Profit
Cost of revenues is primarily comprised of three general categories: (i) standard product costs which account for the majority of the product cost of revenues that are provided to customers, and are inclusive of purchased material, labor to build the product, and overhead costs associated with production; (ii) costs of providing services and installation costs, including costs of personnel and other expenses; and (iii) other costs, including variances in standard costs and overhead, scrap costs, rework, provisions for excess and obsolete inventory, and amortization of software development costs and intangibles.
56
Year Ended December 31,Change in
20232022$%
(Dollars in thousands)
Cost of revenues:
Cost of product revenues$414,106 $493,626 $(79,520)(16)%
As a percentage of related revenues58%55%
Cost of services and other revenues236,166 213,334 22,832 11%
As a percentage of related revenues54%54%
Total cost of revenues$650,272 $706,960 $(56,688)(8)%
As a percentage of total revenues57%55%
Gross profit$496,840 $588,987 $(92,147)(16)%
Gross margin43%45%
Cost of revenues for the year ended December 31, 2023 compared to the year ended December 31, 2022 decreased by $56.7 million, primarily driven by a $79.5 million decrease in cost of product revenues, partially offset by a $22.8 million increase in cost of services and other revenues.
The decrease in cost of product revenues was primarily driven by the decrease in product revenues of $194.7 million for the year ended December 31, 2023 compared to the year ended December 31, 2022. The decrease in cost of product revenues has not decreased proportionally with the decrease in product revenues for the year ended December 31, 2023, primarily due to certain fixed costs, such as labor and overhead. In addition, the decrease in cost of product revenues was also driven by lower inventory-related costs as pricing for semiconductors, steel, freight, and other costs has decreased from the prior period, as well as the impact from restructuring activities. The increase in cost of services and other revenues was primarily driven by the increase in services and other revenues of $45.8 million for the year ended December 31, 2023 compared to the year ended December 31, 2022.
The overall decrease in gross margin primarily relates to lower product revenues for the year ended December 31, 2023 compared to the year ended December 31, 2022 whereas the decrease in cost of product revenues has not decreased proportionally with the decrease in product revenues, primarily due to certain fixed costs, such as labor and overhead. The decrease is partially offset by lower inventory-related costs and the impact from restructuring activities. Our gross profit for the year ended December 31, 2023 was $496.8 million, as compared to $589.0 million for the year ended December 31, 2022.
Operating Expenses and Interest and Other Income (Expense), Net
Year Ended December 31,Change in
20232022$%
(Dollars in thousands)
Operating expenses:
Research and development$97,115 $104,969 $(7,854)(7)%
As a percentage of total revenues8%8%
Selling, general, and administrative434,593 486,341 (51,748)(11)%
As a percentage of total revenues38%38%
Total operating expenses$531,708 $591,310 $(59,602)(10)%
As a percentage of total revenues46%46%
Interest and other income (expense), net$14,760 $(130)$14,890 (11454)%
Research and Development. Research and development expenses decreased by $7.9 million for the year ended December 31, 2023 compared to the year ended December 31, 2022. The decrease was primarily attributed to a decrease of $5.4 million in consulting expenses, a decrease in employee-related expenses of $4.8 million, and other decreases from cost saving initiatives, partially offset by an increase of $4.3 million due to the timing of capitalized software projects.
Selling, General, and Administrative. Selling, general, and administrative expenses decreased by $51.7 million for the year ended December 31, 2023 compared to the year ended December 31, 2022. The decrease was primarily due to a decrease
57
of $21.9 million in employee-related expenses, including the impact of restructuring activities, a decrease of $9.8 million in consulting expenses, a decrease of $7.3 million in commissions expenses, a decrease of $6.0 million in freight out, and a decrease of $4.8 million in travel expenses. The decrease is also driven by a decrease of $2.8 million of ransomware-related expenses, net of insurance recoveries, related to the ransomware incident we experienced in May 2022. The decrease is partially offset by an increase of $2.2 million in executive transition costs incurred during the year ended December 31, 2023, and an impairment of certain long-lived assets of $1.0 million during the year ended December 31, 2023.
Interest and Other Income (Expense), Net. Interest and other income (expense), net, changed by $14.9 million for the year ended December 31, 2023 compared to the year ended December 31, 2022, primarily driven by a $14.6 million increase in other income. The increase in other income during the year ended December 31, 2023 compared to the year ended December 31, 2022 is primarily attributable to higher interest income received due to higher interest rates and higher cash and cash equivalents balances.
Provision for (Benefit from) Income Taxes
Year Ended December 31,Change in
20232022$%
(Dollars in thousands)
Provision for (benefit from) income taxes$263 $(8,101)$8,364 (103)%
Effective tax rate on earnings(1)%330%
We recorded a provision for income taxes of $0.3 million on a loss before taxes of $20.1 million, which resulted in a negative effective tax rate of 1% for the year ended December 31, 2023, compared to an income tax benefit of $8.1 million on a loss before taxes of $2.5 million, which resulted in an effective tax rate of 330% for the year ended December 31, 2022. The 2023 annual effective tax rate differed from the statutory tax rate of 21%, primarily due to an unfavorable impact of non-deductible equity compensation charges partially offset by a favorable impact of research and development credits, and foreign-derived intangible income (“FDII”) deduction.
Refer to Note 17, Income Taxes, of the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K for additional information.
LIQUIDITY AND CAPITAL RESOURCES
We had cash and cash equivalents of $468.0 million at December 31, 2023, compared to $330.4 million at December 31, 2022. All of our cash and cash equivalents are invested in bank accounts and money market funds held in sweep and asset management accounts with financial institutions of high credit quality.
Our cash position and working capital at December 31, 2023 and 2022 were as follows:
December 31,
20232022
(In thousands)
Cash and cash equivalents$467,972 $330,362 
Working capital$559,779 $453,366 
Our ratio of current assets to current liabilities was 2.5:1 and 2.1:1 at December 31, 2023 and 2022, respectively.
Sources of Cash
Revolving Credit Facility
On November 15, 2019, we entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million.
On September 22, 2020 and March 29, 2023, we entered into amendments to the Prior A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge
58
transactions, as described in Note 11, Convertible Senior Notes, expand our flexibility to repurchase our common stock and make other restricted payments, and replace the total net leverage covenant, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to borrowings under the A&R Credit Agreement with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics.
On October 10, 2023, we entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million and 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable.
As of December 31, 2023, we had $350.0 million of funds available under the Current Revolving Credit Facility and as of December 31, 2022, we had $500.0 million of funds available under the Prior Revolving Credit Facility. As of December 31, 2023 and 2022, there was no outstanding balance under the Prior or Current Revolving Credit Facility and we were in full compliance with all covenants.
Refer to Note 10, Debt and Credit Agreement, of the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K for additional information. We expect to use future loans under the Current Revolving Credit Facility, if any, for working capital, potential acquisitions, and other general corporate purposes.
Uses of Cash
Our future uses of cash are expected to be primarily for working capital, capital expenditures, and other contractual obligations. We also expect a continued use of cash for potential acquisitions and acquisition-related activities, as well as repurchases of our common stock. In addition, we may also use a portion of our cash, as we consider various options related to our outstanding debt.
The 2016 Repurchase Program has a total of $2.7 million remaining for future repurchases as of December 31, 2023, which may result in additional use of cash. During the year ended December 31, 2022, we repurchased approximately 389,300 shares of our common stock under the repurchase programs at an average price of $134.11 per share for an aggregate purchase price of approximately $52.2 million. There were no stock repurchases during the year ended December 31, 2023. Refer to Note 16, Stock Repurchase Programs, of the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K for additional information.
Based on our current business plan and backlog, we believe that our existing cash and cash equivalents, our anticipated cash flows from operations, cash generated from the exercise of employee stock options and purchases under our Employee Stock Purchase Plan (“ESPP”), along with the availability of funds under the Current Revolving Credit Facility will be sufficient to meet our cash needs for working capital, capital expenditures, potential acquisitions, and other contractual obligations for at least the next twelve months. For periods beyond the next twelve months, we also anticipate that our net operating cash flows plus existing balances of cash and cash equivalents will suffice to fund the continued growth of our business.
59
Cash Flows
The following table summarizes, for the periods indicated, selected items in our Consolidated Statements of Cash Flows:
Year Ended December 31,
20232022
(In thousands)
Net cash provided by (used in):
Operating activities$181,094 $77,781 
Investing activities(55,016)(58,669)
Financing activities23,420 (20,953)
Effect of exchange rate changes on cash and cash equivalents(1,354)(944)
Net increase (decrease) in cash, cash equivalents, and restricted cash$148,144 $(2,785)
Operating Activities
We expect cash from our operating activities to fluctuate in future periods as a result of a number of factors, including the timing of our billings and collections, our operating results, and the timing of other liability payments.
Net cash provided by operating activities was $181.1 million for the year ended December 31, 2023, primarily consisting of net loss of $20.4 million adjusted for non-cash items of $157.8 million and changes in assets and liabilities of $43.7 million. The non-cash items primarily consisted of depreciation and amortization expense of $87.3 million, share-based compensation expense of $55.3 million, impairment and abandonment of operating lease right-of-use assets related to facilities of $10.0 million, amortization of operating lease right-of-use assets of $8.2 million, amortization of debt issuance costs of $4.4 million, and a change in deferred income taxes of $11.0 million. Changes in assets and liabilities include cash inflows from (i) a decrease in accounts receivable and unbilled receivables of $49.2 million primarily due to the timing of billings, shipments, and collections, as well as the impacts of lower revenues, (ii) a decrease in inventories of $38.0 million primarily due to management of inventory levels to align with the current forecasted demand, (iii) an increase in deferred revenues of $24.1 million primarily due to an increase in billings for certain technical service and Advanced Service offerings, (iv) a decrease in prepaid commissions of $7.1 million, (v) a decrease in other long-term assets of $2.1 million, and (vi) a decrease in prepaid expenses of $1.1 million. These cash inflows were partially offset by (i) a decrease in accrued compensation of $21.5 million primarily due to a decrease in the accrual for restructuring initiatives, lower commissions, as well as timing of ESPP purchases, (ii) a decrease in accounts payables of $17.5 million primarily due to an overall decrease in spending, as well as timing of payments, (iii) a decrease in operating lease liabilities of $10.9 million, (iv) an increase in investment in sales-type leases of $10.4 million primarily due to the acceptance of certain Advanced Services products under sales-type lease arrangements, (v) a decrease in accrued liabilities of $10.3 million, and (vi) an increase in other current assets of $6.8 million.
Net cash provided by operating activities was $77.8 million for the year ended December 31, 2022, primarily consisting of net income of $5.6 million adjusted for non-cash items of $145.6 million, offset by changes in assets and liabilities of $73.5 million. The non-cash items primarily consisted of depreciation and amortization expense of $86.9 million, share-based compensation expense of $68.2 million, amortization of operating lease right-of-use assets of $12.2 million, impairment and abandonment of operating lease right-of-use assets related to facilities of $9.4 million, amortization of debt issuance costs of $4.2 million, and a change in deferred income taxes of $37.3 million. Changes in assets and liabilities include cash outflows from (i) an increase in accounts receivable and unbilled receivables of $60.4 million primarily due to an increase in billings driven by overall business growth and the timing of shipments as well as collections, (ii) an increase in inventories of $30.1 million primarily to support forecasted sales, including advanced purchases of certain components, such as semiconductors, as well as higher costs of inventory and timing of shipments, (iii) an increase in investment in sales-type leases of $15.4 million primarily due to the increase in sales-type lease revenues associated with certain Advanced Services products, (iv) a decrease in operating lease liabilities of $13.8 million, (v) a decrease in accounts payables of $7.8 million primarily due to an overall decrease in spending during the fourth quarter of 2022, including inventory spending, as well as timing of payments, and (vi) an increase in prepaid expenses of $4.7 million. These cash outflows were partially offset by (i) an increase in deferred revenues of $24.5 million primarily due to an increase in billings for certain service and subscription offerings, (ii) an increase in accrued liabilities of $16.7 million primarily due to an increase in taxes payable and an increase in general liabilities, (iii) a decrease in other current assets of $6.4 million, (iv) a decrease in other long-term assets of $5.0 million, (v) a decrease in prepaid commissions of $4.3 million, and (vi) an increase in accrued compensation of $2.4 million.
60
Investing Activities
Net cash used in investing activities was $55.0 million for the year ended December 31, 2023, which consisted of capital expenditures of $41.5 million for property and equipment and $13.5 million for external-use software development costs.
Net cash used in investing activities was $58.7 million for the year ended December 31, 2022, which consisted of capital expenditures of $47.5 million for property and equipment, $13.2 million for external-use software development costs, and $3.4 million consideration paid for the acquisition of Hub and Spoke Innovations, net of cash acquired, partially offset by purchase price adjustments from business acquisitions of $5.5 million.
Financing Activities
Net cash provided by financing activities was $23.4 million for the year ended December 31, 2023, primarily due to $23.2 million in proceeds from employee stock option exercises and ESPP purchases and a net change in the customer funds balances of $10.5 million, partially offset by $7.4 million in employees’ taxes paid related to restricted stock unit vesting and $3.0 million in payments for debt issuance costs.
Net cash used in financing activities was $21.0 million for the year ended December 31, 2022, primarily due to $52.2 million for repurchases of our stock and $13.5 million in employees’ taxes paid related to restricted stock unit vesting, partially offset by $40.2 million in proceeds from employee stock option exercises and ESPP purchases and a net change in the customer funds balances of $4.6 million.
Contractual Obligations
Contractual obligations as of December 31, 2023 were as follows:
Payments Due By Period
Total20242025 - 20262027 - 20282029 and thereafter
(In thousands)
Operating leases (1)
$50,600 $12,722 $20,324 $15,720 $1,834 
Purchase obligations (2)
93,901 84,215 9,621 65 — 
Convertible senior notes (3)
577,876 1,438 576,438 — — 
Total (4)
$722,377 $98,375 $606,383 $15,785 $1,834 
_________________________________________________
(1)Commitments under operating leases relate primarily to leased office buildings, data centers, office equipment, and vehicles. Refer to Note 13, Lessee Leases, of the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K for additional information.
(2)We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. These amounts are associated with agreements that are enforceable and legally binding. The amounts under such contracts are included in the table above because we believe that cancellation of these contracts is unlikely and we expect to make future cash payments according to the contract terms or in similar amounts for similar materials.
(3)We issued convertible senior notes in September 2020 that are due in September 2025. The obligations presented above include both principal and interest for these notes. Although these notes mature in 2025, they may be converted into cash and shares of our common stock prior to maturity if certain conditions are met. Any conversion prior to maturity can result in repayment of the principal amounts sooner than the scheduled repayment as indicated in the table above. Refer to Note 11, Convertible Senior Notes, of the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K for additional information.
(4)Refer to Note 14, Commitments and Contingencies, of the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K for additional information.
ITEM 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risks related to fluctuations in foreign currency exchange rates and interest rates.
Foreign Currency Exchange Risk
We operate in foreign countries which expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which are the British Pound and the Euro. In order to manage foreign currency risk, at times we enter into foreign exchange forward contracts to mitigate risks
61
associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of our foreign subsidiaries. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We do not enter into derivative contracts for trading purposes. As of December 31, 2023, we did not have any outstanding foreign exchange forward contracts.
Interest Rate Fluctuation Risk
We are exposed to interest rate risk through our borrowing activities. As of December 31, 2023, there was no outstanding balance under the Current A&R Credit Agreement, and the net carrying amount under our convertible senior notes was $569.7 million. Although our convertible senior notes are based on a fixed rate, changes in interest rates could impact the fair value of such notes. As of December 31, 2023, the fair market value of our convertible senior notes was $527.2 million. Refer to Note 5, Fair Value of Financial Instruments, and Note 11, Convertible Senior Notes, of the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K for additional information.
We have used, and in the future we may use, interest rate swap agreements to protect against adverse fluctuations in interest rates by reducing our exposure to variability in cash flows relating to interest payments on a portion of our outstanding debt. We do not hold or issue any derivative financial instruments for speculative trading purposes. As of December 31, 2023, we did not have any outstanding interest rate swap agreements.
ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The Report of Independent Auditors and Consolidated Financial Statements are included in Item 15 of this Annual Report on Form 10-K beginning on page F-1 and are incorporated herein by reference.
ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A.    CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2023 to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable assurance that the objectives of the internal control system are met.
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023 using the criteria for effective internal control over financial reporting as described in “Internal Control—Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO Criteria). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2023.
62
Deloitte & Touche LLP, an independent registered public accounting firm, has issued its attestation report on our internal control over financial reporting as of December 31, 2023, which is included in Part IV, Item 15 of this Annual Report on Form 10-K.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the year ended December 31, 2023.
ITEM 9B.    OTHER INFORMATION
Securities Trading Plans of Directors and Officers
During the three months ended December 31, 2023, none of our directors or officers adopted or terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as each term is defined in Item 408(a) of Regulation S-K).
ITEM 9C.    DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.
Not applicable.
63
PART III
Certain information required by Part III is omitted from this Annual Report on Form 10-K because the registrant will file with the United States Securities and Exchange Commission a definitive proxy statement pursuant to Regulation 14A in connection with the solicitation of proxies for Omnicell’s Annual Meeting of Stockholders expected to be held in May 2024 (the “Proxy Statement”) not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and certain information included therein is incorporated herein by reference.
ITEM 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this Item with respect to directors and executive officers may be found under the heading “Information About Our Executive Officers” in Part I, Item 1 of this Annual Report on Form 10-K, and in the sections entitled “Board and Corporate Governance Matters—Election of Directors” and “Board and Corporate Governance Matters—Information about our Directors and Nominees” appearing in the Proxy Statement. Such information is incorporated herein by reference.
The information required by this Item with respect to our audit committee and audit committee financial expert may be found in the section entitled “Board and Corporate Governance Matters—Information Regarding Committees of the Board of Directors—Audit Committee” appearing in the Proxy Statement. Such information is incorporated herein by reference.
The information required by this Item with respect to compliance with Section 16(a) of the Securities Exchange Act of 1934 may be found in the sections entitled “Delinquent Section 16(a) Reports” appearing in the Proxy Statement. Such information is incorporated herein by reference.
Our written Code of Conduct applies to all of our directors and employees, including executive officers, including without limitation our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Conduct is available on our investor relations website is located at ir.omnicell.com under the hyperlink entitled “Leadership & Governance—Governance Documents.” Changes to or waivers of the Code of Conduct will be disclosed on the same website. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding any amendment to, or waiver of, any provision of the Code of Conduct by disclosing such information on the same website.
ITEM 11.    EXECUTIVE COMPENSATION
The information required by this Item with respect to director and executive officer compensation is incorporated by reference to the sections of our Proxy Statement entitled “Executive Compensation” and “Board and Corporate Governance Matters—Director Compensation.”
The information required by this Item with respect to Compensation Committee interlocks and insider participation is incorporated herein by reference to the section of our Proxy Statement entitled “Board and Corporate Governance Matters—Information Regarding Committees of the Board of Directors—Compensation Committee—Compensation Committee Interlocks and Insider Participation.”
The information required by this Item with respect to our Compensation Committee’s review and discussion of the Compensation Discussion and Analysis included in the Proxy Statement is incorporated herein by reference to the section of our Proxy Statement entitled “Executive Compensation—Compensation Committee Report.”
ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this Item with respect to security ownership of certain beneficial owners and management is incorporated herein by reference to the section of our Proxy Statement entitled “Stock Ownership—Security Ownership of Certain Beneficial Owners and Management.”
The information required by this Item with respect to securities authorized for issuance under our equity compensation plans is incorporated herein by reference to the section of our Proxy Statement entitled “Equity Plan Information—Equity Compensation Plan Information.”
ITEM 13.    CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
The information required by this Item with respect to related party transactions is incorporated herein by reference to the section of our Proxy Statement entitled “Board and Corporate Governance Matters—Certain Relationships and Related Transactions.”
64
The information required by this Item with respect to director independence is incorporated herein by reference to the section of our Proxy Statement entitled “Board and Corporate Governance Matters—Independence of the Board of Directors.”
ITEM 14.    PRINCIPAL ACCOUNTANT FEES AND SERVICES
The information required by this Item is incorporated herein by reference to the section of our Proxy Statement entitled “Audit Matters—Ratification of Selection of Independent Registered Public Accounting Firm—Principal Accountant Fees and Services.”
65
PART IV
ITEM 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULE
The following documents are included as part of this Annual Report on Form 10-K:
(2)    Exhibits: The information required by this item is set forth on the exhibit index which precedes the signature page of this Annual Report on Form 10-K.
ITEM 16.    FORM 10-K SUMMARY
None.
66
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of Omnicell, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Omnicell, Inc. and subsidiaries (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 2024, expressed an unqualified opinion on the Company’s internal control over financial reporting.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Inventory Valuation — Refer to Note 1 to the financial statements
Critical Audit Matter Description
The Company records write-downs for excess and slow-moving inventory based on the Company’s estimate of demand for its products, potential obsolescence of technology, product life cycles, and whether pricing trends or forecasts indicate that the carrying value of inventory exceeds its estimated selling price. These estimates require management judgment and are impacted by market and economic conditions, technology changes, and new product introductions. The Company’s consolidated inventory balance is $110.1 million as of December 31, 2023.
We identified the inventory valuation as a critical audit matter because of the assumptions and judgments made by management to estimate the excess and slow-moving inventory, especially considering the presence of inventory with evolving product life cycles. The analysis of equipment-related inventory valuation required a high degree of auditor judgment when performing audit procedures to evaluate qualitative and quantitative factors considered and the reasonableness of the relevant management assumptions and judgments.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures over the inventory valuation included the following, among others:
F-1
•    We tested the effectiveness of internal controls over inventory for valuation.
•    We evaluated the appropriateness of management’s method, assumptions, and judgments used in developing their estimate of the excess and slow-moving equipment-related inventory, which included consideration of demand for its products, potential obsolescence of technology, and product life cycles.
•    We tested certain underlying data used and considered in the excess and obsolete equipment-related inventory assessment, including the amount of inventory on hand and forecasted demand.
•    We compared actual equipment-related inventory usage and write-off activity in the current year to the excess and obsolete estimates by management of individual equipment-related inventory items selected for testing in the prior year to evaluate management’s ability to make reasonably accurate estimates.
•    We evaluated the valuation of excess and obsolete equipment-related inventory for understatement by making selections of equipment-related individual inventory items and evaluating the appropriateness of the equipment-related inventory valuation and management judgments based on relevant product-specific information. These procedures also included certain inquiries of purchasing employees.
Capitalized Software - Internal Software Development Costs — Refer to Notes 1 and 7 to the financial statements
Critical Audit Matter Description
The Company capitalizes certain costs related to computer software developed or obtained for internal use when costs are incurred in the application development phase and amortizes these costs over the estimated lives of the software. The determination of whether a project’s software development costs are capitalized or expensed could have a significant impact on the financial statements. The Company capitalized $32.2 million of costs related to the application development of enterprise-level software and its subscription and cloud-based offerings in the year ended December 31, 2023.
We identified management’s determination of internal use capitalized software development costs to be a critical audit matter. Evaluating the Company’s determination of the project and related software development activities to be capitalized under relevant accounting guidance, including the extent to which software development costs incurred were capitalized, required subjective auditor judgment.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures to assess the appropriateness of capitalized internal software development costs included the following, among others:
•    We tested the effectiveness of internal controls related to management’s capitalized internal software development costs.
•    We obtained an understanding of management’s process for evaluating internal software development costs and the nature of internal software development costs capitalized.
•    We tested management’s method of calculating capitalized internal software development costs. For a sample of projects, we performed audit procedures to agree capitalized labor costs to time records and made certain inquiries of project members to further assess the reasonableness of time allocated to the selected projects.
•    For a sample of internal software development projects, we obtained an understanding of the new software enhancements and features planned for development by reviewing management’s project documentation and inquiring of project managers and engineers.
•    For a sample of internal software development projects, we tested the timing of internal software development cost recognition as either a capitalized or an expensed development cost. We also inquired of project managers and engineers regarding when application development was reached and observed the new features developed.

/s/ Deloitte & Touche LLP
San Jose, California
February 28, 2024
We have served as the Company’s auditor since 2014.
F-2
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the stockholders and the Board of Directors of Omnicell, Inc.
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of Omnicell, Inc. and subsidiaries (the “Company”) as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2023, of the Company and our report dated February 28, 2024, expressed an unqualified opinion on those financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Deloitte & Touche LLP
San Jose, California
February 28, 2024
F-3
OMNICELL, INC.
CONSOLIDATED BALANCE SHEETS
December 31,
20232022
(In thousands, except par value)
ASSETS
Current assets:
Cash and cash equivalents$467,972 $330,362 
Accounts receivable and unbilled receivables, net of allowances of $5,564 and $5,153, respectively
252,025 299,469 
Inventories110,099 147,549 
Prepaid expenses25,966 27,070 
Other current assets71,509 77,362 
Total current assets927,571 881,812 
Property and equipment, net108,601 93,961 
Long-term investment in sales-type leases, net42,954 32,924 
Operating lease right-of-use assets24,988 38,052 
Goodwill735,810 734,274 
Intangible assets, net211,173 242,906 
Long-term deferred tax assets32,901 22,329 
Prepaid commissions52,414 59,483 
Other long-term assets90,466 105,017 
Total assets$2,226,878 $2,210,758 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$45,028 $63,389 
Accrued compensation51,754 73,455 
Accrued liabilities149,276 172,655 
Deferred revenues, net121,734 118,947 
Total current liabilities367,792 428,446 
Long-term deferred revenues58,622 37,385 
Long-term deferred tax liabilities1,620 2,095 
Long-term operating lease liabilities33,910 39,405 
Other long-term liabilities6,318 6,719 
Convertible senior notes, net569,662 566,571 
Total liabilities1,037,924 1,080,621 
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued
— — 
Common stock, $0.001 par value, 100,000 shares authorized; 55,822 and 55,030 shares issued; 45,539 and 44,747 shares outstanding, respectively
56 55 
Treasury stock at cost, 10,283 shares outstanding, respectively
(290,319)(290,319)
Additional paid-in capital1,122,292 1,046,760 
Retained earnings370,357 390,728 
Accumulated other comprehensive loss(13,432)(17,087)
Total stockholders’ equity1,188,954 1,130,137 
Total liabilities and stockholders’ equity$2,226,878 $2,210,758 
The accompanying notes are an integral part of these Consolidated Financial Statements.
F-4
OMNICELL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Year Ended December 31,
202320222021
(In thousands, except per share data)
Revenues:
Product revenues$708,561 $903,222 $812,512 
Services and other revenues438,551 392,725 319,506 
Total revenues1,147,112 1,295,947 1,132,018 
Cost of revenues:
Cost of product revenues414,106 493,626 422,855 
Cost of services and other revenues236,166 213,334 154,510 
Total cost of revenues650,272 706,960 577,365 
Gross profit496,840 588,987 554,653 
Operating expenses:
Research and development97,115 104,969 75,716 
Selling, general, and administrative434,593 486,341 389,430 
Total operating expenses531,708 591,310 465,146 
Income (loss) from operations(34,868)(2,323)89,507 
Interest and other income (expense), net14,760 (130)(23,500)
Income (loss) before income taxes(20,108)(2,453)66,007 
Provision for (benefit from) income taxes263 (8,101)(11,842)
Net income (loss)$(20,371)$5,648 $77,849 
Net income (loss) per share:
Basic$(0.45)$0.13 $1.79 
Diluted$(0.45)$0.12 $1.62 
Weighted-average shares outstanding:
Basic45,212 44,398 43,475 
Diluted45,212 45,891 47,943 
The accompanying notes are an integral part of these Consolidated Financial Statements.

F-5
OMNICELL, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Year Ended December 31,
202320222021
(In thousands)
Net income (loss)$(20,371)$5,648 $77,849 
Other comprehensive income (loss):
Foreign currency translation adjustments3,655 (8,680)(2,885)
Other comprehensive income (loss)3,655 (8,680)(2,885)
Comprehensive income (loss)$(16,716)$(3,032)$74,964 
The accompanying notes are an integral part of these Consolidated Financial Statements.
F-6
OMNICELL, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Common StockTreasury Stock
Additional
Paid-In
Capital
Retained
Earnings
Accumulated Other
Comprehensive Income (Loss)
Stockholders’
Equity
SharesAmountSharesAmount
(In thousands)
Balances as of December 31, 202052,677 $53 (9,894)$(238,109)$920,359 $290,722 $(5,522)$967,503 
Net income— — — — — 77,849 — 77,849 
Other comprehensive loss— — — — — — (2,885)(2,885)
Share-based compensation— — — 53,160 — — 53,160 
Issuance of common stock under employee stock plans1,396 1 — — 67,347 — — 67,348 
Tax payments related to restricted stock units— — — — (16,286)— — (16,286)
Balances as of December 31, 202154,073 54 (9,894)(238,109)1,024,580 368,571 (8,407)1,146,689 
Net income— — — — — 5,648 — 5,648 
Other comprehensive loss— — — — — — (8,680)(8,680)
Stock repurchases— — (389)(52,210)— — — (52,210)
Share-based compensation— — — — 68,247 — — 68,247 
Issuance of common stock under employee stock plans957 1 — — 40,181 — — 40,182 
Tax payments related to restricted stock units— — — (13,506)— — (13,506)
Cumulative effect of a change in accounting principle related to convertible debt— — — — (72,742)16,509 — (56,233)
Balances as of December 31, 202255,030 55 (10,283)(290,319)1,046,760 390,728 (17,087)1,130,137 
Net loss— — — — — (20,371)— (20,371)
Other comprehensive income— — — — — — 3,655 3,655 
Share-based compensation— — — — 59,683 — — 59,683 
Issuance of common stock under employee stock plans792 1 — — 23,215 — — 23,216 
Tax payments related to restricted stock units— — — — (7,366)— — (7,366)
Balances as of December 31, 202355,822 $56 (10,283)$(290,319)$1,122,292 $370,357 $(13,432)$1,188,954 
The accompanying notes are an integral part of these Consolidated Financial Statements.
F-7
OMNICELL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
202320222021
(In thousands)
Operating Activities
Net income (loss)$(20,371)$5,648 $77,849 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization87,319 86,931 72,990 
Loss on disposal of property and equipment2,572 678 433 
Share-based compensation expense55,300 68,247 53,160 
Deferred income taxes(11,047)(37,316)(3,272)
Amortization of operating lease right-of-use assets8,239 12,238 11,941 
Impairment and abandonment of operating lease right-of-use assets related to facilities9,998 9,382 — 
Impairment of internal-use and external-use software development costs, net— 1,275 — 
Impairment of certain long-lived assets1,014 — — 
Amortization of debt issuance costs4,397 4,164 3,440 
Amortization of discount on convertible senior notes— — 18,608 
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivables49,150 (60,357)(40,973)
Inventories38,016 (30,115)(25,695)
Prepaid expenses1,149 (4,671)(5,678)
Other current assets(6,821)6,360 2,801 
Investment in sales-type leases(10,411)(15,354)3,346 
Prepaid commissions7,069 4,312 (6,876)
Other long-term assets2,111 5,027 (3,258)
Accounts payable(17,525)(7,754)29,084 
Accrued compensation(21,461)2,446 12,312 
Accrued liabilities(10,343)16,651 34,859 
Deferred revenues24,058 24,469 24,179 
Operating lease liabilities(10,918)(13,781)(12,503)
Other long-term liabilities(401)(699)(14,938)
Net cash provided by operating activities181,094 77,781 231,809 
Investing Activities
External-use software development costs (13,542)(13,204)(29,368)
Purchases of property and equipment(41,474)(47,536)(28,967)
Business acquisitions, net of cash acquired— (3,392)(354,163)
Purchase price adjustments from business acquisitions— 5,463 — 
Net cash used in investing activities(55,016)(58,669)(412,498)
Financing Activities
Payments for debt issuance costs for revolving credit facility(2,967)— — 
Proceeds from issuances under stock-based compensation plans23,216 40,182 67,348 
Employees’ taxes paid related to restricted stock units(7,366)(13,506)(16,286)
Stock repurchases— (52,210)— 
Change in customer funds, net10,537 4,581 (3,699)
Net cash provided by (used in) financing activities23,420 (20,953)47,363 
Effect of exchange rate changes on cash and cash equivalents(1,354)(944)(974)
Net increase (decrease) in cash, cash equivalents, and restricted cash148,144 (2,785)(134,300)
Cash, cash equivalents, and restricted cash at beginning of period352,835 355,620 489,920 
Cash, cash equivalents, and restricted cash at end of period$500,979 $352,835 $355,620 
The accompanying notes are an integral part of these Consolidated Financial Statements.
F-8
OMNICELL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
Year Ended December 31,
202320222021
(In thousands)
Reconciliation of cash, cash equivalents, and restricted cash to the Consolidated Balance Sheets:
Cash and cash equivalents$467,972 $330,362 $349,051 
Restricted cash included in other current assets33,007 22,473 6,569 
Cash, cash equivalents, and restricted cash at end of period$500,979 $352,835 $355,620 
Supplemental cash flow information
Cash paid for interest$1,438 $1,438 $1,917 
Income taxes paid (refunds received), net$20,209 $19,005 $(1,733)
Supplemental disclosure of non-cash investing activities
Unpaid purchases of property and equipment$877 $892 $883 
Transfers between inventory and property and equipment, net$— $314 $1,876 
The accompanying notes are an integral part of these Consolidated Financial Statements.
F-9
OMNICELL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1.     Organization and Summary of Significant Accounting Policies
Business
Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” refer to Omnicell, Inc. and its subsidiaries, collectively.
Basis of Presentation
The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations, and cash flows for the periods presented.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying Notes to Consolidated Financial Statements. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. Those policies are revenue recognition; allowance for credit losses for accounts receivable and unbilled receivables; notes receivable from investment in sales-type leases; operating lease right-of-use assets and liabilities; inventory valuation; internal-use and external-use software development costs; impairment of goodwill; purchased intangibles and long-lived assets; fair value of assets acquired and liabilities assumed in business combinations; share-based compensation; and accounting for income taxes. As of December 31, 2023, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.
Segment Reporting
The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.
Foreign Currency Translation and Remeasurement
Most of the Company’s foreign subsidiaries use the local currency of their respective countries as their functional currency. The Company translates the assets and liabilities of such non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income (loss) in stockholders’ equity.
Assets and liabilities denominated in a currency other than the functional currency are remeasured into the respective entity’s functional currency. Monetary assets and liabilities are remeasured at exchange rates in effect at the end of each period, and non-monetary assets and liabilities are remeasured at historical rates. Gains and losses from foreign currency remeasurement of monetary assets and liabilities are recorded in interest and other income (expense), net.
F-10
Revenue Recognition
The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories:
Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service.
Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions.
Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements.
Advanced Services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth®, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service.
The following table summarizes revenue recognition for each revenue category:
Revenue Category
Timing of Revenue Recognition
Income Statement Classification
Connected devices, software licenses, and other
Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer
Product
Consumables
Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer
Product
Technical services
Over time, as services are provided, typically ratably over the service term
Service
Advanced Services
Over time, as services are provided
Service
Prior to recognizing revenue, the Company identifies the contract, performance obligations, and transaction price, and allocates the transaction price to the performance obligations. All identified contracts meet the following required criteria:
Parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations. A majority of the Company’s contracts are evidenced by a non-cancelable written agreement. Contracts for consumable products are generally evidenced by an order placed via our online portal, phone, or a purchase order.
Entity can identify each party’s rights regarding the goods or services to be transferred. Contract terms are documented within the written agreements. Where a written contract does not exist, such as for consumable products, the rights of each party are understood as following the Company’s standard business process and terms.
The entity can identify the payment terms for the goods or services to be transferred. Payment terms are documented within the agreement and are generally net 30 to 60 days from shipment of tangible product or services performed for customers in the United States. Where a written contract does not exist, the Company’s standard payment terms are net 30 day terms.
The contract has commercial substance (that is the risk, timing, or amount of the entity’s future cash flows is expected to change as a result of the contract). The Company’s agreements are an exchange of cash for a combination of products and services which result in changes in the amount of the Company’s future cash flows.
It is probable the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company performs a credit check for all significant customers or
F-11
transactions and where collectability is not probable, payment in full or a substantial down payment prior to shipment is typically required to help ensure the full agreed upon contract price will be collected.
Distinct goods or services are identified as performance obligations. A series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer are considered a single performance obligation. Where a good or service is determined not to be distinct, the Company combines the good or service with other promised goods or services until a bundle of goods or services that is distinct is identified. To identify its performance obligations, the Company considers all products or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. When performance obligations are included in separate contracts, the Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Most of the Company’s sales, other than renewals of support and maintenance, contain multiple performance obligations, with a combination of hardware systems, software products, support and maintenance, and professional services.
The transaction price of a contract is determined based on the fixed consideration, net of an estimate for variable consideration such as various discounts or rebates provided to customers. As a result of the Company’s commercial selling practices, contract prices are generally fixed with minimal, if any, variable consideration.
The transaction price is allocated to separate performance obligations proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.
The Company recognizes revenue when the performance obligation has been satisfied by transferring a promised good or service to a customer. The good or service is transferred when or as the customer obtains control of the good or service. Determining when control transfers requires management to make judgments that affect the timing of revenues recognized. Generally, for products requiring a complex implementation, control passes when the product is installed and ready for use. For all other products, control generally passes when product has been shipped and title has passed. For maintenance contracts and certain other services, including Advanced Services provided on a subscription basis, control passes to the customer over time, generally ratably over the service term as the Company provides a stand-ready service for the customer’s equipment. Time and material services transfer control to the customer at the time the services are provided.
The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues, net of deferred cost of goods sold. Deferred revenues from product sales primarily relate to delivered and invoiced products, pending installation and acceptance. Deferred revenues from service contracts primarily relate to services that have been invoiced, where services have not yet been provided. Short-term deferred revenues are expected to be recognized within the next twelve months. Long-term deferred revenues substantially consist of deferred revenues on long-term technical and Advanced Services contracts which have been invoiced and are expected to be recognized as revenue beyond twelve months, generally not more than ten years.
In addition, the Company has remaining performance obligations associated with contracts for which the associated products have been accepted or associated services have started, but where invoicing has not yet occurred and therefore are not reflected in deferred revenue. These remaining performance obligations are comprised of the non-variable portions of technical services and Advanced Services provided under non-cancellable contracts with minimum commitments. Remaining performance obligations which are not included in deferred revenues are $353.9 million as of December 31, 2023. Remaining performance obligations are expected to be recognized ratably over the remaining terms of the associated contracts, which terms vary but are generally not more than ten years. Remaining performance obligations do not include product obligations, services where the associated product has not been accepted, services which have not yet started, variable portions of services, and certain other obligations.
Revenues, contract assets, and contract liabilities are recorded net of associated taxes.
The Company generally invoices customers for products upon shipment. Invoicing associated with the service portion of agreements is generally periodic and is billed on a monthly, quarterly, or annual basis, and in certain circumstances, multiple years are billed at one time. Advanced Services agreements are generally invoiced periodically on a monthly, quarterly or annual basis over the life of the agreement. In certain circumstances portions of these agreements may be invoiced lump sum.
The amount invoiced for equipment and software is typically reflected in both accounts receivable and deferred revenues, net. The Company typically recognizes product revenue, and correspondingly reduces deferred revenues, net, for equipment and on-premise software upon written customer acceptance of installation. Consumables are recorded as revenue upon shipment to or receipt by the customer, depending upon contract terms.
F-12
From time to time, the Company enters into change orders which modify the product to be received by the customer pursuant to certain contracts. Changes to any contract are accounted for as a modification of the existing contract to the extent the goods and services to be delivered as part of the contract are generally consistent with the nature and type of those to be provided under the terms of the original contract. Examples of such change orders include the addition or removal of units of equipment or changes to the configuration of the equipment where the overall nature of the contract remains intact. The Company’s change orders generally result in the change being accounted for as modifications of existing contracts given the nature of the impacted orders.
In the normal course of business, the Company typically does not accept product returns unless the item is defective as manufactured or the configuration of the product is incorrect. The Company establishes provisions for estimated returns based on historical product returns. The allowance for sales returns is not material to the Consolidated Financial Statements for any periods presented.
A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”), each of which functions as a purchasing agent on behalf of member hospitals and other healthcare providers. The Company also has a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”), allowing the Department of Veterans Affairs, the Department of Defense, and other federal government customers to purchase the Company’s products. Pursuant to the terms of GPO agreements and the GSA Contract, each member or agency contracts directly with Omnicell and can purchase the Company’s products at pre-negotiated contract terms and pricing. GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $11.2 million, $17.6 million, and $17.5 million for the years ended December 31, 2023, 2022, and 2021, respectively. The accounts receivable balances are with individual members of the GPOs and federal agencies that purchase under the GSA Contract, and therefore no significant concentration of credit risk exists. During the year ended December 31, 2023, sales to members of the ten largest GPOs and federal agencies that purchase under the GSA Contract accounted for approximately 64% of the Company’s total consolidated revenues.
Contract Assets and Contract Liabilities
A contract asset is a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration. A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. Contract liabilities include customer deposits under non-cancelable contracts, and current and non-current deferred revenue balances. The Company’s contract balances are reported in a net contract asset or liability position on a contract-by-contract basis at the end of each reporting period.
Significant changes in the contract assets and the contract liabilities balances during the period are the result of the issuance of invoices and recognition of deferred revenues in the normal course of business. The contract modifications entered into during the year ended December 31, 2023 did not have a significant impact on the Company’s contract assets or deferred revenues.
Contract Costs
The Company has determined that certain incentive portions of its sales commission plans require capitalization since these payments are directly related to sales achieved during a time period. These commissions are earned on the basis of: (i) the value of new bookings for connected devices, software products, and Advanced Services, provided that for Advanced Services a commission will only be paid on the amount that represents the minimum commitment and (ii) the value of new orders for consumables. Since there are no commensurate commissions earned on renewal of the service bookings, the Company concluded that the capitalized asset is related to services provided under both the initial contract and renewal periods. The Company applies a practical expedient to account for the incremental costs of obtaining a contract as part of a portfolio of contracts with similar characteristics as the Company expects the effect on the financial statements of applying the practical expedient would not differ materially from applying the accounting guidance to the individual contracts within the portfolio. A pool of contracts is defined as all contracts booked in a particular quarter. The amortization for the capitalized asset is an estimate of the pool’s original contract term, generally one to five years, plus an estimate of future customer renewal periods resulting in a total amortization period of ten years. Costs to obtain a contract are allocated amongst performance obligations and recognized as sales and marketing expense consistent with the pattern of revenue recognition. In accordance with GAAP, while certain compensation elements are expensed as incurred, a portion of the pool’s capitalized asset is recorded as an expense over the first seven quarters after booking, which represents the estimated period during which the product revenue associated with the contract is recorded. The remaining capitalized contract costs are recorded as expense ratably over the ten
F-13
year estimated initial and renewal service periods. The Company recognized contract cost expense of $23.3 million, $30.6 million, and $25.8 million during the years ended December 31, 2023, 2022, and 2021, respectively. The commission expenses paid or due to be paid as of the consolidated balance sheet date to be recognized in future periods are recorded in long-term prepaid commissions on the Consolidated Balance Sheets. Capitalized costs are periodically reviewed for impairment. There was no impairment loss recorded related to capitalized prepaid commissions as of and for the year ended December 31, 2023.
Lessor Leases
The Company determines if an arrangement is or contains a lease at inception. The transaction price is allocated to separate performance obligations, generally consisting of a combination of hardware systems, software products, support and maintenance, and professional services, proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.
Sales-Type Leases
The Company enters into non-cancelable sales-type lease arrangements with the leases varying in length from one to ten years, most of which do not have an option to extend the lease term. At the end of the lease term, the customer must either return the equipment or negotiate a new agreement, resulting in a new purchase or lease transaction. Failure of the customer to either return the equipment or negotiate a new agreement results in the contract becoming a month-to-month rental. Certain sales-type leases automatically renew for successive one-year periods at the end of each lease term without written notice from the customer. The Company’s sales-type lease agreements do not contain any material residual value guarantees.
For sales-type leases, the Company recognizes revenues for its hardware and software products, net of lease execution costs, post-installation product maintenance, professional services associated with Advanced Services offerings, and technical support, at the net present value of the lease payment stream upon customer acceptance. The Company recognizes service revenues associated with sales-type leases ratably over the term of the agreement in service revenues in the Consolidated Statements of Operations. The Company recognizes interest income from sales-type leases using the effective interest method. Both hardware and software revenues, and interest income from sales-types leases are recorded in product revenues in the Consolidated Statements of Operations.
The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold.
Allowance for Credit Losses
The Company is exposed to credit losses primarily through sales of its products and services, as well as its sales-type leasing arrangements. The Company performs credit evaluations of its customers’ financial condition in order to assess each customer’s ability to pay. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history, and a financial review of the customer. The Company continues to monitor customers’ creditworthiness on an ongoing basis.
The Company maintains an allowance for credit losses for accounts receivable, unbilled receivables, and net investment in sales-type leases based on expected credit losses resulting from the inability of its customers to make required payments. The allowance for credit losses is measured using a loss rate method, considering factors such as customers’ credit risk, historical loss experience, current conditions, and forecasts. The allowance for credit losses is measured on a collective (pool) basis by aggregating customer balances with similar risk characteristics. The Company also records a specific allowance based on an analysis of individual past due balances or customer-specific information, such as a decline in creditworthiness or bankruptcy. Actual collection losses may differ from management’s estimates, and such differences could be material to the Company’s financial position and results of operations.
F-14
The allowance for credit losses is presented in the Consolidated Balance Sheets as a deduction from the respective asset balance. As of December 31, 2023 and 2022, the allowance for credit losses for long-term unbilled receivables and net investment in sales-type leases were not material.
Funds Held for Customers and Customer Fund Liabilities
The Company offers certain products and services in which it is customary for pharmacies or insurance payors to owe funds to the Company which are collected on behalf of, and, after a short holding period, disbursed to, the Company’s customers. The Company presents amounts due from pharmacies and amounts due to be disbursed to customers on a gross basis within other current assets and accrued liabilities, respectively, in the Consolidated Balance Sheets, as such amounts are expected to be settled within one year. Generally, any funds received from the pharmacies or insurance payors that are held by the Company are segregated from its other corporate cash accounts. These funds are classified as restricted cash as the Company is contractually obligated to disburse these amounts to customers.
Sales of Accounts Receivable
The Company records the sale of its accounts receivables in accordance with accounting guidance for transfers and servicing of financial assets. The Company transferred non-recourse accounts receivable totaling $5.7 million, $45.3 million, and $46.7 million during the years ended December 31, 2023, 2022, and 2021, respectively, which approximated fair value, to leasing companies on a non-recourse basis. Accounts receivable balance included approximately $1.1 million and $6.7 million due from third-party leasing companies for transferred non-recourse accounts receivable as of December 31, 2023 and 2022, respectively.
Cash and Cash Equivalents
The Company classifies all highly-liquid investments with original maturities of three months or less as cash equivalents. The Company’s cash and cash equivalent balances include bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with financial institutions of high credit quality. The Company continuously monitors the credit worthiness of the financial institutions in which it invests. The Company has not experienced any credit losses from its cash equivalents. Cash and cash equivalents were $468.0 million and $330.4 million as of December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, cash equivalents were $451.0 million and $301.0 million, respectively, which consisted of money market funds held in sweep and asset management accounts.
Financial Instruments
For assets and liabilities measured at fair value, the amounts are based on an expected exit price representing the amount that would be received from the sale of an asset or paid to transfer a liability in a transaction between market participants. The fair value may be based on assumptions that market participants would use in pricing an asset or liability. ASC 820, Fair Value Measurement, establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs used in valuation techniques are assigned a hierarchical level, as follows:
Level 1 – Observable inputs, such as quoted prices in active markets for identical instruments;
Level 2 – Quoted prices for similar instruments in active markets, or quoted prices for identical instruments in inactive markets; and
Level 3 – Unobservable inputs for financial instruments reflecting Company’s assumptions.
Inventory
Inventories are stated at the lower of cost, computed using the first-in, first-out method, and net realizable value. Inbound shipping costs are included in cost of inventory. The Company regularly monitors inventory quantities on hand and records write-downs for excess and obsolete inventories based on the Company’s estimate of demand for its products, potential obsolescence of technology, product life cycles, and whether pricing trends or forecasts indicate that the carrying value of inventory exceeds its estimated selling price. These factors are impacted by market and economic conditions, technology changes, and new product introductions and require estimates that may include elements that are uncertain. Actual demand may differ from forecasted demand and may have a material effect on gross margins. If inventory is written down, a new cost basis is established that cannot be increased in future periods. Shipments from suppliers or contract manufacturers before the Company receives them are recorded as in-transit inventory when title and the significant risks and rewards of ownership have passed to the Company.
The Company has a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in its hardware products. There are no minimum purchase requirements. The
F-15
contract with the Company’s supplier may be terminated by either the supplier or by the Company without cause and at any time upon delivery of six months’ notice. Purchases from this supplier were $65.8 million, $105.7 million, and $103.2 million for the years ended December 31, 2023, 2022, and 2021, respectively.
Shipping Costs
Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general, and administrative expense. Shipping and handling expenses were $18.6 million, $24.5 million, and $18.2 million for the years ended December 31, 2023, 2022, and 2021, respectively.
Property and Equipment
Property and equipment less accumulated depreciation are stated at historical cost. The Company’s expenditures for property and equipment are primarily for computer equipment and software used in the administration of its business, and for leasehold improvements to its leased facilities. The Company also develops molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components.
The Company capitalizes costs related to computer software developed or obtained for internal-use in accordance with ASC 350-40, Internal-Use Software. Software developed or obtained for internal-use includes certain costs for the development of the Company’s subscription and cloud-based offerings sold to its customers, as well as enterprise-level business and finance software that the Company customizes to meet its specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. The Company capitalized $32.2 million and $33.0 million of costs related to the application development of enterprise-level software and its subscription and cloud-based offerings, which are included in property and equipment during the years ended December 31, 2023 and 2022, respectively. Capitalized costs related to computer software developed or obtained for internal-use are included in purchases of property and equipment in the Consolidated Statements of Cash Flows.
Depreciation and amortization is computed by use of the straight-line method over the estimated useful lives of the assets as stated below:
Purchased software and internal-use software development costs
3 - 5 years
Leasehold and building improvementsShorter of the lease term or the estimated useful life
Furniture and fixtures
5 - 7 years
Equipment
2 - 12 years
External-Use Software Development Costs
The Company capitalizes certain software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed, under which those costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. The Company establishes technological feasibility when it completes a detail program design or a working model. The Company amortizes development costs over the estimated lives of the related products, which is generally five years. All development costs prior to the completion of a detail program design or a working model are recognized as research and development expense. The Company capitalized external-use software development costs of $14.6 million and $13.2 million, that were included in other long-term assets as of December 31, 2023 and 2022, respectively.
Lessee Leases
The Company determines if an arrangement is or contains a lease at inception. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of its lease contracts do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available at the commencement date in determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize a right-of-use asset and a lease liability for leases with an initial term of twelve months or less. The Company elected the practical expedient to not separate lease components from nonlease components and applied that practical expedient to all material classes of leased assets.
Many of the Company’s operating leases include an option to extend the lease. The specific terms and conditions of the extension options vary from lease to lease, but are consistent with standard industry practices in each area that the Company operates. The Company reviews each of its lease options at a time required by the terms of the lease contract, and notifies the
F-16
lessor if it chooses to exercise the lease renewal option. Until the Company is reasonably certain that it will extend the lease contract, the renewal option periods will not be recognized as right-of-use assets or lease liabilities.
Certain leases include provisions for early termination, which allow the contract parties to terminate their obligations under the lease contract. The terms and conditions of the termination options vary by contract. When the Company has made a decision to exercise an early termination option, the right-of-use assets and associated lease liabilities are remeasured in accordance with the present value of the remaining cash flows under the lease contract.
Certain building lease agreements include rental payments subject to change annually based on fluctuations in various indexes (i.e., Consumer Price Index (“CPI”), Retail Price Index, and other international indexes). Certain data center lease agreements include rental payments subject to change based on usage and CPI fluctuations. The changes based on usage and indexes are treated as variable lease costs and recognized in the period in which the obligation for those payments was incurred. 
The Company’s operating lease agreements do not contain any material residual value guarantees, restrictions, or restriction covenants.
Business Combinations
The Company uses the acquisition method of accounting under ASC 805, Business Combinations. Each acquired company’s operating results are included in the Company’s Consolidated Financial Statements starting on the acquisition date. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the acquisition date are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed.
Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on available historical information as well as future expectations, and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, acquired technology, backlog, trade names, and non-compete agreements.
Goodwill and Acquired Intangible Assets
Goodwill
The Company assesses goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. This assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. The Company has one reporting unit, which is the same as its operating segment. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. A qualitative assessment includes, among others, consideration of: (i) past, current, and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this qualitative assessment indicates that it is more likely than not that impairment exists, or if the Company decides to bypass this option, it proceeds to the quantitative assessment. The quantitative assessment involves a comparison between the estimated fair value of the Company’s reporting unit with its carrying amount including goodwill. If the carrying value exceeds estimated fair value, the Company will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill.
To determine the reporting unit’s fair value under the quantitative approach, the Company uses a combination of income and market approaches, such as estimated discounted future cash flows of the reporting unit, multiples of earnings or revenues, and analysis of recent sales or offerings of comparable entities. The Company also considers its market capitalization on the date of the analysis to ensure the reasonableness of its reporting unit’s fair value.
The Company elected to perform a quantitative impairment assessment analysis as of October 1, 2023 for its reporting unit. The Company determined that the fair value of the reporting unit exceeded the carrying value and thus no impairment was indicated. Based on the result of this analysis, an impairment does not exist as of December 31, 2023, and there were no accumulated impairment losses.
F-17
Intangible Assets
In connection with its acquisitions, the Company generally recognizes assets for customer relationships, acquired technology, backlog, trade names, and non-compete agreements. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets. Amortization for acquired technology and backlog is recognized in cost of revenues, and amortization for customer relationships, trade names, non-compete agreements, and patents is recognized in selling, general, and administrative expenses.
The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. The Company’s cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of the Company’s intangible assets are subjective and are affected by changes to its business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of the Company’s assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on the Company’s operating results and financial condition. For the years ended December 31, 2023 and 2022, there were no events or changes in circumstances to indicate that intangible assets carrying amounts may not be recoverable.
Convertible Debt
The Company accounts for convertible debt and related transactions in accordance with ASC 470-20, Debt with Conversion and Other Options, ASC 815, Derivatives and Hedging, and ASC 480, Distinguishing Liabilities from Equity. The Company evaluates convertible debt instruments and related transactions at inception to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for.
Prior to the adoption of Accounting Standards Update (“ASU”) 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner. The difference between the principal amount of the convertible senior notes and the liability component, inclusive of issuance costs, represented the debt discount, which the Company amortized to interest expense over the term of the convertible senior notes. The determination of the discount rate required certain estimates and assumptions.
Upon adoption of ASU 2020-06, effective January 1, 2022, the convertible senior notes are no longer separated into liability and equity components, and are accounted for as a single liability, measured at amortized cost in the Consolidated Balance Sheets. Issuance costs are amortized using the effective interest method over the term of the convertible senior notes.
Convertible note hedge and warrant transactions associated with convertible debt instruments are accounted for as equity instruments, and are recorded in additional paid-in capital in the Consolidated Balance Sheets.
Valuation of Share-Based Compensation
The Company accounts for share-based compensation in accordance with ASC 718, Stock Compensation. The Company recognizes compensation expense related to share-based compensation based on the grant date estimated fair value.
The fair value of stock options (“options”) on the grant date is estimated using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of its common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on the Company’s historical experience of employee stock option exercises, including forfeitures. Expense is recognized on a straight-line basis over the requisite service period.
The fair value of restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) is based on the stock price on the grant date. The RSUs and RSAs are subject to a service vesting condition and are recognized on a straight-line basis over the requisite service period.
F-18
The fair value of performance-based stock unit awards (“PSUs”) with service and market conditions is estimated using a Monte Carlo simulation model applying a multiple awards approach. Expense is recognized when it is probable that the performance condition will be met using the accelerated attribution method over the requisite service period.
Forfeiture rates are estimated based on the Company’s historical experience with equity awards that were granted and forfeited prior to vesting. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods.
Accounting for Income Taxes
The Company records an income tax provision for (benefit from) the anticipated tax consequences of the reported results of operations. In accordance with ASC 740, Income Taxes, the provision for (benefit from) income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, the Company will incur a benefit or detriment on its income tax expense in the period of enactment. If the Company were to determine that all or part of the net deferred tax assets are not realizable in the future, it will record a valuation allowance that would be charged to earnings in the period such determination is made.
In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of ASC 740 and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on the Company’s financial condition and operating results.
Recently Adopted Authoritative Guidance
In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The Company adopted ASU 2021-08 beginning January 1, 2023 and will apply the guidance prospectively to acquisitions occurring on or after the adoption date.
Recently Issued Authoritative Guidance
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements.
There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Consolidated Financial Statements through the reporting date.
Note 2.    Business Combinations
The Company’s Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Consolidated Statements of Operations.
F-19
2022 Acquisition
Hub and Spoke Innovations
On January 10, 2022, the Company completed the acquisition of all of the outstanding equity interests in Hub and Spoke Innovations pursuant to the terms and conditions of the Share Purchase Agreement, dated January 10, 2022, by and among Omnicell Limited (a wholly-owned subsidiary of the Company), Hub and Spoke Innovations Limited, and certain beneficial stockholders specified therein for a base purchase price of £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date), prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The purchase price transferred for the transaction, net of cash acquired, was £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date). Of the purchase price transferred, £1.9 million (approximately $2.5 million based on the exchange rate in effect at the acquisition date) was allocated to goodwill; £0.8 million (approximately $1.1 million based on the exchange rate in effect at the acquisition date) was allocated to intangible assets, which included customer relationships; and the remainder was allocated to net assets acquired. The Hub and Spoke Innovations acquisition is expected to complement Omnicell’s total solution technology portfolio for retail pharmacy in the United Kingdom to help pharmacies improve workflows, offer patients 24/7 access to their medications and provide enhanced patient care.
2021 Acquisitions
MarkeTouch Media
On December 31, 2021, the Company completed the acquisition of all of the outstanding equity interests in MarkeTouch Media, LLC (“MarkeTouch Media”) pursuant to the terms and conditions of the Unit Purchase Agreement, dated December 31, 2021, by and among ateb, Inc. (a wholly-owned subsidiary of the Company), MarkeTouch Media, LLC, MarkeTouch Holdings, Inc., Toucan Enterprises, Inc., and certain beneficial stockholders specified therein for a base purchase price of $82.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The MarkeTouch Media acquisition adds mobile and web-based technology and patient engagement solutions, which is expected to expand the footprint of EnlivenHealth® across the retail pharmacy sector, while enhancing potential growth opportunities in new market segments like specialty pharmacy and pharmacy benefits management.
ReCept
On December 29, 2021, the Company completed the acquisition of all outstanding equity securities of ReCept pursuant to the terms and conditions of the Agreement and Plan of Merger, dated December 1, 2021, by and among Omnicell, Inc., ReCept Holdings, Inc., Redfish Acquisition Corp, and the representative of the securityholders for a base purchase price of $100.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The addition of ReCept’s specialty pharmacy management services, now a part of the Company’s Specialty Pharmacy Services, for health systems, provider groups, and federally qualified health centers expands Omnicell’s Advanced Services portfolio in an effort to address the growing and complex specialty pharmacy market.
FDS Amplicare
On September 9, 2021, the Company completed the acquisition of all of the outstanding equity interests in RxInnovation, Inc., operating as FDS Amplicare® (“FDS Amplicare”), pursuant to the terms and conditions of the Agreement and Plan of Merger, dated July 25, 2021, by and among RxInnovation Inc., Omnicell, Inc., Fleming Acquisition Corp., and the representative of the securityholders for a base purchase price of $177.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The FDS Amplicare acquisition adds a comprehensive and complementary suite of software-as-a-service (“SaaS”) financial management, analytics, and population health solutions to the Company’s EnlivenHealth offering.
The Company incurred approximately $7.0 million in acquisition-related costs related to the FDS Amplicare acquisition during the year ended December 31, 2021. Revenues and net losses from the FDS Amplicare operations since the acquisition date through December 31, 2021 were $11.3 million and $0.9 million, respectively.
F-20
The following tables represent the allocation of the respective purchase price to the assets acquired and the liabilities assumed by the Company as part of each acquisition included in the Company’s Consolidated Balance Sheets, and is reconciled to the respective purchase price transferred:
FDS Amplicare (1)
ReCept (2) (3)
MarkeTouch Media (4)
(In thousands)
Purchase price transferred:
Base purchase price$177,000 $100,000 $82,000 
Add: Closing cash465 6,569 237 
Add: Net working capital adjustment1,654 (7,357)147 
Less: Assumed indebtedness(653)(1,973)(15)
Total purchase price transferred$178,466 $97,239 $82,369 
FDS Amplicare (1)
ReCept (2) (3)
MarkeTouch Media (4)
Fair value of assets acquired and liabilities assumed:
Cash and cash equivalents$465 $— $237 
Accounts receivable and unbilled receivables5,330 2,383 2,302 
Prepaid expenses506 192 96 
Other current assets45 12,223 — 
Total current assets6,346 14,798 2,635 
Property and equipment444 172 177 
Operating lease right-of-use assets2,252 773 602 
Goodwill117,784 77,644 42,273 
Intangible assets70,000 28,100 38,000 
Other long-term assets51 195 2,850 
Total assets196,877 121,682 86,537 
Accounts payable950 219 473 
Accrued compensation1,312 1,756 — 
Accrued liabilities1,497 18,249 292 
Deferred revenues1,916 222 347 
Long-term deferred tax liabilities11,686 3,383 — 
Long-term operating lease liabilities920 614 206 
Other long-term liabilities130 — 2,850 
Total liabilities18,411 24,443 4,168 
Total purchase price$178,466 $97,239 $82,369 
Total purchase price, net of cash acquired$178,001 $90,670 $82,132 
_________________________________________________
(1)    During the year ended December 31, 2021, the Company recorded measurement period adjustments of $1.5 million to goodwill, consisting of an increase in intangible assets, accounts receivable and unbilled receivables, and long-term deferred tax liabilities of $0.4 million, $1.1 million, and $0.1 million, respectively, and a net working capital adjustment of $0.1 million. During the year ended December 31, 2022, the Company recorded a measurement period adjustments of $0.4 million to goodwill, consisting of an increase in long-term deferred tax liabilities and accrued liabilities of $0.3 million and $0.1 million, respectively.
(2)    Closing cash is included in other current assets due to its restrictive nature as cash held for customers.
(3)    During the year ended December 31, 2022, the Company recorded measurement period adjustments of $3.9 million to goodwill, consisting of a purchase price adjustment of $5.2 million, a decrease in long-term deferred tax liabilities of $0.2 million and a decrease in accrued liabilities of $0.3 million, partially offset by a decrease to other current assets of $1.7 million.
(4)    During the year ended December 31, 2022, the Company recorded a measurement period adjustment of $0.3 million to goodwill related to a purchase price adjustment.
F-21
The $117.8 million of goodwill arising from the FDS Amplicare acquisition is primarily attributed to future sales of SaaS solutions and FDS Amplicare’s assembled workforce. The $77.6 million of goodwill arising from the ReCept acquisition is primarily attributed to future sales of its offerings and services and ReCept’s assembled workforce. None of the FDS Amplicare and ReCept goodwill is expected to be deductible for tax purposes as these acquisitions were treated as stock acquisitions for U.S. tax purposes. The $42.3 million of goodwill arising from the MarkeTouch Media acquisition is primarily attributed to future sales of SaaS solutions and MarkeTouch Media’s assembled workforce. The full amount of the MarkeTouch Media goodwill is expected to be deductible for tax purposes as this acquisition was treated as an asset acquisition for U.S. tax purposes.
The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows:
FDS Amplicare (1)
ReCeptMarkeTouch Media
Fair valueUseful life
(years)		Fair valueUseful life
(years)		Fair valueUseful life
(years)
(In thousands, except for years)
Customer relationships$59,900 23$28,100 23$34,100 26
Acquired technology7,700 
5 - 7
— —2,100 4
Backlog— —— —1,800 2
Trade names2,400 5— —— —
Total purchased intangible assets$70,000 $28,100 $38,000 
_________________________________________________
(1)    During the year ended December 31, 2021, the Company recorded a measurement period adjustment of $0.4 million in customer relationships.
The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions.
The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions.
The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization.
F-22
Pro Forma Financial Information
The following table presents certain unaudited pro forma consolidated financial information for the year ended December 31, 2021 as if the FDS Amplicare, ReCept, and MarkeTouch Media acquisitions had been completed on January 1, 2020. The pro forma effects of the Hub and Spoke Innovations acquisition were not material to the Company’s consolidated results of operations. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of what would have occurred had the acquisitions taken place on those respective dates. The unaudited pro forma financial information combines the historical results of the acquisitions with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, amortization and depreciation of intangible assets and property and equipment acquired; imputed interest, interest expense, and amortization of debt issuance costs related to acquisitions, as applicable; and certain acquisition-related costs incurred.
Year Ended December 31,
2021
(In thousands)
Pro forma revenues$1,195,473 
Pro forma net income$79,981 
Note 3.    Revenues
Disaggregation of Revenues
The following table summarizes the Company’s revenues disaggregated by revenue type for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Connected devices, software licenses, and other$623,584 $827,917 $739,074 
Consumables84,977 75,305 73,438 
Technical services225,831 206,687 206,989 
Advanced Services
212,720 186,038 112,517 
Total revenues$1,147,112 $1,295,947 $1,132,018 
The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
United States$1,011,380$1,168,202$1,020,788
Rest of world (1)
135,732127,745111,230
Total revenues$1,147,112$1,295,947$1,132,018
_________________________________________________
(1)    No individual country represented more than 10% of total revenues.
F-23
Contract Assets and Contract Liabilities
The following table reflects the Company’s contract assets and contract liabilities:
December 31,
20232022
(In thousands)
Short-term unbilled receivables, net (1)
$22,524 $25,763 
Long-term unbilled receivables, net (2)
11,850 14,744 
Total contract assets$34,374 $40,507 
Short-term deferred revenues, net
$121,734 $118,947 
Long-term deferred revenues
58,622 37,385 
Total contract liabilities$180,356 $156,332 
_________________________________________________
(1)     Included in accounts receivable and unbilled receivables in the Consolidated Balance Sheets.
(2)    Included in other long-term assets in the Consolidated Balance Sheets.
Short-term deferred revenues, net of $121.7 million and $118.9 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $12.4 million and $15.8 million, as of December 31, 2023 and 2022, respectively. During the year ended December 31, 2023, the Company recognized revenues of $115.7 million that were included in the corresponding gross short-term deferred revenues balance of $134.7 million as of December 31, 2022.
Significant Customers
There were no customers that accounted for more than 10% of the Company’s total revenues for the years ended December 31, 2023, 2022, and 2021. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of December 31, 2023 and 2022.
Note 4.    Net Income (Loss) Per Share
Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method for share-based awards and warrants, and the if-converted method for convertible senior notes. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 11, Convertible Senior Notes. For periods prior to the adoption of ASU 2020-06 on January 1, 2022, the Company applied the treasury stock method to calculate the dilutive impact of the convertible senior notes. Upon adoption of ASU 2020-06, effective January 1, 2022, the Company applies the if-converted method for calculating the dilutive impact of the convertible senior notes. Following the Company’s irrevocable election in December 2021 to settle the principal portion of the convertible senior notes in cash with any conversion consideration in excess of the principal portion in cash and/or shares of the Company’s common stock at the Company’s option upon conversion, only the amounts expected to be settled in excess of the principal portion are considered dilutive in calculating earnings per share under the if-converted method. Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share.
F-24
The basic and diluted net income (loss) per share calculations for the years ended December 31, 2023, 2022, and 2021 were as follows:
Year Ended December 31,
202320222021
(In thousands, except per share data)
Net income (loss)$(20,371)$5,648 $77,849 
Weighted-average shares outstanding – basic45,212 44,398 43,475 
Effect of dilutive securities from stock award plans— 1,019 2,136 
Effect of convertible senior notes— 474 2,044 
Effect of warrants— — 288 
Weighted-average shares outstanding – diluted45,212 45,891 47,943 
Net income (loss) per share – basic$(0.45)$0.13 $1.79 
Net income (loss) per share – diluted$(0.45)$0.12 $1.62 
Anti-dilutive weighted-average shares related to stock award plans3,368 725 156 
Anti-dilutive weighted-average shares related to convertible senior notes and warrants11,816 5,908 — 
Note 5.    Fair Value of Financial Instruments
The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of December 31, 2023 and 2022, the fair value of the convertible senior notes was $527.2 million and $501.4 million, respectively, compared to their carrying values of $569.7 million and $566.6 million, respectively, which are net of unamortized debt issuance costs. Refer to Note 10, Debt and Credit Agreement, for further information regarding the Company’s credit facility and Note 11, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes.

F-25
Note 6.    Balance Sheet Components
Balance sheet details as of December 31, 2023 and 2022 are presented in the tables below:
December 31,
20232022
(In thousands)
Inventories:
Raw materials$51,439 $75,854 
Work in process1,327 9,280 
Finished goods57,333 62,415 
Total inventories$110,099 $147,549 
Other current assets:
Funds held for customers, including restricted cash (1)
$43,649 $56,703 
Net investment in sales-type leases, current portion11,867 11,486 
Prepaid income taxes8,279 1,702 
Other current assets7,714 7,471 
Total other current assets$71,509 $77,362 
Other long-term assets:
External-use software development costs, net$66,659 $80,760 
Unbilled receivables, net11,850 14,744 
Deferred debt issuance costs3,718 2,058 
Other long-term assets8,239 7,455 
Total other long-term assets$90,466 $105,017 
Accrued liabilities:
Operating lease liabilities, current portion$10,518 $10,761 
Customer fund liabilities43,649 56,703 
Advance payments from customers10,551 11,556 
Rebate liabilities51,277 42,802 
Group purchasing organization fees4,445 7,723 
Taxes payable2,191 9,642 
Other accrued liabilities26,645 33,468 
Total accrued liabilities$149,276 $172,655 
_________________________________________________
(1)    Includes restricted cash of $33.0 million and $22.5 million as of December 31, 2023 and 2022, respectively.
The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the years ended December 31, 2023 and 2022:
(In thousands)
Balance as of December 31, 2021$(8,407)
Other comprehensive loss(8,680)
Balance as of December 31, 2022(17,087)
Other comprehensive income3,655 
Balance as of December 31, 2023$(13,432)
F-26
Note 7.    Property and Equipment
The following table represents the property and equipment balances as of December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
Equipment$95,996 $91,391 
Furniture and fixtures4,500 5,154 
Leasehold improvements17,919 19,510 
Purchased software and internal-use software development costs118,004 76,327 
Construction in progress11,614 28,223 
Property and equipment, gross248,033 220,605 
Accumulated depreciation and amortization(139,432)(126,644)
Total property and equipment, net$108,601 $93,961 
Depreciation and amortization expense of property and equipment was $27.0 million, $22.8 million, and $20.1 million for the years ended December 31, 2023, 2022, and 2021, respectively.
The geographic location of the Company’s property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
United States$104,312 $89,989 
Rest of world (1)
4,289 3,972 
Total property and equipment, net$108,601 $93,961 
_________________________________________________
(1)    No individual country represented more than 10% of total property and equipment, net.
Note 8.    External-Use Software Development Costs
The carrying amounts of external-use software development costs as of December 31, 2023 and 2022 were as follows:
December 31,
20232022
(In thousands)
Gross carrying amount$239,038 $225,004 
Accumulated amortization(172,379)(144,244)
External-use software development costs, net (1)
$66,659 $80,760 
_________________________________________________
(1)     Included in other long-term assets in the Consolidated Balance Sheets.
The Company recorded $28.7 million, $29.0 million, and $26.4 million to cost of revenues for amortization of external-use software development costs for the years ended December 31, 2023, 2022, and 2021, respectively.
F-27
The estimated future amortization expenses for external-use software development costs were as follows:
December 31, 2023
(In thousands)
2024$25,354 
202518,331 
202612,792 
20276,837 
20282,980 
Thereafter365 
Total$66,659
Note 9.    Goodwill and Intangible Assets
Goodwill
The following table represents changes in the carrying amount of goodwill:
(In thousands)
Balance as of December 31, 2021$738,900 
Additions (1)
2,549 
Measurement period adjustments (1)
(3,770)
Foreign currency exchange rate fluctuations(3,405)
Balance as of December 31, 2022734,274 
Foreign currency exchange rate fluctuations1,536 
Balance as of December 31, 2023$735,810 
_________________________________________________
(1)     Refer to Note 2, Business Combinations, for further information.
F-28
Intangible Assets, Net
The carrying amounts and useful lives of intangible assets as of December 31, 2023 and 2022 were as follows:
December 31, 2023
Gross carrying
amount		Accumulated
amortization		Foreign currency exchange
rate fluctuations		Net carrying
amount		Useful life
(years)
(In thousands, except for years)
Customer relationships$307,418 $(115,232)$(1,326)$190,860 
4 - 30
Acquired technology84,876 (67,033)— 17,843 
4 - 20
Backlog1,800 (1,800)— — 2
Trade names9,200 (7,680)— 1,520 
5 - 12
Patents2,404 (1,454)— 950 
2 - 20
Total intangibles assets, net$405,698 $(193,199)$(1,326)$211,173 

December 31, 2022
Gross carrying
amount		Accumulated
amortization		 Foreign currency exchange
rate fluctuations		Net carrying
amount		Useful life
(years)
(In thousands, except for years)
Customer relationships$311,089 $(99,177)$(1,514)$210,398 
4 - 30
Acquired technology92,066 (64,299)— 27,767 
4 - 20
Backlog1,800 (900)— 900 2
Trade names9,200 (6,633)— 2,567 
5 - 12
Patents2,430 (1,306)— 1,124 
2 - 20
Non-compete agreements600 (450)— 150 3
Total intangibles assets, net$417,185 $(172,765)$(1,514)$242,906 
Amortization expense of intangible assets was $31.6 million, $35.2 million, and $26.5 million for the years ended December 31, 2023, 2022, and 2021, respectively.
The estimated future amortization expenses for amortizable intangible assets were as follows:
December 31,
2023
(In thousands)
2024$22,736 
202521,060 
202618,080 
202716,245 
202815,180 
Thereafter117,872 
Total$211,173 
Note 10.    Debt and Credit Agreement
On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental
F-29
Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Prior A&R Credit Agreement had an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings would be due and payable.
On September 22, 2020 and March 29, 2023, the Company entered into amendments to the Prior A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 11, Convertible Senior Notes, expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to borrowings under the A&R Credit Agreement with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics.
Subsequent to the March 29, 2023 amendment, loans under the Prior Revolving Credit Facility bore interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Prior A&R Credit Agreement), plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Prior A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for a one month tenor plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Prior Revolving Credit Facility were subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Prior Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Prior Incremental Facility would be determined prior to the incurrence of such loans. The Company was permitted to make voluntary prepayments at any time without payment of a premium or penalty.
The Prior A&R Credit Agreement contained customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Prior A&R Credit Agreement also contained financial covenants that required the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the Prior A&R Credit Agreement contained certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.
The Company entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) on October 10, 2023, with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million or 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable.
Loans under the Current Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Second A&R Credit Agreement), plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Second A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. Subject to the terms and conditions of the Current Revolving Credit Facility or Current Incremental Facility the Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The availability of funds under the Current Revolving Credit Facility may be subject to reduction in order to maintain compliance with the financial covenants under the Second A&R Credit Agreement.
F-30
The Second A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Second A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated secured net leverage ratio (not to exceed 3.00:1) and maintain a minimum consolidated interest coverage ratio (not to be less than 3.00:1). In addition, the Second A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.
The Company’s obligations under the Second A&R Credit Agreement and, at the election of the Company and the contracting counterparty, any secured swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the Second A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement.
The refinancing of the Prior Credit Agreement was evaluated in accordance with ASC 470-50, Debt - Modifications and Extinguishments. In determining whether the refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether lenders within the syndicate remained the same or changed and whether the changes in debt terms were substantial. This assessment was performed on an individual lender basis within the syndicate. As a result, the refinancing was accounted for as a modification with the exception of certain lenders that exited the syndicate. The exit of certain lenders resulted in an immaterial write-off of existing unamortized debt issuance costs. The remaining unamortized debt issuance costs related to debt modification, along with the new deferred costs, will be amortized over the remaining term of the Second A&R Credit Agreement.
In connection with the Second A&R Credit Agreement, the Company incurred and capitalized an additional $3.0 million of debt issuance costs. The debt issuance costs are being amortized to interest expense using the straight-line method through 2028.
As of December 31, 2023, the Company had $350.0 million of funds available under the Current Revolving Credit Facility and as of December 31, 2022, the Company had $500.0 million of funds available under the Prior Revolving Credit Facility. As of December 31, 2023 and 2022, the Company had no outstanding balance under the Prior or Current Revolving Credit Facility. The Company was in compliance with all covenants as of December 31, 2023.
Note 11.     Convertible Senior Notes
0.25% Convertible Senior Notes due 2025
On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted.
The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on
F-31
the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions.
During the three months ended December 31, 2023 and 2022, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the first quarter of 2024, commencing on January 1, 2024, and were not convertible during the first quarter of 2023, commencing on January 1, 2023. Accordingly, the Company classified the Notes as a long-term liability in its Consolidated Financial Statements as of December 31, 2023 and 2022. Whether the Notes will be convertible following the first fiscal quarter of 2024 will depend on the satisfaction of the conversion conditions in the future.
Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be.
If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of December 31, 2023, none of the criteria for a fundamental change or a conversion rate adjustment had been met.
As of September 20, 2023, the Company may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes.
The debt issuance costs associated with the Notes are being amortized to interest expense over the term of the Notes using an effective interest rate of 0.80%. As of December 31, 2023, the remaining life of the Notes and the related issuance cost accretion is approximately 1.7 years.
The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of December 31, 2023, the if-converted value of the Notes did not exceed the principal amount.
The Notes consisted of the following balances reported in the Consolidated Balance Sheets as of December 31, 2023 and 2022:
December 31,
20232022
Principal amount$575,000 $575,000 
Unamortized debt issuance costs(5,338)(8,429)
Convertible senior notes, net$569,662 $566,571 


F-32
The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021:
Year Ended December 31,
2023
2022 (1)
2021
(In thousands)
Contractual coupon interest$1,438 $1,438 $1,438 
Amortization of discount$— $— $18,608 
Amortization of debt issuance costs$3,091 $3,066 $2,343 
_________________________________________________
(1)    Refer to Note 1, Organization and Summary of Significant Accounting Policies, for further information regarding the adoption of ASU 2020-06, effective January 1, 2022.
Convertible Note Hedge and Warrant Transactions
In connection with the issuance of the Notes in September 2020, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock.
The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes.
Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.
Note 12.     Lessor Leases
Sales-Type Leases
The following table presents the Company’s income recognized from sales-type leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Sales-type lease revenues$36,208 $38,959 $21,887 
Cost of sales-type lease revenues(18,093)(19,359)(8,918)
Selling profit on sales-type lease revenues$18,115 $19,600 $12,969 
Interest income on sales-type lease receivables$2,475 $2,106 $1,869 
F-33
The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
Net minimum lease payments to be received$65,017 $50,755 
Less: Unearned interest income portion(10,196)(6,345)
Net investment in sales-type leases54,821 44,410 
Less: Current portion (1)
(11,867)(11,486)
Long-term investment in sales-type leases, net$42,954 $32,924 
_________________________________________________
(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Consolidated Balance Sheets.
The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.
The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Consolidated Balance Sheets was as follows:
December 31,
2023
(In thousands)
2024$14,504 
202512,385 
202610,113 
20278,369 
20287,281 
Thereafter12,365 
Total future minimum sales-type lease payments65,017 
Present value adjustment(10,196)
Total net investment in sales-type leases$54,821 
Operating Leases
The following table represents the Company’s income recognized from operating leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Rental income$6,591 $9,460 $10,467 
The maturity schedule of future minimum lease payments under operating leases was as follows:
December 31, 2023
(In thousands)
2024$3,547 
2025842 
2026763 
2027763 
2028571 
Total future minimum operating lease payments$6,486 
F-34
Note 13.     Lessee Leases
The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of one to twelve years. As of December 31, 2023, the Company did not have any additional material operating leases that were entered into, but not yet commenced.
The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Consolidated Balance Sheets was as follows:
December 31, 2023
(In thousands)
2024$12,722 
202510,609 
20269,715 
20278,070 
20287,650 
Thereafter1,834 
Total operating lease payments50,600 
Present value adjustment(6,172)
Total operating lease liabilities (1)
$44,428 
_________________________________________________
(1)    Amount consists of a current and long-term portion of operating lease liabilities of $10.5 million and $33.9 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities in the Consolidated Balance Sheets.
Operating lease costs were $10.8 million, $18.9 million, and $15.0 million for the years ended December 31, 2023, 2022, and 2021, respectively. Short-term lease costs and variable lease costs were not material for the years ended December 31, 2023, 2022, and 2021. During the year ended December 31, 2023, the Company recorded impairment and abandonment charges to operating lease right-of-use assets of $10.0 million, in connection with restructuring activities to reduce its real estate footprint and for optimization of certain leased facilities. The impairment and abandonment charges were recorded to selling, general, and administrative expenses on the Company’s Consolidated Statements of Operations. Refer to Note 18, Restructuring Expenses, for additional information regarding the Company’s restructuring activities.
The following table summarizes supplemental cash flow information related to the Company’s operating leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities$13,469 $16,452 $15,625 
Right-of-use assets obtained in exchange for new lease liabilities$6,431 $12,372 $5,503 
The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of December 31, 2023 and 2022:
December 31,
20232022
Weighted-average remaining lease term, years4.65.0
Weighted-average discount rate, %5.8 %5.7 %
Note 14.     Commitments and Contingencies
Purchase Obligations
In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of December 31, 2023, the Company had non-cancelable purchase commitments of $93.9 million, of which $84.2 million are expected to be paid within the next twelve months. 
F-35
Ransomware Incident
During the year ended December 31, 2023, the Company did not incur any material expenses or recoveries related to the previously disclosed ransomware incident in May 2022. During the year ended December 31, 2022, the Company incurred $13.6 million of expenses related to the ransomware incident, partially offset by $11.1 million of expected insurance recoveries. Expenses included costs to investigate and remediate the ransomware incident, as well as legal and other professional services, all of which were expensed as incurred. For the year ended December 31, 2022, the Company included net expenses related to the ransomware incident in cost of revenues of $0.3 million, in research and development of $0.2 million, and in selling general and administrative expenses of $2.0 million, in the Company’s Consolidated Statements of Operations.
As of December 31, 2023, the Company has incurred $13.6 million of cumulative expenses related to the ransomware incident since it was detected, partially offset by $12.2 million of insurance recoveries, all of which have been received as of December 31, 2023.
Legal Proceedings
The Company is currently involved in various legal proceedings.
As required under ASC 450, Contingencies, the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with any current legal proceedings based on its belief that any potential material loss, while reasonably possible, is not probable. Furthermore, any possible range of loss in such matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of legal proceedings or because of the diversion of management’s attention and the creation of significant expenses, regardless of outcome.
The Company is not a party to any legal proceedings that management believes may have a material impact on the Company’s financial position or results of operations.
Guarantees
Under the Company’s certificate of incorporation and bylaws, the Company has agreed to indemnify its directors and executive officers to the fullest extent not prohibited by Delaware and other applicable law, subject to certain exceptions. The Company has entered into individual indemnification agreements with its directors and officers. The term of the indemnification period is for the entirety of the director’s or officer’s service to the Company and continues so long as the director or officer may be subject to any claim, action, or proceeding, and there is no limit on the potential amount of future payments that the Company could be required to make under these indemnification agreements. The Company has purchased a directors’ and officers’ liability insurance policy that may enable it to recover a portion of any future payments that it may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits, and other policy provisions, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive and time-consuming litigation against the insurers.
Additionally, the Company undertakes indemnification obligations in its ordinary course of business in connection with, among other things, the sale or licensing of its products and the provision of its support services. In the ordinary course of the Company’s business, the Company has in the past and may in the future agree to indemnify another party, generally its business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, its gross negligence or intentional acts in the performance of services, and violations of laws. The term of these indemnification obligations is generally perpetual, but typically will not extend beyond the applicable statute of limitation pursuant to applicable law. In general, the Company attempts to limit the maximum potential amount of future payments that it may be required to make under these indemnification obligations to the amounts paid to it by a customer, but in some cases the obligation may not be so limited.
In addition, the Company has in the past and may in the future warrant to its customers that its products will conform to certain representations, which may include functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that its software media is free from material defects. Sales contracts for certain of the Company’s medication packaging systems may have in the past and may in the future include limited warranties for up to six months, but the periodic activity and ending warranty balances the Company records have historically not been material.
F-36
From time to time, the Company may also warrant that its professional services will conform to certain representations, which may include that such services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. The Company generally seeks to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality, and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive, or similar damages. In some states, such disclaimers may not be enforceable. If necessary, the Company would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. The Company has not been subject to any significant claims for such losses and has not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of December 31, 2023 and 2022.
Note 15.     Employee Benefits and Share-Based Compensation
Stock Purchase Plan
1997 Employee Stock Purchase Plan
The Company has an Employee Stock Purchase Plan (“ESPP”), under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their earnings; provided, however, an eligible employee’s right to purchase shares of the Company’s common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period.
There was a total of 3.3 million shares reserved for future issuance under the ESPP as of December 31, 2023.
Stock Award Plans
2009 Equity Incentive Plan
The 2009 Equity Incentive Plan (“2009 Plan”), as amended, provides for the issuance of incentive stock options, RSAs, RSUs, PSUs, and other stock awards to the Company’s employees, directors, and consultants. There were 5.9 million shares of common stock reserved for future issuance under the 2009 Plan as of December 31, 2023.
Options granted under the 2009 Plan generally become exercisable over periods of up to four years, with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter. The exercise prices of the options is the fair market value of common stock on the date of grant. RSUs generally vest over periods of up to four years, with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 12 equal quarterly installments thereafter. Awards of restricted stock to non-employee directors are granted on the date of the annual meeting of stockholders and vest in full on the date of the next annual meeting of stockholders, provided such non-employee director remains a director on such date. PSUs granted to the Company’s executives may include performance and market conditions. PSUs become eligible for vesting when certain market or performance conditions are met.
F-37
Share-Based Compensation Expense
The following table sets forth the total share-based compensation expense recognized in the Company’s Consolidated Statements of Operations:
Year Ended December 31,
202320222021
(In thousands)
Cost of product and service revenues$8,288 $9,067 $7,994 
Research and development6,941 11,368 7,663 
Selling, general, and administrative40,071 47,812 37,503 
Total share-based compensation expense$55,300 $68,247 $53,160 
During the year ended December 31, 2023, the Company capitalized approximately $4.4 million of non-cash share-based compensation expense to internal-use and external-use software development costs related to internal labor. The Company did not capitalize any material non-cash share-based compensation expense to inventory during the years ended December 31, 2023, 2022, and 2021, or any material non-cash share-based compensation expense to internal-use and external-use software development costs during the years ended December 31, 2022 and 2021. Income tax benefit (expense) realized from share-based compensation was an expense of $6.5 million for the year ended December 31, 2023, and a benefit of $5.2 million and $26.6 million for the years ended December 31, 2022 and 2021, respectively.
Employee Stock Purchase Plan (“ESPP”)
The following assumptions were used to value shares under the ESPP for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
Expected life, years
0.5 - 2.0
0.5 - 2.0
0.5 - 2.0
Expected volatility, %
31.7% - 63.9%
28.8% - 45.6%
27.4% - 53.5%
Risk-free interest rate, %
0.1% - 5.5%
0.1% - 3.2%
0.1% - 2.6%
Dividend yield, %— %— %— %
For the years ended December 31, 2023 and 2022, employees purchased approximately 353,000 and 316,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $46.68 and $67.63, respectively. As of December 31, 2023, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $1.1 million and is expected to be recognized over a weighted-average period of 1.4 years.
Stock Options
The following assumptions were used to value stock options granted pursuant to the 2009 Plan for the years ended December 31, 2023 and 2021. There were no stock options granted during the year ended December 31, 2022:
Year Ended December 31,
20232021
Expected life, years3.24.9
Expected volatility, %44.8 %31.5 %
Risk-free interest rate, %3.7 %0.9 %
Estimated forfeiture rate, %10.0 %7.9 %
Dividend yield, %— %— %
F-38
The following table summarizes the stock option activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Exercise Price
Weighted-Average
Remaining Years
Aggregate
Intrinsic Value
(In thousands, except per share data)
Outstanding at December 31, 20222,434 $68.65 6.1$7,887 
Granted200 55.60 
Exercised(165)41.01 
Expired(242)79.49 
Forfeited(204)74.92 
Outstanding at December 31, 20232,023 $67.68 4.6$1,013 
Exercisable at December 31, 20231,784 $67.18 4.5$1,013 
Vested and expected to vest at December 31, 2023 and thereafter2,013 $67.64 4.6$1,013 
The weighted-average fair value per share of options granted during the years ended December 31, 2023 and 2021 was 19.48 and 35.17, respectively. The intrinsic value of options exercised during the years ended December 31, 2023, 2022, and 2021 was $3.2 million, $23.9 million, and $88.0 million, respectively. The tax benefit (expense) realized from stock options exercised was expense of $1.3 million for the year ended December 31, 2023, and benefit of $4.4 million and $18.3 million for the years ended December 31, 2022 and 2021, respectively.
As of December 31, 2023, total unrecognized compensation cost related to unvested stock options was $3.3 million, which is expected to be recognized over a weighted-average vesting period of 0.7 years.
Restricted Stock Units (“RSUs”)
The following table summarizes the RSU activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Grant Date Fair Value
Weighted-Average
Remaining Years
Aggregate
Intrinsic Value
(In thousands, except per share data)
Outstanding at December 31, 20221,117 $115.75 1.6$56,297 
Granted (Awarded)695 63.74 
Vested (Released)(335)113.64 
Forfeited(399)107.89 
Outstanding and unvested at December 31, 20231,078 $84.66 1.5$40,551 
The weighted-average grant date fair value per share of RSUs granted during the years ended December 31, 2023, 2022, and 2021 was $63.74, $111.12, and $149.65, respectively. The total fair value of RSUs that vested in the years ended December 31, 2023, 2022, and 2021 was $38.0 million, $30.7 million, and $16.7 million, respectively.
As of December 31, 2023, total unrecognized compensation cost related to RSUs was $64.3 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.0 years.
F-39
Restricted Stock Awards (“RSAs”)
The following table summarizes the RSA activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Grant Date Fair Value
(In thousands, except per share data)
Outstanding at December 31, 202213 $109.39 
Granted (Awarded)24 70.96 
Vested (Released)(13)109.39 
Outstanding and unvested at December 31, 202324 $70.96 
The weighted-average grant date fair value per share of RSAs granted during the years ended December 31, 2023, 2022, and 2021 was $70.96, $109.39, and $137.36, respectively. The total fair value of RSAs that vested in the years ended December 31, 2023, 2022, and 2021 was $1.4 million, $1.6 million, and $1.4 million, respectively.
As of December 31, 2023, total unrecognized compensation cost related to RSAs was $0.6 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.4 years.
Performance-Based Stock Unit Awards (“PSUs”)
During the year ended December 31, 2022, the Company granted 56,237 PSUs to its executive officers, none of which became eligible for vesting as the achievement of a certain level of shareholder return was not achieved. During the year ended December 31, 2023, the Company granted 65,000 PSUs to its executive officers, of which 0% to 200% may become eligible for vesting depending on the level of shareholder return for the period from March 1, 2023 through March 1, 2024.
The number of shares that vest at the end of the performance period depends on the percentile ranking of the total shareholder return for Omnicell stock over the performance period relative to the total shareholder return of each of the other companies in the NASDAQ Health Care Index. Stock price appreciation is calculated based on the trailing 20-day average stock price just prior to the first trading day of March in the grant year, compared to the trailing 20-day average stock price just prior to the first trading day of March in the year subsequent to the grant year.
PSUs generally vest over periods of up to four years, with one-fourth of the shares vesting approximately one year from the vesting commencement date with respect to initial grants and upon confirmation by the Compensation Committee that the performance target has been met, and the remaining shares generally vesting in equal semi-annual or quarterly installments over the remaining three years. Vesting is contingent upon continued service.
In addition to executive officers’ PSU awards, from time to time, the Company may grant PSUs with specific performance and service conditions to certain employees on an ad hoc basis.
The following table summarizes the PSU activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Grant Date Fair Value
(In thousands, except per share data)
Outstanding at December 31, 2022135 $147.42 
Granted65 122.29 
Vested(55)111.05 
Forfeited(70)153.77 
Outstanding and unvested at December 31, 202375 $127.14 
The weighted-average grant date fair value per share of PSUs granted during the years ended December 31, 2023, 2022, and 2021 was $122.29, $155.27, and $162.16, respectively. The total fair value of PSUs that vested in the years ended December 31, 2023, 2022, and 2021 was $6.1 million, $15.0 million, and $4.4 million, respectively.
As of December 31, 2023, total unrecognized compensation cost related to PSUs was approximately $5.0 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.4 years.
F-40
Summary of Shares Reserved for Future Issuance under Equity Incentive Plans
The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of December 31, 2023:
Number of Shares
(In thousands)
Stock options outstanding2,023 
Non-vested restricted stock awards1,177 
Shares authorized for future issuance2,669 
ESPP shares available for future issuance3,250 
Total shares reserved for future issuance9,119 
401(k) Plan
The Company has established a pre-tax savings plan under Section 401(k) of the Internal Revenue Code of 1986, as amended. The 401(k) Plan allows eligible employees in the United States to voluntarily contribute a portion of their pre-tax salary, subject to a maximum limit specified in the Internal Revenue Code. The Company generally matches 50% of employee contributions up to $3,000, annually. The Company’s contributions under this plan were $7.9 million, $8.1 million, and $6.8 million in the years ended December 31, 2023, 2022, and 2021, respectively.
Note 16.    Stock Repurchase Programs
On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2014 Repurchase Program”). During the year ended December 31, 2022, the 2014 Repurchase Program was completed, and as of December 31, 2023, the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million.
The timing, price, and volume of repurchases are to be based on market conditions, relevant securities laws, and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions, or pursuant to a Rule 10b-18 plan, subject to the terms and conditions of that certain A&R Credit Agreement, as amended. The 2016 Repurchase Program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the 2016 Repurchase Program at any time.
During the year ended December 31, 2022, the Company repurchased approximately 389,300 shares of its common stock under the repurchase programs at an average price of $134.11 per share for an aggregate purchase price of approximately $52.2 million. During the years ended December 31, 2023 and 2021, the Company did not repurchase any of its outstanding common stock under the stock repurchase programs.
F-41
Note 17.     Income Taxes
The following is a geographical breakdown of income (loss) before income taxes:
Year Ended December 31,
202320222021
(In thousands)
Domestic$(28,105)$369 $67,103 
Foreign7,997 (2,822)(1,096)
Income (loss) before income taxes$(20,108)$(2,453)$66,007 
The provision for (benefit from) income taxes consisted of the following:
Year Ended December 31,
202320222021
(In thousands)
Current:
Federal$8,556 $17,973 $(7,841)
State1,471 8,024 187 
Foreign840 192 (234)
Total current income taxes10,867 26,189 (7,888)
Deferred:
Federal(8,002)(25,753)(2,708)
State(2,261)(7,976)(1,217)
Foreign(341)(561)(29)
Total deferred income taxes(10,604)(34,290)(3,954)
Total provision for (benefit from) income taxes$263 $(8,101)$(11,842)
F-42
The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows:
Year Ended December 31,
202320222021
(In thousands)
U.S. federal tax provision at statutory rate$(4,223)$(515)$13,861 
State taxes(624)38 (814)
Section 162(m) limitation1,286 3,071 6,382 
Non-deductible expenses531 134 363 
Uncertain tax positions(620)(776)(835)
Share-based compensation tax expense (benefit)7,384 (3,264)(20,717)
Research tax credits(4,587)(6,948)(5,170)
Restructuring impact— — (6,116)
Foreign-derived intangible income deduction(325)(753)(68)
Global intangible low-taxed income inclusion— 960 195 
Foreign rate differential219 186 (170)
Foreign branch taxes6 (51)(9)
Transaction cost— 68 1,097 
Provision to return true up697 (84)205 
State rate true up528 (135)(80)
Other(9)(32)34 
Total provision for (benefit from) income taxes$263 $(8,101)$(11,842)
On August 16, 2022, the Inflation Reduction Act of 2022, (the “IRA”), was signed into law. Among other things, the IRA imposes a 15% corporate alternative minimum tax for tax years beginning after December 31, 2022, levies a 1% excise tax on net stock repurchases after December 31, 2022, and provides tax incentives to promote clean energy. The provisions of the IRA did not have a material impact on the Company’s results of operations or financial position.
The Organization for Economic Co-Operation and Development (“OECD”) introduced Base Erosion and Profit Shifting (“BEPS”) Pillar Two rules that impose a global minimum tax rate of 15% on multi-national corporations. The rules are effective for the Company’s financial year beginning January 1, 2024. Numerous countries have enacted or substantively enacted legislation to implement these rules. While the Company does not expect Pillar Two to have a material impact on its tax provision or effective tax rate, the Company continues to monitor evolving tax legislation in the jurisdictions in which it operates.
F-43
Significant components of the Company’s deferred tax assets (liabilities) were as follows:
December 31,
20232022
(In thousands)
Deferred tax assets (liabilities):
Deferred revenues$11,343 $13,514 
Share-based compensation11,763 12,064 
Inventory-related items5,136 4,567 
Tax credit carryforwards12,505 12,173 
Reserves and accruals5,660 6,244 
Loss carryforwards7,802 10,255 
Lease liability11,457 12,884 
Convertible debt9,649 15,037 
Capitalized research and development41,635 30,881 
Other, net591 1,557 
Gross deferred tax assets117,541 119,176 
Valuation allowance— — 
Total net deferred tax assets117,541 119,176 
Intangibles(30,366)(36,357)
Depreciation and amortization(35,402)(37,286)
Prepaid expenses(13,858)(15,574)
Right-of-use assets(6,626)(9,725)
Other, net(8)— 
Total deferred tax liabilities(86,260)(98,942)
Net deferred tax assets $31,281 $20,234 
Deferred income tax assets (liabilities) are provided for temporary differences that will result in future tax deductions or future taxable income, as well as the future benefit of tax credit carryforwards. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. As of December 31, 2023 and 2022, the Company does not have a valuation allowance against any of its deferred tax assets.
As of December 31, 2023, the Company had no federal net operating loss carryforward, $19.0 million of state net operating loss carryforwards expiring at various dates beginning in 2029, and $22.3 million of foreign net operating losses carried forward indefinitely. For income tax purposes, the Company had no federal research tax credit carryforward and a California research tax credit carryforward of $20.9 million. California research tax credits are carried forward indefinitely to reduce cash taxes payable.
It is the Company’s practice and intention to reinvest the earnings of its non-U.S. subsidiaries in those operations. As of December 31, 2023, the Company has not made a provision for U.S. federal income, withholding, and state income taxes on the outside basis difference related to certain foreign subsidiaries because earnings are intended to be indefinitely reinvested in operations outside the U.S.
The Company files income tax returns in the United States and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, France, the United Kingdom and India. With few exceptions, as of December 31, 2023, the Company was no longer subject to U.S., state, and foreign tax examinations for years before 2020, 2019, and 2019, respectively.
F-44
The aggregate change in the balance of gross unrecognized tax benefit, which excludes interest and penalties, for the years ended December 31, 2023, 2022, and 2021:
(In thousands)
Balance as of December 31, 2020$18,246 
Increases related to tax positions taken during a prior period40 
Decreases related to tax positions taken during the prior period(8,908)
Increases related to tax positions taken during the current period1,219 
Decreases related to expiration of statute of limitations(1,636)
Balance as of December 31, 20218,961 
Increases related to tax positions taken during a prior period3 
Decreases related to tax positions taken during the prior period(59)
Increases related to tax positions taken during the current period1,629 
Decreases related to expiration of statute of limitations(1,238)
Balance as of December 31, 20229,296 
Increases related to tax positions taken during a prior period
750 
Decreases related to tax positions taken during the prior period(161)
Increases related to tax positions taken during the current period1,566 
Decreases related to expiration of statute of limitations(703)
Balance as of December 31, 2023$10,748 
The total amount of gross unrecognized tax benefit that, if realized, would favorably affect the Company’s effective income tax rate in future periods, was $10.7 million and $9.3 million as of December 31, 2023 and 2022, respectively. The Company recognizes interest and penalties related to uncertain tax positions in interest and other income (expense), net in the Consolidated Statements of Operations, accruing $0.2 million, $0.2 million, and $0.3 million for the years ended December 31, 2023, 2022, and 2021, respectively. Accrued interest and penalties are included within other long-term liabilities on the Consolidated Balance Sheets. The combined amount of cumulative accrued interest and penalties was approximately $0.4 million, $0.2 million, and $0.6 million for the years ended December 31, 2023, 2022, and 2021, respectively. The Company does not believe there will be any significant changes in its unrecognized tax positions over the next twelve months.
Note 18.    Restructuring Expenses
During the first quarter of 2021, the Company continued its organizational realignment initiative that was announced in 2020, incurring $2.0 million of employee severance costs and related expenses.
During the first quarter of 2022, the Company initiated certain domestic and international restructuring initiatives in order to enhance and streamline certain engineering functions for its domestic operations and to realign its international sales organization to better serve its customers in various international markets. During the third quarter of 2022, the Company initiated restructuring initiatives associated with the integration and functionalization of certain acquisitions, primarily the 340B Link business acquisition, to further accelerate the expansion of the Company’s pharmacy inventory management capabilities. On November 23, 2022, the Company committed to a plan to reduce the Company’s headcount (“the 2022 Plan”) as part of the Company’s expense containment efforts being implemented due to ongoing macroeconomic headwinds, primarily consisting of employee severance and benefits costs. During the year ended December 31, 2022, the restructuring plans incurred $22.8 million of employee severance costs and related expenses. As of December 31, 2023, there was no material unpaid balance related to these restructuring plans.
During the first quarter of 2023, as a result of continued exploration of expense containment measures, the Company committed to further reduce its headcount across many of its functions as a continuation of the 2022 Plan, and also committed to reduce its real estate footprint to align with its broader hybrid work strategy and in an effort to further reduce costs. During the year ended December 31, 2023, the Company recorded an immaterial reversal of previously recognized restructuring expenses associated with the 2022 Plan.
On November 2, 2023, the Company committed to a plan to reduce the Company’s headcount and real estate footprint (the “2023 Plan”) as part of the Company’s expense containment initiatives and other actions to reduce discretionary spending being implemented due to challenging industry dynamics and macroeconomic conditions. During the year ended December 31,
F-45
2023, the restructuring plans incurred $15.5 million of employee severance costs and related expenses, net of reversals. As of December 31, 2023, the unpaid balance related to these restructuring plans was $8.9 million.
Refer to Note 13, Lessee Leases for information regarding the Company’s restructuring activities for the reduction of its real estate footprint and optimization of certain leased facilities.
The following table summarizes the total employee-related restructuring expenses recognized in the Company’s Consolidated Statements of Operations for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Cost of product and service revenues$3,089 $8,018 $389 
Research and development3,829 3,615 105 
Selling, general, and administrative8,621 11,170 1,526 
Total restructuring expenses, net of reversals$15,539 $22,803 $2,020 
F-46
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS
Balance at
Beginning of Period (1)
Charged (Credited) to
Costs and Expenses (2)
Amounts
Written Off (3)
Other Adjustments (4)
Balance at
End of Period (1)
(In thousands)
Year ended December 31, 2021
Accounts receivable and unbilled receivables$4,286 $2,130 $(2,079)$935 $5,272 
Long-term unbilled receivables30 (4)— — 26 
Net investment in sales-type leases265 (37)— — 228 
Total allowances deducted from assets$4,581 $2,089 $(2,079)$935 $5,526 
Year ended December 31, 2022
Accounts receivable and unbilled receivables$5,272 $2,658 $(2,551)$(226)$5,153 
Long-term unbilled receivables26 9 — — 35 
Net investment in sales-type leases228 80 — — 308 
Total allowances deducted from assets$5,526 $2,747 $(2,551)$(226)$5,496 
Year ended December 31, 2023
Accounts receivable and unbilled receivables$5,153 $2,726 $(2,441)$126 $5,564 
Long-term unbilled receivables35 (4)— 31 
Net investment in sales-type leases308 (51)— — 257 
Total allowances deducted from assets$5,496 $2,671 $(2,441)$126 $5,852 
__________________________________________________
(1)Allowance for credit losses.
(2)Represents amounts charged and credited for provisions for credit losses.
(3)Represents amounts written off from the allowance and receivable.
(4)Represents other adjustments, such as foreign currency translation and purchase price accounting adjustments in connection with acquisitions.
F-47
INDEX TO EXHIBITS
Incorporated By Reference
Exhibit NumberExhibit DescriptionFormExhibitFiling Date
2.18-K2.110/29/2015
2.28-K2.111/29/2016
2.38-K2.18/12/2020
2.410-Q2.210/30/2020
3.18-K3.19/20/2001
3.210-Q3.28/9/2010
3.310-K3.23/28/2003
3.48-K3.110/21/2022
4.1Reference is made to Exhibits 3.1, 3.2, 3.3, and 3.4
4.2S-1/A4.17/24/2001
4.310-K4.72/26/2020
4.48-K4.19/25/2020
4.58-K4.29/25/2020
10.1*S-899.15/26/2023
10.2*S-899.25/26/2023
10.3*10-Q10.48/9/2012
10.4*10-Q10.58/9/2012
10.5*S-899.45/24/2018
10.6*8-K10.13/8/2019
10.7*10-Q10.17/31/2020
10.8*10-K10.92/24/2021
10.9*10-K10.102/24/2021
10.10*8-K10.13/17/2010

Incorporated By Reference
Exhibit NumberExhibit DescriptionFormExhibitFiling Date
10.11*10-Q10.311/6/2015
10.12*10-K10.412/27/2019
10.13*10-K10.322/25/2022
10.1410-Q10.35/6/2016
10.1510-K10.242/24/2021
10.1610-K10.252/24/2021
10.1710-K10.262/24/2021
10.1810-K10.272/24/2021
10.1910-Q10.35/5/2017
10.2010-K10.392/26/2020
10.218-K10.19/25/2020
10.228-K10.29/25/2020
10.23*10K10.3103/01/2023
10.24*10Q10.308/04/2023
10.25*10Q10.408/04/2023
10.26*10Q10.111/03/2023
10.27*10Q10.211/03/2023
10.28*10Q10.311/03/2023
10.29*10Q10.411/03/2023
10.308-K10.110/16/2023
10.31*8-K10.111/09/2023
10.32*+
21.1+
23.1+

Incorporated By Reference
Exhibit NumberExhibit DescriptionFormExhibitFiling Date
24.1+
31.1+
31.2+
32.1+
97.1+
101.INS+
Inline XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH+
Inline XBRL Taxonomy Extension Schema Document
101.CAL+
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB+
Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE+
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104+
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).
_________________________________________________
*    Indicates a management contract, compensation plan, or arrangement.
+    Filed herewith.

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
OMNICELL, INC.
Date:February 28, 2024By:/s/ NCHACHA E. ETTA
Nchacha E. Etta,
Executive Vice President & Chief Financial Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each of the persons whose signature appears below hereby constitutes and appoints Randall A. Lipps and Nchacha E. Etta, each of them acting individually, as his or her attorney-in-fact, each with the full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming our signatures as they may be signed by our said attorney-in-fact and any and all amendments to this Annual Report on Form 10-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
SignatureTitleDate
/s/ RANDALL A. LIPPSChief Executive Officer, President and Chairman of the Board (Principal Executive Officer)February 28, 2024
Randall A. Lipps
/s/ NCHACHA E. ETTAExecutive Vice President & Chief Financial Officer
(Principal Financial Officer)		February 28, 2024
Nchacha E. Etta
/s/ JOSEPH B. SPEARSSenior Vice President, Chief Accounting Officer and Corporate Controller (Principal Accounting Officer)February 28, 2024
Joseph B. Spears
/s/ JOANNE B. BAUERFebruary 28, 2024
Joanne B. BauerDirector
/s/ EDWARD P. BOUSAFebruary 28, 2024
Edward P. BousaDirector
/s/ MARY A. GARRETTFebruary 28, 2024
Mary A. GarrettDirector
/s/ KAUSHIK GHOSHALFebruary 28, 2024
Kaushik GhoshalDirector
/s/ VANCE B. MOOREFebruary 28, 2024
Vance B. Moore Director
/s/ MARK W. PARRISHFebruary 28, 2024
Mark W. ParrishDirector
/s/ BRUCE E. SCOTTFebruary 28, 2024
Bruce E. ScottDirector
/s/ ROBIN G. SEIMFebruary 28, 2024
Robin G. SeimDirector
/s/ EILEEN J. VOYNICKFebruary 28, 2024
Eileen J. VoynickDirector
S-1
 EX-10.32 2 exhibit1032-draftindemnity.htm EX-10.32 Document

INDEMNITY AGREEMENT

This Indemnity Agreement (the “Agreement”) is made and entered into this ______ day of _______, ______ by and between OMNICELL, INC. a Delaware corporation (the “Corporation”) and _______________ (“Agent”).

WHEREAS, Agent performs a valuable service to the Corporation in his/her capacity as ___________ of the Corporation;

WHEREAS, the stockholders of the Corporation have adopted bylaws (the “Bylaws”) providing for the indemnification of the directors, officers, employees and other agents of the Corporation, including persons serving at the request of the Corporation in such capacities with other corporations or enterprises, as authorized by the Delaware General Corporation Law, as
amended (the “Code”);

WHEREAS, the Bylaws and the Code, by their non-exclusive nature, permit contracts between the Corporation and its agents, officers, employees and other agents with respect to indemnification of such persons; and

WHEREAS, in order to induce Agent to continue to serve as a ___________ of the Corporation, the Corporation has determined and agreed to enter into this Agreement with Agent;

NOW, THEREFORE, in consideration of Agent’s continued service as _________ after the date hereof, the parties hereto agree as follows:

1. SERVICES TO THE CORPORATION. Agent will serve, at the will of the Corporation or under separate contract, if any such contract exists, as ___________of the Corporation or as a director, officer or other fiduciary of an affiliate of the Corporation (including any employee benefit plan of the Corporation) faithfully and to the best of his or her ability so long as he or she is duly elected and qualified in accordance with the provisions of the Bylaws or other applicable charter documents of the Corporation or such affiliate; PROVIDED, HOWEVER, that Agent may at any time and for any reason resign from such position (subject to any contractual obligation that Agent may have assumed apart from this Agreement) and that the Corporation or any affiliate shall have no obligation under this Agreement to continue Agent in any such position.

2. INDEMNITY OF AGENT. The Corporation hereby agrees to hold harmless and indemnify Agent to the fullest extent authorized or permitted by the provisions of the Bylaws and the Code, as the same may be amended from time to time (but, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than the Bylaws or the Code
permitted prior to adoption of such amendment), provided that the Corporation’s commitment set forth in this Section 2 shall be subject to the limitations and procedural requirements set forth in this Agreement.

3. ADDITIONAL INDEMNITY. In addition to, and not in limitation of, the indemnification otherwise provided for herein, and subject only to the exclusions set forth in Section 4 hereof, the Corporation hereby further agrees to hold harmless and indemnify Agent: (a) against any and all expenses (including attorneys’ fees), witness fees, damages, judgments, fines and amounts paid in settlement and any other amounts that Agent becomes legally obligated to pay because of any claim or claims made against or by him in connection with any threatened, pending or completed action, suit or proceeding, whether civil, criminal, arbitrational, administrative or investigative (including an action by or in the right of the Corporation) to which Agent is, was or at any time becomes a party, or is threatened to be made a party, by reason of the fact that Agent is, was or at any time becomes a director, officer, employee or other agent of Corporation, or is or was


serving or at any time serves at the request of the Corporation as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise; and (b) otherwise to the fullest extent as may be provided to Agent by the Corporation under the non-exclusivity provisions of the Code and Section 45 of the Bylaws. In the event of any change after the date of this Agreement in any applicable law, statute or rule that expands the right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, employee, controlling person, agent or fiduciary, it is the intent of the parties hereto that Agent shall enjoy by this Agreement the greater benefits afforded by such change. In the event of any change in any applicable law, statute or rule that narrows the right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, employee, controlling person, agent or fiduciary, such change, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the parties rights and obligations hereunder except as set forth in Section 4 hereof.

4. LIMITATIONS ON ADDITIONAL INDEMNITY. No indemnity pursuant to Section 3 hereof shall be paid by the Corporation: (a) on account of any claim against Agent (i) for an accounting of profits made from the purchase or sale by Agent of securities of the Corporation pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934 and amendments thereto or similar provisions of any federal, state or local statutory law or (ii) pursuant to Section 304 or 306 of the Sarbanes-Oxley Act of 2002, as amended, or any rule or regulation promulgated pursuant thereto; (b) on account of Agent’s conduct that was knowingly fraudulent or deliberately dishonest or that constituted willful misconduct; (c) on account of Agent’s conduct that constituted a breach of Agent’s duty of loyalty to the Corporation or resulted in any personal profit or advantage to which Agent was not legally entitled; (d) for which payment is actually made to Agent under a valid and collectible insurance policy or under a valid and enforceable indemnity clause, bylaw or agreement, except in respect of any excess beyond payment under such insurance, clause, bylaw or agreement; (e) if, and to the extent, that a court of competent jurisdiction renders a final, unappealable decision that such indemnification is not lawful (and, in this respect, both the Corporation and Agent have been advised that the Securities and Exchange Commission (“SEC”) believes that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore, unenforceable and that claims for indemnification should be submitted to appropriate courts for adjudication); or (f) in connection with any proceeding (or part thereof) initiated by Agent, or any proceeding by Agent against the Corporation or its directors, officers, employees or other agents, unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Board of Directors of the Corporation, (iii) such indemnification is provided by the Corporation, in its sole discretion, pursuant to the powers vested in the Corporation under the Code, or (iv) the proceeding is initiated pursuant to Section 11 hereof.

5. CONTINUATION OF INDEMNITY. All agreements and obligations of the Corporation contained herein shall continue during the period Agent is a director, officer, employee or other agent of the Corporation (or is or was serving at the request of the Corporation as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise) and shall continue thereafter so long as Agent shall be subject to any possible claim or threatened, pending or completed action, suit or proceeding, whether civil, criminal, arbitrational, administrative or investigative, for any action Agent took or did not take while serving in an indemnified capacity or by reason of the fact that Agent was serving in the capacity referred to herein even though Agent may have ceased to serve in such capacity.

6. PARTIAL INDEMNIFICATION. Agent shall be entitled under this Agreement to indemnification by the Corporation for a portion of the expenses (including attorneys’ fees), witness fees, damages, judgments, fines and amounts paid in settlement and any other amounts that Agent becomes legally obligated to pay in connection with any action, suit or proceeding
2


referred to in Section 3 hereof even if not entitled hereunder to indemnification for the total amount thereof, and the Corporation shall indemnify Agent for the portion thereof to which Agent is entitled.

7. NOTIFICATION AND DEFENSE OF CLAIM. As soon as practicable, but not later than thirty (30) days after receipt by Agent of notice of the commencement of any action, suit or proceeding, Agent will, if a claim in respect thereof is to be made against the Corporation under this Agreement, notify the Corporation of the commencement thereof; but the omission or failure so to notify the Corporation will not relieve it from any obligation or liability which it may have to Agent under this Agreement or otherwise, except if, and then only to the extent that, such failure increases the liability of the Corporation under this Agreement. With respect to any such action, suit or proceeding as to which Agent notifies the Corporation of the commencement thereof: (a) the Corporation will be entitled to participate therein at its own expense; (b) except as otherwise provided below, the Corporation may, at its option and jointly with any other indemnifying party similarly notified and electing to assume such defense, assume the defense thereof, with counsel selected by the Corporation. After notice from the Corporation to Agent of its election to assume the defense thereof, the Corporation will not be liable to Agent under this Agreement for any legal or other expenses subsequently incurred by Agent in connection with the defense thereof except for reasonable costs of investigation or otherwise as provided below. Agent shall have the right to employ separate counsel in such action, suit or proceeding but the fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense of Agent unless (i) the employment of counsel by Agent previously has been authorized by the Corporation, (ii) counsel for Agent shall have provided the Corporation with written advice that there is a conflict of interest between the Corporation and Agent in the conduct of the defense of such action or (iii) the Corporation shall not in fact have employed counsel to assume the defense of, or shall not continue to retain counsel to defend, such action, in each of which cases the fees and expenses of Agent’s separate counsel shall be at the expense of the Corporation. The Corporation shall not be entitled to assume the defense of any action, suit or proceeding brought by or on behalf of the Corporation or as to which Agent shall have provided the written advice as set forth in clause (ii) above; and (c) the Corporation shall not be liable to indemnify Agent under this Agreement for any amounts paid in settlement of any action or claim effected without its written consent, which shall not be unreasonably withheld. The Corporation shall be permitted to settle any action except that it shall not settle any action or claim in any manner which would impose any penalty or limitation on Agent without Agent’s written consent, which shall not be unreasonably withheld. The Corporation shall not be liable to indemnify the Agent under this Agreement with regard to any judicial award if the Corporation was not given a reasonable and timely opportunity, at its expense, to participate in the defense of such action; the Corporation’s liability hereunder shall not be excused if participation in any action, suit or proceeding by the Corporation was barred by this Agreement.

The Corporation shall give prompt written notice of any such action, suit or proceeding, as to which Agent notifies the Corporation of the commencement thereof, which may be covered by the Corporation’s liability insurance, to the insurers in accordance with the procedures set forth in each of the applicable policies of insurance. The Corporation shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Agent, all amounts payable as a result of such action, suit or proceeding in accordance with the terms of such policies; provided that nothing in this Section 7 shall affect the Corporation’s obligations under this Agreement or the Corporation’s obligations to comply with the provisions of this Agreement in a timely manner as provided.

3


8. DETERMINATION OF RIGHT TO INDEMNIFICATION.
(a)Successful Proceeding. To the extent Agent has been successful, on the merits or otherwise, in defense of any action, suit or proceeding referred to in Section 2, the Corporation shall indemnify Agent against losses and expenses incurred by Agent in connection therewith. If Agent is not wholly successful in such action, suit or proceeding, but is successful, on the merits or otherwise, as to one or more but less than all claims in such action, suit or proceeding, the Corporation shall indemnify Agent against all losses and expenses actually or reasonably incurred by Agent in connection with each successfully resolved claim.
(b)Other Proceedings. In the event that Section 8(a) is inapplicable, the Corporation shall nevertheless indemnify Agent as provided in Section 2 or Section 6, as applicable, or provide a contribution payment to the Agent as provided in Section 10, to the extent determined by the Reviewing Party (as defined herein).
(c)Reviewing Party Determination. A Reviewing Party chosen by the Corporation’s Board of Directors shall determine whether Agent is entitled to indemnification, subject to the following:
(i)A Reviewing Party, so chosen, shall act in the utmost good faith to assure Agent a complete opportunity to present to such Reviewing Party Agent’s case that Agent has met the applicable standard of conduct.
(ii)Agent shall be deemed to have acted in good faith if Agent’s action is based on the records or books of account of the Corporation or any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise Agent is or was serving at the request of the Corporation as a director, officer, employee or other agent (“Covered Entity”), including, without limitation, its financial statements, or on information supplied to Agent by the officers or employees of a Covered Entity in the course of their duties, or on the advice of legal counsel for a Covered Entity or on information or records given, or reports made, to a Covered Entity by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by a Covered Entity. In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of a Covered Entity shall not be imputed to Agent for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 8(c)(ii) are satisfied, it shall in any event be presumed that Agent has at all times acted in good faith and in a manner Agent reasonably believed to be in or not opposed to the best interests of the Corporation. Any person seeking to overcome this presumption shall have the burden of proof and the burden of persuasion, by clear and convincing evidence.
(iii)If a Reviewing Party chosen pursuant to this Section 8(c) shall not have made a determination whether Agent is entitled to indemnification within ninety (90) days after receipt by the Corporation of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Agent shall be entitled to such indemnification, absent (A) a misstatement by Agent of a material fact, or an omission of a material fact necessary to make Agent’s statement not materially misleading, in connection with the request for indemnification, or (B) a prohibition of such indemnification under applicable law; provided that the foregoing provisions of this Section 8(c)(iii) shall not apply if (I) the determination of entitlement to indemnification is to be made by the stockholders of the Corporation, (II) a special meeting of stockholders is called by the Board of Directors of the Corporation for such purpose within thirty (30) days after the stockholders are chosen as the Reviewing Party,
4


(III) such meeting is held for such purpose within sixty (60) days after having been so called, and (IV) such determination is made thereat.
(iv)Definitions. For purposes of this Section 8(c):
(A)“Reviewing Party” means, with respect to any determination contemplated by this Agreement, any one of the following: (i) a majority of the members of the Corporation’s Board of Directors that are not a party to any action, suit or proceeding then pending for which Agent is seeking indemnification (“Disinterested Directors”), even if such persons would not constitute a quorum of the Corporation’s Board of Directors; (ii) a committee consisting solely of Disinterested Directors, even if such persons would not constitute a quorum of the Corporation’s Board of Directors, so long as such committee was designated by a majority of the Disinterested Directors; (iii) Independent Legal Counsel (as defined below) designated by the Disinterested Directors (or, if there are no Disinterested Directors, the Corporation’s Board of Directors) (in which case, any determination shall be evidenced by the rendering of a written opinion); or (iv) in the absence of any Disinterested Directors, the Corporation’s stockholders; provided, that, in the event that a Change in Control (as defined below) has occurred, the Reviewing Party shall be Independent Legal Counsel (selected by Agent) in a written opinion to the Corporation’s Board of Directors, a copy of which shall be delivered to the Agent.
(B)“Independent Legal Counsel” means an attorney or firm of attorneys that is experienced in matters of corporate law and neither presently is, nor in the thirty-six (36) months prior to such designation has been, retained to represent: (i) the Corporation or Agent in any matter material to either such party, or (ii) any other party to any action, suit or proceeding giving rise to a claim for indemnification hereunder.
(C)“Change of Control” means each of the following:
(a)The date any person (individual, partnership, corporation, limited liability company, association, joint stock company, trust, joint venture, unincorporated organization or other entity or government or agency or political subdivision thereof) (“Person”) becomes the “Beneficial Owner,” as such term is defined in Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended, of 30% or more of the combined voting power of the Corporation’s outstanding shares of common stock, other than beneficial ownership by (A) the Corporation or any subsidiary of the Corporation, (B) any employee benefit plan of the Corporation or any subsidiary of the Corporation or (C) any entity of the Corporation for or pursuant to the terms of any such plan. Notwithstanding the foregoing, a Change in Control shall not occur as the result of an acquisition of outstanding shares of common stock of the Corporation by the Corporation which, by reducing the number of shares outstanding, increases the proportionate number of shares beneficially owned by a Person to 30% or more of the
5


shares of the Corporation then outstanding; provided, however, that if a Person becomes the Beneficial Owner of 30% or more of the shares of the common stock of the Corporation then outstanding by reason of share purchases by the Corporation and shall, after such share purchases by the Corporation, become the Beneficial Owner of any additional shares of the Corporation, then a Change in Control shall be deemed to have occurred; or
(b)The date the Corporation consummates a merger or consolidation with another entity, or engages in a reorganization with or a statutory share exchange or an exchange offer for the Corporation’s outstanding voting stock of any class with another entity or acquires another entity by means of a statutory share exchange or an exchange offer, or engages in a similar transaction; provided that no Change in Control shall have occurred by reason of this paragraph unless either:
(i)the stockholders of the Corporation immediately prior to the consummation of the transaction would not, immediately after such consummation, as a result of their beneficial ownership of voting stock of the Corporation immediately prior to such consummation (I) be the Beneficial Owners, directly or indirectly, of securities of the resulting or acquiring entity entitled to elect a majority of the members of the board of directors or other governing body of the resulting or acquiring entity; and (II) be the Beneficial Owners of the resulting or acquiring entity in substantially the same proportion as their beneficial ownership of the voting stock of the Corporation immediately prior to such transaction; or
(ii)those Persons who were directors of the Corporation immediately prior to the consummation of the proposed transaction would not, immediately after such consummation, constitute a majority of the directors of the resulting entity.
(iii) The date of the sale or disposition, in one or a series of related transactions, of all or substantially all of the assets of the Corporation to any Person (as defined in paragraph (a) above) other than an affiliate of the Corporation (meaning any corporation that is part of a controlled group within the meaning of the Internal Revenue Code of 1986, as amended, Section 414(b) or (c)); or
(iv)The date the number of duly elected and qualified directors of the Corporation who were not either elected by the Corporation’s Board of Directors or nominated by the Board of Directors or its corporate governance committee for election by the stockholders shall constitute a majority of the
6


total number of directors of the Corporation as fixed by Board of Directors prior to such election.

(d)Presumption of Success. The Corporation acknowledges that a settlement or other disposition short of final judgment shall be deemed a successful resolution for purposes of Section 8(a) if it permits a party to avoid expense, delay, distraction, disruption or uncertainty. In the event that any action, suit or proceeding to which Agent is a party is resolved in any manner other than by adverse judgment against Agent (including, without limitation, settlement of such action, suit or proceeding with or without payment of money or other consideration), it shall be presumed that Agent has been successful on the merits or otherwise in such action, suit or proceeding. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion, by clear and convincing evidence.

9. EXPENSES. The Corporation shall advance, prior to the final disposition of any proceeding, promptly following request therefor, which request shall be accompanied by vouchers, invoices or similar evidence documenting in reasonable detail the expenses incurred or to be incurred by Agent; provided, however, that Agent need not submit to the Corporation any information that counsel for Agent reasonably deems is privileged and exempt from compulsory disclosure in any proceeding, all expenses incurred, or to be incurred, by Agent in connection with such proceeding, to the fullest extent permitted by the Code, as such law may be amended from time to time (but in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than were permitted prior thereto), as soon as practicable, Agent but in any event not later than 30 days after written request therefor by Agent. Execution and delivery of this Agreement by the Agent constitutes an undertaking to repay such amounts advanced only if, and to the extent that, it shall ultimately be determined that Agent is not entitled to be indemnified by the Corporation as authorized by this Agreement, the Bylaws, the Code or otherwise. No other form of undertaking shall be required other than the execution of this Agreement.

10. CONTRIBUTION. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Agent for any reason whatsoever, the Corporation, in lieu of indemnifying Agent, shall contribute to the amount incurred by Agent, whether for losses or expenses, in connection with any action suit or proceeding, for which Agent is seeking indemnification under this Agreement, in such proportion as is deemed fair and reasonable by the Reviewing Party in light of all of the circumstances of such action, suit or proceeding, in order to reflect (1) the relative benefits received by the Corporation and Agent as a result of the event(s) and/or transaction(s) giving rise to such action, suit or proceeding; and (2) the relative fault of the Corporation (and its directors, officers, employees and agents) and Agent in connection with such event(s) and/or transaction(s).

11. ENFORCEMENT. Notwithstanding a determination by a Reviewing Party chosen pursuant to Section 8(c) that Agent is not entitled to indemnification, in whole or in part, with respect to a specific action, suit or proceeding (an “Adverse Determination”), any right to indemnification or advances granted by this Agreement to Agent shall be enforceable by or on behalf of Agent in any court in which that action, suit or proceeding is or was pending or the courts in the state of Delaware for the purpose of enforcing Agent's right to indemnification pursuant to this Agreement, provided that Agent shall commence any such Proceeding seeking to enforce Agent’s right to indemnification within one (1) year following the date upon which Agent is notified in writing by the Corporation of the Adverse Determination. Agent, in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting his claim. It shall be a defense to any action for which a claim for indemnification is made under Section 3 hereof (other than an action brought to enforce a claim for expenses
7


pursuant to Section 9 hereof) that Agent is not entitled to indemnification because of the limitations set forth in Section 4 hereof. A determination by the Corporation (including its Board of Directors or its stockholders) that such indemnification is improper shall not be a defense to the action or create a presumption that Agent is not entitled to indemnification under this Agreement or otherwise. In the event of any dispute between the parties concerning their respective rights and obligations hereunder, the Corporation shall have the burden of proving that the Corporation is not obligated to make the payment or advance claimed by Agent.

12. MUTUAL ACKNOWLEDGEMENT. Both the Corporation and Agent acknowledge that, in certain instances, Federal law or public policy may override applicable state law and prohibit the Corporation from indemnifying its directors and officers under this Agreement or otherwise. For example, the Corporation and Agent acknowledinge that the SEC believes that indemnification for liabilities arising under the Federal securities laws is against public policy and is, therefore, unenforceable, and has taken the position that indemnification is not permissible for liabilities arising under certain Federal securities laws, and Federal legislation prohibits indemnification for certain violations of the Employee Retirement Income Security Act of 1979, as amended. Agent understands and acknowledges that the Corporation has undertaken, or may be required in the future to undertake, with the SEC to submit the question of indemnification to a court in certain circumstances for a determination of the Corporation’s right under public policy to indemnify Agent, and any right to indemnification hereunder shall be subject to, and conditioned upon, any such required court determination.
13. LIABILITY INSURANCE. The Corporation shall maintain liability insurance applicable to directors and officers of the Corporation and shall afford Agent the same rights and benefits as are accorded to the most favorably insured of the Corporation’s officers and directors (other than in the case of an independent director liability insurance policy if Agent is not an independent or outside director). The Corporation shall advise Agent as to the general terms of, and the amounts of coverage provided by, any liability insurance policy described in this Section 13 and shall promptly notify Agent if, at any time, any such insurance policy is terminated or expired without renewal or if the amount of coverage under any such insurance policy will be decreased.
14. SUBROGATION. In the event of payment under this Agreement, the Corporation shall be subrogated to the extent of such payment to all of the rights of recovery of Agent, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Corporation effectively to bring suit to enforce such rights.

15. NON-EXCLUSIVITY OF RIGHTS. The rights conferred on Agent by this Agreement shall not be exclusive of, and shall be in addition to, any other right which Agent may have or hereafter acquire under any statute, provision of the Corporation’s Certificate of Incorporation or Bylaws, agreement, vote of stockholders or directors, or otherwise, both as to action in his official capacity and as to action in another capacity while holding office. Furthermore, no right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion of any right or remedy hereunder or otherwise shall not prevent the concurrent assertion of any other right or remedy.

16. SURVIVAL OF RIGHTS. (a) The rights conferred on Agent by this Agreement shall continue after Agent has ceased to be a director, officer, employee or other agent of the Corporation or to serve at the request of the Corporation as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise and shall inure to the benefit of Agent’s heirs, executors and administrators; (b) The Corporation shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Corporation,
8


expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Corporation would be required to perform if no such succession had taken place.

17. SEPARABILITY. Each of the provisions of this Agreement is a separate and distinct agreement and independent of the others, so that if any provision hereof shall be held to be invalid for any reason, such invalidity or unenforceability shall not affect the validity or enforceability of the other provisions hereof. Furthermore, if this Agreement shall be invalidated in its entirety on any ground, then the Corporation shall nevertheless indemnify Agent to the fullest extent provided by the Bylaws, the Code or any other applicable law.

18. GOVERNING LAW. This Agreement shall be interpreted and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof.

19. AMENDMENT AND TERMINATION. No amendment, modification, termination or cancellation of this Agreement shall be effective unless in writing signed by both parties hereto. Notice of same shall be provided to all parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

20. IDENTICAL COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute but one and the same Agreement. Only one such counterpart need be produced to evidence the existence of this Agreement.

21. HEADINGS. The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction hereof.

22. NO CONSTRUCTION AS EMPLOYMENT AGREEMENT. This Agreement is not an employment agreement between the Corporation and the Agent and nothing contained in this Agreement shall be construed as giving Agent any right to be retained or continue in the employ or service of any Covered Entity.

23. SUPERSEDES PREVIOUS AGREEMENTS. This Agreement supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof. All such prior agreements and understandings are hereby terminated and deemed of no further force or effect.

24. ENFORCEABILITY. This Agreement is a legal, valid and binding obligation of the Corporation, enforceable against the Corporation in accordance with its terms.

25. NOTICES. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given (i) upon delivery if delivered by hand to the party to whom such communication was directed or (ii) upon the third business day after the date on which such communication was mailed if mailed by certified or registered mail with postage prepaid:

(a) If to Agent, at the address indicated on the signature page hereof.

(b) If to the Corporation, to

Omnicell, Inc.
500 Cranberry Woods Drive 
Cranberry Township, PA 16066
9



or to such other address as may have been furnished to Agent by the Corporation.





[Signatures on Following Page]

10



IN WITNESS WHEREOF, the parties hereto have executed this Agreement on and as of the day and year first above written.


OMNICELL, INC.

By:
_____________________________

Title:
_____________________________


AGENT

By:
_____________________________

Address:

_____________________________

_____________________________

_____________________________
11

 EX-21.1 3 exhibit211q4-23.htm EX-21.1 Document

Exhibit 21.1
List of Subsidiaries
Entity's name for conducting businessJurisdiction of incorporation
Omnicell Pty LtdAustralia
Omnicell (Beijing) Technology Co. LtdChina
Omnicell GmbHGermany
Omnicell SASFrance
Omnicell S.r.l.Italy
Omnicell India Private LimitedIndia
Omnicell B.V.Netherlands
Omnicell LimitedUnited Kingdom
Hub and Spoke Innovations LimitedUnited Kingdom
ateb, Inc. United States
RxInnovation Inc.United States
FDS, Inc.United States
FDS Insurance Agency, LLCUnited States
MarkeTouch Media, LLCUnited States
MedPak Holdings, Inc.United States
MTS Medication Technologies, Inc.United States
MTS Packaging Systems, Inc.United States
Omnicell International, LLCUnited States
Omnicell Specialty Pharmacy Services, Inc.United States





 EX-23.1 4 exhibit231q4-23.htm EX-23.1 Document

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-117592 and 333-221332 on Form S-3 and Registration Statement Nos. 333-67828, 333-82818, 333-104427, 333-107356, 333-116103, 333-125080, 333-132556, 333-142857, 333-149758, 333-159562, 333-176146, 333-190930, 333-205465, 333-225179, 333-231669, 333-256979, 333-265767, and 333-272242 on Form S-8 of our reports dated February 28, 2024, relating to the financial statements of Omnicell, Inc. and the effectiveness of Omnicell, Inc.’s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.

/s/ Deloitte & Touche LLP

San Jose, California
February 28, 2024





EX-31.1 5 exhibit311q4-23.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATION
 
I, Randall A. Lipps, certify that:
 
1.I have reviewed this annual report on Form 10-K of Omnicell, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
February 28, 2024 
 /s/ Randall A. Lipps
 Randall A. Lipps
 President and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 6 exhibit312q4-23.htm EX-31.2 Document

Exhibit 31.2
 
CERTIFICATION
 
I, Nchacha E. Etta, certify that:
 
1.I have reviewed this annual report on Form 10-K of Omnicell, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
February 28, 2024 
 /s/ Nchacha E. Etta
 Nchacha E. Etta
 Executive Vice President & Chief Financial Officer
(Principal Financial Officer)


 EX-32.1 7 exhibit321q4-23.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION
 
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Randall A. Lipps, the President and Chief Executive Officer of Omnicell, Inc. (the “Company”) and Nchacha E. Etta, the Executive Vice President & Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
1.The Company’s Annual Report on Form 10-K for the period ended December 31, 2023, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
2.The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations the Company.
In Witness Whereof, the undersigned have set their hands hereto as of the 28th day of February 2024.
/s/ Randall A. Lipps /s/ Nchacha E. Etta
Randall A. Lipps Nchacha E. Etta
President and Chief Executive Officer Executive Vice President & Chief Financial Officer
(Principal Executive Officer)(Principal Financial Officer)
 
“This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Omnicell, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.”

 EX-97.1 8 exhibit971omclcompensation.htm EX-97.1 Document


OMNICELL, INC.
POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION

Introduction
The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Omnicell, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company. This Policy shall be interpreted to comply with the requirements of U.S. Securities and Exchange Commission (“SEC”) rules and Nasdaq Stock Market (“Nasdaq”) listing standards implementing Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”) and, to the extent this Policy is in any manner deemed inconsistent with such rules, this Policy shall be treated as retroactively amended to be compliant with such rules.
Administration
This Policy shall be administered by the Compensation Committee. Any determinations made by the Compensation Committee shall be final and binding on all affected individuals. The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in all cases consistent with the Dodd-Frank Act. The Board or Compensation Committee may amend this Policy from time to time in its discretion.
Covered Executives
This Policy applies to any current or former “executive officer,” within the meaning of Rule 10D-1 under the Securities Exchange Act of 1934, as amended, of the Company or a subsidiary of the Company (each such individual, an “Executive”). This Policy shall be binding and enforceable against all Executives and their beneficiaries, executors, administrators, and other legal representatives.
Recoupment Upon Financial Restatement
If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a “Financial Restatement”), the Compensation Committee shall cause the Company to recoup from each Executive, as promptly as reasonably possible, any erroneously awarded Incentive-Based Compensation, as defined below.
No-Fault Recovery
Recoupment under this Policy shall be required regardless of whether the Executive or any other person was at fault or responsible for accounting errors that contributed to the need for the Financial Restatement or engaged in any misconduct.
1



Compensation Subject to Recovery; Enforcement
This Policy applies to all compensation granted, earned or vested based wholly or in part upon the attainment of any financial reporting measure determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measures, whether or not presented within the Company’s financial statements or included in a filing with the SEC, including stock price and total shareholder return (“TSR”), including but not limited to performance-based cash, stock, options or other equity-based awards paid or granted to the Executive (“Incentive-Based Compensation”). Compensation that is granted, vests or is earned based solely upon the occurrence of non-financial events, such as base salary, restricted stock or options with time-based vesting, or a bonus awarded solely at the discretion of the Board or Compensation Committee and not based on the attainment of any financial measure, is not subject to this Policy.
In the event of a Financial Restatement, the amount to be recovered will be the excess of (i) the Incentive-Based Compensation received by the Executive during the Recovery Period (as defined below) based on the erroneous data and calculated without regard to any taxes paid or withheld, over (ii) the Incentive-Based Compensation that would have been received by the Executive had it been calculated based on the restated financial information, as determined by the Compensation Committee. For purposes of this Policy, “Recovery Period” means the three completed fiscal years immediately preceding the date on which the Company is required to prepare the Financial Restatement, as determined in accordance with the last sentence of this paragraph, or any transition period that results from a change in the Company’s fiscal year (as set forth in Section 5608(b)(i)(D) of the Nasdaq Listing Rules). The date on which the Company is required to prepare a Financial Restatement is the earlier to occur of (A) the date the Board or a Board committee (or authorized officers of the Company if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Financial Restatement.
For Incentive-Based Compensation based on stock price or TSR, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the Compensation Committee shall determine the amount to be recovered based on a reasonable estimate of the effect of the Financial Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received and the Company shall document the determination of that estimate and provide it to Nasdaq.
Incentive-Based Compensation is considered to have been received by an Executive in the fiscal year during which the applicable financial reporting measure was attained or purportedly attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.                                
The Company may use any legal or equitable remedies that are available to the Company to
2



recoup any erroneously awarded Incentive-Based Compensation, including but not limited to by collecting from the Executive cash payments or shares of Company common stock from or by forfeiting any amounts that the Company owes to the Executive.
No Indemnification
The Company shall not indemnify any Executive or pay or reimburse the premium for any insurance policy to cover any losses incurred by such Executive under this Policy or any claims relating to the Company’s enforcement of rights under this Policy.
Exceptions
The compensation recouped under this Policy shall not include Incentive-Based Compensation received by an Executive (i) prior to beginning service as an Executive or (ii) if he or she did not serve as an Executive at any time during the performance period applicable to the Incentive-Based Compensation in question. The Compensation Committee (or a majority of independent directors serving on the Board) may determine not to seek recovery from an Executive in whole or part to the extent it determines in its sole discretion that such recovery would be impracticable because (A) the direct expense paid to a third party to assist in enforcing recovery would exceed the recoverable amount (after having made a reasonable attempt to recover the erroneously awarded Incentive-Based Compensation and providing corresponding documentation of such attempt to Nasdaq), (B) recovery would violate the home country law that was adopted prior to November 28, 2022, as determined by an opinion of counsel licensed in the applicable jurisdiction that is acceptable to and provided to Nasdaq, or (C) recovery would likely cause the Company’s 401(k) plan or any other tax-qualified retirement plan to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.
Other Remedies Not Precluded
The exercise by the Compensation Committee of any rights pursuant to this Policy shall be without prejudice to any other rights or remedies that the Company, the Board or the Compensation Committee may have with respect to any Executive subject to this Policy, whether arising under applicable law (including pursuant to Section 304 of the Sarbanes-Oxley Act of 2002), regulation or pursuant to the terms of any other policy of the Company, employment agreement, equity award, cash incentive award or other agreement applicable to an Executive. Notwithstanding the foregoing, there shall be no duplication of recovery of the same Incentive-Based Compensation under this Policy and any other such rights or remedies.
Acknowledgment
To the extent required by the Compensation Committee, each Executive shall be required to sign and return to the Company the acknowledgement form attached hereto as Exhibit A pursuant to which such Executive will agree to be bound by the terms of, and comply with, this Policy. For the avoidance of doubt, each Executive shall be fully bound by, and must comply with, the Policy, whether or not such Executive has executed and returned such acknowledgment form to the Company.
3



Effective Date and Applicability
This Policy has been adopted by the Compensation Committee on November 7, 2023 and shall apply to any Incentive-Based Compensation that is received by an Executive on or after October 2, 2023.


4



EXHIBIT A
OMNICELL, INC.
POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION

ACKNOWLEDGEMENT FORM
Capitalized terms used but not otherwise defined in this Acknowledgement Form (this “Acknowledgement Form”) shall have the meanings ascribed to such terms in the Omnicell, Inc. Policy on Recoupment of Incentive Compensation (the “Policy”).
By signing this Acknowledgement Form, the undersigned acknowledges, confirms and agrees that the undersigned: (i) has received and reviewed a copy of the Policy; (ii) is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned’s employment with the Company; and (iii) will abide by the terms of the Policy, including, without limitation, by reasonably promptly returning any Recoverable Compensation to the Company as required by the Policy, as determined by the Compensation Committee in its sole discretion.

Sign:    _____________________________
Name: [Employee]


Date:    _____________________________





5

 EX-101.SCH 9 omcl-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - External-Use Software Development Costs link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Debt and Credit Agreement link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Convertible Senior Notes link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Lessor Leases link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Lessee Leases link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Employee Benefits and Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Stock Repurchase Programs link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Restructuring Expenses link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Schedule II Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Leases, Codification Topic 842 (Policies) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - External-Use Software Development Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Convertible Senior Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Lessor Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Lessee Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Employee Benefits and Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Restructuring Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Organization and Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Business Combinations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Business Combinations - Summary of Preliminary Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Business Combinations - Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed By the Company (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Business Combinations - Summary of Identifiable Intangible Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Business Combinations - Pro Forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Revenues - Disaggregation of Revenues by Revenue Type (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Revenues - Disaggregation of Revenues by Geographic Region (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Revenues - Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Revenues - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Balance Sheet Components - Balance Sheet Components (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Property and Equipment - Property and Equipment Balances (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - External-Use Software Development Costs - Schedule of Capitalized Computer Software (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - External-Use Software Development Costs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - External-Use Software Development Costs - Schedule of Future Amortization Expenses For Capitalized Software Development Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Goodwill and Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Debt and Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Convertible Senior Notes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Convertible Senior Notes - Convertible Debt Balances (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Convertible Senior Notes - Summary of the Components of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Lessor Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Lessor Leases - Income Recognized from Sales-Type Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Lessor Leases - Components of Sales-Type Lease Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Lessor Leases - Income Recognized from Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Lessee Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Employee Benefits and Share-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - Stock Repurchase Programs (Details) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - Income Taxes - Geographical Breakdown of Income (Loss) before the Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - Income Taxes - Provision for (Benefit from) Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - Income Taxes - Difference between the Provision For (Benefit From) Income Taxes Compared to Income Taxes Computed at the Statutory Federal Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954540 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954541 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954542 - Disclosure - Income Taxes - Change in the Balance of Gross Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954543 - Disclosure - Restructuring Expenses - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954544 - Disclosure - Restructuring Expenses - Summary of Restructuring Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954545 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 omcl-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 omcl-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 omcl-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Increase (decrease) in accrued liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Liabilities Non-recourse accounts receivable transferred Transfer of Financial Assets Accounted for as Sales, Fair Value of Derecognized Assets Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed By the Company Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Purchase of convertible note hedge Adjustments To Additional Paid In Capital, Convertible Note Hedge Adjustments To Additional Paid In Capital, Convertible Note Hedge Long-term deferred tax liabilities Deferred Income Tax Liabilities, Net Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Supplier [Axis] Supplier [Axis] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Other long-term assets Increase (Decrease) in Other Noncurrent Assets Accrued liabilities: Accrued Liabilities, Current [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 2027 Sales-Type and Direct Financing Leases, Payment to be Received, Year Four Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Section 162(m) limitation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation Under Section 162(m), Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation Under Section 162(m), Amount Federal Deferred Federal Income Tax Expense (Benefit) Accumulated impairment loss on goodwill Goodwill, Impaired, Accumulated Impairment Loss Measurement input used in estimating the fair values of intangible assets Business Combination, Acquired Intangible Assets, Measurement Input Business Combination, Acquired Intangible Assets, Measurement Input Impairment of certain long-lived assets Impairment, Long-Lived Asset, Held-for-Use Diluted (in dollars per share) Net income per share - diluted (in dollars per share) Earnings Per Share, Diluted Revenue from contract with customer, maximum contract term Revenue From Contract With Customer, Maximum Contract Term Revenue From Contract With Customer, Maximum Contract Term Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible Enumeration] Fees to GPOs Group Purchasing Organization Fees Group Purchasing Organization Fees Line of Credit Line of Credit [Member] External-Use Software Development Costs Research, Development, and Computer Software Disclosure [Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Trading Symbol Trading Symbol Debt Instrument, Covenant Terms [Axis] Debt Instrument, Covenant Terms [Axis] Debt Instrument, Covenant Terms Non-compete agreements Noncompete Agreements [Member] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Standard warranty period (up to) Standard Product Warrant Description, Duration Following Installation Standard Product Warrant Description, Duration Following Installation Total future minimum operating lease payments Lessor, Operating Lease, Payment to be Received Amortization of discount on convertible senior notes Amortization of discount Amortization of Debt Discount (Premium) ESPP ESPP shares available for future issuance Employee Stock [Member] Limited warranty period (up to) Standard Product Warrant, Duration of Limited Warranty Standard Product Warrant, Duration of Limited Warranty Prepaid income taxes Prepaid Taxes Stockholders’ equity: Equity, Attributable to Parent [Abstract] Other long-term assets Other Assets, Miscellaneous, Noncurrent Change in the Balance of Gross Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Total contract liabilities Contract with Customer, Liability 2026 Sales-Type and Direct Financing Leases, Payment to be Received, Year Three Calculation of Basic and Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Executive Category: Executive Category [Axis] 2027 Lessor, Operating Lease, Payment to be Received, Year Four Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Total net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Long-term operating lease liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liabilities Estimated Useful Lives of Assets Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Strike price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Allowance for Credit Losses Credit Loss, Financial Instrument [Policy Text Block] Accrued liabilities Increase (Decrease) in Accrued Liabilities Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Prepaid expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Entity Small Business Entity Small Business 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Term of sales-type leases Lessor, Sales-type Lease, Term of Contract Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letter of Credit Letter of Credit [Member] Convertible debt Deferred Tax Assets, Convertible Notes Payable Deferred Tax Assets, Convertible Notes Payable Retirement Plan Type [Domain] Retirement Plan Type [Domain] RSUs Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation and amortization expense of property and equipment Depreciation Share-based compensation tax expense (benefit) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Original terms of contracts Capitalized Contract Cost, Original Term Of Contract Capitalized Contract Cost, Original Term Of Contract Tax payments related to restricted stock units Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Increase (decrease) in deferred tax liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities, Noncurrent Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities, Noncurrent Change in customer funds, net Proceeds From (Payments For) Customer Funds, Net Proceeds From (Payments For) Customer Funds, Net Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses Other long-term assets: Other Assets, Noncurrent [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Unpaid balance related to restructuring plan Restructuring Reserve Acquisition related costs Business Combination, Acquisition Related Costs Fair value of awards vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Award Type [Axis] Award Type [Axis] Anti-dilutive weighted-average shares related to stock award plans (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Awards granted (in shares) Granted (Awarded) (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Property and equipment, gross Property, Plant and Equipment, Gross Right-of-use assets obtained in exchange for new lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Provision for (Benefit from) Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating lease liabilities, current portion Current portion of operating lease liabilities Operating Lease, Liability, Current Prepaid expenses Prepaid Expense, Current Shares purchased under ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued Preferred Stock, Value, Outstanding Restructuring impact Effective Income Tax Rate Reconciliation, Restructuring Impact Effective Income Tax Rate Reconciliation, Restructuring Impact 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Net carrying amount Total Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Adopted Authoritative Guidance and Recently Issued Authoritative Guidance New Accounting Pronouncements, Policy [Policy Text Block] Average price of repurchased shares (in dollars per share) Shares Acquired, Average Cost Per Share Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Geographical Breakdown of Income (Loss) before the Provision for Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Total purchase price transferred Business Combination, Consideration Transferred Gross profit Gross Profit Estimated forfeiture rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate Deferred revenues, net Short-term deferred revenues, net Contract with Customer, Liability, Current Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Assumptions Used to Value Stock Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Valuation of Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Selling, general, and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Percentage of award vesting Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Stock Options Stock options outstanding Employee Stock Option [Member] Period for notice of termination Contract Termination Requirement, Period of Notification Contract Termination Requirement, Period of Notification Maximum Maximum [Member] Summary of Restructuring Expenses Restructuring and Related Costs [Table Text Block] Net investment in sales-type leases, current portion Less: Current portion Net Investment in Lease, after Allowance for Credit Loss, Current Cash equivalents Cash Equivalents, at Carrying Value Document Type Document Type Additions Goodwill, Acquired During Period Tabular List, Table Tabular List [Table Text Block] Aggregate purchase price of treasury stock Treasury Stock, Value, Acquired, Cost Method Weighted-Average Remaining Years Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Term [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Term Inventory Inventory, Policy [Policy Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Federal Current Federal Tax Expense (Benefit) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Accounts receivable and unbilled receivables, net of allowance Accounts Receivable, Allowance for Credit Loss, Current Customer Concentration Risk Customer Concentration Risk [Member] Lessor Leases Lessor, Sales-type Leases [Text Block] State Deferred State and Local Income Tax Expense (Benefit) Variable Rate [Axis] Variable Rate [Axis] 2024 Lessor, Operating Lease, Payment to be Received, Year One Raw materials Inventory, Raw Materials, Net of Reserves Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Business Combinations Business Combination Disclosure [Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Outstanding (in dollars per share) Outstanding (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Foreign currency exchange rate fluctuations Goodwill, Foreign Currency Translation Gain (Loss) Inventory-related items Deferred Tax Assets, Inventory Share-based payment arrangement, amount capitalized Share-Based Payment Arrangement, Amount Capitalized Statistical Measurement [Axis] Statistical Measurement [Axis] Loss contingency, cumulative insurance recoveries Insurance Recoveries Other current assets Increase (Decrease) in Other Current Assets Contractual coupon interest Interest Expense, Debt, Excluding Amortization 2027 Capitalized Computer Software, Amortization, Year Four Capitalized Computer Software, Amortization, Year Four Balance Sheet Location [Domain] Balance Sheet Location [Domain] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product revenues Product [Member] Accounts receivable due from third-party leasing companies for transferred non-recourse accounts receivable Transfer of Financial Assets Accounted for as Sales, Receivable from Third-Party Leasing Company, Amount Transfer of Financial Assets Accounted for as Sales, Receivable from Third-Party Leasing Company, Amount Goodwill and Acquired Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Omnicell Plan Omnicell Plan [Member] Omnicell Plan [Member] Advance payments from customers Contract with Customer, Liability, Customer Advances and Deposits, Current Contract with Customer, Liability, Customer Advances and Deposits, Current Other Assets Other Assets [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition and Shipping Costs Revenue from Contract with Customer [Policy Text Block] Income Recognized from Sales-Type Leases Sales-type Lease, Lease Income [Table Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Future Amortization Expenses For Capitalized Software Development Costs Schedule Of Future Amortization Expenses For Capitalized Software Development Costs [Table Text Block] Schedule Of Future Amortization Expenses For Capitalized Software Development Costs Significant Components of Deferred Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Non-cancelable purchase commitments expected to be paid within the next twelve months Purchase Obligation, to be Paid, Year One 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Common stock, shares outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Impairment and abandonment of operating lease right-of-use assets related to facilities Operating Lease, Impairment Loss Add: Net working capital adjustment Business Combination, Estimated Net Working Capital Adjustment Business Combination, Estimated Net Working Capital Adjustment PEO PEO [Member] Interest and penalties accrued Income Tax Examination, Penalties and Interest Accrued Maturity Schedule of Future Minimum Lease Payments under Operating Leases Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Auditor Location Auditor Location Summary of Revenue Recognition for Revenue Categories Revenue From Contract With Customer, Timing And Classification Of Revenue Categories [Table Text Block] Revenue From Contract With Customer, Timing And Classification Of Revenue Categories Long-term unbilled receivables, net Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Weighted-average price (in dollars per share) Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Purchased In Period, Weighted Average Price Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Purchased In Period, Weighted Average Price State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share One Month Secured Overnight Financing Rate (SOFR) Applicable Margin One Month Secured Overnight Financing Rate (SOFR) Applicable Margin [Member] One Month Secured Overnight Financing Rate (SOFR) Applicable Margin Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Debt Instrument [Axis] Debt Instrument [Axis] 2028 Sales-Type and Direct Financing Leases, Payment to be Received, Year Five Revenue from operations since the acquisition date Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Measurement Input Type [Domain] Measurement Input Type [Domain] Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Total current income taxes Current Income Tax Expense (Benefit) Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Title of Individual [Axis] Title of Individual [Axis] 2026 Lessor, Operating Lease, Payment to be Received, Year Three Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank Wells Fargo Securities, LLC, Citizens Bank, N.A. And JPMorgan Chase Bank, N.A [Member] Wells Fargo Securities, LLC, Citizens Bank, N.A. And JPMorgan Chase Bank, N.A Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Capitalized research and development Deferred Tax Assets, in Process Research and Development Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Transfers between inventory and property and equipment, net Transfers Between Inventory And Property And Equipment, Net Transfers Between Inventory And Property And Equipment, Net Thereafter Sales-Type and Direct Financing Leases, Payment to be Received, after Year Five Purchases from suppliers Payments to Suppliers External-Use Software Development Costs Research, Development, and Computer Software, Policy [Policy Text Block] Deferred tax asset related to the convertible note hedge transaction Deferred Tax Asset, Convertible Debt Hedge Deferred Tax Asset, Convertible Debt Hedge Maximum secured net leverage ratio Debt Instrument, Covenant, Maximum Secured Net Leverage Ratio Debt Instrument, Covenant, Maximum Secured Net Leverage Ratio Hub and Spoke Innovations Hub And Spoke Innovations Limited [Member] Hub And Spoke Innovations Limited Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Segment Reporting Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Royalty Rate Measurement Input, Royalty Rate [Member] Measurement Input, Royalty Rate Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Interest income on sales-type lease receivables Sales-type Lease, Interest Income, Lease Receivable Retirement Plan Name [Domain] Retirement Plan Name [Domain] Minimum required purchase obligation Non-cancelable purchase commitments Purchase Obligation Net Income Per Share Earnings Per Share, Policy [Policy Text Block] Principal amount of notes, minimum Debt Instrument, Convertible, Principal Amount Of Notes, Minimum Debt Instrument, Convertible, Principal Amount Of Notes, Minimum Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Stock repurchases (in shares) Stock Repurchased During Period, Shares Concentration risk percentage Concentration Risk, Percentage Connected devices, software licenses, and other Connected Devices, Software Licenses, And Other [Member] Connected Devices, Software Licenses, And Other Summary of Identifiable Intangible Assets Acquired Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Options and warrants to purchase shares (in shares) Class of Warrant or Right, Outstanding Summary of Changes in Accumulated Balances of Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Weighted-average grant date fair value per award granted (in dollars per share) Granted (Awarded) (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Other Postretirement Benefit Plan Other Postretirement Benefits Plan [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Estimated Future Amortization Expense for Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Depreciation and amortization Depreciation, Depletion and Amortization Furniture and fixtures Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Convertible Senior Notes Convertible Senior Notes [Member] Convertible Senior Notes Business Combination and Asset Acquisition [Abstract] Pro forma revenues Business Acquisition, Pro Forma Revenue Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Deferred revenues recognized Contract with Customer, Liability, Revenue Recognized SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax 2025 Capitalized Computer Software, Amortization, Year Two Capitalized Computer Software, Amortization, Year Two ReCept ReCept Holdings, Inc. [Member] ReCept Holdings, Inc. Long-term deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Long-term investment in sales-type leases, net Long-term investment in sales-type leases, net Net Investment in Lease, after Allowance for Credit Loss, Noncurrent Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Net income (loss) per share: Earnings Per Share Reconciliation [Abstract] Retirement Plan Name [Axis] Retirement Plan Name [Axis] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Total liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Entity Emerging Growth Company Entity Emerging Growth Company Deferred debt issuance costs Debt Issuance Costs, Net Technical services Technical Services [Member] Technical Services Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Gross deferred tax assets Deferred Tax Assets, Gross Income Recognized from Operating Leases Operating Lease, Lease Income [Table Text Block] 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Ransomware incident, expense Loss Contingency, Expense Loss Contingency, Expense Common Stock Common Stock [Member] Individual: Individual [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Decreases related to expiration of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Income Statement Location [Domain] Income Statement Location [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Total future minimum sales-type lease payments Sales-Type and Direct Financing Leases, Payment to be Received Share-based Goods and Nonemployee Services Transaction, Supplier [Domain] Supplier [Domain] Minimum Minimum [Member] Property and equipment, net Total property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Accounts receivable and unbilled receivables, net of allowances of $5,564 and $5,153, respectively Receivables, Net, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Employees’ taxes paid related to restricted stock units Payment, Tax Withholding, Share-Based Payment Arrangement Schedule II Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Other, net Deferred Tax Assets, Other Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Long-term deferred tax assets Deferred Income Tax Assets, Net Retirement Plan Type [Axis] Retirement Plan Type [Axis] Gross short-term deferred revenue Contract with Customer, Liability, Current, Gross Contract with Customer, Liability, Current, Gross Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Retained Earnings Retained Earnings [Member] Goodwill expected to be deductible for tax purposes Business Acquisition, Goodwill, Expected Tax Deductible Amount Selling profit on sales-type lease revenues Sales-type Lease, Selling Profit (Loss) Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Basic (in dollars per share) Net income per share - basic (in dollars per share) Earnings Per Share, Basic Unrecognized compensation cost of unvested stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Convertible Note Hedge Equity Option [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Loss on disposal of property and equipment Gain (Loss) on Disposition of Assets Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Net deferred tax assets Deferred Tax Assets, Net Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Convertible Debt Balances Convertible Debt [Table Text Block] Accounting Policies [Line Items] Accounting Policies [Line Items] [Line Items] for Accounting Policies [Table] Line of credit facility, accordion feature, higher borrowing capacity option Line Of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option Line Of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Principles of Consolidation Consolidation, Policy [Policy Text Block] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Measurement period adjustments Goodwill, Purchase Accounting Adjustments Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Acquired Technology Acquired technology Technology-Based Intangible Assets [Member] Accounts payable Increase (Decrease) in Accounts Payable Accumulated amortization Capitalized Computer Software, Accumulated Amortization Entity Public Float Entity Public Float Purchasing period Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Price Of Common Stock, Purchasing Period Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Price Of Common Stock, Purchasing Period Maximum fair market value of shares Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Amount Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Amount Property, Plant and Equipment [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Primary Supplier Primary Supplier [Member] Primary Supplier [Member] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Compensation Amount Outstanding Recovery Compensation Amount 2014 Share Repurchase Program 2014 Share Repurchase Program [Member] 2014 Share Repurchase Program Components of Sales-Type Lease Receivables Schedule of Receivables with Imputed Interest [Table Text Block] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Right-of-use assets Deferred Tax Liabilities, Leasing Arrangements Total deferred income taxes Deferred Income Tax Expense (Benefit) Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Backlog Backlog Order or Production Backlog [Member] Convertible Debt Convertible Debt [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Period 1 Debt Instrument, Redemption, Period One [Member] Funds held for customers, including restricted cash Funds Held for Clients Total purchase price, net of cash acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Of Cash Acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Of Cash Acquired Effect of dilutive securities from stock award plans (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Contract cost expense Capitalized Contract Costs Recognized Capitalized Contract Costs Recognized Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Document Period End Date Document Period End Date Deferred revenues Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Adoption Date Trading Arrangement Adoption Date Pro Forma Financial Information Business Acquisition, Pro Forma Information [Table Text Block] Treasury Stock Treasury Stock, Common [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Foreign branch taxes Effective Income Tax Rate Reconciliation, Foreign Branch Taxes, Amount Effective Income Tax Rate Reconciliation, Foreign Branch Taxes, Amount Provision for (benefit from) income taxes Total provision for (benefit from) income taxes Income Tax Expense (Benefit) Rest of world Non-US [Member] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Vesting [Axis] Vesting [Axis] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Lender Name [Axis] Lender Name [Axis] Equity [Abstract] Equity [Abstract] Weighted-average remaining lease term, years Operating Lease, Weighted Average Remaining Lease Term Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] 2025 Lessor, Operating Lease, Payment to be Received, Year Two Assumptions Used to Value ESPP Shares Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Summary of Performance-Based Restricted Stock Activity Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Tax credit carryforward amount Tax Credit Carryforward, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Business acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Credit Facility [Domain] Credit Facility [Domain] Number of shares repurchased (in shares) Treasury Stock, Shares, Acquired Investment in sales-type leases Increase (Decrease) in Leasing Receivables Spread on variable interest rate Debt Instrument, Basis Spread on Variable Rate Useful life of property and equipment Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Maximum amount of employer contribution Defined Contribution Plan, Employer Matching Contribution, Maximum Contribution Defined Contribution Plan, Employer Matching Contribution, Maximum Contribution Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Contract Assets and Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Revenues Revenue from Contract with Customer [Text Block] Additional Paid-In Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Balance Sheet Location [Axis] Balance Sheet Location [Axis] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover page. Cover [Abstract] Amortization of debt issuance costs Amortization of Debt Issuance Costs Remaining life of debt discount and issuance cost accretion Debt Instrument, Convertible, Remaining Discount Amortization Period United States UNITED STATES Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Other long-term liabilities Other Liabilities, Noncurrent Total operating lease payments Lessee, Operating Lease, Liability, to be Paid Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Employee Benefits and Share-Based Compensation Compensation and Employee Benefit Plans [Text Block] Total operating expenses Operating Expenses Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Offering period Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Price Of Common Stock, Offering Period Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Price Of Common Stock, Offering Period Equity Component [Domain] Equity Component [Domain] Purchase price of common stock, percent Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent State and Local Jurisdiction State and Local Jurisdiction [Member] Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Other, net Deferred Tax Liabilities, Other Inventories: Inventory, Net, Items Net of Reserve Alternative [Abstract] Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Ten Largest GPOs Ten Largest Group Purchasing Organizations (GPOs) [Member] Ten Largest Group Purchasing Organizations (GPOs) [Member] Income (loss) from operations Operating Income (Loss) Number of reporting units Number of Reporting Units Less: Unearned interest income portion Present value adjustment Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount Shipping Costs Shipping and Handling [Member] Lessor Leases Lessor, Leases [Policy Text Block] Total deferred tax liabilities Deferred Tax Liabilities, Gross 2016 and 2014 Share Repurchase Programs 2016 and 2014 Share Repurchase Programs [Member] 2016 and 2014 Share Repurchase Programs [Member] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer relationships Customer Relationships [Member] Transaction cost Effective Income Tax Rate Reconciliation, Transaction Costs Effective Income Tax Rate Reconciliation, Transaction Costs Vesting One Year from Commencement Date Share-Based Payment Arrangement, Tranche One [Member] External-use software development costs, net External-use software development costs, net Capitalized Computer Software, Net FDS Amplicare FDS Amplicare [Member] FDS Amplicare Deferred income taxes Deferred Income Taxes and Tax Credits Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Statistical Measurement [Domain] Statistical Measurement [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Outstanding (in shares) Outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Debt and Credit Agreement Convertible Senior Notes Debt Disclosure [Text Block] Net investment in sales-type leases Net Investment in Lease, after Allowance for Credit Loss Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] PSUs Performance-Based Restricted Stock Performance Shares [Member] Convertible Debt Securities and Warrants Convertible Debt Securities And Warrants [Member] Convertible Debt Securities And Warrants Accounts payable Accounts Payable, Current Losses from operations since the acquisition date Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Research and Development [Abstract] Restatement Determination Date: Restatement Determination Date [Axis] Impairment loss related to capitalized prepaid commissions Capitalized Contract Cost, Impairment Loss Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Interest and other income (expense), net Nonoperating Income (Expense) Commitments and contingencies (Note 14) Commitments and Contingencies Summary of Restricted Stock Awards Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Ordinary Shares Reserved for Future Issuance Under Equity Incentive Plans Schedule of Share-based Compensation, Future Issuance of Shares [Table Text Block] Schedule of Share-based Compensation, Future Issuance of Shares Software development costs capitalized Capitalized Computer Software, Period Increase (Decrease) Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Sales of Accounts Receivable Transfers and Servicing of Financial Assets, Transfers of Financial Assets, Sales, Policy [Policy Text Block] Deferred revenues Increase (Decrease) in Contract with Customer, Liability Other current assets Other Assets, Miscellaneous, Current Lessee Leases Lessee, Leases [Policy Text Block] Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Trading days used for stock price appreciation calculation Share-based Compensation Arrangement by Share-based Payment Award, Trading Days Share-based Compensation Arrangement by Share-based Payment Award, Trading Days Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value PEO Total Compensation Amount PEO Total Compensation Amount 2025 Sales-Type and Direct Financing Leases, Payment to be Received, Year Two Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Goodwill [Roll Forward] Goodwill [Roll Forward] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Group purchasing organization fees Accrued Group Purchasing Organization Fees Accrued Group Purchasing Organization Fees Treasury stock, shares outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Treasury Stock, Common, Shares Lessor Leases Lessor, Operating Leases [Text Block] Outstanding at beginning of year (in shares) Outstanding at end of year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Weighted-average fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Long-term debt, fair value Long-Term Debt, Fair Value Net income (loss) Net income (loss) Net income (loss) Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Foreign Currency Translation and Remeasurement Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Lessee Leases Lessee, Operating Leases [Text Block] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Stock repurchases Stock Repurchased During Period, Value Federal Funds Fed Funds Effective Rate Overnight Index Swap Rate [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC [Member] Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC And TD Securities (USA) LLC Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Convertible senior notes, net Convertible Notes Payable, Noncurrent Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Long-term unbilled receivables Contract with Customer, Asset, Unbilled Receivables, Noncurrent [Member] Contract with Customer, Asset, Unbilled Receivables, Noncurrent Cost of revenues Cost of Goods and Services Sold Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Useful life (years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Name Measure Name Patents Patents [Member] Name Forgone Recovery, Individual Name Goodwill Balance at beginning of period Balance at end of period Goodwill Increases related to tax positions taken during a prior period Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Underlying Securities Award Underlying Securities Amount Selling, general, and administrative Selling, general, and administrative Selling, General and Administrative Expenses [Member] Warrant Warrant [Member] Long-term operating lease liabilities Long-term portion of operating lease liabilities Operating Lease, Liability, Noncurrent Term of debt instrument Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Cumulative Effect of a Change in Accounting Principle Cumulative Effect, Period of Adoption, Adjustment [Member] Payments for debt issuance costs for revolving credit facility Payments of debt issuance costs Payments of Debt Issuance Costs Income Statement Location [Axis] Income Statement Location [Axis] Secured Overnight Financing Rate (SOFR) Applicable Margin Secured Overnight Financing Rate (SOFR) Applicable Margin [Member] Secured Overnight Financing Rate (SOFR) Applicable Margin Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Incremental Loan Facility Incremental Loan Facility [Member] Incremental Loan Facility State rate true up Effective Income Tax Rate Reconciliation, State Rate True Up Effective Income Tax Rate Reconciliation, State Rate True Up Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Reserves and accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Summary of Supplemental Cash Flow Information and Weighted-Average Remaining Lease Term and Discount Rate Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Short-term unbilled receivables, net Contract with Customer, Asset, after Allowance for Credit Loss, Current Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Plan Name [Domain] Plan Name [Domain] Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unpaid purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Fair value Finite-Lived Intangible Assets Acquired Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Arrangement: Trading Arrangement [Axis] Debt Instrument, Covenant Terms [Domain] Debt Instrument, Covenant Terms [Domain] Debt Instrument, Covenant Terms Use of Estimates Use of Estimates, Policy [Policy Text Block] Rebate liabilities Accrued Liabilities, Rebate Liabilities, Current Accrued Liabilities, Rebate Liabilities, Current Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Other current assets: Other Assets, Current [Abstract] Other Assets, Current Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Discount Rate Measurement Input, Discount Rate [Member] Decreases related to tax positions taken during the prior period Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Amortization expense of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Risk-free interest rate (minimum) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Funds Held for Customers and Customer Fund Liabilities Funds Held For Customers And Customer Fund Liabilities [Policy Text Block] Funds Held For Customers And Customer Fund Liabilities Restatement Determination Date Restatement Determination Date Prepaid expenses Increase (Decrease) in Prepaid Expense Increases related to tax positions taken during the current period Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Maximum number of shares issuable upon conversion (in shares) Debt Instrument, Convertible, Number Of Shares Issuable Debt Instrument, Convertible, Number Of Shares Issuable Operating lease cost Operating Lease, Cost Weighted-average shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Shares authorized for future issuance Future Grants And Awards [Member] future grants and awards [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Summary of Restricted Stock Unit Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Vested (Released) (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Treasury stock at cost, 10,283 shares outstanding, respectively Treasury Stock, Common, Value Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Carrying value of debt Outstanding balance Convertible senior notes, net Long-Term Debt Estimated useful life of software-related products Capitalized Computer Software, Estimated Useful Life Capitalized Computer Software, Estimated Useful Life Employer matching contribution, percent of employee contribution Defined Contribution Plan, Employer Matching Contribution, Percent of Match Balance at Beginning of Period Balance at End of Period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Weighted average period of compensation cost recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration] Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration] Uncertain tax positions Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Internal Revenue Service (IRS) Domestic Tax Authority [Member] Entity Address, Address Line One Entity Address, Address Line One Deferred tax assets (liabilities): Components of Deferred Tax Assets and Liabilities [Abstract] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Taxes payable Taxes Payable, Current Uncertain tax positions, interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Net operating loss Operating Loss Carryforwards Maximum percentage of earnings allowed for purchase of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases Sales-Type and Direct Financing Leases, Payment to be Received, Maturity [Table Text Block] Deferred revenues Deferred Tax Assets, Deferred Income Income Statement [Abstract] Income Statement [Abstract] Adjustment, intangibles Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Amortization period for capitalized contract costs Capitalized Contract Cost, Amortization Period Pro forma net income Business Acquisition, Pro Forma Net Income (Loss) Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Issuance of common stock under employee stock plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other current assets Total other current assets Other Assets, Current U.S. federal tax provision at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Inventories Total inventories Inventory, Net Other long-term assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Reconciliation of cash, cash equivalents, and restricted cash to the Consolidated Balance Sheets: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Stock repurchases Aggregate purchase price for repurchased shares Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Foreign Deferred Foreign Income Tax Expense (Benefit) Balance Sheet Components Condensed Balance Sheet [Table Text Block] Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Principal amount Debt Instrument, Face Amount Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Convertible Note Hedge Rights Convertible Note Hedge Rights [Member] Convertible Note Hedge Rights Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Conversion ratio Debt Instrument, Convertible, Conversion Ratio Accounts receivable and unbilled receivables Increase (Decrease) in Accounts and Other Receivables Supplemental disclosure of non-cash investing activities Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Additional principal amount subject to purchasers' option Debt Instrument, Accordion Feature, Increase Limit Debt Instrument, Accordion Feature, Increase Limit Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Customer [Domain] Customer [Domain] Other Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Cost of sales-type lease revenues Cost of Goods Sold, Sales-type Lease Purchase price adjustments from business acquisitions Business Combination, Adjustment, Purchase Price Adjustment Business Combination, Adjustment, Purchase Price Adjustment Total operating lease liabilities Operating Lease, Liability Services and other revenues Service [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Vesting [Domain] Vesting [Domain] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Charged (Credited) to Costs and Expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 401(k) contributions Defined Contribution Plan, Cost All Executive Categories All Executive Categories [Member] Long-term deferred revenues Long-term deferred revenues Contract with Customer, Liability, Noncurrent Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Consumables Consumables [Member] Consumables Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Income tax (expense) benefit from share-based compensation Share-Based Payment Arrangement, Expense, Tax Benefit Number of reporting segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Net investment in sales-type leases Net Investment in Sales-Type Leases [Member] Net Investment in Sales-Type Leases [Member] Common stock, $0.001 par value, 100,000 shares authorized; 55,822 and 55,030 shares issued; 45,539 and 44,747 shares outstanding, respectively Common Stock, Value, Issued Repurchase price as a percent of principal amount Debt Instrument, Redemption Price, Percentage Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Trade Names Trade names Trade Names [Member] Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] 2028 Lessor, Operating Lease, Payment to be Received, Year Five Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Restricted cash included in other current assets Restricted Cash All Individuals All Individuals [Member] Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Value of shares authorized for repurchase under stock repurchase programs (up to) Stock Repurchase Program, Authorized Amount Difference Between the Provision for (Benefit from) Income Taxes Compared to Income Taxes Computed at the Statutory Federal Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Balance at beginning of period Balance at end of period Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Expected volatility (minimum) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Convertible Debt Debt, Policy [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Lease liability Deferred Tax Assets, Leasing Arrangements Deferred Tax Assets, Leasing Arrangements Restricted cash Restricted Cash, Current Changes in the Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Base purchase price Business Combination, Base Purchase Price Business Combination, Base Purchase Price Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Amounts Written Off SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Ransomware incident, expense, net of insurance recoveries Loss Contingency, Expense, Net Of Insurance Recoveries Loss Contingency, Expense, Net Of Insurance Recoveries Other accrued liabilities Other Accrued Liabilities, Current SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Debt issuance costs Debt Issuance Costs, Line of Credit Arrangements, Gross Interest rate Debt Instrument, Interest Rate, Stated Percentage Accrued compensation Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Balance at beginning of period Balance at end of period Equity, Attributable to Parent RSAs Restricted Stock [Member] Stock Repurchase Programs Treasury Stock [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term MarkeTouch Media MarkeTouch Media, LLC [Member] MarkeTouch Media, LLC Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Unbilled receivables, net Unbilled Contracts Receivable Fair Value Hierarchy Fair Value Measurement, Policy [Policy Text Block] Accounts receivable and unbilled receivables Accounts Receivable And Unbilled Receivables [Member] Accounts Receivable And Unbilled Receivables Restructuring Expenses Restructuring and Related Activities Disclosure [Text Block] Adjustment, accounts receivable and unbilled receivables Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable And Unbilled Receivables Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable And Unbilled Receivables Summary of the Components of Interest Expense Schedule Of Interest Expense, Debt [Table Text Block] Schedule Of Interest Expense, Debt Long-lived Assets by Geographic Areas Long-Lived Assets by Geographic Areas [Table Text Block] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Total purchase price Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] 2024 Capitalized Computer Software, Amortization, Year One Capitalized Computer Software, Amortization, Year One Deferred cost of sales Contract With Customer, Asset, Current, Deferred Cost Of Goods And Services Sold Contract With Customer, Asset, Current, Deferred Cost Of Goods And Services Sold Document Fiscal Period Focus Document Fiscal Period Focus Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Useful life Finite-Lived Intangible Asset, Useful Life Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity One Month Secured Overnight Financing Rate (SOFR) One Month Secured Overnight Financing Rate (SOFR) [Member] One Month Secured Overnight Financing Rate (SOFR) 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Stock Award Plans Share-Based Payment Arrangement [Member] Outstanding at beginning of year (in dollars per share) Outstanding at end of year (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Disaggregation of Revenues by Geographical Location Revenue from External Customers by Geographic Areas [Table Text Block] Operating lease right-of-use assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets Foreign Tax Authority Foreign Tax Authority [Member] City Area Code City Area Code Net Income Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Term of operating leases Lessee, Operating Lease, Term of Contract Purchased software and internal-use software development costs Software and Software Development Costs [Member] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Organization and Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Adjustment, deferred tax liability, noncurrent Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability, Noncurrent Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability, Noncurrent Summary of Share Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Carrying Amounts and Useful Lives of Intangible Assets Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Maximum cash Debt Instrument, Convertible, Maximum Cash Debt Instrument, Convertible, Maximum Cash Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Initial term and renewal service periods Capitalized Contract Cost, Initial Term And Renewal Service Periods Capitalized Contract Cost, Initial Term And Renewal Service Periods Income taxes paid (refunds received), net Income Taxes Paid, Net SOFR Plus 1.00% Secured Overnight Financing Rate (SOFR) Plus 1.00% [Member] Secured Overnight Financing Rate (SOFR) Plus 1.00% Commitments and Contingencies Commitments Contingencies and Guarantees [Text Block] Guarantees Guarantees, Indemnifications and Warranties Policies [Policy Text Block] Thereafter Capitalized Computer Software, Amortization, After Year Five Capitalized Computer Software, Amortization, After Year Five Share-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Property and Equipment Property, Plant and Equipment [Member] Total liabilities and stockholders’ equity Liabilities and Equity Other long-term assets Total other long-term assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Decrease in other assets, current Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets, Current Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets, Current Officer Officer [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Risk-free interest rate (maximum) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Foreign Current Foreign Tax Expense (Benefit) Expected volatility (maximum) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Impairment of internal-use and external-use software development costs, net Capitalized Computer Software, Impairments Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Restructuring charges Restructuring Charges Consideration in excess, amount Debt Instrument, Convertible, Consideration In Excess, Amount Debt Instrument, Convertible, Consideration In Excess, Amount Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Remaining value of shares authorized for repurchase under stock repurchase programs Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Amortization of capitalized software development costs Capitalized Computer Software, Amortization Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Schedule of Capitalized Computer Software Schedule Of Capitalized Computer Software, Net [Table Text Block] Schedule Of Capitalized Computer Software, Net Prepaid commissions Increase (Decrease) in Prepaid Commissions Increase (Decrease) in Prepaid Commissions Sales-type lease revenues Sales-type Lease, Revenue Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Swing Line Loan Bridge Loan [Member] Award Timing Disclosures [Line Items] Relationship to Entity [Domain] Title of Individual [Domain] Total assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Fair value of awards vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Additional paid-in capital Additional Paid in Capital Convertible Debt Securities Convertible Debt Securities [Member] Internal Use Software and Software Development Costs Internal Use Software and Software Development Costs [Member] Internal Use Software and Software Development Costs [Member] Total net investment in sales-type leases Sales-type and Direct Financing Leases, Lease Receivable Less: Assumed indebtedness Business Combination, Consideration Transferred, Liabilities Incurred Percentage of shares eligible for time-based vesting Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Percent Eligible for Time-based Vesting Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Percent Eligible for Time-based Vesting Foreign currency exchange rate fluctuations Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Accounting for Income Taxes Income Tax, Policy [Policy Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Add: Closing cash Business Combination, Estimated Closing Cash Business Combination, Estimated Closing Cash Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt instrument, covenant, minimum interest coverage ratio Debt Instrument, Covenant, Minimum Interest Coverage Ratio Debt Instrument, Covenant, Minimum Interest Coverage Ratio Insider Trading Arrangements [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Customer fund liabilities Customer Fund Liability, Current Customer Fund Liability, Current Accrued compensation Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Compensation Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Compensation Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Non-vested restricted stock awards Restricted Stock (RSAs), Restricted Stock Units (RSUs) And Preformance Shares (PSUs) [Member] Restricted Stock (RSAs), Restricted Stock Units (RSUs) And Preformance Shares (PSUs) Other Adjustments SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Issuance of common stock under employee stock plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Tax (expense) benefit realized from stock options exercised Income Tax (Expense) Benefit, Awards Exercised Income Tax (Expense) Benefit, Awards Exercised Vesting in Equal Monthly Installments Share-Based Payment Arrangement, Tranche Two [Member] Cost of product and service revenues Cost of Sales [Member] Auditor Name Auditor Name Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment External-use software development costs Payments for Software, For External Use Payments for Software, For External Use Entity Central Index Key Entity Central Index Key Share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross carrying amount Finite-Lived Intangible Assets, Gross Finished goods Inventory, Finished Goods, Net of Reserves Accounts receivable and unbilled receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Income Tax Authority [Domain] Income Tax Authority [Domain] Accrued compensation Employee-related Liabilities, Current 2016 Repurchase Program 2016 Repurchase Program [Member] The 2016 Repurchase Program [Member] Revenues Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Disaggregation of Revenues by Revenue Type Disaggregation of Revenue [Table Text Block] Aggregate principal amount of Notes that must be outstanding and not subject to redemption if the Company redeems less than all of the Notes Debt Instrument, Redemption, Face Amount Of Notes That Must Be Outstanding Debt Instrument, Redemption, Face Amount Of Notes That Must Be Outstanding Prepaid commissions Capitalized Contract Cost, Net, Noncurrent Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Loss contingency, expense incurred to date Loss Contingency, Expense Incurred To Date Loss Contingency, Expense Incurred To Date Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag 2028 Capitalized Computer Software, Amortization, Year Five Capitalized Computer Software, Amortization, Year Five Weighted-average discount rate, % Operating Lease, Weighted Average Discount Rate, Percent 2026 Capitalized Computer Software, Amortization, Year Three Capitalized Computer Software, Amortization, Year Three SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Advanced Services Advanced Services [Member] Advanced Services Auditor Information [Abstract] Auditor Information Provision to return true up Effective Income Tax Rate Reconciliation, Provision To Return True Up Effective Income Tax Rate Reconciliation, Provision To Return True Up Business Combinations Business Combinations Policy [Policy Text Block] Leasehold improvements Leasehold Improvements [Member] Diluted (in shares) Weighted-average shares outstanding — diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration] Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Loss contingency, cumulative expected insurance recoveries Loss Contingency, Cumulative Expected Insurance Recoveries Loss Contingency, Cumulative Expected Insurance Recoveries Global intangible low-taxed income inclusion Effective Income Tax Rate Reconciliation, GILTI, Amount 2024 Sales-Type and Direct Financing Leases, Payment to be Received, Year One Gross carrying amount Capitalized Computer Software, Gross Operating expenses: Operating Expenses [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Equipment Equipment [Member] Proceeds from sale of warrants Proceeds from Issuance of Warrants Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Proceeds from issuance of convertible senior notes, net of issuance costs Proceeds from Convertible Debt Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Vested (Released) (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Construction in progress Construction in Progress [Member] Debt instrument, covenant, adjusted EBITDA threshold Debt Instrument, Covenant, Adjusted EBITDA Threshold Debt Instrument, Covenant, Adjusted EBITDA Threshold Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Calendar Quarters Up To and Including March 31, 2021 Debt Instrument, Covenant Period 1 [Member] Debt Instrument, Covenant Period 1 Loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Debt Instrument [Line Items] Debt Instrument [Line Items] Total contract assets Contract with Customer, Asset, after Allowance for Credit Loss Basic (in shares) Weighted-average shares outstanding — basic (in shares) Weighted Average Number of Shares Outstanding, Basic Unamortized debt issuance costs Unamortized Debt Issuance Expense Depreciation and amortization Deferred Tax Liabilities, Property, Plant and Equipment Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Period 2 Debt Instrument, Redemption, Period Two [Member] Calendar Quarters After March 31, 2021 Debt Instrument, Covenant Period 2 [Member] Debt Instrument, Covenant Period 2 2009 Plan 2009 Plan [Member] 2009 Plan [Member] Rental income Operating Lease, Lease Income Proceeds from issuances under stock-based compensation plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Weighted-Average Remaining Years Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted-Average Remaining Term [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted-Average Remaining Term Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Commitment fee rate on undrawn commitments Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Statement [Line Items] Statement [Line Items] Foreign-derived intangible income deduction Effective Income Tax Rate Reconciliation, FDII, Amount Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Intangibles Deferred Tax Liabilities, Intangible Assets Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Accounting Standards Update 2020-06 [Member] EX-101.PRE 13 omcl-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 omcl-20231231_g1.jpg GRAPHIC begin 644 omcl-20231231_g1.jpg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

;O[4\I,O<:/(P\S..3Y,FV4=E1IC1_P0%_8]_X4[^SS=_M M*>+]+\O7_B'M_LOS4P]OH\;'R\9Y'G2;I3V9%A-?I4N*HRX9>+32J_!;^]W] M+>]^!]]+B.+X?>)VJ?#;^]W^[7\#[%^"7[,?[/G[.&D#1/@;\']!\-1&,)+- MIM@HN)P/^>LYS+*?=V8UW5%%?DM2I4K322D7[ELG!),>X^O-& MH/NZ;XA1="\0J@Z(EPN;>4@=7ERS''%?6M%>C#-,5RJ%6U2*Z35_N?Q+Y-'? M',<1RJ-6TX]I*_W/XE\FCY@\%?\ !5O]GZ/Q##\/_P!I;PSXG^"_B>4[5TWX MC:2]K:S,.K0WJ@PO'_TTMS2>9)%X6U)KG2+F3UGT^X8QR#IA%9%& M.E7;*L3LW2?_ (%'])+[IE6RVOLW3?\ X%'])+[I'U317R5_PN/_ (*@?LS_ M +KXT? '0OC7X=@^]XE^&-Q]BUA8Q_'+ITWRS2'^Y!@78F,7."4X]XN_WVU7S2/>Z* 01D&BO/.$**** "OF MC]HG_C'G]L[X>?M+V_[G0_&B_P#"$>-7'"+)(3)I]PW;(D4HSGHB@9YKZ7KS MS]J[X(VW[1/[/GB?X2MM6[U'3F?29V./(OHB);=\_P .)43)'\)([U[_ UC ML/@LVBL2[4:J=.I_@FN5OUAI-?WHH^?XGP&(QV4R>&5ZU)JI3_QTWS*/I.S@ M_P"[)GH=%>6?L7_&ZX_: _9Q\.^/-9W)K<5N=/\ $MO(,/#J-N?*G#+_ EF M7>!V$@KU.O,S# XC+,=5PE=6G3DXOUB[/Y=CU,NQ^'S3 4L90=X5(J2])*Z^ M??S"BBBN,[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?&GQ%\! M_#BWLKOQ[XOT[1XM2U&&PL)-1NEB%Q=2MMCA4L1EF/ %;77I7XU_M0?%/P)\ M%_\ @K]XJ^%?_!3KX7V$^B_%#XD^%+SX(_$[QIIT%SX>B\-VMN$O=#$UP#'8 MD7#;Y8_E$SR%Y>#"S_J)^S/^R]X(_9G^$NI?!3P%>7$?A>YUW4[W1-/M;R:( M:19WDS3"RMG5]T,41D98A&5$:!0@7:* /3PZ%B@<%EQD \BEK\]_^"&OAFU\ M)_'']MC0M/U75KVUL/VHK^RM)M;UFYU"Y$45C;;4:XN9))9-N[ +NQP ,U5_ M94N?"/\ P5(_X*%?M3:M^TEX4LO%OP_^"GBFT^&_PX\':Y +C3M/NX8Y6U?4 M?(;*&]DG\M$N<"2*) B,,L2 ?HE17XQW_P#P52_:0^#/_!*CXM_ WP_\1;Z[ M^+7@/]JF_P#V>? WCG5)3[;34IG?)FN8K(3HLC99I+>.1]Q+%OHK]M M>U\-?\$D_BK^RW\8/@ ]_8:%XS^,>F_"SXJ6=UJ4UR?%-MJUM-Y.JZ@TC,;F M_MY[7SA=MF9A)+&6*/MH _1*BBB@#X1_X+>?M>_M0_LF:%\/M4_9J^)A\.OJ MK:LVMJ-%LKS[2D/V+RS_ *5#)LV^:Y^7&0QSG Q^=_\ P^T_X*=?]',_^69H MO_R'7W)_P< Q1SQ?"B&9 R.NO*RD<$'^SLBOR"\5Z%)XTC-N*;YE5J*+;:ZQ5O^W3+PXXNRW->-LV MX7QM.#JT/9U*3<4VZ2;YN]I]HGOGP]_X*T_\%!/A7HDWASP%\?_ M +!9SW\U[+#_ ,(KI,NZ>5MTCYDM6(RW.,X'8"NN\*?\%EO^"GWB/78-+7]I MD[&;=,P\&:+\J#J?^//\/J17R)7J_P $M8^"/@7P[)XC\>:C/?ZM=2$1:3:J MRI'&IX\QP,Y8Y.%[8S[=6"R?AZ.,INOA(RA?51A"[ZVO+EBK[7E**5]S[_Q MA4ROA+%5,IPL98J4>6G:GS6E+3GY80E)\BO.T8R;M:VI_1YXP\=>#?A]I#:[ MXW\3V.E6BY_?WUPL88_W5R,[ M&N8[-Q;0$]&<#!13ZRM"/>OFSPO\;Y1YDEY-R?G$EE_9/\ VQ/VE9EOOVF_C6GAC1Y&#?\ "->'-D\P7^ZQP+>- MA_>Q<'_:KV#X,?L5?LX? JYBUKP?\/(+K6HP/^*BUQS>WV?599<^5](PB^U> M4_\ "9?\%E/&G_("^#/P-\%1OU_X27Q%J&I2QCV^R *6^O%'_#/7_!5KQGSX MM_X*!^$O"2-_K(/!WPN@N^/19+QPR_7K6TZ^*A2=*%>G0@]'&#>J[2E!3E-> M4I278QAPO@%55;%5HU)K52G+GL^\8QBX1?G",;]3ZKIEQ<6]I"US=3I%&@R\ MDC!54>I)Z5\K_P##MGXI>*OF^+?_ 4H^.FJ;O\ 6P^'->@T6&3V*0QM\OMF MGV__ 1L_8?U"9;OXD^'_%OC:=3N\_Q;X[U&X8MZD1RQ@_B,5Y?U;+(?'7;_ M ,,&_P#TIQ/6]AE\?BK-_P"&#?\ Z4XGL_C']K/]EKX>[QXZ_:0\":0Z?>BU M#Q99Q/GT"M(&)]@,UY9XI_X*^?\ !.CPG/\ 8Y_VEM/U"X)VQV^AZ5>W[2-Z M*;>%U_7%=5X._P""<7[!W@3:?#_[)?@5F3[DFH^'XKUU/J&N YS[YKU/PM\/ MO 7@:#[-X)\$:1H\>,>7I6FQ6ZX],1J*+Y/#I4E\XQ_287RN'20?=I)G3:OOBC_ (;6_;P\7)?+?[MUXQ\?Z=I/ECU:)@S'Z YKZKHH^MX"'P89/_ !2D_P#TEQ#ZS@H_ M#03_ ,4I/\G$^5/^$F_X+,^-.-(^&7P'\%0O][^WM9U+4KB,?[/V8",M]>*/ M^&;_ /@J;XSY\8_\%%/#OA>-O];:>#OA9:W&1Z++=/O7Z@9KZKHH_M.>*?G^+?_!1OX\ZQG_6VVA^ M*(M(MY?9HX8FR/;-26?_ 1K_81N;E-0\?\ @CQ'XRND.5NO%?C?4KAMWJ0D MR*?Q&*^IZ*7]L9FOAJN/^'W?_2;!_:F8?9J./^'W?_2;'C?@[_@GC^POX#VM MX<_9,\!*Z?K;_,Y:F(KUOXDV_5MA1116)B%%%% !1110 444 M4 %%%% %37M#T?Q/H=[X:\0Z=%>:?J-I);7UI.FZ.>&12CHP[JRD@CT-&@Z' MH_AC0[+PUX>TZ*ST_3K2.VL;2!-L<$,:A$11V55 'H*MT4^:5K7T'=VMT"B MBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH *X7XV_LR_L_?M'Z-_87QR^$.A>)H0A2&74K%6G@!_P"> M4PQ)$?=&4UW5%73J5*,U.#::ZK1EPJ3I24H-IKJM#Y*/_!.OXT_ (_;OV#?V MQO$OA2SBYB\!^.?^)[H1':*/S?WUJO3+*7?CK1_PW+^UO^SO_HG[;7[%VIRZ M9#Q-X_\ A%*=7TW'>62T8BXMHQW9R3SPM?6M%>C_ &FZVF*IJIY[2_\ E9M M_P"+F.[^T'5TQ$%/SVE_X$M_^WKGF?P"_;(_9@_:@LEN?@9\:M#UZ8IODTR. MY\F^B'F5XM\??^">W[(G[2-ZVO_$3X.V$.O>9YL7BC02V MG:G'*.1)]HMRK2,#R/,W@>E>9_\ #,W_ 44_9K_ '_[,7[65K\2-!@_U?@S MXT6S2W(0?PQZI;XE9\<*'"H,#/>CZMEV(_@U>1]I_I..GWJ*#V&!K_PJG*^T M_P!)+3[U$^M:*^3['_@J+#\)[V+P[^W9^S5XS^$%VT@B_M^2T.KZ!*^<#9?6 MBGDG!VE#M!&6[U]'?#/XN_"SXT>'$\7?"3XB:+XETQ\#[;HFI1W,:D_PL4)V MMZJ<$=Q7-B,!B\+'FJ0]U[-:Q?I)73^3,*^"Q.'7-..G=:I^C5T_O/"OA-_Q MCI^WOXP^#$O[GP]\6+(^+?#"GA$U6(;-0A7U=P!.?156OI>OGS_@HMX/UZ#X M4Z3^T9X$LS+XD^$NNQ>(K-4X:>R4A;VW)[(T.6;U$6*Z7XO_ +=O[+GP"^&7 MA?XP? RZ-X>\8PQR:!J2Z'>WD<^^%9E5C:PR^6Q1L@-C.UL9VMCZ3.:-7 M.,%A,RHQ MG5;;27]RJJBLMHN&RL>O45\J_P##[3_@F+_T'_ &+G'_0-4_\ )?Y'W/]DYI_SXG_ . R_P CZJHKY@T' M_@LO_P $W?$^N67AKP]^T1+>:AJ-W';6-I!X)UII)YI&"(BC['RS,0 /4U]/ MURXC!XO"-*O3E"^W,FK^ESFKX7%85I5H.-]KIK\PHHHKF, HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO /\ @HE^VGXP M_81^$%C\:=&^!/\ PF^DMJJV6M;/$9T]M-\P?N93_HTV]&<%"?EVLR#G=Q\5 M?\1-'_5D_P#YDC_[VU[.!X?S?,J'ML-3YH[7YHK5>3:9ZN$R3,\?1]K0I\T= MMXK\VF?JI17Y5_\ $31_U9/_ .9(_P#O;75_ [_@X'\8?M ?%_PY\%O 7[#G MFZMXDU6*RM,_$U=4^$^(*<'.5&R6K?-#;_P(Z)\ M-9W3@Y2I62U?O1_^2/TIHHHKYP\(**** "BBB@ HHHH _/3]O']IO_@G]^V# MX*/ ?@_QI>Z/J/BKP_;WT_A_55U+1 MI)U)-I=B*2(2K_M!)9%YX^;U K7H _.G_@@_\5OAAX]^,_[:J^$/B)H>JW-] M^UKXBOK2#3]5AF>>P%O9Q1W2!&)>!G5U6094E3@U+_P3[M_"?_!/G]N_]LSX M6?M">+M+\*:9XV\?CXN^$==\07\=I:ZKI&H1.;^2*24A6^QW*&*89RGF1L1M MD4G]#/L5G]K^W_9(O/V;//\ +&_;G.W/7&>U4?$G@GP9XS-H?&'A'3-5^P7( MN;#^TK".?[-,.DD>]3L<=F�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htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2023
Feb. 21, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 000-33043    
Entity Registrant Name OMNICELL, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 94-3166458    
Entity Address, Address Line One 4220 North Freeway    
Entity Address, City or Town Fort Worth    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 76137    
City Area Code 877    
Local Phone Number 415-9990    
Title of 12(b) Security Common Stock, $0.001 par value    
Trading Symbol OMCL    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 3.3
Entity Common Stock, Shares Outstanding   45,915,296  
Documents Incorporated by Reference
Portions of the registrant’s definitive Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the United States Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference in Part III, Items 10-14 of this Form 10-K.
    
Document Fiscal Period Focus FY    
Amendment Flag false    
Document Fiscal Year Focus 2023    
Entity Central Index Key 0000926326    

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Auditor Information [Abstract]  
Auditor Firm ID 34
Auditor Name Deloitte & Touche LLP
Auditor Location San Jose, California
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
shares in Thousands, $ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 467,972 $ 330,362
Accounts receivable and unbilled receivables, net of allowances of $5,564 and $5,153, respectively 252,025 299,469
Inventories 110,099 147,549
Prepaid expenses 25,966 27,070
Other current assets 71,509 77,362
Total current assets 927,571 881,812
Property and equipment, net 108,601 93,961
Long-term investment in sales-type leases, net 42,954 32,924
Operating lease right-of-use assets 24,988 38,052
Goodwill 735,810 734,274
Intangible assets, net 211,173 242,906
Long-term deferred tax assets 32,901 22,329
Prepaid commissions 52,414 59,483
Other long-term assets 90,466 105,017
Total assets 2,226,878 2,210,758
Current liabilities:    
Accounts payable 45,028 63,389
Accrued compensation 51,754 73,455
Accrued liabilities 149,276 172,655
Deferred revenues, net 121,734 118,947
Total current liabilities 367,792 428,446
Long-term deferred revenues 58,622 37,385
Long-term deferred tax liabilities 1,620 2,095
Long-term operating lease liabilities 33,910 39,405
Other long-term liabilities 6,318 6,719
Convertible senior notes, net 569,662 566,571
Total liabilities 1,037,924 1,080,621
Commitments and contingencies (Note 14)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued 0 0
Common stock, $0.001 par value, 100,000 shares authorized; 55,822 and 55,030 shares issued; 45,539 and 44,747 shares outstanding, respectively 56 55
Treasury stock at cost, 10,283 shares outstanding, respectively (290,319) (290,319)
Additional paid-in capital 1,122,292 1,046,760
Retained earnings 370,357 390,728
Accumulated other comprehensive loss (13,432) (17,087)
Total stockholders’ equity 1,188,954 1,130,137
Total liabilities and stockholders’ equity $ 2,226,878 $ 2,210,758
Treasury stock, shares outstanding (in shares) 10,283 10,283
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Accounts receivable and unbilled receivables, net of allowance $ 5,564 $ 5,153
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 55,822,000 55,030,000
Common stock, shares outstanding (in shares) 45,539,000 44,747,000
Treasury stock, shares outstanding (in shares) 10,283,000 10,283,000
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues $ 1,147,112 $ 1,295,947 $ 1,132,018
Cost of revenues 650,272 706,960 577,365
Gross profit 496,840 588,987 554,653
Operating expenses:      
Research and development 97,115 104,969 75,716
Selling, general, and administrative 434,593 486,341 389,430
Total operating expenses 531,708 591,310 465,146
Income (loss) from operations (34,868) (2,323) 89,507
Interest and other income (expense), net 14,760 (130) (23,500)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total (20,108) (2,453) 66,007
Provision for (benefit from) income taxes 263 (8,101) (11,842)
Net income (loss) $ (20,371) $ 5,648 $ 77,849
Net income (loss) per share:      
Basic (in dollars per share) $ (0.45) $ 0.13 $ 1.79
Diluted (in dollars per share) $ (0.45) $ 0.12 $ 1.62
Weighted-average shares outstanding:      
Basic (in shares) 45,212 44,398 43,475
Diluted (in shares) 45,212 45,891 47,943
Product revenues      
Revenues $ 708,561 $ 903,222 $ 812,512
Cost of revenues 414,106 493,626 422,855
Services and other revenues      
Revenues 438,551 392,725 319,506
Cost of revenues $ 236,166 $ 213,334 $ 154,510
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ (20,371) $ 5,648 $ 77,849
Other comprehensive income (loss):      
Foreign currency translation adjustments 3,655 (8,680) (2,885)
Other comprehensive income (loss) 3,655 (8,680) (2,885)
Comprehensive income (loss) $ (16,716) $ (3,032) $ 74,964
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect of a Change in Accounting Principle
Common Stock
Treasury Stock
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect of a Change in Accounting Principle
Retained Earnings
Retained Earnings
Cumulative Effect of a Change in Accounting Principle
Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2020     52,677            
Balance at beginning of period (in shares) at Dec. 31, 2020       (9,894)          
Balance at beginning of period at Dec. 31, 2020 $ 967,503   $ 53 $ (238,109) $ 920,359   $ 290,722   $ (5,522)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) 77,849           77,849    
Other comprehensive income (loss) (2,885)               (2,885)
Share-based compensation 53,160       53,160        
Issuance of common stock under employee stock plans (in shares)     1,396            
Issuance of common stock under employee stock plans 67,348   $ 1   67,347        
Tax payments related to restricted stock units (16,286)       (16,286)        
Balance at end of period (in shares) at Dec. 31, 2021     54,073            
Balance at end of period (in shares) at Dec. 31, 2021       (9,894)          
Balance at end of period at Dec. 31, 2021 $ 1,146,689 $ (56,233) $ 54 $ (238,109) 1,024,580 $ (72,742) 368,571 $ 16,509 (8,407)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Accounting Standards Update [Extensible List] Accounting Standards Update 2020-06 [Member]                
Net income (loss) $ 5,648           5,648    
Other comprehensive income (loss) (8,680)               (8,680)
Stock repurchases (in shares)       (389)          
Stock repurchases (52,210)     $ (52,210)          
Share-based compensation 68,247       68,247        
Issuance of common stock under employee stock plans (in shares)     957            
Issuance of common stock under employee stock plans 40,182   $ 1   40,181        
Tax payments related to restricted stock units $ (13,506)       (13,506)        
Balance at end of period (in shares) at Dec. 31, 2022 44,747   55,030            
Balance at end of period (in shares) at Dec. 31, 2022 (10,283)     (10,283)          
Balance at end of period at Dec. 31, 2022 $ 1,130,137   $ 55 $ (290,319) 1,046,760   390,728   (17,087)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) (20,371)           (20,371)    
Other comprehensive income (loss) 3,655               3,655
Share-based compensation 59,683       59,683        
Issuance of common stock under employee stock plans (in shares)     792            
Issuance of common stock under employee stock plans 23,216   $ 1   23,215        
Tax payments related to restricted stock units $ (7,366)       (7,366)        
Balance at end of period (in shares) at Dec. 31, 2023 45,539   55,822            
Balance at end of period (in shares) at Dec. 31, 2023 (10,283)     (10,283)          
Balance at end of period at Dec. 31, 2023 $ 1,188,954   $ 56 $ (290,319) $ 1,122,292   $ 370,357   $ (13,432)
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating Activities      
Net income (loss) $ (20,371) $ 5,648 $ 77,849
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Depreciation and amortization 87,319 86,931 72,990
Loss on disposal of property and equipment 2,572 678 433
Share-based compensation expense 55,300 68,247 53,160
Deferred income taxes (11,047) (37,316) (3,272)
Amortization of operating lease right-of-use assets 8,239 12,238 11,941
Impairment and abandonment of operating lease right-of-use assets related to facilities 9,998 9,382 0
Impairment of internal-use and external-use software development costs, net 0 1,275 0
Impairment of certain long-lived assets 1,014 0 0
Amortization of debt issuance costs 4,397 4,164 3,440
Amortization of discount on convertible senior notes 0 0 18,608
Changes in operating assets and liabilities:      
Accounts receivable and unbilled receivables 49,150 (60,357) (40,973)
Inventories 38,016 (30,115) (25,695)
Prepaid expenses 1,149 (4,671) (5,678)
Other current assets (6,821) 6,360 2,801
Investment in sales-type leases (10,411) (15,354) 3,346
Prepaid commissions 7,069 4,312 (6,876)
Other long-term assets 2,111 5,027 (3,258)
Accounts payable (17,525) (7,754) 29,084
Accrued compensation (21,461) 2,446 12,312
Accrued liabilities (10,343) 16,651 34,859
Deferred revenues 24,058 24,469 24,179
Operating lease liabilities (10,918) (13,781) (12,503)
Other long-term liabilities (401) (699) (14,938)
Net cash provided by operating activities 181,094 77,781 231,809
Investing Activities      
External-use software development costs (13,542) (13,204) (29,368)
Purchases of property and equipment (41,474) (47,536) (28,967)
Business acquisitions, net of cash acquired 0 (3,392) (354,163)
Purchase price adjustments from business acquisitions 0 5,463 0
Net cash used in investing activities (55,016) (58,669) (412,498)
Financing Activities      
Payments for debt issuance costs for revolving credit facility (2,967) 0 0
Proceeds from issuances under stock-based compensation plans 23,216 40,182 67,348
Employees’ taxes paid related to restricted stock units (7,366) (13,506) (16,286)
Stock repurchases 0 (52,210) 0
Change in customer funds, net 10,537 4,581 (3,699)
Net cash provided by (used in) financing activities 23,420 (20,953) 47,363
Effect of exchange rate changes on cash and cash equivalents (1,354) (944) (974)
Net increase (decrease) in cash, cash equivalents, and restricted cash 148,144 (2,785) (134,300)
Cash, cash equivalents, and restricted cash at beginning of period 352,835 355,620 489,920
Cash, cash equivalents, and restricted cash at end of period 500,979 352,835 355,620
Reconciliation of cash, cash equivalents, and restricted cash to the Consolidated Balance Sheets:      
Cash and cash equivalents 467,972 330,362 349,051
Restricted cash included in other current assets 33,007 22,473 6,569
Cash, cash equivalents, and restricted cash at end of period 500,979 352,835 355,620
Supplemental cash flow information      
Cash paid for interest 1,438 1,438 1,917
Income taxes paid (refunds received), net 20,209 19,005 (1,733)
Supplemental disclosure of non-cash investing activities      
Unpaid purchases of property and equipment 877 892 883
Transfers between inventory and property and equipment, net $ 0 $ 314 $ 1,876
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Organization and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Organization and Summary of Significant Accounting Policies Organization and Summary of Significant Accounting Policies
Business
Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” refer to Omnicell, Inc. and its subsidiaries, collectively.
Basis of Presentation
The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations, and cash flows for the periods presented.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying Notes to Consolidated Financial Statements. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. Those policies are revenue recognition; allowance for credit losses for accounts receivable and unbilled receivables; notes receivable from investment in sales-type leases; operating lease right-of-use assets and liabilities; inventory valuation; internal-use and external-use software development costs; impairment of goodwill; purchased intangibles and long-lived assets; fair value of assets acquired and liabilities assumed in business combinations; share-based compensation; and accounting for income taxes. As of December 31, 2023, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.
Segment Reporting
The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.
Foreign Currency Translation and Remeasurement
Most of the Company’s foreign subsidiaries use the local currency of their respective countries as their functional currency. The Company translates the assets and liabilities of such non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income (loss) in stockholders’ equity.
Assets and liabilities denominated in a currency other than the functional currency are remeasured into the respective entity’s functional currency. Monetary assets and liabilities are remeasured at exchange rates in effect at the end of each period, and non-monetary assets and liabilities are remeasured at historical rates. Gains and losses from foreign currency remeasurement of monetary assets and liabilities are recorded in interest and other income (expense), net.
Revenue Recognition
The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories:
Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service.
Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions.
Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements.
Advanced Services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth®, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service.
The following table summarizes revenue recognition for each revenue category:
Revenue Category
Timing of Revenue Recognition
Income Statement Classification
Connected devices, software licenses, and other
Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer
Product
Consumables
Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer
Product
Technical services
Over time, as services are provided, typically ratably over the service term
Service
Advanced Services
Over time, as services are provided
Service
Prior to recognizing revenue, the Company identifies the contract, performance obligations, and transaction price, and allocates the transaction price to the performance obligations. All identified contracts meet the following required criteria:
Parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations. A majority of the Company’s contracts are evidenced by a non-cancelable written agreement. Contracts for consumable products are generally evidenced by an order placed via our online portal, phone, or a purchase order.
Entity can identify each party’s rights regarding the goods or services to be transferred. Contract terms are documented within the written agreements. Where a written contract does not exist, such as for consumable products, the rights of each party are understood as following the Company’s standard business process and terms.
The entity can identify the payment terms for the goods or services to be transferred. Payment terms are documented within the agreement and are generally net 30 to 60 days from shipment of tangible product or services performed for customers in the United States. Where a written contract does not exist, the Company’s standard payment terms are net 30 day terms.
The contract has commercial substance (that is the risk, timing, or amount of the entity’s future cash flows is expected to change as a result of the contract). The Company’s agreements are an exchange of cash for a combination of products and services which result in changes in the amount of the Company’s future cash flows.
It is probable the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company performs a credit check for all significant customers or
transactions and where collectability is not probable, payment in full or a substantial down payment prior to shipment is typically required to help ensure the full agreed upon contract price will be collected.
Distinct goods or services are identified as performance obligations. A series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer are considered a single performance obligation. Where a good or service is determined not to be distinct, the Company combines the good or service with other promised goods or services until a bundle of goods or services that is distinct is identified. To identify its performance obligations, the Company considers all products or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. When performance obligations are included in separate contracts, the Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Most of the Company’s sales, other than renewals of support and maintenance, contain multiple performance obligations, with a combination of hardware systems, software products, support and maintenance, and professional services.
The transaction price of a contract is determined based on the fixed consideration, net of an estimate for variable consideration such as various discounts or rebates provided to customers. As a result of the Company’s commercial selling practices, contract prices are generally fixed with minimal, if any, variable consideration.
The transaction price is allocated to separate performance obligations proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.
The Company recognizes revenue when the performance obligation has been satisfied by transferring a promised good or service to a customer. The good or service is transferred when or as the customer obtains control of the good or service. Determining when control transfers requires management to make judgments that affect the timing of revenues recognized. Generally, for products requiring a complex implementation, control passes when the product is installed and ready for use. For all other products, control generally passes when product has been shipped and title has passed. For maintenance contracts and certain other services, including Advanced Services provided on a subscription basis, control passes to the customer over time, generally ratably over the service term as the Company provides a stand-ready service for the customer’s equipment. Time and material services transfer control to the customer at the time the services are provided.
The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues, net of deferred cost of goods sold. Deferred revenues from product sales primarily relate to delivered and invoiced products, pending installation and acceptance. Deferred revenues from service contracts primarily relate to services that have been invoiced, where services have not yet been provided. Short-term deferred revenues are expected to be recognized within the next twelve months. Long-term deferred revenues substantially consist of deferred revenues on long-term technical and Advanced Services contracts which have been invoiced and are expected to be recognized as revenue beyond twelve months, generally not more than ten years.
In addition, the Company has remaining performance obligations associated with contracts for which the associated products have been accepted or associated services have started, but where invoicing has not yet occurred and therefore are not reflected in deferred revenue. These remaining performance obligations are comprised of the non-variable portions of technical services and Advanced Services provided under non-cancellable contracts with minimum commitments. Remaining performance obligations which are not included in deferred revenues are $353.9 million as of December 31, 2023. Remaining performance obligations are expected to be recognized ratably over the remaining terms of the associated contracts, which terms vary but are generally not more than ten years. Remaining performance obligations do not include product obligations, services where the associated product has not been accepted, services which have not yet started, variable portions of services, and certain other obligations.
Revenues, contract assets, and contract liabilities are recorded net of associated taxes.
The Company generally invoices customers for products upon shipment. Invoicing associated with the service portion of agreements is generally periodic and is billed on a monthly, quarterly, or annual basis, and in certain circumstances, multiple years are billed at one time. Advanced Services agreements are generally invoiced periodically on a monthly, quarterly or annual basis over the life of the agreement. In certain circumstances portions of these agreements may be invoiced lump sum.
The amount invoiced for equipment and software is typically reflected in both accounts receivable and deferred revenues, net. The Company typically recognizes product revenue, and correspondingly reduces deferred revenues, net, for equipment and on-premise software upon written customer acceptance of installation. Consumables are recorded as revenue upon shipment to or receipt by the customer, depending upon contract terms.
From time to time, the Company enters into change orders which modify the product to be received by the customer pursuant to certain contracts. Changes to any contract are accounted for as a modification of the existing contract to the extent the goods and services to be delivered as part of the contract are generally consistent with the nature and type of those to be provided under the terms of the original contract. Examples of such change orders include the addition or removal of units of equipment or changes to the configuration of the equipment where the overall nature of the contract remains intact. The Company’s change orders generally result in the change being accounted for as modifications of existing contracts given the nature of the impacted orders.
In the normal course of business, the Company typically does not accept product returns unless the item is defective as manufactured or the configuration of the product is incorrect. The Company establishes provisions for estimated returns based on historical product returns. The allowance for sales returns is not material to the Consolidated Financial Statements for any periods presented.
A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”), each of which functions as a purchasing agent on behalf of member hospitals and other healthcare providers. The Company also has a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”), allowing the Department of Veterans Affairs, the Department of Defense, and other federal government customers to purchase the Company’s products. Pursuant to the terms of GPO agreements and the GSA Contract, each member or agency contracts directly with Omnicell and can purchase the Company’s products at pre-negotiated contract terms and pricing. GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $11.2 million, $17.6 million, and $17.5 million for the years ended December 31, 2023, 2022, and 2021, respectively. The accounts receivable balances are with individual members of the GPOs and federal agencies that purchase under the GSA Contract, and therefore no significant concentration of credit risk exists. During the year ended December 31, 2023, sales to members of the ten largest GPOs and federal agencies that purchase under the GSA Contract accounted for approximately 64% of the Company’s total consolidated revenues.
Contract Assets and Contract Liabilities
A contract asset is a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration. A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. Contract liabilities include customer deposits under non-cancelable contracts, and current and non-current deferred revenue balances. The Company’s contract balances are reported in a net contract asset or liability position on a contract-by-contract basis at the end of each reporting period.
Significant changes in the contract assets and the contract liabilities balances during the period are the result of the issuance of invoices and recognition of deferred revenues in the normal course of business. The contract modifications entered into during the year ended December 31, 2023 did not have a significant impact on the Company’s contract assets or deferred revenues.
Contract Costs
The Company has determined that certain incentive portions of its sales commission plans require capitalization since these payments are directly related to sales achieved during a time period. These commissions are earned on the basis of: (i) the value of new bookings for connected devices, software products, and Advanced Services, provided that for Advanced Services a commission will only be paid on the amount that represents the minimum commitment and (ii) the value of new orders for consumables. Since there are no commensurate commissions earned on renewal of the service bookings, the Company concluded that the capitalized asset is related to services provided under both the initial contract and renewal periods. The Company applies a practical expedient to account for the incremental costs of obtaining a contract as part of a portfolio of contracts with similar characteristics as the Company expects the effect on the financial statements of applying the practical expedient would not differ materially from applying the accounting guidance to the individual contracts within the portfolio. A pool of contracts is defined as all contracts booked in a particular quarter. The amortization for the capitalized asset is an estimate of the pool’s original contract term, generally one to five years, plus an estimate of future customer renewal periods resulting in a total amortization period of ten years. Costs to obtain a contract are allocated amongst performance obligations and recognized as sales and marketing expense consistent with the pattern of revenue recognition. In accordance with GAAP, while certain compensation elements are expensed as incurred, a portion of the pool’s capitalized asset is recorded as an expense over the first seven quarters after booking, which represents the estimated period during which the product revenue associated with the contract is recorded. The remaining capitalized contract costs are recorded as expense ratably over the ten
year estimated initial and renewal service periods. The Company recognized contract cost expense of $23.3 million, $30.6 million, and $25.8 million during the years ended December 31, 2023, 2022, and 2021, respectively. The commission expenses paid or due to be paid as of the consolidated balance sheet date to be recognized in future periods are recorded in long-term prepaid commissions on the Consolidated Balance Sheets. Capitalized costs are periodically reviewed for impairment. There was no impairment loss recorded related to capitalized prepaid commissions as of and for the year ended December 31, 2023.
Lessor Leases
The Company determines if an arrangement is or contains a lease at inception. The transaction price is allocated to separate performance obligations, generally consisting of a combination of hardware systems, software products, support and maintenance, and professional services, proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.
Sales-Type Leases
The Company enters into non-cancelable sales-type lease arrangements with the leases varying in length from one to ten years, most of which do not have an option to extend the lease term. At the end of the lease term, the customer must either return the equipment or negotiate a new agreement, resulting in a new purchase or lease transaction. Failure of the customer to either return the equipment or negotiate a new agreement results in the contract becoming a month-to-month rental. Certain sales-type leases automatically renew for successive one-year periods at the end of each lease term without written notice from the customer. The Company’s sales-type lease agreements do not contain any material residual value guarantees.
For sales-type leases, the Company recognizes revenues for its hardware and software products, net of lease execution costs, post-installation product maintenance, professional services associated with Advanced Services offerings, and technical support, at the net present value of the lease payment stream upon customer acceptance. The Company recognizes service revenues associated with sales-type leases ratably over the term of the agreement in service revenues in the Consolidated Statements of Operations. The Company recognizes interest income from sales-type leases using the effective interest method. Both hardware and software revenues, and interest income from sales-types leases are recorded in product revenues in the Consolidated Statements of Operations.
The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold.
Allowance for Credit Losses
The Company is exposed to credit losses primarily through sales of its products and services, as well as its sales-type leasing arrangements. The Company performs credit evaluations of its customers’ financial condition in order to assess each customer’s ability to pay. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history, and a financial review of the customer. The Company continues to monitor customers’ creditworthiness on an ongoing basis.
The Company maintains an allowance for credit losses for accounts receivable, unbilled receivables, and net investment in sales-type leases based on expected credit losses resulting from the inability of its customers to make required payments. The allowance for credit losses is measured using a loss rate method, considering factors such as customers’ credit risk, historical loss experience, current conditions, and forecasts. The allowance for credit losses is measured on a collective (pool) basis by aggregating customer balances with similar risk characteristics. The Company also records a specific allowance based on an analysis of individual past due balances or customer-specific information, such as a decline in creditworthiness or bankruptcy. Actual collection losses may differ from management’s estimates, and such differences could be material to the Company’s financial position and results of operations.
The allowance for credit losses is presented in the Consolidated Balance Sheets as a deduction from the respective asset balance. As of December 31, 2023 and 2022, the allowance for credit losses for long-term unbilled receivables and net investment in sales-type leases were not material.
Funds Held for Customers and Customer Fund Liabilities
The Company offers certain products and services in which it is customary for pharmacies or insurance payors to owe funds to the Company which are collected on behalf of, and, after a short holding period, disbursed to, the Company’s customers. The Company presents amounts due from pharmacies and amounts due to be disbursed to customers on a gross basis within other current assets and accrued liabilities, respectively, in the Consolidated Balance Sheets, as such amounts are expected to be settled within one year. Generally, any funds received from the pharmacies or insurance payors that are held by the Company are segregated from its other corporate cash accounts. These funds are classified as restricted cash as the Company is contractually obligated to disburse these amounts to customers.
Sales of Accounts Receivable
The Company records the sale of its accounts receivables in accordance with accounting guidance for transfers and servicing of financial assets. The Company transferred non-recourse accounts receivable totaling $5.7 million, $45.3 million, and $46.7 million during the years ended December 31, 2023, 2022, and 2021, respectively, which approximated fair value, to leasing companies on a non-recourse basis. Accounts receivable balance included approximately $1.1 million and $6.7 million due from third-party leasing companies for transferred non-recourse accounts receivable as of December 31, 2023 and 2022, respectively.
Cash and Cash Equivalents
The Company classifies all highly-liquid investments with original maturities of three months or less as cash equivalents. The Company’s cash and cash equivalent balances include bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with financial institutions of high credit quality. The Company continuously monitors the credit worthiness of the financial institutions in which it invests. The Company has not experienced any credit losses from its cash equivalents. Cash and cash equivalents were $468.0 million and $330.4 million as of December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, cash equivalents were $451.0 million and $301.0 million, respectively, which consisted of money market funds held in sweep and asset management accounts.
Financial Instruments
For assets and liabilities measured at fair value, the amounts are based on an expected exit price representing the amount that would be received from the sale of an asset or paid to transfer a liability in a transaction between market participants. The fair value may be based on assumptions that market participants would use in pricing an asset or liability. ASC 820, Fair Value Measurement, establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs used in valuation techniques are assigned a hierarchical level, as follows:
Level 1 – Observable inputs, such as quoted prices in active markets for identical instruments;
Level 2 – Quoted prices for similar instruments in active markets, or quoted prices for identical instruments in inactive markets; and
Level 3 – Unobservable inputs for financial instruments reflecting Company’s assumptions.
Inventory
Inventories are stated at the lower of cost, computed using the first-in, first-out method, and net realizable value. Inbound shipping costs are included in cost of inventory. The Company regularly monitors inventory quantities on hand and records write-downs for excess and obsolete inventories based on the Company’s estimate of demand for its products, potential obsolescence of technology, product life cycles, and whether pricing trends or forecasts indicate that the carrying value of inventory exceeds its estimated selling price. These factors are impacted by market and economic conditions, technology changes, and new product introductions and require estimates that may include elements that are uncertain. Actual demand may differ from forecasted demand and may have a material effect on gross margins. If inventory is written down, a new cost basis is established that cannot be increased in future periods. Shipments from suppliers or contract manufacturers before the Company receives them are recorded as in-transit inventory when title and the significant risks and rewards of ownership have passed to the Company.
The Company has a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in its hardware products. There are no minimum purchase requirements. The
contract with the Company’s supplier may be terminated by either the supplier or by the Company without cause and at any time upon delivery of six months’ notice. Purchases from this supplier were $65.8 million, $105.7 million, and $103.2 million for the years ended December 31, 2023, 2022, and 2021, respectively.
Shipping Costs
Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general, and administrative expense. Shipping and handling expenses were $18.6 million, $24.5 million, and $18.2 million for the years ended December 31, 2023, 2022, and 2021, respectively.
Property and Equipment
Property and equipment less accumulated depreciation are stated at historical cost. The Company’s expenditures for property and equipment are primarily for computer equipment and software used in the administration of its business, and for leasehold improvements to its leased facilities. The Company also develops molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components.
The Company capitalizes costs related to computer software developed or obtained for internal-use in accordance with ASC 350-40, Internal-Use Software. Software developed or obtained for internal-use includes certain costs for the development of the Company’s subscription and cloud-based offerings sold to its customers, as well as enterprise-level business and finance software that the Company customizes to meet its specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. The Company capitalized $32.2 million and $33.0 million of costs related to the application development of enterprise-level software and its subscription and cloud-based offerings, which are included in property and equipment during the years ended December 31, 2023 and 2022, respectively. Capitalized costs related to computer software developed or obtained for internal-use are included in purchases of property and equipment in the Consolidated Statements of Cash Flows.
Depreciation and amortization is computed by use of the straight-line method over the estimated useful lives of the assets as stated below:
Purchased software and internal-use software development costs
3 - 5 years
Leasehold and building improvementsShorter of the lease term or the estimated useful life
Furniture and fixtures
5 - 7 years
Equipment
2 - 12 years
External-Use Software Development Costs
The Company capitalizes certain software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed, under which those costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. The Company establishes technological feasibility when it completes a detail program design or a working model. The Company amortizes development costs over the estimated lives of the related products, which is generally five years. All development costs prior to the completion of a detail program design or a working model are recognized as research and development expense. The Company capitalized external-use software development costs of $14.6 million and $13.2 million, that were included in other long-term assets as of December 31, 2023 and 2022, respectively.
Lessee Leases
The Company determines if an arrangement is or contains a lease at inception. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of its lease contracts do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available at the commencement date in determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize a right-of-use asset and a lease liability for leases with an initial term of twelve months or less. The Company elected the practical expedient to not separate lease components from nonlease components and applied that practical expedient to all material classes of leased assets.
Many of the Company’s operating leases include an option to extend the lease. The specific terms and conditions of the extension options vary from lease to lease, but are consistent with standard industry practices in each area that the Company operates. The Company reviews each of its lease options at a time required by the terms of the lease contract, and notifies the
lessor if it chooses to exercise the lease renewal option. Until the Company is reasonably certain that it will extend the lease contract, the renewal option periods will not be recognized as right-of-use assets or lease liabilities.
Certain leases include provisions for early termination, which allow the contract parties to terminate their obligations under the lease contract. The terms and conditions of the termination options vary by contract. When the Company has made a decision to exercise an early termination option, the right-of-use assets and associated lease liabilities are remeasured in accordance with the present value of the remaining cash flows under the lease contract.
Certain building lease agreements include rental payments subject to change annually based on fluctuations in various indexes (i.e., Consumer Price Index (“CPI”), Retail Price Index, and other international indexes). Certain data center lease agreements include rental payments subject to change based on usage and CPI fluctuations. The changes based on usage and indexes are treated as variable lease costs and recognized in the period in which the obligation for those payments was incurred. 
The Company’s operating lease agreements do not contain any material residual value guarantees, restrictions, or restriction covenants.
Business Combinations
The Company uses the acquisition method of accounting under ASC 805, Business Combinations. Each acquired company’s operating results are included in the Company’s Consolidated Financial Statements starting on the acquisition date. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the acquisition date are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed.
Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on available historical information as well as future expectations, and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, acquired technology, backlog, trade names, and non-compete agreements.
Goodwill and Acquired Intangible Assets
Goodwill
The Company assesses goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. This assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. The Company has one reporting unit, which is the same as its operating segment. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. A qualitative assessment includes, among others, consideration of: (i) past, current, and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this qualitative assessment indicates that it is more likely than not that impairment exists, or if the Company decides to bypass this option, it proceeds to the quantitative assessment. The quantitative assessment involves a comparison between the estimated fair value of the Company’s reporting unit with its carrying amount including goodwill. If the carrying value exceeds estimated fair value, the Company will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill.
To determine the reporting unit’s fair value under the quantitative approach, the Company uses a combination of income and market approaches, such as estimated discounted future cash flows of the reporting unit, multiples of earnings or revenues, and analysis of recent sales or offerings of comparable entities. The Company also considers its market capitalization on the date of the analysis to ensure the reasonableness of its reporting unit’s fair value.
The Company elected to perform a quantitative impairment assessment analysis as of October 1, 2023 for its reporting unit. The Company determined that the fair value of the reporting unit exceeded the carrying value and thus no impairment was indicated. Based on the result of this analysis, an impairment does not exist as of December 31, 2023, and there were no accumulated impairment losses.
Intangible Assets
In connection with its acquisitions, the Company generally recognizes assets for customer relationships, acquired technology, backlog, trade names, and non-compete agreements. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets. Amortization for acquired technology and backlog is recognized in cost of revenues, and amortization for customer relationships, trade names, non-compete agreements, and patents is recognized in selling, general, and administrative expenses.
The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. The Company’s cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of the Company’s intangible assets are subjective and are affected by changes to its business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of the Company’s assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on the Company’s operating results and financial condition. For the years ended December 31, 2023 and 2022, there were no events or changes in circumstances to indicate that intangible assets carrying amounts may not be recoverable.
Convertible Debt
The Company accounts for convertible debt and related transactions in accordance with ASC 470-20, Debt with Conversion and Other Options, ASC 815, Derivatives and Hedging, and ASC 480, Distinguishing Liabilities from Equity. The Company evaluates convertible debt instruments and related transactions at inception to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for.
Prior to the adoption of Accounting Standards Update (“ASU”) 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner. The difference between the principal amount of the convertible senior notes and the liability component, inclusive of issuance costs, represented the debt discount, which the Company amortized to interest expense over the term of the convertible senior notes. The determination of the discount rate required certain estimates and assumptions.
Upon adoption of ASU 2020-06, effective January 1, 2022, the convertible senior notes are no longer separated into liability and equity components, and are accounted for as a single liability, measured at amortized cost in the Consolidated Balance Sheets. Issuance costs are amortized using the effective interest method over the term of the convertible senior notes.
Convertible note hedge and warrant transactions associated with convertible debt instruments are accounted for as equity instruments, and are recorded in additional paid-in capital in the Consolidated Balance Sheets.
Valuation of Share-Based Compensation
The Company accounts for share-based compensation in accordance with ASC 718, Stock Compensation. The Company recognizes compensation expense related to share-based compensation based on the grant date estimated fair value.
The fair value of stock options (“options”) on the grant date is estimated using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of its common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on the Company’s historical experience of employee stock option exercises, including forfeitures. Expense is recognized on a straight-line basis over the requisite service period.
The fair value of restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) is based on the stock price on the grant date. The RSUs and RSAs are subject to a service vesting condition and are recognized on a straight-line basis over the requisite service period.
The fair value of performance-based stock unit awards (“PSUs”) with service and market conditions is estimated using a Monte Carlo simulation model applying a multiple awards approach. Expense is recognized when it is probable that the performance condition will be met using the accelerated attribution method over the requisite service period.
Forfeiture rates are estimated based on the Company’s historical experience with equity awards that were granted and forfeited prior to vesting. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods.
Accounting for Income Taxes
The Company records an income tax provision for (benefit from) the anticipated tax consequences of the reported results of operations. In accordance with ASC 740, Income Taxes, the provision for (benefit from) income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, the Company will incur a benefit or detriment on its income tax expense in the period of enactment. If the Company were to determine that all or part of the net deferred tax assets are not realizable in the future, it will record a valuation allowance that would be charged to earnings in the period such determination is made.
In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of ASC 740 and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on the Company’s financial condition and operating results.
Recently Adopted Authoritative Guidance
In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The Company adopted ASU 2021-08 beginning January 1, 2023 and will apply the guidance prospectively to acquisitions occurring on or after the adoption date.
Recently Issued Authoritative Guidance
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Combinations
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combinations Business Combinations
The Company’s Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Consolidated Statements of Operations.
2022 Acquisition
Hub and Spoke Innovations
On January 10, 2022, the Company completed the acquisition of all of the outstanding equity interests in Hub and Spoke Innovations pursuant to the terms and conditions of the Share Purchase Agreement, dated January 10, 2022, by and among Omnicell Limited (a wholly-owned subsidiary of the Company), Hub and Spoke Innovations Limited, and certain beneficial stockholders specified therein for a base purchase price of £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date), prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The purchase price transferred for the transaction, net of cash acquired, was £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date). Of the purchase price transferred, £1.9 million (approximately $2.5 million based on the exchange rate in effect at the acquisition date) was allocated to goodwill; £0.8 million (approximately $1.1 million based on the exchange rate in effect at the acquisition date) was allocated to intangible assets, which included customer relationships; and the remainder was allocated to net assets acquired. The Hub and Spoke Innovations acquisition is expected to complement Omnicell’s total solution technology portfolio for retail pharmacy in the United Kingdom to help pharmacies improve workflows, offer patients 24/7 access to their medications and provide enhanced patient care.
2021 Acquisitions
MarkeTouch Media
On December 31, 2021, the Company completed the acquisition of all of the outstanding equity interests in MarkeTouch Media, LLC (“MarkeTouch Media”) pursuant to the terms and conditions of the Unit Purchase Agreement, dated December 31, 2021, by and among ateb, Inc. (a wholly-owned subsidiary of the Company), MarkeTouch Media, LLC, MarkeTouch Holdings, Inc., Toucan Enterprises, Inc., and certain beneficial stockholders specified therein for a base purchase price of $82.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The MarkeTouch Media acquisition adds mobile and web-based technology and patient engagement solutions, which is expected to expand the footprint of EnlivenHealth® across the retail pharmacy sector, while enhancing potential growth opportunities in new market segments like specialty pharmacy and pharmacy benefits management.
ReCept
On December 29, 2021, the Company completed the acquisition of all outstanding equity securities of ReCept pursuant to the terms and conditions of the Agreement and Plan of Merger, dated December 1, 2021, by and among Omnicell, Inc., ReCept Holdings, Inc., Redfish Acquisition Corp, and the representative of the securityholders for a base purchase price of $100.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The addition of ReCept’s specialty pharmacy management services, now a part of the Company’s Specialty Pharmacy Services, for health systems, provider groups, and federally qualified health centers expands Omnicell’s Advanced Services portfolio in an effort to address the growing and complex specialty pharmacy market.
FDS Amplicare
On September 9, 2021, the Company completed the acquisition of all of the outstanding equity interests in RxInnovation, Inc., operating as FDS Amplicare® (“FDS Amplicare”), pursuant to the terms and conditions of the Agreement and Plan of Merger, dated July 25, 2021, by and among RxInnovation Inc., Omnicell, Inc., Fleming Acquisition Corp., and the representative of the securityholders for a base purchase price of $177.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The FDS Amplicare acquisition adds a comprehensive and complementary suite of software-as-a-service (“SaaS”) financial management, analytics, and population health solutions to the Company’s EnlivenHealth offering.
The Company incurred approximately $7.0 million in acquisition-related costs related to the FDS Amplicare acquisition during the year ended December 31, 2021. Revenues and net losses from the FDS Amplicare operations since the acquisition date through December 31, 2021 were $11.3 million and $0.9 million, respectively.
The following tables represent the allocation of the respective purchase price to the assets acquired and the liabilities assumed by the Company as part of each acquisition included in the Company’s Consolidated Balance Sheets, and is reconciled to the respective purchase price transferred:
FDS Amplicare (1)
ReCept (2) (3)
MarkeTouch Media (4)
(In thousands)
Purchase price transferred:
Base purchase price$177,000 $100,000 $82,000 
Add: Closing cash465 6,569 237 
Add: Net working capital adjustment1,654 (7,357)147 
Less: Assumed indebtedness(653)(1,973)(15)
Total purchase price transferred$178,466 $97,239 $82,369 
FDS Amplicare (1)
ReCept (2) (3)
MarkeTouch Media (4)
Fair value of assets acquired and liabilities assumed:
Cash and cash equivalents$465 $— $237 
Accounts receivable and unbilled receivables5,330 2,383 2,302 
Prepaid expenses506 192 96 
Other current assets45 12,223 — 
Total current assets6,346 14,798 2,635 
Property and equipment444 172 177 
Operating lease right-of-use assets2,252 773 602 
Goodwill117,784 77,644 42,273 
Intangible assets70,000 28,100 38,000 
Other long-term assets51 195 2,850 
Total assets196,877 121,682 86,537 
Accounts payable950 219 473 
Accrued compensation1,312 1,756 — 
Accrued liabilities1,497 18,249 292 
Deferred revenues1,916 222 347 
Long-term deferred tax liabilities11,686 3,383 — 
Long-term operating lease liabilities920 614 206 
Other long-term liabilities130 — 2,850 
Total liabilities18,411 24,443 4,168 
Total purchase price$178,466 $97,239 $82,369 
Total purchase price, net of cash acquired$178,001 $90,670 $82,132 
_________________________________________________
(1)    During the year ended December 31, 2021, the Company recorded measurement period adjustments of $1.5 million to goodwill, consisting of an increase in intangible assets, accounts receivable and unbilled receivables, and long-term deferred tax liabilities of $0.4 million, $1.1 million, and $0.1 million, respectively, and a net working capital adjustment of $0.1 million. During the year ended December 31, 2022, the Company recorded a measurement period adjustments of $0.4 million to goodwill, consisting of an increase in long-term deferred tax liabilities and accrued liabilities of $0.3 million and $0.1 million, respectively.
(2)    Closing cash is included in other current assets due to its restrictive nature as cash held for customers.
(3)    During the year ended December 31, 2022, the Company recorded measurement period adjustments of $3.9 million to goodwill, consisting of a purchase price adjustment of $5.2 million, a decrease in long-term deferred tax liabilities of $0.2 million and a decrease in accrued liabilities of $0.3 million, partially offset by a decrease to other current assets of $1.7 million.
(4)    During the year ended December 31, 2022, the Company recorded a measurement period adjustment of $0.3 million to goodwill related to a purchase price adjustment.
The $117.8 million of goodwill arising from the FDS Amplicare acquisition is primarily attributed to future sales of SaaS solutions and FDS Amplicare’s assembled workforce. The $77.6 million of goodwill arising from the ReCept acquisition is primarily attributed to future sales of its offerings and services and ReCept’s assembled workforce. None of the FDS Amplicare and ReCept goodwill is expected to be deductible for tax purposes as these acquisitions were treated as stock acquisitions for U.S. tax purposes. The $42.3 million of goodwill arising from the MarkeTouch Media acquisition is primarily attributed to future sales of SaaS solutions and MarkeTouch Media’s assembled workforce. The full amount of the MarkeTouch Media goodwill is expected to be deductible for tax purposes as this acquisition was treated as an asset acquisition for U.S. tax purposes.
The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows:
FDS Amplicare (1)
ReCeptMarkeTouch Media
Fair valueUseful life
(years)		Fair valueUseful life
(years)		Fair valueUseful life
(years)
(In thousands, except for years)
Customer relationships$59,900 23$28,100 23$34,100 26
Acquired technology7,700 
5 - 7
— —2,100 4
Backlog— —— —1,800 2
Trade names2,400 5— —— —
Total purchased intangible assets$70,000 $28,100 $38,000 
_________________________________________________
(1)    During the year ended December 31, 2021, the Company recorded a measurement period adjustment of $0.4 million in customer relationships.
The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions.
The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions.
The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization.
Pro Forma Financial Information
The following table presents certain unaudited pro forma consolidated financial information for the year ended December 31, 2021 as if the FDS Amplicare, ReCept, and MarkeTouch Media acquisitions had been completed on January 1, 2020. The pro forma effects of the Hub and Spoke Innovations acquisition were not material to the Company’s consolidated results of operations. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of what would have occurred had the acquisitions taken place on those respective dates. The unaudited pro forma financial information combines the historical results of the acquisitions with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, amortization and depreciation of intangible assets and property and equipment acquired; imputed interest, interest expense, and amortization of debt issuance costs related to acquisitions, as applicable; and certain acquisition-related costs incurred.
Year Ended December 31,
2021
(In thousands)
Pro forma revenues$1,195,473 
Pro forma net income$79,981 
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenues
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Disaggregation of Revenues
The following table summarizes the Company’s revenues disaggregated by revenue type for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Connected devices, software licenses, and other$623,584 $827,917 $739,074 
Consumables84,977 75,305 73,438 
Technical services225,831 206,687 206,989 
Advanced Services
212,720 186,038 112,517 
Total revenues$1,147,112 $1,295,947 $1,132,018 
The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
United States$1,011,380$1,168,202$1,020,788
Rest of world (1)
135,732127,745111,230
Total revenues$1,147,112$1,295,947$1,132,018
_________________________________________________
(1)    No individual country represented more than 10% of total revenues.
Contract Assets and Contract Liabilities
The following table reflects the Company’s contract assets and contract liabilities:
December 31,
20232022
(In thousands)
Short-term unbilled receivables, net (1)
$22,524 $25,763 
Long-term unbilled receivables, net (2)
11,850 14,744 
Total contract assets$34,374 $40,507 
Short-term deferred revenues, net
$121,734 $118,947 
Long-term deferred revenues
58,622 37,385 
Total contract liabilities$180,356 $156,332 
_________________________________________________
(1)     Included in accounts receivable and unbilled receivables in the Consolidated Balance Sheets.
(2)    Included in other long-term assets in the Consolidated Balance Sheets.
Short-term deferred revenues, net of $121.7 million and $118.9 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $12.4 million and $15.8 million, as of December 31, 2023 and 2022, respectively. During the year ended December 31, 2023, the Company recognized revenues of $115.7 million that were included in the corresponding gross short-term deferred revenues balance of $134.7 million as of December 31, 2022.
Significant Customers
There were no customers that accounted for more than 10% of the Company’s total revenues for the years ended December 31, 2023, 2022, and 2021. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of December 31, 2023 and 2022.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income (Loss) Per Share
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Net Income Per Share Net Income (Loss) Per Share
Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method for share-based awards and warrants, and the if-converted method for convertible senior notes. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 11, Convertible Senior Notes. For periods prior to the adoption of ASU 2020-06 on January 1, 2022, the Company applied the treasury stock method to calculate the dilutive impact of the convertible senior notes. Upon adoption of ASU 2020-06, effective January 1, 2022, the Company applies the if-converted method for calculating the dilutive impact of the convertible senior notes. Following the Company’s irrevocable election in December 2021 to settle the principal portion of the convertible senior notes in cash with any conversion consideration in excess of the principal portion in cash and/or shares of the Company’s common stock at the Company’s option upon conversion, only the amounts expected to be settled in excess of the principal portion are considered dilutive in calculating earnings per share under the if-converted method. Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share.
The basic and diluted net income (loss) per share calculations for the years ended December 31, 2023, 2022, and 2021 were as follows:
Year Ended December 31,
202320222021
(In thousands, except per share data)
Net income (loss)$(20,371)$5,648 $77,849 
Weighted-average shares outstanding – basic45,212 44,398 43,475 
Effect of dilutive securities from stock award plans— 1,019 2,136 
Effect of convertible senior notes— 474 2,044 
Effect of warrants— — 288 
Weighted-average shares outstanding – diluted45,212 45,891 47,943 
Net income (loss) per share – basic$(0.45)$0.13 $1.79 
Net income (loss) per share – diluted$(0.45)$0.12 $1.62 
Anti-dilutive weighted-average shares related to stock award plans3,368 725 156 
Anti-dilutive weighted-average shares related to convertible senior notes and warrants11,816 5,908 — 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial InstrumentsThe Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of December 31, 2023 and 2022, the fair value of the convertible senior notes was $527.2 million and $501.4 million, respectively, compared to their carrying values of $569.7 million and $566.6 million, respectively, which are net of unamortized debt issuance costs. Refer to Note 10, Debt and Credit Agreement, for further information regarding the Company’s credit facility and Note 11, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Components
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Components Balance Sheet Components
Balance sheet details as of December 31, 2023 and 2022 are presented in the tables below:
December 31,
20232022
(In thousands)
Inventories:
Raw materials$51,439 $75,854 
Work in process1,327 9,280 
Finished goods57,333 62,415 
Total inventories$110,099 $147,549 
Other current assets:
Funds held for customers, including restricted cash (1)
$43,649 $56,703 
Net investment in sales-type leases, current portion11,867 11,486 
Prepaid income taxes8,279 1,702 
Other current assets7,714 7,471 
Total other current assets$71,509 $77,362 
Other long-term assets:
External-use software development costs, net$66,659 $80,760 
Unbilled receivables, net11,850 14,744 
Deferred debt issuance costs3,718 2,058 
Other long-term assets8,239 7,455 
Total other long-term assets$90,466 $105,017 
Accrued liabilities:
Operating lease liabilities, current portion$10,518 $10,761 
Customer fund liabilities43,649 56,703 
Advance payments from customers10,551 11,556 
Rebate liabilities51,277 42,802 
Group purchasing organization fees4,445 7,723 
Taxes payable2,191 9,642 
Other accrued liabilities26,645 33,468 
Total accrued liabilities$149,276 $172,655 
_________________________________________________
(1)    Includes restricted cash of $33.0 million and $22.5 million as of December 31, 2023 and 2022, respectively.
The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the years ended December 31, 2023 and 2022:
(In thousands)
Balance as of December 31, 2021$(8,407)
Other comprehensive loss(8,680)
Balance as of December 31, 2022(17,087)
Other comprehensive income3,655 
Balance as of December 31, 2023$(13,432)
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property and Equipment
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
The following table represents the property and equipment balances as of December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
Equipment$95,996 $91,391 
Furniture and fixtures4,500 5,154 
Leasehold improvements17,919 19,510 
Purchased software and internal-use software development costs118,004 76,327 
Construction in progress11,614 28,223 
Property and equipment, gross248,033 220,605 
Accumulated depreciation and amortization(139,432)(126,644)
Total property and equipment, net$108,601 $93,961 
Depreciation and amortization expense of property and equipment was $27.0 million, $22.8 million, and $20.1 million for the years ended December 31, 2023, 2022, and 2021, respectively.
The geographic location of the Company’s property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
United States$104,312 $89,989 
Rest of world (1)
4,289 3,972 
Total property and equipment, net$108,601 $93,961 
_________________________________________________
(1)    No individual country represented more than 10% of total property and equipment, net.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
External-Use Software Development Costs
 12 Months Ended
Dec. 31, 2023
Research and Development [Abstract]  
External-Use Software Development Costs External-Use Software Development Costs
The carrying amounts of external-use software development costs as of December 31, 2023 and 2022 were as follows:
December 31,
20232022
(In thousands)
Gross carrying amount$239,038 $225,004 
Accumulated amortization(172,379)(144,244)
External-use software development costs, net (1)
$66,659 $80,760 
_________________________________________________
(1)     Included in other long-term assets in the Consolidated Balance Sheets.
The Company recorded $28.7 million, $29.0 million, and $26.4 million to cost of revenues for amortization of external-use software development costs for the years ended December 31, 2023, 2022, and 2021, respectively.
The estimated future amortization expenses for external-use software development costs were as follows:
December 31, 2023
(In thousands)
2024$25,354 
202518,331 
202612,792 
20276,837 
20282,980 
Thereafter365 
Total$66,659
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Goodwill and Intangible Assets
Goodwill
The following table represents changes in the carrying amount of goodwill:
(In thousands)
Balance as of December 31, 2021$738,900 
Additions (1)
2,549 
Measurement period adjustments (1)
(3,770)
Foreign currency exchange rate fluctuations(3,405)
Balance as of December 31, 2022734,274 
Foreign currency exchange rate fluctuations1,536 
Balance as of December 31, 2023$735,810 
_________________________________________________
(1)     Refer to Note 2, Business Combinations, for further information.
Intangible Assets, Net
The carrying amounts and useful lives of intangible assets as of December 31, 2023 and 2022 were as follows:
December 31, 2023
Gross carrying
amount		Accumulated
amortization		Foreign currency exchange
rate fluctuations		Net carrying
amount		Useful life
(years)
(In thousands, except for years)
Customer relationships$307,418 $(115,232)$(1,326)$190,860 
4 - 30
Acquired technology84,876 (67,033)— 17,843 
4 - 20
Backlog1,800 (1,800)— — 2
Trade names9,200 (7,680)— 1,520 
5 - 12
Patents2,404 (1,454)— 950 
2 - 20
Total intangibles assets, net$405,698 $(193,199)$(1,326)$211,173 

December 31, 2022
Gross carrying
amount		Accumulated
amortization		 Foreign currency exchange
rate fluctuations		Net carrying
amount		Useful life
(years)
(In thousands, except for years)
Customer relationships$311,089 $(99,177)$(1,514)$210,398 
4 - 30
Acquired technology92,066 (64,299)— 27,767 
4 - 20
Backlog1,800 (900)— 900 2
Trade names9,200 (6,633)— 2,567 
5 - 12
Patents2,430 (1,306)— 1,124 
2 - 20
Non-compete agreements600 (450)— 150 3
Total intangibles assets, net$417,185 $(172,765)$(1,514)$242,906 
Amortization expense of intangible assets was $31.6 million, $35.2 million, and $26.5 million for the years ended December 31, 2023, 2022, and 2021, respectively.
The estimated future amortization expenses for amortizable intangible assets were as follows:
December 31,
2023
(In thousands)
2024$22,736 
202521,060 
202618,080 
202716,245 
202815,180 
Thereafter117,872 
Total$211,173 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt and Credit Agreement
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Debt and Credit Agreement Debt and Credit Agreement
On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental
Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Prior A&R Credit Agreement had an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings would be due and payable.
On September 22, 2020 and March 29, 2023, the Company entered into amendments to the Prior A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 11, Convertible Senior Notes, expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to borrowings under the A&R Credit Agreement with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics.
Subsequent to the March 29, 2023 amendment, loans under the Prior Revolving Credit Facility bore interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Prior A&R Credit Agreement), plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Prior A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for a one month tenor plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Prior Revolving Credit Facility were subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Prior Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Prior Incremental Facility would be determined prior to the incurrence of such loans. The Company was permitted to make voluntary prepayments at any time without payment of a premium or penalty.
The Prior A&R Credit Agreement contained customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Prior A&R Credit Agreement also contained financial covenants that required the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the Prior A&R Credit Agreement contained certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.
The Company entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) on October 10, 2023, with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million or 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable.
Loans under the Current Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Second A&R Credit Agreement), plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Second A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. Subject to the terms and conditions of the Current Revolving Credit Facility or Current Incremental Facility the Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The availability of funds under the Current Revolving Credit Facility may be subject to reduction in order to maintain compliance with the financial covenants under the Second A&R Credit Agreement.
The Second A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Second A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated secured net leverage ratio (not to exceed 3.00:1) and maintain a minimum consolidated interest coverage ratio (not to be less than 3.00:1). In addition, the Second A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.
The Company’s obligations under the Second A&R Credit Agreement and, at the election of the Company and the contracting counterparty, any secured swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the Second A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement.
The refinancing of the Prior Credit Agreement was evaluated in accordance with ASC 470-50, Debt - Modifications and Extinguishments. In determining whether the refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether lenders within the syndicate remained the same or changed and whether the changes in debt terms were substantial. This assessment was performed on an individual lender basis within the syndicate. As a result, the refinancing was accounted for as a modification with the exception of certain lenders that exited the syndicate. The exit of certain lenders resulted in an immaterial write-off of existing unamortized debt issuance costs. The remaining unamortized debt issuance costs related to debt modification, along with the new deferred costs, will be amortized over the remaining term of the Second A&R Credit Agreement.
In connection with the Second A&R Credit Agreement, the Company incurred and capitalized an additional $3.0 million of debt issuance costs. The debt issuance costs are being amortized to interest expense using the straight-line method through 2028.
As of December 31, 2023, the Company had $350.0 million of funds available under the Current Revolving Credit Facility and as of December 31, 2022, the Company had $500.0 million of funds available under the Prior Revolving Credit Facility. As of December 31, 2023 and 2022, the Company had no outstanding balance under the Prior or Current Revolving Credit Facility. The Company was in compliance with all covenants as of December 31, 2023.
Convertible Senior Notes
0.25% Convertible Senior Notes due 2025
On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted.
The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on
the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions.
During the three months ended December 31, 2023 and 2022, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the first quarter of 2024, commencing on January 1, 2024, and were not convertible during the first quarter of 2023, commencing on January 1, 2023. Accordingly, the Company classified the Notes as a long-term liability in its Consolidated Financial Statements as of December 31, 2023 and 2022. Whether the Notes will be convertible following the first fiscal quarter of 2024 will depend on the satisfaction of the conversion conditions in the future.
Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be.
If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of December 31, 2023, none of the criteria for a fundamental change or a conversion rate adjustment had been met.
As of September 20, 2023, the Company may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes.
The debt issuance costs associated with the Notes are being amortized to interest expense over the term of the Notes using an effective interest rate of 0.80%. As of December 31, 2023, the remaining life of the Notes and the related issuance cost accretion is approximately 1.7 years.
The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of December 31, 2023, the if-converted value of the Notes did not exceed the principal amount.
The Notes consisted of the following balances reported in the Consolidated Balance Sheets as of December 31, 2023 and 2022:
December 31,
20232022
Principal amount$575,000 $575,000 
Unamortized debt issuance costs(5,338)(8,429)
Convertible senior notes, net$569,662 $566,571 
The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021:
Year Ended December 31,
2023
2022 (1)
2021
(In thousands)
Contractual coupon interest$1,438 $1,438 $1,438 
Amortization of discount$— $— $18,608 
Amortization of debt issuance costs$3,091 $3,066 $2,343 
_________________________________________________
(1)    Refer to Note 1, Organization and Summary of Significant Accounting Policies, for further information regarding the adoption of ASU 2020-06, effective January 1, 2022.
Convertible Note Hedge and Warrant Transactions
In connection with the issuance of the Notes in September 2020, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock.
The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes.
Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Senior Notes
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Convertible Senior Notes Debt and Credit Agreement
On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental
Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Prior A&R Credit Agreement had an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings would be due and payable.
On September 22, 2020 and March 29, 2023, the Company entered into amendments to the Prior A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 11, Convertible Senior Notes, expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to borrowings under the A&R Credit Agreement with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics.
Subsequent to the March 29, 2023 amendment, loans under the Prior Revolving Credit Facility bore interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Prior A&R Credit Agreement), plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Prior A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for a one month tenor plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Prior Revolving Credit Facility were subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Prior Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Prior Incremental Facility would be determined prior to the incurrence of such loans. The Company was permitted to make voluntary prepayments at any time without payment of a premium or penalty.
The Prior A&R Credit Agreement contained customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Prior A&R Credit Agreement also contained financial covenants that required the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the Prior A&R Credit Agreement contained certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.
The Company entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) on October 10, 2023, with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million or 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable.
Loans under the Current Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Second A&R Credit Agreement), plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Second A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. Subject to the terms and conditions of the Current Revolving Credit Facility or Current Incremental Facility the Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The availability of funds under the Current Revolving Credit Facility may be subject to reduction in order to maintain compliance with the financial covenants under the Second A&R Credit Agreement.
The Second A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Second A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated secured net leverage ratio (not to exceed 3.00:1) and maintain a minimum consolidated interest coverage ratio (not to be less than 3.00:1). In addition, the Second A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.
The Company’s obligations under the Second A&R Credit Agreement and, at the election of the Company and the contracting counterparty, any secured swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the Second A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement.
The refinancing of the Prior Credit Agreement was evaluated in accordance with ASC 470-50, Debt - Modifications and Extinguishments. In determining whether the refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether lenders within the syndicate remained the same or changed and whether the changes in debt terms were substantial. This assessment was performed on an individual lender basis within the syndicate. As a result, the refinancing was accounted for as a modification with the exception of certain lenders that exited the syndicate. The exit of certain lenders resulted in an immaterial write-off of existing unamortized debt issuance costs. The remaining unamortized debt issuance costs related to debt modification, along with the new deferred costs, will be amortized over the remaining term of the Second A&R Credit Agreement.
In connection with the Second A&R Credit Agreement, the Company incurred and capitalized an additional $3.0 million of debt issuance costs. The debt issuance costs are being amortized to interest expense using the straight-line method through 2028.
As of December 31, 2023, the Company had $350.0 million of funds available under the Current Revolving Credit Facility and as of December 31, 2022, the Company had $500.0 million of funds available under the Prior Revolving Credit Facility. As of December 31, 2023 and 2022, the Company had no outstanding balance under the Prior or Current Revolving Credit Facility. The Company was in compliance with all covenants as of December 31, 2023.
Convertible Senior Notes
0.25% Convertible Senior Notes due 2025
On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted.
The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on
the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions.
During the three months ended December 31, 2023 and 2022, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the first quarter of 2024, commencing on January 1, 2024, and were not convertible during the first quarter of 2023, commencing on January 1, 2023. Accordingly, the Company classified the Notes as a long-term liability in its Consolidated Financial Statements as of December 31, 2023 and 2022. Whether the Notes will be convertible following the first fiscal quarter of 2024 will depend on the satisfaction of the conversion conditions in the future.
Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be.
If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of December 31, 2023, none of the criteria for a fundamental change or a conversion rate adjustment had been met.
As of September 20, 2023, the Company may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes.
The debt issuance costs associated with the Notes are being amortized to interest expense over the term of the Notes using an effective interest rate of 0.80%. As of December 31, 2023, the remaining life of the Notes and the related issuance cost accretion is approximately 1.7 years.
The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of December 31, 2023, the if-converted value of the Notes did not exceed the principal amount.
The Notes consisted of the following balances reported in the Consolidated Balance Sheets as of December 31, 2023 and 2022:
December 31,
20232022
Principal amount$575,000 $575,000 
Unamortized debt issuance costs(5,338)(8,429)
Convertible senior notes, net$569,662 $566,571 
The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021:
Year Ended December 31,
2023
2022 (1)
2021
(In thousands)
Contractual coupon interest$1,438 $1,438 $1,438 
Amortization of discount$— $— $18,608 
Amortization of debt issuance costs$3,091 $3,066 $2,343 
_________________________________________________
(1)    Refer to Note 1, Organization and Summary of Significant Accounting Policies, for further information regarding the adoption of ASU 2020-06, effective January 1, 2022.
Convertible Note Hedge and Warrant Transactions
In connection with the issuance of the Notes in September 2020, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock.
The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes.
Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessor Leases
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Lessor Leases Lessor Leases
Sales-Type Leases
The following table presents the Company’s income recognized from sales-type leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Sales-type lease revenues$36,208 $38,959 $21,887 
Cost of sales-type lease revenues(18,093)(19,359)(8,918)
Selling profit on sales-type lease revenues$18,115 $19,600 $12,969 
Interest income on sales-type lease receivables$2,475 $2,106 $1,869 
The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
Net minimum lease payments to be received$65,017 $50,755 
Less: Unearned interest income portion(10,196)(6,345)
Net investment in sales-type leases54,821 44,410 
Less: Current portion (1)
(11,867)(11,486)
Long-term investment in sales-type leases, net$42,954 $32,924 
_________________________________________________
(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Consolidated Balance Sheets.
The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.
The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Consolidated Balance Sheets was as follows:
December 31,
2023
(In thousands)
2024$14,504 
202512,385 
202610,113 
20278,369 
20287,281 
Thereafter12,365 
Total future minimum sales-type lease payments65,017 
Present value adjustment(10,196)
Total net investment in sales-type leases$54,821 
Operating Leases
The following table represents the Company’s income recognized from operating leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Rental income$6,591 $9,460 $10,467 
The maturity schedule of future minimum lease payments under operating leases was as follows:
December 31, 2023
(In thousands)
2024$3,547 
2025842 
2026763 
2027763 
2028571 
Total future minimum operating lease payments$6,486 
Lessor Leases Lessor Leases
Sales-Type Leases
The following table presents the Company’s income recognized from sales-type leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Sales-type lease revenues$36,208 $38,959 $21,887 
Cost of sales-type lease revenues(18,093)(19,359)(8,918)
Selling profit on sales-type lease revenues$18,115 $19,600 $12,969 
Interest income on sales-type lease receivables$2,475 $2,106 $1,869 
The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
Net minimum lease payments to be received$65,017 $50,755 
Less: Unearned interest income portion(10,196)(6,345)
Net investment in sales-type leases54,821 44,410 
Less: Current portion (1)
(11,867)(11,486)
Long-term investment in sales-type leases, net$42,954 $32,924 
_________________________________________________
(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Consolidated Balance Sheets.
The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.
The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Consolidated Balance Sheets was as follows:
December 31,
2023
(In thousands)
2024$14,504 
202512,385 
202610,113 
20278,369 
20287,281 
Thereafter12,365 
Total future minimum sales-type lease payments65,017 
Present value adjustment(10,196)
Total net investment in sales-type leases$54,821 
Operating Leases
The following table represents the Company’s income recognized from operating leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Rental income$6,591 $9,460 $10,467 
The maturity schedule of future minimum lease payments under operating leases was as follows:
December 31, 2023
(In thousands)
2024$3,547 
2025842 
2026763 
2027763 
2028571 
Total future minimum operating lease payments$6,486 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessee Leases
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Lessee Leases Lessee Leases
The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of one to twelve years. As of December 31, 2023, the Company did not have any additional material operating leases that were entered into, but not yet commenced.
The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Consolidated Balance Sheets was as follows:
December 31, 2023
(In thousands)
2024$12,722 
202510,609 
20269,715 
20278,070 
20287,650 
Thereafter1,834 
Total operating lease payments50,600 
Present value adjustment(6,172)
Total operating lease liabilities (1)
$44,428 
_________________________________________________
(1)    Amount consists of a current and long-term portion of operating lease liabilities of $10.5 million and $33.9 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities in the Consolidated Balance Sheets.
Operating lease costs were $10.8 million, $18.9 million, and $15.0 million for the years ended December 31, 2023, 2022, and 2021, respectively. Short-term lease costs and variable lease costs were not material for the years ended December 31, 2023, 2022, and 2021. During the year ended December 31, 2023, the Company recorded impairment and abandonment charges to operating lease right-of-use assets of $10.0 million, in connection with restructuring activities to reduce its real estate footprint and for optimization of certain leased facilities. The impairment and abandonment charges were recorded to selling, general, and administrative expenses on the Company’s Consolidated Statements of Operations. Refer to Note 18, Restructuring Expenses, for additional information regarding the Company’s restructuring activities.
The following table summarizes supplemental cash flow information related to the Company’s operating leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities$13,469 $16,452 $15,625 
Right-of-use assets obtained in exchange for new lease liabilities$6,431 $12,372 $5,503 
The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of December 31, 2023 and 2022:
December 31,
20232022
Weighted-average remaining lease term, years4.65.0
Weighted-average discount rate, %5.8 %5.7 %
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Purchase Obligations
In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of December 31, 2023, the Company had non-cancelable purchase commitments of $93.9 million, of which $84.2 million are expected to be paid within the next twelve months. 
Ransomware Incident
During the year ended December 31, 2023, the Company did not incur any material expenses or recoveries related to the previously disclosed ransomware incident in May 2022. During the year ended December 31, 2022, the Company incurred $13.6 million of expenses related to the ransomware incident, partially offset by $11.1 million of expected insurance recoveries. Expenses included costs to investigate and remediate the ransomware incident, as well as legal and other professional services, all of which were expensed as incurred. For the year ended December 31, 2022, the Company included net expenses related to the ransomware incident in cost of revenues of $0.3 million, in research and development of $0.2 million, and in selling general and administrative expenses of $2.0 million, in the Company’s Consolidated Statements of Operations.
As of December 31, 2023, the Company has incurred $13.6 million of cumulative expenses related to the ransomware incident since it was detected, partially offset by $12.2 million of insurance recoveries, all of which have been received as of December 31, 2023.
Legal Proceedings
The Company is currently involved in various legal proceedings.
As required under ASC 450, Contingencies, the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with any current legal proceedings based on its belief that any potential material loss, while reasonably possible, is not probable. Furthermore, any possible range of loss in such matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of legal proceedings or because of the diversion of management’s attention and the creation of significant expenses, regardless of outcome.
The Company is not a party to any legal proceedings that management believes may have a material impact on the Company’s financial position or results of operations.
Guarantees
Under the Company’s certificate of incorporation and bylaws, the Company has agreed to indemnify its directors and executive officers to the fullest extent not prohibited by Delaware and other applicable law, subject to certain exceptions. The Company has entered into individual indemnification agreements with its directors and officers. The term of the indemnification period is for the entirety of the director’s or officer’s service to the Company and continues so long as the director or officer may be subject to any claim, action, or proceeding, and there is no limit on the potential amount of future payments that the Company could be required to make under these indemnification agreements. The Company has purchased a directors’ and officers’ liability insurance policy that may enable it to recover a portion of any future payments that it may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits, and other policy provisions, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive and time-consuming litigation against the insurers.
Additionally, the Company undertakes indemnification obligations in its ordinary course of business in connection with, among other things, the sale or licensing of its products and the provision of its support services. In the ordinary course of the Company’s business, the Company has in the past and may in the future agree to indemnify another party, generally its business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, its gross negligence or intentional acts in the performance of services, and violations of laws. The term of these indemnification obligations is generally perpetual, but typically will not extend beyond the applicable statute of limitation pursuant to applicable law. In general, the Company attempts to limit the maximum potential amount of future payments that it may be required to make under these indemnification obligations to the amounts paid to it by a customer, but in some cases the obligation may not be so limited.
In addition, the Company has in the past and may in the future warrant to its customers that its products will conform to certain representations, which may include functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that its software media is free from material defects. Sales contracts for certain of the Company’s medication packaging systems may have in the past and may in the future include limited warranties for up to six months, but the periodic activity and ending warranty balances the Company records have historically not been material.
From time to time, the Company may also warrant that its professional services will conform to certain representations, which may include that such services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. The Company generally seeks to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality, and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive, or similar damages. In some states, such disclaimers may not be enforceable. If necessary, the Company would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. The Company has not been subject to any significant claims for such losses and has not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of December 31, 2023 and 2022.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Employee Benefits and Share-Based Compensation Employee Benefits and Share-Based Compensation
Stock Purchase Plan
1997 Employee Stock Purchase Plan
The Company has an Employee Stock Purchase Plan (“ESPP”), under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their earnings; provided, however, an eligible employee’s right to purchase shares of the Company’s common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period.
There was a total of 3.3 million shares reserved for future issuance under the ESPP as of December 31, 2023.
Stock Award Plans
2009 Equity Incentive Plan
The 2009 Equity Incentive Plan (“2009 Plan”), as amended, provides for the issuance of incentive stock options, RSAs, RSUs, PSUs, and other stock awards to the Company’s employees, directors, and consultants. There were 5.9 million shares of common stock reserved for future issuance under the 2009 Plan as of December 31, 2023.
Options granted under the 2009 Plan generally become exercisable over periods of up to four years, with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter. The exercise prices of the options is the fair market value of common stock on the date of grant. RSUs generally vest over periods of up to four years, with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 12 equal quarterly installments thereafter. Awards of restricted stock to non-employee directors are granted on the date of the annual meeting of stockholders and vest in full on the date of the next annual meeting of stockholders, provided such non-employee director remains a director on such date. PSUs granted to the Company’s executives may include performance and market conditions. PSUs become eligible for vesting when certain market or performance conditions are met.
Share-Based Compensation Expense
The following table sets forth the total share-based compensation expense recognized in the Company’s Consolidated Statements of Operations:
Year Ended December 31,
202320222021
(In thousands)
Cost of product and service revenues$8,288 $9,067 $7,994 
Research and development6,941 11,368 7,663 
Selling, general, and administrative40,071 47,812 37,503 
Total share-based compensation expense$55,300 $68,247 $53,160 
During the year ended December 31, 2023, the Company capitalized approximately $4.4 million of non-cash share-based compensation expense to internal-use and external-use software development costs related to internal labor. The Company did not capitalize any material non-cash share-based compensation expense to inventory during the years ended December 31, 2023, 2022, and 2021, or any material non-cash share-based compensation expense to internal-use and external-use software development costs during the years ended December 31, 2022 and 2021. Income tax benefit (expense) realized from share-based compensation was an expense of $6.5 million for the year ended December 31, 2023, and a benefit of $5.2 million and $26.6 million for the years ended December 31, 2022 and 2021, respectively.
Employee Stock Purchase Plan (“ESPP”)
The following assumptions were used to value shares under the ESPP for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
Expected life, years
0.5 - 2.0
0.5 - 2.0
0.5 - 2.0
Expected volatility, %
31.7% - 63.9%
28.8% - 45.6%
27.4% - 53.5%
Risk-free interest rate, %
0.1% - 5.5%
0.1% - 3.2%
0.1% - 2.6%
Dividend yield, %— %— %— %
For the years ended December 31, 2023 and 2022, employees purchased approximately 353,000 and 316,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $46.68 and $67.63, respectively. As of December 31, 2023, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $1.1 million and is expected to be recognized over a weighted-average period of 1.4 years.
Stock Options
The following assumptions were used to value stock options granted pursuant to the 2009 Plan for the years ended December 31, 2023 and 2021. There were no stock options granted during the year ended December 31, 2022:
Year Ended December 31,
20232021
Expected life, years3.24.9
Expected volatility, %44.8 %31.5 %
Risk-free interest rate, %3.7 %0.9 %
Estimated forfeiture rate, %10.0 %7.9 %
Dividend yield, %— %— %
The following table summarizes the stock option activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Exercise Price
Weighted-Average
Remaining Years
Aggregate
Intrinsic Value
(In thousands, except per share data)
Outstanding at December 31, 20222,434 $68.65 6.1$7,887 
Granted200 55.60 
Exercised(165)41.01 
Expired(242)79.49 
Forfeited(204)74.92 
Outstanding at December 31, 20232,023 $67.68 4.6$1,013 
Exercisable at December 31, 20231,784 $67.18 4.5$1,013 
Vested and expected to vest at December 31, 2023 and thereafter2,013 $67.64 4.6$1,013 
The weighted-average fair value per share of options granted during the years ended December 31, 2023 and 2021 was 19.48 and 35.17, respectively. The intrinsic value of options exercised during the years ended December 31, 2023, 2022, and 2021 was $3.2 million, $23.9 million, and $88.0 million, respectively. The tax benefit (expense) realized from stock options exercised was expense of $1.3 million for the year ended December 31, 2023, and benefit of $4.4 million and $18.3 million for the years ended December 31, 2022 and 2021, respectively.
As of December 31, 2023, total unrecognized compensation cost related to unvested stock options was $3.3 million, which is expected to be recognized over a weighted-average vesting period of 0.7 years.
Restricted Stock Units (“RSUs”)
The following table summarizes the RSU activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Grant Date Fair Value
Weighted-Average
Remaining Years
Aggregate
Intrinsic Value
(In thousands, except per share data)
Outstanding at December 31, 20221,117 $115.75 1.6$56,297 
Granted (Awarded)695 63.74 
Vested (Released)(335)113.64 
Forfeited(399)107.89 
Outstanding and unvested at December 31, 20231,078 $84.66 1.5$40,551 
The weighted-average grant date fair value per share of RSUs granted during the years ended December 31, 2023, 2022, and 2021 was $63.74, $111.12, and $149.65, respectively. The total fair value of RSUs that vested in the years ended December 31, 2023, 2022, and 2021 was $38.0 million, $30.7 million, and $16.7 million, respectively.
As of December 31, 2023, total unrecognized compensation cost related to RSUs was $64.3 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.0 years.
Restricted Stock Awards (“RSAs”)
The following table summarizes the RSA activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Grant Date Fair Value
(In thousands, except per share data)
Outstanding at December 31, 202213 $109.39 
Granted (Awarded)24 70.96 
Vested (Released)(13)109.39 
Outstanding and unvested at December 31, 202324 $70.96 
The weighted-average grant date fair value per share of RSAs granted during the years ended December 31, 2023, 2022, and 2021 was $70.96, $109.39, and $137.36, respectively. The total fair value of RSAs that vested in the years ended December 31, 2023, 2022, and 2021 was $1.4 million, $1.6 million, and $1.4 million, respectively.
As of December 31, 2023, total unrecognized compensation cost related to RSAs was $0.6 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.4 years.
Performance-Based Stock Unit Awards (“PSUs”)
During the year ended December 31, 2022, the Company granted 56,237 PSUs to its executive officers, none of which became eligible for vesting as the achievement of a certain level of shareholder return was not achieved. During the year ended December 31, 2023, the Company granted 65,000 PSUs to its executive officers, of which 0% to 200% may become eligible for vesting depending on the level of shareholder return for the period from March 1, 2023 through March 1, 2024.
The number of shares that vest at the end of the performance period depends on the percentile ranking of the total shareholder return for Omnicell stock over the performance period relative to the total shareholder return of each of the other companies in the NASDAQ Health Care Index. Stock price appreciation is calculated based on the trailing 20-day average stock price just prior to the first trading day of March in the grant year, compared to the trailing 20-day average stock price just prior to the first trading day of March in the year subsequent to the grant year.
PSUs generally vest over periods of up to four years, with one-fourth of the shares vesting approximately one year from the vesting commencement date with respect to initial grants and upon confirmation by the Compensation Committee that the performance target has been met, and the remaining shares generally vesting in equal semi-annual or quarterly installments over the remaining three years. Vesting is contingent upon continued service.
In addition to executive officers’ PSU awards, from time to time, the Company may grant PSUs with specific performance and service conditions to certain employees on an ad hoc basis.
The following table summarizes the PSU activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Grant Date Fair Value
(In thousands, except per share data)
Outstanding at December 31, 2022135 $147.42 
Granted65 122.29 
Vested(55)111.05 
Forfeited(70)153.77 
Outstanding and unvested at December 31, 202375 $127.14 
The weighted-average grant date fair value per share of PSUs granted during the years ended December 31, 2023, 2022, and 2021 was $122.29, $155.27, and $162.16, respectively. The total fair value of PSUs that vested in the years ended December 31, 2023, 2022, and 2021 was $6.1 million, $15.0 million, and $4.4 million, respectively.
As of December 31, 2023, total unrecognized compensation cost related to PSUs was approximately $5.0 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.4 years.
Summary of Shares Reserved for Future Issuance under Equity Incentive Plans
The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of December 31, 2023:
Number of Shares
(In thousands)
Stock options outstanding2,023 
Non-vested restricted stock awards1,177 
Shares authorized for future issuance2,669 
ESPP shares available for future issuance3,250 
Total shares reserved for future issuance9,119 
401(k) Plan
The Company has established a pre-tax savings plan under Section 401(k) of the Internal Revenue Code of 1986, as amended. The 401(k) Plan allows eligible employees in the United States to voluntarily contribute a portion of their pre-tax salary, subject to a maximum limit specified in the Internal Revenue Code. The Company generally matches 50% of employee contributions up to $3,000, annually. The Company’s contributions under this plan were $7.9 million, $8.1 million, and $6.8 million in the years ended December 31, 2023, 2022, and 2021, respectively.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock Repurchase Programs
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Stock Repurchase Programs Stock Repurchase Programs
On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2014 Repurchase Program”). During the year ended December 31, 2022, the 2014 Repurchase Program was completed, and as of December 31, 2023, the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million.
The timing, price, and volume of repurchases are to be based on market conditions, relevant securities laws, and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions, or pursuant to a Rule 10b-18 plan, subject to the terms and conditions of that certain A&R Credit Agreement, as amended. The 2016 Repurchase Program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the 2016 Repurchase Program at any time.
During the year ended December 31, 2022, the Company repurchased approximately 389,300 shares of its common stock under the repurchase programs at an average price of $134.11 per share for an aggregate purchase price of approximately $52.2 million. During the years ended December 31, 2023 and 2021, the Company did not repurchase any of its outstanding common stock under the stock repurchase programs.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The following is a geographical breakdown of income (loss) before income taxes:
Year Ended December 31,
202320222021
(In thousands)
Domestic$(28,105)$369 $67,103 
Foreign7,997 (2,822)(1,096)
Income (loss) before income taxes$(20,108)$(2,453)$66,007 
The provision for (benefit from) income taxes consisted of the following:
Year Ended December 31,
202320222021
(In thousands)
Current:
Federal$8,556 $17,973 $(7,841)
State1,471 8,024 187 
Foreign840 192 (234)
Total current income taxes10,867 26,189 (7,888)
Deferred:
Federal(8,002)(25,753)(2,708)
State(2,261)(7,976)(1,217)
Foreign(341)(561)(29)
Total deferred income taxes(10,604)(34,290)(3,954)
Total provision for (benefit from) income taxes$263 $(8,101)$(11,842)
The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows:
Year Ended December 31,
202320222021
(In thousands)
U.S. federal tax provision at statutory rate$(4,223)$(515)$13,861 
State taxes(624)38 (814)
Section 162(m) limitation1,286 3,071 6,382 
Non-deductible expenses531 134 363 
Uncertain tax positions(620)(776)(835)
Share-based compensation tax expense (benefit)7,384 (3,264)(20,717)
Research tax credits(4,587)(6,948)(5,170)
Restructuring impact— — (6,116)
Foreign-derived intangible income deduction(325)(753)(68)
Global intangible low-taxed income inclusion— 960 195 
Foreign rate differential219 186 (170)
Foreign branch taxes6 (51)(9)
Transaction cost— 68 1,097 
Provision to return true up697 (84)205 
State rate true up528 (135)(80)
Other(9)(32)34 
Total provision for (benefit from) income taxes$263 $(8,101)$(11,842)
On August 16, 2022, the Inflation Reduction Act of 2022, (the “IRA”), was signed into law. Among other things, the IRA imposes a 15% corporate alternative minimum tax for tax years beginning after December 31, 2022, levies a 1% excise tax on net stock repurchases after December 31, 2022, and provides tax incentives to promote clean energy. The provisions of the IRA did not have a material impact on the Company’s results of operations or financial position.
The Organization for Economic Co-Operation and Development (“OECD”) introduced Base Erosion and Profit Shifting (“BEPS”) Pillar Two rules that impose a global minimum tax rate of 15% on multi-national corporations. The rules are effective for the Company’s financial year beginning January 1, 2024. Numerous countries have enacted or substantively enacted legislation to implement these rules. While the Company does not expect Pillar Two to have a material impact on its tax provision or effective tax rate, the Company continues to monitor evolving tax legislation in the jurisdictions in which it operates.
Significant components of the Company’s deferred tax assets (liabilities) were as follows:
December 31,
20232022
(In thousands)
Deferred tax assets (liabilities):
Deferred revenues$11,343 $13,514 
Share-based compensation11,763 12,064 
Inventory-related items5,136 4,567 
Tax credit carryforwards12,505 12,173 
Reserves and accruals5,660 6,244 
Loss carryforwards7,802 10,255 
Lease liability11,457 12,884 
Convertible debt9,649 15,037 
Capitalized research and development41,635 30,881 
Other, net591 1,557 
Gross deferred tax assets117,541 119,176 
Valuation allowance— — 
Total net deferred tax assets117,541 119,176 
Intangibles(30,366)(36,357)
Depreciation and amortization(35,402)(37,286)
Prepaid expenses(13,858)(15,574)
Right-of-use assets(6,626)(9,725)
Other, net(8)— 
Total deferred tax liabilities(86,260)(98,942)
Net deferred tax assets $31,281 $20,234 
Deferred income tax assets (liabilities) are provided for temporary differences that will result in future tax deductions or future taxable income, as well as the future benefit of tax credit carryforwards. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. As of December 31, 2023 and 2022, the Company does not have a valuation allowance against any of its deferred tax assets.
As of December 31, 2023, the Company had no federal net operating loss carryforward, $19.0 million of state net operating loss carryforwards expiring at various dates beginning in 2029, and $22.3 million of foreign net operating losses carried forward indefinitely. For income tax purposes, the Company had no federal research tax credit carryforward and a California research tax credit carryforward of $20.9 million. California research tax credits are carried forward indefinitely to reduce cash taxes payable.
It is the Company’s practice and intention to reinvest the earnings of its non-U.S. subsidiaries in those operations. As of December 31, 2023, the Company has not made a provision for U.S. federal income, withholding, and state income taxes on the outside basis difference related to certain foreign subsidiaries because earnings are intended to be indefinitely reinvested in operations outside the U.S.
The Company files income tax returns in the United States and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, France, the United Kingdom and India. With few exceptions, as of December 31, 2023, the Company was no longer subject to U.S., state, and foreign tax examinations for years before 2020, 2019, and 2019, respectively.
The aggregate change in the balance of gross unrecognized tax benefit, which excludes interest and penalties, for the years ended December 31, 2023, 2022, and 2021:
(In thousands)
Balance as of December 31, 2020$18,246 
Increases related to tax positions taken during a prior period40 
Decreases related to tax positions taken during the prior period(8,908)
Increases related to tax positions taken during the current period1,219 
Decreases related to expiration of statute of limitations(1,636)
Balance as of December 31, 20218,961 
Increases related to tax positions taken during a prior period3 
Decreases related to tax positions taken during the prior period(59)
Increases related to tax positions taken during the current period1,629 
Decreases related to expiration of statute of limitations(1,238)
Balance as of December 31, 20229,296 
Increases related to tax positions taken during a prior period
750 
Decreases related to tax positions taken during the prior period(161)
Increases related to tax positions taken during the current period1,566 
Decreases related to expiration of statute of limitations(703)
Balance as of December 31, 2023$10,748 
The total amount of gross unrecognized tax benefit that, if realized, would favorably affect the Company’s effective income tax rate in future periods, was $10.7 million and $9.3 million as of December 31, 2023 and 2022, respectively. The Company recognizes interest and penalties related to uncertain tax positions in interest and other income (expense), net in the Consolidated Statements of Operations, accruing $0.2 million, $0.2 million, and $0.3 million for the years ended December 31, 2023, 2022, and 2021, respectively. Accrued interest and penalties are included within other long-term liabilities on the Consolidated Balance Sheets. The combined amount of cumulative accrued interest and penalties was approximately $0.4 million, $0.2 million, and $0.6 million for the years ended December 31, 2023, 2022, and 2021, respectively. The Company does not believe there will be any significant changes in its unrecognized tax positions over the next twelve months.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring Expenses
 12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring Expenses Restructuring Expenses
During the first quarter of 2021, the Company continued its organizational realignment initiative that was announced in 2020, incurring $2.0 million of employee severance costs and related expenses.
During the first quarter of 2022, the Company initiated certain domestic and international restructuring initiatives in order to enhance and streamline certain engineering functions for its domestic operations and to realign its international sales organization to better serve its customers in various international markets. During the third quarter of 2022, the Company initiated restructuring initiatives associated with the integration and functionalization of certain acquisitions, primarily the 340B Link business acquisition, to further accelerate the expansion of the Company’s pharmacy inventory management capabilities. On November 23, 2022, the Company committed to a plan to reduce the Company’s headcount (“the 2022 Plan”) as part of the Company’s expense containment efforts being implemented due to ongoing macroeconomic headwinds, primarily consisting of employee severance and benefits costs. During the year ended December 31, 2022, the restructuring plans incurred $22.8 million of employee severance costs and related expenses. As of December 31, 2023, there was no material unpaid balance related to these restructuring plans.
During the first quarter of 2023, as a result of continued exploration of expense containment measures, the Company committed to further reduce its headcount across many of its functions as a continuation of the 2022 Plan, and also committed to reduce its real estate footprint to align with its broader hybrid work strategy and in an effort to further reduce costs. During the year ended December 31, 2023, the Company recorded an immaterial reversal of previously recognized restructuring expenses associated with the 2022 Plan.
On November 2, 2023, the Company committed to a plan to reduce the Company’s headcount and real estate footprint (the “2023 Plan”) as part of the Company’s expense containment initiatives and other actions to reduce discretionary spending being implemented due to challenging industry dynamics and macroeconomic conditions. During the year ended December 31,
2023, the restructuring plans incurred $15.5 million of employee severance costs and related expenses, net of reversals. As of December 31, 2023, the unpaid balance related to these restructuring plans was $8.9 million.
Refer to Note 13, Lessee Leases for information regarding the Company’s restructuring activities for the reduction of its real estate footprint and optimization of certain leased facilities.
The following table summarizes the total employee-related restructuring expenses recognized in the Company’s Consolidated Statements of Operations for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Cost of product and service revenues$3,089 $8,018 $389 
Research and development3,829 3,615 105 
Selling, general, and administrative8,621 11,170 1,526 
Total restructuring expenses, net of reversals$15,539 $22,803 $2,020 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule II Valuation and Qualifying Accounts
 12 Months Ended
Dec. 31, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II Valuation and Qualifying Accounts
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS
Balance at
Beginning of Period (1)
Charged (Credited) to
Costs and Expenses (2)
Amounts
Written Off (3)
Other Adjustments (4)
Balance at
End of Period (1)
(In thousands)
Year ended December 31, 2021
Accounts receivable and unbilled receivables$4,286 $2,130 $(2,079)$935 $5,272 
Long-term unbilled receivables30 (4)— — 26 
Net investment in sales-type leases265 (37)— — 228 
Total allowances deducted from assets$4,581 $2,089 $(2,079)$935 $5,526 
Year ended December 31, 2022
Accounts receivable and unbilled receivables$5,272 $2,658 $(2,551)$(226)$5,153 
Long-term unbilled receivables26 9 — — 35 
Net investment in sales-type leases228 80 — — 308 
Total allowances deducted from assets$5,526 $2,747 $(2,551)$(226)$5,496 
Year ended December 31, 2023
Accounts receivable and unbilled receivables$5,153 $2,726 $(2,441)$126 $5,564 
Long-term unbilled receivables35 (4)— 31 
Net investment in sales-type leases308 (51)— — 257 
Total allowances deducted from assets$5,496 $2,671 $(2,441)$126 $5,852 
__________________________________________________
(1)Allowance for credit losses.
(2)Represents amounts charged and credited for provisions for credit losses.
(3)Represents amounts written off from the allowance and receivable.
(4)Represents other adjustments, such as foreign currency translation and purchase price accounting adjustments in connection with acquisitions.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure      
Net income (loss) $ (20,371) $ 5,648 $ 77,849
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Organization and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations, and cash flows for the periods presented.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying Notes to Consolidated Financial Statements. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. Those policies are revenue recognition; allowance for credit losses for accounts receivable and unbilled receivables; notes receivable from investment in sales-type leases; operating lease right-of-use assets and liabilities; inventory valuation; internal-use and external-use software development costs; impairment of goodwill; purchased intangibles and long-lived assets; fair value of assets acquired and liabilities assumed in business combinations; share-based compensation; and accounting for income taxes.
Segment Reporting
The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.
Foreign Currency Translation and Remeasurement
Most of the Company’s foreign subsidiaries use the local currency of their respective countries as their functional currency. The Company translates the assets and liabilities of such non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income (loss) in stockholders’ equity.
Assets and liabilities denominated in a currency other than the functional currency are remeasured into the respective entity’s functional currency. Monetary assets and liabilities are remeasured at exchange rates in effect at the end of each period, and non-monetary assets and liabilities are remeasured at historical rates. Gains and losses from foreign currency remeasurement of monetary assets and liabilities are recorded in interest and other income (expense), net.
Revenue Recognition and Shipping Costs
The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories:
Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service.
Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions.
Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements.
Advanced Services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth®, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service.
The following table summarizes revenue recognition for each revenue category:
Revenue Category
Timing of Revenue Recognition
Income Statement Classification
Connected devices, software licenses, and other
Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer
Product
Consumables
Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer
Product
Technical services
Over time, as services are provided, typically ratably over the service term
Service
Advanced Services
Over time, as services are provided
Service
Prior to recognizing revenue, the Company identifies the contract, performance obligations, and transaction price, and allocates the transaction price to the performance obligations. All identified contracts meet the following required criteria:
Parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations. A majority of the Company’s contracts are evidenced by a non-cancelable written agreement. Contracts for consumable products are generally evidenced by an order placed via our online portal, phone, or a purchase order.
Entity can identify each party’s rights regarding the goods or services to be transferred. Contract terms are documented within the written agreements. Where a written contract does not exist, such as for consumable products, the rights of each party are understood as following the Company’s standard business process and terms.
The entity can identify the payment terms for the goods or services to be transferred. Payment terms are documented within the agreement and are generally net 30 to 60 days from shipment of tangible product or services performed for customers in the United States. Where a written contract does not exist, the Company’s standard payment terms are net 30 day terms.
The contract has commercial substance (that is the risk, timing, or amount of the entity’s future cash flows is expected to change as a result of the contract). The Company’s agreements are an exchange of cash for a combination of products and services which result in changes in the amount of the Company’s future cash flows.
It is probable the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company performs a credit check for all significant customers or
transactions and where collectability is not probable, payment in full or a substantial down payment prior to shipment is typically required to help ensure the full agreed upon contract price will be collected.
Distinct goods or services are identified as performance obligations. A series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer are considered a single performance obligation. Where a good or service is determined not to be distinct, the Company combines the good or service with other promised goods or services until a bundle of goods or services that is distinct is identified. To identify its performance obligations, the Company considers all products or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. When performance obligations are included in separate contracts, the Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Most of the Company’s sales, other than renewals of support and maintenance, contain multiple performance obligations, with a combination of hardware systems, software products, support and maintenance, and professional services.
The transaction price of a contract is determined based on the fixed consideration, net of an estimate for variable consideration such as various discounts or rebates provided to customers. As a result of the Company’s commercial selling practices, contract prices are generally fixed with minimal, if any, variable consideration.
The transaction price is allocated to separate performance obligations proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.
The Company recognizes revenue when the performance obligation has been satisfied by transferring a promised good or service to a customer. The good or service is transferred when or as the customer obtains control of the good or service. Determining when control transfers requires management to make judgments that affect the timing of revenues recognized. Generally, for products requiring a complex implementation, control passes when the product is installed and ready for use. For all other products, control generally passes when product has been shipped and title has passed. For maintenance contracts and certain other services, including Advanced Services provided on a subscription basis, control passes to the customer over time, generally ratably over the service term as the Company provides a stand-ready service for the customer’s equipment. Time and material services transfer control to the customer at the time the services are provided.
The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues, net of deferred cost of goods sold. Deferred revenues from product sales primarily relate to delivered and invoiced products, pending installation and acceptance. Deferred revenues from service contracts primarily relate to services that have been invoiced, where services have not yet been provided. Short-term deferred revenues are expected to be recognized within the next twelve months. Long-term deferred revenues substantially consist of deferred revenues on long-term technical and Advanced Services contracts which have been invoiced and are expected to be recognized as revenue beyond twelve months, generally not more than ten years.
In addition, the Company has remaining performance obligations associated with contracts for which the associated products have been accepted or associated services have started, but where invoicing has not yet occurred and therefore are not reflected in deferred revenue. These remaining performance obligations are comprised of the non-variable portions of technical services and Advanced Services provided under non-cancellable contracts with minimum commitments. Remaining performance obligations which are not included in deferred revenues are $353.9 million as of December 31, 2023. Remaining performance obligations are expected to be recognized ratably over the remaining terms of the associated contracts, which terms vary but are generally not more than ten years. Remaining performance obligations do not include product obligations, services where the associated product has not been accepted, services which have not yet started, variable portions of services, and certain other obligations.
Revenues, contract assets, and contract liabilities are recorded net of associated taxes.
The Company generally invoices customers for products upon shipment. Invoicing associated with the service portion of agreements is generally periodic and is billed on a monthly, quarterly, or annual basis, and in certain circumstances, multiple years are billed at one time. Advanced Services agreements are generally invoiced periodically on a monthly, quarterly or annual basis over the life of the agreement. In certain circumstances portions of these agreements may be invoiced lump sum.
The amount invoiced for equipment and software is typically reflected in both accounts receivable and deferred revenues, net. The Company typically recognizes product revenue, and correspondingly reduces deferred revenues, net, for equipment and on-premise software upon written customer acceptance of installation. Consumables are recorded as revenue upon shipment to or receipt by the customer, depending upon contract terms.
From time to time, the Company enters into change orders which modify the product to be received by the customer pursuant to certain contracts. Changes to any contract are accounted for as a modification of the existing contract to the extent the goods and services to be delivered as part of the contract are generally consistent with the nature and type of those to be provided under the terms of the original contract. Examples of such change orders include the addition or removal of units of equipment or changes to the configuration of the equipment where the overall nature of the contract remains intact. The Company’s change orders generally result in the change being accounted for as modifications of existing contracts given the nature of the impacted orders.
In the normal course of business, the Company typically does not accept product returns unless the item is defective as manufactured or the configuration of the product is incorrect. The Company establishes provisions for estimated returns based on historical product returns. The allowance for sales returns is not material to the Consolidated Financial Statements for any periods presented.
A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”), each of which functions as a purchasing agent on behalf of member hospitals and other healthcare providers. The Company also has a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”), allowing the Department of Veterans Affairs, the Department of Defense, and other federal government customers to purchase the Company’s products. Pursuant to the terms of GPO agreements and the GSA Contract, each member or agency contracts directly with Omnicell and can purchase the Company’s products at pre-negotiated contract terms and pricing. GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $11.2 million, $17.6 million, and $17.5 million for the years ended December 31, 2023, 2022, and 2021, respectively. The accounts receivable balances are with individual members of the GPOs and federal agencies that purchase under the GSA Contract, and therefore no significant concentration of credit risk exists. During the year ended December 31, 2023, sales to members of the ten largest GPOs and federal agencies that purchase under the GSA Contract accounted for approximately 64% of the Company’s total consolidated revenues.
Contract Assets and Contract Liabilities
A contract asset is a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration. A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. Contract liabilities include customer deposits under non-cancelable contracts, and current and non-current deferred revenue balances. The Company’s contract balances are reported in a net contract asset or liability position on a contract-by-contract basis at the end of each reporting period.
Significant changes in the contract assets and the contract liabilities balances during the period are the result of the issuance of invoices and recognition of deferred revenues in the normal course of business. The contract modifications entered into during the year ended December 31, 2023 did not have a significant impact on the Company’s contract assets or deferred revenues.
Contract Costs
The Company has determined that certain incentive portions of its sales commission plans require capitalization since these payments are directly related to sales achieved during a time period. These commissions are earned on the basis of: (i) the value of new bookings for connected devices, software products, and Advanced Services, provided that for Advanced Services a commission will only be paid on the amount that represents the minimum commitment and (ii) the value of new orders for consumables. Since there are no commensurate commissions earned on renewal of the service bookings, the Company concluded that the capitalized asset is related to services provided under both the initial contract and renewal periods. The Company applies a practical expedient to account for the incremental costs of obtaining a contract as part of a portfolio of contracts with similar characteristics as the Company expects the effect on the financial statements of applying the practical expedient would not differ materially from applying the accounting guidance to the individual contracts within the portfolio. A pool of contracts is defined as all contracts booked in a particular quarter. The amortization for the capitalized asset is an estimate of the pool’s original contract term, generally one to five years, plus an estimate of future customer renewal periods resulting in a total amortization period of ten years. Costs to obtain a contract are allocated amongst performance obligations and recognized as sales and marketing expense consistent with the pattern of revenue recognition. In accordance with GAAP, while certain compensation elements are expensed as incurred, a portion of the pool’s capitalized asset is recorded as an expense over the first seven quarters after booking, which represents the estimated period during which the product revenue associated with the contract is recorded. The remaining capitalized contract costs are recorded as expense ratably over the ten
year estimated initial and renewal service periods.Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general, and administrative expense.
Lessor Leases
The Company determines if an arrangement is or contains a lease at inception. The transaction price is allocated to separate performance obligations, generally consisting of a combination of hardware systems, software products, support and maintenance, and professional services, proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.
Sales-Type Leases
The Company enters into non-cancelable sales-type lease arrangements with the leases varying in length from one to ten years, most of which do not have an option to extend the lease term. At the end of the lease term, the customer must either return the equipment or negotiate a new agreement, resulting in a new purchase or lease transaction. Failure of the customer to either return the equipment or negotiate a new agreement results in the contract becoming a month-to-month rental. Certain sales-type leases automatically renew for successive one-year periods at the end of each lease term without written notice from the customer. The Company’s sales-type lease agreements do not contain any material residual value guarantees.
For sales-type leases, the Company recognizes revenues for its hardware and software products, net of lease execution costs, post-installation product maintenance, professional services associated with Advanced Services offerings, and technical support, at the net present value of the lease payment stream upon customer acceptance. The Company recognizes service revenues associated with sales-type leases ratably over the term of the agreement in service revenues in the Consolidated Statements of Operations. The Company recognizes interest income from sales-type leases using the effective interest method. Both hardware and software revenues, and interest income from sales-types leases are recorded in product revenues in the Consolidated Statements of Operations.
The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold.
Allowance for Credit Losses
The Company is exposed to credit losses primarily through sales of its products and services, as well as its sales-type leasing arrangements. The Company performs credit evaluations of its customers’ financial condition in order to assess each customer’s ability to pay. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history, and a financial review of the customer. The Company continues to monitor customers’ creditworthiness on an ongoing basis.
The Company maintains an allowance for credit losses for accounts receivable, unbilled receivables, and net investment in sales-type leases based on expected credit losses resulting from the inability of its customers to make required payments. The allowance for credit losses is measured using a loss rate method, considering factors such as customers’ credit risk, historical loss experience, current conditions, and forecasts. The allowance for credit losses is measured on a collective (pool) basis by aggregating customer balances with similar risk characteristics. The Company also records a specific allowance based on an analysis of individual past due balances or customer-specific information, such as a decline in creditworthiness or bankruptcy. Actual collection losses may differ from management’s estimates, and such differences could be material to the Company’s financial position and results of operations.
The allowance for credit losses is presented in the Consolidated Balance Sheets as a deduction from the respective asset balance. As of December 31, 2023 and 2022, the allowance for credit losses for long-term unbilled receivables and net investment in sales-type leases were not material.
Funds Held for Customers and Customer Fund Liabilities
The Company offers certain products and services in which it is customary for pharmacies or insurance payors to owe funds to the Company which are collected on behalf of, and, after a short holding period, disbursed to, the Company’s customers. The Company presents amounts due from pharmacies and amounts due to be disbursed to customers on a gross basis within other current assets and accrued liabilities, respectively, in the Consolidated Balance Sheets, as such amounts are expected to be settled within one year. Generally, any funds received from the pharmacies or insurance payors that are held by the Company are segregated from its other corporate cash accounts. These funds are classified as restricted cash as the Company is contractually obligated to disburse these amounts to customers.
Sales of Accounts Receivable The Company records the sale of its accounts receivables in accordance with accounting guidance for transfers and servicing of financial assets.
Cash and Cash Equivalents The Company classifies all highly-liquid investments with original maturities of three months or less as cash equivalents. The Company’s cash and cash equivalent balances include bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with financial institutions of high credit quality. The Company continuously monitors the credit worthiness of the financial institutions in which it invests. The Company has not experienced any credit losses from its cash equivalents.
Financial Instruments
For assets and liabilities measured at fair value, the amounts are based on an expected exit price representing the amount that would be received from the sale of an asset or paid to transfer a liability in a transaction between market participants. The fair value may be based on assumptions that market participants would use in pricing an asset or liability. ASC 820, Fair Value Measurement, establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs used in valuation techniques are assigned a hierarchical level, as follows:
Level 1 – Observable inputs, such as quoted prices in active markets for identical instruments;
Level 2 – Quoted prices for similar instruments in active markets, or quoted prices for identical instruments in inactive markets; and
Level 3 – Unobservable inputs for financial instruments reflecting Company’s assumptions.
Inventory
Inventories are stated at the lower of cost, computed using the first-in, first-out method, and net realizable value. Inbound shipping costs are included in cost of inventory. The Company regularly monitors inventory quantities on hand and records write-downs for excess and obsolete inventories based on the Company’s estimate of demand for its products, potential obsolescence of technology, product life cycles, and whether pricing trends or forecasts indicate that the carrying value of inventory exceeds its estimated selling price. These factors are impacted by market and economic conditions, technology changes, and new product introductions and require estimates that may include elements that are uncertain. Actual demand may differ from forecasted demand and may have a material effect on gross margins. If inventory is written down, a new cost basis is established that cannot be increased in future periods. Shipments from suppliers or contract manufacturers before the Company receives them are recorded as in-transit inventory when title and the significant risks and rewards of ownership have passed to the Company.
The Company has a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in its hardware products. There are no minimum purchase requirements. The
contract with the Company’s supplier may be terminated by either the supplier or by the Company without cause and at any time upon delivery of six months’ notice.
Property and Equipment
Property and equipment less accumulated depreciation are stated at historical cost. The Company’s expenditures for property and equipment are primarily for computer equipment and software used in the administration of its business, and for leasehold improvements to its leased facilities. The Company also develops molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components.
The Company capitalizes costs related to computer software developed or obtained for internal-use in accordance with ASC 350-40, Internal-Use Software. Software developed or obtained for internal-use includes certain costs for the development of the Company’s subscription and cloud-based offerings sold to its customers, as well as enterprise-level business and finance software that the Company customizes to meet its specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. The Company capitalized $32.2 million and $33.0 million of costs related to the application development of enterprise-level software and its subscription and cloud-based offerings, which are included in property and equipment during the years ended December 31, 2023 and 2022, respectively. Capitalized costs related to computer software developed or obtained for internal-use are included in purchases of property and equipment in the Consolidated Statements of Cash Flows.
External-Use Software Development Costs The Company capitalizes certain software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed, under which those costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. The Company establishes technological feasibility when it completes a detail program design or a working model. The Company amortizes development costs over the estimated lives of the related products, which is generally five years. All development costs prior to the completion of a detail program design or a working model are recognized as research and development expense.
Lessee Leases
The Company determines if an arrangement is or contains a lease at inception. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of its lease contracts do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available at the commencement date in determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize a right-of-use asset and a lease liability for leases with an initial term of twelve months or less. The Company elected the practical expedient to not separate lease components from nonlease components and applied that practical expedient to all material classes of leased assets.
Many of the Company’s operating leases include an option to extend the lease. The specific terms and conditions of the extension options vary from lease to lease, but are consistent with standard industry practices in each area that the Company operates. The Company reviews each of its lease options at a time required by the terms of the lease contract, and notifies the
lessor if it chooses to exercise the lease renewal option. Until the Company is reasonably certain that it will extend the lease contract, the renewal option periods will not be recognized as right-of-use assets or lease liabilities.
Certain leases include provisions for early termination, which allow the contract parties to terminate their obligations under the lease contract. The terms and conditions of the termination options vary by contract. When the Company has made a decision to exercise an early termination option, the right-of-use assets and associated lease liabilities are remeasured in accordance with the present value of the remaining cash flows under the lease contract.
Certain building lease agreements include rental payments subject to change annually based on fluctuations in various indexes (i.e., Consumer Price Index (“CPI”), Retail Price Index, and other international indexes). Certain data center lease agreements include rental payments subject to change based on usage and CPI fluctuations. The changes based on usage and indexes are treated as variable lease costs and recognized in the period in which the obligation for those payments was incurred. 
The Company’s operating lease agreements do not contain any material residual value guarantees, restrictions, or restriction covenants.
Business Combinations
The Company uses the acquisition method of accounting under ASC 805, Business Combinations. Each acquired company’s operating results are included in the Company’s Consolidated Financial Statements starting on the acquisition date. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the acquisition date are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed.
Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on available historical information as well as future expectations, and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, acquired technology, backlog, trade names, and non-compete agreements.
The Company’s Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Consolidated Statements of Operations.
The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions.
The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions.
The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization.
Goodwill and Acquired Intangible Assets
Goodwill
The Company assesses goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. This assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. The Company has one reporting unit, which is the same as its operating segment. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. A qualitative assessment includes, among others, consideration of: (i) past, current, and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this qualitative assessment indicates that it is more likely than not that impairment exists, or if the Company decides to bypass this option, it proceeds to the quantitative assessment. The quantitative assessment involves a comparison between the estimated fair value of the Company’s reporting unit with its carrying amount including goodwill. If the carrying value exceeds estimated fair value, the Company will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill.
To determine the reporting unit’s fair value under the quantitative approach, the Company uses a combination of income and market approaches, such as estimated discounted future cash flows of the reporting unit, multiples of earnings or revenues, and analysis of recent sales or offerings of comparable entities. The Company also considers its market capitalization on the date of the analysis to ensure the reasonableness of its reporting unit’s fair value.
The Company elected to perform a quantitative impairment assessment analysis as of October 1, 2023 for its reporting unit. The Company determined that the fair value of the reporting unit exceeded the carrying value and thus no impairment was indicated. Based on the result of this analysis, an impairment does not exist as of December 31, 2023, and there were no accumulated impairment losses.
Intangible Assets
In connection with its acquisitions, the Company generally recognizes assets for customer relationships, acquired technology, backlog, trade names, and non-compete agreements. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets. Amortization for acquired technology and backlog is recognized in cost of revenues, and amortization for customer relationships, trade names, non-compete agreements, and patents is recognized in selling, general, and administrative expenses.
The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. The Company’s cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of the Company’s intangible assets are subjective and are affected by changes to its business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of the Company’s assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on the Company’s operating results and financial condition.
Convertible Debt
The Company accounts for convertible debt and related transactions in accordance with ASC 470-20, Debt with Conversion and Other Options, ASC 815, Derivatives and Hedging, and ASC 480, Distinguishing Liabilities from Equity. The Company evaluates convertible debt instruments and related transactions at inception to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for.
Prior to the adoption of Accounting Standards Update (“ASU”) 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner. The difference between the principal amount of the convertible senior notes and the liability component, inclusive of issuance costs, represented the debt discount, which the Company amortized to interest expense over the term of the convertible senior notes. The determination of the discount rate required certain estimates and assumptions.
Upon adoption of ASU 2020-06, effective January 1, 2022, the convertible senior notes are no longer separated into liability and equity components, and are accounted for as a single liability, measured at amortized cost in the Consolidated Balance Sheets. Issuance costs are amortized using the effective interest method over the term of the convertible senior notes.
Convertible note hedge and warrant transactions associated with convertible debt instruments are accounted for as equity instruments, and are recorded in additional paid-in capital in the Consolidated Balance Sheets.
Valuation of Share-Based Compensation
The Company accounts for share-based compensation in accordance with ASC 718, Stock Compensation. The Company recognizes compensation expense related to share-based compensation based on the grant date estimated fair value.
The fair value of stock options (“options”) on the grant date is estimated using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of its common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on the Company’s historical experience of employee stock option exercises, including forfeitures. Expense is recognized on a straight-line basis over the requisite service period.
The fair value of restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) is based on the stock price on the grant date. The RSUs and RSAs are subject to a service vesting condition and are recognized on a straight-line basis over the requisite service period.
The fair value of performance-based stock unit awards (“PSUs”) with service and market conditions is estimated using a Monte Carlo simulation model applying a multiple awards approach. Expense is recognized when it is probable that the performance condition will be met using the accelerated attribution method over the requisite service period.
Forfeiture rates are estimated based on the Company’s historical experience with equity awards that were granted and forfeited prior to vesting. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods.
Awards of restricted stock to non-employee directors are granted on the date of the annual meeting of stockholders and vest in full on the date of the next annual meeting of stockholders, provided such non-employee director remains a director on such date. PSUs granted to the Company’s executives may include performance and market conditions. PSUs become eligible for vesting when certain market or performance conditions are met.
Accounting for Income Taxes
The Company records an income tax provision for (benefit from) the anticipated tax consequences of the reported results of operations. In accordance with ASC 740, Income Taxes, the provision for (benefit from) income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, the Company will incur a benefit or detriment on its income tax expense in the period of enactment. If the Company were to determine that all or part of the net deferred tax assets are not realizable in the future, it will record a valuation allowance that would be charged to earnings in the period such determination is made.
In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of ASC 740 and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on the Company’s financial condition and operating results.
Recently Adopted Authoritative Guidance and Recently Issued Authoritative Guidance
Recently Adopted Authoritative Guidance
In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The Company adopted ASU 2021-08 beginning January 1, 2023 and will apply the guidance prospectively to acquisitions occurring on or after the adoption date.
Recently Issued Authoritative Guidance
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements.
Net Income Per Share
Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method for share-based awards and warrants, and the if-converted method for convertible senior notes. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 11, Convertible Senior Notes. For periods prior to the adoption of ASU 2020-06 on January 1, 2022, the Company applied the treasury stock method to calculate the dilutive impact of the convertible senior notes. Upon adoption of ASU 2020-06, effective January 1, 2022, the Company applies the if-converted method for calculating the dilutive impact of the convertible senior notes. Following the Company’s irrevocable election in December 2021 to settle the principal portion of the convertible senior notes in cash with any conversion consideration in excess of the principal portion in cash and/or shares of the Company’s common stock at the Company’s option upon conversion, only the amounts expected to be settled in excess of the principal portion are considered dilutive in calculating earnings per share under the if-converted method. Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share.
Fair Value Hierarchy The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period.
Commitments and Contingencies
The Company is not a party to any legal proceedings that management believes may have a material impact on the Company’s financial position or results of operations.
Guarantees
Under the Company’s certificate of incorporation and bylaws, the Company has agreed to indemnify its directors and executive officers to the fullest extent not prohibited by Delaware and other applicable law, subject to certain exceptions. The Company has entered into individual indemnification agreements with its directors and officers. The term of the indemnification period is for the entirety of the director’s or officer’s service to the Company and continues so long as the director or officer may be subject to any claim, action, or proceeding, and there is no limit on the potential amount of future payments that the Company could be required to make under these indemnification agreements. The Company has purchased a directors’ and officers’ liability insurance policy that may enable it to recover a portion of any future payments that it may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits, and other policy provisions, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive and time-consuming litigation against the insurers.
Additionally, the Company undertakes indemnification obligations in its ordinary course of business in connection with, among other things, the sale or licensing of its products and the provision of its support services. In the ordinary course of the Company’s business, the Company has in the past and may in the future agree to indemnify another party, generally its business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, its gross negligence or intentional acts in the performance of services, and violations of laws. The term of these indemnification obligations is generally perpetual, but typically will not extend beyond the applicable statute of limitation pursuant to applicable law. In general, the Company attempts to limit the maximum potential amount of future payments that it may be required to make under these indemnification obligations to the amounts paid to it by a customer, but in some cases the obligation may not be so limited.
In addition, the Company has in the past and may in the future warrant to its customers that its products will conform to certain representations, which may include functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that its software media is free from material defects. Sales contracts for certain of the Company’s medication packaging systems may have in the past and may in the future include limited warranties for up to six months, but the periodic activity and ending warranty balances the Company records have historically not been material.
From time to time, the Company may also warrant that its professional services will conform to certain representations, which may include that such services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. The Company generally seeks to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality, and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive, or similar damages. In some states, such disclaimers may not be enforceable. If necessary, the Company would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. The Company has not been subject to any significant claims for such losses and has not incurred any material costs in defending or settling claims related to these indemnification obligations.
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Organization and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Revenue Recognition for Revenue Categories
The following table summarizes revenue recognition for each revenue category:
Revenue Category
Timing of Revenue Recognition
Income Statement Classification
Connected devices, software licenses, and other
Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer
Product
Consumables
Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer
Product
Technical services
Over time, as services are provided, typically ratably over the service term
Service
Advanced Services
Over time, as services are provided
Service
Estimated Useful Lives of Assets
Depreciation and amortization is computed by use of the straight-line method over the estimated useful lives of the assets as stated below:
Purchased software and internal-use software development costs
3 - 5 years
Leasehold and building improvementsShorter of the lease term or the estimated useful life
Furniture and fixtures
5 - 7 years
Equipment
2 - 12 years
The following table represents the property and equipment balances as of December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
Equipment$95,996 $91,391 
Furniture and fixtures4,500 5,154 
Leasehold improvements17,919 19,510 
Purchased software and internal-use software development costs118,004 76,327 
Construction in progress11,614 28,223 
Property and equipment, gross248,033 220,605 
Accumulated depreciation and amortization(139,432)(126,644)
Total property and equipment, net$108,601 $93,961 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Combinations (Tables)
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed By the Company
The following tables represent the allocation of the respective purchase price to the assets acquired and the liabilities assumed by the Company as part of each acquisition included in the Company’s Consolidated Balance Sheets, and is reconciled to the respective purchase price transferred:
FDS Amplicare (1)
ReCept (2) (3)
MarkeTouch Media (4)
(In thousands)
Purchase price transferred:
Base purchase price$177,000 $100,000 $82,000 
Add: Closing cash465 6,569 237 
Add: Net working capital adjustment1,654 (7,357)147 
Less: Assumed indebtedness(653)(1,973)(15)
Total purchase price transferred$178,466 $97,239 $82,369 
FDS Amplicare (1)
ReCept (2) (3)
MarkeTouch Media (4)
Fair value of assets acquired and liabilities assumed:
Cash and cash equivalents$465 $— $237 
Accounts receivable and unbilled receivables5,330 2,383 2,302 
Prepaid expenses506 192 96 
Other current assets45 12,223 — 
Total current assets6,346 14,798 2,635 
Property and equipment444 172 177 
Operating lease right-of-use assets2,252 773 602 
Goodwill117,784 77,644 42,273 
Intangible assets70,000 28,100 38,000 
Other long-term assets51 195 2,850 
Total assets196,877 121,682 86,537 
Accounts payable950 219 473 
Accrued compensation1,312 1,756 — 
Accrued liabilities1,497 18,249 292 
Deferred revenues1,916 222 347 
Long-term deferred tax liabilities11,686 3,383 — 
Long-term operating lease liabilities920 614 206 
Other long-term liabilities130 — 2,850 
Total liabilities18,411 24,443 4,168 
Total purchase price$178,466 $97,239 $82,369 
Total purchase price, net of cash acquired$178,001 $90,670 $82,132 
_________________________________________________
(1)    During the year ended December 31, 2021, the Company recorded measurement period adjustments of $1.5 million to goodwill, consisting of an increase in intangible assets, accounts receivable and unbilled receivables, and long-term deferred tax liabilities of $0.4 million, $1.1 million, and $0.1 million, respectively, and a net working capital adjustment of $0.1 million. During the year ended December 31, 2022, the Company recorded a measurement period adjustments of $0.4 million to goodwill, consisting of an increase in long-term deferred tax liabilities and accrued liabilities of $0.3 million and $0.1 million, respectively.
(2)    Closing cash is included in other current assets due to its restrictive nature as cash held for customers.
(3)    During the year ended December 31, 2022, the Company recorded measurement period adjustments of $3.9 million to goodwill, consisting of a purchase price adjustment of $5.2 million, a decrease in long-term deferred tax liabilities of $0.2 million and a decrease in accrued liabilities of $0.3 million, partially offset by a decrease to other current assets of $1.7 million.
(4)    During the year ended December 31, 2022, the Company recorded a measurement period adjustment of $0.3 million to goodwill related to a purchase price adjustment.
Summary of Identifiable Intangible Assets Acquired
The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows:
FDS Amplicare (1)
ReCeptMarkeTouch Media
Fair valueUseful life
(years)		Fair valueUseful life
(years)		Fair valueUseful life
(years)
(In thousands, except for years)
Customer relationships$59,900 23$28,100 23$34,100 26
Acquired technology7,700 
5 - 7
— —2,100 4
Backlog— —— —1,800 2
Trade names2,400 5— —— —
Total purchased intangible assets$70,000 $28,100 $38,000 
_________________________________________________
(1)    During the year ended December 31, 2021, the Company recorded a measurement period adjustment of $0.4 million in customer relationships.
Pro Forma Financial Information
The following table presents certain unaudited pro forma consolidated financial information for the year ended December 31, 2021 as if the FDS Amplicare, ReCept, and MarkeTouch Media acquisitions had been completed on January 1, 2020. The pro forma effects of the Hub and Spoke Innovations acquisition were not material to the Company’s consolidated results of operations. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of what would have occurred had the acquisitions taken place on those respective dates. The unaudited pro forma financial information combines the historical results of the acquisitions with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, amortization and depreciation of intangible assets and property and equipment acquired; imputed interest, interest expense, and amortization of debt issuance costs related to acquisitions, as applicable; and certain acquisition-related costs incurred.
Year Ended December 31,
2021
(In thousands)
Pro forma revenues$1,195,473 
Pro forma net income$79,981 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenues (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenues by Revenue Type
The following table summarizes the Company’s revenues disaggregated by revenue type for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Connected devices, software licenses, and other$623,584 $827,917 $739,074 
Consumables84,977 75,305 73,438 
Technical services225,831 206,687 206,989 
Advanced Services
212,720 186,038 112,517 
Total revenues$1,147,112 $1,295,947 $1,132,018 
Disaggregation of Revenues by Geographical Location
The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
United States$1,011,380$1,168,202$1,020,788
Rest of world (1)
135,732127,745111,230
Total revenues$1,147,112$1,295,947$1,132,018
_________________________________________________
(1)    No individual country represented more than 10% of total revenues.
Contract Assets and Liabilities
The following table reflects the Company’s contract assets and contract liabilities:
December 31,
20232022
(In thousands)
Short-term unbilled receivables, net (1)
$22,524 $25,763 
Long-term unbilled receivables, net (2)
11,850 14,744 
Total contract assets$34,374 $40,507 
Short-term deferred revenues, net
$121,734 $118,947 
Long-term deferred revenues
58,622 37,385 
Total contract liabilities$180,356 $156,332 
_________________________________________________
(1)     Included in accounts receivable and unbilled receivables in the Consolidated Balance Sheets.
(2)    Included in other long-term assets in the Consolidated Balance Sheets.
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income (Loss) Per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Calculation of Basic and Diluted Net Income Per Share
The basic and diluted net income (loss) per share calculations for the years ended December 31, 2023, 2022, and 2021 were as follows:
Year Ended December 31,
202320222021
(In thousands, except per share data)
Net income (loss)$(20,371)$5,648 $77,849 
Weighted-average shares outstanding – basic45,212 44,398 43,475 
Effect of dilutive securities from stock award plans— 1,019 2,136 
Effect of convertible senior notes— 474 2,044 
Effect of warrants— — 288 
Weighted-average shares outstanding – diluted45,212 45,891 47,943 
Net income (loss) per share – basic$(0.45)$0.13 $1.79 
Net income (loss) per share – diluted$(0.45)$0.12 $1.62 
Anti-dilutive weighted-average shares related to stock award plans3,368 725 156 
Anti-dilutive weighted-average shares related to convertible senior notes and warrants11,816 5,908 — 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Components (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Components
Balance sheet details as of December 31, 2023 and 2022 are presented in the tables below:
December 31,
20232022
(In thousands)
Inventories:
Raw materials$51,439 $75,854 
Work in process1,327 9,280 
Finished goods57,333 62,415 
Total inventories$110,099 $147,549 
Other current assets:
Funds held for customers, including restricted cash (1)
$43,649 $56,703 
Net investment in sales-type leases, current portion11,867 11,486 
Prepaid income taxes8,279 1,702 
Other current assets7,714 7,471 
Total other current assets$71,509 $77,362 
Other long-term assets:
External-use software development costs, net$66,659 $80,760 
Unbilled receivables, net11,850 14,744 
Deferred debt issuance costs3,718 2,058 
Other long-term assets8,239 7,455 
Total other long-term assets$90,466 $105,017 
Accrued liabilities:
Operating lease liabilities, current portion$10,518 $10,761 
Customer fund liabilities43,649 56,703 
Advance payments from customers10,551 11,556 
Rebate liabilities51,277 42,802 
Group purchasing organization fees4,445 7,723 
Taxes payable2,191 9,642 
Other accrued liabilities26,645 33,468 
Total accrued liabilities$149,276 $172,655 
_________________________________________________
(1)    Includes restricted cash of $33.0 million and $22.5 million as of December 31, 2023 and 2022, respectively.
Summary of Changes in Accumulated Balances of Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the years ended December 31, 2023 and 2022:
(In thousands)
Balance as of December 31, 2021$(8,407)
Other comprehensive loss(8,680)
Balance as of December 31, 2022(17,087)
Other comprehensive income3,655 
Balance as of December 31, 2023$(13,432)
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment
Depreciation and amortization is computed by use of the straight-line method over the estimated useful lives of the assets as stated below:
Purchased software and internal-use software development costs
3 - 5 years
Leasehold and building improvementsShorter of the lease term or the estimated useful life
Furniture and fixtures
5 - 7 years
Equipment
2 - 12 years
The following table represents the property and equipment balances as of December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
Equipment$95,996 $91,391 
Furniture and fixtures4,500 5,154 
Leasehold improvements17,919 19,510 
Purchased software and internal-use software development costs118,004 76,327 
Construction in progress11,614 28,223 
Property and equipment, gross248,033 220,605 
Accumulated depreciation and amortization(139,432)(126,644)
Total property and equipment, net$108,601 $93,961 
Long-lived Assets by Geographic Areas The following table summarizes the geographic information for property and equipment, net, as of December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
United States$104,312 $89,989 
Rest of world (1)
4,289 3,972 
Total property and equipment, net$108,601 $93,961 
_________________________________________________
(1)    No individual country represented more than 10% of total property and equipment, net.
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
External-Use Software Development Costs (Tables)
 12 Months Ended
Dec. 31, 2023
Research and Development [Abstract]  
Schedule of Capitalized Computer Software
The carrying amounts of external-use software development costs as of December 31, 2023 and 2022 were as follows:
December 31,
20232022
(In thousands)
Gross carrying amount$239,038 $225,004 
Accumulated amortization(172,379)(144,244)
External-use software development costs, net (1)
$66,659 $80,760 
_________________________________________________
(1)     Included in other long-term assets in the Consolidated Balance Sheets.
Schedule of Future Amortization Expenses For Capitalized Software Development Costs
The estimated future amortization expenses for external-use software development costs were as follows:
December 31, 2023
(In thousands)
2024$25,354 
202518,331 
202612,792 
20276,837 
20282,980 
Thereafter365 
Total$66,659
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in the Carrying Amount of Goodwill
The following table represents changes in the carrying amount of goodwill:
(In thousands)
Balance as of December 31, 2021$738,900 
Additions (1)
2,549 
Measurement period adjustments (1)
(3,770)
Foreign currency exchange rate fluctuations(3,405)
Balance as of December 31, 2022734,274 
Foreign currency exchange rate fluctuations1,536 
Balance as of December 31, 2023$735,810 
_________________________________________________
(1)     Refer to Note 2, Business Combinations, for further information.
Carrying Amounts and Useful Lives of Intangible Assets
The carrying amounts and useful lives of intangible assets as of December 31, 2023 and 2022 were as follows:
December 31, 2023
Gross carrying
amount		Accumulated
amortization		Foreign currency exchange
rate fluctuations		Net carrying
amount		Useful life
(years)
(In thousands, except for years)
Customer relationships$307,418 $(115,232)$(1,326)$190,860 
4 - 30
Acquired technology84,876 (67,033)— 17,843 
4 - 20
Backlog1,800 (1,800)— — 2
Trade names9,200 (7,680)— 1,520 
5 - 12
Patents2,404 (1,454)— 950 
2 - 20
Total intangibles assets, net$405,698 $(193,199)$(1,326)$211,173 

December 31, 2022
Gross carrying
amount		Accumulated
amortization		 Foreign currency exchange
rate fluctuations		Net carrying
amount		Useful life
(years)
(In thousands, except for years)
Customer relationships$311,089 $(99,177)$(1,514)$210,398 
4 - 30
Acquired technology92,066 (64,299)— 27,767 
4 - 20
Backlog1,800 (900)— 900 2
Trade names9,200 (6,633)— 2,567 
5 - 12
Patents2,430 (1,306)— 1,124 
2 - 20
Non-compete agreements600 (450)— 150 3
Total intangibles assets, net$417,185 $(172,765)$(1,514)$242,906 
Estimated Future Amortization Expense for Intangible Assets
The estimated future amortization expenses for amortizable intangible assets were as follows:
December 31,
2023
(In thousands)
2024$22,736 
202521,060 
202618,080 
202716,245 
202815,180 
Thereafter117,872 
Total$211,173 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Senior Notes (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Convertible Debt Balances
The Notes consisted of the following balances reported in the Consolidated Balance Sheets as of December 31, 2023 and 2022:
December 31,
20232022
Principal amount$575,000 $575,000 
Unamortized debt issuance costs(5,338)(8,429)
Convertible senior notes, net$569,662 $566,571 
Summary of the Components of Interest Expense
The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021:
Year Ended December 31,
2023
2022 (1)
2021
(In thousands)
Contractual coupon interest$1,438 $1,438 $1,438 
Amortization of discount$— $— $18,608 
Amortization of debt issuance costs$3,091 $3,066 $2,343 
_________________________________________________
(1)    Refer to Note 1, Organization and Summary of Significant Accounting Policies, for further information regarding the adoption of ASU 2020-06, effective January 1, 2022.
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessor Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Income Recognized from Sales-Type Leases
The following table presents the Company’s income recognized from sales-type leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Sales-type lease revenues$36,208 $38,959 $21,887 
Cost of sales-type lease revenues(18,093)(19,359)(8,918)
Selling profit on sales-type lease revenues$18,115 $19,600 $12,969 
Interest income on sales-type lease receivables$2,475 $2,106 $1,869 
Components of Sales-Type Lease Receivables
The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2023 and 2022:
December 31,
20232022
(In thousands)
Net minimum lease payments to be received$65,017 $50,755 
Less: Unearned interest income portion(10,196)(6,345)
Net investment in sales-type leases54,821 44,410 
Less: Current portion (1)
(11,867)(11,486)
Long-term investment in sales-type leases, net$42,954 $32,924 
_________________________________________________
(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Consolidated Balance Sheets.
Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases
The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Consolidated Balance Sheets was as follows:
December 31,
2023
(In thousands)
2024$14,504 
202512,385 
202610,113 
20278,369 
20287,281 
Thereafter12,365 
Total future minimum sales-type lease payments65,017 
Present value adjustment(10,196)
Total net investment in sales-type leases$54,821 
Income Recognized from Operating Leases
The following table represents the Company’s income recognized from operating leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Rental income$6,591 $9,460 $10,467 
Maturity Schedule of Future Minimum Lease Payments under Operating Leases
The maturity schedule of future minimum lease payments under operating leases was as follows:
December 31, 2023
(In thousands)
2024$3,547 
2025842 
2026763 
2027763 
2028571 
Total future minimum operating lease payments$6,486 
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessee Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities
The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Consolidated Balance Sheets was as follows:
December 31, 2023
(In thousands)
2024$12,722 
202510,609 
20269,715 
20278,070 
20287,650 
Thereafter1,834 
Total operating lease payments50,600 
Present value adjustment(6,172)
Total operating lease liabilities (1)
$44,428 
_________________________________________________
(1)    Amount consists of a current and long-term portion of operating lease liabilities of $10.5 million and $33.9 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities in the Consolidated Balance Sheets.
Summary of Supplemental Cash Flow Information and Weighted-Average Remaining Lease Term and Discount Rate
The following table summarizes supplemental cash flow information related to the Company’s operating leases for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities$13,469 $16,452 $15,625 
Right-of-use assets obtained in exchange for new lease liabilities$6,431 $12,372 $5,503 
The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of December 31, 2023 and 2022:
December 31,
20232022
Weighted-average remaining lease term, years4.65.0
Weighted-average discount rate, %5.8 %5.7 %
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Expense
The following table sets forth the total share-based compensation expense recognized in the Company’s Consolidated Statements of Operations:
Year Ended December 31,
202320222021
(In thousands)
Cost of product and service revenues$8,288 $9,067 $7,994 
Research and development6,941 11,368 7,663 
Selling, general, and administrative40,071 47,812 37,503 
Total share-based compensation expense$55,300 $68,247 $53,160 
Assumptions Used to Value ESPP Shares
The following assumptions were used to value shares under the ESPP for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
Expected life, years
0.5 - 2.0
0.5 - 2.0
0.5 - 2.0
Expected volatility, %
31.7% - 63.9%
28.8% - 45.6%
27.4% - 53.5%
Risk-free interest rate, %
0.1% - 5.5%
0.1% - 3.2%
0.1% - 2.6%
Dividend yield, %— %— %— %
Assumptions Used to Value Stock Options Granted
The following assumptions were used to value stock options granted pursuant to the 2009 Plan for the years ended December 31, 2023 and 2021. There were no stock options granted during the year ended December 31, 2022:
Year Ended December 31,
20232021
Expected life, years3.24.9
Expected volatility, %44.8 %31.5 %
Risk-free interest rate, %3.7 %0.9 %
Estimated forfeiture rate, %10.0 %7.9 %
Dividend yield, %— %— %
Summary of Share Option Activity
The following table summarizes the stock option activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Exercise Price
Weighted-Average
Remaining Years
Aggregate
Intrinsic Value
(In thousands, except per share data)
Outstanding at December 31, 20222,434 $68.65 6.1$7,887 
Granted200 55.60 
Exercised(165)41.01 
Expired(242)79.49 
Forfeited(204)74.92 
Outstanding at December 31, 20232,023 $67.68 4.6$1,013 
Exercisable at December 31, 20231,784 $67.18 4.5$1,013 
Vested and expected to vest at December 31, 2023 and thereafter2,013 $67.64 4.6$1,013 
Summary of Restricted Stock Unit Activity
The following table summarizes the RSU activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Grant Date Fair Value
Weighted-Average
Remaining Years
Aggregate
Intrinsic Value
(In thousands, except per share data)
Outstanding at December 31, 20221,117 $115.75 1.6$56,297 
Granted (Awarded)695 63.74 
Vested (Released)(335)113.64 
Forfeited(399)107.89 
Outstanding and unvested at December 31, 20231,078 $84.66 1.5$40,551 
Summary of Restricted Stock Awards Activity
The following table summarizes the RSA activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Grant Date Fair Value
(In thousands, except per share data)
Outstanding at December 31, 202213 $109.39 
Granted (Awarded)24 70.96 
Vested (Released)(13)109.39 
Outstanding and unvested at December 31, 202324 $70.96 
Summary of Performance-Based Restricted Stock Activity
The following table summarizes the PSU activity under the 2009 Plan during the year ended December 31, 2023:
Number of
Shares
Weighted-Average
Grant Date Fair Value
(In thousands, except per share data)
Outstanding at December 31, 2022135 $147.42 
Granted65 122.29 
Vested(55)111.05 
Forfeited(70)153.77 
Outstanding and unvested at December 31, 202375 $127.14 
Ordinary Shares Reserved for Future Issuance Under Equity Incentive Plans
The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of December 31, 2023:
Number of Shares
(In thousands)
Stock options outstanding2,023 
Non-vested restricted stock awards1,177 
Shares authorized for future issuance2,669 
ESPP shares available for future issuance3,250 
Total shares reserved for future issuance9,119 
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Geographical Breakdown of Income (Loss) before the Provision for Income Taxes
The following is a geographical breakdown of income (loss) before income taxes:
Year Ended December 31,
202320222021
(In thousands)
Domestic$(28,105)$369 $67,103 
Foreign7,997 (2,822)(1,096)
Income (loss) before income taxes$(20,108)$(2,453)$66,007 
Provision for (Benefit from) Income Taxes
The provision for (benefit from) income taxes consisted of the following:
Year Ended December 31,
202320222021
(In thousands)
Current:
Federal$8,556 $17,973 $(7,841)
State1,471 8,024 187 
Foreign840 192 (234)
Total current income taxes10,867 26,189 (7,888)
Deferred:
Federal(8,002)(25,753)(2,708)
State(2,261)(7,976)(1,217)
Foreign(341)(561)(29)
Total deferred income taxes(10,604)(34,290)(3,954)
Total provision for (benefit from) income taxes$263 $(8,101)$(11,842)
Difference Between the Provision for (Benefit from) Income Taxes Compared to Income Taxes Computed at the Statutory Federal Tax Rate
The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows:
Year Ended December 31,
202320222021
(In thousands)
U.S. federal tax provision at statutory rate$(4,223)$(515)$13,861 
State taxes(624)38 (814)
Section 162(m) limitation1,286 3,071 6,382 
Non-deductible expenses531 134 363 
Uncertain tax positions(620)(776)(835)
Share-based compensation tax expense (benefit)7,384 (3,264)(20,717)
Research tax credits(4,587)(6,948)(5,170)
Restructuring impact— — (6,116)
Foreign-derived intangible income deduction(325)(753)(68)
Global intangible low-taxed income inclusion— 960 195 
Foreign rate differential219 186 (170)
Foreign branch taxes6 (51)(9)
Transaction cost— 68 1,097 
Provision to return true up697 (84)205 
State rate true up528 (135)(80)
Other(9)(32)34 
Total provision for (benefit from) income taxes$263 $(8,101)$(11,842)
Significant Components of Deferred Tax Assets (Liabilities)
Significant components of the Company’s deferred tax assets (liabilities) were as follows:
December 31,
20232022
(In thousands)
Deferred tax assets (liabilities):
Deferred revenues$11,343 $13,514 
Share-based compensation11,763 12,064 
Inventory-related items5,136 4,567 
Tax credit carryforwards12,505 12,173 
Reserves and accruals5,660 6,244 
Loss carryforwards7,802 10,255 
Lease liability11,457 12,884 
Convertible debt9,649 15,037 
Capitalized research and development41,635 30,881 
Other, net591 1,557 
Gross deferred tax assets117,541 119,176 
Valuation allowance— — 
Total net deferred tax assets117,541 119,176 
Intangibles(30,366)(36,357)
Depreciation and amortization(35,402)(37,286)
Prepaid expenses(13,858)(15,574)
Right-of-use assets(6,626)(9,725)
Other, net(8)— 
Total deferred tax liabilities(86,260)(98,942)
Net deferred tax assets $31,281 $20,234 
Change in the Balance of Gross Unrecognized Tax Benefits
The aggregate change in the balance of gross unrecognized tax benefit, which excludes interest and penalties, for the years ended December 31, 2023, 2022, and 2021:
(In thousands)
Balance as of December 31, 2020$18,246 
Increases related to tax positions taken during a prior period40 
Decreases related to tax positions taken during the prior period(8,908)
Increases related to tax positions taken during the current period1,219 
Decreases related to expiration of statute of limitations(1,636)
Balance as of December 31, 20218,961 
Increases related to tax positions taken during a prior period3 
Decreases related to tax positions taken during the prior period(59)
Increases related to tax positions taken during the current period1,629 
Decreases related to expiration of statute of limitations(1,238)
Balance as of December 31, 20229,296 
Increases related to tax positions taken during a prior period
750 
Decreases related to tax positions taken during the prior period(161)
Increases related to tax positions taken during the current period1,566 
Decreases related to expiration of statute of limitations(703)
Balance as of December 31, 2023$10,748 
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring Expenses (Tables)
 12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Summary of Restructuring Expenses
The following table summarizes the total employee-related restructuring expenses recognized in the Company’s Consolidated Statements of Operations for the years ended December 31, 2023, 2022, and 2021:
Year Ended December 31,
202320222021
(In thousands)
Cost of product and service revenues$3,089 $8,018 $389 
Research and development3,829 3,615 105 
Selling, general, and administrative8,621 11,170 1,526 
Total restructuring expenses, net of reversals$15,539 $22,803 $2,020 
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Organization and Summary of Significant Accounting Policies - Narrative (Details)
 12 Months Ended
Dec. 31, 2023
USD ($)
segment
reporting_unit
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Accounting Policies [Line Items]      
Number of operating segments | segment 1    
Number of reporting segments | segment 1    
Revenue from contract with customer, maximum contract term 10 years    
Revenue, remaining performance obligation, amount $ 353,900,000    
Fees to GPOs $ 11,200,000 $ 17,600,000 $ 17,500,000
Amortization period for capitalized contract costs 10 years    
Initial term and renewal service periods 10 years    
Contract cost expense $ 23,300,000 30,600,000 25,800,000
Impairment loss related to capitalized prepaid commissions 0    
Non-recourse accounts receivable transferred 5,700,000 45,300,000 46,700,000
Accounts receivable due from third-party leasing companies for transferred non-recourse accounts receivable 1,100,000 6,700,000  
Cash and cash equivalents 467,972,000 330,362,000 349,051,000
Cash equivalents 451,000,000 301,000,000  
Minimum required purchase obligation 93,900,000    
Selling, general, and administrative $ 434,593,000 486,341,000 $ 389,430,000
Estimated useful life of software-related products 5 years    
Number of reporting units | reporting_unit 1    
Accumulated impairment loss on goodwill $ 0    
Accounting Standards Update [Extensible List]     Accounting Standards Update 2020-06 [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01      
Accounting Policies [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 10 years    
Other Assets      
Accounting Policies [Line Items]      
Software development costs capitalized $ 14,600,000 13,200,000  
Internal Use Software and Software Development Costs | Property and Equipment      
Accounting Policies [Line Items]      
Software development costs capitalized $ 32,200,000 33,000,000  
Estimated useful life of software-related products 5 years    
Shipping Costs      
Accounting Policies [Line Items]      
Selling, general, and administrative $ 18,600,000 24,500,000 $ 18,200,000
Primary Supplier      
Accounting Policies [Line Items]      
Minimum required purchase obligation $ 0    
Period for notice of termination 6 months    
Purchases from suppliers $ 65,800,000 $ 105,700,000 $ 103,200,000
Minimum      
Accounting Policies [Line Items]      
Original terms of contracts 1 year    
Term of sales-type leases 1 year    
Maximum      
Accounting Policies [Line Items]      
Original terms of contracts 5 years    
Term of sales-type leases 10 years    
Customer Concentration Risk | Revenues | Ten Largest GPOs      
Accounting Policies [Line Items]      
Concentration risk percentage 64.00%    
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Organization and Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)
Dec. 31, 2023
Purchased software and internal-use software development costs | Minimum  
Property, Plant and Equipment [Line Items]  
Useful life of property and equipment 3 years
Purchased software and internal-use software development costs | Maximum  
Property, Plant and Equipment [Line Items]  
Useful life of property and equipment 5 years
Furniture and fixtures | Minimum  
Property, Plant and Equipment [Line Items]  
Useful life of property and equipment 5 years
Furniture and fixtures | Maximum  
Property, Plant and Equipment [Line Items]  
Useful life of property and equipment 7 years
Equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Useful life of property and equipment 2 years
Equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Useful life of property and equipment 12 years
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Combinations - Narrative (Details)
$ in Thousands, £ in Millions
 12 Months Ended
Jan. 10, 2022
USD ($)
Jan. 10, 2022
GBP (£)
Dec. 31, 2021
USD ($)
Dec. 29, 2021
USD ($)
Sep. 09, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jan. 10, 2022
GBP (£)
Acquired Finite-Lived Intangible Assets [Line Items]                  
Goodwill     $ 738,900     $ 738,900 $ 735,810 $ 734,274  
Hub and Spoke Innovations                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Base purchase price $ 3,400 £ 2.5              
Total purchase price transferred 3,400 £ 2.5              
Goodwill 2,500               £ 1.9
Intangible assets $ 1,100               £ 0.8
MarkeTouch Media                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Base purchase price     82,000            
Total purchase price transferred     82,369            
Goodwill     42,273     42,273      
Intangible assets     38,000     38,000      
Goodwill expected to be deductible for tax purposes     $ 42,300     $ 42,300      
MarkeTouch Media | Discount Rate                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Measurement input used in estimating the fair values of intangible assets     0.115     0.115      
MarkeTouch Media | Acquired Technology | Royalty Rate                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Measurement input used in estimating the fair values of intangible assets     0.100     0.100      
ReCept                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Base purchase price       $ 100,000          
Total purchase price transferred       97,239          
Goodwill       77,644          
Intangible assets       28,100          
Goodwill expected to be deductible for tax purposes       $ 0          
ReCept | Discount Rate                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Measurement input used in estimating the fair values of intangible assets       0.150          
FDS Amplicare                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Base purchase price         $ 177,000        
Total purchase price transferred         178,466        
Goodwill         117,784        
Intangible assets         $ 70,000        
Acquisition related costs           $ 7,000      
Revenue from operations since the acquisition date           11,300      
Losses from operations since the acquisition date           $ 900      
FDS Amplicare | Discount Rate                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Measurement input used in estimating the fair values of intangible assets         0.130        
FDS Amplicare | Acquired Technology | Royalty Rate                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Measurement input used in estimating the fair values of intangible assets         0.100        
FDS Amplicare | Trade Names | Royalty Rate                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Measurement input used in estimating the fair values of intangible assets         0.020        
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Combinations - Summary of Preliminary Purchase Price (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 29, 2021
Sep. 09, 2021
FDS Amplicare      
Business Acquisition [Line Items]      
Base purchase price     $ 177,000
Add: Closing cash     465
Add: Net working capital adjustment     1,654
Less: Assumed indebtedness     (653)
Total purchase price transferred     $ 178,466
ReCept      
Business Acquisition [Line Items]      
Base purchase price   $ 100,000  
Add: Closing cash   6,569  
Add: Net working capital adjustment   (7,357)  
Less: Assumed indebtedness   (1,973)  
Total purchase price transferred   $ 97,239  
MarkeTouch Media      
Business Acquisition [Line Items]      
Base purchase price $ 82,000    
Add: Closing cash 237    
Add: Net working capital adjustment 147    
Less: Assumed indebtedness (15)    
Total purchase price transferred $ 82,369    
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Combinations - Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed By the Company (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 29, 2021
Sep. 09, 2021
Business Acquisition [Line Items]          
Goodwill $ 735,810 $ 734,274 $ 738,900    
Measurement period adjustments   (3,770)      
Purchase price adjustments from business acquisitions $ 0 5,463 0    
FDS Amplicare          
Business Acquisition [Line Items]          
Cash and cash equivalents         $ 465
Accounts receivable and unbilled receivables         5,330
Prepaid expenses         506
Other current assets         45
Total current assets         6,346
Property and equipment         444
Operating lease right-of-use assets         2,252
Goodwill         117,784
Intangible assets         70,000
Other long-term assets         51
Total assets         196,877
Accounts payable         950
Accrued compensation         1,312
Accrued liabilities         1,497
Deferred revenues         1,916
Long-term deferred tax liabilities         11,686
Long-term operating lease liabilities         920
Other long-term liabilities         130
Total liabilities         18,411
Total purchase price         178,466
Total purchase price, net of cash acquired         $ 178,001
Measurement period adjustments   400 (1,500)    
Adjustment, accounts receivable and unbilled receivables     1,100    
Adjustment, deferred tax liability, noncurrent     100    
Purchase price adjustments from business acquisitions     100    
Increase (decrease) in deferred tax liabilities   300      
Increase (decrease) in accrued liabilities   100      
FDS Amplicare | Customer relationships          
Business Acquisition [Line Items]          
Adjustment, intangibles     400    
ReCept          
Business Acquisition [Line Items]          
Cash and cash equivalents       $ 0  
Accounts receivable and unbilled receivables       2,383  
Prepaid expenses       192  
Other current assets       12,223  
Total current assets       14,798  
Property and equipment       172  
Operating lease right-of-use assets       773  
Goodwill       77,644  
Intangible assets       28,100  
Other long-term assets       195  
Total assets       121,682  
Accounts payable       219  
Accrued compensation       1,756  
Accrued liabilities       18,249  
Deferred revenues       222  
Long-term deferred tax liabilities       3,383  
Long-term operating lease liabilities       614  
Other long-term liabilities       0  
Total liabilities       24,443  
Total purchase price       97,239  
Total purchase price, net of cash acquired       $ 90,670  
Measurement period adjustments   (3,900)      
Purchase price adjustments from business acquisitions   5,200      
Increase (decrease) in deferred tax liabilities   (200)      
Increase (decrease) in accrued liabilities   (300)      
Decrease in other assets, current   1,700      
MarkeTouch Media          
Business Acquisition [Line Items]          
Cash and cash equivalents     237    
Accounts receivable and unbilled receivables     2,302    
Prepaid expenses     96    
Other current assets     0    
Total current assets     2,635    
Property and equipment     177    
Operating lease right-of-use assets     602    
Goodwill     42,273    
Intangible assets     38,000    
Other long-term assets     2,850    
Total assets     86,537    
Accounts payable     473    
Accrued compensation     0    
Accrued liabilities     292    
Deferred revenues     347    
Long-term deferred tax liabilities     0    
Long-term operating lease liabilities     206    
Other long-term liabilities     2,850    
Total liabilities     4,168    
Total purchase price     82,369    
Total purchase price, net of cash acquired     $ 82,132    
Measurement period adjustments   $ (300)      
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Combinations - Summary of Identifiable Intangible Assets Acquired (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 29, 2021
Sep. 09, 2021
FDS Amplicare      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value     $ 70,000
FDS Amplicare | Customer relationships      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value     $ 59,900
Useful life (years)     23 years
FDS Amplicare | Acquired technology      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value     $ 7,700
FDS Amplicare | Acquired technology | Minimum      
Acquired Finite-Lived Intangible Assets [Line Items]      
Useful life (years)     5 years
FDS Amplicare | Acquired technology | Maximum      
Acquired Finite-Lived Intangible Assets [Line Items]      
Useful life (years)     7 years
FDS Amplicare | Backlog      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value     $ 0
FDS Amplicare | Trade names      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value     $ 2,400
Useful life (years)     5 years
ReCept      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value   $ 28,100  
ReCept | Customer relationships      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value   $ 28,100  
Useful life (years)   23 years  
ReCept | Acquired technology      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value   $ 0  
ReCept | Backlog      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value   0  
ReCept | Trade names      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value   $ 0  
MarkeTouch Media      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value $ 38,000    
MarkeTouch Media | Customer relationships      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value $ 34,100    
Useful life (years) 26 years    
MarkeTouch Media | Acquired technology      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value $ 2,100    
Useful life (years) 4 years    
MarkeTouch Media | Backlog      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value $ 1,800    
Useful life (years) 2 years    
MarkeTouch Media | Trade names      
Acquired Finite-Lived Intangible Assets [Line Items]      
Fair value $ 0    
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Combinations - Pro Forma Financial Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Business Combination and Asset Acquisition [Abstract]  
Pro forma revenues $ 1,195,473
Pro forma net income $ 79,981
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenues - Disaggregation of Revenues by Revenue Type (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Revenues $ 1,147,112 $ 1,295,947 $ 1,132,018
Connected devices, software licenses, and other      
Disaggregation of Revenue [Line Items]      
Revenues 623,584 827,917 739,074
Consumables      
Disaggregation of Revenue [Line Items]      
Revenues 84,977 75,305 73,438
Technical services      
Disaggregation of Revenue [Line Items]      
Revenues 225,831 206,687 206,989
Advanced Services      
Disaggregation of Revenue [Line Items]      
Revenues $ 212,720 $ 186,038 $ 112,517
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenues - Disaggregation of Revenues by Geographic Region (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Revenues $ 1,147,112 $ 1,295,947 $ 1,132,018
United States      
Disaggregation of Revenue [Line Items]      
Revenues 1,011,380 1,168,202 1,020,788
Rest of world      
Disaggregation of Revenue [Line Items]      
Revenues $ 135,732 $ 127,745 $ 111,230
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenues - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]    
Short-term unbilled receivables, net $ 22,524 $ 25,763
Long-term unbilled receivables, net 11,850 14,744
Total contract assets 34,374 40,507
Short-term deferred revenues, net 121,734 118,947
Long-term deferred revenues 58,622 37,385
Total contract liabilities $ 180,356 $ 156,332
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenues - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]    
Short-term deferred revenues, net $ 121,734 $ 118,947
Deferred cost of sales 12,400 15,800
Deferred revenues recognized 115,700  
Gross short-term deferred revenue   134,700
Long-term deferred revenues $ 58,622 $ 37,385
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Net income (loss) $ (20,371) $ 5,648 $ 77,849
Weighted-average shares outstanding — basic (in shares) 45,212 44,398 43,475
Weighted-average shares outstanding — diluted (in shares) 45,212 45,891 47,943
Net income per share - basic (in dollars per share) $ (0.45) $ 0.13 $ 1.79
Net income per share - diluted (in dollars per share) $ (0.45) $ 0.12 $ 1.62
Stock Award Plans      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Effect of dilutive securities from stock award plans (in shares) 0 1,019 2,136
Anti-dilutive weighted-average shares related to stock award plans (in shares) 3,368 725 156
Convertible Debt Securities      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Effect of dilutive securities from stock award plans (in shares) 0 474 2,044
Warrant      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Effect of dilutive securities from stock award plans (in shares) 0 0 288
Convertible Debt Securities and Warrants      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive weighted-average shares related to stock award plans (in shares) 11,816 5,908 0
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments (Details) - Convertible Senior Notes - Convertible Debt - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Cash and Cash Equivalents [Line Items]    
Long-term debt, fair value $ 527,200 $ 501,400
Carrying value of debt $ 569,662 $ 566,571
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Components - Balance Sheet Components (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Inventories:    
Raw materials $ 51,439 $ 75,854
Work in process 1,327 9,280
Finished goods 57,333 62,415
Total inventories 110,099 147,549
Other current assets:    
Funds held for customers, including restricted cash 43,649 56,703
Net investment in sales-type leases, current portion 11,867 11,486
Prepaid income taxes 8,279 1,702
Other current assets 7,714 7,471
Total other current assets 71,509 77,362
Other long-term assets:    
External-use software development costs, net 66,659 80,760
Unbilled receivables, net 11,850 14,744
Deferred debt issuance costs 3,718 2,058
Other long-term assets 8,239 7,455
Total other long-term assets 90,466 105,017
Accrued liabilities:    
Operating lease liabilities, current portion $ 10,518 $ 10,761
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Total accrued liabilities Total accrued liabilities
Customer fund liabilities $ 43,649 $ 56,703
Advance payments from customers 10,551 11,556
Rebate liabilities 51,277 42,802
Group purchasing organization fees 4,445 7,723
Taxes payable 2,191 9,642
Other accrued liabilities 26,645 33,468
Total accrued liabilities 149,276 172,655
Restricted cash $ 33,000 $ 22,500
Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration] Total other current assets Total other current assets
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period $ 1,130,137 $ 1,146,689 $ 967,503
Other comprehensive income (loss) 3,655 (8,680) (2,885)
Balance at end of period 1,188,954 1,130,137 1,146,689
Accumulated Other Comprehensive Income (Loss)      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period (17,087) (8,407) (5,522)
Other comprehensive income (loss) 3,655 (8,680) (2,885)
Balance at end of period $ (13,432) $ (17,087) $ (8,407)
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property and Equipment - Property and Equipment Balances (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 248,033 $ 220,605
Accumulated depreciation and amortization (139,432) (126,644)
Total property and equipment, net 108,601 93,961
Equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 95,996 91,391
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 4,500 5,154
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 17,919 19,510
Purchased software and internal-use software development costs    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 118,004 76,327
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 11,614 $ 28,223
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property and Equipment - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]      
Depreciation and amortization expense of property and equipment $ 27.0 $ 22.8 $ 20.1
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment, net $ 108,601 $ 93,961
United States    
Property, Plant and Equipment [Line Items]    
Property and equipment, net 104,312 89,989
Rest of world    
Property, Plant and Equipment [Line Items]    
Property and equipment, net $ 4,289 $ 3,972
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
External-Use Software Development Costs - Schedule of Capitalized Computer Software (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Gross carrying amount $ 239,038 $ 225,004
Accumulated amortization (172,379) (144,244)
External-use software development costs, net $ 66,659 $ 80,760
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
External-Use Software Development Costs - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Research and Development [Abstract]      
Amortization of capitalized software development costs $ 28.7 $ 29.0 $ 26.4
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
External-Use Software Development Costs - Schedule of Future Amortization Expenses For Capitalized Software Development Costs (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
2024 $ 25,354  
2025 18,331  
2026 12,792  
2027 6,837  
2028 2,980  
Thereafter 365  
External-use software development costs, net $ 66,659 $ 80,760
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Goodwill [Roll Forward]    
Balance at beginning of period $ 734,274 $ 738,900
Additions   2,549
Measurement period adjustments   (3,770)
Foreign currency exchange rate fluctuations 1,536 (3,405)
Balance at end of period $ 735,810 $ 734,274
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 405,698 $ 417,185
Accumulated amortization (193,199) (172,765)
Foreign currency exchange rate fluctuations (1,326) (1,514)
Net carrying amount 211,173 242,906
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 307,418 311,089
Accumulated amortization (115,232) (99,177)
Foreign currency exchange rate fluctuations (1,326) (1,514)
Net carrying amount $ 190,860 $ 210,398
Customer relationships | Minimum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful life 4 years 4 years
Customer relationships | Maximum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful life 30 years 30 years
Acquired technology    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 84,876 $ 92,066
Accumulated amortization (67,033) (64,299)
Foreign currency exchange rate fluctuations 0 0
Net carrying amount $ 17,843 $ 27,767
Acquired technology | Minimum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful life 4 years 4 years
Acquired technology | Maximum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful life 20 years 20 years
Backlog    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 1,800 $ 1,800
Accumulated amortization (1,800) (900)
Foreign currency exchange rate fluctuations 0 0
Net carrying amount $ 0 $ 900
Useful life 2 years 2 years
Trade names    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 9,200 $ 9,200
Accumulated amortization (7,680) (6,633)
Foreign currency exchange rate fluctuations 0 0
Net carrying amount $ 1,520 $ 2,567
Trade names | Minimum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful life 5 years 5 years
Trade names | Maximum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful life 12 years 12 years
Patents    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 2,404 $ 2,430
Accumulated amortization (1,454) (1,306)
Foreign currency exchange rate fluctuations 0 0
Net carrying amount $ 950 $ 1,124
Patents | Minimum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful life 2 years 2 years
Patents | Maximum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful life 20 years 20 years
Non-compete agreements    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount   $ 600
Accumulated amortization   (450)
Foreign currency exchange rate fluctuations   0
Net carrying amount   $ 150
Useful life   3 years
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]      
Amortization expense of intangible assets $ 31.6 $ 35.2 $ 26.5
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
2024 $ 22,736  
2025 21,060  
2026 18,080  
2027 16,245  
2028 15,180  
Thereafter 117,872  
Total $ 211,173 $ 242,906
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt and Credit Agreement (Details) - Line of Credit
Oct. 10, 2023
USD ($)
Mar. 29, 2023
Nov. 15, 2019
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 22, 2020
Debt Instrument [Line Items]            
Debt issuance costs $ 3,000,000          
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Minimum            
Debt Instrument [Line Items]            
Commitment fee rate on undrawn commitments 0.20% 0.15%        
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Maximum            
Debt Instrument [Line Items]            
Commitment fee rate on undrawn commitments 0.35% 0.30%        
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Secured Overnight Financing Rate (SOFR)            
Debt Instrument [Line Items]            
Spread on variable interest rate   1.00%        
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Secured Overnight Financing Rate (SOFR) | Minimum            
Debt Instrument [Line Items]            
Spread on variable interest rate   1.25%        
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Secured Overnight Financing Rate (SOFR) | Maximum            
Debt Instrument [Line Items]            
Spread on variable interest rate   2.00%        
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Federal Funds            
Debt Instrument [Line Items]            
Spread on variable interest rate 0.50% 0.50%        
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | SOFR Plus 1.00% | Minimum            
Debt Instrument [Line Items]            
Spread on variable interest rate   0.25%        
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | SOFR Plus 1.00% | Maximum            
Debt Instrument [Line Items]            
Spread on variable interest rate   1.00%        
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Secured Overnight Financing Rate (SOFR) Applicable Margin | Minimum            
Debt Instrument [Line Items]            
Spread on variable interest rate 1.50%          
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Secured Overnight Financing Rate (SOFR) Applicable Margin | Maximum            
Debt Instrument [Line Items]            
Spread on variable interest rate 2.25%          
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | One Month Secured Overnight Financing Rate (SOFR)            
Debt Instrument [Line Items]            
Spread on variable interest rate 1.00%          
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | One Month Secured Overnight Financing Rate (SOFR) Applicable Margin | Minimum            
Debt Instrument [Line Items]            
Spread on variable interest rate 0.50%          
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | One Month Secured Overnight Financing Rate (SOFR) Applicable Margin | Maximum            
Debt Instrument [Line Items]            
Spread on variable interest rate 1.25%          
Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC            
Debt Instrument [Line Items]            
Maximum secured net leverage ratio 3.00          
Debt instrument, covenant, minimum interest coverage ratio 3.00          
Revolving Credit Facility            
Debt Instrument [Line Items]            
Outstanding balance       $ 0 $ 0  
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank            
Debt Instrument [Line Items]            
Term of debt instrument     5 years      
Maximum borrowing capacity     $ 500,000,000      
Line of credit facility, remaining borrowing capacity       $ 350,000,000 $ 500,000,000  
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Calendar Quarters Up To and Including March 31, 2021            
Debt Instrument [Line Items]            
Maximum secured net leverage ratio           3.50
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Calendar Quarters After March 31, 2021            
Debt Instrument [Line Items]            
Maximum secured net leverage ratio           3.00
Revolving Credit Facility | Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC            
Debt Instrument [Line Items]            
Term of debt instrument 5 years          
Maximum borrowing capacity $ 350,000,000          
Line of credit facility, accordion feature, higher borrowing capacity option $ 250,000,000          
Debt instrument, covenant, adjusted EBITDA threshold 100.00%          
Incremental Loan Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank            
Debt Instrument [Line Items]            
Maximum borrowing capacity     250,000,000      
Letter of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank            
Debt Instrument [Line Items]            
Maximum borrowing capacity     15,000,000      
Letter of Credit | Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC            
Debt Instrument [Line Items]            
Maximum borrowing capacity $ 15,000,000          
Swing Line Loan | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank            
Debt Instrument [Line Items]            
Maximum borrowing capacity     $ 25,000,000      
Swing Line Loan | Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC            
Debt Instrument [Line Items]            
Maximum borrowing capacity $ 25,000,000          
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Senior Notes - Narrative (Details)
$ / shares in Units, shares in Millions
 12 Months Ended
Dec. 13, 2021
USD ($)
$ / shares
Sep. 25, 2020
USD ($)
day
$ / shares
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Debt Instrument [Line Items]          
Proceeds from issuance of convertible senior notes, net of issuance costs   $ 559,700,000      
Payments of debt issuance costs     $ 2,967,000 $ 0 $ 0
Purchase of convertible note hedge   100,600,000      
Proceeds from sale of warrants   51,300,000      
Convertible Note Hedge          
Debt Instrument [Line Items]          
Deferred tax asset related to the convertible note hedge transaction   $ 25,800,000      
Convertible Note Hedge Rights          
Debt Instrument [Line Items]          
Options and warrants to purchase shares (in shares) | shares   5.9      
Strike price (in dollars per share) | $ / shares   $ 97.32      
Warrant          
Debt Instrument [Line Items]          
Options and warrants to purchase shares (in shares) | shares   5.9      
Strike price (in dollars per share) | $ / shares   $ 141.56      
Convertible Senior Notes          
Debt Instrument [Line Items]          
Principal amount of notes, minimum $ 1,000        
Maximum cash 1,000        
Consideration in excess, amount $ 1,000        
Convertible Senior Notes | Convertible Debt          
Debt Instrument [Line Items]          
Interest rate   0.25%      
Principal amount   $ 575,000,000 $ 575,000,000 $ 575,000,000  
Additional principal amount subject to purchasers' option   75,000,000      
Payments of debt issuance costs   $ 15,300,000      
Conversion ratio   0.0102751      
Conversion price (in dollars per share) | $ / shares $ 97.32        
Repurchase price as a percent of principal amount   100.00%      
Aggregate principal amount of Notes that must be outstanding and not subject to redemption if the Company redeems less than all of the Notes   $ 150,000,000      
Effective interest rate     0.80%    
Remaining life of debt discount and issuance cost accretion     1 year 8 months 12 days    
Maximum number of shares issuable upon conversion (in shares) | shares   5.9      
Convertible Senior Notes | Convertible Debt | Period 1          
Debt Instrument [Line Items]          
Threshold trading days | day   20      
Threshold consecutive trading days | day   30      
Threshold percentage of stock price trigger   130.00%      
Convertible Senior Notes | Convertible Debt | Period 2          
Debt Instrument [Line Items]          
Threshold trading days | day   5      
Threshold consecutive trading days | day   10      
Threshold percentage of stock price trigger   98.00%      
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Senior Notes - Convertible Debt Balances (Details) - Convertible Debt - Convertible Senior Notes - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Sep. 25, 2020
Debt Instrument [Line Items]      
Principal amount $ 575,000,000 $ 575,000,000 $ 575,000,000
Unamortized debt issuance costs (5,338,000) (8,429,000)  
Convertible senior notes, net $ 569,662,000 $ 566,571,000  
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
Convertible Senior Notes - Summary of the Components of Interest Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]      
Amortization of discount $ 0 $ 0 $ 18,608
Amortization of debt issuance costs 4,397 4,164 3,440
Convertible Senior Notes | Convertible Debt      
Debt Instrument [Line Items]      
Contractual coupon interest 1,438 1,438 1,438
Amortization of discount     18,608
Amortization of debt issuance costs $ 3,091 $ 3,066 $ 2,343
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessor Leases - Narrative (Details)
Dec. 31, 2023
Minimum  
Lessor, Lease, Description [Line Items]  
Term of sales-type leases 1 year
Maximum  
Lessor, Lease, Description [Line Items]  
Term of sales-type leases 10 years
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessor Leases - Income Recognized from Sales-Type Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Leases [Abstract]      
Sales-type lease revenues $ 36,208 $ 38,959 $ 21,887
Cost of sales-type lease revenues (18,093) (19,359) (8,918)
Selling profit on sales-type lease revenues 18,115 19,600 12,969
Interest income on sales-type lease receivables $ 2,475 $ 2,106 $ 1,869
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessor Leases - Components of Sales-Type Lease Receivables (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
Total future minimum sales-type lease payments $ 65,017 $ 50,755
Less: Unearned interest income portion (10,196) (6,345)
Net investment in sales-type leases 54,821 44,410
Less: Current portion (11,867) (11,486)
Long-term investment in sales-type leases, net $ 42,954 $ 32,924
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
2024 $ 14,504  
2025 12,385  
2026 10,113  
2027 8,369  
2028 7,281  
Thereafter 12,365  
Total future minimum sales-type lease payments 65,017 $ 50,755
Present value adjustment (10,196) $ (6,345)
Total net investment in sales-type leases $ 54,821  
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessor Leases - Income Recognized from Operating Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Leases [Abstract]      
Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration] Revenues Revenues Revenues
Rental income $ 6,591 $ 9,460 $ 10,467
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Leases [Abstract]  
2024 $ 3,547
2025 842
2026 763
2027 763
2028 571
Total future minimum operating lease payments $ 6,486
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessee Leases - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Lessee, Lease, Description [Line Items]      
Operating lease cost $ 10,800 $ 18,900 $ 15,000
Impairment and abandonment of operating lease right-of-use assets related to facilities $ 9,998 $ 9,382 $ 0
Minimum      
Lessee, Lease, Description [Line Items]      
Term of operating leases 1 year    
Maximum      
Lessee, Lease, Description [Line Items]      
Term of operating leases 12 years    
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
2024 $ 12,722  
2025 10,609  
2026 9,715  
2027 8,070  
2028 7,650  
Thereafter 1,834  
Total operating lease payments 50,600  
Present value adjustment (6,172)  
Total operating lease liabilities 44,428  
Current portion of operating lease liabilities 10,518 $ 10,761
Long-term portion of operating lease liabilities $ 33,910 $ 39,405
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Leases [Abstract]      
Cash paid for amounts included in the measurement of lease liabilities $ 13,469 $ 16,452 $ 15,625
Right-of-use assets obtained in exchange for new lease liabilities $ 6,431 $ 12,372 $ 5,503
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
Weighted-average remaining lease term, years 4 years 7 months 6 days 5 years
Weighted-average discount rate, % 5.80% 5.70%
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Loss Contingencies [Line Items]    
Non-cancelable purchase commitments $ 93.9  
Non-cancelable purchase commitments expected to be paid within the next twelve months 84.2  
Ransomware incident, expense 0.0 $ 13.6
Loss contingency, cumulative expected insurance recoveries   11.1
Loss contingency, expense incurred to date 13.6  
Loss contingency, cumulative insurance recoveries $ 12.2  
Standard warranty period (up to) 30 days  
Limited warranty period (up to) 6 months  
Cost of product and service revenues    
Loss Contingencies [Line Items]    
Ransomware incident, expense, net of insurance recoveries   0.3
Research and development    
Loss Contingencies [Line Items]    
Ransomware incident, expense, net of insurance recoveries   0.2
Selling, general, and administrative    
Loss Contingencies [Line Items]    
Ransomware incident, expense, net of insurance recoveries   $ 2.0
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares reserved for future issuance (in shares) 9,119,000    
Share-based payment arrangement, amount capitalized $ 4,400,000    
Income tax (expense) benefit from share-based compensation $ (6,500,000) $ 5,200,000 $ 26,600,000
Shares purchased under ESPP (in shares) 353,000 316,000  
Granted (in shares) 200,000 0  
2009 Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares reserved for future issuance (in shares) 5,900,000    
Omnicell Plan | Other Postretirement Benefit Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Employer matching contribution, percent of employee contribution 50.00%    
Maximum amount of employer contribution $ 3,000    
401(k) contributions $ 7,900,000 $ 8,100,000 $ 6,800,000
ESPP      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Maximum percentage of earnings allowed for purchase of shares 15.00%    
Maximum fair market value of shares $ 25,000    
Purchase price of common stock, percent 85.00%    
Offering period 24 months    
Purchasing period 6 months    
Shares reserved for future issuance (in shares) 3,250,000    
Weighted-average price (in dollars per share) $ 46.68 $ 67.63  
Total unrecognized compensation cost $ 1,100,000    
Weighted average period of compensation cost recognized 1 year 4 months 24 days    
Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares reserved for future issuance (in shares) 2,023,000    
Vesting period 4 years    
Weighted average period of compensation cost recognized 8 months 12 days    
Weighted-average fair value per share (in dollars per share) $ 19.48   $ 35.17
Intrinsic value of options exercised $ 3,200,000 $ 23,900,000 $ 88,000,000
Tax (expense) benefit realized from stock options exercised (1,300,000) $ 4,400,000 $ 18,300,000
Unrecognized compensation cost of unvested stock options $ 3,300,000    
Stock Options | Vesting One Year from Commencement Date      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 1 year    
Percentage of award vesting 25.00%    
Stock Options | Vesting in Equal Monthly Installments      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 36 months    
RSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 4 years    
Total unrecognized compensation cost $ 64,300,000    
Weighted average period of compensation cost recognized 3 years    
Weighted-average grant date fair value per award granted (in dollars per share) $ 63.74 $ 111.12 $ 149.65
Fair value of awards vested $ 38,000,000 $ 30,700,000 $ 16,700,000
Awards granted (in shares) 695,000    
RSUs | Vesting One Year from Commencement Date      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 1 year    
Percentage of award vesting 25.00%    
RSUs | Vesting in Equal Monthly Installments      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
RSAs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total unrecognized compensation cost $ 600,000    
Weighted average period of compensation cost recognized 4 months 24 days    
Weighted-average grant date fair value per award granted (in dollars per share) $ 70.96 $ 109.39 $ 137.36
Fair value of awards vested $ 1,400,000 $ 1,600,000 $ 1,400,000
Awards granted (in shares) 24,000    
PSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 4 years    
Total unrecognized compensation cost $ 5,000,000    
Weighted average period of compensation cost recognized 1 year 4 months 24 days    
Weighted-average grant date fair value per award granted (in dollars per share) $ 122.29 $ 155.27 $ 162.16
Awards granted (in shares) 65,000    
Trading days used for stock price appreciation calculation 20 days    
Fair value of awards vested $ 6,100,000 $ 15,000,000 $ 4,400,000
PSUs | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percentage of shares eligible for time-based vesting 0.00%    
PSUs | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percentage of shares eligible for time-based vesting 200.00%    
PSUs | Officer      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Awards granted (in shares) 65,000 56,237  
PSUs | Vesting One Year from Commencement Date      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 1 year    
Percentage of award vesting 25.00%    
PSUs | Vesting in Equal Monthly Installments      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Share-based compensation expense $ 55,300 $ 68,247 $ 53,160
Cost of product and service revenues      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Share-based compensation expense 8,288 9,067 7,994
Research and development      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Share-based compensation expense 6,941 11,368 7,663
Selling, general, and administrative      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Share-based compensation expense $ 40,071 $ 47,812 $ 37,503
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares Granted (Details) - ESPP
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected volatility (minimum) 31.70% 28.80% 27.40%
Expected volatility (maximum) 63.90% 45.60% 53.50%
Risk-free interest rate (minimum) 0.10% 0.10% 0.10%
Risk-free interest rate (maximum) 5.50% 3.20% 2.60%
Dividend yield 0.00% 0.00% 0.00%
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected life 6 months 6 months 6 months
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected life 2 years 2 years 2 years
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details) - Stock Options
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected life 3 years 2 months 12 days 4 years 10 months 24 days
Expected volatility 44.80% 31.50%
Risk-free interest rate 3.70% 0.90%
Estimated forfeiture rate 10.00% 7.90%
Dividend yield 0.00% 0.00%
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Number of Shares    
Outstanding at beginning of year (in shares) 2,434,000  
Granted (in shares) 200,000 0
Exercised (in shares) (165,000)  
Expired (in shares) (242,000)  
Forfeited (in shares) (204,000)  
Outstanding at end of year (in shares) 2,023,000 2,434,000
Exercisable (in shares) 1,784,000  
Vested and expected to vest (in shares) 2,013,000  
Weighted-Average Exercise Price    
Outstanding at beginning of year (in dollars per share) $ 68.65  
Granted (in dollars per share) 55.60  
Exercised (in dollars per share) 41.01  
Expired (in dollars per share) 79.49  
Forfeited (in dollars per share) 74.92  
Outstanding at end of year (in dollars per share) 67.68 $ 68.65
Exercisable (in dollars per share) 67.18  
Vested and expected to vest (in dollars per share) $ 67.64  
Weighted-Average Remaining Years    
Outstanding 4 years 7 months 6 days 6 years 1 month 6 days
Exercisable 4 years 6 months  
Vested and expected to vest 4 years 7 months 6 days  
Aggregate Intrinsic Value    
Outstanding $ 1,013 $ 7,887
Exercisable 1,013  
Vested and expected to vest $ 1,013  
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - RSUs - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Number of Shares      
Outstanding (in shares) 1,117    
Granted (Awarded) (in shares) 695    
Vested (Released) (in shares) (335)    
Forfeited (in shares) (399)    
Outstanding (in shares) 1,078 1,117  
Weighted-Average Grant Date Fair Value      
Outstanding (in dollars per share) $ 115.75    
Granted (Awarded) (in dollars per share) 63.74 $ 111.12 $ 149.65
Vested (Released) (in dollars per share) 113.64    
Forfeited (in dollars per share) 107.89    
Outstanding (in dollars per share) $ 84.66 $ 115.75  
Weighted-Average Remaining Years      
Outstanding 1 year 6 months 1 year 7 months 6 days  
Aggregate Intrinsic Value      
Outstanding $ 40,551 $ 56,297  
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details) - RSAs - $ / shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Number of Shares      
Outstanding (in shares) 13    
Granted (Awarded) (in shares) 24    
Vested (Released) (in shares) (13)    
Outstanding (in shares) 24 13  
Weighted-Average Grant Date Fair Value      
Outstanding (in dollars per share) $ 109.39    
Granted (Awarded) (in dollars per share) 70.96 $ 109.39 $ 137.36
Vested (Released) (in dollars per share) 109.39    
Outstanding (in dollars per share) $ 70.96 $ 109.39  
XML 106 R92.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details) - Performance-Based Restricted Stock - $ / shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Number of Shares      
Outstanding (in shares) 135    
Granted (Awarded) (in shares) 65    
Vested (Released) (in shares) (55)    
Forfeited (in shares) (70)    
Outstanding (in shares) 75 135  
Weighted-Average Grant Date Fair Value      
Outstanding (in dollars per share) $ 147.42    
Granted (Awarded) (in dollars per share) 122.29 $ 155.27 $ 162.16
Vested (Released) (in dollars per share) 111.05    
Forfeited (in dollars per share) 153.77    
Outstanding (in dollars per share) $ 127.14 $ 147.42  
XML 107 R93.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details)
shares in Thousands
Dec. 31, 2023
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares reserved for future issuance (in shares) 9,119
Stock options outstanding  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares reserved for future issuance (in shares) 2,023
Non-vested restricted stock awards  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares reserved for future issuance (in shares) 1,177
Shares authorized for future issuance  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares reserved for future issuance (in shares) 2,669
ESPP shares available for future issuance  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares reserved for future issuance (in shares) 3,250
XML 108 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock Repurchase Programs (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Aug. 02, 2016
Nov. 04, 2014
Equity, Class of Treasury Stock [Line Items]          
Number of shares repurchased (in shares) 0   0    
Aggregate purchase price for repurchased shares $ 0 $ 52,210,000 $ 0    
2016 and 2014 Share Repurchase Programs          
Equity, Class of Treasury Stock [Line Items]          
Remaining value of shares authorized for repurchase under stock repurchase programs $ 2,700,000        
Number of shares repurchased (in shares)   389,300      
Average price of repurchased shares (in dollars per share)   $ 134.11      
Aggregate purchase price of treasury stock   $ 52,200,000      
2016 Repurchase Program          
Equity, Class of Treasury Stock [Line Items]          
Value of shares authorized for repurchase under stock repurchase programs (up to)       $ 50,000,000  
2014 Share Repurchase Program          
Equity, Class of Treasury Stock [Line Items]          
Value of shares authorized for repurchase under stock repurchase programs (up to)         $ 50,000,000
XML 109 R95.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Geographical Breakdown of Income (Loss) before the Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Domestic $ (28,105) $ 369 $ 67,103
Foreign 7,997 (2,822) (1,096)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total $ (20,108) $ (2,453) $ 66,007
XML 110 R96.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Provision for (Benefit from) Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Current:      
Federal $ 8,556 $ 17,973 $ (7,841)
State 1,471 8,024 187
Foreign 840 192 (234)
Total current income taxes 10,867 26,189 (7,888)
Deferred:      
Federal (8,002) (25,753) (2,708)
State (2,261) (7,976) (1,217)
Foreign (341) (561) (29)
Total deferred income taxes (10,604) (34,290) (3,954)
Total provision for (benefit from) income taxes $ 263 $ (8,101) $ (11,842)
XML 111 R97.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Difference between the Provision For (Benefit From) Income Taxes Compared to Income Taxes Computed at the Statutory Federal Tax Rate (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
U.S. federal tax provision at statutory rate $ (4,223) $ (515) $ 13,861
State taxes (624) 38 (814)
Section 162(m) limitation 1,286 3,071 6,382
Non-deductible expenses 531 134 363
Uncertain tax positions (620) (776) (835)
Share-based compensation tax expense (benefit) 7,384 (3,264) (20,717)
Research tax credits (4,587) (6,948) (5,170)
Restructuring impact 0 0 (6,116)
Foreign-derived intangible income deduction (325) (753) (68)
Global intangible low-taxed income inclusion 0 960 195
Foreign rate differential 219 186 (170)
Foreign branch taxes 6 (51) (9)
Transaction cost 0 68 1,097
Provision to return true up 697 (84) 205
State rate true up 528 (135) (80)
Other (9) (32) 34
Total provision for (benefit from) income taxes $ 263 $ (8,101) $ (11,842)
XML 112 R98.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Narrative (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Tax Credit Carryforward [Line Items]      
Valuation allowance $ 0 $ 0  
Uncertain tax positions, interest and penalties 200,000 200,000 $ 300,000
Interest and penalties accrued 400,000 $ 200,000 $ 600,000
Internal Revenue Service (IRS)      
Tax Credit Carryforward [Line Items]      
Net operating loss 0    
Internal Revenue Service (IRS) | Research Tax Credit Carryforward      
Tax Credit Carryforward [Line Items]      
Tax credit carryforward amount 0    
State and Local Jurisdiction      
Tax Credit Carryforward [Line Items]      
Net operating loss 19,000,000    
State and Local Jurisdiction | Research Tax Credit Carryforward      
Tax Credit Carryforward [Line Items]      
Tax credit carryforward amount 20,900,000    
Foreign Tax Authority      
Tax Credit Carryforward [Line Items]      
Net operating loss $ 22,300,000    
XML 113 R99.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets (liabilities):    
Deferred revenues $ 11,343,000 $ 13,514,000
Share-based compensation 11,763,000 12,064,000
Inventory-related items 5,136,000 4,567,000
Tax credit carryforwards 12,505,000 12,173,000
Reserves and accruals 5,660,000 6,244,000
Loss carryforwards 7,802,000 10,255,000
Lease liability 11,457,000 12,884,000
Convertible debt 9,649,000 15,037,000
Capitalized research and development 41,635,000 30,881,000
Other, net 591,000 1,557,000
Gross deferred tax assets 117,541,000 119,176,000
Valuation allowance 0 0
Total net deferred tax assets 117,541,000 119,176,000
Intangibles (30,366,000) (36,357,000)
Depreciation and amortization (35,402,000) (37,286,000)
Prepaid expenses (13,858,000) (15,574,000)
Right-of-use assets (6,626,000) (9,725,000)
Other, net (8,000) 0
Total deferred tax liabilities (86,260,000) (98,942,000)
Net deferred tax assets $ 31,281,000 $ 20,234,000
XML 114 R100.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Change in the Balance of Gross Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at beginning of period $ 9,296 $ 8,961 $ 18,246
Increases related to tax positions taken during a prior period 750 3 40
Decreases related to tax positions taken during the prior period (161) (59) (8,908)
Increases related to tax positions taken during the current period 1,566 1,629 1,219
Decreases related to expiration of statute of limitations (703) (1,238) (1,636)
Balance at end of period $ 10,748 $ 9,296 $ 8,961
XML 115 R101.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring Expenses - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Restructuring and Related Activities [Abstract]        
Restructuring charges $ 2,000 $ 15,539 $ 22,803 $ 2,020
Unpaid balance related to restructuring plan   $ 8,900    
XML 116 R102.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring Expenses - Summary of Restructuring Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 2,000 $ 15,539 $ 22,803 $ 2,020
Cost of product and service revenues        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges   3,089 8,018 389
Research and development        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges   3,829 3,615 105
Selling, general, and administrative        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges   $ 8,621 $ 11,170 $ 1,526
XML 117 R103.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule II Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period $ 5,496 $ 5,526 $ 4,581
Charged (Credited) to Costs and Expenses 2,671 2,747 2,089
Amounts Written Off (2,441) (2,551) (2,079)
Other Adjustments 126 (226) 935
Balance at End of Period 5,852 5,496 5,526
Accounts receivable and unbilled receivables      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period 5,153 5,272 4,286
Charged (Credited) to Costs and Expenses 2,726 2,658 2,130
Amounts Written Off (2,441) (2,551) (2,079)
Other Adjustments 126 (226) 935
Balance at End of Period 5,564 5,153 5,272
Long-term unbilled receivables      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period 35 26 30
Charged (Credited) to Costs and Expenses (4) 9 (4)
Amounts Written Off 0 0 0
Other Adjustments 0 0
Balance at End of Period 31 35 26
Net investment in sales-type leases      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period 308 228 265
Charged (Credited) to Costs and Expenses (51) 80 (37)
Amounts Written Off 0 0 0
Other Adjustments 0 0 0
Balance at End of Period $ 257 $ 308 $ 228
EXCEL 119 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

1M$.,4(V&@ .#C#= M7;=IR)LBXQ/VV2)R2G_*)D'FUHU7K^_& E1TX;!.6)/O9@9V9T=T@58@^M>( MLZZ>9?_Q$8PN%L0]W#+14X2$))REM*=T)W+D&J!H@(8^,+8.V>OP_ V3)CW_ M[C?2G.?FU@E20,B$$%R)MAM=95CIT0?&G@%@@O%,P1SUIX' '?';\ M"<0S_CV?6I(IAJW''-7+X%X#2_5HJBQ07G2N*)$8MML>F/@@L/3=#@#'.X\# M?Z!:]ACC=.2Y@4 "2=N+< W?8QY&OTBO.R-^C:BG0!D*FX#JU+A,WWG^&NC% M7=$Y (J='C2]^(+ VVGJ6SPO@^:KM?KRPV@F19# V677?\Y169*G*F#FV0

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

&PO=V]R:W-H965T !X;"]W;W)K&UL4$L! A0#% @ M0XI<6,OD7:-T! /@L !D ("!!.T 'AL+W=O&UL4$L! A0#% @ 0XI<6-PZR2)&! MX0H !D ("!Y@4! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI<6%<_9%'!/ G-< !D M ("!=P\! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 0XI<6&\?G7NT! 40P !D ("!65H! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI< M6 /Q5+,Q! ;@H !D ("!GV@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI<6#$JK>OF P )PD M !D ("!^'4! 'AL+W=O@$ M>&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI<6-CLG;@S!P ,Q< !D M ("!=(0! 'AL+W=OWZOB,( #0%@ &0 @('>BP$ >&PO=V]R:W-H965T M&UL4$L! A0# M% @ 0XI<6.>$"=]Y"0 FS\ !D ("!C)&PO=V]R:W-H965T; 9 " @:>D M 0!X;"]W;W)K&UL4$L! A0#% @ 0XI<6'&D M3-1T! :1P !D ("!+[ ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI<6,?!RBEE @ 804 !D M ("!5,H! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 0XI<6-T#CMOG @ E0@ !D ("! M:M0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 0XI<6(@F3,E\ @ ]@4 !D ("!T-\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI<6#*#D4ZN @ J@8 !D M ("!?_8! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 0XI<6/IL*S04 P UP@ !D ("!:/\! M 'AL+W=O M*.X' //0 &0 @(&S @( >&PO=V]R:W-H965T&UL4$L! A0#% @ M0XI<6&CL:4O5 @ M@D !D ("!F0T" 'AL+W=O @!X;"]W M;W)K&UL4$L! A0#% @ 0XI<6'P!DB:J @ M+ @ !D ("!QB<" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI<6$#A/$D, P /PD !D M ("!H# " 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 0XI<6,]>>%3) @ ZP< !D ("!;#H" 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI< M6"1B'IF! P .@T !D ("!O4," 'AL+W=OT" #>!P &0 M @(%U1P( >&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI<6!+2Z,%M! "A4 M !D ("!,DT" 'AL+W=O&PO=V]R:W-H965T @!X;"]W;W)K&UL4$L! A0#% @ 0XI<6)8)--[+ P I!$ !D M ("!IF(" 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 0XI<6"Q>PL>5! ]18 !D ("!7V\" 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI<6+TM MU-E+ P @PT !D ("!.GP" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0XI<6+PK]M^I P \@T !D M ("!YX<" 'AL+W=OV%<% #X$P &0 @(''BP( >&PO M=V]R:W-H965T&UL4$L! A0#% @ 0XI<6(O\7-Z;! WQ$ !D ("! MQ)4" 'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T% &@ @(&!H0( >&PO=V]R M:W-H965T&PO=V]R:W-H965T&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !#BEQ8A'6; MAV," !A.@ $P @ &#N@( 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 ;P!O (0> 7O0( ! end XML 120 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 121 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 123 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 323 572 1 false 94 0 false 8 false false R1.htm 0000001 - Document - Cover Sheet http://www.omnicell.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.omnicell.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets Sheet http://www.omnicell.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Operations Sheet http://www.omnicell.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows Sheet http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Business Combinations Sheet http://www.omnicell.com/role/BusinessCombinations Business Combinations Notes 10 false false R11.htm 0000011 - Disclosure - Revenues Sheet http://www.omnicell.com/role/Revenues Revenues Notes 11 false false R12.htm 0000012 - Disclosure - Net Income (Loss) Per Share Sheet http://www.omnicell.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value of Financial Instruments Sheet http://www.omnicell.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 13 false false R14.htm 0000014 - Disclosure - Balance Sheet Components Sheet http://www.omnicell.com/role/BalanceSheetComponents Balance Sheet Components Notes 14 false false R15.htm 0000015 - Disclosure - Property and Equipment Sheet http://www.omnicell.com/role/PropertyandEquipment Property and Equipment Notes 15 false false R16.htm 0000016 - Disclosure - External-Use Software Development Costs Sheet http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCosts External-Use Software Development Costs Notes 16 false false R17.htm 0000017 - Disclosure - Goodwill and Intangible Assets Sheet http://www.omnicell.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 17 false false R18.htm 0000018 - Disclosure - Debt and Credit Agreement Sheet http://www.omnicell.com/role/DebtandCreditAgreement Debt and Credit Agreement Notes 18 false false R19.htm 0000019 - Disclosure - Convertible Senior Notes Notes http://www.omnicell.com/role/ConvertibleSeniorNotes Convertible Senior Notes Notes 19 false false R20.htm 0000020 - Disclosure - Lessor Leases Sheet http://www.omnicell.com/role/LessorLeases Lessor Leases Notes 20 false false R21.htm 0000021 - Disclosure - Lessee Leases Sheet http://www.omnicell.com/role/LesseeLeases Lessee Leases Notes 21 false false R22.htm 0000022 - Disclosure - Commitments and Contingencies Sheet http://www.omnicell.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 22 false false R23.htm 0000023 - Disclosure - Employee Benefits and Share-Based Compensation Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensation Employee Benefits and Share-Based Compensation Notes 23 false false R24.htm 0000024 - Disclosure - Stock Repurchase Programs Sheet http://www.omnicell.com/role/StockRepurchasePrograms Stock Repurchase Programs Notes 24 false false R25.htm 0000025 - Disclosure - Income Taxes Sheet http://www.omnicell.com/role/IncomeTaxes Income Taxes Notes 25 false false R26.htm 0000026 - Disclosure - Restructuring Expenses Sheet http://www.omnicell.com/role/RestructuringExpenses Restructuring Expenses Notes 26 false false R27.htm 0000027 - Disclosure - Schedule II Valuation and Qualifying Accounts Sheet http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccounts Schedule II Valuation and Qualifying Accounts Notes 27 false false R28.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 28 false false R29.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 29 false false R30.htm 9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPolicies 30 false false R31.htm 9954473 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPolicies 31 false false R32.htm 9954474 - Disclosure - Business Combinations (Tables) Sheet http://www.omnicell.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.omnicell.com/role/BusinessCombinations 32 false false R33.htm 9954475 - Disclosure - Revenues (Tables) Sheet http://www.omnicell.com/role/RevenuesTables Revenues (Tables) Tables http://www.omnicell.com/role/Revenues 33 false false R34.htm 9954476 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.omnicell.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://www.omnicell.com/role/NetIncomeLossPerShare 34 false false R35.htm 9954477 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.omnicell.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.omnicell.com/role/BalanceSheetComponents 35 false false R36.htm 9954478 - Disclosure - Property and Equipment (Tables) Sheet http://www.omnicell.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.omnicell.com/role/PropertyandEquipment 36 false false R37.htm 9954479 - Disclosure - External-Use Software Development Costs (Tables) Sheet http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsTables External-Use Software Development Costs (Tables) Tables http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCosts 37 false false R38.htm 9954480 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.omnicell.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.omnicell.com/role/GoodwillandIntangibleAssets 38 false false R39.htm 9954481 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.omnicell.com/role/ConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://www.omnicell.com/role/ConvertibleSeniorNotes 39 false false R40.htm 9954482 - Disclosure - Lessor Leases (Tables) Sheet http://www.omnicell.com/role/LessorLeasesTables Lessor Leases (Tables) Tables http://www.omnicell.com/role/LessorLeases 40 false false R41.htm 9954483 - Disclosure - Lessee Leases (Tables) Sheet http://www.omnicell.com/role/LesseeLeasesTables Lessee Leases (Tables) Tables http://www.omnicell.com/role/LesseeLeases 41 false false R42.htm 9954484 - Disclosure - Employee Benefits and Share-Based Compensation (Tables) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables Employee Benefits and Share-Based Compensation (Tables) Tables http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensation 42 false false R43.htm 9954485 - Disclosure - Income Taxes (Tables) Sheet http://www.omnicell.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.omnicell.com/role/IncomeTaxes 43 false false R44.htm 9954486 - Disclosure - Restructuring Expenses (Tables) Sheet http://www.omnicell.com/role/RestructuringExpensesTables Restructuring Expenses (Tables) Tables http://www.omnicell.com/role/RestructuringExpenses 44 false false R45.htm 9954487 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails Organization and Summary of Significant Accounting Policies - Narrative (Details) Details http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 45 false false R46.htm 9954488 - Disclosure - Organization and Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) Sheet http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails Organization and Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) Details 46 false false R47.htm 9954489 - Disclosure - Business Combinations - Narrative (Details) Sheet http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails Business Combinations - Narrative (Details) Details 47 false false R48.htm 9954490 - Disclosure - Business Combinations - Summary of Preliminary Purchase Price (Details) Sheet http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails Business Combinations - Summary of Preliminary Purchase Price (Details) Details 48 false false R49.htm 9954491 - Disclosure - Business Combinations - Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed By the Company (Details) Sheet http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails Business Combinations - Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed By the Company (Details) Details 49 false false R50.htm 9954492 - Disclosure - Business Combinations - Summary of Identifiable Intangible Assets Acquired (Details) Sheet http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails Business Combinations - Summary of Identifiable Intangible Assets Acquired (Details) Details 50 false false R51.htm 9954493 - Disclosure - Business Combinations - Pro Forma Financial Information (Details) Sheet http://www.omnicell.com/role/BusinessCombinationsProFormaFinancialInformationDetails Business Combinations - Pro Forma Financial Information (Details) Details 51 false false R52.htm 9954494 - Disclosure - Revenues - Disaggregation of Revenues by Revenue Type (Details) Sheet http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails Revenues - Disaggregation of Revenues by Revenue Type (Details) Details 52 false false R53.htm 9954495 - Disclosure - Revenues - Disaggregation of Revenues by Geographic Region (Details) Sheet http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyGeographicRegionDetails Revenues - Disaggregation of Revenues by Geographic Region (Details) Details 53 false false R54.htm 9954496 - Disclosure - Revenues - Contract Assets and Liabilities (Details) Sheet http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails Revenues - Contract Assets and Liabilities (Details) Details 54 false false R55.htm 9954497 - Disclosure - Revenues - Narrative (Details) Sheet http://www.omnicell.com/role/RevenuesNarrativeDetails Revenues - Narrative (Details) Details 55 false false R56.htm 9954498 - Disclosure - Net Income (Loss) Per Share (Details) Sheet http://www.omnicell.com/role/NetIncomeLossPerShareDetails Net Income (Loss) Per Share (Details) Details http://www.omnicell.com/role/NetIncomeLossPerShareTables 56 false false R57.htm 9954499 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://www.omnicell.com/role/FairValueofFinancialInstruments 57 false false R58.htm 9954500 - Disclosure - Balance Sheet Components - Balance Sheet Components (Details) Sheet http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails Balance Sheet Components - Balance Sheet Components (Details) Details 58 false false R59.htm 9954501 - Disclosure - Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) Details 59 false false R60.htm 9954502 - Disclosure - Property and Equipment - Property and Equipment Balances (Details) Sheet http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails Property and Equipment - Property and Equipment Balances (Details) Details 60 false false R61.htm 9954503 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://www.omnicell.com/role/PropertyandEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 61 false false R62.htm 9954504 - Disclosure - Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details) Sheet http://www.omnicell.com/role/PropertyandEquipmentSummaryofGeographicInformationforPropertyandEquipmentNetDetails Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details) Details 62 false false R63.htm 9954505 - Disclosure - External-Use Software Development Costs - Schedule of Capitalized Computer Software (Details) Sheet http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofCapitalizedComputerSoftwareDetails External-Use Software Development Costs - Schedule of Capitalized Computer Software (Details) Details 63 false false R64.htm 9954506 - Disclosure - External-Use Software Development Costs - Narrative (Details) Sheet http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsNarrativeDetails External-Use Software Development Costs - Narrative (Details) Details 64 false false R65.htm 9954507 - Disclosure - External-Use Software Development Costs - Schedule of Future Amortization Expenses For Capitalized Software Development Costs (Details) Sheet http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails External-Use Software Development Costs - Schedule of Future Amortization Expenses For Capitalized Software Development Costs (Details) Details 65 false false R66.htm 9954508 - Disclosure - Goodwill and Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) Sheet http://www.omnicell.com/role/GoodwillandIntangibleAssetsChangesintheCarryingAmountofGoodwillDetails Goodwill and Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) Details 66 false false R67.htm 9954509 - Disclosure - Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details) Sheet http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details) Details 67 false false R68.htm 9954510 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) Sheet http://www.omnicell.com/role/GoodwillandIntangibleAssetsNarrativeDetails Goodwill and Intangible Assets - Narrative (Details) Details 68 false false R69.htm 9954511 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails Goodwill and Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details) Details 69 false false R70.htm 9954512 - Disclosure - Debt and Credit Agreement (Details) Sheet http://www.omnicell.com/role/DebtandCreditAgreementDetails Debt and Credit Agreement (Details) Details http://www.omnicell.com/role/DebtandCreditAgreement 70 false false R71.htm 9954513 - Disclosure - Convertible Senior Notes - Narrative (Details) Notes http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails Convertible Senior Notes - Narrative (Details) Details 71 false false R72.htm 9954514 - Disclosure - Convertible Senior Notes - Convertible Debt Balances (Details) Notes http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails Convertible Senior Notes - Convertible Debt Balances (Details) Details 72 false false R73.htm 9954515 - Disclosure - Convertible Senior Notes - Summary of the Components of Interest Expense (Details) Notes http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails Convertible Senior Notes - Summary of the Components of Interest Expense (Details) Details 73 false false R74.htm 9954516 - Disclosure - Lessor Leases - Narrative (Details) Sheet http://www.omnicell.com/role/LessorLeasesNarrativeDetails Lessor Leases - Narrative (Details) Details 74 false false R75.htm 9954517 - Disclosure - Lessor Leases - Income Recognized from Sales-Type Leases (Details) Sheet http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromSalesTypeLeasesDetails Lessor Leases - Income Recognized from Sales-Type Leases (Details) Details 75 false false R76.htm 9954518 - Disclosure - Lessor Leases - Components of Sales-Type Lease Receivables (Details) Sheet http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails Lessor Leases - Components of Sales-Type Lease Receivables (Details) Details 76 false false R77.htm 9954519 - Disclosure - Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) Sheet http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) Details 77 false false R78.htm 9954520 - Disclosure - Lessor Leases - Income Recognized from Operating Leases (Details) Sheet http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromOperatingLeasesDetails Lessor Leases - Income Recognized from Operating Leases (Details) Details 78 false false R79.htm 9954521 - Disclosure - Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases (Details) Sheet http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases (Details) Details 79 false false R80.htm 9954522 - Disclosure - Lessee Leases - Narrative (Details) Sheet http://www.omnicell.com/role/LesseeLeasesNarrativeDetails Lessee Leases - Narrative (Details) Details 80 false false R81.htm 9954523 - Disclosure - Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and??the Reconciliation to the Operating Lease Liabilities (Details) Sheet http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and??the Reconciliation to the Operating Lease Liabilities (Details) Details 81 false false R82.htm 9954524 - Disclosure - Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) Sheet http://www.omnicell.com/role/LesseeLeasesSupplementalCashFlowInformationRelatedtoOperatingLeasesDetails Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) Details 82 false false R83.htm 9954525 - Disclosure - Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details) Sheet http://www.omnicell.com/role/LesseeLeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateDetails Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details) Details 83 false false R84.htm 9954526 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.omnicell.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.omnicell.com/role/CommitmentsandContingencies 84 false false R85.htm 9954527 - Disclosure - Employee Benefits and Share-Based Compensation - Narrative (Details) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails Employee Benefits and Share-Based Compensation - Narrative (Details) Details 85 false false R86.htm 9954528 - Disclosure - Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) Details 86 false false R87.htm 9954529 - Disclosure - Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares Granted (Details) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares Granted (Details) Details 87 false false R88.htm 9954530 - Disclosure - Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details) Details 88 false false R89.htm 9954531 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details) Details 89 false false R90.htm 9954532 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) Details 90 false false R91.htm 9954533 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details) Details 91 false false R92.htm 9954534 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details) Details 92 false false R93.htm 9954535 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) Sheet http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) Details 93 false false R94.htm 9954536 - Disclosure - Stock Repurchase Programs (Details) Sheet http://www.omnicell.com/role/StockRepurchaseProgramsDetails Stock Repurchase Programs (Details) Details http://www.omnicell.com/role/StockRepurchasePrograms 94 false false R95.htm 9954537 - Disclosure - Income Taxes - Geographical Breakdown of Income (Loss) before the Provision for Income Taxes (Details) Sheet http://www.omnicell.com/role/IncomeTaxesGeographicalBreakdownofIncomeLossbeforetheProvisionforIncomeTaxesDetails Income Taxes - Geographical Breakdown of Income (Loss) before the Provision for Income Taxes (Details) Details 95 false false R96.htm 9954538 - Disclosure - Income Taxes - Provision for (Benefit from) Income Taxes (Details) Sheet http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails Income Taxes - Provision for (Benefit from) Income Taxes (Details) Details 96 false false R97.htm 9954539 - Disclosure - Income Taxes - Difference between the Provision For (Benefit From) Income Taxes Compared to Income Taxes Computed at the Statutory Federal Tax Rate (Details) Sheet http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails Income Taxes - Difference between the Provision For (Benefit From) Income Taxes Compared to Income Taxes Computed at the Statutory Federal Tax Rate (Details) Details 97 false false R98.htm 9954540 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.omnicell.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 98 false false R99.htm 9954541 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details) Sheet http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails Income Taxes - Significant Components of Deferred Tax Assets (Details) Details 99 false false R100.htm 9954542 - Disclosure - Income Taxes - Change in the Balance of Gross Unrecognized Tax Benefits (Details) Sheet http://www.omnicell.com/role/IncomeTaxesChangeintheBalanceofGrossUnrecognizedTaxBenefitsDetails Income Taxes - Change in the Balance of Gross Unrecognized Tax Benefits (Details) Details 100 false false R101.htm 9954543 - Disclosure - Restructuring Expenses - Narrative (Details) Sheet http://www.omnicell.com/role/RestructuringExpensesNarrativeDetails Restructuring Expenses - Narrative (Details) Details 101 false false R102.htm 9954544 - Disclosure - Restructuring Expenses - Summary of Restructuring Expenses (Details) Sheet http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails Restructuring Expenses - Summary of Restructuring Expenses (Details) Details 102 false false R103.htm 9954545 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details) Sheet http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails Schedule II Valuation and Qualifying Accounts (Details) Details http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccounts 103 false false All Reports Book All Reports omcl-20231231.htm omcl-20231231.xsd omcl-20231231_cal.xml omcl-20231231_def.xml omcl-20231231_lab.xml omcl-20231231_pre.xml omcl-20231231_g1.jpg http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 126 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "omcl-20231231.htm": { "nsprefix": "omcl", "nsuri": "http://www.omnicell.com/20231231", "dts": { "inline": { "local": [ "omcl-20231231.htm" ] }, "schema": { "local": [ "omcl-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "omcl-20231231_cal.xml" ] }, "definitionLink": { "local": [ "omcl-20231231_def.xml" ] }, "labelLink": { "local": [ "omcl-20231231_lab.xml" ] }, "presentationLink": { "local": [ "omcl-20231231_pre.xml" ] } }, "keyStandard": 492, "keyCustom": 80, "axisStandard": 35, "axisCustom": 1, "memberStandard": 58, "memberCustom": 35, "hidden": { "total": 20, "http://www.omnicell.com/20231231": 1, "http://fasb.org/us-gaap/2023": 15, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 323, "entityCount": 1, "segmentCount": 94, "elementCount": 920, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1338, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 4, "http://fasb.org/srt/2023": 2 }, "report": { "R1": { "role": "http://www.omnicell.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.omnicell.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "longName": "0000003 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R4": { "role": "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "longName": "0000005 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R6": { "role": "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R7": { "role": "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R9": { "role": "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Organization and Summary of Significant Accounting Policies", "shortName": "Organization and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.omnicell.com/role/BusinessCombinations", "longName": "0000010 - Disclosure - Business Combinations", "shortName": "Business Combinations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.omnicell.com/role/Revenues", "longName": "0000011 - Disclosure - Revenues", "shortName": "Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.omnicell.com/role/NetIncomeLossPerShare", "longName": "0000012 - Disclosure - Net Income (Loss) Per Share", "shortName": "Net Income (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.omnicell.com/role/FairValueofFinancialInstruments", "longName": "0000013 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.omnicell.com/role/BalanceSheetComponents", "longName": "0000014 - Disclosure - Balance Sheet Components", "shortName": "Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.omnicell.com/role/PropertyandEquipment", "longName": "0000015 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCosts", "longName": "0000016 - Disclosure - External-Use Software Development Costs", "shortName": "External-Use Software Development Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.omnicell.com/role/GoodwillandIntangibleAssets", "longName": "0000017 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.omnicell.com/role/DebtandCreditAgreement", "longName": "0000018 - Disclosure - Debt and Credit Agreement", "shortName": "Debt and Credit Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://www.omnicell.com/role/ConvertibleSeniorNotes", "longName": "0000019 - Disclosure - Convertible Senior Notes", "shortName": "Convertible Senior Notes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://www.omnicell.com/role/LessorLeases", "longName": "0000020 - Disclosure - Lessor Leases", "shortName": "Lessor Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LessorSalesTypeLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LessorSalesTypeLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.omnicell.com/role/LesseeLeases", "longName": "0000021 - Disclosure - Lessee Leases", "shortName": "Lessee Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.omnicell.com/role/CommitmentsandContingencies", "longName": "0000022 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensation", "longName": "0000023 - Disclosure - Employee Benefits and Share-Based Compensation", "shortName": "Employee Benefits and Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.omnicell.com/role/StockRepurchasePrograms", "longName": "0000024 - Disclosure - Stock Repurchase Programs", "shortName": "Stock Repurchase Programs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.omnicell.com/role/IncomeTaxes", "longName": "0000025 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.omnicell.com/role/RestructuringExpenses", "longName": "0000026 - Disclosure - Restructuring Expenses", "shortName": "Restructuring Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccounts", "longName": "0000027 - Disclosure - Schedule II Valuation and Qualifying Accounts", "shortName": "Schedule II Valuation and Qualifying Accounts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables", "longName": "9954473 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)", "shortName": "Organization and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "omcl:RevenueFromContractWithCustomerTimingAndClassificationOfRevenueCategoriesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "omcl:RevenueFromContractWithCustomerTimingAndClassificationOfRevenueCategoriesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.omnicell.com/role/BusinessCombinationsTables", "longName": "9954474 - Disclosure - Business Combinations (Tables)", "shortName": "Business Combinations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.omnicell.com/role/RevenuesTables", "longName": "9954475 - Disclosure - Revenues (Tables)", "shortName": "Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.omnicell.com/role/NetIncomeLossPerShareTables", "longName": "9954476 - Disclosure - Net Income (Loss) Per Share (Tables)", "shortName": "Net Income (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.omnicell.com/role/BalanceSheetComponentsTables", "longName": "9954477 - Disclosure - Balance Sheet Components (Tables)", "shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.omnicell.com/role/PropertyandEquipmentTables", "longName": "9954478 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R37": { "role": "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsTables", "longName": "9954479 - Disclosure - External-Use Software Development Costs (Tables)", "shortName": "External-Use Software Development Costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "omcl:ScheduleOfCapitalizedComputerSoftwareNetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "omcl:ScheduleOfCapitalizedComputerSoftwareNetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.omnicell.com/role/GoodwillandIntangibleAssetsTables", "longName": "9954480 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.omnicell.com/role/ConvertibleSeniorNotesTables", "longName": "9954481 - Disclosure - Convertible Senior Notes (Tables)", "shortName": "Convertible Senior Notes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.omnicell.com/role/LessorLeasesTables", "longName": "9954482 - Disclosure - Lessor Leases (Tables)", "shortName": "Lessor Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.omnicell.com/role/LesseeLeasesTables", "longName": "9954483 - Disclosure - Lessee Leases (Tables)", "shortName": "Lessee Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables", "longName": "9954484 - Disclosure - Employee Benefits and Share-Based Compensation (Tables)", "shortName": "Employee Benefits and Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.omnicell.com/role/IncomeTaxesTables", "longName": "9954485 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.omnicell.com/role/RestructuringExpensesTables", "longName": "9954486 - Disclosure - Restructuring Expenses (Tables)", "shortName": "Restructuring Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954487 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Organization and Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "longName": "9954488 - Disclosure - Organization and Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)", "shortName": "Organization and Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-68", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-68", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "longName": "9954489 - Disclosure - Business Combinations - Narrative (Details)", "shortName": "Business Combinations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-30", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-76", "name": "omcl:BusinessCombinationBasePurchasePrice", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R48": { "role": "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails", "longName": "9954490 - Disclosure - Business Combinations - Summary of Preliminary Purchase Price (Details)", "shortName": "Business Combinations - Summary of Preliminary Purchase Price (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-80", "name": "omcl:BusinessCombinationBasePurchasePrice", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-80", "name": "omcl:BusinessCombinationEstimatedClosingCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R49": { "role": "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "longName": "9954491 - Disclosure - Business Combinations - Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed By the Company (Details)", "shortName": "Business Combinations - Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed By the Company (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-82", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R50": { "role": "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "longName": "9954492 - Disclosure - Business Combinations - Summary of Identifiable Intangible Assets Acquired (Details)", "shortName": "Business Combinations - Summary of Identifiable Intangible Assets Acquired (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-80", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-80", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.omnicell.com/role/BusinessCombinationsProFormaFinancialInformationDetails", "longName": "9954493 - Disclosure - Business Combinations - Pro Forma Financial Information (Details)", "shortName": "Business Combinations - Pro Forma Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails", "longName": "9954494 - Disclosure - Revenues - Disaggregation of Revenues by Revenue Type (Details)", "shortName": "Revenues - Disaggregation of Revenues by Revenue Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-109", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R53": { "role": "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyGeographicRegionDetails", "longName": "9954495 - Disclosure - Revenues - Disaggregation of Revenues by Geographic Region (Details)", "shortName": "Revenues - Disaggregation of Revenues by Geographic Region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-121", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R54": { "role": "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails", "longName": "9954496 - Disclosure - Revenues - Contract Assets and Liabilities (Details)", "shortName": "Revenues - Contract Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.omnicell.com/role/RevenuesNarrativeDetails", "longName": "9954497 - Disclosure - Revenues - Narrative (Details)", "shortName": "Revenues - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "omcl:ContractWithCustomerAssetCurrentDeferredCostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R56": { "role": "http://www.omnicell.com/role/NetIncomeLossPerShareDetails", "longName": "9954498 - Disclosure - Net Income (Loss) Per Share (Details)", "shortName": "Net Income (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-127", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R57": { "role": "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails", "longName": "9954499 - Disclosure - Fair Value of Financial Instruments (Details)", "shortName": "Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-139", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-139", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "longName": "9954500 - Disclosure - Balance Sheet Components - Balance Sheet Components (Details)", "shortName": "Balance Sheet Components - Balance Sheet Components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954501 - Disclosure - Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails", "longName": "9954502 - Disclosure - Property and Equipment - Property and Equipment Balances (Details)", "shortName": "Property and Equipment - Property and Equipment Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.omnicell.com/role/PropertyandEquipmentNarrativeDetails", "longName": "9954503 - Disclosure - Property and Equipment - Narrative (Details)", "shortName": "Property and Equipment - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.omnicell.com/role/PropertyandEquipmentSummaryofGeographicInformationforPropertyandEquipmentNetDetails", "longName": "9954504 - Disclosure - Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details)", "shortName": "Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-151", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R63": { "role": "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofCapitalizedComputerSoftwareDetails", "longName": "9954505 - Disclosure - External-Use Software Development Costs - Schedule of Capitalized Computer Software (Details)", "shortName": "External-Use Software Development Costs - Schedule of Capitalized Computer Software (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CapitalizedComputerSoftwareGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "omcl:ScheduleOfCapitalizedComputerSoftwareNetTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CapitalizedComputerSoftwareGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "omcl:ScheduleOfCapitalizedComputerSoftwareNetTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsNarrativeDetails", "longName": "9954506 - Disclosure - External-Use Software Development Costs - Narrative (Details)", "shortName": "External-Use Software Development Costs - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CapitalizedComputerSoftwareAmortization1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CapitalizedComputerSoftwareAmortization1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails", "longName": "9954507 - Disclosure - External-Use Software Development Costs - Schedule of Future Amortization Expenses For Capitalized Software Development Costs (Details)", "shortName": "External-Use Software Development Costs - Schedule of Future Amortization Expenses For Capitalized Software Development Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-5", "name": "omcl:CapitalizedComputerSoftwareAmortizationYearOne", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "omcl:ScheduleOfFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "omcl:CapitalizedComputerSoftwareAmortizationYearOne", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "omcl:ScheduleOfFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.omnicell.com/role/GoodwillandIntangibleAssetsChangesintheCarryingAmountofGoodwillDetails", "longName": "9954508 - Disclosure - Goodwill and Intangible Assets - Changes in the Carrying Amount of Goodwill (Details)", "shortName": "Goodwill and Intangible Assets - Changes in the Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R67": { "role": "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails", "longName": "9954509 - Disclosure - Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details)", "shortName": "Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.omnicell.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "longName": "9954510 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)", "shortName": "Goodwill and Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails", "longName": "9954511 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details)", "shortName": "Goodwill and Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.omnicell.com/role/DebtandCreditAgreementDetails", "longName": "9954512 - Disclosure - Debt and Credit Agreement (Details)", "shortName": "Debt and Credit Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-221", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-221", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "longName": "9954513 - Disclosure - Convertible Senior Notes - Narrative (Details)", "shortName": "Convertible Senior Notes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-227", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-227", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "longName": "9954514 - Disclosure - Convertible Senior Notes - Convertible Debt Balances (Details)", "shortName": "Convertible Senior Notes - Convertible Debt Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-139", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-139", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R73": { "role": "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails", "longName": "9954515 - Disclosure - Convertible Senior Notes - Summary of the Components of Interest Expense (Details)", "shortName": "Convertible Senior Notes - Summary of the Components of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfDebtDiscountPremium", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-233", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "omcl:ScheduleOfInterestExpenseDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R74": { "role": "http://www.omnicell.com/role/LessorLeasesNarrativeDetails", "longName": "9954516 - Disclosure - Lessor Leases - Narrative (Details)", "shortName": "Lessor Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-58", "name": "us-gaap:LessorSalesTypeLeaseTermOfContract1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LessorLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": null }, "R75": { "role": "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromSalesTypeLeasesDetails", "longName": "9954517 - Disclosure - Lessor Leases - Income Recognized from Sales-Type Leases (Details)", "shortName": "Lessor Leases - Income Recognized from Sales-Type Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SalesTypeLeaseRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SalesTypeLeaseRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails", "longName": "9954518 - Disclosure - Lessor Leases - Components of Sales-Type Lease Receivables (Details)", "shortName": "Lessor Leases - Components of Sales-Type Lease Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfReceivablesWithImputedInterestTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:NetInvestmentInLeaseAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfReceivablesWithImputedInterestTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R77": { "role": "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails", "longName": "9954519 - Disclosure - Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details)", "shortName": "Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromOperatingLeasesDetails", "longName": "9954520 - Disclosure - Lessor Leases - Income Recognized from Operating Leases (Details)", "shortName": "Lessor Leases - Income Recognized from Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails", "longName": "9954521 - Disclosure - Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases (Details)", "shortName": "Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails", "longName": "9954522 - Disclosure - Lessee Leases - Narrative (Details)", "shortName": "Lessee Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails", "longName": "9954523 - Disclosure - Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and\u00a0the Reconciliation to the Operating Lease Liabilities (Details)", "shortName": "Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and\u00a0the Reconciliation to the Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.omnicell.com/role/LesseeLeasesSupplementalCashFlowInformationRelatedtoOperatingLeasesDetails", "longName": "9954524 - Disclosure - Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)", "shortName": "Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.omnicell.com/role/LesseeLeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateDetails", "longName": "9954525 - Disclosure - Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)", "shortName": "Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.omnicell.com/role/CommitmentsandContingenciesDetails", "longName": "9954526 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:PurchaseObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R85": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "longName": "9954527 - Disclosure - Employee Benefits and Share-Based Compensation - Narrative (Details)", "shortName": "Employee Benefits and Share-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "omcl:ScheduleofSharebasedCompensationFutureIssuanceofSharesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R86": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails", "longName": "9954528 - Disclosure - Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details)", "shortName": "Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "longName": "9954529 - Disclosure - Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares Granted (Details)", "shortName": "Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-243", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-243", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails", "longName": "9954530 - Disclosure - Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details)", "shortName": "Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-245", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-245", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails", "longName": "9954531 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details)", "shortName": "Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R90": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails", "longName": "9954532 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)", "shortName": "Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-267", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-248", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R91": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "longName": "9954533 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details)", "shortName": "Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-271", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-272", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R92": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "longName": "9954534 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details)", "shortName": "Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-283", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-280", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R93": { "role": "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails", "longName": "9954535 - Disclosure - Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details)", "shortName": "Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "omcl:ScheduleofSharebasedCompensationFutureIssuanceofSharesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-287", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "omcl:ScheduleofSharebasedCompensationFutureIssuanceofSharesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R94": { "role": "http://www.omnicell.com/role/StockRepurchaseProgramsDetails", "longName": "9954536 - Disclosure - Stock Repurchase Programs (Details)", "shortName": "Stock Repurchase Programs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.omnicell.com/role/IncomeTaxesGeographicalBreakdownofIncomeLossbeforetheProvisionforIncomeTaxesDetails", "longName": "9954537 - Disclosure - Income Taxes - Geographical Breakdown of Income (Loss) before the Provision for Income Taxes (Details)", "shortName": "Income Taxes - Geographical Breakdown of Income (Loss) before the Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails", "longName": "9954538 - Disclosure - Income Taxes - Provision for (Benefit from) Income Taxes (Details)", "shortName": "Income Taxes - Provision for (Benefit from) Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails", "longName": "9954539 - Disclosure - Income Taxes - Difference between the Provision For (Benefit From) Income Taxes Compared to Income Taxes Computed at the Statutory Federal Tax Rate (Details)", "shortName": "Income Taxes - Difference between the Provision For (Benefit From) Income Taxes Compared to Income Taxes Computed at the Statutory Federal Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails", "longName": "9954540 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:DeferredTaxAssetsValuationAllowance", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R99": { "role": "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails", "longName": "9954541 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)", "shortName": "Income Taxes - Significant Components of Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DeferredTaxAssetsDeferredIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DeferredTaxAssetsDeferredIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.omnicell.com/role/IncomeTaxesChangeintheBalanceofGrossUnrecognizedTaxBenefitsDetails", "longName": "9954542 - Disclosure - Income Taxes - Change in the Balance of Gross Unrecognized Tax Benefits (Details)", "shortName": "Income Taxes - Change in the Balance of Gross Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-20", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R101": { "role": "http://www.omnicell.com/role/RestructuringExpensesNarrativeDetails", "longName": "9954543 - Disclosure - Restructuring Expenses - Narrative (Details)", "shortName": "Restructuring Expenses - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-302", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R102": { "role": "http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails", "longName": "9954544 - Disclosure - Restructuring Expenses - Summary of Restructuring Expenses (Details)", "shortName": "Restructuring Expenses - Summary of Restructuring Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-302", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-250", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } }, "R103": { "role": "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails", "longName": "9954545 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)", "shortName": "Schedule II Valuation and Qualifying Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-20", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "omcl-20231231.htm", "unique": true } } }, "tag": { "omcl_A2009PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "A2009PlanMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2009 Plan", "label": "2009 Plan [Member]", "documentation": "2009 Plan [Member]" } } }, "auth_ref": [] }, "omcl_A2014ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "A2014ShareRepurchaseProgramMember", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2014 Share Repurchase Program", "label": "2014 Share Repurchase Program [Member]", "documentation": "2014 Share Repurchase Program" } } }, "auth_ref": [] }, "omcl_A2016RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "A2016RepurchaseProgramMember", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 Repurchase Program", "label": "2016 Repurchase Program [Member]", "documentation": "The 2016 Repurchase Program [Member]" } } }, "auth_ref": [] }, "omcl_A2016and2014ShareRepurchaseProgramsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "A2016and2014ShareRepurchaseProgramsMember", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 and 2014 Share Repurchase Programs", "label": "2016 and 2014 Share Repurchase Programs [Member]", "documentation": "2016 and 2014 Share Repurchase Programs [Member]" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "omcl_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "AccountingPoliciesLineItems", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "documentation": "[Line Items] for Accounting Policies [Table]" } } }, "auth_ref": [] }, "omcl_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "AccountingPoliciesTable", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Table]", "label": "Accounting Policies [Table]", "documentation": "Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdateExtensibleList", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update [Extensible List]", "label": "Accounting Standards Update [Extensible Enumeration]", "documentation": "Indicates amendment to accounting standards." } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r244", "r296", "r297", "r298", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r399", "r594", "r595", "r596", "r627", "r628", "r641", "r642", "r643", "r649", "r650", "r651", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r673", "r674", "r676", "r677", "r678", "r679", "r688", "r689", "r692", "r693", "r694", "r718", "r719", "r720", "r721", "r722", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r1033" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39", "r907" ] }, "omcl_AccountsReceivableAndUnbilledReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "AccountsReceivableAndUnbilledReceivablesMember", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and unbilled receivables", "label": "Accounts Receivable And Unbilled Receivables [Member]", "documentation": "Accounts Receivable And Unbilled Receivables" } } }, "auth_ref": [] }, "omcl_AccruedGroupPurchasingOrganizationFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "AccruedGroupPurchasingOrganizationFees", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Group purchasing organization fees", "label": "Accrued Group Purchasing Organization Fees", "documentation": "Accrued Group Purchasing Organization Fees" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r43" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAbstract", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities:", "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "omcl_AccruedLiabilitiesRebateLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "AccruedLiabilitiesRebateLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Rebate liabilities", "label": "Accrued Liabilities, Rebate Liabilities, Current", "documentation": "Accrued Liabilities, Rebate Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r84", "r251", "r744" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r269", "r270", "r682", "r683", "r684", "r685", "r686", "r687" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r53", "r54", "r150", "r256", "r740", "r765", "r769" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r269", "r270", "r682", "r683", "r684", "r685", "r686", "r687" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r7", "r22", "r54", "r653", "r656", "r722", "r760", "r761", "r1017", "r1018", "r1019", "r1030", "r1031", "r1032" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life (years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r171" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r961" ] }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing activities", "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r145", "r907", "r1188" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r594", "r595", "r596", "r776", "r1030", "r1031", "r1032", "r1160", "r1189" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r967" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r967" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r967" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r967" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax payments related to restricted stock units", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "omcl_AdjustmentsToAdditionalPaidInCapitalConvertibleNoteHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleNoteHedge", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of convertible note hedge", "label": "Adjustments To Additional Paid In Capital, Convertible Note Hedge", "documentation": "Adjustments To Additional Paid In Capital, Convertible Note Hedge" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r102", "r103", "r559" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "omcl_AdvancedServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "AdvancedServicesMember", "presentation": [ "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advanced Services", "label": "Advanced Services [Member]", "documentation": "Advanced Services" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r931", "r943", "r953", "r979" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r934", "r946", "r956", "r982" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r967" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r974" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r938", "r947", "r957", "r974", "r983", "r987", "r995" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r993" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r591", "r601" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and unbilled receivables, net of allowance", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r257", "r349", "r366" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of discount on convertible senior notes", "verboseLabel": "Amortization of discount", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r12", "r132", "r159", "r451" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r153", "r451", "r690", "r1023" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r12", "r76", "r81" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive weighted-average shares related to stock award plans (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r319" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r66" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r66" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r202", "r255", "r281", "r325", "r338", "r342", "r352", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r645", "r647", "r675", "r736", "r804", "r907", "r920", "r1058", "r1059", "r1172" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r246", "r262", "r281", "r352", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r645", "r647", "r675", "r907", "r1058", "r1059", "r1172" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.omnicell.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r925", "r926", "r939" ] }, "omcl_AuditorInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "AuditorInformationAbstract", "lang": { "en-us": { "role": { "label": "Auditor Information [Abstract]", "documentation": "Auditor Information" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.omnicell.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r925", "r926", "r939" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.omnicell.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r925", "r926", "r939" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r990" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r991" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r986" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r562", "r563", "r564", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r590" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r989" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r988" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r987" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r987" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r123", "r126" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BridgeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BridgeLoanMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swing Line Loan", "label": "Bridge Loan [Member]", "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r639", "r897", "r900" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r109", "r111", "r639", "r897", "r900" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r639" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Pro Forma Financial Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r1008", "r1009" ] }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill expected to be deductible for tax purposes", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes." } } }, "auth_ref": [ "r121" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro forma net income", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r637", "r638" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro forma revenues", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r637", "r638" ] }, "omcl_BusinessCombinationAcquiredIntangibleAssetsMeasurementInput": { "xbrltype": "pureItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationAcquiredIntangibleAssetsMeasurementInput", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement input used in estimating the fair values of intangible assets", "label": "Business Combination, Acquired Intangible Assets, Measurement Input", "documentation": "Business Combination, Acquired Intangible Assets, Measurement Input" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition related costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r108" ] }, "omcl_BusinessCombinationAdjustmentPurchasePriceAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationAdjustmentPurchasePriceAdjustment", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price adjustments from business acquisitions", "label": "Business Combination, Adjustment, Purchase Price Adjustment", "documentation": "Business Combination, Adjustment, Purchase Price Adjustment" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "omcl_BusinessCombinationBasePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationBasePurchasePrice", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base purchase price", "label": "Business Combination, Base Purchase Price", "documentation": "Business Combination, Base Purchase Price" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price transferred", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r4", "r5", "r17" ] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Assumed indebtedness", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r4", "r5", "r120", "r644" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.omnicell.com/role/BusinessCombinations" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r197", "r640" ] }, "omcl_BusinessCombinationEstimatedClosingCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationEstimatedClosingCash", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Add: Closing cash", "label": "Business Combination, Estimated Closing Cash", "documentation": "Business Combination, Estimated Closing Cash" } } }, "auth_ref": [] }, "omcl_BusinessCombinationEstimatedNetWorkingCapitalAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationEstimatedNetWorkingCapitalAdjustment", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Add: Net working capital adjustment", "label": "Business Combination, Estimated Net Working Capital Adjustment", "documentation": "Business Combination, Estimated Net Working Capital Adjustment" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Losses from operations since the acquisition date", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r110" ] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from operations since the acquisition date", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r110" ] }, "omcl_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivableAndUnbilledReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivableAndUnbilledReceivables", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment, accounts receivable and unbilled receivables", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable And Unbilled Receivables", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable And Unbilled Receivables" } } }, "auth_ref": [] }, "omcl_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedLiabilities", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in accrued liabilities", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Liabilities", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Liabilities" } } }, "auth_ref": [] }, "omcl_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in deferred tax liabilities", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities, Noncurrent", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities, Noncurrent" } } }, "auth_ref": [] }, "omcl_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment, deferred tax liability, noncurrent", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability, Noncurrent", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment, intangibles", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r115" ] }, "omcl_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in other assets, current", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets, Current", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets, Current" } } }, "auth_ref": [] }, "omcl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Compensation", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Compensation" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and unbilled receivables", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "omcl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term deferred tax liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total purchase price", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r112", "r113" ] }, "omcl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetOfCashAcquired", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price, net of cash acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Of Cash Acquired", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Of Cash Acquired" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "omcl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liabilities", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liabilities" } } }, "auth_ref": [] }, "omcl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r112", "r113" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r107" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid purchases of property and equipment", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r63", "r64", "r65" ] }, "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwareAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofCapitalizedComputerSoftwareDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofCapitalizedComputerSoftwareDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Capitalized Computer Software, Accumulated Amortization", "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs." } } }, "auth_ref": [ "r1195" ] }, "us-gaap_CapitalizedComputerSoftwareAmortization1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwareAmortization1", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of capitalized software development costs", "label": "Capitalized Computer Software, Amortization", "documentation": "Amount of expense for amortization of capitalized computer software costs." } } }, "auth_ref": [ "r18", "r209" ] }, "omcl_CapitalizedComputerSoftwareAmortizationAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedComputerSoftwareAmortizationAfterYearFive", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Capitalized Computer Software, Amortization, After Year Five", "documentation": "Capitalized Computer Software, Amortization, After Year Five" } } }, "auth_ref": [] }, "omcl_CapitalizedComputerSoftwareAmortizationYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedComputerSoftwareAmortizationYearFive", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Capitalized Computer Software, Amortization, Year Five", "documentation": "Capitalized Computer Software, Amortization, Year Five" } } }, "auth_ref": [] }, "omcl_CapitalizedComputerSoftwareAmortizationYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedComputerSoftwareAmortizationYearFour", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Capitalized Computer Software, Amortization, Year Four", "documentation": "Capitalized Computer Software, Amortization, Year Four" } } }, "auth_ref": [] }, "omcl_CapitalizedComputerSoftwareAmortizationYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedComputerSoftwareAmortizationYearOne", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Capitalized Computer Software, Amortization, Year One", "documentation": "Capitalized Computer Software, Amortization, Year One" } } }, "auth_ref": [] }, "omcl_CapitalizedComputerSoftwareAmortizationYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedComputerSoftwareAmortizationYearThree", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Capitalized Computer Software, Amortization, Year Three", "documentation": "Capitalized Computer Software, Amortization, Year Three" } } }, "auth_ref": [] }, "omcl_CapitalizedComputerSoftwareAmortizationYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedComputerSoftwareAmortizationYearTwo", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Capitalized Computer Software, Amortization, Year Two", "documentation": "Capitalized Computer Software, Amortization, Year Two" } } }, "auth_ref": [] }, "omcl_CapitalizedComputerSoftwareEstimatedUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedComputerSoftwareEstimatedUsefulLife", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life of software-related products", "label": "Capitalized Computer Software, Estimated Useful Life", "documentation": "Capitalized Computer Software, Estimated Useful Life" } } }, "auth_ref": [] }, "us-gaap_CapitalizedComputerSoftwareGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwareGross", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofCapitalizedComputerSoftwareDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofCapitalizedComputerSoftwareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying amount", "label": "Capitalized Computer Software, Gross", "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software." } } }, "auth_ref": [ "r1195" ] }, "us-gaap_CapitalizedComputerSoftwareImpairments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwareImpairments1", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of internal-use and external-use software development costs, net", "label": "Capitalized Computer Software, Impairments", "documentation": "Amount of impairment loss from capitalized computer software costs." } } }, "auth_ref": [ "r19", "r209" ] }, "us-gaap_CapitalizedComputerSoftwareNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwareNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofCapitalizedComputerSoftwareDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofCapitalizedComputerSoftwareDetails", "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsScheduleofFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "External-use software development costs, net", "totalLabel": "External-use software development costs, net", "label": "Capitalized Computer Software, Net", "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date." } } }, "auth_ref": [ "r861" ] }, "us-gaap_CapitalizedComputerSoftwarePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwarePeriodIncreaseDecrease", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Software development costs capitalized", "label": "Capitalized Computer Software, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in capitalized computer software costs." } } }, "auth_ref": [ "r138" ] }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostAmortizationPeriod", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization period for capitalized contract costs", "label": "Capitalized Contract Cost, Amortization Period", "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1007" ] }, "us-gaap_CapitalizedContractCostImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss related to capitalized prepaid commissions", "label": "Capitalized Contract Cost, Impairment Loss", "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r387" ] }, "omcl_CapitalizedContractCostInitialTermAndRenewalServicePeriods": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedContractCostInitialTermAndRenewalServicePeriods", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial term and renewal service periods", "label": "Capitalized Contract Cost, Initial Term And Renewal Service Periods", "documentation": "Capitalized Contract Cost, Initial Term And Renewal Service Periods" } } }, "auth_ref": [] }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostNetNoncurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid commissions", "label": "Capitalized Contract Cost, Net, Noncurrent", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent." } } }, "auth_ref": [ "r386" ] }, "omcl_CapitalizedContractCostOriginalTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedContractCostOriginalTermOfContract", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Original terms of contracts", "label": "Capitalized Contract Cost, Original Term Of Contract", "documentation": "Capitalized Contract Cost, Original Term Of Contract" } } }, "auth_ref": [] }, "omcl_CapitalizedContractCostsRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CapitalizedContractCostsRecognized", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract cost expense", "label": "Capitalized Contract Costs Recognized", "documentation": "Capitalized Contract Costs Recognized" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r60", "r249", "r865" ] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Line Items]", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r61" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "totalLabel": "Cash, cash equivalents, and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r60", "r162", "r279" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash to the Consolidated Balance Sheets:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r6", "r162" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r1015", "r1183" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r965" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Treasury Stock [Table]", "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r92", "r93", "r94", "r95" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r96" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strike price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r459" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options and warrants to purchase shares (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r966" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r966" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 14)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r49", "r136", "r738", "r791" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r88", "r849" ] }, "us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsContingenciesAndGuaranteesTextBlock", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments Contingencies and Guarantees [Text Block]", "documentation": "The entire disclosure for commitments, contingencies, and guarantees." } } }, "auth_ref": [ "r177", "r178", "r1053" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r50" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r910", "r911", "r912", "r914", "r915", "r916", "r917", "r1030", "r1031", "r1160", "r1186", "r1189" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r144" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r144", "r792" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r144" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r23", "r144", "r792", "r810", "r1189", "r1190" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value, 100,000 shares authorized; 55,822 and 55,030 shares issued; 45,539 and 44,747 shares outstanding, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r144", "r739", "r907" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r971" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r970" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r972" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r969" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefits and Share-Based Compensation", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r187", "r188", "r189", "r190" ] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets (liabilities):", "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r55", "r265", "r267", "r272", "r732", "r748" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r68", "r70", "r130", "r131", "r347", "r848" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r68", "r70", "r130", "r131", "r347", "r770", "r848" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r68", "r70", "r130", "r131", "r347", "r848", "r1006" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r68", "r70", "r130", "r131", "r347" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r68", "r70", "r130", "r131", "r347", "r848" ] }, "omcl_ConnectedDevicesSoftwareLicensesAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ConnectedDevicesSoftwareLicensesAndOtherMember", "presentation": [ "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Connected devices, software licenses, and other", "label": "Connected Devices, Software Licenses, And Other [Member]", "documentation": "Connected Devices, Software Licenses, And Other" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r122", "r873" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "omcl_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ConsumablesMember", "presentation": [ "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consumables", "label": "Consumables [Member]", "documentation": "Consumables" } } }, "auth_ref": [] }, "omcl_ContractTerminationRequirementPeriodofNotification": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ContractTerminationRequirementPeriodofNotification", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period for notice of termination", "label": "Contract Termination Requirement, Period of Notification", "documentation": "Contract Termination Requirement, Period of Notification" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.omnicell.com/role/RevenuesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Assets and Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1062" ] }, "omcl_ContractWithCustomerAssetCurrentDeferredCostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ContractWithCustomerAssetCurrentDeferredCostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/RevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred cost of sales", "label": "Contract With Customer, Asset, Current, Deferred Cost Of Goods And Services Sold", "documentation": "Contract With Customer, Asset, Current, Deferred Cost Of Goods And Services Sold" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total contract assets", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r461", "r463", "r482" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_ContractWithCustomerAssetNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term unbilled receivables, net", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r461", "r463", "r482" ] }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetNoncurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_ContractWithCustomerAssetNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term unbilled receivables, net", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent." } } }, "auth_ref": [ "r461", "r463", "r482" ] }, "omcl_ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term unbilled receivables", "label": "Contract with Customer, Asset, Unbilled Receivables, Noncurrent [Member]", "documentation": "Contract with Customer, Asset, Unbilled Receivables, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total contract liabilities", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r461", "r462", "r482" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 1.0 }, "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails", "http://www.omnicell.com/role/RevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues, net", "verboseLabel": "Short-term deferred revenues, net", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r461", "r462", "r482" ] }, "omcl_ContractWithCustomerLiabilityCustomerAdvancesAndDepositsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ContractWithCustomerLiabilityCustomerAdvancesAndDepositsCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance payments from customers", "label": "Contract with Customer, Liability, Customer Advances and Deposits, Current", "documentation": "Contract with Customer, Liability, Customer Advances and Deposits, Current" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "http://www.omnicell.com/role/RevenuesContractAssetsandLiabilitiesDetails", "http://www.omnicell.com/role/RevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term deferred revenues", "terseLabel": "Long-term deferred revenues", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r461", "r462", "r482" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/RevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r483" ] }, "omcl_ContractwithCustomerLiabilityCurrentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ContractwithCustomerLiabilityCurrentGross", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/RevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross short-term deferred revenue", "label": "Contract with Customer, Liability, Current, Gross", "documentation": "Contract with Customer, Liability, Current, Gross" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails", "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r180", "r430", "r431", "r441", "r442", "r443", "r447", "r448", "r449", "r450", "r451", "r882", "r883", "r884", "r885", "r886" ] }, "omcl_ConvertibleDebtSecuritiesAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ConvertibleDebtSecuritiesAndWarrantsMember", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt Securities and Warrants", "label": "Convertible Debt Securities And Warrants [Member]", "documentation": "Convertible Debt Securities And Warrants" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt Securities", "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r1087" ] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt Balances", "label": "Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible senior notes, net", "label": "Convertible Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r47" ] }, "omcl_ConvertibleNoteHedgeRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ConvertibleNoteHedgeRightsMember", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Note Hedge Rights", "label": "Convertible Note Hedge Rights [Member]", "documentation": "Convertible Note Hedge Rights" } } }, "auth_ref": [] }, "omcl_ConvertibleSeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ConvertibleSeniorNotesMember", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails", "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Senior Notes", "label": "Convertible Senior Notes [Member]", "documentation": "Convertible Senior Notes" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenues", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r155", "r728" ] }, "us-gaap_CostOfGoodsSoldSalesTypeLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsSoldSalesTypeLease", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromSalesTypeLeasesDetails": { "parentTag": "us-gaap_SalesTypeLeaseSellingProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of sales-type lease revenues", "label": "Cost of Goods Sold, Sales-type Lease", "documentation": "Cost of goods sold for sales-type financing lease." } } }, "auth_ref": [ "r323", "r715" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails", "http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product and service revenues", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Credit Losses", "label": "Credit Loss, Financial Instrument [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status." } } }, "auth_ref": [ "r226", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380" ] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect of a Change in Accounting Principle", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r242", "r295", "r301", "r307", "r356", "r362", "r594", "r595", "r596", "r627", "r628", "r652", "r653", "r654", "r656", "r657", "r658", "r662", "r665", "r667", "r668", "r720" ] }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Axis]", "label": "Cumulative Effect, Period of Adoption [Axis]", "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r242", "r295", "r301", "r307", "r356", "r362", "r594", "r595", "r596", "r627", "r628", "r652", "r653", "r654", "r656", "r657", "r658", "r662", "r665", "r667", "r668", "r720" ] }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Domain]", "label": "Cumulative Effect, Period of Adoption [Domain]", "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r242", "r295", "r301", "r307", "r356", "r362", "r594", "r595", "r596", "r627", "r628", "r652", "r653", "r654", "r656", "r657", "r658", "r662", "r665", "r667", "r668", "r720" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1012", "r1027", "r1158" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1012", "r1027" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current income taxes", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r196", "r626", "r632", "r1027" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current:", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1012", "r1027", "r1158" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r69", "r347" ] }, "omcl_CustomerFundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "CustomerFundLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer fund liabilities", "label": "Customer Fund Liability, Current", "documentation": "Customer Fund Liability, Current" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r119" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotes", "http://www.omnicell.com/role/DebtandCreditAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Debt and Credit Agreement", "verboseLabel": "Convertible Senior Notes", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r179", "r280", "r429", "r435", "r436", "r437", "r438", "r439", "r440", "r445", "r452", "r453", "r455" ] }, "omcl_DebtInstrumentAccordionFeatureIncreaseLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentAccordionFeatureIncreaseLimit", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional principal amount subject to purchasers' option", "label": "Debt Instrument, Accordion Feature, Increase Limit", "documentation": "Debt Instrument, Accordion Feature, Increase Limit" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails", "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r38", "r139", "r140", "r203", "r205", "r284", "r430", "r431", "r432", "r433", "r434", "r436", "r441", "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r451", "r691", "r882", "r883", "r884", "r885", "r886", "r1025" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spread on variable interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "omcl_DebtInstrumentConvertibleConsiderationInExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentConvertibleConsiderationInExcessAmount", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration in excess, amount", "label": "Debt Instrument, Convertible, Consideration In Excess, Amount", "documentation": "Debt Instrument, Convertible, Consideration In Excess, Amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r181", "r432" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion ratio", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r46", "r90", "r183", "r184", "r432" ] }, "omcl_DebtInstrumentConvertibleMaximumCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentConvertibleMaximumCash", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum cash", "label": "Debt Instrument, Convertible, Maximum Cash", "documentation": "Debt Instrument, Convertible, Maximum Cash" } } }, "auth_ref": [] }, "omcl_DebtInstrumentConvertibleNumberOfSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentConvertibleNumberOfSharesIssuable", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares issuable upon conversion (in shares)", "label": "Debt Instrument, Convertible, Number Of Shares Issuable", "documentation": "Debt Instrument, Convertible, Number Of Shares Issuable" } } }, "auth_ref": [] }, "omcl_DebtInstrumentConvertiblePrincipalAmountOfNotesMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentConvertiblePrincipalAmountOfNotesMinimum", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount of notes, minimum", "label": "Debt Instrument, Convertible, Principal Amount Of Notes, Minimum", "documentation": "Debt Instrument, Convertible, Principal Amount Of Notes, Minimum" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining life of debt discount and issuance cost accretion", "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period", "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r32" ] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold consecutive trading days", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold percentage of stock price trigger", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold trading days", "label": "Debt Instrument, Convertible, Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "omcl_DebtInstrumentCovenantAdjustedEBITDAThreshold": { "xbrltype": "percentItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentCovenantAdjustedEBITDAThreshold", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, adjusted EBITDA threshold", "label": "Debt Instrument, Covenant, Adjusted EBITDA Threshold", "documentation": "Debt Instrument, Covenant, Adjusted EBITDA Threshold" } } }, "auth_ref": [] }, "omcl_DebtInstrumentCovenantMaximumSecuredNetLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentCovenantMaximumSecuredNetLeverageRatio", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum secured net leverage ratio", "label": "Debt Instrument, Covenant, Maximum Secured Net Leverage Ratio", "documentation": "Debt Instrument, Covenant, Maximum Secured Net Leverage Ratio" } } }, "auth_ref": [] }, "omcl_DebtInstrumentCovenantMinimumInterestCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentCovenantMinimumInterestCoverageRatio", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, minimum interest coverage ratio", "label": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio", "documentation": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio" } } }, "auth_ref": [] }, "omcl_DebtInstrumentCovenantPeriod1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentCovenantPeriod1Member", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Calendar Quarters Up To and Including March 31, 2021", "label": "Debt Instrument, Covenant Period 1 [Member]", "documentation": "Debt Instrument, Covenant Period 1" } } }, "auth_ref": [] }, "omcl_DebtInstrumentCovenantPeriod2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentCovenantPeriod2Member", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Calendar Quarters After March 31, 2021", "label": "Debt Instrument, Covenant Period 2 [Member]", "documentation": "Debt Instrument, Covenant Period 2" } } }, "auth_ref": [] }, "omcl_DebtInstrumentCovenantTermsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentCovenantTermsAxis", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Covenant Terms [Axis]", "label": "Debt Instrument, Covenant Terms [Axis]", "documentation": "Debt Instrument, Covenant Terms" } } }, "auth_ref": [] }, "omcl_DebtInstrumentCovenantTermsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentCovenantTermsDomain", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Covenant Terms [Domain]", "label": "Debt Instrument, Covenant Terms [Domain]", "documentation": "Debt Instrument, Covenant Terms" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r133", "r135", "r430", "r691", "r883", "r884" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r45", "r133", "r457", "r691" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r45", "r431" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails", "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r284", "r430", "r431", "r432", "r433", "r434", "r436", "r441", "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r451", "r454", "r691", "r882", "r883", "r884", "r885", "r886", "r1025" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails", "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r47", "r284", "r430", "r431", "r432", "r433", "r434", "r436", "r441", "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r451", "r691", "r882", "r883", "r884", "r885", "r886", "r1025" ] }, "omcl_DebtInstrumentRedemptionFaceAmountOfNotesThatMustBeOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DebtInstrumentRedemptionFaceAmountOfNotesThatMustBeOutstanding", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount of Notes that must be outstanding and not subject to redemption if the Company redeems less than all of the Notes", "label": "Debt Instrument, Redemption, Face Amount Of Notes That Must Be Outstanding", "documentation": "Debt Instrument, Redemption, Face Amount Of Notes That Must Be Outstanding" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information about timing of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r27" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r27" ] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period 1", "label": "Debt Instrument, Redemption, Period One [Member]", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r27" ] }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period 2", "label": "Debt Instrument, Redemption, Period Two [Member]", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r27" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase price as a percent of principal amount", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails", "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r47", "r90", "r91", "r132", "r133", "r135", "r137", "r182", "r184", "r284", "r430", "r431", "r432", "r433", "r434", "r436", "r441", "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r451", "r454", "r691", "r882", "r883", "r884", "r885", "r886", "r1025" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of debt instrument", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r37" ] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r14" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1027", "r1157", "r1158" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r134", "r1061" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r196", "r1027", "r1157" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r608", "r609" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r12", "r196", "r225", "r631", "r632", "r1027" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred:", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r141", "r142", "r204", "r620" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r608", "r609", "r737" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r164" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1027", "r1157", "r1158" ] }, "omcl_DeferredTaxAssetConvertibleDebtHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DeferredTaxAssetConvertibleDebtHedge", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset related to the convertible note hedge transaction", "label": "Deferred Tax Asset, Convertible Debt Hedge", "documentation": "Deferred Tax Asset, Convertible Debt Hedge" } } }, "auth_ref": [] }, "omcl_DeferredTaxAssetsConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DeferredTaxAssetsConvertibleNotesPayable", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt", "label": "Deferred Tax Assets, Convertible Notes Payable", "documentation": "Deferred Tax Assets, Convertible Notes Payable" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsDeferredIncome", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues", "label": "Deferred Tax Assets, Deferred Income", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r621" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research and development", "label": "Deferred Tax Assets, in Process Research and Development", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory-related items", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r106", "r1156" ] }, "omcl_DeferredTaxAssetsLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DeferredTaxAssetsLeasingArrangements", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Deferred Tax Assets, Leasing Arrangements", "documentation": "Deferred Tax Assets, Leasing Arrangements" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1155" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1155" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforwards", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r105", "r106", "r1156" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves and accruals", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails", "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "negatedTerseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r622" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Intangibles", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Right-of-use assets", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses", "label": "Deferred Tax Liabilities, Prepaid Expenses", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation and amortization", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r106", "r1156" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "401(k) contributions", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r544" ] }, "omcl_DefinedContributionPlanEmployerMatchingContributionMaximumContribution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "DefinedContributionPlanEmployerMatchingContributionMaximumContribution", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount of employer contribution", "label": "Defined Contribution Plan, Employer Matching Contribution, Maximum Contribution", "documentation": "Defined Contribution Plan, Employer Matching Contribution, Maximum Contribution" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer matching contribution, percent of employee contribution", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense of property and equipment", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r12", "r83" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r12", "r328" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r781", "r783", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r805", "r806", "r807", "r808", "r818", "r819", "r820", "r821", "r824", "r825", "r826", "r827", "r840", "r841", "r842", "r843", "r910", "r912" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r124", "r125", "r127", "r128", "r781", "r783", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r805", "r806", "r807", "r808", "r818", "r819", "r820", "r821", "r824", "r825", "r826", "r827", "r840", "r841", "r842", "r843", "r872", "r910", "r912" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyGeographicRegionDetails", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r481", "r888", "r889", "r890", "r891", "r892", "r893", "r894" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyGeographicRegionDetails", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r481", "r888", "r889", "r890", "r891", "r892", "r893", "r894" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.omnicell.com/role/RevenuesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenues by Revenue Type", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1063" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r925", "r926", "r939" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r925", "r926", "r939", "r975" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r960" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r923" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal Revenue Service (IRS)", "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income per share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r273", "r299", "r300", "r301", "r302", "r303", "r309", "r311", "r316", "r317", "r318", "r322", "r668", "r669", "r733", "r749", "r875" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income per share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r273", "r299", "r300", "r301", "r302", "r303", "r311", "r316", "r317", "r318", "r322", "r668", "r669", "r733", "r749", "r875" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r66", "r67" ] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r308", "r319", "r320", "r321" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r681" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationFdiiAmount", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign-derived intangible income deduction", "label": "Effective Income Tax Rate Reconciliation, FDII, Amount", "documentation": "Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)." } } }, "auth_ref": [ "r1152" ] }, "omcl_EffectiveIncomeTaxRateReconciliationForeignBranchTaxesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationForeignBranchTaxesAmount", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign branch taxes", "label": "Effective Income Tax Rate Reconciliation, Foreign Branch Taxes, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Foreign Branch Taxes, Amount" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global intangible low-taxed income inclusion", "label": "Effective Income Tax Rate Reconciliation, GILTI, Amount", "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)." } } }, "auth_ref": [ "r1152" ] }, "omcl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationUnderSection162mAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationUnderSection162mAmount", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Section 162(m) limitation", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation Under Section 162(m), Amount", "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation Under Section 162(m), Amount" } } }, "auth_ref": [] }, "omcl_EffectiveIncomeTaxRateReconciliationProvisionToReturnTrueUp": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationProvisionToReturnTrueUp", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision to return true up", "label": "Effective Income Tax Rate Reconciliation, Provision To Return True Up", "documentation": "Effective Income Tax Rate Reconciliation, Provision To Return True Up" } } }, "auth_ref": [] }, "omcl_EffectiveIncomeTaxRateReconciliationRestructuringImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationRestructuringImpact", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring impact", "label": "Effective Income Tax Rate Reconciliation, Restructuring Impact", "documentation": "Effective Income Tax Rate Reconciliation, Restructuring Impact" } } }, "auth_ref": [] }, "omcl_EffectiveIncomeTaxRateReconciliationStateRateTrueUp": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationStateRateTrueUp", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State rate true up", "label": "Effective Income Tax Rate Reconciliation, State Rate True Up", "documentation": "Effective Income Tax Rate Reconciliation, State Rate True Up" } } }, "auth_ref": [] }, "omcl_EffectiveIncomeTaxRateReconciliationTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationTransactionCosts", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction cost", "label": "Effective Income Tax Rate Reconciliation, Transaction Costs", "documentation": "Effective Income Tax Rate Reconciliation, Transaction Costs" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r43" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement, amount capitalized", "label": "Share-Based Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r592" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period of compensation cost recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r593" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1151" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost of unvested stock options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1151" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax (expense) benefit from share-based compensation", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r591" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP", "verboseLabel": "ESPP shares available for future issuance", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "verboseLabel": "Stock options outstanding", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r922" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r922" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r922" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1000" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r922" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r922" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r922" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r922" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1001" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Class of Treasury Stock [Line Items]", "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r23", "r242", "r269", "r270", "r271", "r292", "r293", "r294", "r297", "r304", "r306", "r324", "r356", "r362", "r460", "r594", "r595", "r596", "r627", "r628", "r652", "r653", "r654", "r655", "r656", "r658", "r667", "r682", "r683", "r684", "r685", "r686", "r687", "r722", "r760", "r761", "r762", "r776", "r830" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r968" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r931", "r943", "r953", "r979" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r928", "r940", "r950", "r976" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r974" ] }, "omcl_FDSAmplicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "FDSAmplicareMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FDS Amplicare", "label": "FDS Amplicare [Member]", "documentation": "FDS Amplicare" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.omnicell.com/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r671" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r15", "r36" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal Funds", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r1159" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r253", "r396" ] }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed." } } }, "auth_ref": [ "r77" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r173" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r173" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r173" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r173" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r173" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r393", "r395", "r396", "r397", "r729", "r730" ] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency exchange rate fluctuations", "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r172", "r730" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r77", "r80" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net carrying amount", "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r172", "r729" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Authority", "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation and Remeasurement", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r680" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r935", "r947", "r957", "r983" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r935", "r947", "r957", "r983" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r935", "r947", "r957", "r983" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r935", "r947", "r957", "r983" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r935", "r947", "r957", "r983" ] }, "us-gaap_FundsHeldForClients": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FundsHeldForClients", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funds held for customers, including restricted cash", "label": "Funds Held for Clients", "documentation": "Carrying amount as of the balance sheet date of the funds held on behalf of others and that are expected to be liquidated within one year or the normal operating cycle, if longer. This does not include funds held under reinsurance agreements." } } }, "auth_ref": [ "r1016" ] }, "omcl_FundsHeldForCustomersAndCustomerFundLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "FundsHeldForCustomersAndCustomerFundLiabilitiesPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Funds Held for Customers and Customer Fund Liabilities", "label": "Funds Held For Customers And Customer Fund Liabilities [Policy Text Block]", "documentation": "Funds Held For Customers And Customer Fund Liabilities" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "omcl_FutureGrantsAndAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "FutureGrantsAndAwardsMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized for future issuance", "label": "Future Grants And Awards [Member]", "documentation": "future grants and awards [Member]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal of property and equipment", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r1023" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 }, "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsChangesintheCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r252", "r388", "r731", "r881", "r907", "r1041", "r1048" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsChangesintheCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r390", "r881" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r170" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Acquired Intangible Assets", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r16", "r74" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsChangesintheCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency exchange rate fluctuations", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r391" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated impairment loss on goodwill", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r389", "r392", "r881" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsChangesintheCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement period adjustments", "label": "Goodwill, Purchase Accounting Adjustments", "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r1", "r1047" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsChangesintheCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r154", "r281", "r325", "r337", "r341", "r343", "r352", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r675", "r877", "r1058" ] }, "omcl_GroupPurchasingOrganizationFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "GroupPurchasingOrganizationFees", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fees to GPOs", "label": "Group Purchasing Organization Fees", "documentation": "Group Purchasing Organization Fees" } } }, "auth_ref": [] }, "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantees", "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]", "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities." } } }, "auth_ref": [ "r418" ] }, "omcl_HubAndSpokeInnovationsLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "HubAndSpokeInnovationsLimitedMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hub and Spoke Innovations", "label": "Hub And Spoke Innovations Limited [Member]", "documentation": "Hub And Spoke Innovations Limited" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r925", "r926", "r939" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of certain long-lived assets", "label": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r12", "r82", "r176" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesGeographicalBreakdownofIncomeLossbeforetheProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesGeographicalBreakdownofIncomeLossbeforetheProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r282", "r633" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.omnicell.com/role/IncomeTaxesGeographicalBreakdownofIncomeLossbeforetheProvisionforIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/IncomeTaxesGeographicalBreakdownofIncomeLossbeforetheProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r151", "r207", "r325", "r337", "r341", "r343", "r734", "r746", "r877" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesGeographicalBreakdownofIncomeLossbeforetheProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesGeographicalBreakdownofIncomeLossbeforetheProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r282", "r633" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails", "http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r398", "r404", "r815" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails", "http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r404", "r815" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r20" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.omnicell.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r283", "r604", "r612", "r618", "r624", "r629", "r634", "r635", "r636", "r775" ] }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and penalties accrued", "label": "Income Tax Examination, Penalties and Interest Accrued", "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations." } } }, "auth_ref": [ "r1153" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails", "http://www.omnicell.com/role/IncomeTaxesProvisionforBenefitfromIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for (benefit from) income taxes", "totalLabel": "Total provision for (benefit from) income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r211", "r227", "r305", "r306", "r329", "r610", "r630", "r750" ] }, "omcl_IncomeTaxExpenseBenefitAwardsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "IncomeTaxExpenseBenefitAwardsExercised", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax (expense) benefit realized from stock options exercised", "label": "Income Tax (Expense) Benefit, Awards Exercised", "documentation": "Income Tax (Expense) Benefit, Awards Exercised" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting for Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r268", "r606", "r607", "r618", "r619", "r623", "r625", "r772" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign rate differential", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. federal tax provision at statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r611" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible expenses", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation tax expense (benefit)", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherReconcilingItems", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State taxes", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxContingencies", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncertain tax positions", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.omnicell.com/role/IncomeTaxesDifferencebetweentheProvisionForBenefitFromIncomeTaxesComparedtoIncomeTaxesComputedattheStatutoryFederalTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research tax credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid (refunds received), net", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r62" ] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable and unbilled receivables", "label": "Increase (Decrease) in Accounts and Other Receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r725", "r1022" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInLeasingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInLeasingReceivables", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in sales-type leases", "label": "Increase (Decrease) in Leasing Receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r1010", "r1022" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other long-term assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "omcl_IncreaseDecreaseinPrepaidCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "IncreaseDecreaseinPrepaidCommissions", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid commissions", "label": "Increase (Decrease) in Prepaid Commissions", "documentation": "Increase (Decrease) in Prepaid Commissions" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.omnicell.com/role/NetIncomeLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities from stock award plans (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r312", "r313", "r314", "r318", "r561" ] }, "omcl_IncrementalLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "IncrementalLoanFacilityMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental Loan Facility", "label": "Incremental Loan Facility [Member]", "documentation": "Incremental Loan Facility" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r938", "r947", "r957", "r974", "r983", "r987", "r995" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r993" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r927", "r999" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r927", "r999" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r927", "r999" ] }, "us-gaap_InsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InsuranceRecoveries", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, cumulative insurance recoveries", "label": "Insurance Recoveries", "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses." } } }, "auth_ref": [ "r156" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r75", "r79" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual coupon interest", "label": "Interest Expense, Debt, Excluding Amortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r160", "r450", "r885", "r886" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r275", "r277", "r278" ] }, "omcl_InternalUseSoftwareandSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "InternalUseSoftwareandSoftwareDevelopmentCostsMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal Use Software and Software Development Costs", "label": "Internal Use Software and Software Development Costs [Member]", "documentation": "Internal Use Software and Software Development Costs [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r169", "r869" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r259", "r866", "r907" ] }, "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories:", "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r212", "r248", "r258", "r381", "r382", "r383", "r727", "r874" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r169", "r871" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r169", "r870" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Supplemental Cash Flow Information and Weighted-Average Remaining Lease Term and Discount Rate", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1167" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r175" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r701" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r701" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r700" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Schedule of Future Minimum Lease Payments under Operating Leases and\u00a0the Reconciliation to the Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1168" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r707" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Present value adjustment", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r707" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of operating leases", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1166" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.omnicell.com/role/LesseeLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r695" ] }, "us-gaap_LessorLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeaseDescriptionLineItems", "presentation": [ "http://www.omnicell.com/role/LessorLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Line Items]", "label": "Lessor, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r713" ] }, "us-gaap_LessorLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeaseDescriptionTable", "presentation": [ "http://www.omnicell.com/role/LessorLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Table]", "label": "Lessor, Lease, Description [Table]", "documentation": "Disclosure of information about lessor's leases." } } }, "auth_ref": [ "r713" ] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeasesPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor Leases", "label": "Lessor, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": [ "r220", "r221", "r222", "r710" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum operating lease payments", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r712" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r712" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r712" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://www.omnicell.com/role/LessorLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Schedule of Future Minimum Lease Payments under Operating Leases", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r1169" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r712" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r712" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r712" ] }, "us-gaap_LessorSalesTypeLeaseTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorSalesTypeLeaseTermOfContract1", "presentation": [ "http://www.omnicell.com/role/LessorLeasesNarrativeDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of sales-type leases", "label": "Lessor, Sales-type Lease, Term of Contract", "documentation": "Term of lessor's sales-type lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1170" ] }, "us-gaap_LessorSalesTypeLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorSalesTypeLeasesTextBlock", "presentation": [ "http://www.omnicell.com/role/LessorLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor Leases", "label": "Lessor, Sales-type Leases [Text Block]", "documentation": "The entire disclosure of lessor's sales-type leases." } } }, "auth_ref": [ "r708" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r42", "r281", "r352", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r646", "r647", "r648", "r675", "r790", "r876", "r920", "r1058", "r1172", "r1173" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r149", "r206", "r742", "r907", "r1026", "r1038", "r1162" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r44", "r247", "r281", "r352", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r646", "r647", "r648", "r675", "r907", "r1058", "r1172", "r1173" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "omcl_LineOfCreditFacilityAccordionFeatureHigherBorrowingCapacityOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "LineOfCreditFacilityAccordionFeatureHigherBorrowingCapacityOption", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, accordion feature, higher borrowing capacity option", "label": "Line Of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option", "documentation": "Line Of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r40", "r1025" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r40", "r1025" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r40" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r40" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee rate on undrawn commitments", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived Assets by Geographic Areas", "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": [ "r30" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/DebtandCreditAgreementDetails", "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of debt", "netLabel": "Outstanding balance", "totalLabel": "Convertible senior notes, net", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r38", "r205", "r442", "r456", "r883", "r884", "r1182" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails", "http://www.omnicell.com/role/DebtandCreditAgreementDetails", "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r47" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://www.omnicell.com/role/ConvertibleSeniorNotesSummaryoftheComponentsofInterestExpenseDetails", "http://www.omnicell.com/role/DebtandCreditAgreementDetails", "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r47", "r89" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r413", "r414", "r415", "r419", "r1054", "r1055" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r413", "r414", "r415", "r419", "r1054", "r1055" ] }, "omcl_LossContingencyCumulativeExpectedInsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "LossContingencyCumulativeExpectedInsuranceRecoveries", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, cumulative expected insurance recoveries", "label": "Loss Contingency, Cumulative Expected Insurance Recoveries", "documentation": "Loss Contingency, Cumulative Expected Insurance Recoveries" } } }, "auth_ref": [] }, "omcl_LossContingencyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "LossContingencyExpense", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ransomware incident, expense", "label": "Loss Contingency, Expense", "documentation": "Loss Contingency, Expense" } } }, "auth_ref": [] }, "omcl_LossContingencyExpenseIncurredToDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "LossContingencyExpenseIncurredToDate", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, expense incurred to date", "label": "Loss Contingency, Expense Incurred To Date", "documentation": "Loss Contingency, Expense Incurred To Date" } } }, "auth_ref": [] }, "omcl_LossContingencyExpenseNetOfInsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "LossContingencyExpenseNetOfInsuranceRecoveries", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ransomware incident, expense, net of insurance recoveries", "label": "Loss Contingency, Expense, Net Of Insurance Recoveries", "documentation": "Loss Contingency, Expense, Net Of Insurance Recoveries" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r347", "r890", "r1063", "r1184", "r1185" ] }, "omcl_MarkeTouchMediaLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "MarkeTouchMediaLLCMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MarkeTouch Media", "label": "MarkeTouch Media, LLC [Member]", "documentation": "MarkeTouch Media, LLC" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/DebtandCreditAgreementDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails", "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails", "http://www.omnicell.com/role/LessorLeasesNarrativeDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r414", "r415", "r416", "r417", "r550", "r724", "r757", "r782", "r783", "r833", "r835", "r837", "r838", "r844", "r859", "r860", "r879", "r887", "r903", "r909", "r1060", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r966" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r966" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1161" ] }, "omcl_MeasurementInputRoyaltyRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "MeasurementInputRoyaltyRateMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Rate", "label": "Measurement Input, Royalty Rate [Member]", "documentation": "Measurement Input, Royalty Rate" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r672" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/DebtandCreditAgreementDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails", "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails", "http://www.omnicell.com/role/LessorLeasesNarrativeDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r414", "r415", "r416", "r417", "r550", "r724", "r757", "r782", "r783", "r833", "r835", "r837", "r838", "r844", "r859", "r860", "r879", "r887", "r903", "r909", "r1060", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r986" ] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r994" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r347", "r890", "r1063", "r1184", "r1185" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r967" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r276" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r276" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r162", "r163", "r164" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows", "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.omnicell.com/role/NetIncomeLossPerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r152", "r164", "r208", "r245", "r263", "r266", "r271", "r281", "r296", "r299", "r300", "r301", "r302", "r305", "r306", "r315", "r325", "r337", "r341", "r343", "r352", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r669", "r675", "r747", "r812", "r828", "r829", "r877", "r918", "r1058" ] }, "us-gaap_NetInvestmentInLeaseAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentInLeaseAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net investment in sales-type leases", "label": "Net Investment in Lease, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of net investment in sales-type and direct financing leases." } } }, "auth_ref": [ "r1002" ] }, "us-gaap_NetInvestmentInLeaseAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentInLeaseAfterAllowanceForCreditLossCurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails": { "parentTag": "us-gaap_NetInvestmentInLeaseAfterAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 }, "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net investment in sales-type leases, current portion", "negatedTerseLabel": "Less: Current portion", "label": "Net Investment in Lease, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of net investment in sales-type and direct financing leases, classified as current." } } }, "auth_ref": [ "r1002", "r1003" ] }, "us-gaap_NetInvestmentInLeaseAfterAllowanceForCreditLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentInLeaseAfterAllowanceForCreditLossNoncurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails": { "parentTag": "us-gaap_NetInvestmentInLeaseAfterAllowanceForCreditLoss", "weight": 1.0, "order": 2.0 }, "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term investment in sales-type leases, net", "terseLabel": "Long-term investment in sales-type leases, net", "label": "Net Investment in Lease, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of net investment in sales-type and direct financing leases, classified as noncurrent." } } }, "auth_ref": [ "r1002", "r1003" ] }, "omcl_NetInvestmentInSalesTypeLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "NetInvestmentInSalesTypeLeasesMember", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net investment in sales-type leases", "label": "Net Investment in Sales-Type Leases [Member]", "documentation": "Net Investment in Sales-Type Leases [Member]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Authoritative Guidance and Recently Issued Authoritative Guidance", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r966" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r935", "r947", "r957", "r974", "r983" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r964" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r963" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r974" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r994" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r994" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentSummaryofGeographicInformationforPropertyandEquipmentNetDetails", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of world", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1191", "r1192", "r1193", "r1194" ] }, "us-gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncompeteAgreementsMember", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-compete agreements", "label": "Noncompete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": [ "r117" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r158" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Awards Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r34" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1036" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reporting segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1036" ] }, "us-gaap_NumberOfReportingUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportingUnits", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reporting units", "label": "Number of Reporting Units", "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment." } } }, "auth_ref": [] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OfficerMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Officer", "label": "Officer [Member]", "documentation": "Person with designation of officer." } } }, "auth_ref": [ "r348", "r1187" ] }, "omcl_OmnicellPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "OmnicellPlanMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Omnicell Plan", "label": "Omnicell Plan [Member]", "documentation": "Omnicell Plan [Member]" } } }, "auth_ref": [] }, "omcl_OneMonthSecuredOvernightFinancingRateSOFRApplicableMarginMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "OneMonthSecuredOvernightFinancingRateSOFRApplicableMarginMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Month Secured Overnight Financing Rate (SOFR) Applicable Margin", "label": "One Month Secured Overnight Financing Rate (SOFR) Applicable Margin [Member]", "documentation": "One Month Secured Overnight Financing Rate (SOFR) Applicable Margin" } } }, "auth_ref": [] }, "omcl_OneMonthSecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "OneMonthSecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Month Secured Overnight Financing Rate (SOFR)", "label": "One Month Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "One Month Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r325", "r337", "r341", "r343", "r877" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r702", "r906" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows", "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment and abandonment of operating lease right-of-use assets related to facilities", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1165" ] }, "us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseIncomeComprehensiveIncomeExtensibleList", "presentation": [ "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of comprehensive income that includes operating lease income." } } }, "auth_ref": [ "r709" ] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental income", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r323", "r709", "r714" ] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": [ "http://www.omnicell.com/role/LessorLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Income Recognized from Operating Leases", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": [ "r323", "r714" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r697" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current portion", "verboseLabel": "Current portion of operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r697" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r698" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "http://www.omnicell.com/role/LesseeLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderOperatingLeasesandtheReconciliationtotheOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities", "verboseLabel": "Long-term portion of operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r697" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesSupplementalCashFlowInformationRelatedtoOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r699", "r703" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r696" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1023" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate, %", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r706", "r906" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term, years", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r705", "r906" ] }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "presentation": [ "http://www.omnicell.com/role/LessorLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor Leases", "label": "Lessor, Operating Leases [Text Block]", "documentation": "The entire disclosure for lessor's operating leases." } } }, "auth_ref": [ "r708" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r105" ] }, "us-gaap_OrderOrProductionBacklogMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrderOrProductionBacklogMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Backlog", "verboseLabel": "Backlog", "label": "Order or Production Backlog [Member]", "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination." } } }, "auth_ref": [ "r118" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Summary of Significant Accounting Policies", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r165", "r166", "r167", "r200" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r43" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "totalLabel": "Total other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r261", "r907" ] }, "omcl_OtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "OtherAssetsCurrentAbstract", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets:", "label": "Other Assets, Current [Abstract]", "documentation": "Other Assets, Current" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r123", "r129" ] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Miscellaneous, Current", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Miscellaneous, Noncurrent", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 }, "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "totalLabel": "Total other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r254" ] }, "us-gaap_OtherAssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrentAbstract", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets:", "label": "Other Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r8" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.omnicell.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r10", "r21", "r201", "r264", "r267" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r48" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r966" ] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Postretirement Benefit Plan", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r895", "r896", "r897", "r898", "r899" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r933", "r945", "r955", "r981" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r936", "r948", "r958", "r984" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r936", "r948", "r958", "r984" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r199" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r962" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows", "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock repurchases", "terseLabel": "Aggregate purchase price for repurchased shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r58" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows", "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for debt issuance costs for revolving credit facility", "terseLabel": "Payments of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r59" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Employees\u2019 taxes paid related to restricted stock units", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r274" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Business acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r56" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r161" ] }, "us-gaap_PaymentsToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToSuppliers", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases from suppliers", "label": "Payments to Suppliers", "documentation": "Payments of cash to suppliers for goods and services during the current period." } } }, "auth_ref": [ "r1020", "r1021" ] }, "omcl_PaymentsforSoftwareForExternalUse": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "PaymentsforSoftwareForExternalUse", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "External-use software development costs", "label": "Payments for Software, For External Use", "documentation": "Payments for Software, For External Use" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r965" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r965" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r964" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r974" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r967" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r963" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "netLabel": "PSUs", "verboseLabel": "Performance-Based Restricted Stock", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r143", "r458" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r143", "r792" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r143", "r458" ] }, "us-gaap_PreferredStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued", "label": "Preferred Stock, Value, Outstanding", "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders." } } }, "auth_ref": [ "r143", "r792" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r260", "r384", "r385", "r867" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid income taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r868", "r880", "r1039" ] }, "omcl_PrimarySupplierMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "PrimarySupplierMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Primary Supplier", "label": "Primary Supplier [Member]", "documentation": "Primary Supplier [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of convertible senior notes, net of issuance costs", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuances under stock-based compensation plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r9", "r26" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of warrants", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r9" ] }, "omcl_ProceedsFromPaymentsForCustomerFundsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ProceedsFromPaymentsForCustomerFundsNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in customer funds, net", "label": "Proceeds From (Payments For) Customer Funds, Net", "documentation": "Proceeds From (Payments For) Customer Funds, Net" } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenues", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r888" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r344", "r728", "r751", "r752", "r753", "r754", "r755", "r756", "r863", "r888", "r908", "r1011", "r1056", "r1057", "r1063", "r1184" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r344", "r728", "r751", "r752", "r753", "r754", "r755", "r756", "r863", "r888", "r908", "r1011", "r1056", "r1057", "r1063", "r1184" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r13" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.omnicell.com/role/PropertyandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r174", "r215", "r223", "r224" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r175", "r250", "r745" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails", "http://www.omnicell.com/role/PropertyandEquipmentSummaryofGeographicInformationforPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails", "http://www.omnicell.com/role/PropertyandEquipmentSummaryofGeographicInformationforPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "netLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r13", "r735", "r745", "r907" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r13", "r215", "r223", "r743" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables", "http://www.omnicell.com/role/PropertyandEquipmentTables" ], "lang": { "en-us": { "role": { "netLabel": "Estimated Useful Lives of Assets", "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r13" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r175" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life of property and equipment", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Minimum required purchase obligation", "terseLabel": "Non-cancelable purchase commitments", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cancelable purchase commitments expected to be paid within the next twelve months", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r962" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r962" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/DebtandCreditAgreementDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails", "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails", "http://www.omnicell.com/role/LessorLeasesNarrativeDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r414", "r415", "r416", "r417", "r507", "r550", "r587", "r588", "r589", "r723", "r724", "r757", "r782", "r783", "r833", "r835", "r837", "r838", "r844", "r859", "r860", "r879", "r887", "r903", "r909", "r912", "r1051", "r1060", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/DebtandCreditAgreementDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails", "http://www.omnicell.com/role/LesseeLeasesNarrativeDetails", "http://www.omnicell.com/role/LessorLeasesNarrativeDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r414", "r415", "r416", "r417", "r507", "r550", "r587", "r588", "r589", "r723", "r724", "r757", "r782", "r783", "r833", "r835", "r837", "r838", "r844", "r859", "r860", "r879", "r887", "r903", "r909", "r912", "r1051", "r1060", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "omcl_ReCeptHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ReCeptHoldingsIncMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ReCept", "label": "ReCept Holdings, Inc. [Member]", "documentation": "ReCept Holdings, Inc." } } }, "auth_ref": [] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and unbilled receivables, net of allowances of $5,564 and $5,153, respectively", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r907" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesChangeintheBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r928", "r940", "r950", "r976" ] }, "us-gaap_ResearchAndDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAbstract", "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r138", "r602", "r1180" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails", "http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCosts" ], "lang": { "en-us": { "role": { "terseLabel": "External-Use Software Development Costs", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period." } } }, "auth_ref": [ "r210", "r603" ] }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "External-Use Software Development Costs", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination." } } }, "auth_ref": [ "r2", "r3", "r138" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit Carryforward", "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r104" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r929", "r941", "r951", "r977" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r930", "r942", "r952", "r978" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r937", "r949", "r959", "r985" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash included in other current assets", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1015", "r1024", "r1181", "r1183" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1015", "r1024" ] }, "us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as current." } } }, "auth_ref": [ "r1024" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "RSAs", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r66" ] }, "omcl_RestrictedStockRSAsRestrictedStockUnitsRSUsAndPreformanceSharesPSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "RestrictedStockRSAsRestrictedStockUnitsRSUsAndPreformanceSharesPSUsMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-vested restricted stock awards", "label": "Restricted Stock (RSAs), Restricted Stock Units (RSUs) And Preformance Shares (PSUs) [Member]", "documentation": "Restricted Stock (RSAs), Restricted Stock Units (RSUs) And Preformance Shares (PSUs)" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "netLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.omnicell.com/role/RestructuringExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Expenses", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r400", "r401", "r403", "r406", "r412" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/RestructuringExpensesNarrativeDetails", "http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r12", "r407", "r409", "r1052" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r402", "r403", "r404", "r405", "r409", "r410", "r411" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/RestructuringExpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid balance related to restructuring plan", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r403", "r408" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r146", "r185", "r741", "r764", "r769", "r774", "r793", "r907" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r242", "r292", "r293", "r294", "r297", "r304", "r306", "r356", "r362", "r594", "r595", "r596", "r627", "r628", "r652", "r654", "r655", "r658", "r667", "r760", "r762", "r776", "r1189" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanNameAxis", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name [Axis]", "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r903", "r1004", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanNameDomain", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name [Domain]", "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r903", "r1004", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r556", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r556", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyGeographicRegionDetails", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r326", "r327", "r336", "r339", "r340", "r344", "r345", "r347", "r480", "r481", "r728" ] }, "omcl_RevenueFromContractWithCustomerMaximumContractTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "RevenueFromContractWithCustomerMaximumContractTerm", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from contract with customer, maximum contract term", "label": "Revenue From Contract With Customer, Maximum Contract Term", "documentation": "Revenue From Contract With Customer, Maximum Contract Term" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition and Shipping Costs", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r228", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r862" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.omnicell.com/role/Revenues" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r228", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r484" ] }, "omcl_RevenueFromContractWithCustomerTimingAndClassificationOfRevenueCategoriesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "RevenueFromContractWithCustomerTimingAndClassificationOfRevenueCategoriesTableTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Revenue Recognition for Revenue Categories", "label": "Revenue From Contract With Customer, Timing And Classification Of Revenue Categories [Table Text Block]", "documentation": "Revenue From Contract With Customer, Timing And Classification Of Revenue Categories" } } }, "auth_ref": [] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.omnicell.com/role/RevenuesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenues by Geographical Location", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r29" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, remaining performance obligation, amount", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r218" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r219" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r219" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/LesseeLeasesSupplementalCashFlowInformationRelatedtoOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for new lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r704", "r906" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r994" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r994" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r347", "r1005" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivable", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total net investment in sales-type leases", "label": "Sales-type and Direct Financing Leases, Lease Receivable", "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases." } } }, "auth_ref": [ "r711", "r717" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "presentation": [ "http://www.omnicell.com/role/LessorLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position." } } }, "auth_ref": [ "r711" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails", "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum sales-type lease payments", "label": "Sales-Type and Direct Financing Leases, Payment to be Received", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases." } } }, "auth_ref": [ "r711" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails_1": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Five", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r711" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails_1": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Four", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r711" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails_1": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year One", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r711" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails_1": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, after Year Five", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r711" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails_1": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Three", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r711" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails_1": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Two", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r711" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 1.0 }, "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesComponentsofSalesTypeLeaseReceivablesDetails", "http://www.omnicell.com/role/LessorLeasesMaturityScheduleofFutureMinimumLeasePaymentsunderSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Unearned interest income portion", "negatedTerseLabel": "Present value adjustment", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount", "documentation": "Amount of undiscounted lease receivable in excess of discounted receivable for sales-type and direct financing leases." } } }, "auth_ref": [ "r711" ] }, "us-gaap_SalesTypeLeaseInterestIncomeLeaseReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseInterestIncomeLeaseReceivable", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income on sales-type lease receivables", "label": "Sales-type Lease, Interest Income, Lease Receivable", "documentation": "Amount of interest income from lease receivable of sales-type lease." } } }, "auth_ref": [ "r323", "r716" ] }, "us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseLeaseIncomeTableTextBlock", "presentation": [ "http://www.omnicell.com/role/LessorLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Income Recognized from Sales-Type Leases", "label": "Sales-type Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from sales-type lease." } } }, "auth_ref": [ "r323", "r714" ] }, "us-gaap_SalesTypeLeaseRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseRevenue", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromSalesTypeLeasesDetails": { "parentTag": "us-gaap_SalesTypeLeaseSellingProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-type lease revenues", "label": "Sales-type Lease, Revenue", "documentation": "Amount of sales-type lease revenue." } } }, "auth_ref": [ "r323", "r715" ] }, "us-gaap_SalesTypeLeaseSellingProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseSellingProfitLoss", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromSalesTypeLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/LessorLeasesIncomeRecognizedfromSalesTypeLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Selling profit on sales-type lease revenues", "label": "Sales-type Lease, Selling Profit (Loss)", "documentation": "Amount of profit (loss) recognized at commencement from sales-type lease." } } }, "auth_ref": [ "r323", "r715" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Accumulated Balances of Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r54", "r1163", "r1164" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r77" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amounts and Useful Lives of Intangible Assets", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r77" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r66" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsPreliminaryAllocationofthePurchasePricetotheAssetsAcquiredandtheLiabilitiesAssumedBytheCompanyDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofPreliminaryPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r109", "r111", "r639" ] }, "omcl_ScheduleOfCapitalizedComputerSoftwareNetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ScheduleOfCapitalizedComputerSoftwareNetTableTextBlock", "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Capitalized Computer Software", "label": "Schedule Of Capitalized Computer Software, Net [Table Text Block]", "documentation": "Schedule Of Capitalized Computer Software, Net" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [ "http://www.omnicell.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents [Table]", "label": "Schedule of Cash and Cash Equivalents [Table]", "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for (Benefit from) Income Taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r195" ] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components", "label": "Condensed Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r1013", "r1028" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Components of Deferred Tax Assets (Liabilities)", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r194" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Calculation of Basic and Diluted Net Income Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1034" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Difference Between the Provision for (Benefit from) Income Taxes Compared to Income Taxes Computed at the Statutory Federal Tax Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r193" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r101" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r101" ] }, "omcl_ScheduleOfFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ScheduleOfFutureAmortizationExpensesForCapitalizedSoftwareDevelopmentCostsTableTextBlock", "presentation": [ "http://www.omnicell.com/role/ExternalUseSoftwareDevelopmentCostsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Amortization Expenses For Capitalized Software Development Costs", "label": "Schedule Of Future Amortization Expenses For Capitalized Software Development Costs [Table Text Block]", "documentation": "Schedule Of Future Amortization Expenses For Capitalized Software Development Costs" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in the Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r881", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical Breakdown of Income (Loss) before the Provision for Income Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1027" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Identifiable Intangible Assets Acquired", "label": "Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of characteristics and cost, by total and major class, of indefinite-lived intangible assets acquired as part of a business combination. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. The future benefit is not expected to diminish over a stated period of time. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total." } } }, "auth_ref": [ "r78", "r114" ] }, "omcl_ScheduleOfInterestExpenseDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ScheduleOfInterestExpenseDebtTableTextBlock", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of the Components of Interest Expense", "label": "Schedule Of Interest Expense, Debt [Table Text Block]", "documentation": "Schedule Of Interest Expense, Debt" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Unit Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r99" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails", "http://www.omnicell.com/role/PropertyandEquipmentSummaryofGeographicInformationforPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ScheduleOfReceivablesWithImputedInterestTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfReceivablesWithImputedInterestTextBlock", "presentation": [ "http://www.omnicell.com/role/LessorLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Sales-Type Lease Receivables", "label": "Schedule of Receivables with Imputed Interest [Table Text Block]", "documentation": "Tabular disclosure of receivables or notes with discounts or premiums resulting from the determination of present value in cash or noncash transactions, including description of the receivable, the effective interest rate, the face amount, amortization period and method." } } }, "auth_ref": [ "r132", "r133", "r134", "r135" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed By the Company", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r198" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r402", "r403", "r404", "r405", "r409", "r410", "r411" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.omnicell.com/role/RestructuringExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restructuring Expenses", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r85", "r86", "r87" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r558", "r560", "r562", "r563", "r564", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r590" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Share Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r24", "r25", "r98" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Assumptions Used to Value ESPP Shares", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r192" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Assumptions Used to Value Stock Options Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r192" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Change in the Balance of Gross Unrecognized Tax Benefits", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r905", "r1154" ] }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccounts" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule II Valuation and Qualifying Accounts", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "documentation": "The entire disclosure for valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r229", "r291" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.omnicell.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Future Amortization Expense for Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r80" ] }, "omcl_ScheduleofSharebasedCompensationFutureIssuanceofSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ScheduleofSharebasedCompensationFutureIssuanceofSharesTableTextBlock", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares Reserved for Future Issuance Under Equity Incentive Plans", "label": "Schedule of Share-based Compensation, Future Issuance of Shares [Table Text Block]", "documentation": "Schedule of Share-based Compensation, Future Issuance of Shares" } } }, "auth_ref": [] }, "omcl_SecuredOvernightFinancingRateSOFRApplicableMarginMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "SecuredOvernightFinancingRateSOFRApplicableMarginMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) Applicable Margin", "label": "Secured Overnight Financing Rate (SOFR) Applicable Margin [Member]", "documentation": "Secured Overnight Financing Rate (SOFR) Applicable Margin" } } }, "auth_ref": [] }, "omcl_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "omcl_SecuredOvernightFinancingRateSOFRPlus100Member": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "SecuredOvernightFinancingRateSOFRPlus100Member", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR Plus 1.00%", "label": "Secured Overnight Financing Rate (SOFR) Plus 1.00% [Member]", "documentation": "Secured Overnight Financing Rate (SOFR) Plus 1.00%" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r921" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r924" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentSummaryofGeographicInformationforPropertyandEquipmentNetDetails", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r345", "r346", "r778", "r779", "r780", "r834", "r836", "r839", "r845", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r864", "r889", "r912", "r1063", "r1184" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r330", "r331", "r332", "r333", "r334", "r335", "r345", "r878" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r157" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSharedbasedCompensationExpenseDetails", "http://www.omnicell.com/role/RestructuringExpensesSummaryofRestructuringExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative", "verboseLabel": "Selling, general, and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Services and other revenues", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r888" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r904" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r579" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r579" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards granted (in shares)", "verboseLabel": "Granted (Awarded) (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r577" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant date fair value per award granted (in dollars per share)", "verboseLabel": "Granted (Awarded) (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r577" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding (in shares)", "periodEndLabel": "Outstanding (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r574", "r575" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding (in dollars per share)", "periodEndLabel": "Outstanding (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r574", "r575" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "omcl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingTermAbstract", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Years", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted-Average Remaining Term [Abstract]", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted-Average Remaining Term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r191" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (Released) (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r578" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of awards vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r581" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (Released) (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r578" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r588" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r587" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (maximum)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (minimum)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r589" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (maximum)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (minimum)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r558", "r560", "r562", "r563", "r564", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r590" ] }, "omcl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum fair market value of shares", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Amount", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Amount" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of earnings allowed for purchase of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r581" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r573" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r572" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r570" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r580" ] }, "omcl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of year (in shares)", "periodEndLabel": "Outstanding at end of year (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r566", "r567" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of year (in dollars per share)", "periodEndLabel": "Outstanding at end of year (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r566", "r567" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "omcl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingTermAbstract", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Years", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Term [Abstract]", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r583" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r583" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r583" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r582" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r582" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r582" ] }, "omcl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockOfferingPeriod", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Price Of Common Stock, Offering Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Price Of Common Stock, Offering Period" } } }, "auth_ref": [] }, "omcl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPurchasingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPurchasingPeriod", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchasing period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Price Of Common Stock, Purchasing Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Price Of Common Stock, Purchasing Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofPerformanceBasedRestrictedStockActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockAwardActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofSharesReservedforFutureIssuanceUnderEquityIncentivePlansDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r562", "r563", "r564", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r590" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r571" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r573" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r572" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r570" ] }, "omcl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsPurchasedInPeriodWeightedAveragePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsPurchasedInPeriodWeightedAveragePrice", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average price (in dollars per share)", "label": "Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Purchased In Period, Weighted Average Price", "documentation": "Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Purchased In Period, Weighted Average Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting One Year from Commencement Date", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting in Equal Monthly Installments", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation of Share-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r557", "r565", "r584", "r585", "r586", "r587", "r590", "r597", "r598", "r599", "r600" ] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Performance-Based Restricted Stock Activity", "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Goods and Nonemployee Services Transaction, Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of award vesting", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1125" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueESPPSharesGrantedDetails", "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r586" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r191" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r583" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r582" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of awards vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r581" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of common stock, percent", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "omcl_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsPercentEligibleforTimebasedVesting": { "xbrltype": "percentItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsPercentEligibleforTimebasedVesting", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares eligible for time-based vesting", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Percent Eligible for Time-based Vesting", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Percent Eligible for Time-based Vesting" } } }, "auth_ref": [] }, "omcl_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsEstimatedForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsEstimatedForfeitureRate", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationAssumptionsUsedtoValueStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated forfeiture rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate" } } }, "auth_ref": [] }, "omcl_SharebasedCompensationArrangementbySharebasedPaymentAwardTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardTradingDays", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trading days used for stock price appreciation calculation", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Trading Days", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Trading Days" } } }, "auth_ref": [] }, "us-gaap_ShippingAndHandlingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShippingAndHandlingMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shipping Costs", "label": "Shipping and Handling [Member]", "documentation": "Packing and transport of product." } } }, "auth_ref": [ "r1064" ] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.omnicell.com/role/PropertyandEquipmentPropertyandEquipmentBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchased software and internal-use software development costs", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "omcl_StandardProductWarrantDescriptionDurationFollowingInstallation": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "StandardProductWarrantDescriptionDurationFollowingInstallation", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard warranty period (up to)", "label": "Standard Product Warrant Description, Duration Following Installation", "documentation": "Standard Product Warrant Description, Duration Following Installation" } } }, "auth_ref": [] }, "omcl_StandardProductWarrantDurationofLimitedWarranty": { "xbrltype": "durationItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "StandardProductWarrantDurationofLimitedWarranty", "presentation": [ "http://www.omnicell.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limited warranty period (up to)", "label": "Standard Product Warrant, Duration of Limited Warranty", "documentation": "Standard Product Warrant, Duration of Limited Warranty" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State and Local Jurisdiction", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r23", "r51", "r242", "r269", "r270", "r271", "r292", "r293", "r294", "r297", "r304", "r306", "r324", "r356", "r362", "r460", "r594", "r595", "r596", "r627", "r628", "r652", "r653", "r654", "r655", "r656", "r658", "r667", "r682", "r683", "r684", "r685", "r686", "r687", "r722", "r760", "r761", "r762", "r776", "r830" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentSummaryofGeographicInformationforPropertyandEquipmentNetDetails", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r230", "r239", "r345", "r346", "r778", "r779", "r780", "r834", "r836", "r839", "r845", "r847", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r864", "r889", "r912", "r1063", "r1184" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r292", "r293", "r294", "r324", "r728", "r771", "r777", "r784", "r785", "r786", "r787", "r788", "r789", "r792", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r805", "r806", "r807", "r808", "r809", "r811", "r813", "r814", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r830", "r913" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r292", "r293", "r294", "r324", "r728", "r771", "r777", "r784", "r785", "r786", "r787", "r788", "r789", "r792", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r805", "r806", "r807", "r808", "r809", "r811", "r813", "r814", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r830", "r913" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r932", "r944", "r954", "r980" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Award Plans", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r1035" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares purchased under ESPP (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r23", "r143", "r144", "r185" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock plans (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r23", "r143", "r144", "r185" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationSummaryofShareOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r23", "r143", "r144", "r185", "r571" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock plans", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r100", "r143", "r144", "r185" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Note Hedge", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r912" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of shares authorized for repurchase under stock repurchase programs (up to)", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining value of shares authorized for repurchase under stock repurchase programs", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock repurchases (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r23", "r143", "r144", "r185", "r773", "r830", "r846" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock repurchases", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r23", "r143", "r144", "r185", "r776", "r830", "r846", "r919" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r144", "r147", "r148", "r168", "r794", "r810", "r831", "r832", "r907", "r920", "r1026", "r1038", "r1162", "r1189" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponents" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r1014" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r973" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward amount", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r105" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r104" ] }, "us-gaap_TaxCreditCarryforwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardLineItems", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Line Items]", "label": "Tax Credit Carryforward [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r104" ] }, "us-gaap_TaxCreditCarryforwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardTable", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Table]", "label": "Tax Credit Carryforward [Table]", "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances." } } }, "auth_ref": [ "r104" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r41" ] }, "omcl_TechnicalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "TechnicalServicesMember", "presentation": [ "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyRevenueTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technical services", "label": "Technical Services [Member]", "documentation": "Technical Services" } } }, "auth_ref": [] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Acquired Technology", "terseLabel": "Acquired technology", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r35" ] }, "omcl_TenLargestGroupPurchasingOrganizationsGPOsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "TenLargestGroupPurchasingOrganizationsGPOsMember", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ten Largest GPOs", "label": "Ten Largest Group Purchasing Organizations (GPOs) [Member]", "documentation": "Ten Largest Group Purchasing Organizations (GPOs) [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]", "documentation": "Information by title of individual or nature of relationship to individual or group of individuals." } } }, "auth_ref": [ "r1037", "r1171" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Relationship to Entity [Domain]", "label": "Title of Individual [Domain]", "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r965" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r972" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.omnicell.com/role/BusinessCombinationsNarrativeDetails", "http://www.omnicell.com/role/BusinessCombinationsSummaryofIdentifiableIntangibleAssetsAcquiredDetails", "http://www.omnicell.com/role/GoodwillandIntangibleAssetsCarryingAmountsandUsefulLivesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade Names", "terseLabel": "Trade names", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r116" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r993" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r995" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.omnicell.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesFairValueOfDerecognizedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfFinancialAssetsAccountedForAsSalesFairValueOfDerecognizedAssets", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-recourse accounts receivable transferred", "label": "Transfer of Financial Assets Accounted for as Sales, Fair Value of Derecognized Assets", "documentation": "Fair value of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction." } } }, "auth_ref": [ "r31" ] }, "omcl_TransferofFinancialAssetsAccountedforasSalesReceivablefromThirdPartyLeasingCompanyAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "TransferofFinancialAssetsAccountedforasSalesReceivablefromThirdPartyLeasingCompanyAmount", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable due from third-party leasing companies for transferred non-recourse accounts receivable", "label": "Transfer of Financial Assets Accounted for as Sales, Receivable from Third-Party Leasing Company, Amount", "documentation": "Transfer of Financial Assets Accounted for as Sales, Receivable from Third-Party Leasing Company, Amount" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialAssetsTransfersOfFinancialAssetsSalesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialAssetsTransfersOfFinancialAssetsSalesPolicy", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of Accounts Receivable", "label": "Transfers and Servicing of Financial Assets, Transfers of Financial Assets, Sales, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing whether a transfer of a financial asset qualifies for sale treatment, and its initial and subsequent accounting for a sale transaction. If an entity has securitized financial assets during any period presented and accounts for that transfer as a sale, for each major asset type (for example, mortgage loans, credit card receivables, and automobile loans), the entity generally discloses its accounting policies for initially and subsequently measuring any interests that it obtains and sells, or those it continues to hold in the transaction, including the methodology (for example, quoted market prices) and significant assumptions used to value such interests, and the gains and losses resulting from the sale." } } }, "auth_ref": [ "r28", "r33" ] }, "omcl_TransfersBetweenInventoryAndPropertyAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "TransfersBetweenInventoryAndPropertyAndEquipmentNet", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers between inventory and property and equipment, net", "label": "Transfers Between Inventory And Property And Equipment, Net", "documentation": "Transfers Between Inventory And Property And Equipment, Net" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r996" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r997" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r995" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r995" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r998" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r996" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average price of repurchased shares (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r92" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r92" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets", "http://www.omnicell.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.omnicell.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares outstanding (in shares)", "negatedPeriodStartLabel": "Balance at beginning of period (in shares)", "negatedPeriodEndLabel": "Balance at end of period (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r92" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock at cost, 10,283 shares outstanding, respectively", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r52", "r92", "r95" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares repurchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r23", "r144", "r185" ] }, "us-gaap_TreasuryStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockTextBlock", "presentation": [ "http://www.omnicell.com/role/StockRepurchasePrograms" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Programs", "label": "Treasury Stock [Text Block]", "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r186" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/StockRepurchaseProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate purchase price of treasury stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r23", "r92", "r185" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.omnicell.com/role/PropertyandEquipmentSummaryofGeographicInformationforPropertyandEquipmentNetDetails", "http://www.omnicell.com/role/RevenuesDisaggregationofRevenuesbyGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesConvertibleDebtBalancesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "us-gaap_UnbilledContractsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnbilledContractsReceivable", "crdr": "debit", "calculation": { "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.omnicell.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled receivables, net", "label": "Unbilled Contracts Receivable", "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet." } } }, "auth_ref": [ "r726" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r992" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesChangeintheBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r605", "r614" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesChangeintheBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decreases related to tax positions taken during the prior period", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r615" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncertain tax positions, interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r613" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesChangeintheBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases related to tax positions taken during the current period", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r616" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesChangeintheBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases related to tax positions taken during a prior period", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r615" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/IncomeTaxesChangeintheBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decreases related to expiration of statute of limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r617" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.omnicell.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r71", "r72", "r73", "r213", "r214", "r216", "r217" ] }, "us-gaap_ValuationAllowancesAndReservesAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesAdjustments", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Adjustments", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment", "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment." } } }, "auth_ref": [ "r1029" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at Beginning of Period", "periodEndLabel": "Balance at End of Period", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r285", "r290" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charged (Credited) to Costs and Expenses", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": [ "r288" ] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts Written Off", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r289" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r285", "r286", "r287", "r289", "r290" ] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r285", "r286", "r287", "r289", "r290" ] }, "srt_ValuationAndQualifyingAccountsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "auth_ref": [] }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r229", "r285", "r286", "r287", "r289", "r290" ] }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsDisclosureTable", "presentation": [ "http://www.omnicell.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "documentation": "Disclosure of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r229", "r285", "r286", "r287", "r289", "r290" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.omnicell.com/role/EmployeeBenefitsandShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.omnicell.com/role/ConvertibleSeniorNotesNarrativeDetails", "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r910", "r911", "r914", "r915", "r916", "r917" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.omnicell.com/role/NetIncomeLossPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average shares outstanding \u2014 diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r310", "r318" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.omnicell.com/role/NetIncomeLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations", "http://www.omnicell.com/role/NetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average shares outstanding \u2014 basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r309", "r318" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.omnicell.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "omcl_WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank", "label": "Wells Fargo Securities, LLC, Citizens Bank, N.A. And JPMorgan Chase Bank, N.A [Member]", "documentation": "Wells Fargo Securities, LLC, Citizens Bank, N.A. And JPMorgan Chase Bank, N.A" } } }, "auth_ref": [] }, "omcl_WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.omnicell.com/20231231", "localname": "WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMember", "presentation": [ "http://www.omnicell.com/role/DebtandCreditAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC", "label": "Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC [Member]", "documentation": "Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC And TD Securities (USA) LLC" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "SubTopic": "50", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-4" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "SubTopic": "40", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "SubTopic": "20", "Topic": "985", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "20", "Topic": "985", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481268/860-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "b", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(1)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(a)", "Paragraph": "4", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "SubTopic": "30", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479359/835-30-S45-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-4A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "460", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//460/tableOfContent" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505-30/tableOfContent" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-2" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "985", "SubTopic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//985-730/tableOfContent" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-14" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.Q4)", "SubTopic": "20", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483530/326-20-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "09", "Publisher": "SEC" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-4A" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-5A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479366/326-20-35-8A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-17" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3C" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3D" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479175/326-30-30-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-13A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-7A" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3C" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3D" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//460/tableOfContent" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-30/tableOfContent" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-10" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "340", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "(a)", "Publisher": "SEC" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" } } } ZIP 127 0000926326-24-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000926326-24-000008-xbrl.zip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�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�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

X$(F&X/<-75][EZ?;AAHP-[>)^Z-/ODU81%_C <*5+2]S("Q%<-8 MQH#60.CH$R2&B9F.0&PG7 C;.57!G4I;O@S.-GZ7I$V]?^#,=WBEU(8_C4^Y MA7[5<:I1SO2OS"3 @_J+;MR/2"BD+F/WH ()403:^_>EN@U#@_=>K_;M" MI2;.?G*5]9WBQH@=DL!I.J1G*(P;?YA877C(">Z E/6<[C 1RPS0M--QNUK9 M6:W5=L?C3TDERPE ='/U.07F*H!5/[U'+?,E4M2E8:JL!53F;N.K?T[!S-LK M>(8RLWJ%=1']";X30XJ#U1EG<\51R';ZQ]9LFD0%<-"ZYF=03,-4N$(F^H=J MZN?'NRKE9=MS/K="->6,P[7^1+!.L:6W-D9&S^+!$;"Y(HK4UQY8HKDXDQ W,7Y?XBB-"W^/A0<&MS;7/KI';IZ]QP/2A6I<#\TKMS9:]W'8?/9W.% M4RFX5$S=3!=L3IVI5T='W&O7H\=0U)/-;+PA*;@?;V\81OFG#9\];.VZY/=I M<\_\W5WGWMRV5!LH8KO/\$ (S-P&5Z297L9TI?- M$W<"G?8[+_9%7 6":0ADL]R^0YOL M:1Y\[:PQ"FBW*#!9=[;Y&.HH#G4,2*9DRIS/GR'P'0[%>.,)492O;,ETDAZMO@PJ,/<- _ZI&-GC,!;:?NK.C%OZ MBG3.*5.K@W/!IP0M14+!(X)+ZU&H-SS0'I@WE#!/QK,E#:A?:=4^:$7/ **, MV8&R;P2C!+T4'+7H0IYM,_):8<#V5&?7\QDC:0+9SL86-(-M&'\T&+'7:UE*UMGA[0,SSX5 MC6K.,K3^:#FRJV(5,S_*S.&4=2JBYWB@VO+D'FA&U!WC>*XVDAEKW(^&9-LV MA'>FA@^T9A0EIXRT7#]U.<*I^Z];H\7?^&Z@-8PPRN_:^#W\DU"TN1$0^6?> M=?AY11:L4:\/-Z"H7X2H0VQ8KJG[<2HX?F1N30><^823 @O"9&,D8;ZX M-/FC SW5YO"XD@,FQ)3@4-0I]-"K"]-8[QLZ"\&8\!+/K^(FM9_(D5[&QX06 MA?B^DS-71(#E@![#@U%0!K47OH>M27=VJJ?G9_)UC&S,^L,#N1?V>EQ==M8? MW?6L3]1VW^&W10[ME25P@SO:5Z,R\0$80,-XE4;O8=[@9.)O+/A-]O) BER= M(,*7['0S1WJ:SG'?HO,3(;IZ/B5=1[/K7,L_OTY7O?^N2A[QY@;5SR6_F&'/ M%>;WUO9M@# K%B RY_E=< T5"L"]O!E9A+MFD@_7NG<1-L,Z&S"J? !R:YTX0F1!@@/W+A!7$/ ?X\YNEUE2X1L'1-ACVY,A& M2M5N\1#3[L[=@$/ B^]_MCV6-\Y=7Z=L#I<$%1RQ3'-2S1+2IUGI_X5L7IWD M#X(QSBON5IZ>0YVZF"Y8Q)H$RO3C41XHY0A0HZC>FU]8O>XZK]:N:[94J-:@ M5Q1VL^^*C3AIV_5^:W [IDL5]D4*7^_,N0_;B?F>/]&9@(OK/()TY(K 63OY M,O70>]A&G,?M4?1"/7F4VJ0A!K+,E&^/*J@%EJ8'[*6;6D-+G@LA<7K^6;+, MO48(E?.E%]#LZV1AB^VU;]4%86X@]@(GXWH+EKO'F--3ZK M,.1=?B:IBT3:R/K5Q][&0+ E@YB5 (SEO=N;*W*L3X8+; M@/XS35G,T6V/9:5F[S9K@,'T"JY( (/*C..48+Q&D\:03XD]V+WXP&+S=80D M1XLM?)C2H1(4!F1):;9,&]#QW!+\#$X)((#;" MLBB,39I "!5SM[4FV?L6*_)PJ0RV]*D/GDXYVY+A*4ZA SOELE;2^*Y$O M@MD5+S%=DO@ 6RR@3ES=I*=W89101\C0;%C=4C63F*0$FW2BK)W#7[(N7%R7 M.V"CG!:^/F'AH//ZOHM3S2I?.O9S;*_LP]EAE&RUV!#Z-N)E4H^#TSF M*KB3K3BBZ,-\&N&&H9?]PS7.\S^XZ95]"KZYHB=[-Z!W\>-/>PB0&B$6O/)< MM^S)D)#.S!%\_Q_ODOK(U@$8I+7TUL3I(G*QGGMS[HA4KM-4>*K. M@_A;ZP70(\R:Z330[S6NR#M!3)<^UTP+= IPKO:!_OF9VZD,])%Q8OQYWT9L M4B32G.G-9]M:.%GF!LBTHT M^831PK-L\G.\Z4[J=(C7R4C7]WU7QG> _[S6 M;ZJ$H_B/G3(79E_CE&-\[!71(\3M_O2%YU74[#T>-W O@1(F12O67)-ZI*%K M?Y+EXSAUX0=R70O]D%O5J!/UP +=CP%-K6/ M?A[H)".J+1.YCHPYC?R2^?%AN.^UKKO[XW?B4O&D9W^BMB!S^Z%:3KG9$89, M?][\X'#).I>\)^ M?EWE,WRA1:"-?Q[@9)JKH#_ ZZRRPW7<>" GQF)5%=MP"A42=E-YG*9;'?*T MV;U+\L*,N+NA2LC%*OW^QS>:I>#1G%2T*!+'#.,\-(/0U?N9A:>7.Z7&]D_^ M$AV6N52XK'..O#=Z\\/&&8G?S1)RZOWJ 7I^?>O#! ]$ M*L9 .D\@D_C&<__D2"*5%> <_#JH2>54Q-(!5M*EJIN2Z])D@:5.U5; @M_: M\_R'=P;^V!NUC6Z$&WI-HH7'./=84F16][5YCRU0O!/B?[D0*WWS[] M(!OJEW;0T^]/%%?X%TL /8.IA=,>,X8HM3-H1>@]'D@!=8.KD?>V\$(U>L9S MW]0^J,FRL-*X\E\C]FO*6K*_O0EOK1K_P.9P9&.V5!3S"J?DIWV.6%+1[@3OX^.P+[($^M'.?>)PICOA=.=2+[.XL^PSP!!?-TE,[!L MB3 2/)-]))9BGQI094^UEU]9.9%8"%\.^]WL..\ZWW=$["5W62.J9NJL]FJ4 MX";0!KK"4 3VF/1W>"XE'2[72L^_^).YR1YU-F[D\79&F96M-<_IQ MPNAR4^KS>=F;*L5ED"F/VPT"&_9LL6WSW+WV@#:8+0DE\8'JIS!]?8"R(Z=R MP#>DKSJK/HS9W^KR /7"M??E>Q/1<%D!B^O\=IP+7YMKYHHXEG$G",;99D%A M(=5(9RN$$ I<"(4$2J3;P6V+]=9^[?2/!UMS)ZO.["E6UO*Q>O95,'IT%EX? MQ9; ;459QJ '%K4!6Y8DD#_J!I13%5C#WKTP"7-U3^O)P#^<":S!Y;;U Y$/ ME/<.!F^K!"6H?8U6F(%=QR>8JW.*,;X8090((S,K1ZF<#(.X!S0WF^B6'_UD MO-$?9WMGPG[7)3G_@@^/>S1-OP2W_54+HF, =1CM-V5T/HPK+%B!GC)76C#N M]3!^>R<+2[$5E%F[SC O1JAU#"V* M)Y#JPS7L$U@PMRCP")<"M,M6K8\0PLC%U\XB5I)CXHYFX6!'5+)>'4R M.#M(0&EF,)WIQ7D&(V7+PWI'4_BD^L):_!C*"_"B9*(1DI_8@B9O)G[!(8'Z M+]/?&-KB#OF\:;Y_T)@9TY]5#@M3EEY_)#B$(;4X!G;R:5=\/:;+I%,5=90( M3EM#ZP2Z27UJ2A;_]*U /" 'KDS-S]Q?@LJ*.\]M9%:PI00'T# SA^#1&"# M(4/V[:4CT\\"%A2%!:7ECSDZKQC?)^M&'GT-1VZ 6T5^8[G"?RV*\(MX@?*; MP)"JB?*_6,I4Z+99.-*]B[CC6IH%3.2'3Z0M ^U_N9!Z^?%)QR-I.WNWG[8< MV'SX!US]K1"6&NX^N@>9?#Z>V7.Q,9?PY_WR?L;5T\M7J!%F^G6Y.\WVVH%0 M"'[7KR']N\VE^"7]M_:N*ZRIM4M'40,"TD% B$B7$J4J+4=%P1,QH@("0N2@ M0&A1$0D2LE5*Z*@F,&'.S3SS MS/QS-W,S%WM?)7GRK;7V>M^U]K>^=Q]Q2SUX\51U.RN^M+V-\)O@P_L?%/GI M'.W*Z('=!S\W:52R:"&#*84[UF&7\+=F#P@:B9[S%K16* 1<.]=Q++D1PFII]]^Q\)CR]QS0HQ\CKUA",*KB8QH1?3F9M.K[W,"?L'=!'EV?KRC M1"L.)6X=%CH0<;*]GC,>]Y5H'BUZG,3/GWP>0"GW89Q>N#BR]=[J9R'V6WF& MULYT98,_] +NB[W'IK(4 3QJ@]+NJ<="1O#;0'#Z[W^S[2D] [;LDZUSJ?EF M+Z#3ZS!T@3CUZ36W1MGH(2>EJJJ:Z2H6+C!>.3ONC@;'BZ?O +>F6Z==_1YZG\7BBQB,(3\^#TU6)]H\0*EX]%8<,<[I,M]ZI/;MV M)NI^Z.0[CU"29UC_!YO%Y>\\$@X%'EZ',:W9@O)E>S,B1E#080J1NY378;+ M_,YG,?DW1C"CRV'W<$6$-+E7;V>43)/4]Q=?;&2S_/EJ@HQU&(Z62 //9*85 M-ID^$6YY#OZ@L\1Q:GJ%#Z?^_E$9_<>UYA)9M/8#DPR]0-M1_U=;+KSRD.:4 M+W?Q5(DB_!2A7R+0V$FFDW)&'>: @:_?R?%NM3T2NC:+/8^Q4]CG['UQ7_?]]$;G MU63K/7WZ2;2+2.81[BSD"@;.!RZ?M=M:1H!WY;U)8!?*H>*_I_;W#ZIBRAUK M/:?LV[AW^LJFVGCZN8[C)QS_4+HLD5.%8STC+\OQ3$BL0A$_$S'6B:93H&_# M_#HL/<<=R;&=IV8TM+;K:KU;&BHFNSWK:*AKV^MK?0<=#OI-ID87[Y456QP4 M![I^7X?AW02I*!R*[)634 &Q%N!+@YSPD1[-/1S4+;Y]>*0)T#T(2**KO";^ MM%IP5<,S6:_$_3P<8]/,LK\6@B=I3-OY\>7B*/;&!$JMR![F[IROM\+YAGZ! M8?.#LCW!OQ9O6]*LW@\:#Z%#=O$NI?74G_]9T<'$&-<'!K7.H2;4N6F0&$AF MS)I"TAS_'DE.$QO+.."PF\#R?A>V\G#HZ3IL>,^:Q=ES36^,QUXA:XNMSM?9 MT3=/*?=U?IW09LQN%W3P12EKJ]:[#@T^"LQ,X:/!=CN]62G0(\DTL&9LI6,: MJ?.N07U\9'EB&F$J&6D4O%13G!-MO7C(G#EDB6USZ3. M=Q:MV/4YES3[?3R09(*\#8#.^$P;?;Z\&+N)KZ#.9M%IXGT5$#/LQH(C!T_. M^Q*TA^+:&O/.-#QH%3SG+':GXV5"W=.VKCEGI^VN;V-NUDA\#P&]L_&3Q)3;EWU>.( MZ![F@]@K*G/F@ #D+WV6$@!.^:[#$A @A)A,%2;_Z,7RK<9I\U@W5U]RTZMU MV"*=!J*$;U>XDU'\GY2-S@BS\+_X?K3,\C@O5/@2U8A9ZF%C;STG]XA">@@[ MZQU;WC,^PK=L[RTH5O:2D-CN?'K2:7=@_]W.O[%%BN[U^R=):O7!(\6Z!O7C MM'? 5&+]E?M[E?Q/*Y;\Y3-.FQ+.H+);6]&MDBVAR.62VP2=H(^)%_=RF@_L M[5P5U]ZB]HLLE+".!5/G^Y8-0WB_$2/ IA1+>Z/N*W;/-6AD(O+*XV3+P[#T MDM71)^)W\PYEY0L]-:1CD'R5**[6F)T$SQ6'4!>J0 '>Z2AV*=/;!7=IA_-X MXJ@!3&B48+A;PY/.H&%H?C*3(4Z"#. 22XHH6^/\X%1]/0^3])3].;+"A=PL MJM3D$P7,K#0[E\UE6E9\G# OE3OD/ /,@JDY%H/ UA0:%48'N3(@HL]2[#G/DL:E"]1 62'WR MF#H0V^&Q#G/078?=6H=QR9TQH:U"8O\Z3&P=MHS)_L\_\5PF 1"!P>0Z3)12 MZ/;Z\X6)=DH<9=:IL?#>]BHF]9;I?KKYY!7<:MP[+7(Z?OBGYF4]\4&7NGB9)GG3U0/749VL%0@2F MH95V+KF^L:,MA'"1]&K5^*J9S.4TIR*JJN"F4)(8)8(\\6FB,;0LHA[9O5\( M=;YC80T(B2]1YD[[WEFFSK@\(JR8L/??3V?]N=/\JT1S_!OF6H9"]SI,1.JG MXN:B^(HH;AODQW,E;AI+^W6L@6=+2$=^^SMQ\U&)8J ?)LP?I MOG#=1[=-HK^&A:O]FGY2VZ?1W7VB/ZTJ[D;B#C=[,>Y^2(/G3-P/D3F!;/RR M*5$IMIIXC'/OR]B-S/COZ!:7G ?2)^L!W;;+K3^?=!XW>3WX02OB MCDPF:FX&D6XCTST3LH#GRU\C/%D\70?M7[!-]Y\_NE*$MY!G0=9G0@84P?\>:X0X3 MXD[.M51!_H)XU:/-D\5WGB>%NRNGGS7O/LSOW_LSXUZ4*!A4EC;QO BM&V\H M6,+M3KS]!/+\Q\0.:?":4)D3D$W]XM&/2KM6D5]J-;+3Q#.LK4*CP/HURX;Q M>E^'SPUQ""7*EG (PSO)1T,S8 P=)<7WF/N*F,51+A,M.>'5CW%F.$H.TZWT MSZ8KP8U<"F'MA+K7MKH+[N+GG=-6ZC?U ET&J+ERE"1JKLC7@".DL*F3/&_H M.&>MRXI)RN;XBX [V:WWM9SC#Y,08]-7!=Q$>/?PG$>S\#6M!LE D&D-B-Y,R""*0>"K1G+\V<<2RCYY1278 MF5=,EZ4_^NQNQ&M6$WJ[VK\?[M!$YS2D;=H5=-?@-(8"=!V@^:$@0SA?87Q^ MG(XA,X]1032]G WO]?'ODWX\$\RD(R;'U6YW:\H8AF$*DM\;(NPNOK_M=&K3 M!T13>A-_-P!&_%B*9=/BD[0X^FD.""CN!&=:N="P?:BHJ8V0-X>3YOJ5(SH@K:ZY=;X@?R]'&A"E_$:I_3YB=1 M[V[#)[,>$?R/GVFW:#<=C^WID@-HMFWW.CR?2=U+MD5--,U%+2/ UCZ4DE!; M."(]5[D!W"72HU.^_MM.K=NPF_WUO^N-W@AZ+K M+^!]+# CZ,6XRW4 AVD!XMBUZ^K_.E M5D'J:??AWV S>S)4+#V$$M@G7TBVZ["XVP >4.*[! !RG_83_(^"S/,"7JQ* M_Y_Q28A6=7'C][LO>_9HGL0TD(9%)2Q\.82-AXQ4>KY"AM9++]D(?7=\ARGOQ0-^L#$?JGFGRPHREE<4^S!5Y5>.G[* %.=^JT_/^9PFY M9@9B@ZBYCQO;5?WI"-"Q,-V:I).Q[]<)-4LAY>JT93L[Q JMKB54#OMHE^%\ M)^/[=YDE))NJ2?C*U8%L%X"4JR>%^F,D)>@&CQX64;B/-5 V]?(RUFYES7.M MX#NX(X%3V N WB+PE=S84D,BL1!P/4%A/2O1ZP,EB>\*&GF,YJW#W*!LI5;* M;<>.U8>WOB4MNN'<)_5PSDG)_J?-?Q5)[9LZG,,%JZXPBOS3%;>ZB<%@-MMA M_,:F,9+-)QH8,=C[(/,FL(.HR_9QH5V:T<(;\[$+Z.H=X@^%PXUZCGE3+C0< MXK+K,T;QEOR?F[PR^8IQ=$3]FQ;1L^V_\9^HRUO!S,Z.G2FHY X=FS.0-=MD MY?FX5*@)L$REZD'6M?368?Y!P4)M!"4A*AT\FO#;LB\C"$[ M-(_/%ZH0K1I -,%]RJ?#>LS][;3W&Z0CXX63<4(1,#V_34?L]<\HBT+P%'(" MPWTLJ #",B=97 KD^03:W.,(;66'""[@G@MK;C3Y[K:^ZWU4Q[$WZ#.NQN]R M=6Z3RI9;Z25B*';?LCVGCGM;T-QA0GI1*'D-D2H'Q8BJ7C+?(:]]O%O:J<<] M+X%173GE0JB=QE3/.+Z4Y&)7!;9? M;M @'/AP*84LBF?ANM4(& M=3,_7(1&P494G,IUH5CG7N.DGO%-I778 M!8!)8Y8J$#MI%R4<] GCO0CI^J^)-Q"I;3O787)M#EROIX46:R_#(G:% M6;:IR#-?O-(X\5SU276&P2X\H+F-E61XZW':'B6 M!C\(P@'^(LX2/^:PBV--OE:]^=>LLVF8:4F!48SU/0])^.M;*Z5K.EHUHP"[U=.O/YI9 M+E"=2_I]-V/>X#+V@,']E["?^EPZJ)],5%^';6OF:].>0Y54Z.[W3&FB5MM( MM=TQ8[K:X?J\0][>0.W48>'A]YL^YE[L3FLYJ/]YHUU[2$"E7Z2%H[14^Z4VQ.;JN==W7C7NU3ZGA"XVRS+#>.T[0T\OPFM^"QF@S;$P M4H0CW0!X+'-2V--UJKNQR4%D8;-\X147!Y>I)FZ:"5;&5_JNG&TCMC?A:DB[B$+CK5S5.9WW"KJY^SI[WJ>G1E'C?QXK8'GF%3; M(]WOM!;[U_2135_GXX*(2>3F7=X2H#GWE(7!>4L=!S=,8,NE6';LX2#J2S,Q,M""T*8?OH,PGK13M'1;3.AXID[2+8TF71@%YB@B?@ZH\\T%.=^H.XD1D&II"%"'2?W6\JU?0Z''JR0O M4EB(N\#%XK+SG&=6I$B^)L7>A%LB_TFE[A2S]#DBW+Z?AP:Z3J%P^ F@<^/$ M*^].3760=LL.606A/4?X,F4^/D%UOA(7@[2/I2N?RXV+SM163=$)>MH24/U. M\%"4=:?$&%CUCEU$HU$'"]VF;I22]4T+A!S?D-*MC+[RE(G+R9KY0OE<.7O4 M.&W"A4.4< %G0'&G[0:8DLU?K\PPLGX]Q2M"1&EWP[DXF3LLI!_8S2Y.DW M'5[T3=\R^0KD7E3C>"K@3Q4/1HCJYL3K!4I0UQ8%)M3(Z!:^8JOGI 0ZAX]. M]!N+!\0[:>^Q4IKL=-OINF+)X&^&(A80"2S))3MSCC;[A' ?Q_@>.HJ-DA\( M-AG[Q<6I'3^Q;YL?/KRTK;E(:O:\*Z/TK]O+D_\[VI#G%WNI\329CH-\AU$' M9>(94%3KE<4]B<;BG_'./XON.%MA1@2?V["=AYK]_KKP7MZH^%%#D6^CR0M"U>6/^(2G'>CK.'$J_;M.Y_(%WOM/74OV!5G,>*.*R]V"1H9*EY$ M;4C-*:S](S5'_0]2:K'2,BZ)'^OV/+05X3_<^CWQQ\;H3A@\2IFS[?YO9GBW M_U!SIT3%XBMF/C>N3C/Q/%WZG4H[=8:ZOUSVB[F%QY7_ZJ33:*MBGK2P_WEC MD4-E!=$\>B4\ !>NE^5+,]&NT;U?B+IW7*\]( 6V*@-=H$VBA,D8H8>HBH $ M+N6D'J!V)>OQH2>?:5*SD@]P.=[1Q>/4GF-?#KG#!^=N;Z)Z_L\[- _&;!S> M(1Z)3-K/]VJ!0AYE*M&3U: \#?L]HVHZ!\_E?8!ELP?Y=0$&,7$^_S%J?&-Y M:&$_( :$(A+&@:VH("I\D(W8'BQ%/OTVL2DF<.LG)P^W^UX#JKEBCYXYZ1XQ M./!B6_NV%!A#1'B0TGQ3T/7A>3J9'?N MDGY]&29VL+M$J.P4\>,^+IZO*]Q5/PK4?#\7:8]L*^-L0]Q;#E>*65U92[:-%W;O^+>>P=$6Q$UT972OE1+9E-[@F3I*,F M*:B@89;G\*/F&%5.ILVV2#U5>.#AG=LJ]X'+>]!JZ3G9^X^/. M_OVZ&?#3Q^T'T/_7TX?_?_VK"UB?_#=02P,$% @ 1(I<6(EY)#[DKP$ M^302 !4 !O;6-L+3(P,C,Q,C,Q7VQA8BYX;6SLO7MSW#B6+_C_? ILS\9& M5830Q0=(@GVGYX;\JG&LR];:JNX[X=C(P%/B="JI(9FVU9]^ 3XRF?S;__SQL 3?1%%F^>JO?_+_[/T)B!7+>;:Z^^N? M?K]]!_&?_N>__\N__-O_ >'_>O7Y WB3L_6#6%7@=2%()3CXGE7WH+H7X.]Y M\8_L&P$W2U+)O'B \-_KVU[GCT]%=G=?@< +4'=9]]OB+VGJ"1GA!"9)*B B M(H!I[ C*QE/8?K1 MF;BWBB'$^ +WAKE8Y.:%>KOB4[V[FZ$N%GU\B5V]%GE%EA.\%MMA>B(O]0\^ MJ+^UP^@'G2#3>IR6NGNBBA^56''1L.7.HT'&__HG];?%NH1WA#PNOE0Y^\?U MXV,A6%93]V>]K)5?KC]_^4T\4%$LJLW[NQ K^/N7;JCZ>98/^Y.%6M61S[,0 M9;XNV'9A>U@>6JW40J67-OS+BCR(\I&T-RBQM170:/+OM<"@+S%H1 8_*:'+ MG__MEZVJ+K!<3@_C\F41!%\;D?_?HU#F;$>XI38A\N(Y/#FSAV?[C99*LQH; M24I:*]<^3 $5A+^(955V/X'Z)_6':C[>+WOOQG71:44*=F::VBM^8;FRIAXK MN#-CLL@?!JI?Y0-?JV8BE%A_ GG!1:%LZ ,J[KW^UXP5:T7#&:'9,JLR4;Y> M%X6RJQ=>BE(9(P0QH\K810Q#+!(/IF$HN?2\F$:I#<\<'6EN_-(*"I9;2>TH MY3BFDB)))>,PQC%6F'H($N;YT$,1"RBE/,9R46T6F8DP/;)VNL2T7C@!&0]9 M,Y)V@M?(Y-R]?CTAKT KICL^/HN$(QX^/LZD_'M6W>>\>_X&.[[-']AR\6I= M9BM1EJ_S!YJM:CJ_*?)OF?9YD.7[E?96U#]]OU)#DJ42(E^OJFQU]W[%ZK+3G8U_$14 CZB,2PY0R#Z(TEA![80AIA&D2()ZDJ1%G3R+MW'A? M25T([>3XB8OF;S^#;#6CUDO7K[0>.T M_==IA)C$"I@4S\Z2F';08;N_VX*L2BF*3_*=DF[%M 1E*:JRE4/P=WEQ77XA M2U&^(UGQ-[)TS7,GUZ3;0N=P/M]&NA]@&-%_4*O0)_E:<4I6O2-,KQY/OY$?V M%/EWM>*\)NJC4#]?<.'%* @1C),(022Q!VG,4QCRF$0"8Y8DTH;+;0:?&UVW M<@+:"0I8*ZD=.5M-@!G_C@7KR!2KQ=8\V0@..LFO0 ?U1GCP^AS4UOPY!#-' M%&DU]*0L. 24YT0WZ!G#N.RS*(6ZZ?YZQ=^(;V*9/VK;^.V/1[$JQ8(HYN)< M,ICX)(:(T01BCQ 8L2#%B&'*(V)#7B='FQM;=<("LN* ;\6UXZK3 )N1DS/8 M1F:C'<1ZDH)65'?48X2((ZXY/=:DY&*D]G,V,;MI&'UT;MXWK9/W_>K3HRA( MU1!45BD+C99J$\:J191@'N @@0F-"$11*"&.B <1]23V44*P#&RXQ'SHN1'+ MZWOU+U%J?WC>B:QV0/6V2'\Y/>?X7^S(QF(ZS)AG')!'IJ'MV<.;_MG#1G+0 MB@Z^=L([C,VP1\P135D,/"EGV0/RG, &/&$8FWVY)X5XI4;@K_,'38^U-_&Z M*/3WJDFS?/6TO>:&/-5^Q.^DX/4?MVI41;(WZF7\J%[/-_D#R58+EL1AXJ<( M^C&1$'$O@-B7RH8*91S*$%./6X5^C"'DW!BREA1H4<'71L+C7^AT,VE&F2\] M/V-'5%A,C7U@VXC8N8J%&T/$:/1H@E?Z1J6BK>_,T82;NMFFG\;1/7+M#&Z4 CVMP*?>#':*@=O-#'[9F<&; MTS,XP(?G%FYG[CY'8DWL&70+YKX3T?'S!^[0V;W@ZZ7X)#]OSG3?OV7^OLT+]:]4/[E&_6S\HT718R*WX4;U2Z/UC@1%7_Q<+& :IXO^41I#H M\PX6A3C4RP&3GM7FW*U\O'JJ?Z7W"F1E>2CL^M4PW.V_W(2/O'1T MFNG9W>H&MLH=G-E#L_JUUA%H)4&MI4N/P3CXNW(6.)9N6C_!.-#NN0A&&F9 M2LDV.+2\S:\YSZHZLO2&9/S]JG4UO\Y7WT1196K,CWDE_D/P.[$0B> AHVHO M$?H^1#B4,.51 *4OXXB1U*.$&Z>*#)5B=HM%MQPH F%;><%*"0SNM<06,?^# MI^8TC4\&^-@>C:T*X#8'6R6 U@*\7W5G7E>@IPG0JH#_F&HJ+-(JIIB2B=(E MQIL:NQ2(2R$]F=HP^.'3I2Q0)D0E)42"8U7;FS'AS6W$^Y*L[J 9Z +P5'%3D MQ_ ,Z7-PFVT1'((X\BK22=HD:"F+78&WDSFMQ'5GNAOBXL@4/S?:I*:UH>K/ M3673VX:1RX'TJGV+7-O:!C9YF]_=_T6;G7-#GO0S%I[G\=!+E*&L&$K9S<*# MJ40<)C(F./1E0H/$AJHFE7YNQ->)!QX;^>QH;MJ)-R/-V4[GR!1\.+GV@/^E M=JD8>F V)2]VV7SSUMR<>6NLJ?U%9L_10C&M[),N.R\R+<\7L9<1PCY6Y/VJ MS-25MP7195-O\F7&U/-OBIQ]4/*_K\3#N=Q.PZ?,B'U::4$K+NCDK8E%"RWX M6HT'OFKA02V] U^N)4Z#HB=,GC]9)(6%LOVH"IO;[-_WS^NE\#T:^=>%&N)A M5?%W2W)G&AIU^.ZYV4E:2J#%A#[H!:&!6[5GU%QDFB5^ J_SE' Y5&,'#9Q% M"7S5(COZ]$_C,>AK/_+(R3[PTRKUO^DS5PYT$V4EN;LK1',JKP]6ZL/[[;K% M?,:8'U H0Q9!%"<,XH!PF")"8JQKYWE6N3CG!IP;#^S*VYQPUA*;K6S#0#?T M%CF$\U)9Z1_SE7AX M7.9/0GP1Q;>,B;(NW-"$ ;UZ^K)^?%QFHKC^D94+)(*(4$X@";3#VO,]B)$G MH.?CV$.<21):54>X3)RYT50G&_BJI1N< C-H9@S#7R;#>^QH%T.H+TAIN00A MY\DK@X1YH3252X [GI!RT5,'%HX192G$)GGQ@TYF['P73VWR2_EF+?Y3D.)= M]DTL!$%I0D4$J:?;HV 40RR]5$ULB((HTB5D[(K'6 HP-T)4+S2V+!5C"[D9 M[XT)Y,A,UXA^U4N'KJ6_VOB&GZYTZ"85=7S"%= J *V#P\(Q ]%S53S&=OAI M"\@,!&>OB,S0YPQP'8FR(E7M)'B3B_)C7GT6M==6.W:_B>)I&U5KZDXR?N+< M**HG.>!*=!WN!HI&>-!);^%E,H?6P/,T"JIC>Z-Z@&JI=604^/P,4/#5:73Q M,+"&N:K,AYG.?66M^HY+R_YN-^7?W1XC/2\*[?$T]CD+H8\]G2HB$*1Q1&%( M?4^D5)EI9CZS%Y%^;BPYN"W(R\S]:6J=_8S..F;AVC9FP6WE^'%?G,LJR<_F M!7K1RO(O_R)=7&M^DHFTK3T_KE O6HM^$KS/U::?1HB1*ET=*\ORZ5%?6/Y- MV7BU])N4WUS_Z-.ZTBUQ=7C"=7OH(-ZOJB);E1EKZH?$<8+C-$DA]R.FS"@F M(?52 J,@X"0,"<614:K4BVLR-Y.J4:2.U-D68\C!-_5CQ[6S1GLW;,\<9CSC M8Q]7: 5AK2'HH[ 3KT&?0/^Z%@I08Z']?S4:5Z#WXKSMO3CZQ^JJ+2IJS>QP M 1M@7%7-FB^*BFH;$&VFXB-*6A M'S,*1:)+%P4I@M0/,$Q328A ZG\A7_3;00\I\7IH9"/R.]OPVB4'UF*"Y2;G MBYQN#W(1[&8KDTLH7[94;@WM5F[GK5\ MOD=V'HPQ:?-W$O1*"??T[A6+W+P3GT]5%Y[.#6 [32^]W3>6 M]X^QK;>%W]GVW7K@@:N4[BW85B5_DQ7J\6TKPC; JJS__+QI0-K%6=WFK]J? MZB:%ZT('794+P@,D,0E@%"<"(L0X)%1Z$(4QIC*(>1Q8U2%V*MW<5A_US266 M:X[3R3)<7UYJ"L9>2[1>L&[[4#?WJE4#&]V:&%*U,'3K1Q-!VFG419$J<1RN M$6- [6H]<"K;M-P_!JQ[/#_*(':<7A;5XC?R7WGQ>EU6^8.BL#KQ)8R#@$0" M01*Q$"*A#RAQG$#!8A8%//;43TQ(^?#CY\:JG7!6*49'D#O-D)?C,3+%F4)A M3%2G-3[%-.K.'LNH?VT9YLA#)Z&(TPIUW_B9JX;V7#[J%%-?:^QYOH"1IWLX ML)1 '-,$$LR93P@CD41V'9;_*"['SD\VW.5XL:_Q#^%DG,RY.)E7<2[N1'L_ MHG,'8AU^]59*94,HJV!3&D]O]G0$UDJW3ZYWD1_S%1=\S>J*G&W[T[<_6!.T MM=EK_JXN*KZ(.OG/CX.'ZP==3V@A*0DBD?@PEKYN%!,ED*9Q##TOCD3JXR1A M1L[#2:2=&T^U @(EX4\//P/=0J ));4(W1U]AD_SW>SF;63*W*C:KP6JM06[ MZEZ!'86[3L_:0\C:2-ZMW['6&NR^#5>@T7U.KX)%U/:<7HF)HK3G\VK8Q65/ M-54GX[!'%V*ZN.NI\-R)LYYLT,L*=+\3ZAZRW C92O%*K(3,E#7A"YE0&D(O M2B5$/D\A1J$'8ZZ/)3D7:4B'U.D^/>SMD1E?D\F''5*.B.3%>=S%>@D[I.O-N MO14<:,G=$98U6(XXRWS<26G+&H[GS&7_ #W'NUJUG=99O\N=\$*==% M'1'P?O6XKA8HPBRE-('9&;3WY0*8% M!&L=YI.M@"BK[*$I *1[+DH=Z?--1U#4+<.SC9Y6:M+'W5Z _E;4V$TW)93GL8TS-BZ:CNYFBBU/*;7&US0XW?OZ+)GK; MHG N9]OZ>0.SO39KYB>IFU9]T/$,S4C_(9;\75[\7HH%]CCVTY!!C ,?HC#P MU-\D@U'BH= +"0HCHS7-:M2Y+6 ]$U'WD11%1=3B56=]+;7\P]*^C/ WL\N= MHSKRPK.5]PK4#=-J@1L*NP):9"CS BJA':9[V6#D*MG+:,QI4[UL8-A+]+*Z M>1@OO26%;NY>WHBB#K-]DRW7RL1?($$0B4(,.8\#B"+!H2(B3]G9/D=(2NE) M*T_!D7'FQCVM6. GQ3@\7RY)48)'48!2RWSUIM?Z98LBQB' ?(%@C*0D;83.4P9CJ!(TS!-9,(9-DJ] M'3C^W%B[:T*A9U]U"0&+#?6 :3)P;8P+_LA< MU.&NI0>=C$#+#UYO<&]5V/[^=G3<+?P7X^(_D=MBA'FP\U8,1_&DDV+ 8Z?S M30S7><BGS M4 JC(%5K3.2I'0!1MBJ/",%,AEPM/9;E'4S&G=O:LA4;;.0&C>#@ZU9TH&6W M[-=B.A-FINL(^(Z\?)A"^W:E2+2H.=1M60@;O-P5AS :=>H2$390'"@4877[ M !OYUR)?/]ZH%^^>E&J<3\4=667_K%^)=T*4BXC["1?4AX(R#E$0)# 5,H5Q M@((XP1*EW*C&I,E@ M5;^)!RJ*1<)8),,D4"PJ8HAB(2%-$@^R.-%5>FG(?<\NK^[Y$'/C3BVA/F5J M9+3-I-L#T,Q2NPR6D9ER%Q'PM1'0:<;<,>V=9.>R; M_BQ*H6ZZ?Z,VEWK82\Q".)KHU% M2,(@(B* 6(0A#(1'F%2#>8E5?/I@2>;&$-J&+59DJ8]'02E[6GT M\'DR8YA)T!_=N=CH<-4'^ZJN1=(ITIN/C2J.^T(Y0]01N0V78U(.O!BNYU1Y M^0/M2X7HZE)-C-"*_S]KLLSDDZX&W>QVRTW:O P2+XA\#P8X4%93(BBD3/%G MF!*!$RJ3)#1*%#8?7M:_"%W0N^7HHKX ?02Z_ 1I7ZD]TJ SIM3/+Q MA\[):9H;+!94I2KD,H.^%OMK%A;I@O$AA(%F<8I_0.$Y,^&COR7.CG58XT$AG MQB'[<)VFBHM &)D1#/4W_KR/ZGJBS:6ZI_F(U5^VW^_^DR;Y3(\JT'V-QR\8 MX)-^(VCU?J4^WMKM]CK_)E9D59_0-<6Q AK(6!(&*<'Z.V1(;:YT"!WVHXAQ M/\34W"=]9K"Y?9I:7+"5]PIT$M>GSJ55[3$CL V\U0XA'/G#GAP]"X^U0Q0G M\EB?0=.1N]H0EY/NZG//F,Y=;:C-CKO:])YAKBW=WD+7)0%9EWH\/-3>:59+"5E1 -K+:^:). M &OF;'(#U\B4NA42;*41W=WKUF#?1$'NQ-L?HF!9*6Z*C(F%8AKA\216G..G$$5< M0HS2!*8IPBP4E/G8I/Z^Z MT.M%U%?I"M03TO:=4'>Z6P4<@.J(U2^19%*6=@#9<]9U\+V^/ M&C&3B2 ^AA[1+7TH1XHF,8%QPJ/8#W# D55+GU.#S8T'>\W">M):'^P:X6S( M?X[0&YO@!@-G3UX&B+ABIU-#34L_!DKO\8O)/0/.B;JDB)LBUR5J_TZTG5B] M$24KLMHJ^B(V/D2Z396[TTVD#OC=Z/&F_@3*HP4_K1U#EAKX#%Y-DZRS-MJ';H09N"Q'[,4-$0A)&OEK,"(8T M)@C*V*,T#GGBX711Y4HN,V/9=&"KE6LS_(@.!#T&D.M*1RP_J(V-SLS/.S7 M4NL!'EM%+--23.?"S* > ^&1%ZA&9.U [O"LI3[6JM)A:HLE5JX27DR'G38- MQA*,O>08V_L'ED/HN0X^21W#H,U_'9EY4XB';/VP(") (J(4QB%2!CB6'B2^ M^B- ))4$2QD$5N$%9T>$YM!4E3-7?JR5A?./ >I#XPQ-TI_^^7F MQK*NX@'@O("2U&,8A@'253=$#!45IS 53*V201A@1"PK65X&W30TK,%KHE-* M0+Z1;*G[50.IEK[6H,_*SOI0"W>"#%W)]1W5:GR MP C35JD\KN)>AYTMU M1_GVO]=9];2)KTEE&$912& 2).IK98Q#RJ(4AMPG(:J=;U9Q3,>'FMNWVY?T M__I7'/C)_P"BEO@OEMD'Q]$U^Z#=8#;V?JX6[ I<5U61T755[WZK'-RH#?&J M&B6&Z3PNKJ+FCP\T;9#[687W8M+/WS&,,CY5]Z)H>V)E)1-+]3*(?%WJ-*YU MH:=\X:4IBR/A0]\/L-KS47U"P@6DH22ID(H_(JMDJ/-#SHU":HF;'E6ZK<"@ M%E4&0)NQB%OX1F:3!KE-.[V^O%=@*[$[+C%'QQ&G& PX*;>8 _"<8RSN'&B> MM/6-/LG?5X5@^=TJ^Z?0AD_;*+O\G"^7[_)"I]+$0"0IABF*,.01 M#9A/HA0EB4V@WLG1K!ASLNB\3:.H92MG9NO2.0VQ&>TY VYD9GN]TW9KVW9H M(ZL[UC*"Q!$QG1YK4NXQ4OLYO9C=--!:(TM1WJI[KU?\3:;(JWJ7K91QT47K ME?6?39R>9JY#T7NW:IZ$3M,K%R&.:>#1&*8^1Q"%.DK82RA,B!]%,B A]XSJ MI8TCWMRL.O6FQI86FMOI,K3:7FP2QK;DM&)0:U:77FUT QOEFI#C\EC,\563 MIEQKYM"<&P5L5R:>6^&F-?M& 7;/%!QGE$NWXL];GKXB9<9J$>O6I\\V;X_%:]I8XFM[' MNC7R^^;P<-/9=^@.W&[&;+??H\W#A'OO0UV4]^=DFJWW(#R=[[OMI'BA3?<@ MJ([ON(<]SHY/!>.+MS\$6U>*GE^32MSEQ5-==-6 !(_>/#=ZVP@).BD-CTZ/ MPW.:EIP@,_9!Z1XHYRKW&K/(6?5/E.Q6][;4P/B6$8X_<9)O_:Q"W5=\_L)Q M4UC?J=>CV0 A3N.8X00&+%7[U1A',,7*Y@E%Q%A /64&I5;=TFPEF!L)J'>!ELIHZAU7+"A'R$\X@BDA#"(MX&@U]B@!$TL3:50V!;/W0"A_OKL!0)?^P?-+O>V+S*M4Q7.=2O\O&KG MCC(QUN5SQY'BA8K*=^5\S8J*JR4S\$DD("6QSD4F"4Q]G,(@\KE /&4>M\I% MGE;\N2V9G7 S*2YO]RHX6D)?;()GL(0:EYC?@/#'K#(_: [G4FC>3OAYK9>C M3(SS6>PL41,1X<8E+Z.J7D>V NA&OUF6V$F6I*(MF MJWH>/V_"6]]SQ5"9S,BV@CM3MKT:_GK%/VS#+=7OE*'/=QUDO=\OD!?[2>J' MD,0Z9BRB#-(84YCP2" O#65B46UB$I'G9B)_V.0L/2\_:1WV.N&\GR:_><[F MR%3:Z0MZ"E^!K^8 MT5MB5_ECT@D[62]D&DFFJS(R*;([M4FF'7EH11.]+E9/-^HSJM3(V@?YJ#_4 M;0!=%".?^IA!*2B!2* $8HQCR 0*4.*GC'*Z4!L!L[W-^0&-:"5M:*4;=D0? M6UEE#T2[27XOA5PO@>[04VH#_GK 5L< ;LHB'U,1P,2+J=I,1A02%A(H%,XA MP[Z?)E8N4D> 3UILII&X#E;N=&,*P'[]&^,[AU;%4?RE']@<,&DO6[[2?K4Z$-'WF8PQBJ!V5D%$ M4IU9[B<0!91X&+-0,KLHAE.CS8UJVE/FK9#G0A@' &QXT.$*MI$IQAJQ =5P M#)!P5A#GU%@3U\0Q4'N_+([)3<-HX[,HA;KIOJW52R3Q4,Q3B.,@@BBE/L3, M9\HXP1$+..=(6!70VGW\W(BADZ[VW+Y65GE6@=>D*)YD<^QN1Q#/H#1CA.$ MC4P!Y[ 9H0;R82P7#0O@$IB1,E7$@$<11%$).,8TCI-X4:K4M&23%W%CB2U5D M_Q#@48OK) 9CV-R8\N/==7G+"U!+>?4LK6?6"8WW;V07/C MM*W 0$G\T[>?>RU\S9/>SN-WFK2<0SL M:#^!SORF@194;?-^R,NRK6! EMNHW9M\F;&G[7LN/2+C* F@#"2'"-,4DD!J M1WK*>9 B+\%6_=5L!I\=MW21+G4[F7;KH%6Q+CUE,P.&YM%(N(YM%6U!O (; MR7MY$^!K(_PX?M\AJ+DR@6R&GM;R&0#*GL$SY!G#Z.S]BA7Z5/&-:/[[?G7- M6+$6_6/(!?9PJ%Y& 6.. XB\*(&8) RF,F4>BX-(8JL"I":#SHZ^&@F'5\PS M0MJ,KESC-S)-=>*"GSJ!?]:QZ!VB3@,JAD#DB).,AIR4BVQ >,Y!5O=.G++; MQG[_6N_XNL#ONN3O C,_27& ($X0U7FY :0!DY!(&B+&DS"E5A;7"#+.C=EJ M$=L\HJ;UG^ODH0'S:'AP]K*S,S)O.LBDW60!-9KV4X!J;6>0&'M^*EXZ^_6$ MA/-*V1D.L;,\5H.AABT6+@/J7C<5_9LKVQ9$;W]H-75]PEXK@$7(,8L"/X8B MH769!P9Q)!F4J9"2S7YZ1UZQ M+@O!)L="L%LH-EE4W0O4PE'?V&^VXFY5>]$)=;3NO8P.DZZ,+SI-S]?.EQ7& M;G7E(EN\50)53U\>R'+9B;Y(TA3%7 C(@\"#*$48I@$-H1=+1C#V44*,"L = M>?[<5J1&1%#+"#HAS9:E8PB>7C %SCB+)$0QD3)1%&P00AX+ $#,JTY3X:605RS-,C+D1@'U]QX'PF]F1XX,Z M,GLT"L!: [!5H;'/KFK#C=7E1WK:C%+N\3(D'5E@ X68U(2Z#*CG-M"%3[ND MSNVFU4"=+7'O$%"M,:07"X%*W9K?;;IP]J]I8W]_E*-$4H%\CW8TP]"GT_"G2; M$ P)03$,49Q0Z6&FME2F>Z?G#Y\;E]3R@5K M@:G^:YI#[CS6Z9+X!B;%LR1 ML-HL'5-YT$YI[V&3;9..J='?(QV]QCZ$5SM M5^+!I V#R6-F] YVXM9M8(HBKSL8+Y^:P\#GAXC]&%6M#*BU<12C:@/W87EQ$R^$XAX,Q> M/3#$Q ;J<27W+=(3UPZH2+=7X>ZUKA:MMMEJU_TQKT1Y0Y[TB<,"QR3U.4;0 M0ZG:_B),88I%#*E'I"_\./+-,OFL1IT;$_3$!%Q00R:P _HT-8P&W\A<<;"F M91_.6F[0"CX&KA9UT,; =Z)29HYPMBM#9HO7R4IBQ@^;KAB8K7X[];RL;QY: M=Z'*BCK 2E>$T=Z*-_D#R5:+!,6^"#T*O4A;;-H>3E%,(-.)1+'/, NMXEJ/ M#30WKM[*69Y^M553Q](-^O'RK36@:VSYV;(='*#S8^4KX6NM_D1@?M M =%:@%8-H/2XT@$*:]/ZDX/@/^^$'A/YD0EH'-"M/-%#T1ODE;8>;#(/]5 8 M^M[JP<\8VF[EL1 L:W;Z,N(R27P?!I$G="%BM?\)_ !R22./()^EQ"H%N?_P MN5%57[8ZMIWT0F:ZK G]Y3SVB^6*8<5R=U V,W^&8C>ZO M\[):\,#CE(0)E GW(8J0#PFG$A*4IAY&+(Z#T+(*P>52S8T[FEQ06N>"LOYQ MKV[0U%''3U2LA,PJRSQ?-]-HQC&33\[(Y/162J&D_B9 HUGMV?U,JL8VVBI8 M=[7=JMBE.%T=3O+=YF.Z,YI&F0%W)18&[%T4@+=V:ZNBC'>R>.%W(PR!-=^(> MACUAF"5YS?]K759UU^?/8JG[;MWFRK;]>U;=W^=+GJWNWN7%83MV$3%,8Q)1 M&#+?ARBD 20>BZ"0) I9$"!E:RY6XDX_URIF+ZLIR#X M1)?9G6/?I@-<'=G'ET@RJ?WL ++G]K6+1[KI8GU3Y-^RLBZ>_7ZE7L*'^J?O M%25D9'G-F'8P*7%JK\/C4E1B*WHO/JY7Q>2C K6I8++PXQ#+B%"=;AM!A'@, M,?(3&$8<+OT,7=L2>81=LVV6.*]*+]LB? ^ESC["E$&&! *;&8$+Q\IS!L[?E2 M66JOU=#Y@RC>K5>\_"BJ!2:>8(F.U0^PU#5$0V7Y)!Z4<1@1AFB:<&1L^1@. M.C>3Y?6]WN9H*X6UD@*I1;T"*V&SV)AB;F!9C(#DR"9!)S'0(H.?.J&!DOIG MT,D-WC6X?AP%5XO5=P1\)UHVG>%LM]!9 G9RA3)]UG1+BZ5V.VN"[;U#XPT/ MK16[13?+!<8\CAF-84!#K/:Q"8>$A@GDD>?C*/8%HD'G:+RUB4Q@!&//8@2X4&:L@2B***<101+WRH?].1H<[,FFUK? MRWQU!_4A.""UW'^QXYW3^)KQC3/41N:9?G'T_A8=?.V$=1A58P2*(V(Y/=:D MA&*D]G,B,;O)/@OLMN#71?%%J"6F M +E++C\[XM0IYJ80'$@T-[[5WM!XORHS=:4BM;HO;;T+RMG'O+KF^6/M?^@Z M,1N:'<8/G!NMM(*#;JWMQ*\_E-J#Q==J/%VZ";2ZF!LIYC"?-UE&07ADUAD M+OCJM.GU(.0&&37FHTQFXE@KWC=X[&^^H$3.FE7*KEK=:=8KOHE%P#W!P@!# MDL0Z;R",(/&(A#*(<(18$ ="6MH[>X/,C8E^7]6N0TK43YG8"_?LI >/ZO<# MBN<\A]C8RKD(N/'-FAXRK7R.*^,(D@?+WQR[UEF'T+JW M6IDU+=CJKT 'KY<+YL2!SB.P]1'1NW-[(>>&U?T MQ-P0!=."7MR4\QCV9G0Q#J(CD\CA>*L^Q*W@=:++N&TJSZ U7F_)8P._=$/( M,X 8='$\]X1AM%5'=M/SK9;ID5;+?U-,JKLL-:V6WY&L^!M9KH6_D")-DS#A M, K#4)$<\R$5/H:A\,.0\""4DMF0W%B"SHT2M63@FQ9-)U<2K4$)OM7"VY'B M:#-K1J%SF*^1";>?4K/3W**G):!/AXMG:%6O0*OL%6C4U2%JC<)7H'X1:IW= M,?78D^*(UT<3<])58&RPGZ\9HX\W,*]2#Z$KT5[_R,H%"L,XCB(?^E&B6P#H M9<$3&&+)B)_P,$J1U0G SM/GQN6U<&T=9"V?9=&-7>3,:'+9PM)7F]N$A##U> "#* A9&.(DCJSL M/B=2S8X8E%*PTPI\%]G=O:)>2+Z)@MP)4&K)=S*EF_3HVAJL'6M(^#KV+';>[)J MK<=?U2.JLK,>%\2/$-$5DWP=HXY(*F":H 22,/1($"4HDE;E,J<2?'8K1>, MN--"*GX9S/J33;P7R$C'!L,$8[7^1]JYC5,/,N(Q3B+)1<(6:IVC^1]YZOL* MC#?YOW:SWK;0_/D/,/\6WJ&9S>G\O46-\J"G/6ABJRNE_]:7U$"P]24Y]A]- M.&TN_4E3B#V]?VG"R3CH;YIR_*&!&?WBM)_D[ZM"_>1NI8N*W9(?KYIBU*T= MI@RNQL[29E=%,FV!W>9O?Y"';%5?_EE4ZV)5?LZ7RW=YH;59<(XI2J6$C*42 MHC3U(8X2!@FAB'L!ENI'=D$>XPH\-Q-G5U^]8^IK7">G=3I?@8W6[1:JWE6U M>NN-2E&#X:9R?LP(,YFFDER%K,S MLK@3Q_], _Y^+-%$X]HM?UQDB_=,%M=J4/767E>5*!O7PKLEN5MX7A3ZDDL8 M^C2!2'A8K5!A0QH1IAL.)^&7U@(;AU%^VQ';FL9/0D9EJ'8D87CW,\KUI&S3I M5J#5]:JVN^OTBU^+O"P7$4LC/_8]F-($0Q0R#HD7Q3HMBU%!TY1);N>I.3W@ M_/PK-P<[6%V!.RVNG9EX!FLS(\\=?B/30R?H5=WIMZKQ>[O%[]>3^%F;56:P M.#**S@PVJ4ECIOAS@\3PKH&[:7U4J8R<4M1YXY^H-F)TU(BR;^HJ6\IJ^:2& M)[HF6MVUH2M1\;2@4F*. @HC$NBC88D@$<176^:$8"IC'BO"L=DH#Y=E;H9) MK0K,)5R7HBTH ?)6'^W($ZU&=7'FE?@.EG4)5NLZJRZFT7##.LWDC+T7[>9% MZ=%4L "?>M/RMC\M&VV:[C&;BCI/#C>8EX/J:N]X@233;@LOAVQOQ^?@D<.[ M70EQY-F_KWA6UN4H!5>2J$O;6(W$(QBE/H)C(B M XJ+&Z-M^D2)BI3YH:0*OR::"IWV7+/OI,>/3\=">KK.6$%?/6?)J2Y-7 MH*\&:/1P'BES$8X.^W'9RS!YIZ[!,!WJX37\8?9E 6Y$?LVJ-5DNGVY(5A]/ M690>.GSWW"S&F[>?0"GX M1QXY6>[]:97ZB?9GKAP8K\;N!5\OA>[R]/"8K^K38KEI/-K6$6E]['53P&TM M"C^@7A+1%)(H%A"1$,.4"@PEEC+!C,J$V(6@#9=E=N31U32O-RX_M3+7T:L_ M]UH$V^XJ+YDMP[BA:>9@[%"@5@M]MKG50_^KUYZYJVC4S<[/;0=2X+2PB$-@ M707K7"#)M/$WET.V%U+CX)&7$NV%8IMR3E,,(X4!QKT\@3;T0)B%# M/B9^D'A6A4_7 )[/$5P^DH XN&'][AOVZ;9Z4A2S'Q)"3"4XL"12&DG G($(H2(@E5 MRX)5U?"3P\V-Y+>.K[VSFRO05<1^S L]/9:UQ$_#CM*(1F%*(='Q/BA!:@*" MA, DP5A$(O:$%]F=\[L#?IIS_M>[Z&IJS8_/AE/PS99 =X".O*2=\MZ^=M5X MS0X55[7<3P\V;3%W(\7WJKF;W34TEJC?76)#+;&D <.*P@53C,Y2#V)?I##@ M29K$L4\CNTIF!T>9&Y%?UG#F,)!F-'$Q/&.[6G?;QHQ "2<1&N_+QD1][^UW7S&A4 (T.F^):C1I7H%,$-!=WJM1AC0XC M&"\$T]5N>J 4TVZ;+X-J;W]\X>,&6TM-BZ[ZR749K4_KJJS(2F> +,(@E314 MFS&1*ML),1;"5/\MI4@A%C+JQU;MLTX/-S:'3:?X'6.7=3[-Z3JUMKU/38FR$.0)[?&NLQ?E+@_/? M&G![TCHUS Q0<6>AG1IL:E/-0/$#-IO)70/Z0K^54C#M ]R<>FE=A-4MLI M?_W^X5&WG&/#_5+%BTGIY@-B9J13W2 MK-@UIKX0SI.-JH<^>[K&U1=JO]/(^M)GC1"SWO73?K,6_RE(<:MF2RPDC66( MO012M4A"%"(.22@#*-/81T$2H\2S,H^M)9B;Q:Q>W-AA)/I!T,V,WU&A''F- M,8E KW) 11TE>@6T#J!68J+H\U/X31%Y?G#\^42=GX+'*N+\Y(.&D=R[;)55 M:H1O.@U(6?%W&5V*MK.NJ!8DD;H-0J F)/(@"@1MBN(*AH-0,AZG?F)W!'MZ MP/D=P2JA "-%\:2_.V(1G&Z*L)]B@=0BP9F(=$9I!'$D&$P"Q(7T)),I7U1Y M1993X[L==#QT;_483O$T6P["PEI2L!5UVY1<.#RD,D/%$:.?&6Q2 M^C93_#E7&][EN ;&AVPEWE?BH5PD(HU1$!!=K#2%B,<^3!E.8,)T$5O?"T1" M[;RQYX:OHLF))U^;3IK7O=G AI]]H[XSWKX2=EP*#C/N7'P$+[@N&$(P$8OJP*H'8IP(&+$6^C (6B-A)^ F3 MGLZ,Q(K)1 13$1+(/)[R)/##%-,!M7GL)9GIH7M/6NTVW(CKS-EU;&(N=H!= M@O,\G&)][*]-L'?I*3L#W_C>LV,"S,6C=@8@"R_;N2=-<.[[/5]@D;) QA0& M--(IXT$**8D03'S,61#'/$+>:*>^W_.YF7;J58U&//-5@(]PXFL'XRS/>[_G M+W3:N\7N)CS/>G=0G/1.6_O,9<6R6@B:%X)F1?;:)HWZC]EE;'K%7^G M?I[=K9[5N$D21@(:!%#H?G@(20S3($Y@Z)$PH)Y(4FH5V'*A/'.CO%]%?E>0 MQ_N,D25XI4SV?_#\^ZI7%N>G#WE9_JR^6*TFJ.X%V"UDY*)RT;"9->/2">=K M[.UPK[1%BWH[*]LYN *=0K5GME5IHBI&%P'LO'K%,&E>J%S%1= =KT]QV6/M MBT!^J?YQ4[!/Q6U9O%5#/-0V[6^BNL_Y]KLU+ EI\JRYL6F;T=9X!I5A\^4S MV,H.&N'-ZT,:H7F:!<< G)?@1W)P:T!S-8L. 0O1[QG-?2D M3#<$E.?<-N@9P]BL[IUU4^0RJQ9!@J00)(#@]VPK+IH@L: 635&0ELV.=_J F='*0!A&9HT&@9O3"%A3P@%='7WQ_2=/ M^D$?4.GY]WKHD@$E#NI0#7JB\3Q]VE[2;SS_CF1%76OANBS7#TVO^7;G*+3_ M28JL6A="9\4NE,D1ATQ]VE[ =1 N0Y#Z(H3*$HDP]D+J2:/CR,DDGIL9LQ%3 MN^9;.8'B9$KN:$E/.V,D"%),(,EVU MBBEQW2EM,>G PW80VO52$%;]/:ON7Z_+*G\0Q5ZYZ$0PSY?(5QL*JNMGI@BF M.)8PY#RAQ*0'#)(T#F&,$?)]/Q7J=W99^:[AGB8W_\M]7E103>T#X%-A;[8E=(WGR'93 M)R[XKN0%G<#C%DFW@T4VOI8[[B@J]9 MI4-QV_+-BS@F* @9@1$1NC:H'^CDSP F:AO*PP#[Q*Y)NL78NLVV-L<%#I'=&1N,J_EMJ/(MI:[ZT:\ V!T>AAH-O(+G/Y907+XN,_N$9<& MP]:6]:OGEG4=._.IL:BUA=U8Y%LK^UD$)2,\2 .?PSB,8H@(E9!P%L,@0:EN M8"-9,K!CG OQYD:-/4'![WIC7>7M/KH)66H5 [^J#5!E>V3H>&;-6/7EYFML M9UHO5+9QA;PZY K9F;>F5G/K3>E-]32QLRXGP'DHK1/A7BBRUB6PQP-MG8YB MMS9PD2W:WG-/;W^P>^U]^:B^C46:$%^&/(8Q0HK= QI!ZA'UM]3C:1RA-/:- MV/W8 '/CYTY&T D)M)1F-'P4Q--$Z@*:L:G0#A5C"CNG^HD8675KPS_J+UO: M.?K 28CCG#K=IW_VNH&&W88_^K[4ACJN5UQ9F(I3U$:B;I31% !9> D.D0Q# M&*0>@2A1^U=ELD60!W$2I#AF86*5O#E AKE1P'8%?[;P]S6R-,P&S(RA]34N MWI.<5SXSJWJ'4*,6(KH .E?&T0 )IK6 AD.T9^9<\*B!="B6ZK=WOXJ5*,A2 MC7'-'[)55E9%75.L\QUY@8_\P*>02H_I_2N#6(8>Y%'@XR"6GN=91;":#3LW MTFNEO@)WC=Q7=>H?V1'=DO/,X#>D.>>@CFXQM7BV(M=P[@K=>>@<,IH52JY( MS&S0:7G+"H@]JK*[>Q@[]6IW?*KN1:%9L1#WZLF;/@\Z]O^CJ#[)6_)C@2A* MXL1+8>PE$B*J8U=]];>8QJD7>$SMRJP:-%J./S>^ZI>XR;7\@/45 $LENQU? MV4Z(&7&-"//(#-9'N!8=[,B^F]I?%^+6]K+2P1V?#03/$;'9CCXIPPV$YCG5 M#7W,!1O44\$^KXX$^]1__$TGG*_N/F=W]U5Y(PIM,)([L4@]%J2!XD.1I,J MHR*$."4I#.*()G&(?"Z0]1;6M91SX\^M9/JK)5IR\*T1?<#6UOF<6FQ^7W*F M)MP>GP_4/'@Z4?\'M*J"1M%V+N/T6_*Q8#ZX:1]ML&&+ MR$[OW\9_\)MXH*)8!&FLMN_8AY@G&"*<"$@8\R"A7I+Z$0M#NRI-1T>:&YGO M'$':T?<)-",9^5'BZ^YM:EGU?0Y3(CW(. \02?422^R"+)W@.5%D98UHWI[> MY@:-=RW1-5O@G" V\B+UK!-[(R7XVLCIT%U[%@M':\3Q<2;E^;/J/N?J\S<, MR-CK8BQO1?'0)NI^%G459DWU34OV7'[,JTQFK,FX\>*("YSZD,1$*A86"-(P M#F#$?1ZCD'NI61/(@>//C9L;&>LJ=RLE9E/MO=JJ8Y$^-6 R3M/,!!"/3#Z; MP.V>]* G?FWJ:OP5Z'T5QD7=(@5M7/0G2BAS/@MV26'#,3R9XC7@L=,E; W7 M>2?]ZH+'V*TF95$M?B,_LH?U0VL!)4&*6(PCF,2Q@(C&VFZG/E3_$C+@.$PC M;+).[#UY;BM *YP9Y>SC=)K"+])^9')NY7)H"Q[5]I3MIV[JV7WJ7UN;;_]Y MDWS!1]7HOLWC%UP:\KW3)OQZQ3^+VOFK>VF4V\A?GPHLL?HBB:^K.OE>"#'& M'A08I;[Z/'WB6>6R6(X_MR_XR_KA@11/>OG:D;\[P1U-A/#)/ M[&+:-(-KSIUJD2<*GK9"S7ETM-GH+Q3^; 7-\?AFN\<,[=E8O5_I@PQMO[Q? MU77EKZ4BB>OE,O^N6PB^RXO7A>!9I0^VNJQ6#X>,4(:4"4)"'01$(!4B@M2/ M)&)1(@@V,D8N$V-NO*?/=+.-&NJOH"1+44(]$EAJG2[?#E:G/_Y+$!CY M,S=3WBIE[Y"F@U+U=AXT68K>(?'[J7D'?S^P^G">\^_9#1M+V+,UA26,#0%S5.#XUU+1%CPV4WJN";'*/?;^K6T+7 M2U)\R,KJ60$.PR971Q\PMX^^%11H2:] +:MY(ZOC,)W^[ITA-/('WP=G%)>W M$1"#NE(=?^IDK:C.*M;O/W7^XF&K_4ZW^J8X:4L5VL?=-+A:!$RFU/<%] .F M=NG*Q(;$(Q[T>81E&$D9!%9G:R:#SHT(KN_NBMH3^KQ;BHZ-:O4!I5;(SCPP MF@ S,\$UK&.S1X=:+6]3ADAL;8>K^BCM7/- :]/!!B1')H31D).:$C8@/#AX_@%O_XF"G(G/HL'DJW4SW7HT#4M MZS"B!<$1]N(DA76J*N)I JED,4P(3P1#?DIB9M=\83KAYT:2GR_,!H*\+4#X[@Q^?*OCFW[ MAGF^0G^<3@Z#7B67W1RFG\#SC1TFE&GB'@_3H[W?[N$%9!A:_ON;&C\OGIIZ M1+V:MTF (IP@F(:80!2+&*9<&F;BX]FEE]RMIG[G>/G/A=5,D0Q?_ MJ:NQ-S[?3_*:-RFB;W)-/HL0QSSR? (#(3!$)$204LH@C]*429]P+S8JIF@^ MY-P(8BLU:,3NI_YTHH.OC?"&9JC%!)SFDW%@'9E9'"%JE6)A!](%N1>& TV6 ME&&G>#];P_+.@37#5E7&L^5:#]/6C\U$J2O'MN\_Q8BS!*50,D0A"M,($L03 M*%A O#0@BH4BJR)A9P:<&_WTY05;@:_JYX:8MY&6H_%[E+M/[!D:9-K&J[X1NR;V\)3_:5*=78B5T9VCI8Y(B M&D)?^ %$7A3JJJD48B9"@2@)96#DZ#4<;VY$T\II&5YZ!E,S(G&(U.BF2Y-[ MT(I:-RYJA04_M>+^[##$U P85S&F9T:;-LC43/6]*%/#VX91R"M29J6R@!C3 M_:=TI$R]'WON P@C3(* >3#"NFH3H2FD//5@2!F2?I*D.+7RI9@-.S="J:76 M)OV->FKG.+:C%T.\S5C&/8HCD\T&P*W(T_AB[)!RQ#Z&@TY*0G9 /. M(^/,CG1:,4%/3O!52VJY1SJ&JR'77([6V.0R "A[(CD-@ROF.#+*M%1Q6M4] M;CAS^4!O2B])[TV^II5<+UOZ*3\+)K)O.C:P2VI%).%4>,I"0:':\(@D@"04 M*?3#2#+I!Q)Q:N5:L1E];L31"0J*C:1UW8;UBF;+9=V%NOMYTXBZ+C+<:6SI M?[&:)D-GS%C@C^V9Z7#?"GDU::+Q(.!<^6VLQI[6B3,$ECV/SJ"'#'7O-/VR M7^=UWYVBJ?R5E?]HBTYY"H0TX0RR2(80>1Z'%'L,4AD*G]#()W9MP[R.0K<""5A#7%QYO$Y/=K$'A\CU?<]/F:W M#6,577(D+[[H&C$Z=[*NA]"K8X7B)/4%83",.(>(Z8I_ 8M@B"6*$8I2;E>? M^_1P<^.41MJF1HAEUN,97,U(Q!U:(W-((^@5^+*M-=0("[Z.XL Q \81B9P9 M;%(.,5/\.848WC6,0=X(*91]P[]4I!+7*_Y!S=ZRZ4.S?U[B!1X-J$0P35(* M$44>3$6@^"3D*/ 11NI_-GQB,_C]Z7(U\<#4$-4=T9#7TI.0T!)3G5#7H&<.(ZV^DR/3V[+,>2;L^$<(^DYA" MB0,,493$,*4IAW%$4>CY7I"DJ0TY/1]@;@34R0>T@(.U<=.F(92W^2O1^&$$ M_ZCLG=OO8OE-_):OJOMRX3&:I,R3T$]D!!$B%!),?1C(* IY2&1*K=IS#A5D M;K2@7BLT9+,S8 ILMD'C CO1!FFC1%=XLDOMJG) !>@TN:K31<&GE<-R;I>B MZ'0W-4",%]AG#0?K\ [L@N==F WUF7S_3=&M(MYETQGTLRA%\4V4BPA%?A12 M#ED4(HB83V#*2 A9'%,J>8!"0>UZAIT?U.;#G*9YF!(5/'2R#LR4.HZQ&Y5,<'?)FLJK, ',VO.G_G!6V"+T@2 M?9<74F356KVB[U=M;;@@E0'GD80LC83N:"$@C84'$Q[C5!=Y1XP-J!@^@JA& MW^7TY<1;204'/^DZ\%JI\K@/9+)Y-6/#EYJF/TR;X$T5@)ZFNJ*YZUJ#(TZ$ MRQ;!CB6:6:]%).1*=$6 M#JORQ\?T'E0">>]ADY5!/J9&OQ3RT6N&678['8!TA;.Z"U!M-'[(5N)])1[* M14B"((A##F,O3" *=)B I 'TD>Q&,V!F5+G&=61*< &IM;UC@Y$C \9HR$DM$AL0GIL85O=>EA2B M;!BZZ8'*\KM5]D_!WW-ELV2R/F.X+DM1E5V!1GV>J'Z<+>O$6_6[]8/@'Q4B M38!F[W>?JGM1+&3*4X$QA2%-"$2)D,H0H2%$D>9"5; MYJ7:=F]C2#'F,8N)#T-!=>48SF'JJ[\)27$DPBB6=D:WV;!S6UT.T=+EZ\HA MO >O"Q>B^ *\#K8BCQ3!:P?3>'QZ:-"7YL,30!CPV:F[[3N=7-_=56^+0CL+ M/^;5?XKJC=!&G!J46S<],7G6W.AEV_9 29ZO1+XN=QWV2A.@5 %;7YIVQL!U9,(9 *EC$K(%;5"'%:,!)FNV8J-NO^^*U7T3GQWK;HO5T_N5=C?4 MD32U\75[3U;M886RT'2K5\&?%1[^53VZ>J/>P'\G$42Q MC&!*2 1%(D,/Z_..+Q4IJI'/FAVJ9O/E/U=P1*? MBIT?3K-\^62 M%"50$C0GU5,=5+M\B8)$=_(-8\B1+R"B/H*4>QPFZN<)YS22&+4OT5NUH_C? M^!7JU/O_7R"K%VCDT(@7>B7F'TO1 -ZR#3^)U I;+:1%AMX#G1;J"$"&B.@ M07+=C'E.<_[281LN5?ICQ'F,,(G. D/&D&UHM'.;)K;= F]ZU" " M4Z@3UR$.)89^@*F,&/,"SRKQ],18<]O"]C(B^VX=R\Y")B";+5^.H!MY51F, MVH"XYK-X. MH/C[2Q)',9U7>#V$^?XN]>^N=TB!?Z?2+7)'2TYNUN,W;)--/ M\NU*YNIMJIGNH3+U7S3B3>< &*-]WA VY?6!!C0W!?9)]6^RS M6.K, 1U14]:F&.V98N6VGZ<7R 1[NKI&Q""2<013QA$4,8X"]792&H56)38N M$F=N%-=;R]67MK-=;!6JX\S49N] [YRL-5TX9R:&5;3S=2$._K-3KVWF1_# M"G,#GJL:'Y<),VW5#R? [=4!5G=E%@[!ZW(_KNO@?)7'B M>9'N'>@1'>@DA 1S'2_409QP%/(4QH+XI$X"*VJ MBY@//3?J:"4&K!49B!_L7J_EH-#>)#XK8L9L/,@!H'XY%YIA.Z3@2M M@>[D!CW!@98<_*1E=U@&S1XP1P:2Q<"3&D/V@#PW? 8\X;*ZC8HIFV#739& MA4_C*(PD@C)*!$0H0I @$4 O$50DG"GVBH=4:=P?:FYI(SB<86/%4T\ M<<Y M J06&["M(G;,-=9\F]'>#&;Q91U;G;1RP\EI234OC(4#_G M_[&'LUL\=&_MS_J5KBO""L_G*4L9E((3M1D.$<01P3".0Y[@4% _,.H5N?/4 MV1&S;OY85IDN0/V;(-IMV3JJS6OJ[L)VFC$'@S$VOPW#P:K3_9[>%S2SWSYK MLG[U>^+W6]+O_W)H))2"7OP'QIC;9ZEWR4#-B2ZYJ3?15X"M']9Z%_U-@*R37W<^:Q6P#87:1]G, MTKD0NY&_XHUTX/-Y9 :$.QW5W5F8T_X($X'"4^MNJ/MPH)0)B$*AR" F 8P"CXDT2I%/<%=;T90.S@]K M]([OUDD-03@01VE^[U &4HN[**LV/.J-H.JO;+G6N3IJ M9U%4V3_K?#5JKN8ZYZLZ M;&&MS&:6KQ_SE?J0&E5LR<@0>5-"AY.[279*U&_)++ZCLI1'\(W8?AG7H[ M%XA1$5(12%*?%CWS=JKSID\+GQE7H-$S-B&@3U:7(: M&\"1":HG.>A$!YWL5SOLU'8!T0J,B#;/69VWU2P,+X7ZCA1_&/2-EXE+X&N6 M"OV$FO]]]?_U&C#HF9.L Y=HVZT%%SUC8-TMLM0[\2_W0E0?6E_YF_R!9*M% MY*4!I8A!3\9<;9J# %(O1A#3 N;R4%M:B@DQ5\;:2U M#(,_@;"91>H&MY$I?BAD]D6TSJ+AJG#6\8&F+99U5N&] EGG[[ _W7J]\2*_ ME5*PJCE$^R2O>5ZG/-=X-8G9$;0GS\\S\2#%$(@G&+!+2*.3&9+"YT<*NK$TCPEI:\+66USYO]SC.9EL65^B-3!## M@1N2:GL6$7>)M,>'FCI-]JS2!Y)@S]\SC$!NBIRO6?6;J+,N/1P@S#VFX_/4 M7L6/M!'!8R@$]GCBBX1+JYH!.T^?&T6TPH&B0=/RO'\7.#,*& S'R-]\A\37 M1C*'G_A!C1U]T[O/GO0C/JC6\Z_V\$4#CJCJG"\IBER^RU9DQ3*R[-H2,!V? M*[C,"U)^(4M1-@VD-3%HJ6_OLX+?D*)ZTIVFZS8\#X]D]=2&X_N$[0FH-*JP$>M"U@V MR@!6:Z.;G2@ 0-7"I#.F5OD*ZJ##M9(:D/WG6ISVC/:.&!S"S6'F1V;(3D5M M#VV4W#:W:=6L)YB4H-:T[HG3O2#URU%K"VMU0:LO:!6VJZ$U[HQ;' 3.8>8G M.C%\\3? [HQQ[)DY>1@YVN#3G5J.C=_.\>;H@UU6Y>)ZQ=^K[VMUEVT:(MWD MRXP];9M3T#!A2,8^])39 %&HS F=)+7GZ,!CX12I= MF -RK-*%Q1.&GIW\72R7__>!&+ ZGV0!Y%$"'U M1\ID#"7Q2<13*D5B%-1W=J2YL55['*"EA?_0XH).7M (;'M^<@QATP,4![A- M>Z/FN?7GD<2C M21@2&++(APA+#JD?Q5!$0G!$&2;"J&K7D>?/C08Z"8$6T6(/>@ Y W_!97B, M_'GO0''>(VJ$B<6.^C)L)MH+6V)DMW,]CL#)/>>!VZ;;+1Z7>6>?=^*R(9D+ M;;;0W[/J_O6ZK/('470=:)^Z'USS;SKNK53&U1OQF)=9578Q#4$0I#%G,<2$ M8(C4_@UBGZ60B)"2@'E!Q(UB65T(,S=";"7MJNN4C?N&M7H8[MZ@4ZC>#78J7=G%_3B9(9O$B>EF:JI$BO%G MS#*YP@W$IY,M+AQCPN0+-VCL)F,X>N8PIV2=I=QX!UKK*L3*5D\QAR2*4UVE M$L-48K68190BBI4%GUCY'O=&F-OBU&36#_$C[H-GYBZ\")*Q#?8>&B-$,!Q5 MW9%?;__YD[KOCJKWW$MW_,*)N_U^R%;BO2[&NF#$)WZ0(AAA$4*4D !B'JD/ MGWI)R@*<<&+UX5\NTMR8HE\H\GQ+3+I;CU!K!KYJW4"MG&7(I(,)-B.G::=M M9#:[N(FIV8Q-UW=T#^27[AJZ%>B/T?-S#T!G'3OWGVS?.*^M[E>G6QDVQNO= M,C>^;$7[BWDKN[[^I^GJ M5'YIQ6*F=Y8TXB]F?!I7965>G/4T[O.F>]7_*-ZY4RMAN-/F!LS:9G,#8@3R)RW M)]R ,K:#9BODIMNM[A#"LV\9UZ7N3@)F976'YM8\-+6I6LY(69VRG@PC\PU'<+U<>WALZEQXT.' M(>?(6K$A_\?>6_:W+B.I0W^%43,Q,2M"*&'"[CU?')N57XC;]IOIJLJ>NX' M!58GNV3*34J9Z?[U X"D1&NA JD>7MZN9EIB\ Y#\0'!P=G(1[!D*6>X!3% MC&;8R@]M-N_#OU0^)*4*(8XC6/H2WJ27[\T0\2\GO984LZ-REH]=3*RUO15 MR>*VZ'VE6D%WFPCN2AR#CKXVI\YQOPO]1#F;%1[;XFL7]\[9XMJ8B1.NMT7D M[!S6?:*0VA'6WU%L[=B+T!MT.]KDTT7CCHW?JS#=T2<;Z%39B774K?JF8&T< M<.GBN'&\:I-_+LQ_+55M66_<;IMM13U*V2.*N=Y:IK1E,^ M\B,NB[QXK.YYJ0,#/^\";C%%69:)#*8B8Q Q+N1AC"/H,>S13/B>L*L8ZTJP MN;%N5R^P5PRTFK7W3SO=%"NTVJF2[77\[A71U:=&XE_61>0JB3% ME;;$GALM5+W.7; CEPW$H.]R(L&ZGL)==-Z[:YP<(\P$"17M8H-9YVVBK$=%$?U MC2T?'T9JG_(BWTB*_,&/JH.=\&@8XS01)@DA8$>7I:>9&@.]Q];VVZG3AYJ>Z GM>-$? QLQ[JA.^ M]'V*/ 2N= #6:N_,L2S"<'H!S*CQ>EA'IKR=@&VX6BNCPY(,O1BXJLMP>I)I MBS/T*GI4H:'_T\,S%%4DR9K^2Y]5JTYFP9)ZV$^\.(%9@B)I7"7R(!EE*:2) M%XJ01)C$F6U"XKG)9L<<6E90*6$7H-+B@G4GU>4W21[UCRUO6GHA][TXCA#& M4+ XA(AB"7E&"?0P2#_ZVMR[>R,/B8UXH MAXKBYEJ"D<#/8A%$0='\C A/-4,.@Y2$08ICQOP/Q;L+:!OIYT$ M>%ZPT2$WVQ5=@3CRWMAPQK>:,VI)%Z CJ]NDV4N(.,R1/3O5Y"FQEY0^E0%[ M\1D7EO;MD[0S2[4G?UY7U9+ZR&>^JE9$LP"B3&!(4.Q!'-$P("GVXL"H]Y+) M9'/;._?2Z6MQ3.1_UT5K7J]W%F1M:)?YX_<-7 NX55V2ZMOTDJ]PXY85F#HP MPP]69X@Q/ASSJ4WR#OY*U+$L\]. C&*?'TSUAE;Z::7[;?4SSPP(TWZWK?*" M5Y5D-9(7M1>AVN1/ZF7YPC?_7)?_4DUBZIBO&_:?VTI?="PS$?@T:(>;&4C>,_3N0\H*?M<" UA(#O!/9(HAVZ,KT M,]%4>(_,4*T&H*/" NR4T*O0J-%&O(*;*5?!(E)Y@M68*!!YI%6QBSF^$L[> MD.*A8T\7,7RE]J\"@J\=R[[JRSU?-V5F#8N\[!Z8VUYP__'.O*3+7NU^\AZL M\=BW\A_O'!;2/:GEH#(L^U$FJ[IR)'BWR,KQ+X>=$]M4X%\??^&GYLV\YP5> MJ4--W16+R_7=W%!:;CE;8H]B'% * \XP1&F(84;C ":8B(!$.(FCU.;H:#G_ MW-[-5CQ]EGQNY5;]=)6T=H="VZ4P.R>."/#(5-!4&5!Q[!W9%^!^#W/=BZ]> M@9L+F%L?* EB_XW5W4\Y^ MQQL51?ERF"P<^ED0R\-IR), (I0AF E*(*Z5PDS*PFZ .R1E1Z/:EY&YV;)&WLVXH%6/O,:,(>@]3/:E5", M3$_&*%@5<#FC[Z!B+8=C35:8Y8P2W2(LYSXRP)-_H=+=0RZ-M4=5LW>%JTIG M -?))L+EBS*G3I7P5*&#[<_W*EEXI<=::X.[@QFLX,B,UJ[,IUX4;7-7VFJBG [&AD9O5=7)V//-30V]U@4G47P1?Z?1+#I3YIP3Z0)YI!%B8 H0@02+THA M#Q)?8$]^-6*C"FMVT\YM#_^\+AZAG.@); N2KU:<@5*?HM2*5 M0<,-[9$OT MS=P;[C$=>5<]U_>UR6S"8J.:,JY6ZY\Z6E292.]++JUC'7&T 'NE7,8\VH#H M+/K1:-*)XR!M@#B.B+1Z>AAW?>!D/_$[H\,S[,J?\H1A2Z)%('F.H2CU ?@RCF/LHCH.( MQU;I2E?*,S>VVTFMHK,;L=7Q1:*\VDQ.H(ND/&=37LD+J^ MEYI'5N>Z1]X]JT]6;14 =EO493*4Y2OW02P)*S:O\3B+SW"B]E1'B6LB&Q57:#5NO5KBL%-?7*3B& M&3A3?@,,?%'S6]>1-P>39K\5>-?3[5?=(VK5%V"GO-QN0*W^ K0 @ :!>D^9 MW[?#IA+P[+XE4]4%GMNWQ;)X\*3KUE]*>!I1)BPL/"FVK\L,3SOUE1&6ZMJF M4/EB>-<@0=7EE-_XSO%KZ2$0>1PGD&:?F^E1M_;8*-$&AE,:XFYV.AP1S9$W_(]"<*H+3G8"*[\J<%^KTG93T46# ME3J=SRMGY8TN5#)"F*4=HJ[#+ UG?YLP2SMHSH996@YS==6.>US>E7H:]@^\ MVO*VZ.0212G**!:0(1Q#Y D$,>,<9HAZ89*0C/N6UP(7YYP;K[VNX?&,2_!# MB7O5FO-\_,J MI^H^[G=*5"_F_4,5%7M5GZ"6=!E&"(L(@@"I, 8H$8C-*4>,1C M*$[1X)69H6X^M=5NMQ-@O-=3%1R@JF+GMJJ+<^:MS #OA+8STRW6P+9<8\;[8$8T=E*+V@4DS? MO]2J=8Y_M7+G$[9U^P:EF,.&CF- [:K-HU/9IFW^. :L1RTA1YED&*>?* $F M;<1/Z_()WQ9"_:%^U&2MW(D;^E];*3'_EDLX]3\JG?'X05U:T*\&8%(/NYW _1*;[09ONG C[PBG"R%*]8#6#W047.S2!=<"M$HVB]M1$R@] M%Z#6U-T^,=HB.-HKW,LWZ7XQ&KR'>\9X$]D7<>S40[]Y?-Q\+$L5Z'7SM#$M MZGAV@+E1_ MVSYQ]K[.'*P_N?2I\#P:9]"/6:0*D00P\RF&'!$1H3")<1#97&N,)NG<;D$> MU!R@2<-L&B)<;2,Z6M3!MN+T2_4F-N->3=#5LTZ;KEJ#D=6!GWM=0:/L C3J M-@^,:CFZ79+Q+$A'D6;@.+TO&$P_:7W_>M%6^+Y^U&.4H^K)]P7BQ3 M+PXX#0CT<11 )/\!,Q*%$'E1Y"?<#SQFU5WN_%1S,T0[D@(M*M#>R#]J:2UO MEGH0-F-K-[B-3+=#(;,FRLMH.&*ZGHDFI:K+"A]RC<$3 Z^D+N4:74@U^@>O M-IK3VL;+#VOUHX^_>$GS2K-?>W*Y+39E7E0YU6&P2Q_[ ?(S! .9&=1V)+6^\WNR[8'@[]F=8X;%OT@PR5E6DD4G" M:HV'-HQW;=,W:_UCU4A]A\JBXWW8 5-G'CB\CWOKQ75U=_=F>DQ[S_?6RW5T M)_CF @W,*],EO#[5'1=?=)12EB _BKP(9LPC$*7R/UD0Q3#)$A8*(>*(&M63 M/3_%W+:LIHY9*^*@<*\30)IM*]?!,S+?6R)CG^9U5GE765W'$TR;Q'56P:.< MK?.?'-B98W_,7_JIE_EIA*$G@D1:N]R#6,0,AH$?(8[]-/-2&]=L9^QY.E-7 M>P$M>U]T4#-[@0=B,?*;^]D /NF$L>JNNH0T1EYVG8/QRH=]6XX\9&!NVWM M9^MTZ%&F G_'"R[RS9(%B'L813#Q4"QWWI1 DJG"[HG<KKI64%OS72GL]SM]^OC6!QM7?W M3S;M/FZD^-&>;O;4Q+ZS3S@O]=E!>__K\T=[[/C'>B6'41:(2I9;!@3Q@'$& MTS"29X$P#F F< #E 4%0FD51AJP:$TX@\]P.%SO?QH^=F!/YQ2S6>60/V#BK M-W]?E]*[J9'1T7RQ]W?ME=Q!)*@'TRAC$'.<8&D8 M"]\/!U8W,I-@;AM++2XH&WEU17Y1]X;,&Y%UW2-=ZZ@:7NS(<'T,[>HQ41_; MU'Y5"*D1'S3+\+6[#$V+SE:'4 DJ6 PVCP_M2 M)8YL7N[E%VZC;@'^:YL_*U;^D%=TM5:7[_NN4#P..0MX!#W,$%2%+2&F7@IC M$N"8BR1$V,I!;S/YW$BPE;V^1FP%M^,Z*_#-:&XL2$=FN%;L!=""OP85[&4' M?XS2LW8(:HZ(S6KJ23EM""B'=#9H##LFJ\K-\B'?K/B=N"U8_B-G6[S2UV#$ M#X*88A\*%G*(@I1"D@0"9E'BIR$*B$B,2N^>G6%NG*2%5-EB>S&MKA3/0]E/ M/DX &IEA!F!C3",7]>_C"OEPAR?DO_8<<7[<28C@HEKMVW[Y@P,O$@U[5ZO> M)DV]@5!$893&3&6!I*HX1 8Q\CBD:>)[+/(9X5:E:.U%F!LIR&]3;'D3:0^[ MX87EJ&".?:^IA5=A9(WX=?6&"\4;M"H.[T$'(^CJNM1>@&EO50<#='3Y.GRD M 95M_\E7J^H3+A_7NHB@OO/]_/G]>_F7_^9%]0X7__IR(PVH_W7_NX0&%^]5 MGX/ZITVU31ZA,,.9#['/?(@BC\(TS! DL1_(?_@,^48Y#F[$F1L+:H6 U@CL M55J 5B.@A-?'CO]U#VJ=@%9*_\*B:.KU"]G/I=,OS\B\>FYEI#X'R[, 7_[M MYM]T:^56LJN'@C/_C:Q?V# >X#RM@. \]9D5O+Z2A'FQ]"3EE@6@6.O+W#(N--Y_Z[0^I6_[YIQWJYYQ,-W7LK]2-+\,D,)84$B8.HA MK%I@>?)OV(>1[Z4^I3Z-,JLJXV[%F]VFM9-L^B82G44S,Z[?;BE&WK^N;2.A M]9EK,XECQ&?43:(CW)^NG<0QL&/TDS@QRT OQV[P;UO5)E&RVY+$C!">4LC" MP(<(<0[3B' 84)%ZH6">9',KK\;Q''-CW'LYD+HCJ^JV#E4KIZ7'X@28AAZ* MZR :F0E;Z13%?;L(C;T3XKSRKIP.)V:8ULEP7L4CIT+/1X>]XZU[M.,;E=2C M4@6W\MWZMA:;G[CD]^M53E_VF0\>IR3S!85^XE.(5.X=(7$ 11S%+,-^2#)J MPP*#I)@;3WS\)6*@E;E[IP#>KRO;:M[#UL>,6$9'?63J:>5?=$%> M:(.L56*W#M(4TWJ /YH_1\E:N0I11WPV3(9)&>\JF XY\;K!!KA>#^^:WJ_E MB;O<*%^\ZM/X-\X>^3(A7N*G/(%AHC)=F$B@_ F!?DQ0$H;(PYF1G60\X]S8 M<'?QNL&_ZCX&H.0KW%3V5*VPZ%X+4*PW''Q7>H"-\F>HCL_K\^W6!RZ*@5O5 M-=237V\O0$=DH'NT:J%=8VGA)W6-Z42.40?8VOE!;7#J=7P:#32=I]-&KU>N M3:L'!S%YMZWN^_4/+L_:F]_QK_QI^Z2C)SG[PC>?Y1"EF,#,3V-I!1.!4I:26" +9K>78&Y,WT@+JEI<=3T&5HW 0'= M.*> M 4MBQ.OC CTZS[_JM:V(J-9@ 5KX&R74O0QHU0!?IX#?:BL8=QDFVQK&6 [; MW6(XE!=VCP$#3[F;#-?[8'>Y8J !N\W?MD0>3+X]K__%;XMB_:/N#?LY?\JE M4;Q+&8MH&',/"IS*S26+*,0(!S"-DRSD\K\L- J1-9UP;GN)%%F?W[70H".U M!8>9X&RP8SA&;^0-0@%W,Z$14S#!'UH%MWYG M2[@&93R9C#]9ZI.%LMT<*)O'KBKG_FVCNG(7[+-S=#(8S-=\-'QX8C,D?E1'\E3^O2U45I;[H.KP0 M#@+,XU >)),H"R3Q, $S'&20>DE&O=@G++*+L329=7;$4PL-=E);1E :(6U& M0L[Q&YF$CJ";YC[="B9708I&V@#PU%(H=7#PTBHSKELZ&X9!YB$B"80 M)YFT:L:W-^YW0 \,_X8#,G8IZ$F MP[J1S!T3G%38T1O_>NQ)W^R3:AV^P:<_-, #?=B[^>OZ!:_J&OZ--R_R2!)A M/X99%GD0^6$*4U_$D'M!2A&*A8]\8__SQ>GF9B T O;WWQ@"JX&[V2E8([_E M1_W8%Z +W1!7\V4,+1S-3K&R^5,# M3V4J/%L/CU?O50SA-_PL.8>U+&/:UT\ MEO3.35666WA7S5>=6T M*#Q(-%MZOOP?AF,8B[ZH?P[VTH^016L. MF>L468.9WR;_U1R2L\FM%D,,S6K;Y+5UI\KO?)%?LZ8F5!*Q((N0/-!FA$+D M)1QFF&8P0QC[7AP%46*9N'9ZHKE1UEY.78H+*$D'EMXZBZT9&[E ;&3J&0;6 M@&2Q?B2Y/+?4=6^6/M28CB..841S")_0 B MP@@DD1_")&,)02@+".'+'[PD:^.<]J-);+[4;G;M]-:IF/'L=5B,S;"LU[J+IB'M]]1XHD@3 E$+-3QZPQBGR8P3>( ML=0/LI#8O/$7YIO=Z\_;TPFX5\GG2F2[]_T2P&8OOT/81F:"5M(]7M-$%A@B MY(@Q+LTV*7T8JG[()::/.T556Y]M0!/ MM<17) ,:+HO!9>?X8(],6R<2 'AV Q=^VFG]ONTTJOH]3W M\C=]-^P,8Q+F_ M+/BC*N?T8''G>W%FHU9J #O2@EI<4,N[J(_^#NN&FJ/CZN+V\H33WM<: W!T36O^Y,!<2:5! ML=&E@8JO>?4O.;;Z 7Z4K)(P3Q7*D]03\4195![$*,U@3%,F(NQ'.,16*9(] MD\W-?GHE*RBEL.!Y)ZUEQF0?QF8$XPJYD:GE-6A*S@6XOXR:?4*D 1RN\B#[ MIIHV_=% Z:.L1Y-G!G@)Y;@%IW+'_\!_Y)17;6G/S_(?A=R3I?%TM_G.RR9> M'"4(94(D$,>2/I"788@)BF%& T1(PD(O-J_ :3?W#'FEEEYUEE3B+T#5UB=> M-1K4=7/72@D+YY3EFABX!L=#>GP>:D#^T(*\*P+]>0>RJB2CY1^2)&&)MH4+ M<#S4)W+]6:+OR-,W#+9>#Y_ED--Y]H;I^LJC-W"(@<=<^IVS[8K?B=N"<9$7 M^8;KSHF')^P;6H? W%3WN-S#L-FQZDYQ<0X HH/=5CK::@H^HHY9 F61-7 M_H)19)S6Q3 FS$=>B5$GNZKH4QWQYVF[S8YL7CG3S%UP7L=IEGL>!9 MR"(/^B$C$ 4\A)BE2/XM#3V$DX0PHRK2UXLRM\VBT>3?!U6(&K(4AMZ020 > M^XS2E*EH8M1.EI#2M^:-,F"OS2@)@]>#ZK;RU!!!WJ(01&$":4A( M*JWMV$NL,@XO33@W(KQ[KE\\Y9?Y60NMNZSM@LKK^Z?A5U$75\"0&1WB.C;_ M*5&52=H(*[^P0(N[ !V!'?*;(32N6.S2=--RE:'R1XQD^MRU?H$;2K=/6]V3 M2+L=5,^HDG^7]"?MRB8M<5U5!P5LHR3"62!4/HO(((JYJF[E,QC$F>*HU$L# MJPNJ*^69&VMUSOKOO\M?2(*2_-11#;S#*Y4AH]_#VA7Z2M'6./E-Z6I[N7[E MVMH>^4=?L0D/]]TENK@L$QW?K\+7^4%]F#1O="2_"KKSA^_KAAW(V,JX>:=" M$=1L=G'D%9:Y =)2XUM]5=M5-T6 M=7##/[G::3B[J1M^Z%]^D)I^PGGY#[S:\J6'D@BAP(>Q".6I/4T3F/E>J,H; MJNJJ(6&Q7;F>N6@VMUVD%1CBIG/.HS;7F*HN)J30X(>26D5' *SPJ'\OF4L9 MPVR]6N&RTK_5AK'M+C*755E&W$>QB#',HBQ197L1)"0*8,AHFJ$D#0C!=KG) ML]'-YALW34KT7]NOD-:7L[_\#_LR&1HWY#DE'6\% (2;E[>N .B39*T>;^-C> M\+>4)F^NG%H27_*0>40$@:1+WX/("V-5A5) $6>$1O)4%/G>D,0D]Z(:O?W3 M9S)I29MS\K#\I1%6=>23R96+]*)&1P1+B_$6QO[/1+^.8!ED (T0( M1$GJP92D3&X1@>>G/"246,53#9!A;D9T[5]XK0-H)-:%+>V(?\BJF!'[R%B/ M3-Q],%=U =&+J1[6%'P%9(XH=H@$DU+H%1 =4N0U0PVCP"]\H\J^WY?K'SF3 M0[_\O5*F>Q.$53S>T$W^(]_DO%K&<4H$#B*8,-5"PJ<(DH S&'"5Y!;R(./8 MIMN6^=16A#=!*RY5?4\WCWAN9%?VTKJ5&^"=X';$9[$69GPW#L(CTYP"5W>2 MN.^ ^YN27)J8?P$[X<'-99BMZ,4Q MVN1/.IRG5N"5=V\7]RW6Y;6EFIRNL%T(UM3K-F$\5J_/5A[R^Q9UBN@LE] [ M#M5R(MJ;Q&VY!/5<$)?3.>SV!$[9\F.I@\:^H%-)$DKQUZK?1F)'L6LGZB=('6R&1G#%1#9PXX[!(J)WBHXO3?'M<_ M_F_Y:$-!E.V9Y^R D[#')75:!KCXN6&6W0?^7'*:Z\62?U]Q[3@L6)<]ED'F MPQO/&!$]K2\<&($<6C-&4DUHF-B <6AQ6SPX,N]F6TI91 M)DO!/N6_U-^JQODH^^=M\'PW-$_RMQ>?RTM>,B?\N)Q :3, MX/WG"*=PC4P1YY :6,KQ/&1VA1N=0#==F4:[ M+YMU/<:+:%RJOGA^@$EK+5[4X["RXN4'AIVP3M3/4DRT"T+)#CK"CU(P:1ANCHX6EI-/>MP8!LSA$63@*->]6)V1J_MR M_6E=/N&O_ .J2^@F#LA;0TI%A K,=:3D";RJFZHBKFJ"M@188-!*[YR8#>!P34M^,;\)" M!A"UPA>RH/L _Y5W_6JM,>:XU:K]4]5DV<989Y%(F*08Q]!E*BR ME&$F($Y2GL4$(9Q9%;@PF'-N?+.3$.!61-LKFLLX>XCR0& ,(Q(1B#S!51GI M%/J">:E W(LQ'I#'Y KNZ?.2)D'=]%[,Z7=V]&NQ6EI=S+.-#=JC>7,1S0'7 M8L;X.+L5NSSCQ)=BQA .L0D23+,$Z%ZIJ2JV+TD MJ#HY'6>41M1/ SJPU-V5DLUMS^C&[=4)>J0WD:_:9_*1XTR^B_$N(R^[&4V^ MR6*.3*;'Z]B?D%GU9F2ZBUL:#7/G-?*NE>N-JN4Y@O-\W3Q7$PSNN*<]%O_, M-]_?;ZO-^HF7GW-,\E6^>6E.%RHR[+'(_YNS911E&9,G 4AXS.0I($P@85D( M XH$\@.N$BTM>_!93#\W.WJMPL]_9S MP?[W%J]R\:+3EZCJ#=]IG_PY+_CMAC^IC$DA3=DXA&F XC2)(,X\R.(1!JP M.)16;VH4DCIH]KFQV[>/[T&[32V 'T OZYX?U=7&7B_0*O:JX[C2#6CE#$W6 M8C+\;8IN2-T@5Q33 M.%.E^=.ZY/EC4;< H2\/TABM5):T%D[_:U6+ROY3,KBR2+_PS9UXP+^681I& M\CLM(*8AAP@S"E.**0Q1%J61YRX)WXEC=< M(RVQF?GY]@LW,C%?K(6_ .VRMHJ"CJ::N3NZ@KVR"Z"2ZM="N6X=EP89;4%< M5@]Q+^3T!49& _ID#9+Q9AL23HF?\XW

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

3RM_N<[[F?><^ONVO>X[IC5QUR><07T6I(33!!+NJ7VSB#E,)<.0B$CZ M*8^B&$=620"=B#4W"V8KOH67;YN@PJ&?K^W@FA'?]$,V,CWV^/INF?/ U[=- MD?$FWKX#D1[7W]=6J#EX_ X$TM#G=VCK S:(FZ7P/1KY.O4V7STKPOFT)(_& M>\/3K\^-5+680,L)_;VKE49DBWWA&;@,MH37(S7V;K ?)/"'EM=14OL+: S; M$)YI<[J]8+]2>]O "X\.O-!G/P17+=]+OA(B&,4Q%Q* GA1 *;^7Q7S;62]J69HL56E?H"L M 16/65Y5!M.E@ ?L/Z\;5B03BI!:Q4*>)! 1&4."4@YC3XB A3Z2G#;#^C$W M/-2<>%!;N68SI$+]^$T&$T=Q%")?CV.,(?*JHR(9088#C",O$AR'B[6N&SZS M@=S)]'\'T5CYXY5U9;JI-1QHPB2GQ8(AB M#E'$!"1>1& LF SB(.%A:A1<,J3SN>T&?R,_M8,AR"MI-8F6E;P@:P0&F^=5 M#EBE5ZDORW_)\N890P?L06/43ZQC(S\RCYZH_K45_J9)MPKN9>T(78)6@Q'A MOJ+4S1 _JQ)ME]I\NX)MAMKVEF\S;6/8SGL_A9W>T"\" M%H2A8 S&<:HC>A"!:1@AR%#L!2*,6Z&!2P_.\@H?69,^3P^;U0>'K?>[H M%,C^D"TWZC&=1VZYTJGE[M;BJ=S69H@I\A(O\*%B!&4\>J$'*1)"40.+L,!Q M2@6RX0(W8LV-/UJM(*G5:JW*U4XAP\HBCH?/C(.F'Y21>:M5"#0:M5;.:FOE M=+126W<]G;-E5KO'&I0WL68ZMP@[8D='0DW*J&Z!/&1AQZT/"E];J^9^+4B^ MUC$$5?1,J[JHQ4'0U.7G!UXE MKYZ>5OGW]8K]<[=1%GPA%'N&24BA+W0)8TQ#Q:.201Z'82 \D2:>59Z*,_W, MC3QK,4&IY;SIGG8J&K4^V[R$L>']T/7(C7WS4X/VO0:M%O(&U&(ZO,WIQ\'5 M/E7]>ANY<+CUWK0?=&':J6RX'87-%5GO^>9HB.VSEZR]6OEU[(+ M7Z8Q"7P_C"%*?0I1G I(29A @H1DDJ,P#8T*PSF19FXL\WWS]$2*UZWO5WT1 M6FD!M!J@56.H;]V0$3-CH\G&863.ZOK?;34Y/1KE=C@:3SRCA !7..5=@:QS M-[TALKR1X]X5L)UWY;NFT8E3D>D+\_7K[BZDK$J /OP@^7V=0^;OE2)W>1TU ML8@]R;PHB& 0)2E$/I.0)L2#BK!Q[ >11P4>4'9B*OF-R&3ZTA2UD."7;Z*Z M'.%_&VXW3O8E&%+_G ;V+Y.4K%:^!#Y% >LV2$H9AD$@O]3T_30>L6>?ZF^D:TXI;GU-H'U=]!7\#?.\F2,,3 MUVDWVB_V66AS12PM=Q5GQ\)LU;@*VFE8?@MG[ MF93H+BE[2$P7GQ^<"&;U)![(S_U;2_6#]X7@6>6$*E2K/Q9^Y(>!D (&% <0 MA8D/*8H9]$(F<))*CJ08P"S& LR4:EKQJKP+K!;9.E&,X1"8$8I;1">J-R!E M3;Z@EKY*=5"5B]Q7XJ;Z1:U'Y3E?*7(#;I]TU4*GJ67L,'278\:PWZF3S=C! M<2+KC&4# VM\K_)'->N?M-/C(F%)Z&$2P0A+"A$*/4B\@$&*><()B_THH5:E MNSN-S^W$]#TIBE?M??)2I7=>2<"5E);5N;O@^9''0R*4(1G2"** >!#K##Q^ M3%%(N(CBD"JZ-PQ^M(9N2^1CQS!V/7MH3Z":6.*J.?>F: )]1[\IRI.:']??3. M?J-(^?M*KM7677PLU]F3MA=_+X7<+#]GRI!-" M3&:B9R_3U?A1@F'*U=JC9 M'24>BM,T-2I_-:#ON2TM6Q'!II(1+)605:Q3HP-LLX\]%RN^8:;V[Y!AZ>>& MD<$>VTM@)SAH)0>MZ#=@-PRU]$"+/Q[2%HY8XR$^D6^64^3MW+6&8=?KP679 MY'1.7<-TW?/S&MC$L,W$!R&S7'>4KXN,;O0W^%5]-Q^?GI>K5U'\1M;LAS(; M]WXOU">9K^]E]LXA R9"GSTP"2&F00,Y2RKR42QE:[4"NEFAV:TLC M.7AJ1->QLEO9;W1. BV]7FU$_:C8>\+.S+Q^0,ULTTF':>15J=$%=(4%6AO% MB^W@M0KM/70#ONX&KWK"G37L#&!')O3U\DQJ=SN#[]!8=]?P,,;6)^+UA=UR MN?I3[^7+.FV"*%Y$^:[>WBO;/@Z([V$8))*K3;J0,&6*E2,6\(1X2&"9VN=W M,NK;9F)/E\>I$4[?D[WKYFBZ<--^Q1"$:>J'1"V':1JF$,4LU-LK-021#&4: M1![V MM<3",-P/@YESKP?ZQ3\8P'O-D"YAS*D1>I[Q_?@]8E[0;X ?1P?3O9 M.*-LM6ASZU1ZN+\VL,+-T=ICUN>DZXL5#(=KB-W+P]:)9D$2WU6;&1.GG3ZV MGHUU-,F#/E+M_EY'57]9K?]+K+]M\S+7$_?3JFA^I)_S%RR-F.0\@@PQ!E$: M>9"(U(?_'W=OVAPWCK6)_A5$S+TSKHA$7R[@-N\G6;9[%.$JZ' G(7Y$8[2-(N)IU4% M[GW$G]J>81N-VT9'USRM>)-V7="4RP?8IO3HBDQ-(>7]?G E40T7HEN5X5L; :(GD)+GMADF=[&CM4\I+*)\(E M+[YR;JN%W@LDEW M[V=A[$4B@IPP+"DG"B$F:0031.+0HT'DAT9%H:Z29FI6<3=>KU4'U/K 2B&P MTPA4*JFXC$HI4&EU;;F"(2.J1W*CC9-K*];Y$%T14WD%M-9C*H?(\DXQE5? M=CZF\II&;:1MK#G_Q#+P^>=:_57V]S4OUW./B\3+TA!RZJD 23^%.*$1#% 6 M4N(1$L=:&82NDF)J1'R4Y+#Z3V/US,"W;15=R0*-*:3F]RD3Z?>=IN#S-/1X+E@BC%"*:_4Z-YCKT:(#)!T3H6$ SE:+MU%C;TZ!YS[R9J_7J<3=G(+"(.KF MY.L#W>1D'^4ZI[?J,RC>FD1^E"1!&F(,,Z;(*8D83%4$3N9[82A2C),@-G)] M.]7+U*A(6NF\6.*%G#2O?+GAH#GF!1_N'K\9'@Z>AE6/?ZX&RS';M/)59')3 M)^)4V8.LI4+4 L*6\]?)/L9UZ.I3\\A)J_=A,PY@/)]_EE2R?KMA3'XA9?.? MK_F2^W.&$@H(R_=K!I _["9^?ZNC3'PMQ=J) MK_?P\"O"U;+*=R(^<<&+HBI.7AU2*;^=KSDFTNY82S-CFT4^)7Y*! L@37P& MD> -)5@]&O+@1"=NLXN,U/>-]-)G94,&;_VW&RJ+S?2+YW0L/A"OPY4AM>/4#6DAQ>+\G =(?X M)R^E(.JF^W93**>PN2"!1S+/@X@1!%$J_\#")U!$/,DB@A, M]V)"5MV^W'%6)21XJ:4T3%1X D6]5>)*9!S3> U)(]X,- ):S$MX7GM;*0E/ M]#!N-L+S*AXE(NQY=-CL_MMR%Z4A6__(EUSDZW)[>_' EWA1F>=+5IVP\W)] M0VFA2H1D 0H%YAP*3D,581]":0#[,*4I4_FJLCBE)G;O%;),S8 ]Z^:W*LLJ96!CGY5S290H0)& (<$$(C_%,(T3%:@8 M1S0E"0^(48SB^:ZFQI-5 ,*N8K,4=ZA_W1&H>DQG!RK'1-;QE)-2@CTQ7;BX MG8/"NA_;44?OY*QV3N'S'FEGWQCYU/)7_#-_WCQO0]LVI*1%7FT5E0?1'%') M((QQR25^5>]*I7U( AA'21)[84B8IY5+S[6@4R.F1MPV"9(Z1U)YD'"A\G-( M4T'%QS?52U]DGS^4YZI*RU=EMQ_I?/+2V#L^A;0XHM,_:VR_AU9;T%6W#FF!;.__3[6_@ H07O/PNWY5V[Z=U0;DBVE]#58U&+F#FFQQ,.7;.=EUY4&'*&B) V-[HC.]#,U[FCN%W8QK!I>)T:XZK&'!;0\N%N*5?%<_?9. MY5X6?,UOV#\WY5H)M4N_4,Y9RGP2) A&(4D@(CZ&690R M*'SY=YH2'F(C]W5GDDZ-D'9"5G?0K9AF9.1N7/7H;!*CY9@06QU!1TFYI]RI M"3IZJHOL2E.P4Q7L=%5A/;MAO],8=F-J=3XDELC9G9RCTKMSN \7"/<=FBTQ MG#*Y:)6Y?/)[P1Y6BUQ%44N1Z U;O:PY^[+ 3SHK@%9#4V/Q1F#PO]*?@L6J1%./<&1LIV&]2C; MD9U>ZZ,0EI&B+>F8O30P:+);Q6A96;LJI>O-\ZI8Y__!35F,?,7F,HE+!44&6U=M7N>&NMT)6P3?JN+;]HIW44;C:K,WX9F MI?Z0Z)F)3H!V3$C[9= :+)7458Z7'?P7JE.8AT.:8F4K"%*[WW%#'TWA. IX M-&[@NBUVE:ZP\2Z61/E%F6._\76]KU=>2O,PYHF@/H*QES4!&YB)#,K?8D)] M/T[,"B!H]SPU&I-"@LI<535RF]31P_:_ET$WV\]:A7*L_6E'Z&I_"BJQJY32 M>UFF[>\UM>&RO'>\W.^[[ 6UX3BWM]-O8' $65UIONLQ^55V?;?FS^6<1BP3 M C&8QH&TLU*/0"+B#**()0AG#)'$B*#ZNYL:*U4IW2IQ]_QZP>]*8E");'AE M< %N/6JR!Z)C/KH*OR'A:!JPV(M,Z^ML[" U#<5/Q*OIO#7096V]HO^Z*\L- M9Y\VA=S%UX:5JF%UIK;'''$4IE3(/1S-),%P1J'72BUAH:ICRP5:\%QY"UKT&QN,IBT?,7,!QO4'&PS0D>_7\)8& M1IZM?_"B]OEH0\\I#C&6IA:4QI6Z1XU\2#+!(0IP+&@@O# V"@LY[F)J1%=) M"&@M7)/FRS#6[!C&C >90(3 S/,$1 GS(18HA2RA@D7(BV(6F!1BNA+&$>HO M5?6PP,H%F'JT?QU$CFF]_LA:YS?KR1#.ZVXK,N^X@W$C\LXJ>!2)=_Y)JXG? MM[_^_%/1,6\"AF_67[AL&R^4Z\Q&CMK;[GT5>D40(W'(&10XDH:FR#!,&?6@ M0#P1,?5C+'P+Z>&'23AO7-IW",4X0QZD))3V'1(QQ'XF?_*Q%Z=!ZB=98);GJMN\R>0>)\%5 M*YUQ2IH]U%(APB3"*8PBH:SBR(,DYC%,B$=]+T TY+Z)53P4L_'LX=P*;KKK MRS T'"\/6[&JJJ(V>?U876NTW&EZ9%8]5NJ8%$\\8\T?>U>\^([);G*1X[:^ M7=F6P#O(SUN6FV?.*L/[-ZEF;777;\RI1Q&29BW$*&00A3&&.$PSR 3.?(I3 MP7TC7QGG$D_-!JYWCHO5\@G*[IX'[:G=#[/9M?8D!F^LZ_ ]=^V=NJ"K;YOG M?%N ]##A>:/T#-2?PT[OYDVG?MMNQLB=_[9E>=_;C]L-_!K^W(XZ-O?KKFRI MZ@3\QVHA7WE<+V^>U[K.W*??GAK/U_9B1TS)%>M-L;RT']8%JY^A[>#D^D9_ M($1&3MC]* SRO#[3Y&CNUOTJ=7VL+SPYU+&Z_*'^_[-DC%>\4%E+'GFY+G*Z MYDS]@^20_5]TGMS%"WL!08D?0<)]=7"*?94%D4,:99&7<=_GL5%=32M238U$ M#@[1F7JT7.L/J'CWA1>0%\^\$E MAYL6O+$R\GJVY>CCZ9CL;JN!4W^"S]V!V^D ZD?42![\LON&FUHY-L&VYCAN M0Z:1GW%;^1)6[P]RG$:<>3B".PP B MG'%5+QG!D/J$4A;'41+-E_Q)L=%W?7J_W+/67,_JN7[4OT,'H,J?JMC*;+C5 MUT"<,B'"$!,84)Q"1*,$$@]+Q(-(L#2+D>=%)BNI):C'C%MZ>BJJ$=VEZ'RI M2L"HX*4=]&Q0UDZ-$=!;T>SBZGBYVN:C4Q#NQ%4F2"TPJ"2VMP3IHV-I?='H M<-3%0Q^ PY7!X,VAA6<[;=4>C9WJ-'/*/<(QB6 :>Q0BCW@0(R^$&4V(B#(4 MQH2;5:#MZVYJY%-+O#QU7K+_.COAOWS^^J!KY37ZY?E+M6HYMG?F=>GQ@F[1!C@ M^PH\?+[?RT8] U]6J_5RI>ODU(?;Y6- "Y YGOZZ:('?K692U0!GT/'@N39' M.Q^\H%3W@/#2H]?E&Y4&"<^?SKGWS+%/0IX(#KE/D=PJXA!BGJ:0>PG/0A+' M 3/R3=?K=FIZ/1=$I/J 7$N/ZGFVV845!;K>9ML76V!EDRUR9IC[^K4^R#)>9C$:>!' M&8P\SU=Q,0DD841@*E#BDR2(O0#KL)!QSU,CHKVK@6H)K@MZZS&3.?#]Y.04 M3M=G_:VT^]:TBCC_FR93(]#=,?16WCK@=T"9J'?Y,O3, MQ3_%>#MF> N%IFHT0 >.QAEP+0'9E;P_^U&YJV__GF-KLV35N^@Q?DVK]QRN MDT6OWE6@8:OQ(U E', M$$P3YD&?(A$P$?HT8R;+YN4NI[:^M1)OJR.:K6L:&.LM0':1<[Q2;$%KI04? M.O*"1F"+IQ3ZZ%CB6HT.1R5%?0 .V M).>'T8%>RDMMCNP5'#$ M*)>;<2\+Y-X\3:61(0A,HI!FL=RY9\+(R#C9R]1(X'8OO8RA3_)I'/4(X&IT M7%^,[N>7<;+CZ\7 TL0_W<>HL[Y7S<,IW__PL/E>5WOS*=U MMC2+#QH?=?J>5NQPWIYY:JC3XPUC.EUP@[JTOY24A!*["IB^,9?/NGMTW4 M'$_TX8 -<&CL1^,*5\8S#8_LQ-BOWK'[XH7GS1T7U7GF#5UO\&+Q]H!S]O?R M1'"EL3^C6:M38X3]FX]&#:#T *_E7\"Y^%Y]KT=#T/N9PRW>SET*!D'MP&5R M&(2#/"D-NQK-P7(8!%V_RX$MF-'6ZIDN9$_+5UZL52F^WU9K_K\X>^*/^=./ M=?DK?R:\F&.:I"Q2"=+3)("(A1G,A$=AB(CGXU@:-5AK)Z+5V_08;"LO4 *# M2F)0BZS'4WHH]U.3=>R?FQ%J_.W.G'\:#CN=3NUSU"; MMHU@J9E:O5*1L=SL^!4AZS4R"@<;Z=/2KME+PPYY?N-K%7A=F9N,LX]O?RLY MNUO>O_ "JU*I-RJO:IU99WOB&P4AP=B#&1,$(I%BF%*/01H@BADE7H:,*E68 MBS U3MZ*"G:RFIT7#1@&O3,EM^ Z)FU5L*O*)M&*KQR4/B@-0+[\!9R"W"#>![,>DUD"S[6=.1PW\QPXEQ&QE=FFIZ=Q\]5<5ODH"XW&*S9\8SJ&6OUC M616DSRGWYTF0REUJ@J6-%(00>4D&<4PDD?B"1D+YXPFMB!WCGB='*UOYFGPG M'_(E8*O% A>EJM]E1'"+XT@E <84E;-%!%FCT4P2ST8L@S7^ZT MXT!0;N3@H]WSA+E+V:(KZR35 &Z-I,QAG I)/?;BZX*D]K$:CZ2:?J=&4OMP M#""I@P8&%[XJE(/$)U[_]VYY0ZGR9"QOEG6*YT=.>?ZJHAS+.4,HCH,XA"Q5 MY0)]RB%!5.7Q\^3^+4O33%H 31X]/:HRZE]KGNUG\W-,6*VPH-A*6>7JW"Q) MOEAPUOF]<6T0DX'1(S3[8(]57:26%WQH)?\%Y.K&LP%?(5Z'R3UJP#VDN)0Y M;/:*1QGT/79Q*'-83A1_&M#(0.]JQJHR]WBASK^^+%9_?%Y4\6>JKV^;EY?Z M;[M_OEN*5?%<1ZNU9\)>R@,B@@1Z*8D@"M,0XBP0,,0AXWXD.(H#(V=L"T)- MS8SKB@U87M+%JMP459[(Y6H)JSS4JFA269TLXX$'^E:&4X\XQQXDQWRZ4Z<^ M^U<2@U:CBDWW1G#W3$+B9?\^=\/0^]A&4TBZ @C$)$.(9I&F90&JD\B$@VOQQ$UH%R0_[)Z5I5!6ASQ!;E_P"K*KS:P%7#9%SZ*=" M@T;R&=B:LI7PCA V\(MQA/1(+C(6$3?SFQD 6Z\+C4E[XWG3#-!RS[%FR/L# M3?M=4':U:5"NE 7_P9=E_LKK9')?5V7Y-5_RNS5_5B4+A?!4JB..LA2B-$H@ M3KT(9@GRO(!SAGEL9,8;"C"Y1:*3?J#>2N]IT"93_*"4^ 7\KO0 E2*&E]3& M Z5IH#N$W[4Q;A]Y<[M[('RV;&S3[L>UIP>"_XG^N MBMM-N98M%XTCB$^9+S +JI):RK,PA@0S'P99%/HL2!(_([J)+<_V,C5R:Z4S M=*SI1[*?F*SAXYA]]*$Q2CYY4?4K$DV>;WNTI)(7U>LFD+S\\."KFZ;N_5Y! MN/;0M/[5\JE>1N.0(A$'%&). HAXX$&<^0CR-.(D\6)5D)@CL,D$V"E$\KA:++ZL"O6/T+.7[:5V= G\SIZJZW M@8$FJW)]+_ZZ6K'RVVK!ON$%+[_+IJH4,'/",0^$Y\& J,HR::!.^[P0TE@( M$2*118R;.2_U]C<]9R4EKB+U4LD)5?M@49V,%_R5+S>F/-^/MAY=7X_@6+'- M-725I$").@/?=C!6XEJ,.M%!Q5;<26]?XT:>Z*A]%'NB]=* J^:/FS)?\K*4 M_$;R94UOVYID#\UE:>4HOOOUW&/$9T$60"(2#%&0A#!3I>PSCN)$F4J+S3Z[!-[B<=CT((]U2NQ@,L^OJ:X#LO;<>U/!X%]C7 MZ+UWDWU50\.,V6T\]M?ZDAR3?)&OW^:$$"K_IZH-!-*,S9@/2>;',/#3A(4B M%0B)^5HE#M(S8L_T8[20;'MS-XGJ9%:K;3Z"VG)=-.(:.X^>0U?/;+6 F>,% M8)>XH1)Q!K9"VC-3+Z!@R4 ]U\NHIND%50^-TDN/#SPCY<6K9)@F^1%A 8D\ M/X5!XC') W$*<9(@N:?%4>S3)(BH4;+@O=:G9D8VPM7.R:OJ8F'8IG4?0\TS MQ:'(N#X*K.6ZG%K+_-#NE,:VSMKVVA[WB.R46DB)WW]_+!\Z+ MOQ:KS8MQ4E#-YJ8V<<_FH/Q["93TH!)?/_FG+JK],]L1H([GNQZ6#K)[&D(U M**VG;A^CY?,T5+J;R-/TU6'FP.?GE\7JC?.&L,Z:57Z]_BR%77$>*6C#O;THUJ'CJ"]M# =-7-^SC>_)V7:\YNEDS-!RI__+Y2 MO_K\DQ3):F&K>)_ MKW-I-*$IR MHD 0$XC B$!'/@UC@$#(2)"Q#:F4URB>WU_K4UKA&N(%)<_>! MTUM@!L/AF.^UD3"FVI,:6V*^_;9'):*3:AWRPNF'G(4I-S<3E <1]^2<]1(J M[>*8>I @C\"4>W[J>VF8(6XY/GF:-S]&X;'68Y&-[HF<8.R8,V[N;^_ S7I= MY&2SKO8)TJI[P'5E6>OW2L8(C1=@_![W4<9P# @IOOH>Z^;I:?VYJ)J^>5[K M7E?MOS4Y4GEZ*BJ7:R!E7"WY:E,>[) ,"L^? .GR[=-P?%P3PI70&%TLG49A MT/W105.C71.=5J%[&W3FB6$6Q&/M]?#(E34BS9('7E0)MJ2<]V21/U5CM-V! MY,_RD7OQ3?ZV%"K/WFKY;8V+]2I"FF"4EA%'BI-#,(DWN&C,(T MBN1_D@C[(3(Q,^R*-S7::+2;@:U^H*,@V&DXVQV2U$I6L70=-:NZK\4:*$W! M[TI7PWV+Y>] S\!YO]%U3'KO,[#&YI,;_"W96):%&]40

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end XML 128 omcl-20231231_htm.xml IDEA: XBRL DOCUMENT 0000926326 2023-01-01 2023-12-31 0000926326 2023-06-30 0000926326 2024-02-21 0000926326 2023-10-01 2023-12-31 0000926326 2023-12-31 0000926326 2022-12-31 0000926326 us-gaap:ProductMember 2023-01-01 2023-12-31 0000926326 us-gaap:ProductMember 2022-01-01 2022-12-31 0000926326 us-gaap:ProductMember 2021-01-01 2021-12-31 0000926326 us-gaap:ServiceMember 2023-01-01 2023-12-31 0000926326 us-gaap:ServiceMember 2022-01-01 2022-12-31 0000926326 us-gaap:ServiceMember 2021-01-01 2021-12-31 0000926326 2022-01-01 2022-12-31 0000926326 2021-01-01 2021-12-31 0000926326 us-gaap:CommonStockMember 2020-12-31 0000926326 us-gaap:TreasuryStockCommonMember 2020-12-31 0000926326 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000926326 us-gaap:RetainedEarningsMember 2020-12-31 0000926326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000926326 2020-12-31 0000926326 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000926326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000926326 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000926326 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000926326 us-gaap:CommonStockMember 2021-12-31 0000926326 us-gaap:TreasuryStockCommonMember 2021-12-31 0000926326 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000926326 us-gaap:RetainedEarningsMember 2021-12-31 0000926326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000926326 2021-12-31 0000926326 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000926326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000926326 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000926326 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000926326 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000926326 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000926326 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0000926326 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0000926326 us-gaap:CommonStockMember 2022-12-31 0000926326 us-gaap:TreasuryStockCommonMember 2022-12-31 0000926326 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000926326 us-gaap:RetainedEarningsMember 2022-12-31 0000926326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000926326 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000926326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000926326 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000926326 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000926326 us-gaap:CommonStockMember 2023-12-31 0000926326 us-gaap:TreasuryStockCommonMember 2023-12-31 0000926326 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000926326 us-gaap:RetainedEarningsMember 2023-12-31 0000926326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000926326 2024-01-01 2023-12-31 0000926326 omcl:TenLargestGroupPurchasingOrganizationsGPOsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000926326 srt:MinimumMember 2023-01-01 2023-12-31 0000926326 srt:MaximumMember 2023-01-01 2023-12-31 0000926326 srt:MinimumMember 2023-12-31 0000926326 srt:MaximumMember 2023-12-31 0000926326 omcl:PrimarySupplierMember 2023-12-31 0000926326 omcl:PrimarySupplierMember 2023-01-01 2023-12-31 0000926326 omcl:PrimarySupplierMember 2022-01-01 2022-12-31 0000926326 omcl:PrimarySupplierMember 2021-01-01 2021-12-31 0000926326 us-gaap:ShippingAndHandlingMember 2023-01-01 2023-12-31 0000926326 us-gaap:ShippingAndHandlingMember 2022-01-01 2022-12-31 0000926326 us-gaap:ShippingAndHandlingMember 2021-01-01 2021-12-31 0000926326 us-gaap:PropertyPlantAndEquipmentMember omcl:InternalUseSoftwareandSoftwareDevelopmentCostsMember 2023-01-01 2023-12-31 0000926326 us-gaap:PropertyPlantAndEquipmentMember omcl:InternalUseSoftwareandSoftwareDevelopmentCostsMember 2022-01-01 2022-12-31 0000926326 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0000926326 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0000926326 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0000926326 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0000926326 srt:MinimumMember us-gaap:EquipmentMember 2023-12-31 0000926326 srt:MaximumMember us-gaap:EquipmentMember 2023-12-31 0000926326 us-gaap:OtherAssetsMember 2023-01-01 2023-12-31 0000926326 us-gaap:OtherAssetsMember 2022-01-01 2022-12-31 0000926326 omcl:HubAndSpokeInnovationsLimitedMember 2022-01-10 2022-01-10 0000926326 omcl:HubAndSpokeInnovationsLimitedMember 2022-01-10 0000926326 omcl:MarkeTouchMediaLLCMember 2021-12-31 2021-12-31 0000926326 omcl:ReCeptHoldingsIncMember 2021-12-29 2021-12-29 0000926326 omcl:FDSAmplicareMember 2021-09-09 2021-09-09 0000926326 omcl:FDSAmplicareMember 2021-01-01 2021-12-31 0000926326 omcl:FDSAmplicareMember 2021-09-09 0000926326 omcl:ReCeptHoldingsIncMember 2021-12-29 0000926326 omcl:MarkeTouchMediaLLCMember 2021-12-31 0000926326 omcl:FDSAmplicareMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0000926326 omcl:FDSAmplicareMember 2022-01-01 2022-12-31 0000926326 omcl:ReCeptHoldingsIncMember 2022-01-01 2022-12-31 0000926326 omcl:MarkeTouchMediaLLCMember 2022-01-01 2022-12-31 0000926326 omcl:FDSAmplicareMember us-gaap:CustomerRelationshipsMember 2021-09-09 2021-09-09 0000926326 omcl:ReCeptHoldingsIncMember us-gaap:CustomerRelationshipsMember 2021-12-29 2021-12-29 0000926326 omcl:MarkeTouchMediaLLCMember us-gaap:CustomerRelationshipsMember 2021-12-31 2021-12-31 0000926326 omcl:FDSAmplicareMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-09-09 2021-09-09 0000926326 srt:MinimumMember omcl:FDSAmplicareMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-09-09 2021-09-09 0000926326 srt:MaximumMember omcl:FDSAmplicareMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-09-09 2021-09-09 0000926326 omcl:ReCeptHoldingsIncMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-29 2021-12-29 0000926326 omcl:MarkeTouchMediaLLCMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 2021-12-31 0000926326 omcl:FDSAmplicareMember us-gaap:OrderOrProductionBacklogMember 2021-09-09 2021-09-09 0000926326 omcl:ReCeptHoldingsIncMember us-gaap:OrderOrProductionBacklogMember 2021-12-29 2021-12-29 0000926326 omcl:MarkeTouchMediaLLCMember us-gaap:OrderOrProductionBacklogMember 2021-12-31 2021-12-31 0000926326 omcl:FDSAmplicareMember us-gaap:TradeNamesMember 2021-09-09 2021-09-09 0000926326 omcl:ReCeptHoldingsIncMember us-gaap:TradeNamesMember 2021-12-29 2021-12-29 0000926326 omcl:MarkeTouchMediaLLCMember us-gaap:TradeNamesMember 2021-12-31 2021-12-31 0000926326 omcl:FDSAmplicareMember us-gaap:TechnologyBasedIntangibleAssetsMember omcl:MeasurementInputRoyaltyRateMember 2021-09-09 0000926326 omcl:MarkeTouchMediaLLCMember us-gaap:TechnologyBasedIntangibleAssetsMember omcl:MeasurementInputRoyaltyRateMember 2021-12-31 0000926326 omcl:FDSAmplicareMember us-gaap:TradeNamesMember omcl:MeasurementInputRoyaltyRateMember 2021-09-09 0000926326 omcl:FDSAmplicareMember us-gaap:MeasurementInputDiscountRateMember 2021-09-09 0000926326 omcl:ReCeptHoldingsIncMember us-gaap:MeasurementInputDiscountRateMember 2021-12-29 0000926326 omcl:MarkeTouchMediaLLCMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0000926326 omcl:ConnectedDevicesSoftwareLicensesAndOtherMember 2023-01-01 2023-12-31 0000926326 omcl:ConnectedDevicesSoftwareLicensesAndOtherMember 2022-01-01 2022-12-31 0000926326 omcl:ConnectedDevicesSoftwareLicensesAndOtherMember 2021-01-01 2021-12-31 0000926326 omcl:ConsumablesMember 2023-01-01 2023-12-31 0000926326 omcl:ConsumablesMember 2022-01-01 2022-12-31 0000926326 omcl:ConsumablesMember 2021-01-01 2021-12-31 0000926326 omcl:TechnicalServicesMember 2023-01-01 2023-12-31 0000926326 omcl:TechnicalServicesMember 2022-01-01 2022-12-31 0000926326 omcl:TechnicalServicesMember 2021-01-01 2021-12-31 0000926326 omcl:AdvancedServicesMember 2023-01-01 2023-12-31 0000926326 omcl:AdvancedServicesMember 2022-01-01 2022-12-31 0000926326 omcl:AdvancedServicesMember 2021-01-01 2021-12-31 0000926326 country:US 2023-01-01 2023-12-31 0000926326 country:US 2022-01-01 2022-12-31 0000926326 country:US 2021-01-01 2021-12-31 0000926326 us-gaap:NonUsMember 2023-01-01 2023-12-31 0000926326 us-gaap:NonUsMember 2022-01-01 2022-12-31 0000926326 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000926326 us-gaap:StockCompensationPlanMember 2023-01-01 2023-12-31 0000926326 us-gaap:StockCompensationPlanMember 2022-01-01 2022-12-31 0000926326 us-gaap:StockCompensationPlanMember 2021-01-01 2021-12-31 0000926326 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-12-31 0000926326 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-12-31 0000926326 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-12-31 0000926326 us-gaap:WarrantMember 2023-01-01 2023-12-31 0000926326 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000926326 us-gaap:WarrantMember 2021-01-01 2021-12-31 0000926326 omcl:ConvertibleDebtSecuritiesAndWarrantsMember 2023-01-01 2023-12-31 0000926326 omcl:ConvertibleDebtSecuritiesAndWarrantsMember 2022-01-01 2022-12-31 0000926326 omcl:ConvertibleDebtSecuritiesAndWarrantsMember 2021-01-01 2021-12-31 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2023-12-31 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2022-12-31 0000926326 us-gaap:EquipmentMember 2023-12-31 0000926326 us-gaap:EquipmentMember 2022-12-31 0000926326 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000926326 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000926326 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000926326 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000926326 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0000926326 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-12-31 0000926326 us-gaap:ConstructionInProgressMember 2023-12-31 0000926326 us-gaap:ConstructionInProgressMember 2022-12-31 0000926326 country:US 2023-12-31 0000926326 country:US 2022-12-31 0000926326 us-gaap:NonUsMember 2023-12-31 0000926326 us-gaap:NonUsMember 2022-12-31 0000926326 us-gaap:CustomerRelationshipsMember 2023-12-31 0000926326 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0000926326 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0000926326 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0000926326 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000926326 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0000926326 srt:MinimumMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000926326 srt:MaximumMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000926326 us-gaap:OrderOrProductionBacklogMember 2023-12-31 0000926326 us-gaap:OrderOrProductionBacklogMember 2023-01-01 2023-12-31 0000926326 us-gaap:TradeNamesMember 2023-12-31 0000926326 us-gaap:TradeNamesMember 2023-01-01 2023-12-31 0000926326 srt:MinimumMember us-gaap:TradeNamesMember 2023-12-31 0000926326 srt:MaximumMember us-gaap:TradeNamesMember 2023-12-31 0000926326 us-gaap:PatentsMember 2023-12-31 0000926326 us-gaap:PatentsMember 2023-01-01 2023-12-31 0000926326 srt:MinimumMember us-gaap:PatentsMember 2023-12-31 0000926326 srt:MaximumMember us-gaap:PatentsMember 2023-12-31 0000926326 us-gaap:CustomerRelationshipsMember 2022-12-31 0000926326 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0000926326 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2022-12-31 0000926326 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2022-12-31 0000926326 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000926326 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000926326 srt:MinimumMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000926326 srt:MaximumMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000926326 us-gaap:OrderOrProductionBacklogMember 2022-12-31 0000926326 us-gaap:OrderOrProductionBacklogMember 2022-01-01 2022-12-31 0000926326 us-gaap:TradeNamesMember 2022-12-31 0000926326 us-gaap:TradeNamesMember 2022-01-01 2022-12-31 0000926326 srt:MinimumMember us-gaap:TradeNamesMember 2022-12-31 0000926326 srt:MaximumMember us-gaap:TradeNamesMember 2022-12-31 0000926326 us-gaap:PatentsMember 2022-12-31 0000926326 us-gaap:PatentsMember 2022-01-01 2022-12-31 0000926326 srt:MinimumMember us-gaap:PatentsMember 2022-12-31 0000926326 srt:MaximumMember us-gaap:PatentsMember 2022-12-31 0000926326 us-gaap:NoncompeteAgreementsMember 2022-12-31 0000926326 us-gaap:NoncompeteAgreementsMember 2022-01-01 2022-12-31 0000926326 us-gaap:RevolvingCreditFacilityMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2019-11-15 2019-11-15 0000926326 us-gaap:RevolvingCreditFacilityMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2019-11-15 0000926326 omcl:IncrementalLoanFacilityMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2019-11-15 0000926326 us-gaap:LetterOfCreditMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2019-11-15 0000926326 us-gaap:BridgeLoanMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2019-11-15 0000926326 us-gaap:RevolvingCreditFacilityMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:DebtInstrumentCovenantPeriod1Member 2020-09-22 0000926326 us-gaap:RevolvingCreditFacilityMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:DebtInstrumentCovenantPeriod2Member 2020-09-22 0000926326 srt:MinimumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:SecuredOvernightFinancingRateSOFRMember 2023-03-29 2023-03-29 0000926326 srt:MaximumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:SecuredOvernightFinancingRateSOFRMember 2023-03-29 2023-03-29 0000926326 omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember us-gaap:FederalFundsEffectiveSwapRateMember 2023-03-29 2023-03-29 0000926326 omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:SecuredOvernightFinancingRateSOFRMember 2023-03-29 2023-03-29 0000926326 srt:MinimumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:SecuredOvernightFinancingRateSOFRPlus100Member 2023-03-29 2023-03-29 0000926326 srt:MaximumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:SecuredOvernightFinancingRateSOFRPlus100Member 2023-03-29 2023-03-29 0000926326 srt:MinimumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2023-03-29 2023-03-29 0000926326 srt:MaximumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2023-03-29 2023-03-29 0000926326 us-gaap:RevolvingCreditFacilityMember omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMember us-gaap:LineOfCreditMember 2023-10-10 2023-10-10 0000926326 us-gaap:RevolvingCreditFacilityMember omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMember us-gaap:LineOfCreditMember 2023-10-10 0000926326 us-gaap:LetterOfCreditMember omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMember us-gaap:LineOfCreditMember 2023-10-10 0000926326 us-gaap:BridgeLoanMember omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMember us-gaap:LineOfCreditMember 2023-10-10 0000926326 srt:MinimumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:SecuredOvernightFinancingRateSOFRApplicableMarginMember 2023-10-10 2023-10-10 0000926326 srt:MaximumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:SecuredOvernightFinancingRateSOFRApplicableMarginMember 2023-10-10 2023-10-10 0000926326 omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember us-gaap:FederalFundsEffectiveSwapRateMember 2023-10-10 2023-10-10 0000926326 omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:OneMonthSecuredOvernightFinancingRateSOFRMember 2023-10-10 2023-10-10 0000926326 srt:MinimumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:OneMonthSecuredOvernightFinancingRateSOFRApplicableMarginMember 2023-10-10 2023-10-10 0000926326 srt:MaximumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember omcl:OneMonthSecuredOvernightFinancingRateSOFRApplicableMarginMember 2023-10-10 2023-10-10 0000926326 srt:MinimumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2023-10-10 2023-10-10 0000926326 srt:MaximumMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2023-10-10 2023-10-10 0000926326 omcl:WellsFargoSecuritiesLLCJPMorganChaseBankNAPNCCapitalMarketsLLCAndTDSecuritiesUSALLCMember us-gaap:LineOfCreditMember 2023-10-10 0000926326 us-gaap:LineOfCreditMember 2023-10-10 0000926326 us-gaap:RevolvingCreditFacilityMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2023-12-31 0000926326 us-gaap:RevolvingCreditFacilityMember omcl:WellsFargoSecuritiesLLCCitizensBankNAAndJPMorganChaseBankNAMember us-gaap:LineOfCreditMember 2022-12-31 0000926326 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-12-31 0000926326 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2020-09-25 0000926326 2020-09-25 2020-09-25 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2020-09-25 2020-09-25 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2020-09-25 2020-09-25 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2020-09-25 2020-09-25 0000926326 omcl:ConvertibleSeniorNotesMember 2021-12-13 2021-12-13 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2021-12-13 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0000926326 omcl:ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0000926326 omcl:ConvertibleNoteHedgeRightsMember 2020-09-25 0000926326 us-gaap:StockOptionMember 2020-09-25 0000926326 us-gaap:WarrantMember 2020-09-25 0000926326 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000926326 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000926326 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000926326 us-gaap:EmployeeStockMember 2023-12-31 0000926326 us-gaap:EmployeeStockMember 2023-01-01 2023-12-31 0000926326 omcl:A2009PlanMember 2023-12-31 0000926326 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000926326 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0000926326 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-12-31 0000926326 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000926326 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0000926326 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0000926326 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000926326 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0000926326 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000926326 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0000926326 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000926326 srt:MinimumMember us-gaap:EmployeeStockMember 2023-01-01 2023-12-31 0000926326 srt:MaximumMember us-gaap:EmployeeStockMember 2023-01-01 2023-12-31 0000926326 srt:MinimumMember us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0000926326 srt:MaximumMember us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0000926326 srt:MinimumMember us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0000926326 srt:MaximumMember us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0000926326 us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0000926326 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0000926326 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000926326 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000926326 us-gaap:EmployeeStockOptionMember 2023-12-31 0000926326 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000926326 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000926326 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000926326 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0000926326 us-gaap:RestrictedStockMember 2022-12-31 0000926326 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000926326 us-gaap:RestrictedStockMember 2023-12-31 0000926326 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000926326 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000926326 srt:OfficerMember us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000926326 srt:OfficerMember us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0000926326 srt:MinimumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0000926326 srt:MaximumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0000926326 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0000926326 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0000926326 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-12-31 0000926326 us-gaap:PerformanceSharesMember 2022-12-31 0000926326 us-gaap:PerformanceSharesMember 2023-12-31 0000926326 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000926326 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0000926326 omcl:RestrictedStockRSAsRestrictedStockUnitsRSUsAndPreformanceSharesPSUsMember 2023-12-31 0000926326 omcl:FutureGrantsAndAwardsMember 2023-12-31 0000926326 omcl:OmnicellPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000926326 omcl:OmnicellPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000926326 omcl:OmnicellPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000926326 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-12-31 0000926326 omcl:A2016RepurchaseProgramMember 2016-08-02 0000926326 omcl:A2014ShareRepurchaseProgramMember 2014-11-04 0000926326 omcl:A2016and2014ShareRepurchaseProgramsMember 2023-12-31 0000926326 omcl:A2016and2014ShareRepurchaseProgramsMember 2022-01-01 2022-12-31 0000926326 us-gaap:DomesticCountryMember 2023-12-31 0000926326 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0000926326 us-gaap:ForeignCountryMember 2023-12-31 0000926326 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2023-12-31 0000926326 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2023-12-31 0000926326 2021-01-01 2021-03-31 0000926326 omcl:AccountsReceivableAndUnbilledReceivablesMember 2020-12-31 0000926326 omcl:AccountsReceivableAndUnbilledReceivablesMember 2021-01-01 2021-12-31 0000926326 omcl:AccountsReceivableAndUnbilledReceivablesMember 2021-12-31 0000926326 omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember 2020-12-31 0000926326 omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember 2021-01-01 2021-12-31 0000926326 omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember 2021-12-31 0000926326 omcl:NetInvestmentInSalesTypeLeasesMember 2020-12-31 0000926326 omcl:NetInvestmentInSalesTypeLeasesMember 2021-01-01 2021-12-31 0000926326 omcl:NetInvestmentInSalesTypeLeasesMember 2021-12-31 0000926326 omcl:AccountsReceivableAndUnbilledReceivablesMember 2022-01-01 2022-12-31 0000926326 omcl:AccountsReceivableAndUnbilledReceivablesMember 2022-12-31 0000926326 omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember 2022-01-01 2022-12-31 0000926326 omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember 2022-12-31 0000926326 omcl:NetInvestmentInSalesTypeLeasesMember 2022-01-01 2022-12-31 0000926326 omcl:NetInvestmentInSalesTypeLeasesMember 2022-12-31 0000926326 omcl:AccountsReceivableAndUnbilledReceivablesMember 2023-01-01 2023-12-31 0000926326 omcl:AccountsReceivableAndUnbilledReceivablesMember 2023-12-31 0000926326 omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember 2023-01-01 2023-12-31 0000926326 omcl:ContractWithCustomerAssetUnbilledReceivablesNoncurrentMember 2023-12-31 0000926326 omcl:NetInvestmentInSalesTypeLeasesMember 2023-01-01 2023-12-31 0000926326 omcl:NetInvestmentInSalesTypeLeasesMember 2023-12-31 iso4217:USD shares iso4217:USD shares omcl:segment pure omcl:reporting_unit iso4217:GBP omcl:day FY false 2023 0000926326 http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member P1Y P1Y http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent 0.0102751 http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax P1Y P3Y 0.25 0.25 0.25 10-K true 2023-12-31 --12-31 false 000-33043 OMNICELL, INC. DE 94-3166458 4220 North Freeway Fort Worth TX 76137 877 415-9990 Common Stock, $0.001 par value OMCL NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 3300000000 45915296 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant’s definitive Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the United States Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference in Part III, Items 10-14 of this Form 10-K.</span></div> false false false false 34 Deloitte & Touche LLP San Jose, California 467972000 330362000 5564000 5153000 252025000 299469000 110099000 147549000 25966000 27070000 71509000 77362000 927571000 881812000 108601000 93961000 42954000 32924000 24988000 38052000 735810000 734274000 211173000 242906000 32901000 22329000 52414000 59483000 90466000 105017000 2226878000 2210758000 45028000 63389000 51754000 73455000 149276000 172655000 121734000 118947000 367792000 428446000 58622000 37385000 1620000 2095000 33910000 39405000 6318000 6719000 569662000 566571000 1037924000 1080621000 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 100000000 100000000 55822000 55030000 45539000 44747000 56000 55000 10283000 10283000 290319000 290319000 1122292000 1046760000 370357000 390728000 -13432000 -17087000 1188954000 1130137000 2226878000 2210758000 708561000 903222000 812512000 438551000 392725000 319506000 1147112000 1295947000 1132018000 414106000 493626000 422855000 236166000 213334000 154510000 650272000 706960000 577365000 496840000 588987000 554653000 97115000 104969000 75716000 434593000 486341000 389430000 531708000 591310000 465146000 -34868000 -2323000 89507000 14760000 -130000 -23500000 -20108000 -2453000 66007000 263000 -8101000 -11842000 -20371000 5648000 77849000 -0.45 0.13 1.79 -0.45 0.12 1.62 45212000 44398000 43475000 45212000 45891000 47943000 -20371000 5648000 77849000 3655000 -8680000 -2885000 3655000 -8680000 -2885000 -16716000 -3032000 74964000 52677000 53000 9894000 -238109000 920359000 290722000 -5522000 967503000 77849000 77849000 -2885000 -2885000 53160000 53160000 1396000 1000 67347000 67348000 16286000 16286000 54073000 54000 9894000 -238109000 1024580000 368571000 -8407000 1146689000 5648000 5648000 -8680000 -8680000 389000 52210000 52210000 68247000 68247000 957000 1000 40181000 40182000 13506000 13506000 -72742000 16509000 -56233000 55030000 55000 10283000 -290319000 1046760000 390728000 -17087000 1130137000 -20371000 -20371000 3655000 3655000 59683000 59683000 792000 1000 23215000 23216000 7366000 7366000 55822000 56000 10283000 -290319000 1122292000 370357000 -13432000 1188954000 -20371000 5648000 77849000 87319000 86931000 72990000 -2572000 -678000 -433000 55300000 68247000 53160000 -11047000 -37316000 -3272000 8239000 12238000 11941000 9998000 9382000 0 0 1275000 0 1014000 0 0 4397000 4164000 3440000 0 0 18608000 -49150000 60357000 40973000 -38016000 30115000 25695000 -1149000 4671000 5678000 6821000 -6360000 -2801000 10411000 15354000 -3346000 -7069000 -4312000 6876000 -2111000 -5027000 3258000 -17525000 -7754000 29084000 -21461000 2446000 12312000 -10343000 16651000 34859000 24058000 24469000 24179000 -10918000 -13781000 -12503000 -401000 -699000 -14938000 181094000 77781000 231809000 13542000 13204000 29368000 41474000 47536000 28967000 0 3392000 354163000 0 5463000 0 -55016000 -58669000 -412498000 2967000 0 0 23216000 40182000 67348000 7366000 13506000 16286000 0 52210000 0 10537000 4581000 -3699000 23420000 -20953000 47363000 -1354000 -944000 -974000 148144000 -2785000 -134300000 352835000 355620000 489920000 500979000 352835000 355620000 467972000 330362000 349051000 33007000 22473000 6569000 500979000 352835000 355620000 1438000 1438000 1917000 20209000 19005000 -1733000 877000 892000 883000 0 314000 1876000 Organization and Summary of Significant Accounting Policies<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” refer to Omnicell, Inc. and its subsidiaries, collectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations, and cash flows for the periods presented.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying Notes to Consolidated Financial Statements. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. Those policies are revenue recognition; allowance for credit losses for accounts receivable and unbilled receivables; notes receivable from investment in sales-type leases; operating lease right-of-use assets and liabilities; inventory valuation; internal-use and external-use software development costs; impairment of goodwill; purchased intangibles and long-lived assets; fair value of assets acquired and liabilities assumed in business combinations; share-based compensation; and accounting for income taxes. As of December 31, 2023, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation and Remeasurement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the Company’s foreign subsidiaries use the local currency of their respective countries as their functional currency. The Company translates the assets and liabilities of such non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income (loss) in stockholders’ equity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities denominated in a currency other than the functional currency are remeasured into the respective entity’s functional currency. Monetary assets and liabilities are remeasured at exchange rates in effect at the end of each period, and non-monetary assets and liabilities are remeasured at historical rates. Gains and losses from foreign currency remeasurement of monetary assets and liabilities are recorded in interest and other income (expense), net.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Connected devices, software licenses, and other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consumables. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Technical services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced Services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue recognition for each revenue category:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Revenue Category</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Timing of Revenue Recognition</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Income Statement Classification</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Connected devices, software licenses, and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Product</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Consumables</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Product</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Technical services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Over time, as services are provided, typically ratably over the service term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Service</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Advanced Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Over time, as services are provided</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Service</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to recognizing revenue, the Company identifies the contract, performance obligations, and transaction price, and allocates the transaction price to the performance obligations. All identified contracts meet the following required criteria:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Parties to the contract have approved the contract </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations. A majority of the Company’s contracts are evidenced by a non-cancelable written agreement. Contracts for consumable products are generally evidenced by an order placed via our online portal, phone, or a purchase order. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Entity can identify each party’s rights regarding the goods or services to be transferred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Contract terms are documented within the written agreements. Where a written contract does not exist, such as for consumable products, the rights of each party are understood as following the Company’s standard business process and terms. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The entity can identify the payment terms for the goods or services to be transferred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Payment terms are documented within the agreement and are generally net 30 to 60 days from shipment of tangible product or services performed for customers in the United States. Where a written contract does not exist, the Company’s standard payment terms are net 30 day terms. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The contract has commercial substance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (that is the risk, timing, or amount of the entity’s future cash flows is expected to change as a result of the contract). The Company’s agreements are an exchange of cash for a combination of products and services which result in changes in the amount of the Company’s future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">It is probable the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company performs a credit check for all significant customers or </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions and where collectability is not probable, payment in full or a substantial down payment prior to shipment is typically required to help ensure the full agreed upon contract price will be collected. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distinct goods or services are identified as performance obligations. A series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer are considered a single performance obligation. Where a good or service is determined not to be distinct, the Company combines the good or service with other promised goods or services until a bundle of goods or services that is distinct is identified. To identify its performance obligations, the Company considers all products or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. When performance obligations are included in separate contracts, the Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Most of the Company’s sales, other than renewals of support and maintenance, contain multiple performance obligations, with a combination of hardware systems, software products, support and maintenance, and professional services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of a contract is determined based on the fixed consideration, net of an estimate for variable consideration such as various discounts or rebates provided to customers. As a result of the Company’s commercial selling practices, contract prices are generally fixed with minimal, if any, variable consideration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is allocated to separate performance obligations proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the performance obligation has been satisfied by transferring a promised good or service to a customer. The good or service is transferred when or as the customer obtains control of the good or service. Determining when control transfers requires management to make judgments that affect the timing of revenues recognized. Generally, for products requiring a complex implementation, control passes when the product is installed and ready for use. For all other products, control generally passes when product has been shipped and title has passed. For maintenance contracts and certain other services, including Advanced Services provided on a subscription basis, control passes to the customer over time, generally ratably over the service term as the Company provides a stand-ready service for the customer’s equipment. Time and material services transfer control to the customer at the time the services are provided.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues, net of deferred cost of goods sold. Deferred revenues from product sales primarily relate to delivered and invoiced products, pending installation and acceptance. Deferred revenues from service contracts primarily relate to services that have been invoiced, where services have not yet been provided. Short-term deferred revenues are expected to be recognized within the next twelve months. Long-term deferred revenues substantially consist of deferred revenues on long-term technical and Advanced Services contracts which have been invoiced and are expected to be recognized as revenue beyond twelve months, generally not more than ten years. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has remaining performance obligations associated with contracts for which the associated products have been accepted or associated services have started, but where invoicing has not yet occurred and therefore are not reflected in deferred revenue. These remaining performance obligations are comprised of the non-variable portions of technical services and Advanced Services provided under non-cancellable contracts with minimum commitments. Remaining performance obligations which are not included in deferred revenues are $353.9 million as of December 31, 2023. Remaining performance obligations are expected to be recognized ratably over the remaining terms of the associated contracts, which terms vary but are generally not more than ten years. Remaining performance obligations do not include product obligations, services where the associated product has not been accepted, services which have not yet started, variable portions of services, and certain other obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, contract assets, and contract liabilities are recorded net of associated taxes.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company generally invoices customers for products upon shipment. Invoicing associated with the service portion of agreements is generally periodic and is billed on a monthly, quarterly, or annual basis, and in certain circumstances, multiple years are billed at one time. Advanced Services agreements are generally invoiced periodically on a monthly, quarterly or annual basis over the life of the agreement. In certain circumstances portions of these agreements may be invoiced lump sum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount invoiced for equipment and software is typically reflected in both accounts receivable and deferred revenues, net. The Company typically recognizes product revenue, and correspondingly reduces deferred revenues, net, for equipment and on-premise software upon written customer acceptance of installation. Consumables are recorded as revenue upon shipment to or receipt by the customer, depending upon contract terms. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into change orders which modify the product to be received by the customer pursuant to certain contracts. Changes to any contract are accounted for as a modification of the existing contract to the extent the goods and services to be delivered as part of the contract are generally consistent with the nature and type of those to be provided under the terms of the original contract. Examples of such change orders include the addition or removal of units of equipment or changes to the configuration of the equipment where the overall nature of the contract remains intact. The Company’s change orders generally result in the change being accounted for as modifications of existing contracts given the nature of the impacted orders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company typically does not accept product returns unless the item is defective as manufactured or the configuration of the product is incorrect. The Company establishes provisions for estimated returns based on historical product returns. The allowance for sales returns is not material to the Consolidated Financial Statements for any periods presented.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”), each of which functions as a purchasing agent on behalf of member hospitals and other healthcare providers. The Company also has a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”), allowing the Department of Veterans Affairs, the Department of Defense, and other federal government customers to purchase the Company’s products. Pursuant to the terms of GPO agreements and the GSA Contract, each member or agency contracts directly with Omnicell and can purchase the Company’s products at pre-negotiated contract terms and pricing. GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $11.2 million, $17.6 million, and $17.5 million for the years ended December 31, 2023, 2022, and 2021, respectively. The accounts receivable balances are with individual members of the GPOs and federal agencies that purchase under the GSA Contract, and therefore no significant concentration of credit risk exists. During the year ended December 31, 2023, sales to members of the ten largest GPOs and federal agencies that purchase under the GSA Contract accounted for approximately 64% of the Company’s total consolidated revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract asset is a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration. A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. Contract liabilities include customer deposits under non-cancelable contracts, and current and non-current deferred revenue balances. The Company’s contract balances are reported in a net contract asset or liability position on a contract-by-contract basis at the end of each reporting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in the contract assets and the contract liabilities balances during the period are the result of the issuance of invoices and recognition of deferred revenues in the normal course of business. The contract modifications entered into during the year ended December 31, 2023 did not have a significant impact on the Company’s contract assets or deferred revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that certain incentive portions of its sales commission plans require capitalization since these payments are directly related to sales achieved during a time period. These commissions are earned on the basis of: (i) the value of new bookings for connected devices, software products, and Advanced Services, provided that for Advanced Services a commission will only be paid on the amount that represents the minimum commitment and (ii) the value of new orders for consumables. Since there are no commensurate commissions earned on renewal of the service bookings, the Company concluded that the capitalized asset is related to services provided under both the initial contract and renewal periods. The Company applies a practical expedient to account for the incremental costs of obtaining a contract as part of a portfolio of contracts with similar characteristics as the Company expects the effect on the financial statements of applying the practical expedient would not differ materially from applying the accounting guidance to the individual contracts within the portfolio. A pool of contracts is defined as all contracts booked in a particular quarter. The amortization for the capitalized asset is an estimate of the pool’s original contract term, generally <span style="-sec-ix-hidden:f-433">one</span> to five years, plus an estimate of future customer renewal periods resulting in a total amortization period of ten years. Costs to obtain a contract are allocated amongst performance obligations and recognized as sales and marketing expense consistent with the pattern of revenue recognition. In accordance with GAAP, while certain compensation elements are expensed as incurred, a portion of the pool’s capitalized asset is recorded as an expense over the first seven quarters after booking, which represents the estimated period during which the product revenue associated with the contract is recorded. The remaining capitalized contract costs are recorded as expense ratably over the ten </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year estimated initial and renewal service periods. The Company recognized contract cost expense of $23.3 million, $30.6 million, and $25.8 million during the years ended December 31, 2023, 2022, and 2021, respectively. The commission expenses paid or due to be paid as of the consolidated balance sheet date to be recognized in future periods are recorded in long-term prepaid commissions on the Consolidated Balance Sheets. Capitalized costs are periodically reviewed for impairment. There was no impairment loss recorded related to capitalized prepaid commissions as of and for the year ended December 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lessor Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. The transaction price is allocated to separate performance obligations, generally consisting of a combination of hardware systems, software products, support and maintenance, and professional services, proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-Type Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into non-cancelable sales-type lease arrangements with the leases varying in length from <span style="-sec-ix-hidden:f-442">one</span> to ten years, most of which do not have an option to extend the lease term. At the end of the lease term, the customer must either return the equipment or negotiate a new agreement, resulting in a new purchase or lease transaction. Failure of the customer to either return the equipment or negotiate a new agreement results in the contract becoming a month-to-month rental. Certain sales-type leases automatically renew for successive one-year periods at the end of each lease term without written notice from the customer. The Company’s sales-type lease agreements do not contain any material residual value guarantees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For sales-type leases, the Company recognizes revenues for its hardware and software products, net of lease execution costs, post-installation product maintenance, professional services associated with Advanced Services offerings, and technical support, at the net present value of the lease payment stream upon customer acceptance. The Company recognizes service revenues associated with sales-type leases ratably over the term of the agreement in service revenues in the Consolidated Statements of Operations. The Company recognizes interest income from sales-type leases using the effective interest method. Both hardware and software revenues, and interest income from sales-types leases are recorded in product revenues in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to credit losses primarily through sales of its products and services, as well as its sales-type leasing arrangements. The Company performs credit evaluations of its customers’ financial condition in order to assess each customer’s ability to pay. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history, and a financial review of the customer. The Company continues to monitor customers’ creditworthiness on an ongoing basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses for accounts receivable, unbilled receivables, and net investment in sales-type leases based on expected credit losses resulting from the inability of its customers to make required payments. The allowance for credit losses is measured using a loss rate method, considering factors such as customers’ credit risk, historical loss experience, current conditions, and forecasts. The allowance for credit losses is measured on a collective (pool) basis by aggregating customer balances with similar risk characteristics. The Company also records a specific allowance based on an analysis of individual past due balances or customer-specific information, such as a decline in creditworthiness or bankruptcy. Actual collection losses may differ from management’s estimates, and such differences could be material to the Company’s financial position and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses is presented in the Consolidated Balance Sheets as a deduction from the respective asset balance. As of December 31, 2023 and 2022, the allowance for credit losses for long-term unbilled receivables and net investment in sales-type leases were not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funds Held for Customers and Customer Fund Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers certain products and services in which it is customary for pharmacies or insurance payors to owe funds to the Company which are collected on behalf of, and, after a short holding period, disbursed to, the Company’s customers. The Company presents amounts due from pharmacies and amounts due to be disbursed to customers on a gross basis within other current assets and accrued liabilities, respectively, in the Consolidated Balance Sheets, as such amounts are expected to be settled within one year. Generally, any funds received from the pharmacies or insurance payors that are held by the Company are segregated from its other corporate cash accounts. These funds are classified as restricted cash as the Company is contractually obligated to disburse these amounts to customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of Accounts Receivable</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the sale of its accounts receivables in accordance with accounting guidance for transfers and servicing of financial assets. The Company transferred non-recourse accounts receivable totaling $5.7 million, $45.3 million, and $46.7 million during the years ended December 31, 2023, 2022, and 2021, respectively, which approximated fair value, to leasing companies on a non-recourse basis. Accounts receivable balance included approximately $1.1 million and $6.7 million due from third-party leasing companies for transferred non-recourse accounts receivable as of December 31, 2023 and 2022, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly-liquid investments with original maturities of three months or less as cash equivalents. The Company’s cash and cash equivalent balances include bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with financial institutions of high credit quality. The Company continuously monitors the credit worthiness of the financial institutions in which it invests. The Company has not experienced any credit losses from its cash equivalents. Cash and cash equivalents were $468.0 million and $330.4 million as of December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, cash equivalents were $451.0 million and $301.0 million, respectively, which consisted of money market funds held in sweep and asset management accounts.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities measured at fair value, the amounts are based on an expected exit price representing the amount that would be received from the sale of an asset or paid to transfer a liability in a transaction between market participants. The fair value may be based on assumptions that market participants would use in pricing an asset or liability. ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs used in valuation techniques are assigned a hierarchical level, as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Observable inputs, such as quoted prices in active markets for identical instruments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Quoted prices for similar instruments in active markets, or quoted prices for identical instruments in inactive markets; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Unobservable inputs for financial instruments reflecting Company’s assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost, computed using the first-in, first-out method, and net realizable value. Inbound shipping costs are included in cost of inventory. The Company regularly monitors inventory quantities on hand and records write-downs for excess and obsolete inventories based on the Company’s estimate of demand for its products, potential obsolescence of technology, product life cycles, and whether pricing trends or forecasts indicate that the carrying value of inventory exceeds its estimated selling price. These factors are impacted by market and economic conditions, technology changes, and new product introductions and require estimates that may include elements that are uncertain. Actual demand may differ from forecasted demand and may have a material effect on gross margins. If inventory is written down, a new cost basis is established that cannot be increased in future periods. Shipments from suppliers or contract manufacturers before the Company receives them are recorded as in-transit inventory when title and the significant risks and rewards of ownership have passed to the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in its hardware products. There are no minimum purchase requirements. The </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract with the Company’s supplier may be terminated by either the supplier or by the Company without cause and at any time upon delivery of six months’ notice. Purchases from this supplier were $65.8 million, $105.7 million, and $103.2 million for the years ended December 31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general, and administrative expense. Shipping and handling expenses were $18.6 million, $24.5 million, and $18.2 million for the years ended December 31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment less accumulated depreciation are stated at historical cost. The Company’s expenditures for property and equipment are primarily for computer equipment and software used in the administration of its business, and for leasehold improvements to its leased facilities. The Company also develops molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs related to computer software developed or obtained for internal-use in accordance with ASC 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Software developed or obtained for internal-use includes certain costs for the development of the Company’s subscription and cloud-based offerings sold to its customers, as well as enterprise-level business and finance software that the Company customizes to meet its specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. The Company capitalized $32.2 million and $33.0 million of costs related to the application development of enterprise-level software and its subscription and cloud-based offerings, which are included in property and equipment during the years ended December 31, 2023 and 2022, respectively. Capitalized costs related to computer software developed or obtained for internal-use are included in purchases of property and equipment in the Consolidated Statements of Cash Flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization is computed by use of the straight-line method over the estimated useful lives of the assets as stated below:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software and internal-use software development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold and building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the lease term or the estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 12 years</span></div></td></tr></table></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">External-Use Software Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain software development costs in accordance with ASC 985-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of Software to Be Sold, Leased, or Marketed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which those costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. The Company establishes technological feasibility when it completes a detail program design or a working model. The Company amortizes development costs over the estimated lives of the related products, which is generally five years. All development costs prior to the completion of a detail program design or a working model are recognized as research and development expense. The Company capitalized external-use software development costs of $14.6 million and $13.2 million, that were included in other long-term assets as of December 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lessee Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of its lease contracts do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available at the commencement date in determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize a right-of-use asset and a lease liability for leases with an initial term of twelve months or less. The Company elected the practical expedient to not separate lease components from nonlease components and applied that practical expedient to all material classes of leased assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the Company’s operating leases include an option to extend the lease. The specific terms and conditions of the extension options vary from lease to lease, but are consistent with standard industry practices in each area that the Company operates. The Company reviews each of its lease options at a time required by the terms of the lease contract, and notifies the </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lessor if it chooses to exercise the lease renewal option. Until the Company is reasonably certain that it will extend the lease contract, the renewal option periods will not be recognized as right-of-use assets or lease liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain leases include provisions for early termination, which allow the contract parties to terminate their obligations under the lease contract. The terms and conditions of the termination options vary by contract. When the Company has made a decision to exercise an early termination option, the right-of-use assets and associated lease liabilities are remeasured in accordance with the present value of the remaining cash flows under the lease contract.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain building lease agreements include rental payments subject to change annually based on fluctuations in various indexes (i.e., Consumer Price Index (“CPI”), Retail Price Index, and other international indexes). Certain data center lease agreements include rental payments subject to change based on usage and CPI fluctuations. The changes based on usage and indexes are treated as variable lease costs and recognized in the period in which the obligation for those payments was incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operating lease agreements do not contain any material residual value guarantees, restrictions, or restriction covenants.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting under ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each acquired company’s operating results are included in the Company’s Consolidated Financial Statements starting on the acquisition date. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the acquisition date are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on available historical information as well as future expectations, and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, acquired technology, backlog, trade names, and non-compete agreements. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Acquired Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. This assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. The Company has one reporting unit, which is the same as its operating segment. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. A qualitative assessment includes, among others, consideration of: (i) past, current, and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this qualitative assessment indicates that it is more likely than not that impairment exists, or if the Company decides to bypass this option, it proceeds to the quantitative assessment. The quantitative assessment involves a comparison between the estimated fair value of the Company’s reporting unit with its carrying amount including goodwill. If the carrying value exceeds estimated fair value, the Company will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the reporting unit’s fair value under the quantitative approach, the Company uses a combination of income and market approaches, such as estimated discounted future cash flows of the reporting unit, multiples of earnings or revenues, and analysis of recent sales or offerings of comparable entities. The Company also considers its market capitalization on the date of the analysis to ensure the reasonableness of its reporting unit’s fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to perform a quantitative impairment assessment analysis as of October 1, 2023 for its reporting unit. The Company determined that the fair value of the reporting unit exceeded the carrying value and thus no impairment was indicated. Based on the result of this analysis, an impairment does not exist as of December 31, 2023, and there were no accumulated impairment losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its acquisitions, the Company generally recognizes assets for customer relationships, acquired technology, backlog, trade names, and non-compete agreements. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets. Amortization for acquired technology and backlog is recognized in cost of revenues, and amortization for customer relationships, trade names, non-compete agreements, and patents is recognized in selling, general, and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. The Company’s cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of the Company’s intangible assets are subjective and are affected by changes to its business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of the Company’s assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on the Company’s operating results and financial condition. For the years ended December 31, 2023 and 2022, there were no events or changes in circumstances to indicate that intangible assets carrying amounts may not be recoverable.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for convertible debt and related transactions in accordance with ASC 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates convertible debt instruments and related transactions at inception to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of Accounting Standards Update (“ASU”) 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner. The difference between the principal amount of the convertible senior notes and the liability component, inclusive of issuance costs, represented the debt discount, which the Company amortized to interest expense over the term of the convertible senior notes. The determination of the discount rate required certain estimates and assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption of ASU 2020-06, effective January 1, 2022, the convertible senior notes are no longer separated into liability and equity components, and are accounted for as a single liability, measured at amortized cost in the Consolidated Balance Sheets. Issuance costs are amortized using the effective interest method over the term of the convertible senior notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note hedge and warrant transactions associated with convertible debt instruments are accounted for as equity instruments, and are recorded in additional paid-in capital in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Share-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based compensation in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes compensation expense related to share-based compensation based on the grant date estimated fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options (“options”) on the grant date is estimated using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of its common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on the Company’s historical experience of employee stock option exercises, including forfeitures. Expense is recognized on a straight-line basis over the requisite service period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) is based on the stock price on the grant date. The RSUs and RSAs are subject to a service vesting condition and are recognized on a straight-line basis over the requisite service period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance-based stock unit awards (“PSUs”) with service and market conditions is estimated using a Monte Carlo simulation model applying a multiple awards approach. Expense is recognized when it is probable that the performance condition will be met using the accelerated attribution method over the requisite service period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rates are estimated based on the Company’s historical experience with equity awards that were granted and forfeited prior to vesting. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records an income tax provision for (benefit from) the anticipated tax consequences of the reported results of operations. In accordance with ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the provision for (benefit from) income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, the Company will incur a benefit or detriment on its income tax expense in the period of enactment. If the Company were to determine that all or part of the net deferred tax assets are not realizable in the future, it will record a valuation allowance that would be charged to earnings in the period such determination is made.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of ASC 740 and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on the Company’s financial condition and operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Authoritative Guidance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company adopted ASU 2021-08 beginning January 1, 2023 and will apply the guidance prospectively to acquisitions occurring on or after the adoption date.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Authoritative Guidance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations, and cash flows for the periods presented.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying Notes to Consolidated Financial Statements. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. Those policies are revenue recognition; allowance for credit losses for accounts receivable and unbilled receivables; notes receivable from investment in sales-type leases; operating lease right-of-use assets and liabilities; inventory valuation; internal-use and external-use software development costs; impairment of goodwill; purchased intangibles and long-lived assets; fair value of assets acquired and liabilities assumed in business combinations; share-based compensation; and accounting for income taxes. <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.</span></div> 1 1 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the Company’s foreign subsidiaries use the local currency of their respective countries as their functional currency. The Company translates the assets and liabilities of such non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income (loss) in stockholders’ equity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities denominated in a currency other than the functional currency are remeasured into the respective entity’s functional currency. Monetary assets and liabilities are remeasured at exchange rates in effect at the end of each period, and non-monetary assets and liabilities are remeasured at historical rates. Gains and losses from foreign currency remeasurement of monetary assets and liabilities are recorded in interest and other income (expense), net.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Connected devices, software licenses, and other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consumables. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Technical services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced Services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue recognition for each revenue category:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Revenue Category</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Timing of Revenue Recognition</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Income Statement Classification</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Connected devices, software licenses, and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Product</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Consumables</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Product</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Technical services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Over time, as services are provided, typically ratably over the service term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Service</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Advanced Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Over time, as services are provided</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Service</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to recognizing revenue, the Company identifies the contract, performance obligations, and transaction price, and allocates the transaction price to the performance obligations. All identified contracts meet the following required criteria:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Parties to the contract have approved the contract </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations. A majority of the Company’s contracts are evidenced by a non-cancelable written agreement. Contracts for consumable products are generally evidenced by an order placed via our online portal, phone, or a purchase order. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Entity can identify each party’s rights regarding the goods or services to be transferred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Contract terms are documented within the written agreements. Where a written contract does not exist, such as for consumable products, the rights of each party are understood as following the Company’s standard business process and terms. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The entity can identify the payment terms for the goods or services to be transferred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Payment terms are documented within the agreement and are generally net 30 to 60 days from shipment of tangible product or services performed for customers in the United States. Where a written contract does not exist, the Company’s standard payment terms are net 30 day terms. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The contract has commercial substance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (that is the risk, timing, or amount of the entity’s future cash flows is expected to change as a result of the contract). The Company’s agreements are an exchange of cash for a combination of products and services which result in changes in the amount of the Company’s future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">It is probable the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company performs a credit check for all significant customers or </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions and where collectability is not probable, payment in full or a substantial down payment prior to shipment is typically required to help ensure the full agreed upon contract price will be collected. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distinct goods or services are identified as performance obligations. A series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer are considered a single performance obligation. Where a good or service is determined not to be distinct, the Company combines the good or service with other promised goods or services until a bundle of goods or services that is distinct is identified. To identify its performance obligations, the Company considers all products or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. When performance obligations are included in separate contracts, the Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Most of the Company’s sales, other than renewals of support and maintenance, contain multiple performance obligations, with a combination of hardware systems, software products, support and maintenance, and professional services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of a contract is determined based on the fixed consideration, net of an estimate for variable consideration such as various discounts or rebates provided to customers. As a result of the Company’s commercial selling practices, contract prices are generally fixed with minimal, if any, variable consideration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is allocated to separate performance obligations proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the performance obligation has been satisfied by transferring a promised good or service to a customer. The good or service is transferred when or as the customer obtains control of the good or service. Determining when control transfers requires management to make judgments that affect the timing of revenues recognized. Generally, for products requiring a complex implementation, control passes when the product is installed and ready for use. For all other products, control generally passes when product has been shipped and title has passed. For maintenance contracts and certain other services, including Advanced Services provided on a subscription basis, control passes to the customer over time, generally ratably over the service term as the Company provides a stand-ready service for the customer’s equipment. Time and material services transfer control to the customer at the time the services are provided.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues, net of deferred cost of goods sold. Deferred revenues from product sales primarily relate to delivered and invoiced products, pending installation and acceptance. Deferred revenues from service contracts primarily relate to services that have been invoiced, where services have not yet been provided. Short-term deferred revenues are expected to be recognized within the next twelve months. Long-term deferred revenues substantially consist of deferred revenues on long-term technical and Advanced Services contracts which have been invoiced and are expected to be recognized as revenue beyond twelve months, generally not more than ten years. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has remaining performance obligations associated with contracts for which the associated products have been accepted or associated services have started, but where invoicing has not yet occurred and therefore are not reflected in deferred revenue. These remaining performance obligations are comprised of the non-variable portions of technical services and Advanced Services provided under non-cancellable contracts with minimum commitments. Remaining performance obligations which are not included in deferred revenues are $353.9 million as of December 31, 2023. Remaining performance obligations are expected to be recognized ratably over the remaining terms of the associated contracts, which terms vary but are generally not more than ten years. Remaining performance obligations do not include product obligations, services where the associated product has not been accepted, services which have not yet started, variable portions of services, and certain other obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, contract assets, and contract liabilities are recorded net of associated taxes.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company generally invoices customers for products upon shipment. Invoicing associated with the service portion of agreements is generally periodic and is billed on a monthly, quarterly, or annual basis, and in certain circumstances, multiple years are billed at one time. Advanced Services agreements are generally invoiced periodically on a monthly, quarterly or annual basis over the life of the agreement. In certain circumstances portions of these agreements may be invoiced lump sum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount invoiced for equipment and software is typically reflected in both accounts receivable and deferred revenues, net. The Company typically recognizes product revenue, and correspondingly reduces deferred revenues, net, for equipment and on-premise software upon written customer acceptance of installation. Consumables are recorded as revenue upon shipment to or receipt by the customer, depending upon contract terms. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into change orders which modify the product to be received by the customer pursuant to certain contracts. Changes to any contract are accounted for as a modification of the existing contract to the extent the goods and services to be delivered as part of the contract are generally consistent with the nature and type of those to be provided under the terms of the original contract. Examples of such change orders include the addition or removal of units of equipment or changes to the configuration of the equipment where the overall nature of the contract remains intact. The Company’s change orders generally result in the change being accounted for as modifications of existing contracts given the nature of the impacted orders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company typically does not accept product returns unless the item is defective as manufactured or the configuration of the product is incorrect. The Company establishes provisions for estimated returns based on historical product returns. The allowance for sales returns is not material to the Consolidated Financial Statements for any periods presented.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”), each of which functions as a purchasing agent on behalf of member hospitals and other healthcare providers. The Company also has a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”), allowing the Department of Veterans Affairs, the Department of Defense, and other federal government customers to purchase the Company’s products. Pursuant to the terms of GPO agreements and the GSA Contract, each member or agency contracts directly with Omnicell and can purchase the Company’s products at pre-negotiated contract terms and pricing. GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $11.2 million, $17.6 million, and $17.5 million for the years ended December 31, 2023, 2022, and 2021, respectively. The accounts receivable balances are with individual members of the GPOs and federal agencies that purchase under the GSA Contract, and therefore no significant concentration of credit risk exists. During the year ended December 31, 2023, sales to members of the ten largest GPOs and federal agencies that purchase under the GSA Contract accounted for approximately 64% of the Company’s total consolidated revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract asset is a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration. A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. Contract liabilities include customer deposits under non-cancelable contracts, and current and non-current deferred revenue balances. The Company’s contract balances are reported in a net contract asset or liability position on a contract-by-contract basis at the end of each reporting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in the contract assets and the contract liabilities balances during the period are the result of the issuance of invoices and recognition of deferred revenues in the normal course of business. The contract modifications entered into during the year ended December 31, 2023 did not have a significant impact on the Company’s contract assets or deferred revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that certain incentive portions of its sales commission plans require capitalization since these payments are directly related to sales achieved during a time period. These commissions are earned on the basis of: (i) the value of new bookings for connected devices, software products, and Advanced Services, provided that for Advanced Services a commission will only be paid on the amount that represents the minimum commitment and (ii) the value of new orders for consumables. Since there are no commensurate commissions earned on renewal of the service bookings, the Company concluded that the capitalized asset is related to services provided under both the initial contract and renewal periods. The Company applies a practical expedient to account for the incremental costs of obtaining a contract as part of a portfolio of contracts with similar characteristics as the Company expects the effect on the financial statements of applying the practical expedient would not differ materially from applying the accounting guidance to the individual contracts within the portfolio. A pool of contracts is defined as all contracts booked in a particular quarter. The amortization for the capitalized asset is an estimate of the pool’s original contract term, generally <span style="-sec-ix-hidden:f-433">one</span> to five years, plus an estimate of future customer renewal periods resulting in a total amortization period of ten years. Costs to obtain a contract are allocated amongst performance obligations and recognized as sales and marketing expense consistent with the pattern of revenue recognition. In accordance with GAAP, while certain compensation elements are expensed as incurred, a portion of the pool’s capitalized asset is recorded as an expense over the first seven quarters after booking, which represents the estimated period during which the product revenue associated with the contract is recorded. The remaining capitalized contract costs are recorded as expense ratably over the ten </span></div>year estimated initial and renewal service periods.Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general, and administrative expense. <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue recognition for each revenue category:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Revenue Category</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Timing of Revenue Recognition</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Income Statement Classification</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Connected devices, software licenses, and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Product</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Consumables</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Product</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Technical services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Over time, as services are provided, typically ratably over the service term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Service</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Advanced Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Over time, as services are provided</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Service</span></div></td></tr></table></div> P10Y 353900000 P10Y 11200000 17600000 17500000 0.64 P5Y P10Y P10Y 23300000 30600000 25800000 0 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. The transaction price is allocated to separate performance obligations, generally consisting of a combination of hardware systems, software products, support and maintenance, and professional services, proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual technical services contracts, the Company’s products and services are not generally sold separately. The Company uses an amount discounted from the list price as a best estimated selling price.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-Type Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into non-cancelable sales-type lease arrangements with the leases varying in length from <span style="-sec-ix-hidden:f-442">one</span> to ten years, most of which do not have an option to extend the lease term. At the end of the lease term, the customer must either return the equipment or negotiate a new agreement, resulting in a new purchase or lease transaction. Failure of the customer to either return the equipment or negotiate a new agreement results in the contract becoming a month-to-month rental. Certain sales-type leases automatically renew for successive one-year periods at the end of each lease term without written notice from the customer. The Company’s sales-type lease agreements do not contain any material residual value guarantees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For sales-type leases, the Company recognizes revenues for its hardware and software products, net of lease execution costs, post-installation product maintenance, professional services associated with Advanced Services offerings, and technical support, at the net present value of the lease payment stream upon customer acceptance. The Company recognizes service revenues associated with sales-type leases ratably over the term of the agreement in service revenues in the Consolidated Statements of Operations. The Company recognizes interest income from sales-type leases using the effective interest method. Both hardware and software revenues, and interest income from sales-types leases are recorded in product revenues in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold.</span></div> P10Y <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to credit losses primarily through sales of its products and services, as well as its sales-type leasing arrangements. The Company performs credit evaluations of its customers’ financial condition in order to assess each customer’s ability to pay. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history, and a financial review of the customer. The Company continues to monitor customers’ creditworthiness on an ongoing basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses for accounts receivable, unbilled receivables, and net investment in sales-type leases based on expected credit losses resulting from the inability of its customers to make required payments. The allowance for credit losses is measured using a loss rate method, considering factors such as customers’ credit risk, historical loss experience, current conditions, and forecasts. The allowance for credit losses is measured on a collective (pool) basis by aggregating customer balances with similar risk characteristics. The Company also records a specific allowance based on an analysis of individual past due balances or customer-specific information, such as a decline in creditworthiness or bankruptcy. Actual collection losses may differ from management’s estimates, and such differences could be material to the Company’s financial position and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses is presented in the Consolidated Balance Sheets as a deduction from the respective asset balance. As of December 31, 2023 and 2022, the allowance for credit losses for long-term unbilled receivables and net investment in sales-type leases were not material.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers certain products and services in which it is customary for pharmacies or insurance payors to owe funds to the Company which are collected on behalf of, and, after a short holding period, disbursed to, the Company’s customers. The Company presents amounts due from pharmacies and amounts due to be disbursed to customers on a gross basis within other current assets and accrued liabilities, respectively, in the Consolidated Balance Sheets, as such amounts are expected to be settled within one year. Generally, any funds received from the pharmacies or insurance payors that are held by the Company are segregated from its other corporate cash accounts. These funds are classified as restricted cash as the Company is contractually obligated to disburse these amounts to customers.</span></div> The Company records the sale of its accounts receivables in accordance with accounting guidance for transfers and servicing of financial assets. 5700000 45300000 46700000 1100000 6700000 The Company classifies all highly-liquid investments with original maturities of three months or less as cash equivalents. The Company’s cash and cash equivalent balances include bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with financial institutions of high credit quality. The Company continuously monitors the credit worthiness of the financial institutions in which it invests. The Company has not experienced any credit losses from its cash equivalents. 468000000 330400000 451000000 301000000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities measured at fair value, the amounts are based on an expected exit price representing the amount that would be received from the sale of an asset or paid to transfer a liability in a transaction between market participants. The fair value may be based on assumptions that market participants would use in pricing an asset or liability. ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs used in valuation techniques are assigned a hierarchical level, as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Observable inputs, such as quoted prices in active markets for identical instruments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Quoted prices for similar instruments in active markets, or quoted prices for identical instruments in inactive markets; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – Unobservable inputs for financial instruments reflecting Company’s assumptions.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost, computed using the first-in, first-out method, and net realizable value. Inbound shipping costs are included in cost of inventory. The Company regularly monitors inventory quantities on hand and records write-downs for excess and obsolete inventories based on the Company’s estimate of demand for its products, potential obsolescence of technology, product life cycles, and whether pricing trends or forecasts indicate that the carrying value of inventory exceeds its estimated selling price. These factors are impacted by market and economic conditions, technology changes, and new product introductions and require estimates that may include elements that are uncertain. Actual demand may differ from forecasted demand and may have a material effect on gross margins. If inventory is written down, a new cost basis is established that cannot be increased in future periods. Shipments from suppliers or contract manufacturers before the Company receives them are recorded as in-transit inventory when title and the significant risks and rewards of ownership have passed to the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in its hardware products. There are no minimum purchase requirements. The </span></div>contract with the Company’s supplier may be terminated by either the supplier or by the Company without cause and at any time upon delivery of six months’ notice. 0 P6M 65800000 105700000 103200000 18600000 24500000 18200000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment less accumulated depreciation are stated at historical cost. The Company’s expenditures for property and equipment are primarily for computer equipment and software used in the administration of its business, and for leasehold improvements to its leased facilities. The Company also develops molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs related to computer software developed or obtained for internal-use in accordance with ASC 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal-Use Software</span>. Software developed or obtained for internal-use includes certain costs for the development of the Company’s subscription and cloud-based offerings sold to its customers, as well as enterprise-level business and finance software that the Company customizes to meet its specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. The Company capitalized $32.2 million and $33.0 million of costs related to the application development of enterprise-level software and its subscription and cloud-based offerings, which are included in property and equipment during the years ended December 31, 2023 and 2022, respectively. Capitalized costs related to computer software developed or obtained for internal-use are included in purchases of property and equipment in the Consolidated Statements of Cash Flows. P5Y 32200000 33000000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization is computed by use of the straight-line method over the estimated useful lives of the assets as stated below:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software and internal-use software development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold and building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the lease term or the estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 12 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the property and equipment balances as of December 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,919 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software and internal-use software development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,033 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,605 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,601 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,961 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P3Y P5Y P5Y P7Y P2Y P12Y <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain software development costs in accordance with ASC 985-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of Software to Be Sold, Leased, or Marketed</span>, under which those costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. The Company establishes technological feasibility when it completes a detail program design or a working model. The Company amortizes development costs over the estimated lives of the related products, which is generally five years. All development costs prior to the completion of a detail program design or a working model are recognized as research and development expense. P5Y 14600000 13200000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of its lease contracts do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available at the commencement date in determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize a right-of-use asset and a lease liability for leases with an initial term of twelve months or less. The Company elected the practical expedient to not separate lease components from nonlease components and applied that practical expedient to all material classes of leased assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the Company’s operating leases include an option to extend the lease. The specific terms and conditions of the extension options vary from lease to lease, but are consistent with standard industry practices in each area that the Company operates. The Company reviews each of its lease options at a time required by the terms of the lease contract, and notifies the </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lessor if it chooses to exercise the lease renewal option. Until the Company is reasonably certain that it will extend the lease contract, the renewal option periods will not be recognized as right-of-use assets or lease liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain leases include provisions for early termination, which allow the contract parties to terminate their obligations under the lease contract. The terms and conditions of the termination options vary by contract. When the Company has made a decision to exercise an early termination option, the right-of-use assets and associated lease liabilities are remeasured in accordance with the present value of the remaining cash flows under the lease contract.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain building lease agreements include rental payments subject to change annually based on fluctuations in various indexes (i.e., Consumer Price Index (“CPI”), Retail Price Index, and other international indexes). Certain data center lease agreements include rental payments subject to change based on usage and CPI fluctuations. The changes based on usage and indexes are treated as variable lease costs and recognized in the period in which the obligation for those payments was incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operating lease agreements do not contain any material residual value guarantees, restrictions, or restriction covenants.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting under ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each acquired company’s operating results are included in the Company’s Consolidated Financial Statements starting on the acquisition date. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the acquisition date are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. </span></div>Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on available historical information as well as future expectations, and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, acquired technology, backlog, trade names, and non-compete agreements.<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. This assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. The Company has one reporting unit, which is the same as its operating segment. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. A qualitative assessment includes, among others, consideration of: (i) past, current, and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this qualitative assessment indicates that it is more likely than not that impairment exists, or if the Company decides to bypass this option, it proceeds to the quantitative assessment. The quantitative assessment involves a comparison between the estimated fair value of the Company’s reporting unit with its carrying amount including goodwill. If the carrying value exceeds estimated fair value, the Company will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the reporting unit’s fair value under the quantitative approach, the Company uses a combination of income and market approaches, such as estimated discounted future cash flows of the reporting unit, multiples of earnings or revenues, and analysis of recent sales or offerings of comparable entities. The Company also considers its market capitalization on the date of the analysis to ensure the reasonableness of its reporting unit’s fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to perform a quantitative impairment assessment analysis as of October 1, 2023 for its reporting unit. The Company determined that the fair value of the reporting unit exceeded the carrying value and thus no impairment was indicated. Based on the result of this analysis, an impairment does not exist as of December 31, 2023, and there were no accumulated impairment losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its acquisitions, the Company generally recognizes assets for customer relationships, acquired technology, backlog, trade names, and non-compete agreements. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets. Amortization for acquired technology and backlog is recognized in cost of revenues, and amortization for customer relationships, trade names, non-compete agreements, and patents is recognized in selling, general, and administrative expenses.</span></div>The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. The Company’s cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of the Company’s intangible assets are subjective and are affected by changes to its business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of the Company’s assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on the Company’s operating results and financial condition. 1 0 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for convertible debt and related transactions in accordance with ASC 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates convertible debt instruments and related transactions at inception to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of Accounting Standards Update (“ASU”) 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner. The difference between the principal amount of the convertible senior notes and the liability component, inclusive of issuance costs, represented the debt discount, which the Company amortized to interest expense over the term of the convertible senior notes. The determination of the discount rate required certain estimates and assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption of ASU 2020-06, effective January 1, 2022, the convertible senior notes are no longer separated into liability and equity components, and are accounted for as a single liability, measured at amortized cost in the Consolidated Balance Sheets. Issuance costs are amortized using the effective interest method over the term of the convertible senior notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note hedge and warrant transactions associated with convertible debt instruments are accounted for as equity instruments, and are recorded in additional paid-in capital in the Consolidated Balance Sheets.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based compensation in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes compensation expense related to share-based compensation based on the grant date estimated fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options (“options”) on the grant date is estimated using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of its common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on the Company’s historical experience of employee stock option exercises, including forfeitures. Expense is recognized on a straight-line basis over the requisite service period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) is based on the stock price on the grant date. The RSUs and RSAs are subject to a service vesting condition and are recognized on a straight-line basis over the requisite service period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance-based stock unit awards (“PSUs”) with service and market conditions is estimated using a Monte Carlo simulation model applying a multiple awards approach. Expense is recognized when it is probable that the performance condition will be met using the accelerated attribution method over the requisite service period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rates are estimated based on the Company’s historical experience with equity awards that were granted and forfeited prior to vesting. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods.</span></div>Awards of restricted stock to non-employee directors are granted on the date of the annual meeting of stockholders and vest in full on the date of the next annual meeting of stockholders, provided such non-employee director remains a director on such date. PSUs granted to the Company’s executives may include performance and market conditions. PSUs become eligible for vesting when certain market or performance conditions are met. <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records an income tax provision for (benefit from) the anticipated tax consequences of the reported results of operations. In accordance with ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the provision for (benefit from) income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, the Company will incur a benefit or detriment on its income tax expense in the period of enactment. If the Company were to determine that all or part of the net deferred tax assets are not realizable in the future, it will record a valuation allowance that would be charged to earnings in the period such determination is made.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of ASC 740 and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on the Company’s financial condition and operating results.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Authoritative Guidance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company adopted ASU 2021-08 beginning January 1, 2023 and will apply the guidance prospectively to acquisitions occurring on or after the adoption date.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Authoritative Guidance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements.</span></div> Business Combinations<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Acquisition</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hub and Spoke Innovations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2022, the Company completed the acquisition of all of the outstanding equity interests in Hub and Spoke Innovations pursuant to the terms and conditions of the Share Purchase Agreement, dated January 10, 2022, by and among Omnicell Limited (a wholly-owned subsidiary of the Company), Hub and Spoke Innovations Limited, and certain beneficial stockholders specified therein for a base purchase price of £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date), prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The purchase price transferred for the transaction, net of cash acquired, was £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date). Of the purchase price transferred, £1.9 million (approximately $2.5 million based on the exchange rate in effect at the acquisition date) was allocated to goodwill; £0.8 million (approximately $1.1 million based on the exchange rate in effect at the acquisition date) was allocated to intangible assets, which included customer relationships; and the remainder was allocated to net assets acquired. The Hub and Spoke Innovations acquisition is expected to complement Omnicell’s total solution technology portfolio for retail pharmacy in the United Kingdom to help pharmacies improve workflows, offer patients 24/7 access to their medications and provide enhanced patient care.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Acquisitions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MarkeTouch Media</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company completed the acquisition of all of the outstanding equity interests in MarkeTouch Media, LLC (“MarkeTouch Media”) pursuant to the terms and conditions of the Unit Purchase Agreement, dated December 31, 2021, by and among ateb, Inc. (a wholly-owned subsidiary of the Company), MarkeTouch Media, LLC, MarkeTouch Holdings, Inc., Toucan Enterprises, Inc., and certain beneficial stockholders specified therein for a base purchase price of $82.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The MarkeTouch Media acquisition adds mobile and web-based technology and patient engagement solutions, which is expected to expand the footprint of EnlivenHealth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> across the retail pharmacy sector, while enhancing potential growth opportunities in new market segments like specialty pharmacy and pharmacy benefits management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ReCept</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 29, 2021, the Company completed the acquisition of all outstanding equity securities of ReCept pursuant to the terms and conditions of the Agreement and Plan of Merger, dated December 1, 2021, by and among Omnicell, Inc., ReCept Holdings, Inc., Redfish Acquisition Corp, and the representative of the securityholders for a base purchase price of $100.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The addition of ReCept’s specialty pharmacy management services, now a part of the Company’s Specialty Pharmacy Services, for health systems, provider groups, and federally qualified health centers expands Omnicell’s Advanced Services portfolio in an effort to address the growing and complex specialty pharmacy market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FDS Amplicare</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Company completed the acquisition of all of the outstanding equity interests in RxInnovation, Inc., operating as FDS Amplicare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“FDS Amplicare”), pursuant to the terms and conditions of the Agreement and Plan of Merger, dated July 25, 2021, by and among RxInnovation Inc., Omnicell, Inc., Fleming Acquisition Corp., and the representative of the securityholders for a base purchase price of $177.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The FDS Amplicare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition adds a comprehensive and complementary suite of software-as-a-service (“SaaS”) financial management, analytics, and population health solutions to the Company’s EnlivenHealth offering.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $7.0 million in acquisition-related costs related to the FDS Amplicare acquisition during the year ended December 31, 2021. Revenues and net losses from the FDS Amplicare operations since the acquisition date through December 31, 2021 were $11.3 million and $0.9 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the allocation of the respective purchase price to the assets acquired and the liabilities assumed by the Company as part of each acquisition included in the Company’s Consolidated Balance Sheets, and is reconciled to the respective purchase price transferred:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FDS Amplicare </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ReCept </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MarkeTouch Media </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase price transferred:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Base purchase price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Closing cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Net working capital adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Assumed indebtedness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price transferred</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,466 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,239 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,369 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FDS Amplicare </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ReCept </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MarkeTouch Media </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of assets acquired and liabilities assumed:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,798 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,877 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,682 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,537 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,411 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,443 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,168 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,466 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,239 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,369 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,001 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,132 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded measurement period adjustments of $1.5 million to goodwill, consisting of an increase in intangible assets, accounts receivable and unbilled receivables, and long-term deferred tax liabilities of $0.4 million, $1.1 million, and $0.1 million, respectively, and a net working capital adjustment of $0.1 million. During the year ended December 31, 2022, the Company recorded a measurement period adjustments of $0.4 million to goodwill, consisting of an increase in long-term deferred tax liabilities and accrued liabilities of $0.3 million and $0.1 million, respectively.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Closing cash is included in other current assets due to its restrictive nature as cash held for customers. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    During the year ended December 31, 2022, the Company recorded measurement period adjustments of $3.9 million to goodwill, consisting of a purchase price adjustment of $5.2 million, a decrease in long-term deferred tax liabilities of $0.2 million and a decrease in accrued liabilities of $0.3 million, partially offset by a decrease to other current assets of $1.7 million.</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded a measurement period adjustment of $0.3 million to goodwill related to a purchase price adjustment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $117.8 million of goodwill arising from the FDS Amplicare acquisition is primarily attributed to future sales of SaaS solutions and FDS Amplicare’s assembled workforce. The $77.6 million of goodwill arising from the ReCept acquisition is primarily attributed to future sales of its offerings and services and ReCept’s assembled workforce. None of the FDS Amplicare and ReCept goodwill is expected to be deductible for tax purposes as these acquisitions were treated as stock acquisitions for U.S. tax purposes. The $42.3 million of goodwill arising from the MarkeTouch Media acquisition is primarily attributed to future sales of SaaS solutions and MarkeTouch Media’s assembled workforce. The full amount of the MarkeTouch Media goodwill is expected to be deductible for tax purposes as this acquisition was treated as an asset acquisition for U.S. tax purposes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FDS Amplicare </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ReCept</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MarkeTouch Media</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except for years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded a measurement period adjustment of $0.4 million in customer relationships.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pro Forma Financial Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents certain unaudited pro forma consolidated financial information for the year ended December 31, 2021 as if the FDS Amplicare, ReCept, and MarkeTouch Media acquisitions had been completed on January 1, 2020. The pro forma effects of the Hub and Spoke Innovations acquisition were not material to the Company’s consolidated results of operations. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of what would have occurred had the acquisitions taken place on those respective dates. The unaudited pro forma financial information combines the historical results of the acquisitions with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, amortization and depreciation of intangible assets and property and equipment acquired; imputed interest, interest expense, and amortization of debt issuance costs related to acquisitions, as applicable; and certain acquisition-related costs incurred.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2500000 3400000 2500000 3400000 1900000 2500000 800000 1100000 82000000 100000000 177000000 7000000 11300000 900000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the allocation of the respective purchase price to the assets acquired and the liabilities assumed by the Company as part of each acquisition included in the Company’s Consolidated Balance Sheets, and is reconciled to the respective purchase price transferred:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FDS Amplicare </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ReCept </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MarkeTouch Media </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase price transferred:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Base purchase price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Closing cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Net working capital adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Assumed indebtedness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price transferred</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,466 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,239 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,369 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FDS Amplicare </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ReCept </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MarkeTouch Media </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of assets acquired and liabilities assumed:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,798 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,877 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,682 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,537 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,411 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,443 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,168 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,466 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,239 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,369 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,001 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,132 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded measurement period adjustments of $1.5 million to goodwill, consisting of an increase in intangible assets, accounts receivable and unbilled receivables, and long-term deferred tax liabilities of $0.4 million, $1.1 million, and $0.1 million, respectively, and a net working capital adjustment of $0.1 million. During the year ended December 31, 2022, the Company recorded a measurement period adjustments of $0.4 million to goodwill, consisting of an increase in long-term deferred tax liabilities and accrued liabilities of $0.3 million and $0.1 million, respectively.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Closing cash is included in other current assets due to its restrictive nature as cash held for customers. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    During the year ended December 31, 2022, the Company recorded measurement period adjustments of $3.9 million to goodwill, consisting of a purchase price adjustment of $5.2 million, a decrease in long-term deferred tax liabilities of $0.2 million and a decrease in accrued liabilities of $0.3 million, partially offset by a decrease to other current assets of $1.7 million.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)    </span>During the year ended December 31, 2022, the Company recorded a measurement period adjustment of $0.3 million to goodwill related to a purchase price adjustment. 177000000 100000000 82000000 465000 6569000 237000 1654000 -7357000 147000 653000 1973000 15000 178466000 97239000 82369000 465000 0 237000 5330000 2383000 2302000 506000 192000 96000 45000 12223000 0 6346000 14798000 2635000 444000 172000 177000 2252000 773000 602000 117784000 77644000 42273000 70000000 28100000 38000000 51000 195000 2850000 196877000 121682000 86537000 950000 219000 473000 1312000 1756000 0 1497000 18249000 292000 1916000 222000 347000 11686000 3383000 0 920000 614000 206000 130000 0 2850000 18411000 24443000 4168000 178466000 97239000 82369000 178001000 90670000 82132000 -1500000 400000 1100000 100000 100000 400000 300000 100000 -3900000 5200000 -200000 -300000 -1700000 -300000 117800000 77600000 0 42300000 42300000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FDS Amplicare </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ReCept</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MarkeTouch Media</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except for years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded a measurement period adjustment of $0.4 million in customer relationships.</span></div> 59900000 P23Y 28100000 P23Y 34100000 P26Y 7700000 P5Y P7Y 0 2100000 P4Y 0 0 1800000 P2Y 2400000 P5Y 0 0 70000000 28100000 38000000 400000 0.100 0.100 0.020 0.130 0.150 0.115 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents certain unaudited pro forma consolidated financial information for the year ended December 31, 2021 as if the FDS Amplicare, ReCept, and MarkeTouch Media acquisitions had been completed on January 1, 2020. The pro forma effects of the Hub and Spoke Innovations acquisition were not material to the Company’s consolidated results of operations. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of what would have occurred had the acquisitions taken place on those respective dates. The unaudited pro forma financial information combines the historical results of the acquisitions with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, amortization and depreciation of intangible assets and property and equipment acquired; imputed interest, interest expense, and amortization of debt issuance costs related to acquisitions, as applicable; and certain acquisition-related costs incurred.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1195473000 79981000 Revenues<div style="margin-bottom:8pt;margin-top:8pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s revenues disaggregated by revenue type for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connected devices, software licenses, and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technical services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147,112 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,947 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,018 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011,380</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,202</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,788</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,732</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,745</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,230</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147,112</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,947</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,018</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No individual country represented more than 10% of total revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s contract assets and contract liabilities:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term unbilled receivables, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term unbilled receivables, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,374 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,507 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenues, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenues</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,332 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in accounts receivable and unbilled receivables in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Included in other long-term assets in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term deferred revenues, net of $121.7 million and $118.9 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $12.4 million and $15.8 million, as of December 31, 2023 and 2022, respectively. During the year ended December 31, 2023, the Company recognized revenues of $115.7 million that were included in the corresponding gross short-term deferred revenues balance of $134.7 million as of December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no customers that accounted for more than 10% of the Company’s total revenues for the years ended December 31, 2023, 2022, and 2021. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of December 31, 2023 and 2022.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s revenues disaggregated by revenue type for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connected devices, software licenses, and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technical services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147,112 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,947 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,018 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 623584000 827917000 739074000 84977000 75305000 73438000 225831000 206687000 206989000 212720000 186038000 112517000 1147112000 1295947000 1132018000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011,380</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,202</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,788</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,732</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,745</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,230</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147,112</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,947</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,018</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No individual country represented more than 10% of total revenues.</span></div> 1011380000 1168202000 1020788000 135732000 127745000 111230000 1147112000 1295947000 1132018000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s contract assets and contract liabilities:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term unbilled receivables, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term unbilled receivables, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,374 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,507 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenues, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenues</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,332 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in accounts receivable and unbilled receivables in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Included in other long-term assets in the Consolidated Balance Sheets.</span></div> 22524000 25763000 11850000 14744000 34374000 40507000 121734000 118947000 58622000 37385000 180356000 156332000 121700000 118900000 12400000 15800000 115700000 134700000 Net Income (Loss) Per Share<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method for share-based awards and warrants, and the if-converted method for convertible senior notes. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For periods prior to the adoption of ASU 2020-06 on January 1, 2022, the Company applied the treasury stock method to calculate the dilutive impact of the convertible senior notes. Upon adoption of ASU 2020-06, effective January 1, 2022, the Company applies the if-converted method for calculating the dilutive impact of the convertible senior notes. Following the Company’s irrevocable election in December 2021 to settle the principal portion of the convertible senior notes in cash with any conversion consideration in excess of the principal portion in cash and/or shares of the Company’s common stock at the Company’s option upon conversion, only the amounts expected to be settled in excess of the principal portion are considered dilutive in calculating earnings per share under the if-converted method. Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basic and diluted net income (loss) per share calculations for the years ended December 31, 2023, 2022, and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding – basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,212 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,398 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,475 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities from stock award plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding – diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,212 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,891 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,943 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share – basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share – diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive weighted-average shares related to stock award plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive weighted-average shares related to convertible senior notes and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method for share-based awards and warrants, and the if-converted method for convertible senior notes. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For periods prior to the adoption of ASU 2020-06 on January 1, 2022, the Company applied the treasury stock method to calculate the dilutive impact of the convertible senior notes. Upon adoption of ASU 2020-06, effective January 1, 2022, the Company applies the if-converted method for calculating the dilutive impact of the convertible senior notes. Following the Company’s irrevocable election in December 2021 to settle the principal portion of the convertible senior notes in cash with any conversion consideration in excess of the principal portion in cash and/or shares of the Company’s common stock at the Company’s option upon conversion, only the amounts expected to be settled in excess of the principal portion are considered dilutive in calculating earnings per share under the if-converted method. Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basic and diluted net income (loss) per share calculations for the years ended December 31, 2023, 2022, and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding – basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,212 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,398 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,475 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities from stock award plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding – diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,212 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,891 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,943 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share – basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share – diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive weighted-average shares related to stock award plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive weighted-average shares related to convertible senior notes and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -20371000 5648000 77849000 45212000 44398000 43475000 0 1019000 2136000 0 474000 2044000 0 0 288000 45212000 45891000 47943000 -0.45 0.13 1.79 -0.45 0.12 1.62 3368000 725000 156000 11816000 5908000 0 Fair Value of Financial Instruments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of December 31, 2023 and 2022, the fair value of the convertible senior notes was $527.2 million and $501.4 million, respectively, compared to their carrying values of $569.7 million and $566.6 million, respectively, which are net of unamortized debt issuance costs. Refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt and Credit Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further information regarding the Company’s credit facility and Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes</span>, for further information regarding the Company’s convertible senior notes. The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. 527200000 501400000 569700000 566600000 Balance Sheet Components<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance sheet details as of December 31, 2023 and 2022 are presented in the tables below:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventories:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,099 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,549 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-733"><span style="-sec-ix-hidden:f-734">Other current assets:</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds held for customers, including restricted cash </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,703 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,509 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,362 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External-use software development costs, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,466 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,017 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-755"><span style="-sec-ix-hidden:f-756">Accrued liabilities:</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer fund liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advance payments from customers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebate liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group purchasing organization fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,276 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,655 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Includes restricted cash of $33.0 million and $22.5 million as of December 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the years ended December 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,407)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,087)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,432)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance sheet details as of December 31, 2023 and 2022 are presented in the tables below:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventories:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,099 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,549 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-733"><span style="-sec-ix-hidden:f-734">Other current assets:</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds held for customers, including restricted cash </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,703 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,509 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,362 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External-use software development costs, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,466 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,017 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-755"><span style="-sec-ix-hidden:f-756">Accrued liabilities:</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer fund liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advance payments from customers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebate liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group purchasing organization fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,276 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,655 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Includes restricted cash of $33.0 million and $22.5 million as of December 31, 2023 and 2022, respectively.</span></div> 51439000 75854000 1327000 9280000 57333000 62415000 110099000 147549000 43649000 56703000 11867000 11486000 8279000 1702000 7714000 7471000 71509000 77362000 66659000 80760000 11850000 14744000 3718000 2058000 8239000 7455000 90466000 105017000 10518000 10761000 43649000 56703000 10551000 11556000 51277000 42802000 4445000 7723000 2191000 9642000 26645000 33468000 149276000 172655000 33000000 22500000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the years ended December 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,407)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,087)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,432)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -8407000 -8680000 -17087000 3655000 -13432000 Property and Equipment<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the property and equipment balances as of December 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,919 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software and internal-use software development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,033 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,605 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,601 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,961 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense of property and equipment was $27.0 million, $22.8 million, and $20.1 million for the years ended December 31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The geographic location of the Company’s property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of December 31, 2023 and 2022:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,601 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    No individual country represented more than 10% of total property and equipment, net.</span></div> 95996000 91391000 4500000 5154000 17919000 19510000 118004000 76327000 11614000 28223000 248033000 220605000 139432000 126644000 108601000 93961000 27000000 22800000 20100000 The following table summarizes the geographic information for property and equipment, net, as of December 31, 2023 and 2022:<div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,601 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    No individual country represented more than 10% of total property and equipment, net.</span></div> 104312000 89989000 4289000 3972000 108601000 93961000 External-Use Software Development Costs<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of external-use software development costs as of December 31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross carrying amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External-use software development costs, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,659 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,760 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in other long-term assets in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $28.7 million, $29.0 million, and $26.4 million to cost of revenues for amortization of external-use software development costs for the years ended December 31, 2023, 2022, and 2021, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expenses for external-use software development costs were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1.75pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,659</span></td></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of external-use software development costs as of December 31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross carrying amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External-use software development costs, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,659 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,760 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in other long-term assets in the Consolidated Balance Sheets.</span></div> 239038000 225004000 172379000 144244000 66659000 80760000 28700000 29000000 26400000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expenses for external-use software development costs were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1.75pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,659</span></td></tr></table></div> 25354000 18331000 12792000 6837000 2980000 365000 66659000 Goodwill and Intangible Assets<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate fluctuations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734,274 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate fluctuations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,810 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for further information.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and useful lives of intangible assets as of December 31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency exchange <br/>rate fluctuations</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except for years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,418 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,860 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 20</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 12</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,698 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193,199)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,326)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:4pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Foreign currency exchange <br/>rate fluctuations</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except for years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 20</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 12</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,185 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,514)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,906 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of intangible assets was $31.6 million, $35.2 million, and $26.5 million for the years ended December 31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expenses for amortizable intangible assets were as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,173 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate fluctuations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734,274 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate fluctuations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,810 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for further information.</span></div> 738900000 2549000 -3770000 -3405000 734274000 1536000 735810000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and useful lives of intangible assets as of December 31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency exchange <br/>rate fluctuations</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except for years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,418 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,860 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 20</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 12</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,698 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193,199)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,326)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:4pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Foreign currency exchange <br/>rate fluctuations</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life<br/>(years)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except for years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 20</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 12</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,185 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,514)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,906 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 307418000 115232000 -1326000 190860000 P4Y P30Y 84876000 67033000 0 17843000 P4Y P20Y 1800000 1800000 0 0 P2Y 9200000 7680000 0 1520000 P5Y P12Y 2404000 1454000 0 950000 P2Y P20Y 405698000 193199000 -1326000 211173000 311089000 99177000 -1514000 210398000 P4Y P30Y 92066000 64299000 0 27767000 P4Y P20Y 1800000 900000 0 900000 P2Y 9200000 6633000 0 2567000 P5Y P12Y 2430000 1306000 0 1124000 P2Y P20Y 600000 450000 0 150000 P3Y 417185000 172765000 -1514000 242906000 31600000 35200000 26500000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expenses for amortizable intangible assets were as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,173 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 22736000 21060000 18080000 16245000 15180000 117872000 211173000 Debt and Credit Agreement <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&amp;R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The Prior A&amp;R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility”). In addition, the Prior A&amp;R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Prior A&amp;R Credit Agreement had an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings would be due and payable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2020 and March 29, 2023, the Company entered into amendments to the Prior A&amp;R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to borrowings under the A&amp;R Credit Agreement with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the March 29, 2023 amendment, loans under the Prior Revolving Credit Facility bore interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Prior A&amp;R Credit Agreement), plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Prior A&amp;R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for a one month tenor plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Prior Revolving Credit Facility were subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Prior Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Prior Incremental Facility would be determined prior to the incurrence of such loans. The Company was permitted to make voluntary prepayments at any time without payment of a premium or penalty.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Prior A&amp;R Credit Agreement contained customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Prior A&amp;R Credit Agreement also contained financial covenants that required the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the Prior A&amp;R Credit Agreement contained certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a Second Amended and Restated Credit Agreement (the “Second A&amp;R Credit Agreement”) on October 10, 2023, with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&amp;R Credit Agreement supersedes the Prior A&amp;R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million or 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&amp;R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Second A&amp;R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans under the Current Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Second A&amp;R Credit Agreement), plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Second A&amp;R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. Subject to the terms and conditions of the Current Revolving Credit Facility or Current Incremental Facility the Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The availability of funds under the Current Revolving Credit Facility may be subject to reduction in order to maintain compliance with the financial covenants under the Second A&amp;R Credit Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second A&amp;R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Second A&amp;R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated secured net leverage ratio (not to exceed 3.00:1) and maintain a minimum consolidated interest coverage ratio (not to be less than 3.00:1). In addition, the Second A&amp;R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s obligations under the Second A&amp;R Credit Agreement and, at the election of the Company and the contracting counterparty, any secured swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the Second A&amp;R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The refinancing of the Prior Credit Agreement was evaluated in accordance with ASC 470-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Modifications and Extinguishments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether the refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether lenders within the syndicate remained the same or changed and whether the changes in debt terms were substantial. This assessment was performed on an individual lender basis within the syndicate. As a result, the refinancing was accounted for as a modification with the exception of certain lenders that exited the syndicate. The exit of certain lenders resulted in an immaterial write-off of existing unamortized debt issuance costs. The remaining unamortized debt issuance costs related to debt modification, along with the new deferred costs, will be amortized over the remaining term of the Second A&amp;R Credit Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Second A&amp;R Credit Agreement, the Company incurred and capitalized an additional $3.0 million of debt issuance costs. The debt issuance costs are being amortized to interest expense using the straight-line method through 2028. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had $350.0 million of funds available under the Current Revolving Credit Facility and as of December 31, 2022, the Company had $500.0 million of funds available under the Prior Revolving Credit Facility. As of December 31, 2023 and 2022, the Company had no outstanding balance under the Prior or Current Revolving Credit Facility. The Company was in compliance with all covenants as of December 31, 2023. </span></div>Convertible Senior Notes<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.25% Convertible Senior Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2023 and 2022, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the first quarter of 2024, commencing on January 1, 2024, and were not convertible during the first quarter of 2023, commencing on January 1, 2023. Accordingly, the Company classified the Notes as a long-term liability in its Consolidated Financial Statements as of December 31, 2023 and 2022. Whether the Notes will be convertible following the first fiscal quarter of 2024 will depend on the satisfaction of the conversion conditions in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of December 31, 2023, none of the criteria for a fundamental change or a conversion rate adjustment had been met. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 20, 2023, the Company may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt issuance costs associated with the Notes are being amortized to interest expense over the term of the Notes using an effective interest rate of 0.80%. As of December 31, 2023, the remaining life of the Notes and the related issuance cost accretion is approximately 1.7 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of December 31, 2023, the if-converted value of the Notes did not exceed the principal amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes consisted of the following balances reported in the Consolidated Balance Sheets as of December 31, 2023 and 2022:</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,662 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,571 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual coupon interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refer to Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Organization and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for further information regarding the adoption of ASU 2020-06, effective January 1, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Note Hedge and Warrant Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Notes in September 2020, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes.</span></div>Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants. P5Y 500000000 250000000 15000000 25000000 3.50 3.00 0.0125 0.0200 0.0050 0.0100 0.0025 0.0100 0.0015 0.0030 P5Y 350000000 250000000 1 15000000 25000000 0.0150 0.0225 0.0050 0.0100 0.0050 0.0125 0.0020 0.0035 3.00 3.00 3000000 350000000 500000000 0 0 0.0025 575000000 0.0025 75000000 559700000 15300000 0.0025 20 30 1.30 5 10 0.98 1000 1000 1000 1000 97.32 1 1.30 20 30 1 150000000 0.0080 P1Y8M12D 5900000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes consisted of the following balances reported in the Consolidated Balance Sheets as of December 31, 2023 and 2022:</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,662 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,571 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 575000000 575000000 5338000 8429000 569662000 566571000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual coupon interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refer to Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Organization and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for further information regarding the adoption of ASU 2020-06, effective January 1, 2022.</span></div> 1438000 1438000 1438000 18608000 3091000 3066000 2343000 5900000 97.32 100600000 25800000 5900000 141.56 51300000 Lessor Leases<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales-Type Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s income recognized from sales-type leases for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales-type lease revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,093)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling profit on sales-type lease revenues</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,115 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,600 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,969 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income on sales-type lease receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2023 and 2022:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net minimum lease payments to be received</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unearned interest income portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,410 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investment in sales-type leases, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,954 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,924 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    The current portion of the net investment in sales-type leases is included in other current assets in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Consolidated Balance Sheets was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum sales-type lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,017 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net investment in sales-type leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s income recognized from operating leases for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1043"><span style="-sec-ix-hidden:f-1044"><span style="-sec-ix-hidden:f-1045">Rental income</span></span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity schedule of future minimum lease payments under operating leases was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum operating lease payments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Lessor Leases<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales-Type Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s income recognized from sales-type leases for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales-type lease revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,093)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling profit on sales-type lease revenues</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,115 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,600 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,969 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income on sales-type lease receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2023 and 2022:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net minimum lease payments to be received</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unearned interest income portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,410 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investment in sales-type leases, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,954 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,924 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    The current portion of the net investment in sales-type leases is included in other current assets in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Consolidated Balance Sheets was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum sales-type lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,017 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net investment in sales-type leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s income recognized from operating leases for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1043"><span style="-sec-ix-hidden:f-1044"><span style="-sec-ix-hidden:f-1045">Rental income</span></span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity schedule of future minimum lease payments under operating leases was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum operating lease payments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s income recognized from sales-type leases for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-type lease revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales-type lease revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,093)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling profit on sales-type lease revenues</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,115 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,600 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,969 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income on sales-type lease receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 36208000 38959000 21887000 18093000 19359000 8918000 18115000 19600000 12969000 2475000 2106000 1869000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2023 and 2022:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net minimum lease payments to be received</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unearned interest income portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,410 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investment in sales-type leases, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,954 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,924 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    The current portion of the net investment in sales-type leases is included in other current assets in the Consolidated Balance Sheets.</span></div> 65017000 50755000 10196000 6345000 54821000 44410000 11867000 11486000 42954000 32924000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Consolidated Balance Sheets was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum sales-type lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,017 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net investment in sales-type leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14504000 12385000 10113000 8369000 7281000 12365000 65017000 10196000 54821000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s income recognized from operating leases for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1043"><span style="-sec-ix-hidden:f-1044"><span style="-sec-ix-hidden:f-1045">Rental income</span></span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6591000 9460000 10467000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity schedule of future minimum lease payments under operating leases was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum operating lease payments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3547000 842000 763000 763000 571000 6486000 Lessee Leases<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of <span style="-sec-ix-hidden:f-1057">one</span> to twelve years. As of December 31, 2023, the Company did not have any additional material operating leases that were entered into, but not yet commenced. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Consolidated Balance Sheets was as follows:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,600 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,428 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Amount consists of a current and long-term portion of operating lease liabilities of $10.5 million and $33.9 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $10.8 million, $18.9 million, and $15.0 million for the years ended December 31, 2023, 2022, and 2021, respectively. Short-term lease costs and variable lease costs were not material for the years ended December 31, 2023, 2022, and 2021. During the year ended December 31, 2023, the Company recorded impairment and abandonment charges to operating lease right-of-use assets of $10.0 million, in connection with restructuring activities to reduce its real estate footprint and for optimization of certain leased facilities. The impairment and abandonment charges were recorded to selling, general, and administrative expenses on the Company’s Consolidated Statements of Operations. Refer to Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information regarding the Company’s restructuring activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes supplemental cash flow information related to the Company’s operating leases for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of December 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term, years</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate, %</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> P12Y <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Consolidated Balance Sheets was as follows:</span></div><div style="margin-bottom:4pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,600 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,428 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Amount consists of a current and long-term portion of operating lease liabilities of $10.5 million and $33.9 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities in the Consolidated Balance Sheets.</span></div> 12722000 10609000 9715000 8070000 7650000 1834000 50600000 6172000 44428000 10500000 33900000 10800000 18900000 15000000 10000000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes supplemental cash flow information related to the Company’s operating leases for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of December 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term, years</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate, %</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 13469000 16452000 15625000 6431000 12372000 5503000 P4Y7M6D P5Y 0.058 0.057 Commitments and Contingencies<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of December 31, 2023, the Company had non-cancelable purchase commitments of $93.9 million, of which $84.2 million are expected to be paid within the next twelve months. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ransomware Incident</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company did not incur any material expenses or recoveries related to the previously disclosed ransomware incident in May 2022. During the year ended December 31, 2022, the Company incurred $13.6 million of expenses related to the ransomware incident, partially offset by $11.1 million of expected insurance recoveries. Expenses included costs to investigate and remediate the ransomware incident, as well as legal and other professional services, all of which were expensed as incurred. For the year ended December 31, 2022, the Company included net expenses related to the ransomware incident in cost of revenues of $0.3 million, in research and development of $0.2 million, and in selling general and administrative expenses of $2.0 million, in the Company’s Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company has incurred $13.6 million of cumulative expenses related to the ransomware incident since it was detected, partially offset by $12.2 million of insurance recoveries, all of which have been received as of December 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently involved in various legal proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required under ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with any current legal proceedings based on its belief that any potential material loss, while reasonably possible, is not probable. Furthermore, any possible range of loss in such matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of legal proceedings or because of the diversion of management’s attention and the creation of significant expenses, regardless of outcome. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any legal proceedings that management believes may have a material impact on the Company’s financial position or results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company’s certificate of incorporation and bylaws, the Company has agreed to indemnify its directors and executive officers to the fullest extent not prohibited by Delaware and other applicable law, subject to certain exceptions. The Company has entered into individual indemnification agreements with its directors and officers. The term of the indemnification period is for the entirety of the director’s or officer’s service to the Company and continues so long as the director or officer may be subject to any claim, action, or proceeding, and there is no limit on the potential amount of future payments that the Company could be required to make under these indemnification agreements. The Company has purchased a directors’ and officers’ liability insurance policy that may enable it to recover a portion of any future payments that it may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits, and other policy provisions, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive and time-consuming litigation against the insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company undertakes indemnification obligations in its ordinary course of business in connection with, among other things, the sale or licensing of its products and the provision of its support services. In the ordinary course of the Company’s business, the Company has in the past and may in the future agree to indemnify another party, generally its business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, its gross negligence or intentional acts in the performance of services, and violations of laws. The term of these indemnification obligations is generally perpetual, but typically will not extend beyond the applicable statute of limitation pursuant to applicable law. In general, the Company attempts to limit the maximum potential amount of future payments that it may be required to make under these indemnification obligations to the amounts paid to it by a customer, but in some cases the obligation may not be so limited. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has in the past and may in the future warrant to its customers that its products will conform to certain representations, which may include functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that its software media is free from material defects. Sales contracts for certain of the Company’s medication packaging systems may have in the past and may in the future include limited warranties for up to six months, but the periodic activity and ending warranty balances the Company records have historically not been material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may also warrant that its professional services will conform to certain representations, which may include that such services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. The Company generally seeks to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality, and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive, or similar damages. In some states, such disclaimers may not be enforceable. If necessary, the Company would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. The Company has not been subject to any significant claims for such losses and has not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of December 31, 2023 and 2022.</span></div> 93900000 84200000 0 13600000 11100000 300000 200000 2000000 13600000 12200000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any legal proceedings that management believes may have a material impact on the Company’s financial position or results of operations.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company’s certificate of incorporation and bylaws, the Company has agreed to indemnify its directors and executive officers to the fullest extent not prohibited by Delaware and other applicable law, subject to certain exceptions. The Company has entered into individual indemnification agreements with its directors and officers. The term of the indemnification period is for the entirety of the director’s or officer’s service to the Company and continues so long as the director or officer may be subject to any claim, action, or proceeding, and there is no limit on the potential amount of future payments that the Company could be required to make under these indemnification agreements. The Company has purchased a directors’ and officers’ liability insurance policy that may enable it to recover a portion of any future payments that it may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits, and other policy provisions, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive and time-consuming litigation against the insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company undertakes indemnification obligations in its ordinary course of business in connection with, among other things, the sale or licensing of its products and the provision of its support services. In the ordinary course of the Company’s business, the Company has in the past and may in the future agree to indemnify another party, generally its business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, its gross negligence or intentional acts in the performance of services, and violations of laws. The term of these indemnification obligations is generally perpetual, but typically will not extend beyond the applicable statute of limitation pursuant to applicable law. In general, the Company attempts to limit the maximum potential amount of future payments that it may be required to make under these indemnification obligations to the amounts paid to it by a customer, but in some cases the obligation may not be so limited. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has in the past and may in the future warrant to its customers that its products will conform to certain representations, which may include functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that its software media is free from material defects. Sales contracts for certain of the Company’s medication packaging systems may have in the past and may in the future include limited warranties for up to six months, but the periodic activity and ending warranty balances the Company records have historically not been material.</span></div>From time to time, the Company may also warrant that its professional services will conform to certain representations, which may include that such services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. The Company generally seeks to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality, and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive, or similar damages. In some states, such disclaimers may not be enforceable. If necessary, the Company would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. The Company has not been subject to any significant claims for such losses and has not incurred any material costs in defending or settling claims related to these indemnification obligations. P30D P6M Employee Benefits and Share-Based Compensation<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Purchase Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1997 Employee Stock Purchase Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an Employee Stock Purchase Plan (“ESPP”), under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their earnings; provided, however, an eligible employee’s right to purchase shares of the Company’s common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was a total of 3.3 million shares reserved for future issuance under the ESPP as of December 31, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Award Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2009 Equity Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2009 Equity Incentive Plan (“2009 Plan”), as amended, provides for the issuance of incentive stock options, RSAs, RSUs, PSUs, and other stock awards to the Company’s employees, directors, and consultants. There were 5.9 million shares of common stock reserved for future issuance under the 2009 Plan as of December 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2009 Plan generally become exercisable over periods of up to four years, with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter. The exercise prices of the options is the fair market value of common stock on the date of grant. RSUs generally vest over periods of up to four years, with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 12 equal quarterly installments thereafter. Awards of restricted stock to non-employee directors are granted on the date of the annual meeting of stockholders and vest in full on the date of the next annual meeting of stockholders, provided such non-employee director remains a director on such date. PSUs granted to the Company’s executives may include performance and market conditions. PSUs become eligible for vesting when certain market or performance conditions are met. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total share-based compensation expense recognized in the Company’s Consolidated Statements of Operations:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product and service revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,994 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,300 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,247 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,160 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company capitalized approximately $4.4 million of non-cash share-based compensation expense to internal-use and external-use software development costs related to internal labor. The Company did not capitalize any material non-cash share-based compensation expense to inventory during the years ended December 31, 2023, 2022, and 2021, or any material non-cash share-based compensation expense to internal-use and external-use software development costs during the years ended December 31, 2022 and 2021. Income tax benefit (expense) realized from share-based compensation was an expense of $6.5 million for the year ended December 31, 2023, and a benefit of $5.2 million and $26.6 million for the years ended December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan (“ESPP”)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to value shares under the ESPP for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life, years</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility, %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7% - 63.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8% - 45.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4% - 53.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate, %</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 5.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 3.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 2.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield, %</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023 and 2022, employees purchased approximately 353,000 and 316,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $46.68 and $67.63, respectively. As of December 31, 2023, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $1.1 million and is expected to be recognized over a weighted-average period of 1.4 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to value stock options granted pursuant to the 2009 Plan for the years ended December 31, 2023 and 2021. There were no stock options granted during the year ended December 31, 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life, years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility, %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate, %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate, %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield, %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2009 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2023 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value per share of options granted during the years ended December 31, 2023 and 2021 was 19.48 and 35.17, respectively. The intrinsic value of options exercised during the years ended December 31, 2023, 2022, and 2021 was $3.2 million, $23.9 million, and $88.0 million, respectively. The tax benefit (expense) realized from stock options exercised was expense of $1.3 million for the year ended December 31, 2023, and benefit of $4.4 million and $18.3 million for the years ended December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, total unrecognized compensation cost related to unvested stock options was $3.3 million, which is expected to be recognized over a weighted-average vesting period of 0.7 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units (“RSUs”)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the 2009 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted (Awarded)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested (Released)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of RSUs granted during the years ended December 31, 2023, 2022, and 2021 was $63.74, $111.12, and $149.65, respectively. The total fair value of RSUs that vested in the years ended December 31, 2023, 2022, and 2021 was $38.0 million, $30.7 million, and $16.7 million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, total unrecognized compensation cost related to RSUs was $64.3 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.0 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards (“RSAs”)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSA activity under the 2009 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted (Awarded)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested (Released)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of RSAs granted during the years ended December 31, 2023, 2022, and 2021 was $70.96, $109.39, and $137.36, respectively. The total fair value of RSAs that vested in the years ended December 31, 2023, 2022, and 2021 was $1.4 million, $1.6 million, and $1.4 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, total unrecognized compensation cost related to RSAs was $0.6 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.4 years. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Performance-Based Stock Unit Awards (“PSUs”)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company granted 56,237 PSUs to its executive officers, none of which became eligible for vesting as the achievement of a certain level of shareholder return was not achieved. During the year ended December 31, 2023, the Company granted 65,000 PSUs to its executive officers, of which 0% to 200% may become eligible for vesting depending on the level of shareholder return for the period from March 1, 2023 through March 1, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares that vest at the end of the performance period depends on the percentile ranking of the total shareholder return for Omnicell stock over the performance period relative to the total shareholder return of each of the other companies in the NASDAQ Health Care Index. Stock price appreciation is calculated based on the trailing 20-day average stock price just prior to the first trading day of March in the grant year, compared to the trailing 20-day average stock price just prior to the first trading day of March in the year subsequent to the grant year. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSUs generally vest over periods of up to four years, with one-fourth of the shares vesting approximately one year from the vesting commencement date with respect to initial grants and upon confirmation by the Compensation Committee that the performance target has been met, and the remaining shares generally vesting in equal semi-annual or quarterly installments over the remaining three years. Vesting is contingent upon continued service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to executive officers’ PSU awards, from time to time, the Company may grant PSUs with specific performance and service conditions to certain employees on an ad hoc basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the PSU activity under the 2009 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of PSUs granted during the years ended December 31, 2023, 2022, and 2021 was $122.29, $155.27, and $162.16, respectively. The total fair value of PSUs that vested in the years ended December 31, 2023, 2022, and 2021 was $6.1 million, $15.0 million, and $4.4 million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, total unrecognized compensation cost related to PSUs was approximately $5.0 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.4 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Shares Reserved for Future Issuance under Equity Incentive Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares authorized for future issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares available for future issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,119 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">401(k) Plan</span></div>The Company has established a pre-tax savings plan under Section 401(k) of the Internal Revenue Code of 1986, as amended. The 401(k) Plan allows eligible employees in the United States to voluntarily contribute a portion of their pre-tax salary, subject to a maximum limit specified in the Internal Revenue Code. The Company generally matches 50% of employee contributions up to $3,000, annually. The Company’s contributions under this plan were $7.9 million, $8.1 million, and $6.8 million in the years ended December 31, 2023, 2022, and 2021, respectively. 0.15 25000 0.85 P24M P6M 3300000 5900000 P4Y P1Y P36M P4Y P1Y <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total share-based compensation expense recognized in the Company’s Consolidated Statements of Operations:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product and service revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,994 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,300 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,247 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,160 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8288000 9067000 7994000 6941000 11368000 7663000 40071000 47812000 37503000 55300000 68247000 53160000 4400000 -6500000 5200000 26600000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to value shares under the ESPP for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life, years</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility, %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7% - 63.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8% - 45.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4% - 53.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate, %</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 5.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 3.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 2.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield, %</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> P0Y6M P2Y P0Y6M P2Y P0Y6M P2Y 0.317 0.639 0.288 0.456 0.274 0.535 0.001 0.055 0.001 0.032 0.001 0.026 0 0 0 353000 316000 46.68 67.63 1100000 P1Y4M24D <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to value stock options granted pursuant to the 2009 Plan for the years ended December 31, 2023 and 2021. There were no stock options granted during the year ended December 31, 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life, years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility, %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate, %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate, %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield, %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0 P3Y2M12D P4Y10M24D 0.448 0.315 0.037 0.009 0.100 0.079 0 0 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2009 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2023 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2434000 68.65 P6Y1M6D 7887000 200000 55.60 165000 41.01 242000 79.49 204000 74.92 2023000 67.68 P4Y7M6D 1013000 1784000 67.18 P4Y6M 1013000 2013000 67.64 P4Y7M6D 1013000 19.48 35.17 3200000 23900000 88000000 -1300000 4400000 18300000 3300000 P0Y8M12D <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the 2009 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted (Awarded)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested (Released)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1117000 115.75 P1Y7M6D 56297000 695000 63.74 335000 113.64 399000 107.89 1078000 84.66 P1Y6M 40551000 63.74 111.12 149.65 38000000 30700000 16700000 64300000 P3Y <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSA activity under the 2009 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted (Awarded)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested (Released)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 13000 109.39 24000 70.96 13000 109.39 24000 70.96 70.96 109.39 137.36 1400000 1600000 1400000 600000 P0Y4M24D 56237 65000 0 2 P20D P20D P4Y P1Y P3Y <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the PSU activity under the 2009 Plan during the year ended December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 135000 147.42 65000 122.29 55000 111.05 70000 153.77 75000 127.14 122.29 155.27 162.16 6100000 15000000 4400000 5000000 P1Y4M24D <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of December 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares authorized for future issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares available for future issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,119 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2023000 1177000 2669000 3250000 9119000 0.50 3000 7900000 8100000 6800000 Stock Repurchase Programs<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2014 Repurchase Program”). During the year ended December 31, 2022, the 2014 Repurchase Program was completed, and as of December 31, 2023, the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing, price, and volume of repurchases are to be based on market conditions, relevant securities laws, and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions, or pursuant to a Rule 10b-18 plan, subject to the terms and conditions of that certain A&amp;R Credit Agreement, as amended. The 2016 Repurchase Program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the 2016 Repurchase Program at any time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company repurchased approximately 389,300 shares of its common stock under the repurchase programs at an average price of $134.11 per share for an aggregate purchase price of approximately $52.2 million. During the years ended December 31, 2023 and 2021, the Company did not repurchase any of its outstanding common stock under the stock repurchase programs.</span></div> 50000000 50000000 2700000 389300 134.11 52200000 0 0 Income Taxes<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a geographical breakdown of income (loss) before income taxes:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,108)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,453)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,007 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,867 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,189 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,888)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,604)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,290)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,954)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,842)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal tax provision at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income inclusion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign branch taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to return true up</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State rate true up</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,842)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022, (the “IRA”), was signed into law. Among other things, the IRA imposes a 15% corporate alternative minimum tax for tax years beginning after December 31, 2022, levies a 1% excise tax on net stock repurchases after December 31, 2022, and provides tax incentives to promote clean energy. The provisions of the IRA did not have a material impact on the Company’s results of operations or financial position.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Co-Operation and Development (“OECD”) introduced Base Erosion and Profit Shifting (“BEPS”) Pillar Two rules that impose a global minimum tax rate of 15% on multi-national corporations. The rules are effective for the Company’s financial year beginning January 1, 2024. Numerous countries have enacted or substantively enacted legislation to implement these rules. While the Company does not expect Pillar Two to have a material impact on its tax provision or effective tax rate, the Company continues to monitor evolving tax legislation in the jurisdictions in which it operates. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company’s deferred tax assets (liabilities) were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory-related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,541 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,176 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,541 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,176 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,260)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,942)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,234 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax assets (liabilities) are provided for temporary differences that will result in future tax deductions or future taxable income, as well as the future benefit of tax credit carryforwards. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. As of December 31, 2023 and 2022, the Company does not have a valuation allowance against any of its deferred tax assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had no federal net operating loss carryforward, $19.0 million of state net operating loss carryforwards expiring at various dates beginning in 2029, and $22.3 million of foreign net operating losses carried forward indefinitely. For income tax purposes, the Company had no federal research tax credit carryforward and a California research tax credit carryforward of $20.9 million. California research tax credits are carried forward indefinitely to reduce cash taxes payable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company’s practice and intention to reinvest the earnings of its non-U.S. subsidiaries in those operations. As of December 31, 2023, the Company has not made a provision for U.S. federal income, withholding, and state income taxes on the outside basis difference related to certain foreign subsidiaries because earnings are intended to be indefinitely reinvested in operations outside the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, France, the United Kingdom and India. With few exceptions, as of December 31, 2023, the Company was no longer subject to U.S., state, and foreign tax examinations for years before 2020, 2019, and 2019, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate change in the balance of gross unrecognized tax benefit, which excludes interest and penalties, for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during a prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to tax positions taken during the prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to expiration of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,961 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during a prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to tax positions taken during the prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during the current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to expiration of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,296 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during a prior period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to tax positions taken during the prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to expiration of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,748 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of gross unrecognized tax benefit that, if realized, would favorably affect the Company’s effective income tax rate in future periods, was $10.7 million and $9.3 million as of December 31, 2023 and 2022, respectively. The Company recognizes interest and penalties related to uncertain tax positions in interest and other income (expense), net in the Consolidated Statements of Operations, accruing $0.2 million, $0.2 million, and $0.3 million for the years ended December 31, 2023, 2022, and 2021, respectively. Accrued interest and penalties are included within other long-term liabilities on the Consolidated Balance Sheets. The combined amount of cumulative accrued interest and penalties was approximately $0.4 million, $0.2 million, and $0.6 million for the years ended December 31, 2023, 2022, and 2021, respectively. The Company does not believe there will be any significant changes in its unrecognized tax positions over the next twelve months.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a geographical breakdown of income (loss) before income taxes:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,108)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,453)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,007 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -28105000 369000 67103000 7997000 -2822000 -1096000 -20108000 -2453000 66007000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,867 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,189 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,888)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,604)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,290)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,954)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,842)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8556000 17973000 -7841000 1471000 8024000 187000 840000 192000 -234000 10867000 26189000 -7888000 -8002000 -25753000 -2708000 -2261000 -7976000 -1217000 -341000 -561000 -29000 -10604000 -34290000 -3954000 263000 -8101000 -11842000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal tax provision at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income inclusion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign branch taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to return true up</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State rate true up</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,842)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -4223000 -515000 13861000 -624000 38000 -814000 1286000 3071000 6382000 531000 134000 363000 -620000 -776000 -835000 7384000 -3264000 -20717000 4587000 6948000 5170000 0 0 6116000 325000 753000 68000 0 960000 195000 219000 186000 -170000 6000 -51000 -9000 0 68000 1097000 697000 -84000 205000 528000 -135000 -80000 -9000 -32000 34000 263000 -8101000 -11842000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company’s deferred tax assets (liabilities) were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory-related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,541 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,176 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,541 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,176 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,260)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,942)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,234 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11343000 13514000 11763000 12064000 5136000 4567000 12505000 12173000 5660000 6244000 7802000 10255000 11457000 12884000 9649000 15037000 41635000 30881000 591000 1557000 117541000 119176000 0 0 117541000 119176000 30366000 36357000 35402000 37286000 13858000 15574000 6626000 9725000 8000 0 86260000 98942000 31281000 20234000 0 0 0 19000000 22300000 0 20900000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate change in the balance of gross unrecognized tax benefit, which excludes interest and penalties, for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during a prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to tax positions taken during the prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to expiration of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,961 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during a prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to tax positions taken during the prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during the current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to expiration of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,296 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during a prior period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to tax positions taken during the prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to expiration of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,748 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 18246000 40000 8908000 1219000 1636000 8961000 3000 59000 1629000 1238000 9296000 750000 161000 1566000 703000 10748000 10700000 9300000 200000 200000 300000 400000 200000 600000 Restructuring Expenses<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, the Company continued its organizational realignment initiative that was announced in 2020, incurring $2.0 million of employee severance costs and related expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, the Company initiated certain domestic and international restructuring initiatives in order to enhance and streamline certain engineering functions for its domestic operations and to realign its international sales organization to better serve its customers in various international markets. During the third quarter of 2022, the Company initiated restructuring initiatives associated with the integration and functionalization of certain acquisitions, primarily the 340B Link business acquisition, to further accelerate the expansion of the Company’s pharmacy inventory management capabilities. On November 23, 2022, the Company committed to a plan to reduce the Company’s headcount (“the 2022 Plan”) as part of the Company’s expense containment efforts being implemented due to ongoing macroeconomic headwinds, primarily consisting of employee severance and benefits costs. During the year ended December 31, 2022, the restructuring plans incurred $22.8 million of employee severance costs and related expenses. As of December 31, 2023, there was no material unpaid balance related to these restructuring plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023, as a result of continued exploration of expense containment measures, the Company committed to further reduce its headcount across many of its functions as a continuation of the 2022 Plan, and also committed to reduce its real estate footprint to align with its broader hybrid work strategy and in an effort to further reduce costs. During the year ended December 31, 2023, the Company recorded an immaterial reversal of previously recognized restructuring expenses associated with the 2022 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2023, the Company committed to a plan to reduce the Company’s headcount and real estate footprint (the “2023 Plan”) as part of the Company’s expense containment initiatives and other actions to reduce discretionary spending being implemented due to challenging industry dynamics and macroeconomic conditions. During the year ended December 31, </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, the restructuring plans incurred $15.5 million of employee severance costs and related expenses, net of reversals. As of December 31, 2023, the unpaid balance related to these restructuring plans was $8.9 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lessee Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding the Company’s restructuring activities for the reduction of its real estate footprint and optimization of certain leased facilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total employee-related restructuring expenses recognized in the Company’s Consolidated Statements of Operations for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product and service revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring expenses, net of reversals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,539 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,803 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2000000 22800000 15500000 8900000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total employee-related restructuring expenses recognized in the Company’s Consolidated Statements of Operations for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product and service revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring expenses, net of reversals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,539 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,803 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3089000 8018000 389000 3829000 3615000 105000 8621000 11170000 1526000 15539000 22803000 2020000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:4pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged (Credited) to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Costs and Expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Written Off </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term unbilled receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total allowances deducted from assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,581 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,079)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,526 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term unbilled receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total allowances deducted from assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,526 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,551)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term unbilled receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total allowances deducted from assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,441)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,852 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Allowance for credit losses.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Represents amounts charged and credited for provisions for credit losses. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Represents amounts written off from the allowance and receivable.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Represents other adjustments, such as foreign currency translation and purchase price accounting adjustments in connection with acquisitions.</span></div> 4286000 2130000 2079000 935000 5272000 30000 -4000 0 0 26000 265000 -37000 0 0 228000 4581000 2089000 2079000 935000 5526000 5272000 2658000 2551000 -226000 5153000 26000 9000 0 0 35000 228000 80000 0 0 308000 5526000 2747000 2551000 -226000 5496000 5153000 2726000 2441000 126000 5564000 35000 -4000 0 31000 308000 -51000 0 0 257000 5496000 2671000 2441000 126000 5852000